id,location,condition,intervention,phase,sponsor_type,sponsor,intervention_group,intervention_details,is_combination,condition_clean_text,condition_group
1,China,Cervical Cancers,DRUG: Chemo-immunotherapy|RADIATION: CCRT,23,OTHER,Women's Hospital School Of Medicine Zhejiang University,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'chemo-immunotherapy'}]",False,cervical cancers,gynecologic
2,China,Malignant Tumors,BIOLOGICAL: EBV mRNA vaccine,1,OTHER,West China Hospital,['vaccine'],"[{'type': 'vaccine', 'subtype': 'mRNA', 'raw': 'ebv mrna vaccine'}]",False,malignant tumors,other
3,China,Malignant Tumor,BIOLOGICAL: EBV immunological agent,1,OTHER,West China Hospital,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'ebv immunological agent'}]",False,malignant tumor,other
4,China,Rectal Malignant Neoplasms,COMBINATION_PRODUCT: Total neoadjuvant therapy integrating iparomlimab/tuvonralimab with chemoradiotherapy,2,OTHER,Shandong Cancer Hospital and Institute,"['other', 'antibody']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'total neoadjuvant therapy integrating iparomlimab'}, {'type': 'other', 'subtype': None, 'raw': 'tuvonralimab with chemoradiotherapy'}]",True,rectal malignant neoplasms,digestive
5,China,Advanced Cancers,BIOLOGICAL: Blood-stage infection of P.vivax,12,INDUSTRY,"CAS Lamvac Biotech Co., Ltd.",['other'],"[{'type': 'other', 'subtype': None, 'raw': 'blood-stage infection of p.vivax'}]",False,advanced cancers,multiple
6,United States,Advanced Malignant Neoplasm|Metastatic Malignant Neoplasm|Recurrent Malignant Neoplasm,OTHER: Laboratory Biomarker Analysis|DRUG: Methylphenidate|OTHER: Physical Activity|OTHER: Placebo|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration,3,OTHER,M.D. Anderson Cancer Center,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'methylphenidate'}]",False,advanced malignant neoplasm metastatic malignant neoplasm recurrent malignant neoplasm,multiple
7,United States,"Neoplasm|Cancer, Malignant Tumors",DRUG: COM503|DRUG: Zimberelimab,1,INDUSTRY,Compugen Ltd,"['other', 'antibody']","[{'type': 'other', 'subtype': None, 'raw': 'com503'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'zimberelimab'}]",True,neoplasm cancer malignant tumors,other
8,China,Advanced Malignant Solid Tumor,OTHER: Plasmodium immunotherapy,12,INDUSTRY,"CAS Lamvac Biotech Co., Ltd.",['other'],"[{'type': 'other', 'subtype': None, 'raw': 'other: plasmodium immunotherapy'}]",False,advanced malignant solid tumor,multiple
9,China,Cervical Cancers,DRUG: Neoadjuvant Chemotherapy|DRUG: Neoadjuvant Chemotherapy|DRUG: Immunotherapy|PROCEDURE: Radical surgery|PROCEDURE: Fertility-preserving surgery,2,OTHER,Obstetrics & Gynecology Hospital of Fudan University,"['chemotherapy', 'immunotherapy']","[{'type': 'chemotherapy', 'subtype': 'neoadjuvant', 'raw': 'neoadjuvant chemotherapy'}, {'type': 'chemotherapy', 'subtype': 'neoadjuvant', 'raw': 'neoadjuvant chemotherapy'}, {'type': 'immunotherapy', 'subtype': 'unspecified', 'raw': 'immunotherapy'}]",True,cervical cancers,gynecologic
10,"Canada, United Kingdom",Gynaecological Cancers,DRUG: Ceralasertib|DRUG: Olaparib|DRUG: Durvalumab,2,OTHER,"Institute of Cancer Research, United Kingdom","['checkpoint inhibitor', 'targeted therapy']","[{'type': 'targeted therapy', 'subtype': 'ATR inhibitor', 'raw': 'ceralasertib'}, {'type': 'targeted therapy', 'subtype': 'PARP inhibitor', 'raw': 'olaparib'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}]",True,gynaecological cancers,gynecologic
11,China,Advanced Solid Tumor,COMBINATION_PRODUCT: Radiotherapy combined with immunotherapy,12,OTHER,China-Japan Friendship Hospital,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'radiotherapy combined with immunotherapy'}]",False,advanced solid tumor,multiple
12,China,Gastrointestinal Cancers,DRUG: Entecavir,3,OTHER,Sun Yat-sen University,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'entecavir'}]",False,gastrointestinal cancers,digestive
13,United States,Advanced Cancers|Melanoma,DRUG: MGN1703|DRUG: Ipilimumab,1,OTHER,M.D. Anderson Cancer Center,"['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'mgn1703'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}]",True,advanced cancers melanoma,skin
14,United States,Pleural Mesothelial Neoplasm,OTHER: Immunotherapy|OTHER: Quality-of-Life Assessment|RADIATION: Stereotactic Body Radiation Therapy,1,OTHER,Mayo Clinic,[],[],False,pleural mesothelial neoplasm,lung/thoracic
15,United Kingdom,Cancer|Neoplasms,BIOLOGICAL: ACIT-1,12,INDUSTRY,Cancer Vaccines Limited,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'acit-1'}]",False,cancer neoplasms,other
16,"China, France, Israel, New Zealand, Republic of, Taiwan, United States",Advanced Liver Cancers,DRUG: Atezolizumab|DRUG: Bevacizumab 15 mg/kg|DRUG: Tiragolumab|DRUG: Tocilizumab|DRUG: TPST-1120|DRUG: Tobemstomig 2100 mg|DRUG: Bevacizumab 10 mg/kg|DRUG: Tobemstomig 600 mg|DRUG: Tobemstomig 1200 mg|DRUG: ADG126|DRUG: IO-108 1800 mg|DRUG: NKT2152|DRUG: IO-108 1200 mg,12,INDUSTRY,Hoffmann-La Roche,"['checkpoint inhibitor', 'other', 'antibody']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'atezolizumab'}, {'type': 'other', 'subtype': None, 'raw': 'bevacizumab 15'}, {'type': 'other', 'subtype': None, 'raw': 'kg'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'tiragolumab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'tocilizumab'}, {'type': 'other', 'subtype': None, 'raw': 'tpst-1120'}, {'type': 'other', 'subtype': None, 'raw': 'tobemstomig 2100'}, {'type': 'other', 'subtype': None, 'raw': 'bevacizumab 10'}, {'type': 'other', 'subtype': None, 'raw': 'kg'}, {'type': 'other', 'subtype': None, 'raw': 'tobemstomig 600'}, {'type': 'other', 'subtype': None, 'raw': 'tobemstomig 1200'}, {'type': 'other', 'subtype': None, 'raw': 'adg126'}, {'type': 'other', 'subtype': None, 'raw': 'io-108 1800'}, {'type': 'other', 'subtype': None, 'raw': 'nkt2152'}, {'type': 'other', 'subtype': None, 'raw': 'io-108 1200'}]",True,advanced liver cancers,digestive
17,China,"Breast Cancer, Metastatic Breast Cancer",RADIATION: Intensity-modulated radiotherapy|DRUG: Immunotherapy Therapy,12,OTHER,Zhongnan Hospital,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'immunotherapy therapy'}]",False,breast cancer metastatic breast cancer,breast
18,"Australia, Canada, Netherlands, Switzerland, United Kingdom",Metastatic Tumors,RADIATION: Palliative Radiation|DRUG: Chemotherapy|DRUG: Immunotherapy|DRUG: Hormones|OTHER: Observation|RADIATION: Stereotactic Ablative Radiotherapy,3,OTHER,David Palma,"['other', 'chemotherapy', 'immunotherapy']","[{'type': 'chemotherapy', 'subtype': 'unspecified', 'raw': 'chemotherapy'}, {'type': 'immunotherapy', 'subtype': 'unspecified', 'raw': 'immunotherapy'}, {'type': 'other', 'subtype': None, 'raw': 'hormones'}]",True,metastatic tumors,multiple
19,United States,"Solid Tumor, Adult",DRUG: DF9001|DRUG: pembrolizumab|DRUG: KEYTRUDA®,12,INDUSTRY,Dragonfly Therapeutics,"['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'df9001'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'other', 'subtype': None, 'raw': 'keytruda®'}]",True,solid tumor adult,multiple
20,China,Cervical Cancers,DRUG: Serplulimab|DRUG: Chemotherapy|RADIATION: radiotherapy,2,OTHER,Tianjin Medical University Cancer Institute and Hospital,"['antibody', 'chemotherapy']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'serplulimab'}, {'type': 'chemotherapy', 'subtype': 'unspecified', 'raw': 'chemotherapy'}]",True,cervical cancers,gynecologic
21,France,LOCALLY ADVANCED CERVICAL CANCERS,COMBINATION_PRODUCT: combination of relatlimab and nivolumab wich are two immunotherapy treatments|OTHER: Nivolumab alone,2,OTHER,ARCAGY/ GINECO GROUP,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'combination of relatlimab and nivolumab wich are two immunotherapy treatments'}]",False,locally advanced cervical cancers,gynecologic
22,China,Cervical Cancers,DRUG: Toripalimab,2,OTHER,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'toripalimab'}]",False,cervical cancers,gynecologic
23,China,Cervical Cancers,DRUG: Neoadjuvant immunochemotherapy,2,OTHER,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'neoadjuvant immunochemotherapy'}]",False,cervical cancers,gynecologic
24,"Australia, France, United States","Solid Tumor, Adult|Solid Tumor Cancer",DRUG: DF6215|DRUG: pembrolizumab|DRUG: KEYTRUDA®,1,INDUSTRY,Dragonfly Therapeutics,"['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'df6215'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'other', 'subtype': None, 'raw': 'keytruda®'}]",True,solid tumor adult solid tumor cancer,multiple
25,China,Glioblastoma (GBM)|Head and Neck Squamous Cell Carcinoma|Non-Small Cell Lung Cancer|Esophageal Cancer,DIAGNOSTIC_TEST: PET/CT （[18F]AlF-NOTA-PCP2）|DIAGNOSTIC_TEST: [18F]AlF-NOTA-PCP2 PET/CT Imaging for PD-L1 Expression in Malignant Tumors,12,OTHER,Man Hu,[],[],False,glioblastoma head and neck squamous cell carcinoma non small cell lung cancer esophageal cancer,digestive
26,China,Gastric Cancers,DRUG: Pre-operative chemotherapy|PROCEDURE: Robotic radical gastrectomy after neoadjuvant therapy,2,OTHER,The First Affiliated Hospital with Nanjing Medical University,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'pre-operative chemotherapy'}]",False,gastric cancers,digestive
27,"Canada, Republic of, Spain, United States",Locally Advanced or Metastatic Solid Tumours,DRUG: AZD0171|DRUG: Durvalumab|DRUG: Gemcitabine|DRUG: Nab-paclitaxel,2,INDUSTRY,AstraZeneca,"['checkpoint inhibitor', 'other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'azd0171'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'gemcitabine'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'nab-paclitaxel'}]",True,locally advanced or metastatic solid tumours,multiple
28,United Kingdom,"Neoplasms|Prostatic Neoplasms, Castration-Resistant|Stomach Neoplasms|Esophageal Neoplasms|Head and Neck Neoplasms|Colorectal Neoplasms|Pancreatic Neoplasms|Lung Neoplasms|Urinary Bladder Neoplasms|Mesothelioma, Malignant|Uterine Cervical Neoplasms|Kidney Neoplasms|Sarcoma|Pheochromocytomas",DRUG: HTL0039732 Capsules|DRUG: HTL0039732 Capsules and atezolizumab infusion,12,OTHER,Cancer Research UK,"['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'htl0039732 capsules'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'htl0039732 capsules and atezolizumab'}]",True,neoplasms prostatic neoplasms castration resistant stomach neoplasms esophageal neoplasms head and neck neoplasms colorectal neoplasms pancreatic neoplasms lung neoplasms urinary bladder neoplasms mesothelioma malignant uterine cervical neoplasms kidney neoplasms sarcoma pheochromocytomas,gynecologic
29,France,Esophagus Cancer|Unresectable Malignant Neoplasm,"DRUG: Durvalumab|COMBINATION_PRODUCT: IMRT 50 Gy + FOLFOX4 simplifIed (oxaliplatin, leucovorin, 5-FU)",2,OTHER,UNICANCER,"['checkpoint inhibitor', 'other']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}, {'type': 'other', 'subtype': None, 'raw': 'imrt 50 gy'}, {'type': 'other', 'subtype': None, 'raw': 'folfox4 simplified'}]",True,esophagus cancer unresectable malignant neoplasm,other
30,United Kingdom,"Tumor, Solid",BIOLOGICAL: LEU011,12,INDUSTRY,Leucid Bio,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'leu011'}]",False,tumor solid,other
31,United States,"Cervical Cancer|HPV Cancers|Anal Cancer|Oropharyngeal Cancer|Vulvar, Vaginal, Penile, Rectal Cancer",BIOLOGICAL: PDS0101|BIOLOGICAL: M7824|BIOLOGICAL: NHS-IL12,12,NIH,National Cancer Institute (NCI),['other'],"[{'type': 'other', 'subtype': None, 'raw': 'pds0101'}, {'type': 'other', 'subtype': None, 'raw': 'm7824'}, {'type': 'other', 'subtype': None, 'raw': 'nhs-il12'}]",False,cervical cancer hpv cancers anal cancer oropharyngeal cancer vulvar vaginal penile rectal cancer,gynecologic
32,China,Solid Tumors,DRUG: Retroviral vector-transduced autologous T cells to express anti-ALPP CARs,12,OTHER,Xinqiao Hospital of Chongqing,['cell therapy'],"[{'type': 'cell therapy', 'subtype': 'other', 'raw': 'retroviral vector-transduced autologous t cells to express anti-alpp cars'}]",False,solid tumors,multiple
33,Canada,All Solid Tumors,BIOLOGICAL: MET-4,23,OTHER,"University Health Network, Toronto",['other'],"[{'type': 'other', 'subtype': None, 'raw': 'met-4'}]",False,all solid tumors,multiple
34,China,Rectal Cancer,DRUG: Camrelizumab ＋Immunotherapy,3,OTHER,Peking University Cancer Hospital & Institute,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'camrelizumab ＋immunotherapy'}]",False,rectal cancer,digestive
35,United States,Malignant Neoplasm|Metastatic Malignant Neoplasm in the Brain|Metastatic Malignant Neoplasm in the Leptomeninges|Breast Cancer|HER2-positive Breast Cancer,BIOLOGICAL: Chimeric Antigen Receptor T-Cell Therapy,1,OTHER,City of Hope Medical Center,['cell therapy'],"[{'type': 'cell therapy', 'subtype': 'other', 'raw': 'chimeric antigen receptor t-cell therapy'}]",False,malignant neoplasm metastatic malignant neoplasm in the brain metastatic malignant neoplasm in the leptomeninges breast cancer her2 positive breast cancer,breast
36,"France, Germany, Italy, Netherlands, Spain, United Kingdom, United States",Pediatric Cancer|Solid Tumor Pediatric|Hematological Malignancies,DRUG: Durvalumab / Tremelimumab Combination Therapy,12,INDUSTRY,AstraZeneca,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'tremelimumab combination therapy'}]",False,pediatric cancer solid tumor pediatric hematological malignancies,hematologic
37,China,Recurrence Tumor|Metastatic Cancer|Solid Tumor,BIOLOGICAL: TIL|DRUG: Aldesleukin|DRUG: Cyclophosphamide|DRUG: Fludarabine,12,OTHER,Tongji Hospital,"['other', 'cytokine therapy', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'til'}, {'type': 'cytokine therapy', 'subtype': 'IL-2', 'raw': 'aldesleukin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide'}, {'type': 'chemotherapy', 'subtype': 'purine analog', 'raw': 'fludarabine'}]",True,recurrence tumor metastatic cancer solid tumor,multiple
38,"Belgium, Denmark, France, Netherlands, Republic of, United States","Solid Tumor, Adult",DRUG: DF1001|DRUG: Nivolumab|DRUG: Nab paclitaxel|DRUG: Sacituzumab Govitecan-hziy,12,INDUSTRY,Dragonfly Therapeutics,"['checkpoint inhibitor', 'other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'df1001'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'nab paclitaxel'}, {'type': 'other', 'subtype': None, 'raw': 'sacituzumab govitecan-hziy'}]",True,solid tumor adult,multiple
39,China,Solid Tumors,DRUG: Methotrexate tablets|DRUG: Anti-PD-1 monoclonal antibody|RADIATION: Radiotherapy,2,OTHER,Yancheng First People's Hospital,"['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'methotrexate tablets'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'anti-pd-1 monoclonal antibody'}]",True,solid tumors,multiple
40,China,Advanced Malignancies,DRUG: IBI363 + chemotherapy|DRUG: IBI363 + Investigator's Choice SOC,1,INDUSTRY,Innovent Biologics (Suzhou) Co. Ltd.,"['other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'ibi363'}, {'type': 'chemotherapy', 'subtype': 'unspecified', 'raw': 'chemotherapy'}, {'type': 'other', 'subtype': None, 'raw': 'ibi363'}, {'type': 'other', 'subtype': None, 'raw': ""investigator's choice soc""}]",True,advanced malignancies,other
41,Republic of,"Solid Tumor, Adult|Solid Tumor|Gastric Cancer|Hepatocellular Carcinoma|Metastatic Colorectal Cancer|Advanced Solid Tumor",DRUG: PB101,1,INDUSTRY,Panolos Bioscience,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'pb101'}]",False,solid tumor adult solid tumor gastric cancer hepatocellular carcinoma metastatic colorectal cancer advanced solid tumor,digestive
42,United States,"Breast Cancer|Breast Tumor|Cancer of Breast|Cancer of the Breast|Malignant Tumor of Breast|Tumors, Breast",BIOLOGICAL: BC1 cell line|BIOLOGICAL: Bria-OTS regimen and CPI (tislelizumab)|BIOLOGICAL: Bria-OTS regimen and CPI (tislelizumab) expansion cohort,12,INDUSTRY,BriaCell Therapeutics Corporation,"['other', 'cell therapy']","[{'type': 'cell therapy', 'subtype': 'other', 'raw': 'bc1 cell line'}, {'type': 'other', 'subtype': None, 'raw': 'bria-ots regimen and cpi'}, {'type': 'other', 'subtype': None, 'raw': 'bria-ots regimen and cpi expansion cohort'}]",True,breast cancer breast tumor cancer of breast cancer of the breast malignant tumor of breast tumors breast,breast
43,United States,Colorectal Neoplasms,DRUG: Botensilimab|DRUG: Balstilimab,2,OTHER,Weill Medical College of Cornell University,['antibody'],"[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'botensilimab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'balstilimab'}]",False,colorectal neoplasms,digestive
44,Netherlands,Resectable MMR-deficient Solid Tumors|Resectable MMR-proficient Solid Tumors,DRUG: botensilimab|DRUG: balstilimab,23,OTHER,The Netherlands Cancer Institute,['antibody'],"[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'botensilimab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'balstilimab'}]",False,resectable mmr deficient solid tumors resectable mmr proficient solid tumors,hematologic
45,France,Localized Resectable Tumor|MSI/dMMR,DRUG: Pembrolizumab,2,OTHER,Centre Leon Berard,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",False,localized resectable tumor msi dmmr,hematologic
46,"Australia, New Zealand",Advanced Biliary Tract Cancer|Neuroendocrine Tumors|Female Reproductive System Neoplasm|MSI-H Solid Malignant Tumor,DRUG: Ipilimumab|DRUG: Nivolumab,2,OTHER,Olivia Newton-John Cancer Research Institute,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}]",False,advanced biliary tract cancer neuroendocrine tumors female reproductive system neoplasm msi h solid malignant tumor,digestive
47,United States,Colorectal Neoplasms,DRUG: GRT-C901|DRUG: GRT-R902|DRUG: Atezolizumab|DRUG: Ipilimumab|DRUG: Fluoropyrimidine plus leucovorin|DRUG: Bevacizumab,23,INDUSTRY,Seattle Project Corporation,"['checkpoint inhibitor', 'other', 'antibody']","[{'type': 'other', 'subtype': None, 'raw': 'grt-c901'}, {'type': 'other', 'subtype': None, 'raw': 'grt-r902'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'atezolizumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}, {'type': 'other', 'subtype': None, 'raw': 'fluoropyrimidine plus leucovorin'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'bevacizumab'}]",True,colorectal neoplasms,digestive
48,United States,Advanced Malignant Solid Neoplasm|Metastatic Malignant Neoplasm in the Liver|Metastatic Malignant Neoplasm in the Lung|Metastatic Malignant Solid Neoplasm,OTHER: Hafnium Oxide-containing Nanoparticles NBTXR3|RADIATION: Radiation Therapy|RADIATION: Radiation Therapy,12,OTHER,M.D. Anderson Cancer Center,[],[],False,advanced malignant solid neoplasm metastatic malignant neoplasm in the liver metastatic malignant neoplasm in the lung metastatic malignant solid neoplasm,digestive
49,United States,Biliary Tract Cancers,DRUG: mBTC vax [0.3 - 2.4 mg peptide + 0.5 mg Poly-ICLC (Hiltonol)]|DRUG: Durvalumab|DRUG: Tremelimumab,1,OTHER,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,"['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'mbtc vax [0.3 - 2.4 peptide'}, {'type': 'other', 'subtype': None, 'raw': '0.5 poly-iclc ]'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'tremelimumab'}]",True,biliary tract cancers,digestive
50,Taiwan,Refractory Tumor|Solid Tumor,BIOLOGICAL: Dendritic Cell Vaccine|DRUG: Lenvatinib|DRUG: Nivolumab,1,OTHER,"National Health Research Institutes, Taiwan","['checkpoint inhibitor', 'vaccine', 'targeted therapy']","[{'type': 'vaccine', 'subtype': 'vaccine', 'raw': 'dendritic cell vaccine'}, {'type': 'targeted therapy', 'subtype': 'other', 'raw': 'lenvatinib'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}]",True,refractory tumor solid tumor,multiple
51,"Puerto Rico, United States",Anal Intraepithelial Neoplasia|High Grade Squamous Intraepithelial Neoplasia|HIV Positivity|Human Papillomavirus-16 Positive|Human Papillomavirus-18 Positive,DEVICE: Electroporation|BIOLOGICAL: HPV DNA Plasmids Therapeutic Vaccine VGX-3100|OTHER: Laboratory Biomarker Analysis,2,NETWORK,AIDS Malignancy Consortium,['vaccine'],"[{'type': 'vaccine', 'subtype': 'vaccine', 'raw': 'hpv dna plasmids therapeutic vaccine vgx-3100'}]",False,anal intraepithelial neoplasia high grade squamous intraepithelial neoplasia hiv positivity human papillomavirus 16 positive human papillomavirus 18 positive,digestive
52,China,Non-Small Cell Lung Cancer|Electroacupuncture|Immune Checkpoint Inhibitors,OTHER: Electroacupuncture combined with immunotherapy|DRUG: Zilongjin tablet combined with immunotherapy|DRUG: Immunotherapy,23,OTHER,Kong Fanming,"['other', 'immunotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'zilongjin tablet combined with immunotherapy'}, {'type': 'immunotherapy', 'subtype': 'unspecified', 'raw': 'immunotherapy'}]",True,non small cell lung cancer electroacupuncture immune checkpoint inhibitors,lung/thoracic
53,United States,Advanced Cancer,DRUG: personalized vaccine|DRUG: Pembrolizumab,1,OTHER,Ezra Cohen,"['checkpoint inhibitor', 'vaccine']","[{'type': 'vaccine', 'subtype': 'vaccine', 'raw': 'personalized vaccine'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",True,advanced cancer,multiple
54,"Australia, Belgium, Canada, France, Germany, Italy, Japan, Netherlands, Republic of, Singapore, Spain, Taiwan, United Kingdom, United States",Locally Advanced Solid Tumor|Metastatic Solid Tumor,DRUG: NVL-520,12,INDUSTRY,Nuvalent Inc.,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'nvl-520'}]",False,locally advanced solid tumor metastatic solid tumor,multiple
55,United States,Relapsed/Refractory Solid Tumors,DRUG: Lamivudine|DRUG: PD-L1 Blocker,12,OTHER,Thomas Marron,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'lamivudine'}, {'type': 'other', 'subtype': None, 'raw': 'pd-l1 blocker'}]",False,relapsed refractory solid tumors,multiple
56,United States,Nerve Sheath Tumors,DRUG: Nivolumab|DRUG: Ipilimumab,1,OTHER,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}]",False,nerve sheath tumors,other
57,"Australia, Belgium, Canada, France, Hungary, Italy, New Zealand, Republic of, Spain, United Kingdom, United States",Advanced Solid Tumors,DRUG: Monalizumab|DRUG: Durvalumab|DRUG: Cetuximab|DRUG: mFOLFOX6|DRUG: Bevacizumab,12,INDUSTRY,MedImmune LLC,"['checkpoint inhibitor', 'other', 'antibody']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'monalizumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'cetuximab'}, {'type': 'other', 'subtype': None, 'raw': 'mfolfox6'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'bevacizumab'}]",True,advanced solid tumors,multiple
58,United States,Oropharyngeal Cancer|Neck Cancer|Human Papillomavirus|HPV|Anal Cancer|Cervical Cancer|Penile Cancer|Vulvar Cancer|Vaginal Cancer|Colon Cancer,DRUG: Bintrafusp Alfa|DRUG: PDS01ADC|DRUG: Entinostat,12,NIH,National Cancer Institute (NCI),['other'],"[{'type': 'other', 'subtype': None, 'raw': 'bintrafusp alfa'}, {'type': 'other', 'subtype': None, 'raw': 'pds01adc'}, {'type': 'other', 'subtype': None, 'raw': 'entinostat'}]",False,oropharyngeal cancer neck cancer human papillomavirus hpv anal cancer cervical cancer penile cancer vulvar cancer vaginal cancer colon cancer,gynecologic
59,"Canada, United States",Advanced Malignant Solid Neoplasm|Metastatic Malignant Solid Neoplasm|Unresectable Malignant Solid Neoplasm,PROCEDURE: Biopsy Procedure|PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|DRUG: Copanlisib Hydrochloride|PROCEDURE: Echocardiography Test|BIOLOGICAL: Ipilimumab|BIOLOGICAL: Nivolumab|PROCEDURE: X-Ray Imaging,12,NIH,National Cancer Institute (NCI),"['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'copanlisib hydrochloride'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}]",True,advanced malignant solid neoplasm metastatic malignant solid neoplasm unresectable malignant solid neoplasm,multiple
60,United States,Gastroesophageal Junction (GEJ) Cancers|Advanced HNSCC,DRUG: N-803|DRUG: Pembrolizumab|BIOLOGICAL: PD-L1 t-haNK,2,NIH,National Cancer Institute (NCI),"['checkpoint inhibitor', 'cytokine therapy', 'cell therapy']","[{'type': 'cytokine therapy', 'subtype': 'IL-15 superagonist', 'raw': 'n-803'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'cell therapy', 'subtype': 'engineered T cell', 'raw': 'pd-l1 t-hank'}]",True,gastroesophageal junction cancers advanced hnscc,digestive
61,China,Head/Neck Neoplasm,DRUG: PD1/PDL1/CTLA4 inhibitors,23,OTHER,Second Affiliated Hospital of Guangzhou Medical University,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'pd1'}, {'type': 'other', 'subtype': None, 'raw': 'pdl1'}, {'type': 'other', 'subtype': None, 'raw': 'ctla4 inhibitors'}]",False,head neck neoplasm,head/neck
62,China,Advanced Breast Cancer|Advanced Liver Cancer,BIOLOGICAL: Blood-stage infection of P.vivax,12,INDUSTRY,"CAS Lamvac Biotech Co., Ltd.",['other'],"[{'type': 'other', 'subtype': None, 'raw': 'blood-stage infection of p.vivax'}]",False,advanced breast cancer advanced liver cancer,digestive
63,China,Small-cell Lung Cancer,DRUG: hypofractionated radiotherapy with immunotherapy,12,OTHER_GOV,Anhui Provincial Hospital,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'hypofractionated radiotherapy with immunotherapy'}]",False,small cell lung cancer,lung/thoracic
64,France,Advanced Solid Tumors|Metastatic Solid Tumors,DRUG: NP137|DRUG: anti-PD-1/PD-L1,2,OTHER,Centre Leon Berard,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'np137'}, {'type': 'other', 'subtype': None, 'raw': 'anti-pd-1'}, {'type': 'other', 'subtype': None, 'raw': 'pd-l1'}]",False,advanced solid tumors metastatic solid tumors,multiple
65,Australia,Solid Tumor,BIOLOGICAL: Radvax,1,INDUSTRY,Vaxine Pty Ltd,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'radvax'}]",False,solid tumor,multiple
66,United States,Recurrent Prostate Cancer,DRUG: ADXS-504,1,OTHER,Mark Stein,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'adxs-504'}]",False,recurrent prostate cancer,genitourinary
67,China,Colon Neoplasm,DRUG: Oxaliplatin|DRUG: Capecitabine|DRUG: Anti-PD-L1 Monoclonal Antibody|DRUG: Clostridium butyricum|PROCEDURE: Colectomy,2,OTHER,"Second Affiliated Hospital, School of Medicine, Zhejiang University","['other', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'oxaliplatin'}, {'type': 'chemotherapy', 'subtype': 'fluoropyrimidine', 'raw': 'capecitabine'}, {'type': 'other', 'subtype': None, 'raw': 'anti-pd-l1 monoclonal antibody'}, {'type': 'other', 'subtype': None, 'raw': 'clostridium butyricum'}]",True,colon neoplasm,digestive
68,United States,Ovarian Cancer|Ovarian Neoplasms,BIOLOGICAL: Vigil|OTHER: Placebo,2,INDUSTRY,"Gradalis, Inc.",['other'],"[{'type': 'other', 'subtype': None, 'raw': 'vigil'}]",False,ovarian cancer ovarian neoplasms,gynecologic
69,"China, France, Japan, Puerto Rico, Republic of, Spain, United States",Advanced Solid Tumors,DRUG: ASP1570|DRUG: pembrolizumab|DRUG: Trifluridine + Tipiracil|DRUG: Bevacizumab|DRUG: Docetaxel,12,INDUSTRY,"Astellas Pharma Global Development, Inc.","['checkpoint inhibitor', 'other', 'antibody', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'asp1570'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'other', 'subtype': None, 'raw': 'trifluridine'}, {'type': 'other', 'subtype': None, 'raw': 'tipiracil'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'bevacizumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'docetaxel'}]",True,advanced solid tumors,multiple
70,China,Advanced Solid Tumor,BIOLOGICAL: Adebrelimab|BIOLOGICAL: SHR-1802|DRUG: Carboplatin/Cisplatin|DRUG: Paclitaxel/Nab-Paclitaxel/Pemetrexed,12,INDUSTRY,"Shanghai Hengrui Pharmaceutical Co., Ltd.","['other', 'antibody', 'chemotherapy']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'adebrelimab'}, {'type': 'other', 'subtype': None, 'raw': 'shr-1802'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'nab-paclitaxel'}, {'type': 'chemotherapy', 'subtype': 'antifolate', 'raw': 'pemetrexed'}]",True,advanced solid tumor,multiple
71,Spain,NSCLC|Pancoast Tumor,DRUG: Carboplatin|DRUG: Paclitaxel|DRUG: Nivolumab,2,OTHER,Fundación GECP,"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}]",True,nsclc pancoast tumor,lung/thoracic
72,"Spain, United States",Advanced Solid Tumor,BIOLOGICAL: Nemvaleukin alfa|BIOLOGICAL: Pembrolizumab,12,INDUSTRY,"Mural Oncology, Inc","['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'nemvaleukin alfa'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",True,advanced solid tumor,multiple
73,China,Lung Cancers|Radiation Treatment for Tumors,RADIATION: Spatially Fractionated Radiation Therapy Combined With Low-dose Radiotherapy|RADIATION: Conventional fractionated radiotherapy,2,OTHER,Tianjin Medical University Cancer Institute and Hospital,[],[],False,lung cancers radiation treatment for tumors,lung/thoracic
74,"Australia, Belgium, Canada, France, Germany, Italy, Japan, Netherlands, Republic of, Singapore, Spain, Switzerland, Taiwan, United Kingdom, United States",Locally Advanced Solid Tumor|Metastatic Solid Tumor,DRUG: NVL-655,12,INDUSTRY,Nuvalent Inc.,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'nvl-655'}]",False,locally advanced solid tumor metastatic solid tumor,multiple
75,China,Stomach Neoplasms|Digestive System Neoplasms|Neoplasms|Digestive System Diseases|Stomach Diseases|Neoplasms by Site,DRUG: Camrelizumab|DRUG: SOX|PROCEDURE: Surgery,2,OTHER,The Second Affiliated Hospital of Fujian Medical University,"['checkpoint inhibitor', 'other']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'camrelizumab'}, {'type': 'other', 'subtype': None, 'raw': 'sox'}]",True,stomach neoplasms digestive system neoplasms neoplasms digestive system diseases stomach diseases neoplasms by site,digestive
76,,Breast Cancer,BIOLOGICAL: DC-CIK Immunotherapy|DRUG: Capecitabine Monotherapy,2,OTHER,The First People's Hospital of Changzhou,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'dc-cik immunotherapy'}, {'type': 'other', 'subtype': None, 'raw': 'capecitabine monotherapy'}]",False,breast cancer,breast
77,China,"Lung Cancer|Liver Cancer|Solid Tumor, Adult",DEVICE: IRSW-MIM,23,OTHER,Second Affiliated Hospital of Guangzhou Medical University,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'device: irsw-mim'}]",False,lung cancer liver cancer solid tumor adult,digestive
78,United States,Metastatic Malignant Neoplasm in the Liver|Metastatic Uveal Melanoma,BIOLOGICAL: Aldesleukin|BIOLOGICAL: Autologous CD8+ SLC45A2-specific T Lymphocytes|DRUG: Cyclophosphamide|BIOLOGICAL: Ipilimumab,1,OTHER,M.D. Anderson Cancer Center,"['checkpoint inhibitor', 'other', 'cytokine therapy', 'chemotherapy']","[{'type': 'cytokine therapy', 'subtype': 'IL-2', 'raw': 'aldesleukin'}, {'type': 'other', 'subtype': None, 'raw': 'autologous cd8'}, {'type': 'other', 'subtype': None, 'raw': 'slc45a2-specific t lymphocytes'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}]",True,metastatic malignant neoplasm in the liver metastatic uveal melanoma,digestive
79,United States,"Medulloblastoma, Childhood|Atypical Teratoid/Rhabdoid Tumor of CNS|Embryonal Tumor With Multilayered Rosettes|Pineoblastoma|Embryonal Tumor of CNS",BIOLOGICAL: Multi-tumor antigen specific cytotoxic T lymphocytes (TSA-T) directed against proteogenomically determined personalized tumor-specific antigens (TSA),1,OTHER,Children's National Research Institute,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'multi-tumor antigen specific cytotoxic t lymphocytes directed against proteogenomically determined personalized tumor-specific antigens'}]",False,medulloblastoma childhood atypical teratoid rhabdoid tumor of cns embryonal tumor with multilayered rosettes pineoblastoma embryonal tumor of cns,brain/CNS
80,"Australia, Canada, France, Japan, Republic of, Spain, United States",Advanced Solid Tumors Cancer,DRUG: ABBV-927|DRUG: ABBV-927|DRUG: ABBV-181,1,INDUSTRY,AbbVie,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'abbv-927'}, {'type': 'other', 'subtype': None, 'raw': 'abbv-927'}, {'type': 'other', 'subtype': None, 'raw': 'abbv-181'}]",False,advanced solid tumors cancer,multiple
81,France,Hematological Malignancies|Regulatory T Cell Depletion|Relapse,PROCEDURE: T-reg depleted DLI|PROCEDURE: Standard DLI,3,OTHER,Assistance Publique - Hôpitaux de Paris,[],[],False,hematological malignancies regulatory t cell depletion relapse,hematologic
82,Brazil,Uterine Cervical Neoplasms,DRUG: Nivolumab 40 mg in 4 ml Injection|DRUG: Ipilimumab 200 MG in 40 ML Injection|RADIATION: Chemoradiation,2,OTHER,Hospital Israelita Albert Einstein,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab 40 in 4 injection'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab 200 in 40 injection'}]",False,uterine cervical neoplasms,gynecologic
83,United States,Advanced Malignant Skin Neoplasm|Metastatic Malignant Skin Neoplasm,DRUG: Atezolizumab|DRUG: Avelumab|BIOLOGICAL: Cemiplimab|BIOLOGICAL: Durvalumab|BIOLOGICAL: Nivolumab|BIOLOGICAL: Pembrolizumab|OTHER: Quality-of-Life Assessment|OTHER: Short-Term Fasting,1,OTHER,University of Southern California,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'atezolizumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'avelumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'cemiplimab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",False,advanced malignant skin neoplasm metastatic malignant skin neoplasm,skin
84,Canada,Metastatic Tumor,RADIATION: Palliative Radiotherapy|DRUG: Chemotherapy|DRUG: Hormone therapy|DRUG: Immunotherapy|DRUG: Targeted Systemic Therapy|OTHER: Observation|RADIATION: Stereotactic Ablative Radiotherapy|PROCEDURE: Surgery|OTHER: Radiofrequency Therapy (RFA)|RADIATION: Fractionated Radiation,3,OTHER,David Palma,"['other', 'chemotherapy', 'immunotherapy']","[{'type': 'chemotherapy', 'subtype': 'unspecified', 'raw': 'chemotherapy'}, {'type': 'other', 'subtype': None, 'raw': 'hormone therapy'}, {'type': 'immunotherapy', 'subtype': 'unspecified', 'raw': 'immunotherapy'}, {'type': 'other', 'subtype': None, 'raw': 'targeted systemic therapy'}]",True,metastatic tumor,multiple
85,China,Nasopharyngeal Neoplasms|PD-1 Inhibitor|Induction Therapy|Complete Response|Chemotherapy,DRUG: Two-cycle induction chemotherapy + immunotherapy|DRUG: Three-cycle induction chemotherapy + immunotherapy,2,OTHER,The First Affiliated Hospital of Xiamen University,"['other', 'immunotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'two-cycle induction chemotherapy'}, {'type': 'immunotherapy', 'subtype': 'unspecified', 'raw': 'immunotherapy'}, {'type': 'other', 'subtype': None, 'raw': 'three-cycle induction chemotherapy'}, {'type': 'immunotherapy', 'subtype': 'unspecified', 'raw': 'immunotherapy'}]",True,nasopharyngeal neoplasms pd 1 inhibitor induction therapy complete response chemotherapy,head/neck
86,"Puerto Rico, United States",Clear Cell Renal Cell Carcinoma|Metastatic Malignant Neoplasm in the Bone|Metastatic Malignant Neoplasm in the Lymph Nodes|Metastatic Malignant Neoplasm in the Soft Tissue|Metastatic Malignant Neoplasm in the Viscera|Rhabdoid Tumor of the Kidney|Sarcomatoid Renal Cell Carcinoma|Stage III Renal Cell Cancer AJCC v8|Stage IV Renal Cell Cancer AJCC v8,PROCEDURE: Biospecimen Collection|PROCEDURE: Bone Scan|DRUG: Cabozantinib|PROCEDURE: Computed Tomography|BIOLOGICAL: Ipilimumab|PROCEDURE: Magnetic Resonance Imaging|BIOLOGICAL: Nivolumab|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration,3,NIH,National Cancer Institute (NCI),"['checkpoint inhibitor', 'targeted therapy']","[{'type': 'targeted therapy', 'subtype': 'other', 'raw': 'cabozantinib'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}]",True,clear cell renal cell carcinoma metastatic malignant neoplasm in the bone metastatic malignant neoplasm in the lymph nodes metastatic malignant neoplasm in the soft tissue metastatic malignant neoplasm in the viscera rhabdoid tumor of the kidney sarcomatoid renal cell carcinoma stage iii renal cell cancer ajcc v8 stage iv renal cell cancer ajcc v8,genitourinary
87,China,Relapsed/Refractory Solid Tumors,BIOLOGICAL: NKG2D-CAR-NK92 cells,1,OTHER,Xinxiang medical university,['cell therapy'],"[{'type': 'cell therapy', 'subtype': 'other', 'raw': 'nkg2d-car-nk92 cells'}]",False,relapsed refractory solid tumors,multiple
88,"Estonia, Iceland, Netherlands, Norway, Sweden",Small-cell Lung Cancer,PROCEDURE: Thoracic radiotherapy|DRUG: Chemo-immunotherapy,3,OTHER,Norwegian University of Science and Technology,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'chemo-immunotherapy'}]",False,small cell lung cancer,lung/thoracic
89,"Germany, Italy",Non Small Cell Lung Cancer|Head and Neck Squamous Cell Carcinoma|Melanoma|Urothelial Carcinoma,RADIATION: Carbon Ion Therapy|DRUG: Immunotherapy (Pembrolizumab),2,OTHER,CNAO National Center of Oncological Hadrontherapy,['immunotherapy'],"[{'type': 'immunotherapy', 'subtype': 'unspecified', 'raw': 'immunotherapy'}]",False,non small cell lung cancer head and neck squamous cell carcinoma melanoma urothelial carcinoma,genitourinary
90,Republic of,Kidney Neoplasm,RADIATION: SBRT(Stereotatic Body Radiation Therapy),3,OTHER,Samsung Medical Center,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'radiation: sbrt'}]",False,kidney neoplasm,genitourinary
91,United States,Solid Tumor,DRUG: ALG.APV-527,12,INDUSTRY,Aptevo Therapeutics,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'alg.apv-527'}]",False,solid tumor,multiple
92,United States,"Tumor, Solid",DRUG: Durvalumab and Tremelimumab,2,OTHER,"John L. Villano, MD, PhD",['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab and tremelimumab'}]",False,tumor solid,other
93,United States,"Central Nervous System Tumor, Pediatric|Glioma|Ependymoma|Medulloblastoma|Germ Cell Tumor|Atypical Teratoid/Rhabdoid Tumor|Primitive Neuroectodermal Tumor|Choroid Plexus Carcinoma|Pineoblastoma",BIOLOGICAL: HER2-specific chimeric antigen receptor (CAR) T cell,1,OTHER,Seattle Children's Hospital,['cell therapy'],"[{'type': 'cell therapy', 'subtype': 'other', 'raw': 'her2-specific chimeric antigen receptor t cell'}]",False,central nervous system tumor pediatric glioma ependymoma medulloblastoma germ cell tumor atypical teratoid rhabdoid tumor primitive neuroectodermal tumor choroid plexus carcinoma pineoblastoma,brain/CNS
94,China,Head and Neck Tumors,"DRUG: Tislelizumab, Paclitaxel (albumin-bound type), Cisplatin, 5-FU",2,OTHER,The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School,"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'tislelizumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}, {'type': 'chemotherapy', 'subtype': 'antimetabolite', 'raw': '5-fu'}]",True,head and neck tumors,head/neck
95,United States,Metastatic Castration-Resistant Prostate Carcinoma|Metastatic Malignant Neoplasm in the Bone|Metastatic Malignant Neoplasm in the Lymph Nodes|Stage IVB Prostate Cancer AJCC v8,DRUG: Avelumab|PROCEDURE: Biospecimen Collection|PROCEDURE: Bone Scan|PROCEDURE: Computed Tomography|PROCEDURE: Magnetic Resonance Imaging|DRUG: Peposertib|OTHER: Questionnaire Administration|RADIATION: Radium Ra 223 Dichloride,12,NIH,National Cancer Institute (NCI),"['checkpoint inhibitor', 'other']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'avelumab'}, {'type': 'other', 'subtype': None, 'raw': 'peposertib'}]",True,metastatic castration resistant prostate carcinoma metastatic malignant neoplasm in the bone metastatic malignant neoplasm in the lymph nodes stage ivb prostate cancer ajcc v8,genitourinary
96,United States,Liver Cancer|Rhabdomyosarcoma|Malignant Rhabdoid Tumor|Liposarcoma|Wilms Tumor|Yolk Sac Tumor,GENETIC: AGAR T cells,1,OTHER,Baylor College of Medicine,['cell therapy'],"[{'type': 'cell therapy', 'subtype': 'other', 'raw': 'genetic: agar t cells'}]",False,liver cancer rhabdomyosarcoma malignant rhabdoid tumor liposarcoma wilms tumor yolk sac tumor,digestive
97,"Belgium, Republic of, Spain, United States","Solid Tumor, Adult|Metastatic Solid Tumor|Refractory Cancer",DRUG: ADU-1805|DRUG: Pembrolizumab,1,INDUSTRY,Sairopa B.V.,"['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'adu-1805'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",True,solid tumor adult metastatic solid tumor refractory cancer,multiple
98,United States,Brain Tumor Adult,BIOLOGICAL: DRI cell therapy,1,OTHER,University of Alabama at Birmingham,['cell therapy'],"[{'type': 'cell therapy', 'subtype': 'other', 'raw': 'dri cell therapy'}]",False,brain tumor adult,brain/CNS
99,"Republic of, Spain, Taiwan, United States",Neoplasms,DRUG: TSR-022|DRUG: Nivolumab|DRUG: TSR-042|DRUG: TSR-033|DRUG: Docetaxel|DRUG: Pemetrexed|DRUG: Cisplatin|DRUG: Carboplatin,1,INDUSTRY,"Tesaro, Inc.","['checkpoint inhibitor', 'other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'tsr-022'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'other', 'subtype': None, 'raw': 'tsr-042'}, {'type': 'other', 'subtype': None, 'raw': 'tsr-033'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'docetaxel'}, {'type': 'chemotherapy', 'subtype': 'antifolate', 'raw': 'pemetrexed'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}]",True,neoplasms,other
100,"Argentina, Brazil, Canada, Czechia, Denmark, France, Italy, Mexico, Poland, Republic of, Spain, United Kingdom, United States",Neoplasms,BIOLOGICAL: Dostarlimab,1,INDUSTRY,"Tesaro, Inc.",['antibody'],"[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'dostarlimab'}]",False,neoplasms,other
101,United States,"Head and Neck Squamous Cell Carcinoma|Cancer|Cancer of Head and Neck|Cancer, Advanced|Cancer, Metastatic|Tumor|Tumor Recurrence|Tumor Neck|Tumor Metastasis|Oral Cancer|Oropharyngeal Cancer|Oropharynx Cancer|Oropharynx Cancer, Stage III|Oropharynx Cancer, Recurrent|Oropharynx Cancer, Metastatic",DRUG: Pembrolizumab|RADIATION: Radiation therapy|DRUG: Cisplatin,2,OTHER,"Loren Mell, MD","['checkpoint inhibitor', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}]",True,head and neck squamous cell carcinoma cancer cancer of head and neck cancer advanced cancer metastatic tumor tumor recurrence tumor neck tumor metastasis oral cancer oropharyngeal cancer oropharynx cancer oropharynx cancer stage iii oropharynx cancer recurrent oropharynx cancer metastatic,head/neck
102,China,Biliary Tract Cancer|Immune Checkpoint Inhibitor|Predictive Cancer Model,DRUG: Immune Checkpoint Inhibitors,12,OTHER,Peking Union Medical College Hospital,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'immune checkpoint inhibitors'}]",False,biliary tract cancer immune checkpoint inhibitor predictive cancer model,digestive
103,China,"Cervical Cancer|Neoplasm Recurrence, Local|Oligometastatic",DRUG: Paclitaxel and Cisplatin/ Carboplatin|DRUG: Iparomlimab and Tuvonralimab|RADIATION: Radiotherapy,2,OTHER,Shandong Cancer Hospital and Institute,"['antibody', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel and cisplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'iparomlimab and tuvonralimab'}]",True,cervical cancer neoplasm recurrence local oligometastatic,gynecologic
104,United States,Cervical Cancer|Cervical Cancer Recurrent|Cervical Cancer Metastatic,RADIATION: Stereotactic body radiation therapy (SBRT)|DRUG: Atezolizumab,2,OTHER,H. Lee Moffitt Cancer Center and Research Institute,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'atezolizumab'}]",False,cervical cancer cervical cancer recurrent cervical cancer metastatic,gynecologic
105,United States,Liver Cancer|Rhabdomyosarcoma|Malignant Rhabdoid Tumor|Liposarcoma|Wilms Tumor|Yolk Sac Tumor,GENETIC: CARE T cells|DRUG: Cytoxan|DRUG: Fludara,1,OTHER,Baylor College of Medicine,"['other', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'alkylating agent', 'raw': 'cytoxan'}, {'type': 'other', 'subtype': None, 'raw': 'fludara'}]",True,liver cancer rhabdomyosarcoma malignant rhabdoid tumor liposarcoma wilms tumor yolk sac tumor,digestive
106,United Kingdom,Head and Neck Cancer,OTHER: Intra-tumoral T4 immunotherapy,1,OTHER,King's College London,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'other: intra-tumoral t4 immunotherapy'}]",False,head and neck cancer,head/neck
107,United States,Breast Cancer|Breast Neoplasms,DRUG: Pembrolizumab|DRUG: IRX 2,2,OTHER,Providence Health & Services,"['checkpoint inhibitor', 'other']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'other', 'subtype': None, 'raw': 'irx 2'}]",True,breast cancer breast neoplasms,breast
108,United States,Breast Cancer|Breast Neoplasm|Metastatic Breast Cancer|Breast Cancer Metastatic,BIOLOGICAL: SV-BR-1-GM|DRUG: Low dose cyclophosphamide|DRUG: Interferon Inoculation|DRUG: retifanlimab,12,INDUSTRY,BriaCell Therapeutics Corporation,"['other', 'antibody', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'sv-br-1-gm'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'low dose cyclophosphamide'}, {'type': 'other', 'subtype': None, 'raw': 'interferon inoculation'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'retifanlimab'}]",True,breast cancer breast neoplasm metastatic breast cancer breast cancer metastatic,breast
109,United States,Liver Cell Carcinoma|Solid Tumor|Wilms Tumor|Malignant Rhabdoid Tumor|Yolk Sac Tumor|Rhabdomyosarcoma|Liposarcoma|Embryonal Sarcoma of the Liver,GENETIC: CATCH T cells,1,OTHER,Baylor College of Medicine,['cell therapy'],"[{'type': 'cell therapy', 'subtype': 'other', 'raw': 'genetic: catch t cells'}]",False,liver cell carcinoma solid tumor wilms tumor malignant rhabdoid tumor yolk sac tumor rhabdomyosarcoma liposarcoma embryonal sarcoma of the liver,digestive
110,China,Colorectal Cancer|Colon Cancer|Rectum Cancer,BIOLOGICAL: Tumor Infiltrating Lymphocytes (TIL)|DRUG: Cyclophosphamide|DRUG: Fludarabine|DRUG: Interleukin-2|DRUG: Pembrolizumab,12,OTHER,Essen Biotech,"['checkpoint inhibitor', 'cytokine therapy', 'chemotherapy', 'cell therapy']","[{'type': 'cell therapy', 'subtype': 'TILs', 'raw': 'tumor infiltrating lymphocytes'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide'}, {'type': 'chemotherapy', 'subtype': 'purine analog', 'raw': 'fludarabine'}, {'type': 'cytokine therapy', 'subtype': 'IL-2', 'raw': 'interleukin-2'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",True,colorectal cancer colon cancer rectum cancer,digestive
111,China,Esophageal Squamous Cell Carcinoma|Unresectable Locally Advanced Esophageal Cancer,DRUG: PD-1inhibitor|DRUG: nab-paclitaxel + cisplatin|RADIATION: Radiotherapy,12,OTHER,Shanghai Chest Hospital,"['other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'pd-1inhibitor'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'nab-paclitaxel'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}]",True,esophageal squamous cell carcinoma unresectable locally advanced esophageal cancer,digestive
112,China,Non Small Cell Lung Cancer,RADIATION: radiotherapy|DRUG: Chemotherapy + immunotherapy,2,OTHER,Hunan Province Tumor Hospital,"['chemotherapy', 'immunotherapy']","[{'type': 'chemotherapy', 'subtype': 'unspecified', 'raw': 'chemotherapy'}, {'type': 'immunotherapy', 'subtype': 'unspecified', 'raw': 'immunotherapy'}]",True,non small cell lung cancer,lung/thoracic
113,China,Non-Small Cell Lung Cancer,RADIATION: hypofractionated radiotherapy with immunotherapy,2,OTHER,Peking University Cancer Hospital & Institute,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'radiation: hypofractionated radiotherapy with immunotherapy'}]",False,non small cell lung cancer,lung/thoracic
114,China,Esophageal Neoplasm Metastatic|Esophageal Cancer Stage IVb,DRUG: TP (Paclitaxel with cisplatin or carboplatin) or PF (Fluoropyrimidine with cisplatin or carboplatin) regimen depended on investigator's choice.|BIOLOGICAL: PD-1 inhibitor|RADIATION: Consolidation Radiation|RADIATION: Salvage Radiation,2,OTHER,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': ""tp or pf regimen depended on investigator's choice.""}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'pd-1 inhibitor'}]",True,esophageal neoplasm metastatic esophageal cancer stage ivb,digestive
115,"Australia, China, Spain, United States",Advanced Solid Tumors,DRUG: BGB-30813|DRUG: Tislelizumab,1,INDUSTRY,BeiGene,"['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'bgb-30813'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'tislelizumab'}]",True,advanced solid tumors,multiple
116,United States,Head and Neck Neoplasm,RADIATION: 50 Gy Radiation Therapy|RADIATION: 55 Gy Radiation Therapy|RADIATION: 60 Gy Radiation Therapy|DRUG: Atezolizumab,1,OTHER,Medical College of Wisconsin,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'atezolizumab'}]",False,head and neck neoplasm,head/neck
117,Belgium,Advanced Solid Tumors,DRUG: EOS301984|DRUG: Anti-PD-1 monoclonal antibody,1,INDUSTRY,iTeos Therapeutics,"['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'eos301984'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'anti-pd-1 monoclonal antibody'}]",True,advanced solid tumors,multiple
118,Thailand,Cholangiocarcinoma|Neuroblastoma,DRUG: cytokine induced killer cells,12,OTHER,Siriraj Hospital,['cell therapy'],"[{'type': 'cell therapy', 'subtype': 'other', 'raw': 'cytokine induced killer cells'}]",False,cholangiocarcinoma neuroblastoma,other
119,Singapore,Advanced Solid Tumor|Metastatic Solid Tumor,DRUG: Intramuscular ACM-CpG Monotherapy (Escalation)|DRUG: Intramuscular ACM-CpG Monotherapy (Expansion),1,OTHER,"National Cancer Centre, Singapore",['other'],"[{'type': 'other', 'subtype': None, 'raw': 'intramuscular acm-cpg monotherapy'}, {'type': 'other', 'subtype': None, 'raw': 'intramuscular acm-cpg monotherapy'}]",False,advanced solid tumor metastatic solid tumor,multiple
120,China,Advanced Gastric Cancer|Advanced Colorectal Cancer|Advanced Ovarian Cancer|Peritoneal Metastasis,RADIATION: Low-Dose Radiation(LDRT) + Stereotactic body radiotherapy (SBRT)|DRUG: Cadonilimab,12,OTHER,Zhang Tao,['antibody'],"[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'cadonilimab'}]",False,advanced gastric cancer advanced colorectal cancer advanced ovarian cancer peritoneal metastasis,gynecologic
121,Canada,Esophageal Cancer,DRUG: Adjuvant Immunoradiotherapy (ARM1) and Adjuvant Immunotherapy (ARM1B)|DRUG: Adjuvant chemoradiotherapy,1,OTHER,University of Manitoba,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'adjuvant immunoradiotherapy and adjuvant immunotherapy'}, {'type': 'other', 'subtype': None, 'raw': 'adjuvant chemoradiotherapy'}]",False,esophageal cancer,digestive
122,China,"Solid Tumor, Adult",BIOLOGICAL: Neoantigen mRNA Vaccine,1,OTHER,Second Affiliated Hospital of Guangzhou Medical University,['vaccine'],"[{'type': 'vaccine', 'subtype': 'mRNA', 'raw': 'neoantigen mrna vaccine'}]",False,solid tumor adult,multiple
123,"France, Greece, Spain, United Kingdom, United States",Advanced Solid Tumor,BIOLOGICAL: RP3|BIOLOGICAL: Nivolumab,1,INDUSTRY,Replimune Inc.,"['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'rp3'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}]",True,advanced solid tumor,multiple
124,China,"Solid Tumor, Adult",BIOLOGICAL: Neoantigen Polypeptide Vaccine,1,OTHER,Second Affiliated Hospital of Guangzhou Medical University,['vaccine'],"[{'type': 'vaccine', 'subtype': 'vaccine', 'raw': 'neoantigen polypeptide vaccine'}]",False,solid tumor adult,multiple
125,China,Esophageal Neoplasms|Esophageal Diseases|Digestive System Neoplasms,DRUG: camrelizumab|DRUG: Paclitaxel drugs|DRUG: Platinum drug|RADIATION: Radiation,2,OTHER_GOV,Fujian Cancer Hospital,"['checkpoint inhibitor', 'other', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'camrelizumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel drugs'}, {'type': 'other', 'subtype': None, 'raw': 'platinum drug'}]",True,esophageal neoplasms esophageal diseases digestive system neoplasms,digestive
126,France,HCC - Hepatocellular Carcinoma|Metastatic Cancer|Metastatic Tumor,DRUG: Ipilimumab Injection|DRUG: Atezolizumab Injection|DRUG: Bevacizumab,23,OTHER,Federation Francophone de Cancerologie Digestive,"['checkpoint inhibitor', 'antibody']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab injection'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'atezolizumab injection'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'bevacizumab'}]",True,hcc hepatocellular carcinoma metastatic cancer metastatic tumor,digestive
127,"Belgium, Spain","Neoplasms, Colon",BIOLOGICAL: Dostarlimab|DRUG: CAPEOX,2,INDUSTRY,GlaxoSmithKline,"['other', 'antibody']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'dostarlimab'}, {'type': 'other', 'subtype': None, 'raw': 'capeox'}]",True,neoplasms colon,digestive
128,United Kingdom,Metastatic Esophageal Cancer|Metastatic Gastric Cancer,DRUG: Atezolizumab,12,OTHER,Royal Marsden NHS Foundation Trust,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'atezolizumab'}]",False,metastatic esophageal cancer metastatic gastric cancer,digestive
129,United States,Malignant Brain Neoplasm|Recurrent Malignant Brain Neoplasm|Refractory Malignant Brain Neoplasm,DRUG: Cyclophosphamide|DRUG: Fludarabine|BIOLOGICAL: IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes,1,OTHER,City of Hope Medical Center,"['other', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide'}, {'type': 'chemotherapy', 'subtype': 'purine analog', 'raw': 'fludarabine'}, {'type': 'other', 'subtype': None, 'raw': 'il13ralpha2-specific hinge-optimized 41bb-co-stimulatory car truncated cd19-expressing autologous t-lymphocytes'}]",True,malignant brain neoplasm recurrent malignant brain neoplasm refractory malignant brain neoplasm,brain/CNS
130,France,Refractory or Recurrent Solid Tumor,DRUG: Spartalizumab in Pediatric cohort|DRUG: Low-dose Pazopanib in Pediatric Cohort|DRUG: Spartalizumab in Adult cohort|DRUG: Low-dose Pazopanib in Adult Cohort,12,OTHER,"University Hospital, Bordeaux",['other'],"[{'type': 'other', 'subtype': None, 'raw': 'spartalizumab in pediatric cohort'}, {'type': 'other', 'subtype': None, 'raw': 'low-dose pazopanib in pediatric cohort'}, {'type': 'other', 'subtype': None, 'raw': 'spartalizumab in adult cohort'}, {'type': 'other', 'subtype': None, 'raw': 'low-dose pazopanib in adult cohort'}]",False,refractory or recurrent solid tumor,multiple
131,China,Cancer,DRUG: research drug in combination with Toripalimab|DRUG: Toripalimab,12,OTHER,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'research drug in combination with toripalimab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'toripalimab'}]",False,cancer,other
132,France,Ovarian Cancer,DRUG: ARM A Durvalumab/chemotherapy association|DRUG: ARM B Durvalumab/Tremelimumab/chemotherapy association,12,OTHER,ARCAGY/ GINECO GROUP,"['checkpoint inhibitor', 'other']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'arm a durvalumab'}, {'type': 'other', 'subtype': None, 'raw': 'chemotherapy association'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'arm b durvalumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'tremelimumab'}, {'type': 'other', 'subtype': None, 'raw': 'chemotherapy association'}]",True,ovarian cancer,gynecologic
133,"Australia, United States",Advanced Solid Tumor,BIOLOGICAL: BNT317 DL1|BIOLOGICAL: BNT317 DL2|BIOLOGICAL: BNT317 DL3|BIOLOGICAL: BNT317 DL4|BIOLOGICAL: BNT317 DL5 (intermediate)|BIOLOGICAL: BNT317 DL6 (intermediate)|BIOLOGICAL: BNT317 DL7 (additional),1,INDUSTRY,BioNTech SE,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'bnt317 dl1'}, {'type': 'other', 'subtype': None, 'raw': 'bnt317 dl2'}, {'type': 'other', 'subtype': None, 'raw': 'bnt317 dl3'}, {'type': 'other', 'subtype': None, 'raw': 'bnt317 dl4'}, {'type': 'other', 'subtype': None, 'raw': 'bnt317 dl5'}, {'type': 'other', 'subtype': None, 'raw': 'bnt317 dl6'}, {'type': 'other', 'subtype': None, 'raw': 'bnt317 dl7'}]",False,advanced solid tumor,multiple
134,Netherlands,"Prostatic Neoplasms, Castration-Resistant",BIOLOGICAL: Ipilimumab|BIOLOGICAL: Nivolumab,2,OTHER,Radboud University Medical Center,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}]",False,prostatic neoplasms castration resistant,genitourinary
135,Canada,Breast Cancer|Lung Cancer|Gastrointestinal Cancer|Genitourinary Cancer|Gynecologic Cancer|Sarcoma|Unknown Primary Tumors|Head and Neck Cancer|Skin Cancer,DRUG: Atezolizumab,2,OTHER,British Columbia Cancer Agency,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'atezolizumab'}]",False,breast cancer lung cancer gastrointestinal cancer genitourinary cancer gynecologic cancer sarcoma unknown primary tumors head and neck cancer skin cancer,gynecologic
136,United States,Pediatric Solid Tumor|Germ Cell Tumor|Retinoblastoma|Hepatoblastoma|Wilms Tumor|Rhabdoid Tumor|Carcinoma|Osteosarcoma|Ewing Sarcoma|Rhabdomyosarcoma|Synovial Sarcoma|Clear Cell Sarcoma|Malignant Peripheral Nerve Sheath Tumors|Desmoplastic Small Round Cell Tumor|Soft Tissue Sarcoma|Neuroblastoma|Melanoma,BIOLOGICAL: second generation 4-1BBζ B7H3-EGFRt-DHFR|BIOLOGICAL: second generation 4-1BBζ B7H3-EGFRt-DHFR(selected) and a second generation 4-1BBζ CD19-Her2tG|DRUG: Pembrolizumab,1,OTHER,Seattle Children's Hospital,"['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'second generation 4-1bbζ b7h3-egfrt-dhfr'}, {'type': 'other', 'subtype': None, 'raw': 'second generation 4-1bbζ b7h3-egfrt-dhfr and a second generation 4-1bbζ cd19-her2tg'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",True,pediatric solid tumor germ cell tumor retinoblastoma hepatoblastoma wilms tumor rhabdoid tumor carcinoma osteosarcoma ewing sarcoma rhabdomyosarcoma synovial sarcoma clear cell sarcoma malignant peripheral nerve sheath tumors desmoplastic small round cell tumor soft tissue sarcoma neuroblastoma melanoma,skin
137,Finland,Solid Tumor,BIOLOGICAL: TILT-123,1,INDUSTRY,TILT Biotherapeutics Ltd.,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'tilt-123'}]",False,solid tumor,multiple
138,United States,"Breast Cancer Female|Breast Cancer, Male|Breast Cancer Stage I|Breast Cancer Stage II|Breast Cancer Stage III|Residual Disease|HER2-positive Breast Cancer|HER2 Positive Breast Carcinoma",BIOLOGICAL: DC1 Vaccine|BIOLOGICAL: WOKVAC Vaccine,2,OTHER,H. Lee Moffitt Cancer Center and Research Institute,['vaccine'],"[{'type': 'vaccine', 'subtype': 'vaccine', 'raw': 'dc1 vaccine'}, {'type': 'vaccine', 'subtype': 'vaccine', 'raw': 'wokvac vaccine'}]",False,breast cancer female breast cancer male breast cancer stage i breast cancer stage ii breast cancer stage iii residual disease her2 positive breast cancer her2 positive breast carcinoma,breast
139,China,Advanced Solid Tumor,DRUG: LTC004+Toripalimab,2,OTHER,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'ltc004'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'toripalimab'}]",True,advanced solid tumor,multiple
140,United Kingdom,Breast Neoplasm,DRUG: AZD6738|DRUG: Olaparib|DRUG: Durvalumab,2,OTHER,"Institute of Cancer Research, United Kingdom","['checkpoint inhibitor', 'targeted therapy', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'azd6738'}, {'type': 'targeted therapy', 'subtype': 'PARP inhibitor', 'raw': 'olaparib'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}]",True,breast neoplasm,breast
141,China,"Pancreas Cancer|Lung Cancer|Liver Cancer|Mesothelioma|CAR-T Cell Therapy|Solid Tumor, Adult",BIOLOGICAL: Cell therapy for solid tumors,1,OTHER,Second Affiliated Hospital of Guangzhou Medical University,['cell therapy'],"[{'type': 'cell therapy', 'subtype': 'other', 'raw': 'cell therapy for solid tumors'}]",False,pancreas cancer lung cancer liver cancer mesothelioma car t cell therapy solid tumor adult,digestive
142,China,Cholangiocarcinoma,BIOLOGICAL: autologous Tcm cellular immunotherapy,2,INDUSTRY,"Newish Technology (Beijing) Co., Ltd.",['cell therapy'],"[{'type': 'cell therapy', 'subtype': 'other', 'raw': 'autologous tcm cellular immunotherapy'}]",False,cholangiocarcinoma,other
143,United States,Urothelial Carcinoma Bladder|Bladder Cancer,RADIATION: Concurrent Immunotherapy and Radiation Therapy,1,OTHER,Abramson Cancer Center at Penn Medicine,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'radiation: concurrent immunotherapy and radiation therapy'}]",False,urothelial carcinoma bladder bladder cancer,genitourinary
144,Italy,Glioblastoma,BIOLOGICAL: Dendritic Cells Vaccine,12,OTHER,Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta,['vaccine'],"[{'type': 'vaccine', 'subtype': 'vaccine', 'raw': 'dendritic cells vaccine'}]",False,glioblastoma,brain/CNS
145,United States,Papillomavirus Infections|Cervical Intraepithelial Neoplasia|Carcinoma In Situ|Vulvar Neoplasms|Vulvar Diseases,BIOLOGICAL: E7 TCR cells|DRUG: Aldesleukin|DRUG: Fludarabine|DRUG: Cyclophosphamide,12,NIH,National Cancer Institute (NCI),"['cytokine therapy', 'chemotherapy', 'cell therapy']","[{'type': 'cell therapy', 'subtype': 'engineered cell', 'raw': 'e7 tcr cells'}, {'type': 'cytokine therapy', 'subtype': 'IL-2', 'raw': 'aldesleukin'}, {'type': 'chemotherapy', 'subtype': 'purine analog', 'raw': 'fludarabine'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide'}]",True,papillomavirus infections cervical intraepithelial neoplasia carcinoma in situ vulvar neoplasms vulvar diseases,gynecologic
146,United States,"Breast Neoplasm|Breast Neoplasm, Male|Triple Negative Breast Cancer",DRUG: Cyclophosphamide|DRUG: Indomethacin|DRUG: Omeprazole|DIETARY_SUPPLEMENT: Multivitamin,1,OTHER,Providence Health & Services,"['other', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide'}, {'type': 'other', 'subtype': None, 'raw': 'indomethacin'}, {'type': 'other', 'subtype': None, 'raw': 'omeprazole'}]",True,breast neoplasm breast neoplasm male triple negative breast cancer,breast
147,China,Elderly Patients|Metastatic Lung Cancer,DRUG: Single drug chemotherapy plus immunotherapy,2,OTHER,Hubei Cancer Hospital,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'single drug chemotherapy plus immunotherapy'}]",False,elderly patients metastatic lung cancer,lung/thoracic
148,China,Hepatocarcinoma|Lung Cancer|Melanoma|Renal Cancer|Head and Neck Cancer|Pancreas Cancer|Ovarian Cancer|Colo-rectal Cancer|Cervical Cancer|Breast Cancer,DRUG: Checkpoint inhibitor (CPI) such as Pembrolizumab plus chemotherapy,23,OTHER,Second Affiliated Hospital of Guangzhou Medical University,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'checkpoint inhibitor such as pembrolizumab plus chemotherapy'}]",False,hepatocarcinoma lung cancer melanoma renal cancer head and neck cancer pancreas cancer ovarian cancer colo rectal cancer cervical cancer breast cancer,gynecologic
149,United States,Small Cell Lung Cancer,DRUG: Combination immunotherapy with Ipilimumab and Nivolumab,2,OTHER,Yale University,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'combination immunotherapy with ipilimumab and nivolumab'}]",False,small cell lung cancer,lung/thoracic
150,Canada,Acute Lymphoblastic Leukemia|Non-Hodgkin's Lymphoma|Chronic Lymphocytic Leukemia,BIOLOGICAL: CLIC-1901,12,OTHER,Ottawa Hospital Research Institute,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'clic-1901'}]",False,acute lymphoblastic leukemia non hodgkin s lymphoma chronic lymphocytic leukemia,hematologic
151,China,Rare Tumor,DRUG: Almonertinib 110 MG|DRUG: Dacomitinib 45 MG|DRUG: Alectinib 150 MG|DRUG: Crizotinib 250 MG|DRUG: Pyrotinib 160/80 MG|DRUG: Imatinib 400 MG|DRUG: Niraparib 200/300 MG|DRUG: Palbociclib 125mg|DRUG: Vemurafenib 240 MG|DRUG: Sintilimab 100MG|DRUG: Atezolizumab 1680 MG,2,OTHER,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","['checkpoint inhibitor', 'targeted therapy', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'almonertinib 110'}, {'type': 'other', 'subtype': None, 'raw': 'dacomitinib 45'}, {'type': 'other', 'subtype': None, 'raw': 'alectinib 150'}, {'type': 'other', 'subtype': None, 'raw': 'crizotinib 250'}, {'type': 'other', 'subtype': None, 'raw': 'pyrotinib 160'}, {'type': 'other', 'subtype': None, 'raw': '80'}, {'type': 'other', 'subtype': None, 'raw': 'imatinib 400'}, {'type': 'targeted therapy', 'subtype': 'PARP inhibitor', 'raw': 'niraparib 200'}, {'type': 'other', 'subtype': None, 'raw': '300'}, {'type': 'other', 'subtype': None, 'raw': 'palbociclib 125mg'}, {'type': 'other', 'subtype': None, 'raw': 'vemurafenib 240'}, {'type': 'other', 'subtype': None, 'raw': 'sintilimab 100mg'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'atezolizumab 1680'}]",True,rare tumor,other
152,United States,"Gastrointestinal Epithelial Cancer|Gastrointestinal Neoplasms|Cancer of Gastrointestinal Tract|Cancer, Gastrointestinal|Gastrointestinal Cancer|Colo-rectal Cancer|Pancreatic Cancer|Gall Bladder Cancer|Colon Cancer|Esophageal Cancer|Stomach Cancer",DRUG: Cyclophosphamide|DRUG: Fludarabine|BIOLOGICAL: Tumor-Infiltrating Lymphocytes (TIL)|DRUG: Aldesleukin,12,INDUSTRY,"Intima Bioscience, Inc.","['other', 'cytokine therapy', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide'}, {'type': 'chemotherapy', 'subtype': 'purine analog', 'raw': 'fludarabine'}, {'type': 'other', 'subtype': None, 'raw': 'tumor-infiltrating lymphocytes'}, {'type': 'cytokine therapy', 'subtype': 'IL-2', 'raw': 'aldesleukin'}]",True,gastrointestinal epithelial cancer gastrointestinal neoplasms cancer of gastrointestinal tract cancer gastrointestinal gastrointestinal cancer colo rectal cancer pancreatic cancer gall bladder cancer colon cancer esophageal cancer stomach cancer,genitourinary
153,Italy,Bladder Cancer|Adult Solid Tumor,DRUG: Nivolumab|DRUG: Visugromab (CTL-002)|DRUG: Placebo,2,INDUSTRY,CatalYm GmbH,"['checkpoint inhibitor', 'antibody']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'visugromab'}]",True,bladder cancer adult solid tumor,genitourinary
154,"Belgium, United States",Selected Advanced Solid Tumors,DRUG: EOS006215|DRUG: Anticancer agent,1,INDUSTRY,iTeos Belgium SA,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'eos006215'}, {'type': 'other', 'subtype': None, 'raw': 'anticancer agent'}]",False,selected advanced solid tumors,multiple
155,"Malaysia, Thailand",Hepatocellular Carcinoma,BIOLOGICAL: AlloStim® immunotherapy|DRUG: FOLFOX regimen|DRUG: Sorafenib|DRUG: Lenvatinib,23,INDUSTRY,"Mirror Biologics, Inc.","['targeted therapy', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'allostim® immunotherapy'}, {'type': 'other', 'subtype': None, 'raw': 'folfox regimen'}, {'type': 'targeted therapy', 'subtype': 'other', 'raw': 'sorafenib'}, {'type': 'targeted therapy', 'subtype': 'other', 'raw': 'lenvatinib'}]",True,hepatocellular carcinoma,digestive
156,Norway,Esophageal Cancer,DRUG: Nivolumab|RADIATION: Radiotherapy|DRUG: Chemotherapy|PROCEDURE: Surgery,12,OTHER,Oslo University Hospital,"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'chemotherapy', 'subtype': 'unspecified', 'raw': 'chemotherapy'}]",True,esophageal cancer,digestive
157,United States,Hematopoietic and Lymphoid Cell Neoplasm|Metastatic Malignant Solid Neoplasm,RADIATION: External Beam Radiation Therapy|OTHER: Laboratory Biomarker Analysis|RADIATION: Stereotactic Body Radiation Therapy,2,OTHER,M.D. Anderson Cancer Center,[],[],False,hematopoietic and lymphoid cell neoplasm metastatic malignant solid neoplasm,multiple
158,China,Gastric Cancer,COMBINATION_PRODUCT: Fecal Microbiota Transplantation (FMT)+chemotherapy+immunotherapy,2,OTHER,Changzhou No.2 People's Hospital,"['other', 'chemotherapy', 'immunotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'fecal microbiota transplantation'}, {'type': 'chemotherapy', 'subtype': 'unspecified', 'raw': 'chemotherapy'}, {'type': 'immunotherapy', 'subtype': 'unspecified', 'raw': 'immunotherapy'}]",True,gastric cancer,digestive
159,France,Advanced Solid Tumor,DRUG: MAQ-001|DRUG: Ipilimumab,1,INDUSTRY,MabQuest SA,"['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'maq-001'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}]",True,advanced solid tumor,multiple
160,United States,Breast Cancer,RADIATION: Stereotactic Body Radiation Therapy (SBRT) (50GY in 5 fractions)|DRUG: Letrozole 2.5Mg Tab|DRUG: Palbociclib 125mg,2,OTHER,Weill Medical College of Cornell University,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'letrozole 2.5mg tab'}, {'type': 'other', 'subtype': None, 'raw': 'palbociclib 125mg'}]",False,breast cancer,breast
161,United States,Ovarian Cancer Recurrent,DRUG: Rintatolimod|DRUG: Pembrolizumab|DRUG: Cisplatin,12,OTHER,Robert Edwards,"['checkpoint inhibitor', 'other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'rintatolimod'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}]",True,ovarian cancer recurrent,gynecologic
162,China,Non-small Cell Lung Cancer,DRUG: Toripalimab|OTHER: Cryoablation,2,OTHER,Shanghai Chest Hospital,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'toripalimab'}]",False,non small cell lung cancer,lung/thoracic
163,United States,Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Neoplasms,DRUG: Olaparib|DRUG: Tremelimumab,12,OTHER,New Mexico Cancer Research Alliance,"['checkpoint inhibitor', 'targeted therapy']","[{'type': 'targeted therapy', 'subtype': 'PARP inhibitor', 'raw': 'olaparib'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'tremelimumab'}]",True,ovarian cancer fallopian tube cancer peritoneal neoplasms,gynecologic
164,United States,Advanced or Metastatic Solid Tumors|Non-Hodgkin Lymphoma,DRUG: WTX-330,12,INDUSTRY,"Werewolf Therapeutics, Inc.",['other'],"[{'type': 'other', 'subtype': None, 'raw': 'wtx-330'}]",False,advanced or metastatic solid tumors non hodgkin lymphoma,hematologic
165,France,Triple Negative Breast Neoplasms,DRUG: Pembrolizumab injection|DRUG: Capecitabine tablets|RADIATION: Local radiotherapy,2,OTHER,UNICANCER,"['checkpoint inhibitor', 'other']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab injection'}, {'type': 'other', 'subtype': None, 'raw': 'capecitabine tablets'}]",True,triple negative breast neoplasms,breast
166,United States,Metastatic Colorectal Cancer|Metastatic Pancreatic Cancer|Metastatic Ovarian Cancer|Metastatic Breast Carcinoma|Metastatic Endocrine Tumors/ Neuroendocrine Tumors,DRUG: Pembrolizumab (Keytruda)|DRUG: Fludarabine|DRUG: Cyclophosphamide|DRUG: Aldesleukin|BIOLOGICAL: Young TIL,2,NIH,National Cancer Institute (NCI),"['checkpoint inhibitor', 'other', 'cytokine therapy', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'chemotherapy', 'subtype': 'purine analog', 'raw': 'fludarabine'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide'}, {'type': 'cytokine therapy', 'subtype': 'IL-2', 'raw': 'aldesleukin'}, {'type': 'other', 'subtype': None, 'raw': 'young til'}]",True,metastatic colorectal cancer metastatic pancreatic cancer metastatic ovarian cancer metastatic breast carcinoma metastatic endocrine tumors neuroendocrine tumors,gynecologic
167,United States,"HPV Positive Cancer|Vulvar, Vaginal, Penile, Rectal Cancer|Anal Cancer|Oropharyngeal Cancer|Cervical Cancer",BIOLOGICAL: PRGN-2009 (Phase I)|BIOLOGICAL: PRGN-2009 (Phase II)|BIOLOGICAL: M7824|DIAGNOSTIC_TEST: MRI|DIAGNOSTIC_TEST: Bone scan|DIAGNOSTIC_TEST: CT scan|DIAGNOSTIC_TEST: Brain CT|DIAGNOSTIC_TEST: Brain MRI|PROCEDURE: Biopsy (Phase I)|PROCEDURE: Biopsy (Phase II),12,NIH,National Cancer Institute (NCI),['other'],"[{'type': 'other', 'subtype': None, 'raw': 'prgn-2009'}, {'type': 'other', 'subtype': None, 'raw': 'prgn-2009'}, {'type': 'other', 'subtype': None, 'raw': 'm7824'}]",False,hpv positive cancer vulvar vaginal penile rectal cancer anal cancer oropharyngeal cancer cervical cancer,gynecologic
168,China,Patients With Advanced Solid Tumor|Advanced Solid Tumor With Oncogenic Driver Mutations,DRUG: PD-1|DRUG: MET inhibitor|DRUG: ALK inhibitor|DRUG: BRAF Inhibito|DRUG: EGFR Monoclonal antibody|DRUG: GH21|DRUG: MEK Inhibitor,2,OTHER,"Suzhou Genhouse Bio Co., Ltd.","['checkpoint inhibitor', 'other']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'pd-1'}, {'type': 'other', 'subtype': None, 'raw': 'met inhibitor'}, {'type': 'other', 'subtype': None, 'raw': 'alk inhibitor'}, {'type': 'other', 'subtype': None, 'raw': 'braf inhibito'}, {'type': 'other', 'subtype': None, 'raw': 'egfr monoclonal antibody'}, {'type': 'other', 'subtype': None, 'raw': 'gh21'}, {'type': 'other', 'subtype': None, 'raw': 'mek inhibitor'}]",True,patients with advanced solid tumor advanced solid tumor with oncogenic driver mutations,multiple
169,China,"Pancreas Cancer|CAR-T Cell Therapy|Mesothelin|Solid Tumor, Adult",BIOLOGICAL: CAR-T cells,1,OTHER,Second Affiliated Hospital of Guangzhou Medical University,['cell therapy'],"[{'type': 'cell therapy', 'subtype': 'engineered cell', 'raw': 'car-t cells'}]",False,pancreas cancer car t cell therapy mesothelin solid tumor adult,multiple
170,"Australia, Canada, Ireland, Portugal, Republic of, Spain, United States","Advanced Solid Tumor|Unresectable Solid Tumor|Clear Cell Renal Cell Carcinoma|Triple Negative Breast Cancer|Non-Small Cell Lung Cancer Squamous|Non-Small Cell Lung Cancer Non-squamous|Colorectal Cancer (MSI-H)|Gastric Cancer|Cervical Cancer|Basal Cell Carcinoma|Bladder Cancer|Merkel Cell Carcinoma|Squamous Cell Carcinoma of Head and Neck|Cutaneous Squamous Cell Carcinoma|Pleural Mesothelioma|Esophageal Cancer|Endometrial Carcinoma|Solid Tumor|Solid Tumor, Adult|MSI-H Solid Malignant Tumor|Cancer With A High Tumor Mutational Burden|Epithelial Ovarian Carcinoma|Primary Peritoneal Cancer|Gastroesophageal Junction (GEJ) Cancer|Acral Melanoma|Mucosal Melanoma|Cutaneous Melanoma|DMMR Solid Malignant Tumor|Fallopian Tube Cancer|Ovarian Cancer|MSI-H Cancer|DMMR Cancer|Pancreas Adenocarcinoma (MSI-H)|Skin Cancer|Viral Cancer|Cervical Cancers|Endometrial Cancer",DRUG: MDNA11|DRUG: Pembrolizumab (KEYTRUDA®),12,INDUSTRY,"Medicenna Therapeutics, Inc.","['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'mdna11'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",True,advanced solid tumor unresectable solid tumor clear cell renal cell carcinoma triple negative breast cancer non small cell lung cancer squamous non small cell lung cancer non squamous colorectal cancer gastric cancer cervical cancer basal cell carcinoma bladder cancer merkel cell carcinoma squamous cell carcinoma of head and neck cutaneous squamous cell carcinoma pleural mesothelioma esophageal cancer endometrial carcinoma solid tumor solid tumor adult msi h solid malignant tumor cancer with a high tumor mutational burden epithelial ovarian carcinoma primary peritoneal cancer gastroesophageal junction cancer acral melanoma mucosal melanoma cutaneous melanoma dmmr solid malignant tumor fallopian tube cancer ovarian cancer msi h cancer dmmr cancer pancreas adenocarcinoma skin cancer viral cancer cervical cancers endometrial cancer,gynecologic
171,United States,Advanced Fallopian Tube Carcinoma|Advanced Malignant Solid Neoplasm|Advanced Melanoma|Advanced Ovarian Carcinoma|Advanced Primary Peritoneal Carcinoma|Advanced Synovial Sarcoma|Clinical Stage III Cutaneous Melanoma AJCC v8|Clinical Stage IV Cutaneous Melanoma AJCC v8|Metastatic Fallopian Tube Carcinoma|Metastatic Melanoma|Metastatic Ovarian Carcinoma|Metastatic Primary Peritoneal Carcinoma|Metastatic Synovial Sarcoma|Pathologic Stage III Cutaneous Melanoma AJCC v8|Pathologic Stage IIIA Cutaneous Melanoma AJCC v8|Pathologic Stage IIIB Cutaneous Melanoma AJCC v8|Pathologic Stage IIIC Cutaneous Melanoma AJCC v8|Pathologic Stage IIID Cutaneous Melanoma AJCC v8|Pathologic Stage IV Cutaneous Melanoma AJCC v8|Platinum-Resistant Fallopian Tube Carcinoma|Platinum-Resistant Ovarian Carcinoma|Platinum-Resistant Primary Peritoneal Carcinoma|Stage III Fallopian Tube Cancer AJCC v8|Stage III Ovarian Cancer AJCC v8|Stage III Primary Peritoneal Cancer AJCC v8|Stage IIIA Fallopian Tube Cancer AJCC v8|Stage IIIA Ovarian Cancer AJCC v8|Stage IIIA Primary Peritoneal Cancer AJCC v8|Stage IIIA1 Fallopian Tube Cancer AJCC v8|Stage IIIA1 Ovarian Cancer AJCC v8|Stage IIIA2 Fallopian Tube Cancer AJCC v8|Stage IIIA2 Ovarian Cancer AJCC v8|Stage IIIB Fallopian Tube Cancer AJCC v8|Stage IIIB Ovarian Cancer AJCC v8|Stage IIIB Primary Peritoneal Cancer AJCC v8|Stage IIIC Fallopian Tube Cancer AJCC v8|Stage IIIC Ovarian Cancer AJCC v8|Stage IIIC Primary Peritoneal Cancer AJCC v8|Stage IV Fallopian Tube Cancer AJCC v8|Stage IV Ovarian Cancer AJCC v8|Stage IV Primary Peritoneal Cancer AJCC v8|Stage IVA Fallopian Tube Cancer AJCC v8|Stage IVA Ovarian Cancer AJCC v8|Stage IVA Primary Peritoneal Cancer AJCC v8|Stage IVB Fallopian Tube Cancer AJCC v8|Stage IVB Ovarian Cancer AJCC v8|Stage IVB Primary Peritoneal Cancer AJCC v8|Unresectable Melanoma|Unresectable Ovarian Carcinoma|Unresectable Synovial Sarcoma,DRUG: Cyclophosphamide|DRUG: Decitabine|OTHER: Laboratory Biomarker Analysis|PROCEDURE: Leukapheresis|BIOLOGICAL: TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes,12,OTHER,Roswell Park Cancer Institute,"['other', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide'}, {'type': 'other', 'subtype': None, 'raw': 'decitabine'}, {'type': 'other', 'subtype': None, 'raw': 'tgfbdnrii-transduced autologous tumor infiltrating lymphocytes'}]",True,advanced fallopian tube carcinoma advanced malignant solid neoplasm advanced melanoma advanced ovarian carcinoma advanced primary peritoneal carcinoma advanced synovial sarcoma clinical stage iii cutaneous melanoma ajcc v8 clinical stage iv cutaneous melanoma ajcc v8 metastatic fallopian tube carcinoma metastatic melanoma metastatic ovarian carcinoma metastatic primary peritoneal carcinoma metastatic synovial sarcoma pathologic stage iii cutaneous melanoma ajcc v8 pathologic stage iiia cutaneous melanoma ajcc v8 pathologic stage iiib cutaneous melanoma ajcc v8 pathologic stage iiic cutaneous melanoma ajcc v8 pathologic stage iiid cutaneous melanoma ajcc v8 pathologic stage iv cutaneous melanoma ajcc v8 platinum resistant fallopian tube carcinoma platinum resistant ovarian carcinoma platinum resistant primary peritoneal carcinoma stage iii fallopian tube cancer ajcc v8 stage iii ovarian cancer ajcc v8 stage iii primary peritoneal cancer ajcc v8 stage iiia fallopian tube cancer ajcc v8 stage iiia ovarian cancer ajcc v8 stage iiia primary peritoneal cancer ajcc v8 stage iiia1 fallopian tube cancer ajcc v8 stage iiia1 ovarian cancer ajcc v8 stage iiia2 fallopian tube cancer ajcc v8 stage iiia2 ovarian cancer ajcc v8 stage iiib fallopian tube cancer ajcc v8 stage iiib ovarian cancer ajcc v8 stage iiib primary peritoneal cancer ajcc v8 stage iiic fallopian tube cancer ajcc v8 stage iiic ovarian cancer ajcc v8 stage iiic primary peritoneal cancer ajcc v8 stage iv fallopian tube cancer ajcc v8 stage iv ovarian cancer ajcc v8 stage iv primary peritoneal cancer ajcc v8 stage iva fallopian tube cancer ajcc v8 stage iva ovarian cancer ajcc v8 stage iva primary peritoneal cancer ajcc v8 stage ivb fallopian tube cancer ajcc v8 stage ivb ovarian cancer ajcc v8 stage ivb primary peritoneal cancer ajcc v8 unresectable melanoma unresectable ovarian carcinoma unresectable synovial sarcoma,gynecologic
172,United States,Cutaneous Malignant Melanoma|Renal Cell Cancer|Urothelial Cancer of Renal Pelvis,RADIATION: Low Dose Rate Brachytherapy (LDR)|DRUG: Standard-of-Care Immunotherapy,1,OTHER,Case Comprehensive Cancer Center,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'standard-of-care immunotherapy'}]",False,cutaneous malignant melanoma renal cell cancer urothelial cancer of renal pelvis,genitourinary
173,China,Metastatic Castration-resistant Prostate Cancer (CRPC),DRUG: Immunotherapy|DRUG: Targeted therapy|DEVICE: Hyperthermia,2,OTHER,Pengyuan Liu,"['other', 'immunotherapy']","[{'type': 'immunotherapy', 'subtype': 'unspecified', 'raw': 'immunotherapy'}, {'type': 'other', 'subtype': None, 'raw': 'targeted therapy'}]",True,metastatic castration resistant prostate cancer,genitourinary
174,"France, Italy, Spain, United States",Hepatocellular Carcinoma,DEVICE: TheraSphere Y-90 glass microsphere therapy|DRUG: Durvalumab (Imfinzi) immunotherapy|DRUG: Tremelimumab immunotherapy,2,INDUSTRY,Boston Scientific Corporation,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab immunotherapy'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'tremelimumab immunotherapy'}]",False,hepatocellular carcinoma,digestive
175,China,Locally Advanced Esophageal Squamous Cell Carcinoma,DRUG: Chemotherapy|DRUG: Immunotherapy (Pembrolizumab)|RADIATION: radiotherapy,23,OTHER,Peking Union Medical College Hospital,"['chemotherapy', 'immunotherapy']","[{'type': 'chemotherapy', 'subtype': 'unspecified', 'raw': 'chemotherapy'}, {'type': 'immunotherapy', 'subtype': 'unspecified', 'raw': 'immunotherapy'}]",True,locally advanced esophageal squamous cell carcinoma,digestive
176,"Canada, United States","Lung Cancer, Nonsmall Cell|Lung Cancer Stage IV|Lung Cancer Metastatic",DRUG: SLC-391|BIOLOGICAL: pembrolizumab,12,INDUSTRY,SignalChem Lifesciences Corporation,"['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'slc-391'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",True,lung cancer nonsmall cell lung cancer stage iv lung cancer metastatic,lung/thoracic
177,China,"Endometrial Neoplasms|Neoplasm Recurrence, Local|Neoplasm Metastasis",DRUG: Paclitaxel and Cisplatin|DRUG: Cadonilimab|RADIATION: Radiotherapy,2,OTHER,Shandong Cancer Hospital and Institute,"['antibody', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel and cisplatin'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'cadonilimab'}]",True,endometrial neoplasms neoplasm recurrence local neoplasm metastasis,gynecologic
178,China,Pancreatic Cancer,DRUG: PD-1|DRUG: Nab-paclitaxel|DRUG: Gemcitabine|RADIATION: PULSAR,2,OTHER,Fudan University,"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'pd-1'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'nab-paclitaxel'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'gemcitabine'}]",True,pancreatic cancer,digestive
179,China,"Nonsmall Cell Lung Cancer|Solid Tumor, Adult",BIOLOGICAL: TCR-T cells,1,OTHER,Second Affiliated Hospital of Guangzhou Medical University,['cell therapy'],"[{'type': 'cell therapy', 'subtype': 'engineered cell', 'raw': 'tcr-t cells'}]",False,nonsmall cell lung cancer solid tumor adult,lung/thoracic
180,China,Anti-cancer Cell Immunotherapy|T Cell and NK Cell,BIOLOGICAL: ITNK cell therapy,12,OTHER,Second Affiliated Hospital of Guangzhou Medical University,['cell therapy'],"[{'type': 'cell therapy', 'subtype': 'other', 'raw': 'itnk cell therapy'}]",False,anti cancer cell immunotherapy t cell and nk cell,hematologic
181,United States,Metastatic Cancer|Melanoma Cancer|Lung Cancer|Bladder Cancer|Renal Cancer|Head/Neck Cancers,"RADIATION: Stereotactic Body Radiotherapy|BIOLOGICAL: Ipilimumab, Nivolumab, Pembrolizumab or Atezolizumab",2,OTHER,Memorial Sloan Kettering Cancer Center,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab or atezolizumab'}]",False,metastatic cancer melanoma cancer lung cancer bladder cancer renal cancer head neck cancers,genitourinary
182,United States,Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy|MSI-H Tumors,DRUG: Nivolumab|DRUG: Relatlimab|DRUG: Nivolumab|DRUG: Relatlimab|DRUG: Nivolumab|DRUG: Relatlimab,2,OTHER,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,"['checkpoint inhibitor', 'antibody']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'relatlimab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'relatlimab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'relatlimab'}]",True,refractory msi h solid tumors prior of pd 1 therapy msi h tumors,multiple
183,United States,"Solid Tumor, Adult",BIOLOGICAL: CF33-CD19 IT Monotherapy|BIOLOGICAL: CF33-CD19 IV Monotherapy|BIOLOGICAL: CF33-CD19 IT Combination|BIOLOGICAL: CF33-CD19 IV Combination|DRUG: Blinatumomab|DRUG: Hydroxyurea,1,INDUSTRY,Imugene Limited,"['other', 'antibody']","[{'type': 'other', 'subtype': None, 'raw': 'cf33-cd19 it monotherapy'}, {'type': 'other', 'subtype': None, 'raw': 'cf33-cd19 monotherapy'}, {'type': 'other', 'subtype': None, 'raw': 'cf33-cd19 it combination'}, {'type': 'other', 'subtype': None, 'raw': 'cf33-cd19 combination'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'blinatumomab'}, {'type': 'other', 'subtype': None, 'raw': 'hydroxyurea'}]",True,solid tumor adult,multiple
184,China,Malignant Neoplasm of Nasopharynx TNM Staging Distant Metastasis (M)|Breast Cancer Recurrent|Gastric Cancer With Metastasis,BIOLOGICAL: EpCAM CAR-T cells,1,OTHER,Sichuan University,['cell therapy'],"[{'type': 'cell therapy', 'subtype': 'engineered cell', 'raw': 'epcam car-t cells'}]",False,malignant neoplasm of nasopharynx tnm staging distant metastasis breast cancer recurrent gastric cancer with metastasis,digestive
185,China,Breast Cancer|Breast Carcinoma|Breast Cancer Metastatic|Breast Cancer Triple Negative,BIOLOGICAL: Tumor Infiltrating Lymphocytes (TIL)|DRUG: Cyclophosphamid|DRUG: Fludarabine|DRUG: Interleukin-2|DRUG: Pembrolizumab,12,OTHER,Essen Biotech,"['other', 'chemotherapy', 'checkpoint inhibitor', 'cell therapy', 'cytokine therapy']","[{'type': 'cell therapy', 'subtype': 'TILs', 'raw': 'tumor infiltrating lymphocytes'}, {'type': 'other', 'subtype': None, 'raw': 'cyclophosphamid'}, {'type': 'chemotherapy', 'subtype': 'purine analog', 'raw': 'fludarabine'}, {'type': 'cytokine therapy', 'subtype': 'IL-2', 'raw': 'interleukin-2'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",True,breast cancer breast carcinoma breast cancer metastatic breast cancer triple negative,breast
186,France,Oligometastatic Non-small Cell Lung Cancer (NSCLC),RADIATION: Radical local treatment|DRUG: SoC-based immunotherapy (+/- chemotherapy),3,OTHER,"Gustave Roussy, Cancer Campus, Grand Paris",['other'],"[{'type': 'other', 'subtype': None, 'raw': 'soc-based immunotherapy'}]",False,oligometastatic non small cell lung cancer,lung/thoracic
187,"France, Germany, Italy, Netherlands, Spain, Sweden, United Kingdom",Advanced Solid Tumor,DRUG: Atezolizumab|DRUG: Futibatinib|DRUG: Amivantamab,2,OTHER,Vall d'Hebron Institute of Oncology,"['checkpoint inhibitor', 'antibody', 'kinase inhibitor']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'atezolizumab'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'futibatinib'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'amivantamab'}]",True,advanced solid tumor,multiple
188,United States,Prostate Cancer,DRUG: Ipilimumab,12,OTHER,Memorial Sloan Kettering Cancer Center,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}]",False,prostate cancer,genitourinary
189,China,Advanced Solid Tumor,DRUG: HS-10386,1,INDUSTRY,"Jiangsu Hansoh Pharmaceutical Co., Ltd.",['other'],"[{'type': 'other', 'subtype': None, 'raw': 'hs-10386'}]",False,advanced solid tumor,multiple
190,United States,Ependymoma|Medulloblastoma|Glioblastoma|Primary Brain Tumor,DRUG: Ibrutinib|DRUG: Indoximod|DRUG: Cyclophosphamide|DRUG: Etoposide,1,OTHER,Theodore S. Johnson,"['other', 'chemotherapy', 'kinase inhibitor']","[{'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'ibrutinib'}, {'type': 'other', 'subtype': None, 'raw': 'indoximod'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'etoposide'}]",True,ependymoma medulloblastoma glioblastoma primary brain tumor,brain/CNS
191,China,Biliary Tract Neoplasms|Immunotherapy,DRUG: Durvalumab|DRUG: Lenvatinib Oral Product|DRUG: Chemotherapy,2,OTHER,Peking Union Medical College Hospital,"['checkpoint inhibitor', 'targeted therapy', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}, {'type': 'targeted therapy', 'subtype': 'other', 'raw': 'lenvatinib product'}, {'type': 'chemotherapy', 'subtype': 'unspecified', 'raw': 'chemotherapy'}]",True,biliary tract neoplasms immunotherapy,digestive
192,Australia,Pancreatic Cancer,DRUG: Durvalumab|DRUG: Oxaliplatin|DRUG: Irinotecan|DRUG: Calcium folinate (leucovorin)|DRUG: Fluorouracil|DRUG: Pegylated G-CSF,2,NETWORK,Australasian Gastro-Intestinal Trials Group,"['checkpoint inhibitor', 'other', 'supportive care', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'oxaliplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'irinotecan'}, {'type': 'supportive care', 'subtype': 'rescue agent', 'raw': 'calcium folinate'}, {'type': 'chemotherapy', 'subtype': 'antimetabolite', 'raw': 'fluorouracil'}, {'type': 'other', 'subtype': None, 'raw': 'pegylated -csf'}]",True,pancreatic cancer,digestive
193,United States,Prostate Cancer|Prostate Disease,DRUG: Nivolumab|RADIATION: Brachytherapy|RADIATION: External Beam Radiation Therapy|DRUG: Androgen Deprivation Therapy,12,OTHER,H. Lee Moffitt Cancer Center and Research Institute,"['checkpoint inhibitor', 'hormonal therapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'hormonal therapy', 'subtype': 'ADT', 'raw': 'androgen deprivation therapy'}]",True,prostate cancer prostate disease,genitourinary
194,"France, Monaco","Non Small Cell Lung Cancer|Non Small Cell Lung Cancer Metastatic|Non-Small Cell Carcinoma of Lung, TNM Stage 4",RADIATION: Radiotherapy|DRUG: Pembrolizumab|DRUG: Chemotherapy,3,OTHER,UNICANCER,"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'chemotherapy', 'subtype': 'unspecified', 'raw': 'chemotherapy'}]",True,non small cell lung cancer non small cell lung cancer metastatic non small cell carcinoma of lung tnm stage 4,lung/thoracic
195,United States,Cancer|Melanoma Stage III|Melanoma Stage IV|Cutaneous Melanoma,BIOLOGICAL: KB707|DRUG: Opdualag|DRUG: KEYTRUDA ®( Pembrolizumab),12,INDUSTRY,"Krystal Biotech, Inc.",['other'],"[{'type': 'other', 'subtype': None, 'raw': 'kb707'}, {'type': 'other', 'subtype': None, 'raw': 'opdualag'}, {'type': 'other', 'subtype': None, 'raw': 'keytruda ®'}]",False,cancer melanoma stage iii melanoma stage iv cutaneous melanoma,skin
196,United States,Pancreatic Cancer|Cancer of the Pancreas,BIOLOGICAL: huCART-meso cells,1,OTHER,University of Pennsylvania,['cell therapy'],"[{'type': 'cell therapy', 'subtype': 'engineered cell', 'raw': 'hucart-meso cells'}]",False,pancreatic cancer cancer of the pancreas,digestive
197,United States,Pediatric Solid Tumor|Germ Cell Tumor|Retinoblastoma|Hepatoblastoma|Wilms Tumor|Rhabdoid Tumor|Carcinoma|Osteosarcoma|Ewing Sarcoma|Rhabdomyosarcoma|Synovial Sarcoma|Clear Cell Sarcoma|Malignant Peripheral Nerve Sheath Tumors|Desmoplastic Small Round Cell Tumor|Soft Tissue Sarcoma|Neuroblastoma,BIOLOGICAL: second generation 4-1BBζ EGFR806-EGFRt|BIOLOGICAL: second generation 4-1BBζ EGFR806-EGFRt and a second generation 4 1BBζ CD19-Her2tG,1,OTHER,Seattle Children's Hospital,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'second generation 4-1bbζ egfr806-egfrt'}, {'type': 'other', 'subtype': None, 'raw': 'second generation 4-1bbζ egfr806-egfrt and a second generation 4 1bbζ cd19-her2tg'}]",False,pediatric solid tumor germ cell tumor retinoblastoma hepatoblastoma wilms tumor rhabdoid tumor carcinoma osteosarcoma ewing sarcoma rhabdomyosarcoma synovial sarcoma clear cell sarcoma malignant peripheral nerve sheath tumors desmoplastic small round cell tumor soft tissue sarcoma neuroblastoma,sarcoma
198,Republic of,Biliary Tract Neoplasms|Gallbladder Cancer|Cholangiocarcinoma,DRUG: Durvalumab + Gem/Cis|DRUG: Gem/Cis,2,OTHER,Asan Medical Center,"['checkpoint inhibitor', 'other']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}, {'type': 'other', 'subtype': None, 'raw': 'gem'}, {'type': 'other', 'subtype': None, 'raw': 'cis'}, {'type': 'other', 'subtype': None, 'raw': 'gem'}, {'type': 'other', 'subtype': None, 'raw': 'cis'}]",True,biliary tract neoplasms gallbladder cancer cholangiocarcinoma,genitourinary
199,China,"Stomach Cancer|Stomach Cancer Recurrent|Stomach Cancer, Adenocarcinoma|Esophageal Cancer|Esophageal Cancer Metastatic to Bone|Esophageal Cancer Metastatic to Lung|Esophageal Cancer Metastatic to Liver",BIOLOGICAL: Tumor Infiltrating Lymphocytes (TIL)|DRUG: Cyclophosphamid|DRUG: Fludarabine|DRUG: Interleukin-2|DRUG: Pembrolizumab,12,OTHER,Essen Biotech,"['other', 'chemotherapy', 'checkpoint inhibitor', 'cell therapy', 'cytokine therapy']","[{'type': 'cell therapy', 'subtype': 'TILs', 'raw': 'tumor infiltrating lymphocytes'}, {'type': 'other', 'subtype': None, 'raw': 'cyclophosphamid'}, {'type': 'chemotherapy', 'subtype': 'purine analog', 'raw': 'fludarabine'}, {'type': 'cytokine therapy', 'subtype': 'IL-2', 'raw': 'interleukin-2'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",True,stomach cancer stomach cancer recurrent stomach cancer adenocarcinoma esophageal cancer esophageal cancer metastatic to bone esophageal cancer metastatic to lung esophageal cancer metastatic to liver,digestive
200,China,Immunotherapy,BIOLOGICAL: CAR-T cell immunotherapy,1,OTHER,The Affiliated Hospital of Xuzhou Medical University,['cell therapy'],"[{'type': 'cell therapy', 'subtype': 'engineered cell', 'raw': 'car-t cell immunotherapy'}]",False,immunotherapy,hematologic
201,China,Small-cell Lung Cancer,RADIATION: split-course adaptive hypofractionated radiotherapy,2,OTHER,Fujian Medical University Union Hospital,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'radiation: split-course adaptive hypofractionated radiotherapy'}]",False,small cell lung cancer,lung/thoracic
202,China,"Lung Cancer|Lung Cancer Metastatic|Lung Cancer, Non-small Cell|Lung Cancer Recurrent",BIOLOGICAL: Tumor Infiltrating Lymphocytes (TIL)|DRUG: Cyclophosphamide|DRUG: Fludarabine|DRUG: Interleukin-2|DRUG: Pembrolizumab,12,OTHER,Essen Biotech,"['checkpoint inhibitor', 'cytokine therapy', 'chemotherapy', 'cell therapy']","[{'type': 'cell therapy', 'subtype': 'TILs', 'raw': 'tumor infiltrating lymphocytes'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide'}, {'type': 'chemotherapy', 'subtype': 'purine analog', 'raw': 'fludarabine'}, {'type': 'cytokine therapy', 'subtype': 'IL-2', 'raw': 'interleukin-2'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",True,lung cancer lung cancer metastatic lung cancer non small cell lung cancer recurrent,lung/thoracic
203,"Netherlands, Spain, United Kingdom",Locally Advanced Solid Tumor,RADIATION: 89Zr-Df-crefmirlimab PET scan|DRUG: Nivolumab|DRUG: Cetrelimab|OTHER: zirconium Zr 89 crefmirlimab berdoxam,2,OTHER,University Medical Center Groningen,"['checkpoint inhibitor', 'antibody']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'cetrelimab'}]",True,locally advanced solid tumor,multiple
204,"Belgium, France",Triple Negative Breast Cancer,DRUG: Paclitaxel|DRUG: Carboplatin|DRUG: MEDI4736|DRUG: MEDI9447,12,OTHER,Jules Bordet Institute,"['other', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'other', 'subtype': None, 'raw': 'medi4736'}, {'type': 'other', 'subtype': None, 'raw': 'medi9447'}]",True,triple negative breast cancer,breast
205,China,Esophageal Carcinoma|Radiotherapy|Immunotherapy,DRUG: Immunotherapy|DRUG: chemotherapy: Paclitaxel/Cisplatin|RADIATION: TDLN-sparing RT,3,OTHER,Fudan University,"['chemotherapy', 'immunotherapy']","[{'type': 'immunotherapy', 'subtype': 'unspecified', 'raw': 'immunotherapy'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'chemotherapy: paclitaxel'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}]",True,esophageal carcinoma radiotherapy immunotherapy,digestive
206,United States,Adult Acute Myeloid Leukemia in Remission|Acute Biphenotypic Leukemia|Early Relapse of Acute Myeloid Leukemia|Late Relapse of Acute Myeloid Leukemia|Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Blastic Plasmacytoid Dendritic Cell Neoplasm|Acute Myeloid Leukemia|Adult Acute Lymphoblastic Leukemia|Interleukin-3 Receptor Subunit Alpha Positive|Minimal Residual Disease|Refractory Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia,DRUG: cyclophosphamide|BIOLOGICAL: Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes|OTHER: laboratory biomarker analysis|BIOLOGICAL: Allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T-lymphocytes|DRUG: Fludarabine Phosphate,1,OTHER,City of Hope Medical Center,"['other', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide'}, {'type': 'other', 'subtype': None, 'raw': 'autologous cd123car-cd28-cd3zeta-egfrt-expressing t lymphocytes'}, {'type': 'other', 'subtype': None, 'raw': 'allogeneic cd123car-cd28-cd3zeta-egfrt-expressing t-lymphocytes'}, {'type': 'chemotherapy', 'subtype': 'purine analog', 'raw': 'fludarabine phosphate'}]",True,adult acute myeloid leukemia in remission acute biphenotypic leukemia early relapse of acute myeloid leukemia late relapse of acute myeloid leukemia recurrent adult acute myeloid leukemia secondary acute myeloid leukemia blastic plasmacytoid dendritic cell neoplasm acute myeloid leukemia adult acute lymphoblastic leukemia interleukin 3 receptor subunit alpha positive minimal residual disease refractory acute myeloid leukemia untreated adult acute myeloid leukemia,hematologic
207,China,"Brain Tumor|Brain Metastases|Brain Cancer|Glioma|Gliomas, Malignant|Glioblastoma|Meningioma",BIOLOGICAL: Tumor Infiltrating Lymphocytes (TIL)|DRUG: Cyclophosphamide|DRUG: Fludarabine|DRUG: Interleukin-2|DRUG: Pembrolizumab,12,OTHER,Essen Biotech,"['checkpoint inhibitor', 'cytokine therapy', 'chemotherapy', 'cell therapy']","[{'type': 'cell therapy', 'subtype': 'TILs', 'raw': 'tumor infiltrating lymphocytes'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide'}, {'type': 'chemotherapy', 'subtype': 'purine analog', 'raw': 'fludarabine'}, {'type': 'cytokine therapy', 'subtype': 'IL-2', 'raw': 'interleukin-2'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",True,brain tumor brain metastases brain cancer glioma gliomas malignant glioblastoma meningioma,brain/CNS
208,Netherlands,Cutaneous Squamous Cell Carcinoma (CSCC)|Cutaneous Squamous Cell Cancer|Cutaneous Squamous Cell Carcinoma of the Head and Neck|Cutaneous Squamous Cell Carcinoma,DRUG: Nivolumab|DRUG: Ipilumimab,2,OTHER,The Netherlands Cancer Institute,"['checkpoint inhibitor', 'antibody']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'ipilumimab'}]",True,cutaneous squamous cell carcinoma cutaneous squamous cell cancer cutaneous squamous cell carcinoma of the head and neck cutaneous squamous cell carcinoma,skin
209,"Canada, China, France, Germany, Hong Kong, Italy, Japan, Republic of, Singapore, Spain, Taiwan, United States","Carcinoma, Non-Small-Cell Lung|Cutaneous Melanoma|Carcinoma, Renal Cell|Carcinoma, Ovarian Epithelial|Nasopharyngeal Carcinoma|Carcinoma, Thymic|Anal Cancer|Mesothelioma|Esophagogastric Cancer|High Microsatellite Instability Colorectal Carcinoma|Squamous Cell Carcinoma of Head and Neck|Triple Negative Breast Neoplasms",DRUG: KFA115|DRUG: pembrolizumab,1,INDUSTRY,Novartis Pharmaceuticals,"['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'kfa115'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",True,carcinoma non small cell lung cutaneous melanoma carcinoma renal cell carcinoma ovarian epithelial nasopharyngeal carcinoma carcinoma thymic anal cancer mesothelioma esophagogastric cancer high microsatellite instability colorectal carcinoma squamous cell carcinoma of head and neck triple negative breast neoplasms,gynecologic
210,"Australia, United States",Solid Tumor,DRUG: ACTM-838,1,INDUSTRY,"Actym Therapeutics, Inc.",['other'],"[{'type': 'other', 'subtype': None, 'raw': 'actm-838'}]",False,solid tumor,multiple
211,"Taiwan, United States","Solid Tumor, Unspecified, Adult|Lymphoma",DRUG: Single Arm,1,INDUSTRY,Cytosite Biopharma Inc.,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'single arm'}]",False,solid tumor unspecified adult lymphoma,hematologic
212,China,Head and Neck Cancer,DRUG: Tislelizumab|DRUG: Afatinib|RADIATION: Low dose radiotherapy,2,OTHER,West China Hospital,"['checkpoint inhibitor', 'kinase inhibitor']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'tislelizumab'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'afatinib'}]",True,head and neck cancer,head/neck
213,Italy,Breast Cancer|Chest Wall Tumor,DRUG: Pembrolizumab,2,OTHER,European Institute of Oncology,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",False,breast cancer chest wall tumor,breast
214,United States,Acute Myeloid Leukemia|Acute Lymphoid Leukemia|Myelodysplastic Syndromes|Acute Leukemia|Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)|Chronic Myeloid Leukemia,BIOLOGICAL: Orca-T,1,INDUSTRY,"Orca Biosystems, Inc.",['other'],"[{'type': 'other', 'subtype': None, 'raw': 'orca-t'}]",False,acute myeloid leukemia acute lymphoid leukemia myelodysplastic syndromes acute leukemia blastic plasmacytoid dendritic cell neoplasm chronic myeloid leukemia,hematologic
215,"Canada, France, Spain, United States","Advanced Solid Tumors|Genital Neoplasm, Female|Urogenital Neoplasms|Lung Neoplasm|Neoplasms by Site|Papillomavirus Infection|Epstein-Barr Virus Infections|Carcinoma|Neoplasms|Vulvar Neoplasms|Vulvar Diseases|Abdominal Neoplasm",DRUG: STAR0602,12,INDUSTRY,"Marengo Therapeutics, Inc.",['other'],"[{'type': 'other', 'subtype': None, 'raw': 'star0602'}]",False,advanced solid tumors genital neoplasm female urogenital neoplasms lung neoplasm neoplasms by site papillomavirus infection epstein barr virus infections carcinoma neoplasms vulvar neoplasms vulvar diseases abdominal neoplasm,gynecologic
216,Denmark,"Pancreas Cancer, Metastatic",DRUG: Pembrolizumab|DEVICE: Irreversible electroporation,2,OTHER,"Ole Thorlacius-Ussing, MD, DMSc, Professor of Surgery",['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",False,pancreas cancer metastatic,multiple
217,United States,"B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma|B-Cell Prolymphocytic Leukemia|High Grade B-Cell Lymphoma, Not Otherwise Specified|Post-Transplant Lymphoproliferative Disorder|Recurrent Adult Burkitt Lymphoma|Recurrent Chronic Lymphocytic Leukemia|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Follicular Lymphoma|Recurrent Hairy Cell Leukemia|Recurrent Lymphoplasmacytic Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma",BIOLOGICAL: Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes|DRUG: Bendamustine Hydrochloride|DRUG: Cyclophosphamide|DRUG: Etoposide|DRUG: Fludarabine Phosphate,1,OTHER,City of Hope Medical Center,"['other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'autologous cd19car-cd28-cd3zeta-egfrt-expressing tn'}, {'type': 'other', 'subtype': None, 'raw': 'mem-enriched t-lymphocytes'}, {'type': 'other', 'subtype': None, 'raw': 'bendamustine hydrochloride'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'etoposide'}, {'type': 'chemotherapy', 'subtype': 'purine analog', 'raw': 'fludarabine phosphate'}]",True,b cell lymphoma unclassifiable with features intermediate between diffuse large b cell lymphoma and classic hodgkin lymphoma b cell prolymphocytic leukemia high grade b cell lymphoma not otherwise specified post transplant lymphoproliferative disorder recurrent adult burkitt lymphoma recurrent chronic lymphocytic leukemia recurrent diffuse large b cell lymphoma recurrent follicular lymphoma recurrent hairy cell leukemia recurrent lymphoplasmacytic lymphoma recurrent mantle cell lymphoma recurrent marginal zone lymphoma recurrent small lymphocytic lymphoma,hematologic
218,"Australia, United States",B-cell Lymphoma|Non-Hodgkin Lymphoma|B-cell Malignancy|Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)|Follicular Lymphoma|Mantle Cell Lymphoma|Marginal Zone Lymphoma|Large B-cell Lymphoma,BIOLOGICAL: CTX112,12,INDUSTRY,CRISPR Therapeutics AG,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'ctx112'}]",False,b cell lymphoma non hodgkin lymphoma b cell malignancy chronic lymphocytic leukemia small lymphocytic lymphoma follicular lymphoma mantle cell lymphoma marginal zone lymphoma large b cell lymphoma,hematologic
219,China,Non-small Cell Lung Cancer,COMBINATION_PRODUCT: Fecal Microbiota Transplantation (FMT)+chemotherapy+immunotherapy,2,OTHER,Changzhou No.2 People's Hospital,"['other', 'chemotherapy', 'immunotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'fecal microbiota transplantation'}, {'type': 'chemotherapy', 'subtype': 'unspecified', 'raw': 'chemotherapy'}, {'type': 'immunotherapy', 'subtype': 'unspecified', 'raw': 'immunotherapy'}]",True,non small cell lung cancer,lung/thoracic
220,United States,Diffuse Intrinsic Pontine Glioma|High Grade Glioma|Embryonal Tumor|Ependymal Tumor,GENETIC: C7R-GD2.CART cells (IV and ICV infusion)|GENETIC: C7R-GD2.CAR T cells (IV infusion),1,OTHER,Baylor College of Medicine,[],[],False,diffuse intrinsic pontine glioma high grade glioma embryonal tumor ependymal tumor,brain/CNS
221,United States,Pancreatic Ductal Adenocarcinoma|Colorectal Cancer|KRAS G12D|KRAS G12R|KRAS G12V|KRAS G12A|KRAS G12C|KRAS G12S|KRAS G13D|NRAS G12D|NRAS G12R|NRAS G12V|NRAS G12C|NRAS G12S,DRUG: ELI-002 7P,12,INDUSTRY,Elicio Therapeutics,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'eli-002 7p'}]",False,pancreatic ductal adenocarcinoma colorectal cancer kras g12d kras g12r kras g12v kras g12a kras g12c kras g12s kras g13d nras g12d nras g12r nras g12v nras g12c nras g12s,digestive
222,"Australia, Canada, United States",Advanced Solid Tumors,DRUG: BMS-986484|BIOLOGICAL: Nivolumab,1,INDUSTRY,Bristol-Myers Squibb,"['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'bms-986484'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}]",True,advanced solid tumors,multiple
223,United States,Bladder Cancer,DRUG: N-803 and BCG|DRUG: N-803,23,INDUSTRY,"ImmunityBio, Inc.","['other', 'cytokine therapy']","[{'type': 'other', 'subtype': None, 'raw': 'n-803 and bcg'}, {'type': 'cytokine therapy', 'subtype': 'IL-15 superagonist', 'raw': 'n-803'}]",True,bladder cancer,genitourinary
224,France,Non Small Cell Lung Cancer,DRUG: ICI treatment discontinuation|DRUG: ICI treatment continuation,2,OTHER,Institut Bergonié,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'ici treatment discontinuation'}, {'type': 'other', 'subtype': None, 'raw': 'ici treatment continuation'}]",False,non small cell lung cancer,lung/thoracic
225,France,Malignant Solid Neoplasms,DRUG: Nilotinib (400 mg BID)|DRUG: Everolimus (10 mg QD)|DRUG: Sorafenib (400 mg BID)|DRUG: Lapatinib (1500 mg QD)|DRUG: Pazopanib (800 mg QD)|DRUG: Olaparib (300 mg BID)|COMBINATION_PRODUCT: Durvalumab + Tremelimumab,2,OTHER,Centre Leon Berard,"['checkpoint inhibitor', 'targeted therapy', 'other', 'kinase inhibitor']","[{'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'nilotinib'}, {'type': 'other', 'subtype': None, 'raw': 'everolimus'}, {'type': 'targeted therapy', 'subtype': 'other', 'raw': 'sorafenib'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'lapatinib'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'pazopanib'}, {'type': 'targeted therapy', 'subtype': 'PARP inhibitor', 'raw': 'olaparib'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'tremelimumab'}]",True,malignant solid neoplasms,other
226,France,Endometrial Carcinoma|Cervix Carcinoma,DRUG: NP137|DRUG: Pembrolizumab|DRUG: Paclitaxel|DRUG: Carboplatin,12,INDUSTRY,NETRIS Pharma,"['checkpoint inhibitor', 'other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'np137'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}]",True,endometrial carcinoma cervix carcinoma,gynecologic
227,Germany,Lung Cancer Non-Small Cell Cancer (NSCLC),"PROCEDURE: surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines|RADIATION: Chemoradiotherapy|DRUG: Immunotherapy",2,OTHER,Eleni Gkika,['immunotherapy'],"[{'type': 'immunotherapy', 'subtype': 'unspecified', 'raw': 'immunotherapy'}]",False,lung cancer non small cell cancer,lung/thoracic
228,Sweden,Colorectal Cancer,DRUG: pTTL,12,INDUSTRY,Neogap Therapeutics AB,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'pttl'}]",False,colorectal cancer,digestive
229,United States,Advanced Unresectable Solid Tumor|Metastatic Solid Tumor,DRUG: TAB004|DRUG: Toripalimab,1,INDUSTRY,TopAlliance Biosciences,"['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'tab004'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'toripalimab'}]",True,advanced unresectable solid tumor metastatic solid tumor,multiple
230,Brazil,Squamous Cell Carcinoma of Larynx,"DRUG: carboplatin AUC of 6, paclitaxel 175 mg/m2, and pembrolizumab 200 mg, i.v. on day 1, every 21 days for 3 cycles|RADIATION: Concurrent radio-immunotherapy: radiation therapy given concurrently with pembrolizumab 200 mg i.v. on day 1, every 21 days for 3 cycles.|DRUG: Consolidation immunotherapy: pembrolizumab 200 mg i.v. on day 1, every 21 days for 11 doses.",2,OTHER,Latin American Cooperative Oncology Group,"['checkpoint inhibitor', 'other', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin auc of 6'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel 175'}, {'type': 'other', 'subtype': None, 'raw': 'm2'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'and pembrolizumab 200'}, {'type': 'other', 'subtype': None, 'raw': 'i.v. on day 1'}, {'type': 'other', 'subtype': None, 'raw': 'every 21 days for 3 cycles'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'consolidation immunotherapy: pembrolizumab 200 i.v. on day 1'}, {'type': 'other', 'subtype': None, 'raw': 'every 21 days for 11 doses.'}]",True,squamous cell carcinoma of larynx,other
231,"Australia, United States",T Cell Lymphoma|B Cell Lymphoma|Acute Myeloid Leukemia,BIOLOGICAL: CTX131,12,INDUSTRY,CRISPR Therapeutics,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'ctx131'}]",False,t cell lymphoma b cell lymphoma acute myeloid leukemia,hematologic
232,United States,Non-Small Cell Lung Cancer|NSCLC|Advanced Non-Small Cell Lung Cancer|Metastatic Non Small Cell Lung Cancer,DRUG: Reduced Dose of Chemotherapy and Immunotherapy,2,OTHER,Virginia Commonwealth University,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'reduced dose of chemotherapy and immunotherapy'}]",False,non small cell lung cancer nsclc advanced non small cell lung cancer metastatic non small cell lung cancer,lung/thoracic
233,United Kingdom,Metastatic Colorectal Cancer,DRUG: Nivolumab,2,OTHER,Royal Marsden NHS Foundation Trust,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}]",False,metastatic colorectal cancer,digestive
234,United States,Acute Myeloid Leukemia|Acute Lymphoid Leukemia|Mixed Phenotype Acute Leukemia|Undifferentiated Leukemia|Myelodysplastic Syndrome|Acute Leukemia|Therapy-Related Myelodysplastic Syndrome,BIOLOGICAL: Orca-T|BIOLOGICAL: Standard-of-Care,3,INDUSTRY,"Orca Biosystems, Inc.",['other'],"[{'type': 'other', 'subtype': None, 'raw': 'orca-t'}, {'type': 'other', 'subtype': None, 'raw': 'standard-of-care'}]",False,acute myeloid leukemia acute lymphoid leukemia mixed phenotype acute leukemia undifferentiated leukemia myelodysplastic syndrome acute leukemia therapy related myelodysplastic syndrome,hematologic
235,Netherlands,"Uveal Melanoma, Metastatic",DRUG: Ipilimumab and nivolumab|DRUG: Melphalan chemosaturation via percutaneous hepatic perfusion,12,OTHER,Leiden University Medical Center,"['checkpoint inhibitor', 'other']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'ipilimumab and nivolumab'}, {'type': 'other', 'subtype': None, 'raw': 'melphalan chemosaturation via percutaneous hepatic perfusion'}]",True,uveal melanoma metastatic,skin
236,United States,Recurrent Pulmonary Osteosarcoma|Recurrent High-grade Glioma,BIOLOGICAL: pp65 RNA LP (DP1)|BIOLOGICAL: pp65/tumor mRNA RNA-LP (DP2)|PROCEDURE: Surgical Biopsy/Resection,12,OTHER,University of Florida,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'pp65 rna lp'}, {'type': 'other', 'subtype': None, 'raw': 'pp65'}, {'type': 'other', 'subtype': None, 'raw': 'tumor mrna rna-lp'}]",False,recurrent pulmonary osteosarcoma recurrent high grade glioma,lung/thoracic
237,China,Esophageal Cancer|Immunotherapy|Induction Therapy|Chemoradiotherapy|Surgery,DRUG: Cardonilizumab|RADIATION: Chemoradiotherapy ±immunotherapy|PROCEDURE: Radical surgery,2,OTHER,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",['antibody'],"[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'cardonilizumab'}]",False,esophageal cancer immunotherapy induction therapy chemoradiotherapy surgery,digestive
238,"Argentina, Belgium, Brazil, Canada, Chile, Czechia, Hungary, India, Italy, Mexico, Republic of, Spain, Taiwan, United States","Carcinoma, Ovarian Epithelial|Ovarian Neoplasms|Ovarian Cancer|Ovarian Serous Adenocarcinoma|Fallopian Tube Neoplasms|Fallopian Tube Adenocarcinoma|Fallopian Tube Serous Adenocarcinoma|Peritoneal Cancer|Peritoneal Carcinoma|Peritoneal Neoplasms",BIOLOGICAL: Oregovomab|DRUG: Paclitaxel|DRUG: Carboplatin|BIOLOGICAL: Placebo|DRUG: Carboplatin,3,INDUSTRY,CanariaBio Inc.,"['antibody', 'chemotherapy']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'oregovomab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}]",True,carcinoma ovarian epithelial ovarian neoplasms ovarian cancer ovarian serous adenocarcinoma fallopian tube neoplasms fallopian tube adenocarcinoma fallopian tube serous adenocarcinoma peritoneal cancer peritoneal carcinoma peritoneal neoplasms,gynecologic
239,United States,Lung Cancer,BIOLOGICAL: CAN-2409 + valacyclovir,1,INDUSTRY,"Candel Therapeutics, Inc.","['antiviral', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'can-2409'}, {'type': 'antiviral', 'subtype': 'nucleoside analog', 'raw': 'valacyclovir'}]",True,lung cancer,lung/thoracic
240,China,Bladder Cancer Stage IV,DRUG: Chidamide,2,OTHER,Sun Yat-sen University,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'chidamide'}]",False,bladder cancer stage iv,genitourinary
241,France,Hepatocellular Carcinoma,DRUG: EXL01,2,OTHER,Center Eugene Marquis,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'exl01'}]",False,hepatocellular carcinoma,digestive
242,China,"Lung Cancer, Small Cell",DRUG: Chemotherapy （Etoposide and Carboplatin）|DRUG: Immunotherapy （Envafolimab）|DRUG: Trilaciclib,2,OTHER,Shanghai Chest Hospital,"['other', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'chemotherapy （etoposide and carboplatin）'}, {'type': 'other', 'subtype': None, 'raw': 'immunotherapy （envafolimab）'}, {'type': 'other', 'subtype': None, 'raw': 'trilaciclib'}]",True,lung cancer small cell,lung/thoracic
243,China,Non-Small Cell Lung Cancer,COMBINATION_PRODUCT: Immunotherapy (with or without chemotherapy) maintenance therapy combined with radiotherapy|DRUG: Immunotherapy (with or without chemotherapy) maintenance therapy,2,OTHER,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",['other'],"[{'type': 'other', 'subtype': None, 'raw': 'immunotherapy maintenance therapy combined with radiotherapy'}, {'type': 'other', 'subtype': None, 'raw': 'immunotherapy maintenance therapy'}]",False,non small cell lung cancer,lung/thoracic
244,Spain,Colorectal Cancer|Endometrial Cancer,DRUG: Durvalumab|DRUG: Tremelimumab,2,OTHER,Vall d'Hebron Institute of Oncology,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'tremelimumab'}]",False,colorectal cancer endometrial cancer,gynecologic
245,Portugal,Triple Negative Breast Cancer (TNBC),OTHER: Morning pembrolizumab infusions,12,OTHER_GOV,"Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E.",['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'other: morning pembrolizumab infusions'}]",False,triple negative breast cancer,breast
246,United States,Gastrointestinal Cancer|Pancreatic Cancer|Gastric Cancer|Colon Cancer|Rectal Cancer,DRUG: Cyclophosphamide|DRUG: Fludarabine|DRUG: Aldesleukin|BIOLOGICAL: anti-KRAS G12D mTCR PBL,12,NIH,National Cancer Institute (NCI),"['cytokine therapy', 'chemotherapy', 'cell therapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide'}, {'type': 'chemotherapy', 'subtype': 'purine analog', 'raw': 'fludarabine'}, {'type': 'cytokine therapy', 'subtype': 'IL-2', 'raw': 'aldesleukin'}, {'type': 'cell therapy', 'subtype': 'engineered cell', 'raw': 'anti-kras g12d mtcr pbl'}]",True,gastrointestinal cancer pancreatic cancer gastric cancer colon cancer rectal cancer,digestive
247,China,Cervical Cancer|Induction Chemotherapy|Immunotherapy,DRUG: Toripalimab,12,OTHER,Tianjin Medical University Cancer Institute and Hospital,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'toripalimab'}]",False,cervical cancer induction chemotherapy immunotherapy,gynecologic
248,Republic of,Ovarian Cancer by FIGO Stage|Ovarian Cancer Stage III|Ovarian Cancer Stage IV,BIOLOGICAL: Oregovomab|DRUG: Bevacizumab|DRUG: Paclitaxel|DRUG: Carboplatin,12,INDUSTRY,CanariaBio Inc.,"['antibody', 'chemotherapy']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'oregovomab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'bevacizumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}]",True,ovarian cancer by figo stage ovarian cancer stage iii ovarian cancer stage iv,gynecologic
249,United States,Urothelial Cancer|Metastatic Urothelial Carcinoma|Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter|Bladder Cancer,DRUG: Sacituzumab Govitecan (SG)|DRUG: Enfortumab vedotin-ejfv (EV)|DRUG: Pembrolizumab,12,OTHER,Dana-Farber Cancer Institute,"['checkpoint inhibitor', 'antibody-drug conjugate', 'other']","[{'type': 'antibody-drug conjugate', 'subtype': 'anti-Trop-2', 'raw': 'sacituzumab govitecan'}, {'type': 'other', 'subtype': None, 'raw': 'enfortumab vedotin-ejfv'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",True,urothelial cancer metastatic urothelial carcinoma metastatic urothelial carcinoma of the renal pelvis and ureter bladder cancer,genitourinary
250,United States,Pancreatic Cancer|Metastatic Pancreatic Cancer,DRUG: Nivolumab|DRUG: Ipilimumab|RADIATION: Radiation,2,OTHER,Massachusetts General Hospital,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}]",False,pancreatic cancer metastatic pancreatic cancer,digestive
251,United States,Cervical Cancer|Throat Cancer|Oropharynx Cancer|Anal Cancer|Vulva Cancer|Vaginal Cancer|Penile Cancer|Metastatic Cancer|HPV-Related Malignancy|HPV-Related Carcinoma|HPV-Related Cervical Carcinoma|HPV-Related Squamous Cell Carcinoma|HPV-Related Adenocarcinoma|HPV Positive Oropharyngeal Squamous Cell Carcinoma|HPV-Associated Vaginal Adenocarcinoma|HPV-Related Adenosquamous Carcinoma|HPV-Related Endocervical Adenocarcinoma|HPV-Related Anal Squamous Cell Carcinoma|HPV-Related Penile Squamous Cell Carcinoma|HPV-Related Vulvar Squamous Cell Carcinoma|HPV Positive Rectal Squamous Cell Carcinoma,BIOLOGICAL: E7 TCR-T cells|DRUG: Aldesleukin,2,OTHER,Christian Hinrichs,"['cytokine therapy', 'cell therapy']","[{'type': 'cell therapy', 'subtype': 'engineered cell', 'raw': 'e7 tcr-t cells'}, {'type': 'cytokine therapy', 'subtype': 'IL-2', 'raw': 'aldesleukin'}]",True,cervical cancer throat cancer oropharynx cancer anal cancer vulva cancer vaginal cancer penile cancer metastatic cancer hpv related malignancy hpv related carcinoma hpv related cervical carcinoma hpv related squamous cell carcinoma hpv related adenocarcinoma hpv positive oropharyngeal squamous cell carcinoma hpv associated vaginal adenocarcinoma hpv related adenosquamous carcinoma hpv related endocervical adenocarcinoma hpv related anal squamous cell carcinoma hpv related penile squamous cell carcinoma hpv related vulvar squamous cell carcinoma hpv positive rectal squamous cell carcinoma,gynecologic
252,United States,Metastatic Colorectal Cancer,BIOLOGICAL: AlloStim,2,INDUSTRY,"Mirror Biologics, Inc.",['other'],"[{'type': 'other', 'subtype': None, 'raw': 'allostim'}]",False,metastatic colorectal cancer,digestive
253,United States,Pancreatic Cancer|Gastric Cancer|Gastrointestinal Cancer|Colon Cancer|Rectal Cancer,DRUG: Cyclophosphamide|DRUG: Fludarabine|BIOLOGICAL: Anti-KRAS G12V mTCR PBL|DRUG: Aldesleukin,12,NIH,National Cancer Institute (NCI),"['cytokine therapy', 'chemotherapy', 'cell therapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide'}, {'type': 'chemotherapy', 'subtype': 'purine analog', 'raw': 'fludarabine'}, {'type': 'cell therapy', 'subtype': 'engineered cell', 'raw': 'anti-kras g12v mtcr pbl'}, {'type': 'cytokine therapy', 'subtype': 'IL-2', 'raw': 'aldesleukin'}]",True,pancreatic cancer gastric cancer gastrointestinal cancer colon cancer rectal cancer,digestive
254,China,Neoadjuvant Therapy|Concurrent Chemoradiotherapy|Immunotherapy|Locally Advanced Non-Small Cell Lung Cancer,DRUG: Neoadjuvant therapy|RADIATION: Concurrent chemoradiotherapy|DRUG: Consolidative immunotherapy,3,OTHER,Sun Yat-sen University,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'neoadjuvant therapy'}, {'type': 'other', 'subtype': None, 'raw': 'consolidative immunotherapy'}]",False,neoadjuvant therapy concurrent chemoradiotherapy immunotherapy locally advanced non small cell lung cancer,lung/thoracic
255,China,Lung Cancer|Surgery|Non-small Cell Lung Cancer,"DRUG: ipilimumab, pembrolizumab, durvalumab, idarubicin, bevacizumab",2,OTHER,Second Affiliated Hospital of Guangzhou Medical University,"['checkpoint inhibitor', 'antibody', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}, {'type': 'chemotherapy', 'subtype': 'anthracycline', 'raw': 'idarubicin'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'bevacizumab'}]",True,lung cancer surgery non small cell lung cancer,lung/thoracic
256,United States,HER2-positive Breast Cancer|Breast Cancer,DRUG: Paclitaxel|DRUG: Trastuzumab|DRUG: Pertuzumab|DRUG: Pembrolizumab,2,OTHER,University of Texas Southwestern Medical Center,"['checkpoint inhibitor', 'antibody', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'trastuzumab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'pertuzumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",True,her2 positive breast cancer breast cancer,breast
257,"Canada, Chile, Republic of, United States","HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer",DRUG: ZW25 (Zanidatamab)|DRUG: Capecitabine|DRUG: Cisplatin|DRUG: Fluorouracil|DRUG: Leucovorin|DRUG: Oxaliplatin|DRUG: Bevacizumab|DRUG: Gemcitabine,2,INDUSTRY,Jazz Pharmaceuticals,"['other', 'antibody', 'supportive care', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'zw25'}, {'type': 'chemotherapy', 'subtype': 'fluoropyrimidine', 'raw': 'capecitabine'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}, {'type': 'chemotherapy', 'subtype': 'antimetabolite', 'raw': 'fluorouracil'}, {'type': 'supportive care', 'subtype': 'folinic acid', 'raw': 'leucovorin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'oxaliplatin'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'bevacizumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'gemcitabine'}]",True,her2 expressing gastrointestinal cancers including gastroesophageal adenocarcinoma biliary tract cancer and colorectal cancer,digestive
258,"Australia, United States","Solid Tumor, Adult|Mesothelioma|NSCLC",DRUG: VT3989|DRUG: Nivolumab & Ipilimumab|DRUG: Osimertinib,1,INDUSTRY,"Vivace Therapeutics, Inc","['checkpoint inhibitor', 'other', 'kinase inhibitor']","[{'type': 'other', 'subtype': None, 'raw': 'vt3989'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab & ipilimumab'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'osimertinib'}]",True,solid tumor adult mesothelioma nsclc,lung/thoracic
259,"Argentina, Brazil, Canada, Denmark, Finland, France, Germany, Greece, Hungary, Italy, Japan, Norway, Poland, Portugal, Republic of, Romania, Spain, Taiwan, Turkey, United States","Neoplasms, Head and Neck",DRUG: Dostarlimab|DRUG: Belrestotug|DRUG: Nelistotug|DRUG: GSK4381562,2,INDUSTRY,GlaxoSmithKline,"['other', 'antibody']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'dostarlimab'}, {'type': 'other', 'subtype': None, 'raw': 'belrestotug'}, {'type': 'other', 'subtype': None, 'raw': 'nelistotug'}, {'type': 'other', 'subtype': None, 'raw': 'gsk4381562'}]",True,neoplasms head and neck,head/neck
260,China,Metastatic Malignant Solid Neoplasm|Radiotherapy|Immune Checkpoint Blockade|Resistance to Immunotherapy,RADIATION: Intestinal Low Dose Radiotherapy-1Gy|RADIATION: Intestinal Low Dose Radiotherapy-2-3Gy|DRUG: PD-1/PD-L1 Inhibitors,2,OTHER,Chuangzhen Chen,"['checkpoint inhibitor', 'other']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'pd-1'}, {'type': 'other', 'subtype': None, 'raw': 'pd-l1 inhibitors'}]",True,metastatic malignant solid neoplasm radiotherapy immune checkpoint blockade resistance to immunotherapy,hematologic
261,China,Advanced Solid Tumor|Tumor Associated Lymph Node T Cell|Immunotherapy,DRUG: Tumor Associated Lymph node T cell|DRUG: cyclophosphamide|DRUG: IL-2|DRUG: Serplulimab Injection,1,INDUSTRY,"Guangzhou FineImmune Biotechnology Co., LTD.","['other', 'cytokine therapy', 'chemotherapy', 'cell therapy']","[{'type': 'cell therapy', 'subtype': 'other', 'raw': 'tumor associated lymph node t cell'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide'}, {'type': 'cytokine therapy', 'subtype': 'IL-2', 'raw': 'il-2'}, {'type': 'other', 'subtype': None, 'raw': 'serplulimab injection'}]",True,advanced solid tumor tumor associated lymph node t cell immunotherapy,hematologic
262,China,Liver Cancer,BIOLOGICAL: Autologous Tumor Infiltrating Lymphocytes,1,OTHER,Zhiyong Huang,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'autologous tumor infiltrating lymphocytes'}]",False,liver cancer,digestive
263,United States,Uveal Melanoma,RADIATION: stereotactic body radiotherapy|DRUG: Immunotherapy,2,OTHER,California Pacific Medical Center Research Institute,['immunotherapy'],"[{'type': 'immunotherapy', 'subtype': 'unspecified', 'raw': 'immunotherapy'}]",False,uveal melanoma,skin
264,United States,Metastatic Malignant Neoplasm in the Liver|Stage IV Colorectal Cancer AJCC v8|Stage IVA Colorectal Cancer AJCC v8|Stage IVB Colorectal Cancer AJCC v8|Stage IVC Colorectal Cancer AJCC v8,PROCEDURE: Hepatectomy|BIOLOGICAL: Pembrolizumab|DRUG: Vactosertib,2,OTHER,"Chloe Atreya, MD, PhD","['checkpoint inhibitor', 'other']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'other', 'subtype': None, 'raw': 'vactosertib'}]",True,metastatic malignant neoplasm in the liver stage iv colorectal cancer ajcc v8 stage iva colorectal cancer ajcc v8 stage ivb colorectal cancer ajcc v8 stage ivc colorectal cancer ajcc v8,digestive
265,Singapore,Locally Recurrent Cancer|Metastatic Nasopharyngeal Cancer,DRUG: pembrolizumab|DRUG: bevacizumab,12,OTHER,"National University Hospital, Singapore","['checkpoint inhibitor', 'antibody']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'bevacizumab'}]",True,locally recurrent cancer metastatic nasopharyngeal cancer,head/neck
266,"Australia, Belgium, Netherlands, Switzerland, United Kingdom, United States","Melanoma|Merkel Cell Carcinoma, Unspecified|Renal Cell Carcinoma|Non Small Cell Lung Cancer",BIOLOGICAL: zirconium Zr 89 crefmirlimab berdoxam,2,INDUSTRY,"ImaginAb, Inc.",['other'],"[{'type': 'other', 'subtype': None, 'raw': 'zirconium zr 89 crefmirlimab berdoxam'}]",False,melanoma merkel cell carcinoma unspecified renal cell carcinoma non small cell lung cancer,genitourinary
267,China,Stomach Neoplasms|Gastric Cancer|Linitis Plastica of Stomach,DRUG: Tislelizumab|DRUG: Oxaliplatin|DRUG: S-1|DRUG: Capecitabine,2,OTHER,Sun Yat-sen University,"['checkpoint inhibitor', 'other', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'tislelizumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'oxaliplatin'}, {'type': 'other', 'subtype': None, 'raw': 's-1'}, {'type': 'chemotherapy', 'subtype': 'fluoropyrimidine', 'raw': 'capecitabine'}]",True,stomach neoplasms gastric cancer linitis plastica of stomach,digestive
268,"Argentina, Australia, Belgium, Brazil, Canada, Chile, China, Estonia, France, Georgia, Germany, Greece, Guatemala, India, Ireland, Italy, Japan, Malaysia, Mexico, Netherlands, Poland, Portugal, Republic of, Romania, Serbia, Singapore, South Africa, Spain, Taiwan, Thailand, Turkey, Ukraine, United Kingdom",Gastric Neoplasms|Gastroesophageal Adenocarcinoma|Esophageal Adenocarcinoma,DRUG: Zanidatamab|DRUG: Tislelizumab|DRUG: Trastuzumab|DRUG: Capecitabine|DRUG: Oxaliplatin|DRUG: Cisplatin|DRUG: 5-Fluorouracil,3,INDUSTRY,Jazz Pharmaceuticals,"['checkpoint inhibitor', 'antibody', 'chemotherapy']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'zanidatamab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'tislelizumab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'trastuzumab'}, {'type': 'chemotherapy', 'subtype': 'fluoropyrimidine', 'raw': 'capecitabine'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'oxaliplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}, {'type': 'chemotherapy', 'subtype': 'antimetabolite', 'raw': '5-fluorouracil'}]",True,gastric neoplasms gastroesophageal adenocarcinoma esophageal adenocarcinoma,digestive
269,China,Esophageal Squamous Cell Carcinoma,DRUG: paclitaxel|DRUG: carboplatin|DRUG: tislelizumab|RADIATION: radiotherapy,12,OTHER,Qiu Guoqin,"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'tislelizumab'}]",True,esophageal squamous cell carcinoma,digestive
270,United States,Neuroblastoma,"BIOLOGICAL: Neuroblastoma Vaccine (unmodified SKNLP, with gene-modified SJNB-JF-IL2 and SJNB-JF-LTN neuroblastoma cells|DRUG: Cytoxan",12,OTHER,Baylor College of Medicine,"['vaccine', 'chemotherapy', 'cell therapy']","[{'type': 'vaccine', 'subtype': 'vaccine', 'raw': 'neuroblastoma vaccine (unmodified sknlp'}, {'type': 'cell therapy', 'subtype': 'other', 'raw': 'with gene-modified sjnb-jf-il2 and sjnb-jf-ltn neuroblastoma cells'}, {'type': 'chemotherapy', 'subtype': 'alkylating agent', 'raw': 'cytoxan'}]",True,neuroblastoma,other
271,"Argentina, Australia, Chile, Singapore, Spain, United States",Metastasis,DRUG: THOR-707|DRUG: Checkpoint inhibitor|DRUG: anti-EGFR antibody,12,INDUSTRY,"Synthorx, Inc, a Sanofi company",['other'],"[{'type': 'other', 'subtype': None, 'raw': 'thor-707'}, {'type': 'other', 'subtype': None, 'raw': 'checkpoint inhibitor'}, {'type': 'other', 'subtype': None, 'raw': 'anti-egfr antibody'}]",False,metastasis,other
272,United States,Metastatic Cancer,DRUG: Keytruda Injectable Product|DRUG: Yervoy Injectable Product|DRUG: GM-CSF|PROCEDURE: Non-ablative Cryosurgical freezing,2,OTHER,"ImmunSYS, LLC",['other'],"[{'type': 'other', 'subtype': None, 'raw': 'keytruda injectable product'}, {'type': 'other', 'subtype': None, 'raw': 'yervoy injectable product'}, {'type': 'other', 'subtype': None, 'raw': 'gm-csf'}]",False,metastatic cancer,multiple
273,Italy,Breast Cancer|Gastrointestinal Cancer|Non Small Cell Lung Cancer|Other Cancer,DRUG: Erlotinib|DRUG: Trastuzumab|DRUG: Trastuzumab emtansine|DRUG: Pertuzumab|DRUG: Lapatinib|DRUG: Everolimus|DRUG: Vemurafenib|DRUG: Cobimetinib|DRUG: Alectinib|DRUG: Brigatinib|DRUG: Palbociclib|DRUG: Ponatinib|DRUG: Vismogedib|DRUG: Itacitinib|DRUG: Ipatasertib|DRUG: Entrectinib|DRUG: Atezolizumab|DRUG: Nivolumab|DRUG: Ipilimumab|DRUG: Pemigatinib|DRUG: Oncology Drugs|DRUG: Pralsetinib|DRUG: Selpercatinib|DRUG: Talazoparib|DRUG: Tepotinib|DRUG: Alpelisib,2,OTHER,Fondazione per la Medicina Personalizzata,"['targeted therapy', 'other', 'kinase inhibitor', 'checkpoint inhibitor', 'antibody']","[{'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'erlotinib'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'trastuzumab'}, {'type': 'other', 'subtype': None, 'raw': 'trastuzumab emtansine'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'pertuzumab'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'lapatinib'}, {'type': 'other', 'subtype': None, 'raw': 'everolimus'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'vemurafenib'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'cobimetinib'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'alectinib'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'brigatinib'}, {'type': 'targeted therapy', 'subtype': 'CDK4/6 inhibitor', 'raw': 'palbociclib'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'ponatinib'}, {'type': 'other', 'subtype': None, 'raw': 'vismogedib'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'itacitinib'}, {'type': 'targeted therapy', 'subtype': 'AKT inhibitor', 'raw': 'ipatasertib'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'entrectinib'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'atezolizumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'pemigatinib'}, {'type': 'other', 'subtype': None, 'raw': 'oncology drugs'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'pralsetinib'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'selpercatinib'}, {'type': 'targeted therapy', 'subtype': 'PARP inhibitor', 'raw': 'talazoparib'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'tepotinib'}, {'type': 'other', 'subtype': None, 'raw': 'alpelisib'}]",True,breast cancer gastrointestinal cancer non small cell lung cancer other cancer,digestive
274,"Puerto Rico, United States",Prostate Cancer,BIOLOGICAL: Aglatimagene besadenovec + valacyclovir|BIOLOGICAL: Placebo + valacyclovir,3,INDUSTRY,"Candel Therapeutics, Inc.","['antiviral', 'gene therapy']","[{'type': 'gene therapy', 'subtype': 'adenoviral vector', 'raw': 'aglatimagene besadenovec'}, {'type': 'antiviral', 'subtype': 'nucleoside analog', 'raw': 'valacyclovir'}, {'type': 'antiviral', 'subtype': 'nucleoside analog', 'raw': 'valacyclovir'}]",True,prostate cancer,genitourinary
275,"Australia, Brazil, China, Denmark, France, Germany, Greece, Italy, Mexico, Poland, Republic of, Spain, Turkey, United Kingdom, United States",Urothelial Cancer,DRUG: Atezolizumab|DRUG: Tobemstomig|DRUG: Tiragolumab,2,INDUSTRY,Hoffmann-La Roche,"['checkpoint inhibitor', 'other', 'antibody']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'atezolizumab'}, {'type': 'other', 'subtype': None, 'raw': 'tobemstomig'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'tiragolumab'}]",True,urothelial cancer,genitourinary
276,United States,Pancreatic Cancer,PROCEDURE: Biopsy|DRUG: FOLFIRINOX|DRUG: Ciprofloxacin|DRUG: Metronidazole|DRUG: Pembrolizumab|PROCEDURE: Surgical Resection,2,OTHER,Icahn School of Medicine at Mount Sinai,"['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'folfirinox'}, {'type': 'other', 'subtype': None, 'raw': 'ciprofloxacin'}, {'type': 'other', 'subtype': None, 'raw': 'metronidazole'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",True,pancreatic cancer,digestive
277,United Kingdom,Non-small Cell Lung Cancer Stage II|Non-small Cell Lung Cancer Stage I,RADIATION: Stereotactic body radiotherapy|DRUG: Nivolumab,12,OTHER,Royal Marsden NHS Foundation Trust,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}]",False,non small cell lung cancer stage ii non small cell lung cancer stage i,lung/thoracic
278,United States,Metastatic Cancer|Cervical Cancer,DRUG: Lorigerlimab,2,OTHER,M.D. Anderson Cancer Center,['antibody'],"[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'lorigerlimab'}]",False,metastatic cancer cervical cancer,gynecologic
279,United States,Gynecologic Cancer|Colorectal Cancer|Pancreatic Cancer|Non-small Cell Lung Cancer|Cholangiocarcinoma|Ovarian Cancer|Endometrial Cancer|Ovarian Carcinoma|Ovary Neoplasm|Squamous Cell Lung Cancer|Adenocarcinoma of Lung|Adenosquamous Cell Lung Cancer,BIOLOGICAL: Neoantigen specific TCR-T cell drug product|BIOLOGICAL: Aldesleukin (IL-2),12,INDUSTRY,Alaunos Therapeutics,"['cytokine therapy', 'cell therapy']","[{'type': 'cell therapy', 'subtype': 'engineered cell', 'raw': 'neoantigen specific tcr-t cell drug product'}, {'type': 'cytokine therapy', 'subtype': 'IL-2', 'raw': 'aldesleukin'}]",True,gynecologic cancer colorectal cancer pancreatic cancer non small cell lung cancer cholangiocarcinoma ovarian cancer endometrial cancer ovarian carcinoma ovary neoplasm squamous cell lung cancer adenocarcinoma of lung adenosquamous cell lung cancer,gynecologic
280,China,"Lung Cancer, Non-small Cell",RADIATION: hypofractionated radiation therapy,2,OTHER,Jiangsu Cancer Institute & Hospital,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'radiation: hypofractionated radiation therapy'}]",False,lung cancer non small cell,lung/thoracic
281,Brazil,Renal Cancer Metastatic,DRUG: Nivolumab|DRUG: Ipilimumab,2,OTHER,Hospital das Clínicas de Ribeirão Preto,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}]",False,renal cancer metastatic,genitourinary
282,China,Esophageal Squamous Cell Carcinoma|Esophageal Cancer|Metastatic Esophageal Squamous Cell Carcinoma,RADIATION: LDRT+CFRT|DRUG: Immunotherapy|DRUG: Chemotherapy,2,OTHER,Shanghai Chest Hospital,"['chemotherapy', 'immunotherapy']","[{'type': 'immunotherapy', 'subtype': 'unspecified', 'raw': 'immunotherapy'}, {'type': 'chemotherapy', 'subtype': 'unspecified', 'raw': 'chemotherapy'}]",True,esophageal squamous cell carcinoma esophageal cancer metastatic esophageal squamous cell carcinoma,digestive
283,China,Melanoma,"BIOLOGICAL: Antigen-specific CAR T, CTL and DCvac to treat melanoma.",12,OTHER,Shenzhen Geno-Immune Medical Institute,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'antigen-specific car t'}, {'type': 'other', 'subtype': None, 'raw': 'ctl and dcvac to treat melanoma.'}]",False,melanoma,skin
284,China,Non-Small Cell Lung Cancer,DRUG: Chemotherapy|DRUG: Immunotherapy|PROCEDURE: Radical resection of lung cancer|RADIATION: SBRT,2,OTHER,First People's Hospital of Hangzhou,"['chemotherapy', 'immunotherapy']","[{'type': 'chemotherapy', 'subtype': 'unspecified', 'raw': 'chemotherapy'}, {'type': 'immunotherapy', 'subtype': 'unspecified', 'raw': 'immunotherapy'}]",True,non small cell lung cancer,lung/thoracic
285,United States,Pancreatic Cancer|Locally Advanced Pancreatic Cancer,DRUG: Pembrolizumab|DEVICE: Irreversible Electroporation,1,OTHER,H. Lee Moffitt Cancer Center and Research Institute,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",False,pancreatic cancer locally advanced pancreatic cancer,digestive
286,United States,"Central Nervous System Tumor|Diffuse Intrinsic Pontine Glioma|Diffuse Midline Glioma|Ependymoma|Medulloblastoma, Childhood|Germ Cell Tumor|Atypical Teratoid/Rhabdoid Tumor|Primitive Neuroectodermal Tumor|Choroid Plexus Carcinoma|Pineoblastoma, Childhood|Glioma",BIOLOGICAL: SCRI-CARB7H3(s); B7H3-specific chimeric antigen receptor (CAR) T cel,1,OTHER,Seattle Children's Hospital,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'scri-carb7h3; b7h3-specific chimeric antigen receptor t cel'}]",False,central nervous system tumor diffuse intrinsic pontine glioma diffuse midline glioma ependymoma medulloblastoma childhood germ cell tumor atypical teratoid rhabdoid tumor primitive neuroectodermal tumor choroid plexus carcinoma pineoblastoma childhood glioma,brain/CNS
287,United States,Endometrial Cancer,DRUG: Atezolizumab - 28 Day Cycle|DRUG: Bevacizumab|DRUG: Ipatasertib|DRUG: Talazoparib|DRUG: Trastuzumab emtansine|DRUG: Tiragolumab|DRUG: Atezolizumab - 21 Day Cycle|DRUG: Inavolisib|DRUG: Letrozole|DRUG: Giredestrant|DRUG: Abemaciclib,12,OTHER,"Alliance Foundation Trials, LLC.","['checkpoint inhibitor', 'targeted therapy', 'other', 'antibody']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'atezolizumab - 28 day cycle'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'bevacizumab'}, {'type': 'targeted therapy', 'subtype': 'AKT inhibitor', 'raw': 'ipatasertib'}, {'type': 'targeted therapy', 'subtype': 'PARP inhibitor', 'raw': 'talazoparib'}, {'type': 'other', 'subtype': None, 'raw': 'trastuzumab emtansine'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'tiragolumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'atezolizumab - 21 day cycle'}, {'type': 'other', 'subtype': None, 'raw': 'inavolisib'}, {'type': 'other', 'subtype': None, 'raw': 'letrozole'}, {'type': 'other', 'subtype': None, 'raw': 'giredestrant'}, {'type': 'targeted therapy', 'subtype': 'CDK4/6 inhibitor', 'raw': 'abemaciclib'}]",True,endometrial cancer,gynecologic
288,Switzerland,Bladder Cancer,DRUG: Recombinant intravesical BCG (Bacillus Calmette-Guérin VPM1002BC)|DRUG: Atezolizumab|DRUG: Cisplatin|DRUG: Gemcitabine,2,OTHER,Swiss Group for Clinical Cancer Research,"['checkpoint inhibitor', 'other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'recombinant intravesical bcg'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'atezolizumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'gemcitabine'}]",True,bladder cancer,genitourinary
289,United States,Metastatic Prostate Cancer|Metastatic Head and Neck Squamous Cell Carcinoma|Metastatic Pancreatic Cancer,DRUG: Evofosfamide|DRUG: Zalifrelimab|DRUG: Balstilimab,12,INDUSTRY,ImmunoGenesis,"['other', 'antibody']","[{'type': 'other', 'subtype': None, 'raw': 'evofosfamide'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'zalifrelimab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'balstilimab'}]",True,metastatic prostate cancer metastatic head and neck squamous cell carcinoma metastatic pancreatic cancer,genitourinary
290,"Mexico, United States",Prostate Cancer,BIOLOGICAL: aglatimagene besadenovec|BIOLOGICAL: placebo|DRUG: valacyclovir,2,INDUSTRY,"Candel Therapeutics, Inc.","['antiviral', 'gene therapy']","[{'type': 'gene therapy', 'subtype': 'adenoviral vector', 'raw': 'aglatimagene besadenovec'}, {'type': 'antiviral', 'subtype': 'nucleoside analog', 'raw': 'valacyclovir'}]",True,prostate cancer,genitourinary
291,France,Non-Small Cell Lung Cancer,DRUG: EXL01,12,OTHER,"University Hospital, Lille",['other'],"[{'type': 'other', 'subtype': None, 'raw': 'exl01'}]",False,non small cell lung cancer,lung/thoracic
292,United States,Cancer|Solid Tumor|Colorectal Cancer|Pancreas Cancer|Non Small Cell Lung Cancer|Head and Neck Cancer|Gynecologic Cancer|Skin Cancer|Kidney Cancer,BIOLOGICAL: DK210 (EGFR)|RADIATION: Radiation therapy|BIOLOGICAL: Immune checkpoint blockers|DRUG: Chemotherapy,1,INDUSTRY,DEKA Biosciences,"['other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'dk210'}, {'type': 'other', 'subtype': None, 'raw': 'immune checkpoint blockers'}, {'type': 'chemotherapy', 'subtype': 'unspecified', 'raw': 'chemotherapy'}]",True,cancer solid tumor colorectal cancer pancreas cancer non small cell lung cancer head and neck cancer gynecologic cancer skin cancer kidney cancer,gynecologic
293,United States,Clinical Stage III Cutaneous Melanoma AJCC v8|Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8|Clinical Stage IV Cutaneous Melanoma AJCC v8|Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8|Metastatic Basal Cell Carcinoma|Metastatic Carcinoma in the Skin|Metastatic Melanoma|Metastatic Merkel Cell Carcinoma|Metastatic Skin Squamous Cell Carcinoma|Unresectable Basal Cell Carcinoma|Unresectable Melanoma|Unresectable Merkel Cell Carcinoma|Unresectable Skin Squamous Cell Carcinoma,PROCEDURE: Biopsy Procedure|PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|BIOLOGICAL: Ipilimumab|PROCEDURE: Kidney Biopsy|PROCEDURE: Magnetic Resonance Imaging|BIOLOGICAL: Nivolumab|DRUG: Prednisone|DRUG: Sirolimus,12,NIH,National Cancer Institute (NCI),"['checkpoint inhibitor', 'other', 'supportive care']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'supportive care', 'subtype': 'steroid', 'raw': 'prednisone'}, {'type': 'other', 'subtype': None, 'raw': 'sirolimus'}]",True,clinical stage iii cutaneous melanoma ajcc v8 clinical stage iii cutaneous merkel cell carcinoma ajcc v8 clinical stage iv cutaneous melanoma ajcc v8 clinical stage iv cutaneous merkel cell carcinoma ajcc v8 metastatic basal cell carcinoma metastatic carcinoma in the skin metastatic melanoma metastatic merkel cell carcinoma metastatic skin squamous cell carcinoma unresectable basal cell carcinoma unresectable melanoma unresectable merkel cell carcinoma unresectable skin squamous cell carcinoma,skin
294,Mexico,Metastatic Cancer|Metastatic Breast Cancer|Metastatic Lung Cancer|Solid Tumor|Cancer,DRUG: SV-101,1,OTHER,Williams Cancer Foundation,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'sv-101'}]",False,metastatic cancer metastatic breast cancer metastatic lung cancer solid tumor cancer,lung/thoracic
295,France,Non-small Cell Lung Cancer Stage IV,DRUG: Durvalumab,2,OTHER,Intergroupe Francophone de Cancerologie Thoracique,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}]",False,non small cell lung cancer stage iv,lung/thoracic
296,China,Hepatic Cancer|Surgery,"DRUG: ipilimumab, pembrolizumab, durvalumab, idarubicin, bevacizumab",2,OTHER,Second Affiliated Hospital of Guangzhou Medical University,"['checkpoint inhibitor', 'antibody', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}, {'type': 'chemotherapy', 'subtype': 'anthracycline', 'raw': 'idarubicin'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'bevacizumab'}]",True,hepatic cancer surgery,other
297,Netherlands,Esophageal Cancer,DRUG: Nivolumab,2,OTHER,Erasmus Medical Center,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}]",False,esophageal cancer,digestive
298,United States,"Solid Tumor, Adult|HCC - Hepatocellular Carcinoma|CRC (Colorectal Cancer)|Pancreatic Adenocarcinoma|NSCLC Non-small Cell Lung Cancer|Squamous Cell Cancer of the Head and Neck|UC (Urothelial Cancer)|MSI-H Cancer",DRUG: Decoy20|DRUG: Tislelizumab,12,INDUSTRY,"Indaptus Therapeutics, Inc","['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'decoy20'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'tislelizumab'}]",True,solid tumor adult hcc hepatocellular carcinoma crc pancreatic adenocarcinoma nsclc non small cell lung cancer squamous cell cancer of the head and neck uc msi h cancer,genitourinary
299,United States,Pancreatic Cancer|Renal Cell Cancer|Breast Cancer|Melanoma|Ovarian Cancer,DRUG: Cyclophosphamide|DRUG: Fludarabine|DRUG: Aldesleukin|BIOLOGICAL: Anti-hCD70 CAR transduced PBL,12,NIH,National Cancer Institute (NCI),"['other', 'cytokine therapy', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide'}, {'type': 'chemotherapy', 'subtype': 'purine analog', 'raw': 'fludarabine'}, {'type': 'cytokine therapy', 'subtype': 'IL-2', 'raw': 'aldesleukin'}, {'type': 'other', 'subtype': None, 'raw': 'anti-hcd70 car transduced pbl'}]",True,pancreatic cancer renal cell cancer breast cancer melanoma ovarian cancer,gynecologic
300,United States,Melanoma,OTHER: Immunotherapy|OTHER: Quality-of-Life Assessment|RADIATION: Radiation Therapy,2,OTHER,M.D. Anderson Cancer Center,[],[],False,melanoma,skin
301,China,Tumor Associated Lymph Node T Cell|Advanced Solid Tumor|Immunotherapy|Serplulimab Injection,BIOLOGICAL: Tumor Associated Lymph node T cell|DRUG: Serplulimab Injection,1,INDUSTRY,"Guangzhou FineImmune Biotechnology Co., LTD.","['other', 'cell therapy']","[{'type': 'cell therapy', 'subtype': 'other', 'raw': 'tumor associated lymph node t cell'}, {'type': 'other', 'subtype': None, 'raw': 'serplulimab injection'}]",True,tumor associated lymph node t cell advanced solid tumor immunotherapy serplulimab injection,hematologic
302,China,Gastric Cancer|Colon Cancer|MSI-H|DMMR Cancer,"DRUG: PD1/PDL1 antibody monotherapy, up to 24 weeks|COMBINATION_PRODUCT: Intensive immunotherapy plus anti-VEGF treatment, up to 24 weeks|PROCEDURE: Radical surgery",2,OTHER,Peking University,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'pd1'}, {'type': 'other', 'subtype': None, 'raw': 'pdl1 antibody monotherapy'}, {'type': 'other', 'subtype': None, 'raw': 'up to 24 weeks'}, {'type': 'other', 'subtype': None, 'raw': 'intensive immunotherapy plus anti-vegf treatment'}, {'type': 'other', 'subtype': None, 'raw': 'up to 24 weeks'}]",False,gastric cancer colon cancer msi h dmmr cancer,digestive
303,United States,Advanced Head and Neck Squamous Cell Carcinoma|Recurrent Head and Neck Squamous Cell Carcinoma|Metastatic Head-and-neck Squamous-cell Carcinoma|Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck|Locally Advanced Head and Neck Squamous Cell Carcinoma|Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck,DRUG: Pembrolizumab (immunotherapy)|RADIATION: Quad-shot palliative radiotherapy,2,OTHER,Wake Forest University Health Sciences,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",False,advanced head and neck squamous cell carcinoma recurrent head and neck squamous cell carcinoma metastatic head and neck squamous cell carcinoma stage iii cutaneous squamous cell carcinoma of the head and neck locally advanced head and neck squamous cell carcinoma stage iv cutaneous squamous cell carcinoma of the head and neck,skin
304,United Kingdom,"Lymphoma, Non-Hodgkin|Lymphoma, Large B-Cell, Diffuse|Lymphoma, Mantle-Cell|Lymphoma, Follicular|Lymphoma, B-Cell|Large B-cell Lymphoma",DRUG: ALETA-001,12,OTHER,Cancer Research UK,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'aleta-001'}]",False,lymphoma non hodgkin lymphoma large b cell diffuse lymphoma mantle cell lymphoma follicular lymphoma b cell large b cell lymphoma,hematologic
305,United States,Advanced Cancer,BIOLOGICAL: pING-hHER3FL,1,OTHER,Herbert Lyerly,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'ping-hher3fl'}]",False,advanced cancer,multiple
306,United States,"Anatomic Stage IV Breast Cancer AJCC V8|Metastatic Breast Carcinoma|Prognostic Stage IV Breast Cancer AJCC V8|Unresectable Breast Carcinoma|Metastatic Melanoma|Unresectable Melanoma|Cutaneous Squamous Cell Carcinoma|Merkel Cell Carcinoma|Soft Tissue Sarcoma|Bone Sarcoma|Sarcoma,Soft Tissue|Sarcoma of Bone|Basal Cell Carcinoma",BIOLOGICAL: Anti-CD40 Agonist Monoclonal Antibody CDX-1140|DRUG: Poly ICLC|RADIATION: Radiation Therapy|BIOLOGICAL: Recombinant Flt3 Ligand|DRUG: Pembrolizumab|DRUG: Tocilizumab,1,OTHER,University of Southern California,"['checkpoint inhibitor', 'other', 'antibody']","[{'type': 'other', 'subtype': None, 'raw': 'anti-cd40 agonist monoclonal antibody cdx-1140'}, {'type': 'other', 'subtype': None, 'raw': 'poly iclc'}, {'type': 'other', 'subtype': None, 'raw': 'recombinant flt3 ligand'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'tocilizumab'}]",True,anatomic stage iv breast cancer ajcc v8 metastatic breast carcinoma prognostic stage iv breast cancer ajcc v8 unresectable breast carcinoma metastatic melanoma unresectable melanoma cutaneous squamous cell carcinoma merkel cell carcinoma soft tissue sarcoma bone sarcoma sarcoma soft tissue sarcoma of bone basal cell carcinoma,breast
307,China,Stage III Non-small Cell Lung Cancer,DRUG: Neoadjuvant chemo-immunotherapy|DRUG: Bevacizumab|RADIATION: Radiotherapy|DRUG: Tislelizumab,2,OTHER,Sun Yat-sen University,"['checkpoint inhibitor', 'other', 'antibody']","[{'type': 'other', 'subtype': None, 'raw': 'neoadjuvant chemo-immunotherapy'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'bevacizumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'tislelizumab'}]",True,stage iii non small cell lung cancer,lung/thoracic
308,United States,Non Small Cell Lung Cancer|Pancreatic Ductal Adenocarcinoma,DRUG: Mavrostobart (PT199)|DRUG: Tislelizumab|DRUG: Gemcitabine + nab-Paclitaxel|DRUG: Docetaxel|DRUG: Pemetrexed|DRUG: Gemcitabine|DRUG: Carboplatin + Pemetrexed|DRUG: Pembrolizumab + Carboplatin + Pemetrexed,12,INDUSTRY,Phanes Therapeutics,"['checkpoint inhibitor', 'other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'mavrostobart'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'tislelizumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'gemcitabine'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'nab-paclitaxel'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'docetaxel'}, {'type': 'chemotherapy', 'subtype': 'antifolate', 'raw': 'pemetrexed'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'gemcitabine'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'chemotherapy', 'subtype': 'antifolate', 'raw': 'pemetrexed'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'chemotherapy', 'subtype': 'antifolate', 'raw': 'pemetrexed'}]",True,non small cell lung cancer pancreatic ductal adenocarcinoma,digestive
309,United States,Muscle-Invasive Bladder Carcinoma|Metastatic Urothelial Carcinoma,DRUG: SEphB4-HSA|DRUG: Pembrolizumab|DRUG: Gemcitabine|DRUG: Cisplatin|DRUG: Enfortumab vedotin,23,INDUSTRY,"Vasgene Therapeutics, Inc","['checkpoint inhibitor', 'antibody-drug conjugate', 'other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'sephb4-hsa'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'gemcitabine'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}, {'type': 'antibody-drug conjugate', 'subtype': 'anti-Nectin-4', 'raw': 'enfortumab vedotin'}]",True,muscle invasive bladder carcinoma metastatic urothelial carcinoma,genitourinary
310,"France, Greece, Republic of, Spain, Taiwan, United Kingdom, United States",Urothelial Carcinoma|Bladder Cancer,DRUG: Atezolizumab|DRUG: Enfortumab Vedotin|DRUG: Niraparib|DRUG: Magrolimab (Hu5F9-G4)|DRUG: Tiragolumab|DRUG: Sacituzumab Govitecan|DRUG: Tocilizumab|DRUG: Cisplatin|DRUG: Gemcitabine,12,INDUSTRY,Hoffmann-La Roche,"['targeted therapy', 'chemotherapy', 'checkpoint inhibitor', 'antibody', 'antibody-drug conjugate']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'atezolizumab'}, {'type': 'antibody-drug conjugate', 'subtype': 'anti-Nectin-4', 'raw': 'enfortumab vedotin'}, {'type': 'targeted therapy', 'subtype': 'PARP inhibitor', 'raw': 'niraparib'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'magrolimab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'tiragolumab'}, {'type': 'antibody-drug conjugate', 'subtype': 'anti-Trop-2', 'raw': 'sacituzumab govitecan'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'tocilizumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'gemcitabine'}]",True,urothelial carcinoma bladder cancer,genitourinary
311,United States,Liver Cancer,GENETIC: GAP T cells|DRUG: Cytoxan|DRUG: Fludara,1,OTHER,Baylor College of Medicine,"['other', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'alkylating agent', 'raw': 'cytoxan'}, {'type': 'other', 'subtype': None, 'raw': 'fludara'}]",True,liver cancer,digestive
312,United States,Gastrointestinal Carcinoma|Pancreatic Cancer|Hepatocellular Cancer|Cholangiocarcinoma|Duodenal Cancer|Colorectal Cancer|Small Bowel Cancer|Metastatic Cancers,BIOLOGICAL: KRAS TCR-Transduced PBL|DRUG: Aldesleukin|DRUG: Fludarabine|DRUG: Cyclophosphamide,2,NIH,National Cancer Institute (NCI),"['cytokine therapy', 'chemotherapy', 'cell therapy']","[{'type': 'cell therapy', 'subtype': 'engineered cell', 'raw': 'kras tcr-transduced pbl'}, {'type': 'cytokine therapy', 'subtype': 'IL-2', 'raw': 'aldesleukin'}, {'type': 'chemotherapy', 'subtype': 'purine analog', 'raw': 'fludarabine'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide'}]",True,gastrointestinal carcinoma pancreatic cancer hepatocellular cancer cholangiocarcinoma duodenal cancer colorectal cancer small bowel cancer metastatic cancers,digestive
313,United States,Lung Adenocarcinoma|Lung Adenosquamous Carcinoma|Lung Non-Small Cell Carcinoma|Stage IIIB Lung Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8|Stage IV Lung Cancer AJCC v8,PROCEDURE: Biopsy Procedure|PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|PROCEDURE: Echocardiography Test|BIOLOGICAL: Ipilimumab|PROCEDURE: Magnetic Resonance Imaging|BIOLOGICAL: Nivolumab|PROCEDURE: Positron Emission Tomography|OTHER: Quality-of-Life Assessment|RADIATION: Radiation Therapy,23,NIH,National Cancer Institute (NCI),['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}]",False,lung adenocarcinoma lung adenosquamous carcinoma lung non small cell carcinoma stage iiib lung cancer ajcc v8 stage iiic lung cancer ajcc v8 stage iv lung cancer ajcc v8,lung/thoracic
314,United States,Metastatic Colorectal Cancer,"DRUG: Retifanlimab|BIOLOGICAL: Therapeutic CEA, Brachyury and MUC1 TriAdeno Vaccine Platform|DRUG: N-803|DRUG: SX-682",12,NIH,National Cancer Institute (NCI),"['vaccine', 'other', 'targeted therapy', 'antibody', 'cytokine therapy']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'retifanlimab'}, {'type': 'other', 'subtype': None, 'raw': 'therapeutic cea'}, {'type': 'vaccine', 'subtype': 'vaccine', 'raw': 'brachyury and muc1 triadeno vaccine platform'}, {'type': 'cytokine therapy', 'subtype': 'IL-15 superagonist', 'raw': 'n-803'}, {'type': 'targeted therapy', 'subtype': 'CXCR1/2 inhibitor', 'raw': 'sx-682'}]",True,metastatic colorectal cancer,digestive
315,"France, Germany, Spain, United States",Non-Small Cell Lung Cancer,DRUG: Cemiplimab|DRUG: Platinum-based chemotherapy|DRUG: REGN7075,2,INDUSTRY,Regeneron Pharmaceuticals,"['checkpoint inhibitor', 'other']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'cemiplimab'}, {'type': 'other', 'subtype': None, 'raw': 'platinum-based chemotherapy'}, {'type': 'other', 'subtype': None, 'raw': 'regn7075'}]",True,non small cell lung cancer,lung/thoracic
316,China,Esophagus Cancer|Neoadjuvant Therapy,DRUG: Tislelizumab,2,OTHER,"Wuhan Union Hospital, China",['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'tislelizumab'}]",False,esophagus cancer neoadjuvant therapy,other
317,Spain,Non Small Cell Lung Cancer,DRUG: Paclitaxel|DRUG: Carboplatin|DRUG: Nivolumab,2,OTHER,Fundación GECP,"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}]",True,non small cell lung cancer,lung/thoracic
318,United States,Biliary Cancer|Bile Duct Cancer|Cancer of the Bile Duct,DRUG: oxaliplatin|DRUG: capecitabine|BIOLOGICAL: Keytruda|BIOLOGICAL: CDX-1140,12,NIH,National Cancer Institute (NCI),"['other', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'oxaliplatin'}, {'type': 'chemotherapy', 'subtype': 'fluoropyrimidine', 'raw': 'capecitabine'}, {'type': 'other', 'subtype': None, 'raw': 'keytruda'}, {'type': 'other', 'subtype': None, 'raw': 'cdx-1140'}]",True,biliary cancer bile duct cancer cancer of the bile duct,digestive
319,China,Esophageal Cancer,COMBINATION_PRODUCT: Experimental: Arm 1 Organ preservation|COMBINATION_PRODUCT: Active Comparator: Arm 2 Surgery,3,OTHER,Ruijin Hospital,"['surgery', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'experimental: arm 1 organ preservation'}, {'type': 'surgery', 'subtype': 'procedure', 'raw': 'active comparator: arm 2 surgery'}]",True,esophageal cancer,digestive
320,United States,Acute Lymphoblastic Leukemia|Large B-cell Lymphoma,"DRUG: KYMRIAH|DRUG: YESCARTA|DRUG: Fludarabine 30mg/m2 4 doses|DRUG: Cyclophosphamide 500 mg/m2; 2 doses|DRUG: Fludarabine 30mg/m2 3 doses|DRUG: Cyclophosphamide 500 mg/m2; 3 doses|DRUG: Fludarabine 25mg/m2 3 days|DRUG: Cyclophosphamide 250 mg/m2; 3 days|DRUG: Tecartus|DRUG: Abecma, Intravenous Suspension|DRUG: Cyclophosphamide 900 mg/m2; 1 day|DRUG: Breyanzi Injectable Product",2,OTHER,"Masonic Cancer Center, University of Minnesota","['other', 'chemotherapy', 'cell therapy']","[{'type': 'other', 'subtype': None, 'raw': 'kymriah'}, {'type': 'cell therapy', 'subtype': 'engineered cell', 'raw': 'yescarta'}, {'type': 'other', 'subtype': None, 'raw': 'fludarabine 30mg'}, {'type': 'other', 'subtype': None, 'raw': 'm2 4 doses'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide 500'}, {'type': 'other', 'subtype': None, 'raw': 'm2; 2 doses'}, {'type': 'other', 'subtype': None, 'raw': 'fludarabine 30mg'}, {'type': 'other', 'subtype': None, 'raw': 'm2 3 doses'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide 500'}, {'type': 'other', 'subtype': None, 'raw': 'm2; 3 doses'}, {'type': 'other', 'subtype': None, 'raw': 'fludarabine 25mg'}, {'type': 'other', 'subtype': None, 'raw': 'm2 3 days'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide 250'}, {'type': 'other', 'subtype': None, 'raw': 'm2; 3 days'}, {'type': 'cell therapy', 'subtype': 'engineered cell', 'raw': 'tecartus'}, {'type': 'other', 'subtype': None, 'raw': 'abecma'}, {'type': 'other', 'subtype': None, 'raw': 'intravenous suspension'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide 900'}, {'type': 'other', 'subtype': None, 'raw': 'm2; 1 day'}, {'type': 'other', 'subtype': None, 'raw': 'breyanzi injectable product'}]",True,acute lymphoblastic leukemia large b cell lymphoma,hematologic
321,United States,Glioblastoma,BIOLOGICAL: Autologous genetically modified gamma-delta T cells|BIOLOGICAL: Allogeneic genetically modified gamma-delta T cells,12,INDUSTRY,In8bio Inc.,['cell therapy'],"[{'type': 'cell therapy', 'subtype': 'other', 'raw': 'autologous genetically modified gamma-delta t cells'}, {'type': 'cell therapy', 'subtype': 'other', 'raw': 'allogeneic genetically modified gamma-delta t cells'}]",False,glioblastoma,brain/CNS
322,United States,Lung Cancer Stage II|Lung Cancer Stage III|Non Small Cell Lung Cancer,RADIATION: SBRT|DRUG: Carboplatin|DRUG: Paclitaxel|DRUG: cis Platinum|DRUG: Etoposide|RADIATION: IMRT|DRUG: Durvalumab,2,OTHER,Wake Forest University Health Sciences,"['checkpoint inhibitor', 'other', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}, {'type': 'other', 'subtype': None, 'raw': 'cis platinum'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'etoposide'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}]",True,lung cancer stage ii lung cancer stage iii non small cell lung cancer,lung/thoracic
323,United States,Breast Cancer,DRUG: Pembrolizumab|RADIATION: RT Boost,12,OTHER,Stephen Shiao,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",False,breast cancer,breast
324,China,Non-small Cell Lung Cancer,DRUG: anlotinib combined with penpulimab,2,OTHER,The First Affiliated Hospital of Zhengzhou University,['antibody'],"[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'anlotinib combined with penpulimab'}]",False,non small cell lung cancer,lung/thoracic
325,United States,Unresectable or Metastatic Microsatellite Stable (MSS) Solid Tumor Along With Microsatellite Stable (MSS) Colon Cancer|Colon Cancer,DRUG: Copanlisib|DRUG: Nivolumab,12,OTHER,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,"['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'copanlisib'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}]",True,unresectable or metastatic microsatellite stable solid tumor along with microsatellite stable colon cancer colon cancer,digestive
326,"Finland, United Kingdom, United States",Acute Myeloid Leukemia|Chronic Myelomonocytic Leukemia|Myelodysplastic Syndromes|Relapsed/Refractory AML,DRUG: Bexmarilimab|DRUG: Azacitidine|DRUG: Venetoclax,12,INDUSTRY,Faron Pharmaceuticals Ltd,"['targeted therapy', 'other', 'antibody']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'bexmarilimab'}, {'type': 'other', 'subtype': None, 'raw': 'azacitidine'}, {'type': 'targeted therapy', 'subtype': 'BCL-2 inhibitor', 'raw': 'venetoclax'}]",True,acute myeloid leukemia chronic myelomonocytic leukemia myelodysplastic syndromes relapsed refractory aml,hematologic
327,United States,Metastatic Breast Cancer,DRUG: HER2 BATs with Pembrolizumab,12,OTHER,University of Virginia,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'her2 bats with pembrolizumab'}]",False,metastatic breast cancer,breast
328,United States,TNBC - Triple-Negative Breast Cancer|Breast Cancer,DRUG: Pembrolizumab|RADIATION: Radiation Therapy|DRUG: Axatilimab,2,OTHER,Stephen Shiao,"['checkpoint inhibitor', 'antibody']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'axatilimab'}]",True,tnbc triple negative breast cancer breast cancer,breast
329,France,Unresectable Gastrointestinal Stromal Tumor (GIST)|Locally Advanced Gastrointestinal Stromal Tumor (GIST)|Metastatic Gastrointestinal Stromal Tumor,DRUG: Atezolizumab 1200 mg|DRUG: Imatinib 400 MG,2,OTHER,Centre Leon Berard,"['checkpoint inhibitor', 'other']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'atezolizumab 1200'}, {'type': 'other', 'subtype': None, 'raw': 'imatinib 400'}]",True,unresectable gastrointestinal stromal tumor locally advanced gastrointestinal stromal tumor metastatic gastrointestinal stromal tumor,digestive
330,"Argentina, Australia, Brazil, Canada, Chile, China, Czechia, Denmark, Finland, France, Germany, Greece, Israel, Italy, Japan, Mexico, Netherlands, Norway, Peru, Poland, Republic of, Romania, Russian Federation, Singapore, Spain, Sweden, Switzerland, Taiwan, Turkey, United States",Urothelial Cancer,BIOLOGICAL: Nivolumab|BIOLOGICAL: Ipilimumab|DRUG: Gemcitabine|DRUG: Cisplatin|DRUG: Carboplatin,3,INDUSTRY,Bristol-Myers Squibb,"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'gemcitabine'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}]",True,urothelial cancer,genitourinary
331,United States,Recurrent Lung Non-Small Cell Carcinoma|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8,BIOLOGICAL: Durvalumab|DRUG: Selumetinib|BIOLOGICAL: Tremelimumab,12,OTHER,M.D. Anderson Cancer Center,"['checkpoint inhibitor', 'kinase inhibitor']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'selumetinib'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'tremelimumab'}]",True,recurrent lung non small cell carcinoma stage iv lung cancer ajcc v8 stage iva lung cancer ajcc v8 stage ivb lung cancer ajcc v8,lung/thoracic
332,France,Oropharynx Cancer|Larynx Cancer|Hypopharynx Cancer|Primary Head and Neck Tumor,DRUG: Vesanoid|RADIATION: Standard radiotherapy|RADIATION: Tailored radiotherapy|DRUG: Cisplatin|DRUG: Cetuximab,3,OTHER,Centre Leon Berard,"['other', 'antibody', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'vesanoid'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'cetuximab'}]",True,oropharynx cancer larynx cancer hypopharynx cancer primary head and neck tumor,head/neck
333,China,Esophageal Cancer,DRUG: neoadjuvant anti-PD-1|DRUG: neoadjuvant anti-PD-1 with LDRT,2,OTHER,Shanghai Chest Hospital,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'neoadjuvant anti-pd-1'}, {'type': 'other', 'subtype': None, 'raw': 'neoadjuvant anti-pd-1 with ldrt'}]",False,esophageal cancer,digestive
334,United States,Advanced Solid Tumor|Refractory Hodgkin Lymphoma,DRUG: HCB301,1,INDUSTRY,FBD Biologics Limited,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'hcb301'}]",False,advanced solid tumor refractory hodgkin lymphoma,hematologic
335,United States,Colorectal Cancer|Breast Cancer|Head and Neck Squamous Cell Carcinoma|Melanoma|Non Small Cell Lung Cancer|Pancreatic Cancer|Liver Cancer,BIOLOGICAL: YE-NEO-001,1,INDUSTRY,"NantBioScience, Inc.",['other'],"[{'type': 'other', 'subtype': None, 'raw': 'ye-neo-001'}]",False,colorectal cancer breast cancer head and neck squamous cell carcinoma melanoma non small cell lung cancer pancreatic cancer liver cancer,digestive
336,United States,Prostate Cancer|Adenocarcinoma of the Prostate,DRUG: Nivolumab|DRUG: Degarelix|DRUG: BMS-986253,12,OTHER,Mark Stein,"['checkpoint inhibitor', 'other']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'other', 'subtype': None, 'raw': 'degarelix'}, {'type': 'other', 'subtype': None, 'raw': 'bms-986253'}]",True,prostate cancer adenocarcinoma of the prostate,genitourinary
337,United States,Rectal Cancer,DRUG: Epacadostat|RADIATION: Short-course radiation therapy|DRUG: CAPOX chemotherapy|DRUG: FOLFOX chemotherapy,12,OTHER,Washington University School of Medicine,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'epacadostat'}, {'type': 'other', 'subtype': None, 'raw': 'capox chemotherapy'}, {'type': 'other', 'subtype': None, 'raw': 'folfox chemotherapy'}]",False,rectal cancer,digestive
338,Netherlands,Melanoma Stage III|Melanoma Stage IV,OTHER: Fecal microbiota transplantation,12,OTHER,The Netherlands Cancer Institute,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'other: fecal microbiota transplantation'}]",False,melanoma stage iii melanoma stage iv,skin
339,China,Cervical Cancer|Adaptive Radiotherapy,COMBINATION_PRODUCT: Moderated hypofractionated online adaptive radiotherapy|COMBINATION_PRODUCT: Conventional radiotherapy,3,OTHER,Peking Union Medical College Hospital,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'moderated hypofractionated online adaptive radiotherapy'}, {'type': 'other', 'subtype': None, 'raw': 'conventional radiotherapy'}]",False,cervical cancer adaptive radiotherapy,gynecologic
340,China,Immunotherapy,BIOLOGICAL: CAR-T cell immunotherapy,1,OTHER,The Affiliated Hospital of Xuzhou Medical University,['cell therapy'],"[{'type': 'cell therapy', 'subtype': 'engineered cell', 'raw': 'car-t cell immunotherapy'}]",False,immunotherapy,hematologic
341,United States,Previously Treated Non-Small Cell Lung Cancer,DRUG: Screening Platform,23,NETWORK,SWOG Cancer Research Network,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'screening platform'}]",False,previously treated non small cell lung cancer,lung/thoracic
342,Netherlands,Urologic Neoplasms|Urogenital Neoplasms|Male Urogenital Diseases|Penile Cancer|Penile Squamous Cell Carcinoma|Locally Advanced Penile Carcinoma,DRUG: Carboplatin/Paclitaxel|DRUG: Pembrolizumab|PROCEDURE: Partial or total penectomy with inguinal and/or pelvic lymph node dissection,2,OTHER,The Netherlands Cancer Institute,"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",True,urologic neoplasms urogenital neoplasms male urogenital diseases penile cancer penile squamous cell carcinoma locally advanced penile carcinoma,genitourinary
343,Taiwan,Premenopausal Breast Cancer|Metastatic Breast Cancer|ER Positive Breast Cancer,DRUG: Goserelin|DRUG: Fulvestrant|DRUG: Capivasertib|DRUG: Durvalumab,2,OTHER,National Taiwan University Hospital,"['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'goserelin'}, {'type': 'other', 'subtype': None, 'raw': 'fulvestrant'}, {'type': 'other', 'subtype': None, 'raw': 'capivasertib'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}]",True,premenopausal breast cancer metastatic breast cancer er positive breast cancer,breast
344,United States,Colorectal Cancer Metastatic,DRUG: isunakinra,2,INDUSTRY,Buzzard Pharmaceuticals,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'isunakinra'}]",False,colorectal cancer metastatic,digestive
345,Netherlands,Colorectal Cancer,BIOLOGICAL: DC vaccination,12,OTHER,Radboud University Medical Center,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'dc vaccination'}]",False,colorectal cancer,digestive
346,"China, Taiwan, United States",Advanced Solid Tumor|Refractory Non-Hodgkin Lymphoma,DRUG: HCB101,1,INDUSTRY,FBD Biologics Limited,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'hcb101'}]",False,advanced solid tumor refractory non hodgkin lymphoma,hematologic
347,China,Non-small Cell Lung Cancer|Small Cell Lung Cancer|Pancreas Cancer|Hepatocellular Carcinoma|Gastric Cancer|Renal Cell Carcinoma,BIOLOGICAL: Infusion of iNKT cells and CD8+T cells,12,OTHER_GOV,Shanghai Public Health Clinical Center,['cell therapy'],"[{'type': 'cell therapy', 'subtype': 'other', 'raw': 'of inkt cells and cd8'}, {'type': 'cell therapy', 'subtype': 'other', 'raw': 't cells'}]",False,non small cell lung cancer small cell lung cancer pancreas cancer hepatocellular carcinoma gastric cancer renal cell carcinoma,genitourinary
348,Denmark,Cancer of Rectum,DRUG: Nivolumab|DRUG: Ipilimumab,2,OTHER,Odense University Hospital,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}]",False,cancer of rectum,other
349,"Australia, Canada, Hong Kong, Republic of, Singapore, Taiwan, United States",Non Small Cell Lung Cancer|Nonsquamous Non Small Cell Lung Cancer|Squamous Non Small Cell Lung Cancer|Lung Cancer,DRUG: Domvanalimab|DRUG: Etrumadenant|DRUG: Zimberelimab,2,INDUSTRY,"Arcus Biosciences, Inc.","['other', 'antibody']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'domvanalimab'}, {'type': 'other', 'subtype': None, 'raw': 'etrumadenant'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'zimberelimab'}]",True,non small cell lung cancer nonsquamous non small cell lung cancer squamous non small cell lung cancer lung cancer,lung/thoracic
350,United States,Advanced or Metastatic Solid Tumors|Microsatellite Instability Low|Microsatellite Instability High|Microsatellite Stable|Ovarian Cancer|Gastric Cancer|Colo-rectal Cancer|Esophageal Cancer|Endometrial Cancer|Head Neck Cancer|Cervical Cancer|Lung Cancer,DRUG: NC410|DRUG: pembrolizumab,12,INDUSTRY,"NextCure, Inc.","['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'nc410'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",True,advanced or metastatic solid tumors microsatellite instability low microsatellite instability high microsatellite stable ovarian cancer gastric cancer colo rectal cancer esophageal cancer endometrial cancer head neck cancer cervical cancer lung cancer,gynecologic
351,China,Lung Cancer (NSCLC),DRUG: Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab,2,OTHER,"Shanghai Pulmonary Hospital, Shanghai, China",['antibody'],"[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'neoadjuvant sugemalimab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'chemotherapy followed by adjuvant sugemalimab'}]",False,lung cancer,lung/thoracic
352,United States,Colorectal Cancer Metastatic|Liver Metastases|Colorectal Cancer,DRUG: Botensilimab|DRUG: Balstilimab|DRUG: AGEN1423|RADIATION: Radiation,2,OTHER,Weill Medical College of Cornell University,"['other', 'antibody']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'botensilimab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'balstilimab'}, {'type': 'other', 'subtype': None, 'raw': 'agen1423'}]",True,colorectal cancer metastatic liver metastases colorectal cancer,digestive
353,China,Immunotherapy|Gastric Cancer|Rectal Cancer|Chemotherapy Effect|Radiotherapy,DRUG: Terelizumab (aka Tislelizumab)|DRUG: CapeOx|DRUG: Trastuzumab|RADIATION: Radiotherapy,2,OTHER,Daping Hospital and the Research Institute of Surgery of the Third Military Medical University,"['other', 'antibody']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'terelizumab'}, {'type': 'other', 'subtype': None, 'raw': 'capeox'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'trastuzumab'}]",True,immunotherapy gastric cancer rectal cancer chemotherapy effect radiotherapy,digestive
354,"Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Czechia, Denmark, Finland, France, Germany, Greece, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, Norway, Poland, Puerto Rico, Republic of, Singapore, Spain, Sweden, Switzerland, United Kingdom, United States",Endometrial Cancer,BIOLOGICAL: Sacituzumab tirumotecan|DRUG: Doxorubicin|DRUG: Paclitaxel|DRUG: Nab-paclitaxel,3,INDUSTRY,Merck Sharp & Dohme LLC,"['other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'sacituzumab tirumotecan'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'doxorubicin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'nab-paclitaxel'}]",True,endometrial cancer,gynecologic
355,Netherlands,Urinary Bladder Cancer|Invasive Bladder Cancer,"COMBINATION_PRODUCT: nivolumab 480mg|COMBINATION_PRODUCT: nivolumab 3mg/kg, ipilimumab 1mg/kg|COMBINATION_PRODUCT: nivolumab 1mg/kg, ipilimumab 3mg/kg",12,OTHER,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA),"['checkpoint inhibitor', 'other']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab 480mg'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab 3mg'}, {'type': 'other', 'subtype': None, 'raw': 'kg'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab 1mg'}, {'type': 'other', 'subtype': None, 'raw': 'kg'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab 1mg'}, {'type': 'other', 'subtype': None, 'raw': 'kg'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab 3mg'}, {'type': 'other', 'subtype': None, 'raw': 'kg'}]",True,urinary bladder cancer invasive bladder cancer,genitourinary
356,China,Non Small Cell Lung Cancer,"DRUG: Albumin-bound paclitaxel, Carboplatin, Toripalimab",2,OTHER,Hao Long,"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'albumin-bound paclitaxel'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'toripalimab'}]",True,non small cell lung cancer,lung/thoracic
357,United States,HPV-Associated Cervical Carcinoma|HPV-Related Carcinoma|HPV-Related Malignancy|HPV Positive Oropharyngeal Squamous Cell Carcinoma|HPV-Related Adenocarcinoma|HPV-Related Adenosquamous Carcinoma|HPV-Related Squamous Cell Carcinoma|HPV-Related Anal Squamous Cell Carcinoma|HPV-Related Penile Squamous Cell Carcinoma|HPV-Related Vulvar Squamous Cell Carcinoma|HPV-Related Endocervical Adenocarcinoma|Cervical Cancer|Oropharynx Cancer|Anal Cancer|Vulvar Cancer|Penile Cancer|Vaginal Cancer,BIOLOGICAL: E7 TCR-T cells|DRUG: Aldesleukin,12,OTHER,Christian Hinrichs,"['cytokine therapy', 'cell therapy']","[{'type': 'cell therapy', 'subtype': 'engineered cell', 'raw': 'e7 tcr-t cells'}, {'type': 'cytokine therapy', 'subtype': 'IL-2', 'raw': 'aldesleukin'}]",True,hpv associated cervical carcinoma hpv related carcinoma hpv related malignancy hpv positive oropharyngeal squamous cell carcinoma hpv related adenocarcinoma hpv related adenosquamous carcinoma hpv related squamous cell carcinoma hpv related anal squamous cell carcinoma hpv related penile squamous cell carcinoma hpv related vulvar squamous cell carcinoma hpv related endocervical adenocarcinoma cervical cancer oropharynx cancer anal cancer vulvar cancer penile cancer vaginal cancer,gynecologic
358,United States,Adult Primary Liver Cancer|Advanced Adult Primary Liver Cancer|Localized Unresectable Adult Primary Liver Cancer,DRUG: TSR-022 and TSR-042,2,OTHER,University of Hawaii,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'tsr-022 and tsr-042'}]",False,adult primary liver cancer advanced adult primary liver cancer localized unresectable adult primary liver cancer,digestive
359,Belgium,Glioblastoma Multiforme of Brain,BIOLOGICAL: Dendritic cell vaccine plus temozolomide chemotherapy,12,OTHER,"University Hospital, Antwerp",['chemotherapy'],"[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'dendritic cell vaccine plus temozolomide chemotherapy'}]",False,glioblastoma multiforme of brain,brain/CNS
360,China,HNSCC|Lysogenic HSV Virus|Neoadjuvant Therapy|Immunotherapy|Targeted Therapy,DRUG: Tislelizumab|DRUG: Afatinib|BIOLOGICAL: Lysogenic HSV virus.,12,OTHER,West China Hospital,"['checkpoint inhibitor', 'other', 'kinase inhibitor']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'tislelizumab'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'afatinib'}, {'type': 'other', 'subtype': None, 'raw': 'lysogenic hsv virus.'}]",True,hnscc lysogenic hsv virus neoadjuvant therapy immunotherapy targeted therapy,hematologic
361,United States,Endocrine Tumors|Non-Small Cell Lung Cancer|Ovarian Cancer|Breast Cancer|Gastrointestinal/Genitourinary Cancers|Neuroendocrine Tumors|Multiple Myeloma,DRUG: Cyclophosphamide|DRUG: Fludarabine|DRUG: Aldesleukin|BIOLOGICAL: Individual Patient TCR-Transduced PBL|DRUG: Pembrolizumab (KEYTRUDA(R)),2,NIH,National Cancer Institute (NCI),"['checkpoint inhibitor', 'cytokine therapy', 'chemotherapy', 'cell therapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide'}, {'type': 'chemotherapy', 'subtype': 'purine analog', 'raw': 'fludarabine'}, {'type': 'cytokine therapy', 'subtype': 'IL-2', 'raw': 'aldesleukin'}, {'type': 'cell therapy', 'subtype': 'engineered cell', 'raw': 'individual patient tcr-transduced pbl'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab )'}]",True,endocrine tumors non small cell lung cancer ovarian cancer breast cancer gastrointestinal genitourinary cancers neuroendocrine tumors multiple myeloma,gynecologic
362,United States,Cancer,OTHER: Treatment recommendations made by Molecular Tumor Board.,2,OTHER,Dartmouth-Hitchcock Medical Center,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'other: treatment recommendations made by molecular tumor board.'}]",False,cancer,other
363,United States,Lung Cancer,DRUG: Pembrolizumab|DRUG: Guadecitabine|DRUG: Mocetinostat,1,OTHER,Memorial Sloan Kettering Cancer Center,"['checkpoint inhibitor', 'other']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'other', 'subtype': None, 'raw': 'guadecitabine'}, {'type': 'other', 'subtype': None, 'raw': 'mocetinostat'}]",True,lung cancer,lung/thoracic
364,United States,Breast Neoplasm Female|Breast Cancer|Breast Carcinoma|Breast Tumor,DRUG: Nivolumab|DRUG: Ipilimumab|DRUG: Bicalutamide,2,OTHER,Providence Health & Services,"['checkpoint inhibitor', 'other']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}, {'type': 'other', 'subtype': None, 'raw': 'bicalutamide'}]",True,breast neoplasm female breast cancer breast carcinoma breast tumor,breast
365,Italy,"Brain Tumor, Pediatric|Medulloblastoma, Childhood|Embryonal Tumor|High Grade Glioma|Diffuse Midline Glioma|Diffuse Intrinsic Pontine Glioma|Brain Tumor Adult",BIOLOGICAL: GD2-CART01 (iC9-GD2-CAR T-cells),1,OTHER,Bambino Gesù Hospital and Research Institute,['cell therapy'],"[{'type': 'cell therapy', 'subtype': 'engineered cell', 'raw': 'gd2-cart01'}]",False,brain tumor pediatric medulloblastoma childhood embryonal tumor high grade glioma diffuse midline glioma diffuse intrinsic pontine glioma brain tumor adult,brain/CNS
366,China,Lung Cancer|Cancer|Immunotherapy|CAR-T Cell,"BIOLOGICAL: CAR-T cells targeting GPC3, Mesothelin, Claudin18.2, GUCY2C, B7-H3, PSCA, PSMA, MUC1, TGFβ, HER2, Lewis-Y, AXL, or EGFR",1,OTHER,Second Affiliated Hospital of Guangzhou Medical University,"['other', 'cell therapy']","[{'type': 'cell therapy', 'subtype': 'engineered cell', 'raw': 'car-t cells targeting gpc3'}, {'type': 'other', 'subtype': None, 'raw': 'mesothelin'}, {'type': 'other', 'subtype': None, 'raw': 'claudin18.2'}, {'type': 'other', 'subtype': None, 'raw': 'gucy2c'}, {'type': 'other', 'subtype': None, 'raw': 'b7-h3'}, {'type': 'other', 'subtype': None, 'raw': 'psca'}, {'type': 'other', 'subtype': None, 'raw': 'psma'}, {'type': 'other', 'subtype': None, 'raw': 'muc1'}, {'type': 'other', 'subtype': None, 'raw': 'tgfβ'}, {'type': 'other', 'subtype': None, 'raw': 'her2'}, {'type': 'other', 'subtype': None, 'raw': 'lewis-y'}, {'type': 'other', 'subtype': None, 'raw': 'axl'}, {'type': 'other', 'subtype': None, 'raw': 'or egfr'}]",True,lung cancer cancer immunotherapy car t cell,lung/thoracic
367,United States,Colon Cancer|Resected Stage,DRUG: Cetuximab|DRUG: Expanded CB-NK cells|DRUG: Fludarabine phosphate|DRUG: Cyclophosphamide,1,OTHER,M.D. Anderson Cancer Center,"['antibody', 'chemotherapy', 'cell therapy']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'cetuximab'}, {'type': 'cell therapy', 'subtype': 'other', 'raw': 'expanded cb-nk cells'}, {'type': 'chemotherapy', 'subtype': 'purine analog', 'raw': 'fludarabine phosphate'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide'}]",True,colon cancer resected stage,digestive
368,United States,Neuroblastoma|Ganglioneuroblastoma,BIOLOGICAL: Patient Derived CD171 specific CAR T cells expressing EGFRt (2nd generation T cells)|BIOLOGICAL: Patient Derived CD171 specific CAR T cells expressing EGFRt (3rd generation T cells)|BIOLOGICAL: Patient Derived CD171 specific CAR T cells expressing EGFRt (long spacer 2nd generation T cells),1,OTHER,Seattle Children's Hospital,['cell therapy'],"[{'type': 'cell therapy', 'subtype': 'other', 'raw': 'patient derived cd171 specific car t cells expressing egfrt'}, {'type': 'cell therapy', 'subtype': 'other', 'raw': 'patient derived cd171 specific car t cells expressing egfrt'}, {'type': 'cell therapy', 'subtype': 'other', 'raw': 'patient derived cd171 specific car t cells expressing egfrt'}]",False,neuroblastoma ganglioneuroblastoma,other
369,United States,Endometrial Cancer,DRUG: Pembrolizumab|DRUG: IMGN853,2,OTHER,Dana-Farber Cancer Institute,"['checkpoint inhibitor', 'other']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'other', 'subtype': None, 'raw': 'imgn853'}]",True,endometrial cancer,gynecologic
370,United States,Advanced Lung Non-Small Cell Carcinoma|Recurrent Lung Non-Small Cell Carcinoma|Stage III Lung Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIB Lung Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8,DIETARY_SUPPLEMENT: Cobalamin|DRUG: Dexamethasone|DRUG: Docetaxel|DIETARY_SUPPLEMENT: Folic Acid|DRUG: Gemcitabine|DRUG: Nogapendekin Alfa|BIOLOGICAL: Pembrolizumab|DRUG: Pemetrexed|BIOLOGICAL: Ramucirumab,23,NETWORK,SWOG Cancer Research Network,"['other', 'chemotherapy', 'checkpoint inhibitor', 'antibody', 'supportive care']","[{'type': 'supportive care', 'subtype': 'steroid', 'raw': 'dexamethasone'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'docetaxel'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'gemcitabine'}, {'type': 'other', 'subtype': None, 'raw': 'nogapendekin alfa'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'chemotherapy', 'subtype': 'antifolate', 'raw': 'pemetrexed'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'ramucirumab'}]",True,advanced lung non small cell carcinoma recurrent lung non small cell carcinoma stage iii lung cancer ajcc v8 stage iiia lung cancer ajcc v8 stage iiib lung cancer ajcc v8 stage iiic lung cancer ajcc v8 stage iv lung cancer ajcc v8 stage iva lung cancer ajcc v8 stage ivb lung cancer ajcc v8,lung/thoracic
371,United States,Extensive Stage Lung Small Cell Carcinoma|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8,DRUG: Carboplatin|BIOLOGICAL: Durvalumab|DRUG: Etoposide|DRUG: Olaparib|RADIATION: Radiation Therapy,12,OTHER,M.D. Anderson Cancer Center,"['checkpoint inhibitor', 'targeted therapy', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'etoposide'}, {'type': 'targeted therapy', 'subtype': 'PARP inhibitor', 'raw': 'olaparib'}]",True,extensive stage lung small cell carcinoma stage iv lung cancer ajcc v8 stage iva lung cancer ajcc v8 stage ivb lung cancer ajcc v8,lung/thoracic
372,France,Breast Cancer,DRUG: Atezolizumab Injection|DRUG: Bevacizumab|DRUG: Pertuzumab|DRUG: Trastuzumab,2,OTHER,"Gustave Roussy, Cancer Campus, Grand Paris","['checkpoint inhibitor', 'antibody']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'atezolizumab injection'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'bevacizumab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'pertuzumab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'trastuzumab'}]",True,breast cancer,breast
373,China,"Pheochromocytoma/Paraganglioma|Rhabdomyosarcoma|Paget Disease, Extramammary|Renal Angiomyolipoma|Perivascular Epithelioid Cell Tumor, Malignant|Sarcoma|Urachal Cancer|Neuroendocrine Cancer|Basal Cell Carcinomas|Sarcomatoid Carcinoma|Penile Cancer|Adrenal Cortical Cancer|Germ Cell Cancer Metastatic|Non-Clear Cell Renal Cell Carcinoma|Prostate Cancers|Clear Cell Renal Cancer|Urothelial Carcinoma|Kidney Cancer|Rare Tumors",DRUG: Ivocizumab,2,OTHER,Fudan University,['antibody'],"[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'ivocizumab'}]",False,pheochromocytoma paraganglioma rhabdomyosarcoma paget disease extramammary renal angiomyolipoma perivascular epithelioid cell tumor malignant sarcoma urachal cancer neuroendocrine cancer basal cell carcinomas sarcomatoid carcinoma penile cancer adrenal cortical cancer germ cell cancer metastatic non clear cell renal cell carcinoma prostate cancers clear cell renal cancer urothelial carcinoma kidney cancer rare tumors,genitourinary
374,China,Esophageal Cancer,DRUG: Trilaciclib Injection [Cosela]|DRUG: Placebo,2,OTHER,The First Affiliated Hospital with Nanjing Medical University,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'trilaciclib injection [cosela]'}]",False,esophageal cancer,digestive
375,China,Local Advanced Non-small Cell Lung Cancer,DRUG: Toripalimab|RADIATION: Concurrent chemoradiation therapy and consolidation immunotherapy,2,OTHER,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'toripalimab'}]",False,local advanced non small cell lung cancer,lung/thoracic
376,China,Multiple Cancer|Colorectal Cancer,DRUG: MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 monoclonal antibody neoadjuvant therapy|DRUG: All-MSI-H (dMMR) sMPCC: single-drug PD-1 monoclonal antibody neoadjuvant therapy,2,OTHER,"Sixth Affiliated Hospital, Sun Yat-sen University",['other'],"[{'type': 'other', 'subtype': None, 'raw': 'msi-h'}, {'type': 'other', 'subtype': None, 'raw': 'mss mixed smpcc: combination of mfolfox6'}, {'type': 'other', 'subtype': None, 'raw': 'pd-1 monoclonal antibody neoadjuvant therapy'}, {'type': 'other', 'subtype': None, 'raw': 'all-msi-h smpcc: single-drug pd-1 monoclonal antibody neoadjuvant therapy'}]",False,multiple cancer colorectal cancer,digestive
377,China,Non-small Cell Lung Cancer,DRUG: Anlotinib plus the same Immune Checkpoint Inhibitors.|DRUG: Anlotinib plus the new Immune Checkpoint Inhibitors.|DRUG: Anlotinib,23,OTHER,Hunan Province Tumor Hospital,"['other', 'kinase inhibitor']","[{'type': 'other', 'subtype': None, 'raw': 'anlotinib plus the same immune checkpoint inhibitors.'}, {'type': 'other', 'subtype': None, 'raw': 'anlotinib plus the new immune checkpoint inhibitors.'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'anlotinib'}]",True,non small cell lung cancer,lung/thoracic
378,Spain,Non-Small Cell Lung Cancer|Adjuvant Chemotherapy,DRUG: Carboplatin|DRUG: Paclitaxel|DRUG: Nivolumab,3,OTHER,Fundación GECP,"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}]",True,non small cell lung cancer adjuvant chemotherapy,lung/thoracic
379,China,Esophagus Cancer,COMBINATION_PRODUCT: Tislelizumab (BGB-A317) with chemoradiotherapy,2,OTHER,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'tislelizumab with chemoradiotherapy'}]",False,esophagus cancer,other
380,United States,Head and Neck Carcinoma of Unknown Primary|Locally Recurrent Head and Neck Squamous Cell Carcinoma|Recurrent Laryngeal Squamous Cell Carcinoma|Recurrent Oral Cavity Squamous Cell Carcinoma|Recurrent Pharyngeal Squamous Cell Carcinoma|Resectable Head and Neck Squamous Cell Carcinoma,RADIATION: External Beam Radiation Therapy|RADIATION: Intraoperative Radiation Therapy|BIOLOGICAL: Pembrolizumab|OTHER: Quality-of-Life Assessment|PROCEDURE: Salvage Surgery,1,OTHER,Ohio State University Comprehensive Cancer Center,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",False,head and neck carcinoma of unknown primary locally recurrent head and neck squamous cell carcinoma recurrent laryngeal squamous cell carcinoma recurrent oral cavity squamous cell carcinoma recurrent pharyngeal squamous cell carcinoma resectable head and neck squamous cell carcinoma,head/neck
381,China,Larynx Cancer|Hypopharyngeal Cancer,PROCEDURE: Surgery|RADIATION: Radiation|DRUG: Toripalimab,2,OTHER,Fudan University,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'toripalimab'}]",False,larynx cancer hypopharyngeal cancer,head/neck
382,"Belgium, Canada, Germany, Netherlands, Spain, Sweden, United Kingdom, United States",Melanoma|Non-Small Cell Lung Cancer|Bladder Cancer|Colorectal Cancer|Triple Negative Breast Cancer|Renal Cancer|Head and Neck Cancer|Other Solid Cancers,DRUG: Autogene cevumeran|DRUG: Atezolizumab,1,INDUSTRY,"Genentech, Inc.","['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'autogene cevumeran'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'atezolizumab'}]",True,melanoma non small cell lung cancer bladder cancer colorectal cancer triple negative breast cancer renal cancer head and neck cancer other solid cancers,genitourinary
383,United States,Malignant Pleural Disease|Mesothelioma|Metastases|Lung Cancer|Breast Cancer,GENETIC: iCasp9M28z T cell infusions|DRUG: cyclophosphamide|DRUG: pembrolizumab,12,OTHER,Memorial Sloan Kettering Cancer Center,"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",True,malignant pleural disease mesothelioma metastases lung cancer breast cancer,lung/thoracic
384,United States,Gliosarcoma|MGMT-Unmethylated Glioblastoma,PROCEDURE: Contrast-enhanced Magnetic Resonance Imaging|BIOLOGICAL: Ipilimumab|BIOLOGICAL: Nivolumab|DEVICE: NovoTTF-100A Device|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration|RADIATION: Radiation Therapy|DRUG: Temozolomide,23,NIH,National Cancer Institute (NCI),"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'temozolomide'}]",True,gliosarcoma mgmt unmethylated glioblastoma,brain/CNS
385,China,Head and Neck Cancer,COMBINATION_PRODUCT: anti-PD-1 or PD-L1 antibody|RADIATION: postoperative radiaotherapy,2,OTHER,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",['other'],"[{'type': 'other', 'subtype': None, 'raw': 'anti-pd-1 or pd-l1 antibody'}]",False,head and neck cancer,head/neck
386,China,Colorectal Cancer|Immunotherapy|Radiotherapy|Targeted Therapy|Liver Metastasis,DRUG: Immunotherapy (Sintilimab)|DRUG: Targeted Therapy Agent (Fruquintinib)|RADIATION: Radiotherapy (SBRT and LDRT),2,OTHER,Shandong Cancer Hospital and Institute,"['other', 'immunotherapy']","[{'type': 'immunotherapy', 'subtype': 'unspecified', 'raw': 'immunotherapy'}, {'type': 'other', 'subtype': None, 'raw': 'targeted therapy agent'}]",True,colorectal cancer immunotherapy radiotherapy targeted therapy liver metastasis,digestive
387,China,Non-small Cell Lung Cancer,DRUG: Immune checkpoint inhibitor,2,OTHER,Peking Union Medical College Hospital,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'immune checkpoint inhibitor'}]",False,non small cell lung cancer,lung/thoracic
388,United States,Glioblastoma Multiforme,DRUG: Pembrolizumab|RADIATION: Stereotactic Radiation Therapy|PROCEDURE: Surgical Resection,12,OTHER,Chirag G. Patil,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",False,glioblastoma multiforme,brain/CNS
389,United States,Glioblastoma,DRUG: Daratumumab,12,OTHER,West Virginia University,['antibody'],"[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'daratumumab'}]",False,glioblastoma,brain/CNS
390,China,Cervical Cancer,DRUG: Neoadjuvant Therapy|RADIATION: CCRT|RADIATION: Brachytherapy,3,OTHER,Sichuan Cancer Hospital and Research Institute,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'neoadjuvant therapy'}]",False,cervical cancer,gynecologic
391,China,Liver Metastases,DRUG: Tislelizumab in Combination with Oxaliplatin and Tegafur,23,OTHER,Zhejiang University,['chemotherapy'],"[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'tislelizumab in combination with oxaliplatin and tegafur'}]",False,liver metastases,digestive
392,China,"SCLC,Extensive Stage|Brain Metastases",RADIATION: HA-WBRT plus SBRT,12,OTHER,Fudan University,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'radiation: ha-wbrt plus sbrt'}]",False,sclc extensive stage brain metastases,brain/CNS
393,"Puerto Rico, United States",Bladder Adenocarcinoma|Bladder Clear Cell Adenocarcinoma|Bladder Mixed Adenocarcinoma|Bladder Neuroendocrine Carcinoma|Bladder Small Cell Neuroendocrine Carcinoma|Bladder Squamous Cell Carcinoma|Chromophobe Renal Cell Carcinoma|Collecting Duct Carcinoma|Invasive Bladder Giant Cell Urothelial Carcinoma|Invasive Bladder Lymphoepithelioma-Like Carcinoma|Invasive Bladder Nested Urothelial Carcinoma|Invasive Bladder Plasmacytoid Urothelial Carcinoma|Invasive Bladder Sarcomatoid Urothelial Carcinoma|Invasive Bladder Urothelial Carcinoma|Kidney Medullary Carcinoma|Large Cell Neuroendocrine Carcinoma|Malignant Testicular Leydig Cell Tumor|Malignant Testicular Sertoli Cell Tumor|Metastatic Bladder Carcinoma|Metastatic Bladder Clear Cell (Glycogen-Rich) Urothelial Carcinoma|Metastatic Bladder Giant Cell Urothelial Carcinoma|Metastatic Bladder Large Cell Neuroendocrine Carcinoma|Metastatic Bladder Lipid-Rich Urothelial Carcinoma|Metastatic Bladder Micropapillary Urothelial Carcinoma|Metastatic Bladder Plasmacytoid Urothelial Carcinoma|Metastatic Bladder Sarcomatoid Urothelial Carcinoma|Metastatic Bladder Small Cell Neuroendocrine Carcinoma|Metastatic Bladder Squamous Cell Carcinoma|Metastatic Chromophobe Renal Cell Carcinoma|Metastatic Kidney Medullary Carcinoma|Metastatic Malignant Genitourinary System Neoplasm|Metastatic Papillary Renal Cell Carcinoma|Metastatic Penile Carcinoma|Metastatic Prostate Small Cell Neuroendocrine Carcinoma|Metastatic Sarcomatoid Renal Cell Carcinoma|Metastatic Urethral Carcinoma|Papillary Renal Cell Carcinoma|Sarcomatoid Renal Cell Carcinoma|Stage IV Bladder Cancer AJCC v8|Stage IV Penile Cancer AJCC v8|Stage IV Renal Cell Cancer AJCC v8|Stage IV Urethral Cancer AJCC v8|Stage IVB Prostate Cancer AJCC v8|Urachal Adenocarcinoma|Urethral Clear Cell Adenocarcinoma,PROCEDURE: Biospecimen Collection|PROCEDURE: Bone Scan|DRUG: Cabozantinib S-malate|PROCEDURE: Computed Tomography|PROCEDURE: Echocardiography Test|BIOLOGICAL: Ipilimumab|PROCEDURE: Magnetic Resonance Imaging|BIOLOGICAL: Nivolumab|PROCEDURE: Positron Emission Tomography,2,NIH,National Cancer Institute (NCI),"['checkpoint inhibitor', 'targeted therapy']","[{'type': 'targeted therapy', 'subtype': 'other', 'raw': 'cabozantinib s-malate'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}]",True,bladder adenocarcinoma bladder clear cell adenocarcinoma bladder mixed adenocarcinoma bladder neuroendocrine carcinoma bladder small cell neuroendocrine carcinoma bladder squamous cell carcinoma chromophobe renal cell carcinoma collecting duct carcinoma invasive bladder giant cell urothelial carcinoma invasive bladder lymphoepithelioma like carcinoma invasive bladder nested urothelial carcinoma invasive bladder plasmacytoid urothelial carcinoma invasive bladder sarcomatoid urothelial carcinoma invasive bladder urothelial carcinoma kidney medullary carcinoma large cell neuroendocrine carcinoma malignant testicular leydig cell tumor malignant testicular sertoli cell tumor metastatic bladder carcinoma metastatic bladder clear cell urothelial carcinoma metastatic bladder giant cell urothelial carcinoma metastatic bladder large cell neuroendocrine carcinoma metastatic bladder lipid rich urothelial carcinoma metastatic bladder micropapillary urothelial carcinoma metastatic bladder plasmacytoid urothelial carcinoma metastatic bladder sarcomatoid urothelial carcinoma metastatic bladder small cell neuroendocrine carcinoma metastatic bladder squamous cell carcinoma metastatic chromophobe renal cell carcinoma metastatic kidney medullary carcinoma metastatic malignant genitourinary system neoplasm metastatic papillary renal cell carcinoma metastatic penile carcinoma metastatic prostate small cell neuroendocrine carcinoma metastatic sarcomatoid renal cell carcinoma metastatic urethral carcinoma papillary renal cell carcinoma sarcomatoid renal cell carcinoma stage iv bladder cancer ajcc v8 stage iv penile cancer ajcc v8 stage iv renal cell cancer ajcc v8 stage iv urethral cancer ajcc v8 stage ivb prostate cancer ajcc v8 urachal adenocarcinoma urethral clear cell adenocarcinoma,genitourinary
394,United Kingdom,Cancer of Unknown Primary Site,DRUG: Pembrolizumab,2,OTHER,Imperial College London,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",False,cancer of unknown primary site,other
395,"Belgium, Georgia, Republic of, Spain, United States",Breast Carcinoma,BIOLOGICAL: eftilagimod alpha|DRUG: Paclitaxel|OTHER: placebo,23,INDUSTRY,Immutep S.A.S.,"['other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'eftilagimod alpha'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}]",True,breast carcinoma,breast
396,Poland,Breast Cancer,DRUG: Keytruda|RADIATION: Preoperative radiation therapy|DRUG: Placebo,2,OTHER,Maria Sklodowska-Curie National Research Institute of Oncology,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'keytruda'}]",False,breast cancer,breast
397,United States,Breast Cancer|Triple Negative Breast Cancer,DRUG: Niraparib|DRUG: Dostarlimab|RADIATION: Radiation therapy,2,OTHER,Massachusetts General Hospital,"['targeted therapy', 'antibody']","[{'type': 'targeted therapy', 'subtype': 'PARP inhibitor', 'raw': 'niraparib'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'dostarlimab'}]",True,breast cancer triple negative breast cancer,breast
398,United States,"Neoplasms, Brain|Glioblastoma Multiforme|Glioblastoma of Cerebellum|Neoplasms|Astrocytoma|Astrocytoma, Cerebellar|Neuroectodermal Tumors|Neuroectodermal Tumors, Primitive|Cerebellar PNET, Childhood|Cerebellar Neoplasms|Cerebellar Neoplasms, Primary|Cerebellar Neoplasm, Malignant|Cerebellar Neoplasm Malignant Primary|Neoplasm Metastases|Neoplasm Malignant|Neoplasms, Neuroepithelial|Neoplasms, Germ Cell and Embryonal|Neoplasms by Histologic Type|Neoplasms, Glandular and Epithelial|Neoplasms, Nerve Tissue|Central Nervous System Neoplasms, Primary|Central Nervous System Neoplasms, Malignant|Nervous System Neoplasms|Neoplasms by Site|Brain Diseases|Central Nervous System Diseases|Nervous System Diseases|Medulloblastoma Recurrent|HSV|Virus|Pediatric Brain Tumor|Nervous System Cancer|Primitive Neuroectodermal Tumor (PNET) of Cerebellum",BIOLOGICAL: G207,1,OTHER,M.D. Anderson Cancer Center,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'g207'}]",False,neoplasms brain glioblastoma multiforme glioblastoma of cerebellum neoplasms astrocytoma astrocytoma cerebellar neuroectodermal tumors neuroectodermal tumors primitive cerebellar pnet childhood cerebellar neoplasms cerebellar neoplasms primary cerebellar neoplasm malignant cerebellar neoplasm malignant primary neoplasm metastases neoplasm malignant neoplasms neuroepithelial neoplasms germ cell and embryonal neoplasms by histologic type neoplasms glandular and epithelial neoplasms nerve tissue central nervous system neoplasms primary central nervous system neoplasms malignant nervous system neoplasms neoplasms by site brain diseases central nervous system diseases nervous system diseases medulloblastoma recurrent hsv virus pediatric brain tumor nervous system cancer primitive neuroectodermal tumor of cerebellum,brain/CNS
399,China,Extensive-stage Small Cell Lung Cancer,RADIATION: Radiotherapy to all residual lesions|DRUG: Chemoimmunotherapy,12,OTHER_GOV,Anhui Provincial Hospital,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'chemoimmunotherapy'}]",False,extensive stage small cell lung cancer,lung/thoracic
400,"France, Germany, Italy, Netherlands, Spain, Switzerland, United Kingdom, United States",Cervical Carcinoma,BIOLOGICAL: LN-145|BIOLOGICAL: LN-145 + pembrolizumab,2,INDUSTRY,"Iovance Biotherapeutics, Inc.","['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'ln-145'}, {'type': 'other', 'subtype': None, 'raw': 'ln-145'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",True,cervical carcinoma,gynecologic
401,United States,"Carcinoma, Non-Small-Cell Lung",DRUG: Nivolumab|DRUG: Ipilimumab|DRUG: Carboplatin|DRUG: Paclitaxel|DRUG: Pemetrexed,2,OTHER,Hackensack Meridian Health,"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}, {'type': 'chemotherapy', 'subtype': 'antifolate', 'raw': 'pemetrexed'}]",True,carcinoma non small cell lung,lung/thoracic
402,"China, Hong Kong, Italy, Japan, Republic of, Spain, Taiwan, United Kingdom, United States",Hepatocellular Carcinoma|Biliary Tract Cancer,DRUG: Volrustomig|DRUG: Bevacizumab|DRUG: Lenvatinib|DRUG: Rilvegostomig|DRUG: Gemcitabine|DRUG: Cisplatin,2,INDUSTRY,AstraZeneca,"['targeted therapy', 'other', 'chemotherapy', 'checkpoint inhibitor', 'antibody']","[{'type': 'other', 'subtype': None, 'raw': 'volrustomig'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'bevacizumab'}, {'type': 'targeted therapy', 'subtype': 'other', 'raw': 'lenvatinib'}, {'type': 'checkpoint inhibitor', 'subtype': 'PD-1/CTLA-4 bispecific', 'raw': 'rilvegostomig'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'gemcitabine'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}]",True,hepatocellular carcinoma biliary tract cancer,digestive
403,China,Toxicity Due to Radiotherapy|Non-small Cell Lung Cancer,RADIATION: High-dose fractionated radiotherapy|RADIATION: Low-dose fractionated radiotherapy,12,OTHER_GOV,Anhui Provincial Hospital,[],[],False,toxicity due to radiotherapy non small cell lung cancer,lung/thoracic
404,China,Head and Neck Cancer,RADIATION: radical radiotherapy (60Gy)|RADIATION: radical radiotherapy (66Gy)|RADIATION: radical radiotherapy (70Gy)|COMBINATION_PRODUCT: anti-PD-1 or PD-L1 antibody,2,OTHER,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",['other'],"[{'type': 'other', 'subtype': None, 'raw': 'anti-pd-1 or pd-l1 antibody'}]",False,head and neck cancer,head/neck
405,United States,Glioblastoma,DRUG: Poly-ICLC|DEVICE: Tumor Treating Fields|BIOLOGICAL: Peptides,1,OTHER,Albert Einstein College of Medicine,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'poly-iclc'}, {'type': 'other', 'subtype': None, 'raw': 'peptides'}]",False,glioblastoma,brain/CNS
406,"Canada, United States",Ovarian Cancer,DRUG: Durvalumab|DRUG: BA3011|DRUG: BA3021|DRUG: ENB003|DRUG: Toripalimab,2,NETWORK,Canadian Cancer Trials Group,"['checkpoint inhibitor', 'other']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}, {'type': 'other', 'subtype': None, 'raw': 'ba3011'}, {'type': 'other', 'subtype': None, 'raw': 'ba3021'}, {'type': 'other', 'subtype': None, 'raw': 'enb003'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'toripalimab'}]",True,ovarian cancer,gynecologic
407,United States,Clear Cell Renal Cell Carcinoma|Cervical Carcinoma|Esophageal Carcinoma|Pancreatic Adenocarcinoma|Malignant Pleural Mesothelioma,BIOLOGICAL: CTX131,12,INDUSTRY,CRISPR Therapeutics AG,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'ctx131'}]",False,clear cell renal cell carcinoma cervical carcinoma esophageal carcinoma pancreatic adenocarcinoma malignant pleural mesothelioma,gynecologic
408,China,Advanced Lung Cancer,BIOLOGICAL: Targeted CEA CAR-T|BIOLOGICAL: Targeted CEA CAR-T,1,INDUSTRY,"Chongqing Precision Biotech Co., Ltd",['cell therapy'],"[{'type': 'cell therapy', 'subtype': 'engineered cell', 'raw': 'targeted cea car-t'}, {'type': 'cell therapy', 'subtype': 'engineered cell', 'raw': 'targeted cea car-t'}]",False,advanced lung cancer,lung/thoracic
409,United States,Colorectal Adenocarcinoma|Colon Cancer|Colon Adenocarcinoma|Rectum Cancer|Rectal Cancer|Rectal Adenocarcinoma|Colorectal Cancer,DRUG: Cabozantinib|DRUG: Nivolumab,2,OTHER,"University of Colorado, Denver","['checkpoint inhibitor', 'targeted therapy']","[{'type': 'targeted therapy', 'subtype': 'other', 'raw': 'cabozantinib'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}]",True,colorectal adenocarcinoma colon cancer colon adenocarcinoma rectum cancer rectal cancer rectal adenocarcinoma colorectal cancer,digestive
410,China,Cervical Cancer,DRUG: Chemoradiotherapy + Adjuvant chemotherapy and Zimberelimab|DRUG: Chemoradiotherapy (small pelvic) + Zimberelimab,2,OTHER,Suzhou Municipal Hospital,"['other', 'antibody']","[{'type': 'other', 'subtype': None, 'raw': 'chemoradiotherapy'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'adjuvant chemotherapy and zimberelimab'}, {'type': 'other', 'subtype': None, 'raw': 'chemoradiotherapy'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'zimberelimab'}]",True,cervical cancer,gynecologic
411,France,Inflammatory Breast Cancer,DRUG: Pembrolizumab Injection|DRUG: neoadjuvant EC-paclitaxel chemotherapy,2,OTHER,Institut Paoli-Calmettes,"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab injection'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'neoadjuvant ec-paclitaxel chemotherapy'}]",True,inflammatory breast cancer,breast
412,China,Non-small Cell Lung Cancer,RADIATION: definitive radiotherapy|DRUG: induction chemo-immunotherapy|DRUG: concurrent chemotherapy|DRUG: Immunotheapy consolidation|DRUG: Thymosin Alpha1,2,OTHER,Sun Yat-sen University,"['other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'induction chemo-immunotherapy'}, {'type': 'chemotherapy', 'subtype': 'concurrent', 'raw': 'concurrent chemotherapy'}, {'type': 'other', 'subtype': None, 'raw': 'immunotheapy consolidation'}, {'type': 'other', 'subtype': None, 'raw': 'thymosin alpha1'}]",True,non small cell lung cancer,lung/thoracic
413,"Canada, Republic of, Spain, United States",Metastatic or Locally Advanced Unresectable Solid Tumors,DRUG: Tuvusertib|DRUG: Lartesertib|DRUG: Avelumab,1,INDUSTRY,"EMD Serono Research & Development Institute, Inc.","['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'tuvusertib'}, {'type': 'other', 'subtype': None, 'raw': 'lartesertib'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'avelumab'}]",True,metastatic or locally advanced unresectable solid tumors,multiple
414,"Canada, United States",Locally Advanced Urothelial Carcinoma|Metastatic Urothelial Carcinoma|Stage III Bladder Cancer AJCC v8|Stage IV Bladder Cancer AJCC v8,PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|PROCEDURE: Magnetic Resonance Imaging|BIOLOGICAL: Pembrolizumab|DRUG: Tazemetostat,12,NIH,National Cancer Institute (NCI),"['checkpoint inhibitor', 'other']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'other', 'subtype': None, 'raw': 'tazemetostat'}]",True,locally advanced urothelial carcinoma metastatic urothelial carcinoma stage iii bladder cancer ajcc v8 stage iv bladder cancer ajcc v8,genitourinary
415,United States,"Recurrent Medulloblastoma|Recurrent Brain Tumor, Childhood|Malignant Glioma",DRUG: PEP-CMV,1,OTHER,Daniel Landi,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'pep-cmv'}]",False,recurrent medulloblastoma recurrent brain tumor childhood malignant glioma,brain/CNS
416,United States,Breast Cancer|HER2+ Breast Cancer,BIOLOGICAL: VRP-HER2|BIOLOGICAL: Pembrolizumab,2,OTHER,Herbert Lyerly,"['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'vrp-her2'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",True,breast cancer her2 breast cancer,breast
417,United States,"Non Small Cell Lung Cancer|Lung Cancer, Nonsmall Cell|Non Small Cell Lung Cancer Metastatic",DRUG: Nivolumab|DRUG: Ipilimumab|DRUG: Nintedanib,12,OTHER,H. Lee Moffitt Cancer Center and Research Institute,"['checkpoint inhibitor', 'kinase inhibitor']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'nintedanib'}]",True,non small cell lung cancer lung cancer nonsmall cell non small cell lung cancer metastatic,lung/thoracic
418,China,Liver Cancer,DRUG: PD1/PDL1 inhibitor,3,OTHER,Second Affiliated Hospital of Guangzhou Medical University,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'pd1'}, {'type': 'other', 'subtype': None, 'raw': 'pdl1 inhibitor'}]",False,liver cancer,digestive
419,Spain,MSI-H Colorectal Cancer|Melanoma|Anal Carcinoma|Mesothelioma|Triple Negative Breast Cancer|Lung Adenocarcinoma|Cholangiocarcinoma|Cervical Carcinoma|Kidney Clear Cell Carcinoma|Stomach Adenocarcinoma|Esophageal Adenocarcinoma|Uterine Adenocarcinoma|Head and Neck Squamous Cell Carcinoma|Sarcoma|Lung Squamous Cell Carcinoma|Urothelial Carcinoma|Thyroid Carcinoma|Hepatocellular Carcinoma|Uveal Melanoma|HER2-positive Breast Cancer|Pancreatic Adenocarcinoma|Squamous Esophageal Carcinoma|Epithelial Ovarian Cancer|Uterine Carcinosarcoma|Small Cell Lung Cancer|Hormone Receptor Positive / HER2-negative Breast Cancer|Lung Adenocarcinoma EGFR-mutated/ ALK Traslocation|Colorectal Adenocarcinoma|Prostate Adenocarcinoma|Carcinoma of Unknown Primary|Other Histology,DRUG: Spartalizumab|DRUG: Tislelizumab,2,OTHER,SOLTI Breast Cancer Research Group,"['checkpoint inhibitor', 'antibody']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'spartalizumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'tislelizumab'}]",True,msi h colorectal cancer melanoma anal carcinoma mesothelioma triple negative breast cancer lung adenocarcinoma cholangiocarcinoma cervical carcinoma kidney clear cell carcinoma stomach adenocarcinoma esophageal adenocarcinoma uterine adenocarcinoma head and neck squamous cell carcinoma sarcoma lung squamous cell carcinoma urothelial carcinoma thyroid carcinoma hepatocellular carcinoma uveal melanoma her2 positive breast cancer pancreatic adenocarcinoma squamous esophageal carcinoma epithelial ovarian cancer uterine carcinosarcoma small cell lung cancer hormone receptor positive her2 negative breast cancer lung adenocarcinoma egfr mutated alk traslocation colorectal adenocarcinoma prostate adenocarcinoma carcinoma of unknown primary other histology,gynecologic
420,China,Esophagus Cancer|Esophagogastric Junction Cancer|Chemoradiation|Targeted Therapy|Immunotherapy|Chemotherapy Effect,RADIATION: Radiotherapy|DRUG: Platinum based chemotherapy|DRUG: Paclitaxel based chemotherapy|DRUG: Immunotherapy|DRUG: 5-FU Analog based chemotherapy|DRUG: Nimotuzumab,3,OTHER,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","['other', 'antibody', 'chemotherapy', 'immunotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'platinum based chemotherapy'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel based chemotherapy'}, {'type': 'immunotherapy', 'subtype': 'unspecified', 'raw': 'immunotherapy'}, {'type': 'other', 'subtype': None, 'raw': '5-fu analog based chemotherapy'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'nimotuzumab'}]",True,esophagus cancer esophagogastric junction cancer chemoradiation targeted therapy immunotherapy chemotherapy effect,digestive
421,France,Bladder Cancer,DRUG: Atezolizumab,2,OTHER,UNICANCER,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'atezolizumab'}]",False,bladder cancer,genitourinary
422,China,Unresectable Locally Advanced Non-small Cell Lung Cancer,DRUG: Adebrelimab + Apatinib,2,OTHER,Wei Zhou,"['antibody', 'kinase inhibitor']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'adebrelimab'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'apatinib'}]",True,unresectable locally advanced non small cell lung cancer,lung/thoracic
423,Netherlands,Rectal Cancer,DRUG: Atezolizumab|DRUG: Bevacizumab,2,OTHER,The Netherlands Cancer Institute,"['checkpoint inhibitor', 'antibody']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'atezolizumab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'bevacizumab'}]",True,rectal cancer,digestive
424,"Germany, Switzerland",Stage III Non-small Cell Lung Cancer|Locally Advanced|Unresectable,RADIATION: standard Radiotherapy|DRUG: Chemotherapy|DRUG: Immunotherapy|RADIATION: Experimental Radiotherapy,2,OTHER,TheraOp,"['chemotherapy', 'immunotherapy']","[{'type': 'chemotherapy', 'subtype': 'unspecified', 'raw': 'chemotherapy'}, {'type': 'immunotherapy', 'subtype': 'unspecified', 'raw': 'immunotherapy'}]",True,stage iii non small cell lung cancer locally advanced unresectable,lung/thoracic
425,Netherlands,Metastatic Pancreatic Cancer,BIOLOGICAL: Durvalumab|DRUG: Rintatolimod,12,OTHER,"Joachim Aerts, MD PhD","['checkpoint inhibitor', 'other']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}, {'type': 'other', 'subtype': None, 'raw': 'rintatolimod'}]",True,metastatic pancreatic cancer,digestive
426,United States,Pancreatic Cancer,BIOLOGICAL: N-803|DRUG: Aldoxorubicin HCl|BIOLOGICAL: PD-L1 t-haNK|DRUG: Nab-paclitaxel|DRUG: Gemcitabine|DRUG: Cyclophosphamide|DRUG: 5-Fluorouracil|DRUG: Leucovorin|PROCEDURE: SBRT|DRUG: Irinotecan liposome,2,INDUSTRY,"ImmunityBio, Inc.","['cytokine therapy', 'supportive care', 'chemotherapy', 'cell therapy']","[{'type': 'cytokine therapy', 'subtype': 'IL-15 superagonist', 'raw': 'n-803'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'aldoxorubicin hcl'}, {'type': 'cell therapy', 'subtype': 'engineered T cell', 'raw': 'pd-l1 t-hank'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'nab-paclitaxel'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'gemcitabine'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide'}, {'type': 'chemotherapy', 'subtype': 'antimetabolite', 'raw': '5-fluorouracil'}, {'type': 'supportive care', 'subtype': 'folinic acid', 'raw': 'leucovorin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'irinotecan liposome'}]",True,pancreatic cancer,digestive
427,United States,Non Hodgkin Lymphoma,DRUG: AB-101|DRUG: Rituximab|DRUG: Interleukin-2|DRUG: Cyclophosphamide|DRUG: Fludarabine|DRUG: Bendamustine,12,INDUSTRY,"Artiva Biotherapeutics, Inc.","['other', 'antibody', 'cytokine therapy', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'ab-101'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'rituximab'}, {'type': 'cytokine therapy', 'subtype': 'IL-2', 'raw': 'interleukin-2'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide'}, {'type': 'chemotherapy', 'subtype': 'purine analog', 'raw': 'fludarabine'}, {'type': 'chemotherapy', 'subtype': 'alkylating agent', 'raw': 'bendamustine'}]",True,non hodgkin lymphoma,hematologic
428,China,Nasopharyngeal Cancer,DRUG: Irinotecan Liposomal combined With Nituzumab,2,OTHER,XIANG YANQUN,['chemotherapy'],"[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'irinotecan liposomal combined with nituzumab'}]",False,nasopharyngeal cancer,head/neck
429,"Germany, Hong Kong, Japan, Spain, Taiwan, United States","Carcinoma, Non-Small-Cell Lung|Melanoma|Nasopharyngeal Carcinoma|Microsatellite Stable Colorectal Cancer|Triple Negative Breast Cancer",DRUG: DKY709|DRUG: PDR001,1,INDUSTRY,Novartis Pharmaceuticals,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'dky709'}, {'type': 'other', 'subtype': None, 'raw': 'pdr001'}]",False,carcinoma non small cell lung melanoma nasopharyngeal carcinoma microsatellite stable colorectal cancer triple negative breast cancer,digestive
430,United States,Endometrial Cancer,DRUG: Pembrolizumab|RADIATION: Vaginal cuff brachytherapy (VCB)|DRUG: Paclitaxel|DRUG: Carboplatin,1,OTHER,University of Oklahoma,"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}]",True,endometrial cancer,gynecologic
431,China,Locally Advanced and Metastatic Pancreatic Cancer,DRUG: PD-L1/CTLA4 BsAb|COMBINATION_PRODUCT: GP|COMBINATION_PRODUCT: FOLFIRINOX,12,OTHER,Changhai Hospital,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'pd-l1'}, {'type': 'other', 'subtype': None, 'raw': 'ctla4 bsab'}, {'type': 'other', 'subtype': None, 'raw': 'gp'}, {'type': 'other', 'subtype': None, 'raw': 'folfirinox'}]",False,locally advanced and metastatic pancreatic cancer,digestive
432,United States,"Locally Advanced Cervical Squamous Cell Carcinoma, Not Otherwise Specified|Stage IB3 Cervical Cancer FIGO 2018|Stage II Cervical Cancer FIGO 2018|Stage IIA Cervical Cancer FIGO 2018|Stage IIA1 Cervical Cancer FIGO 2018|Stage IIA2 Cervical Cancer FIGO 2018|Stage IIB Cervical Cancer FIGO 2018|Stage III Cervical Cancer FIGO 2018|Stage IIIA Cervical Cancer FIGO 2018|Stage IIIB Cervical Cancer FIGO 2018|Stage IIIC Cervical Cancer FIGO 2018|Stage IIIC1 Cervical Cancer FIGO 2018|Stage IIIC2 Cervical Cancer FIGO 2018|Stage IVA Cervical Cancer FIGO 2018",DRUG: Cisplatin|BIOLOGICAL: Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101|RADIATION: Radiation Therapy,2,OTHER,M.D. Anderson Cancer Center,"['vaccine', 'other', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}, {'type': 'other', 'subtype': None, 'raw': 'liposomal hpv-16 e6'}, {'type': 'vaccine', 'subtype': 'vaccine', 'raw': 'e7 multipeptide vaccine pds0101'}]",True,locally advanced cervical squamous cell carcinoma not otherwise specified stage ib3 cervical cancer figo 2018 stage ii cervical cancer figo 2018 stage iia cervical cancer figo 2018 stage iia1 cervical cancer figo 2018 stage iia2 cervical cancer figo 2018 stage iib cervical cancer figo 2018 stage iii cervical cancer figo 2018 stage iiia cervical cancer figo 2018 stage iiib cervical cancer figo 2018 stage iiic cervical cancer figo 2018 stage iiic1 cervical cancer figo 2018 stage iiic2 cervical cancer figo 2018 stage iva cervical cancer figo 2018,gynecologic
433,Hong Kong,Neuroblastoma Recurrent,BIOLOGICAL: Natural killer cell|DRUG: Dinutuximab beta|DRUG: Interleukin-2|DRUG: Granulocyte-Macrophage Colony-Stimulating Factor|DRUG: Spironolactone|DRUG: Naxitamab,2,OTHER,Hong Kong Children's Hospital,"['other', 'antibody', 'cytokine therapy', 'cell therapy']","[{'type': 'cell therapy', 'subtype': 'other', 'raw': 'natural killer cell'}, {'type': 'other', 'subtype': None, 'raw': 'dinutuximab beta'}, {'type': 'cytokine therapy', 'subtype': 'IL-2', 'raw': 'interleukin-2'}, {'type': 'other', 'subtype': None, 'raw': 'granulocyte-macrophage colony-stimulating factor'}, {'type': 'other', 'subtype': None, 'raw': 'spironolactone'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'naxitamab'}]",True,neuroblastoma recurrent,other
434,"Italy, Netherlands, Spain, Switzerland",Non-small Cell Lung Cancer|Stage IV|Oligometastasis,DRUG: Durvalumab|DRUG: Carboplatin|DRUG: Paclitaxel|RADIATION: Stereotactic body radiation therapy (SBRT)|PROCEDURE: Surgical resection - definitive local treatment.|RADIATION: Radical radiotherapy - definitive local treatment.|DRUG: Tremelimumab,2,NETWORK,ETOP IBCSG Partners Foundation,"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'tremelimumab'}]",True,non small cell lung cancer stage iv oligometastasis,lung/thoracic
435,"Denmark, Sweden",Breast Cancer|Triple Negative Breast Neoplasms,"DRUG: epirubicin, cyclophosphamide, paclitaxel, carboplatin, pembrolizumab|DRUG: epirubicin, cyclophosphamide, capecitabine, paclitaxel, carboplatin, pembrolizumab",3,OTHER,Lund University Hospital,"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'anthracycline', 'raw': 'epirubicin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'chemotherapy', 'subtype': 'anthracycline', 'raw': 'epirubicin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide'}, {'type': 'chemotherapy', 'subtype': 'fluoropyrimidine', 'raw': 'capecitabine'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",True,breast cancer triple negative breast neoplasms,breast
436,Mexico,Metastatic Castration-resistant Prostate Cancer,DRUG: SV-102,1,OTHER,Williams Cancer Foundation,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'sv-102'}]",False,metastatic castration resistant prostate cancer,genitourinary
437,United States,Urothelial Carcinoma|Bladder Cancer,DRUG: Durvalumab (Cohort 1-3)|RADIATION: External Beam Radiotherapy (EBRT)|BIOLOGICAL: Bacillus Calmette-Guérin (BCG)|DRUG: Gemcitabine|DRUG: Docetaxel|BIOLOGICAL: Tremelimumab|DRUG: Durvalumab (Cohort 4/5)|OTHER: To be determined,12,OTHER,"Noah Hahn, M.D.","['checkpoint inhibitor', 'other', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}, {'type': 'other', 'subtype': None, 'raw': 'bacillus calmette-guérin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'gemcitabine'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'docetaxel'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'tremelimumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}]",True,urothelial carcinoma bladder cancer,genitourinary
438,Netherlands,Epithelial Ovarian Cancer|Ovarian Carcinoma,BIOLOGICAL: XP-DC vaccinations,12,OTHER,Radboud University Medical Center,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'xp-dc vaccinations'}]",False,epithelial ovarian cancer ovarian carcinoma,gynecologic
439,"Australia, Georgia, Germany, Netherlands, Poland, Romania, Spain",Advanced Cancer|Metastatic Cancer,DRUG: FS222,1,INDUSTRY,invoX Pharma Limited,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'fs222'}]",False,advanced cancer metastatic cancer,multiple
440,United States,"Acute Myeloid Leukemia|Chronic Lymphocytic Leukemia|Chronic Myeloid Leukemia|Myelodysplasia|Myeloproliferative Disorder|Myelofibrosis|Lymphoma|Lymphoma, Non-Hodgkin|Plasma Cell Disorder",DRUG: Cyclophosphamide|DRUG: Fludarabine|RADIATION: Total Body Irradiation|DRUG: Tacrolimus|DRUG: cellcept|DRUG: g-csf|PROCEDURE: Peripheral Blood Transplant,3,OTHER,Dartmouth-Hitchcock Medical Center,"['other', 'chemotherapy', 'cell therapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide'}, {'type': 'chemotherapy', 'subtype': 'purine analog', 'raw': 'fludarabine'}, {'type': 'other', 'subtype': None, 'raw': 'tacrolimus'}, {'type': 'cell therapy', 'subtype': 'other', 'raw': 'cellcept'}, {'type': 'other', 'subtype': None, 'raw': '-csf'}]",True,acute myeloid leukemia chronic lymphocytic leukemia chronic myeloid leukemia myelodysplasia myeloproliferative disorder myelofibrosis lymphoma lymphoma non hodgkin plasma cell disorder,hematologic
441,United States,Metastatic Solid Cancers|Colorectal Cancer|Breast Cancer|Non-Small Cell Lung Cancer|Gastrointestinal Cancer|Ovarian Cancer|Genitourinary Cancer,DRUG: Aldesleukin|DRUG: Fludarabine|DRUG: Cyclophosphamide|BIOLOGICAL: KRAS TCR-Transduced PBL|BIOLOGICAL: GRT-C903/GRT-R904,1,NIH,National Cancer Institute (NCI),"['other', 'cytokine therapy', 'chemotherapy', 'cell therapy']","[{'type': 'cytokine therapy', 'subtype': 'IL-2', 'raw': 'aldesleukin'}, {'type': 'chemotherapy', 'subtype': 'purine analog', 'raw': 'fludarabine'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide'}, {'type': 'cell therapy', 'subtype': 'engineered cell', 'raw': 'kras tcr-transduced pbl'}, {'type': 'other', 'subtype': None, 'raw': 'grt-c903'}, {'type': 'other', 'subtype': None, 'raw': 'grt-r904'}]",True,metastatic solid cancers colorectal cancer breast cancer non small cell lung cancer gastrointestinal cancer ovarian cancer genitourinary cancer,gynecologic
442,United States,Neuroblastoma,DRUG: Dinutuximab|BIOLOGICAL: NK Cells|DRUG: Lenalidomide,1,OTHER,New Approaches to Neuroblastoma Therapy Consortium,"['other', 'antibody', 'cell therapy']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'dinutuximab'}, {'type': 'cell therapy', 'subtype': 'other', 'raw': 'nk cells'}, {'type': 'other', 'subtype': None, 'raw': 'lenalidomide'}]",True,neuroblastoma,other
443,China,"Nutrition Disorders|Immunotherapy|Cancer|Survival, Prosthesis",DRUG: Megestrol Acetate and olanzapine|DRUG: Starch powder 50 mg,3,OTHER,Qingdao Central Hospital,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'megestrol acetate and olanzapine'}, {'type': 'other', 'subtype': None, 'raw': 'starch powder 50'}]",False,nutrition disorders immunotherapy cancer survival prosthesis,hematologic
444,United Kingdom,Bladder Cancer,DRUG: Durvalumab|BIOLOGICAL: S-488210/S-488211,12,OTHER,"University College, London","['checkpoint inhibitor', 'other']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}, {'type': 'other', 'subtype': None, 'raw': 's-488210'}, {'type': 'other', 'subtype': None, 'raw': 's-488211'}]",True,bladder cancer,genitourinary
445,China,Esophageal Cancer,DRUG: Carboplatin|DRUG: Nab paclitaxel|DRUG: Sintilimab,2,OTHER,Sichuan University,"['antibody', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'nab paclitaxel'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'sintilimab'}]",True,esophageal cancer,digestive
446,United States,Metastatic Non-small Cell Lung Cancer,DRUG: Dupilumab|DRUG: PD-1/PD-L1 blockade|DRUG: Anakinra,12,OTHER,Thomas Marron,"['checkpoint inhibitor', 'other', 'antibody']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'dupilumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'pd-1'}, {'type': 'other', 'subtype': None, 'raw': 'pd-l1 blockade'}, {'type': 'other', 'subtype': None, 'raw': 'anakinra'}]",True,metastatic non small cell lung cancer,lung/thoracic
447,China,Breast Cancer,RADIATION: Stereotactic Body Radiation Therapy (SBRT)|DRUG: Toripalimab|DRUG: Neoadjuvant Chemotherapy|PROCEDURE: Surgery|DRUG: Adjuvant Chemotherapy|RADIATION: Adjuvant Radiotherapy|DRUG: Endocrine therapy,2,OTHER,Xijing Hospital,"['checkpoint inhibitor', 'other', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'toripalimab'}, {'type': 'chemotherapy', 'subtype': 'neoadjuvant', 'raw': 'neoadjuvant chemotherapy'}, {'type': 'other', 'subtype': None, 'raw': 'adjuvant chemotherapy'}, {'type': 'other', 'subtype': None, 'raw': 'endocrine therapy'}]",True,breast cancer,breast
448,Netherlands,Colorectal Cancer|Liver Metastases|Liver Metastasis Colon Cancer,DRUG: IP-001,12,OTHER,M.R. Meijerink,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'ip-001'}]",False,colorectal cancer liver metastases liver metastasis colon cancer,digestive
449,United States,Head and Neck Cancer|Head and Neck Squamous Cell Carcinoma,DRUG: Nivolumab|PROCEDURE: Surgical Resection|RADIATION: Radiation (5 days)|RADIATION: Radiation (3 days),12,OTHER,Providence Health & Services,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}]",False,head and neck cancer head and neck squamous cell carcinoma,head/neck
450,United States,Billiary Track Cancer,DRUG: Gemcitabine|DRUG: Cisplatin|DRUG: Pembrolizumab,2,OTHER,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'gemcitabine'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",True,billiary track cancer,other
451,China,Recurrent Nasopharyngeal Carcinoma,PROCEDURE: endoscopic surgery,2,OTHER,Eye & ENT Hospital of Fudan University,['surgery'],"[{'type': 'surgery', 'subtype': 'procedure', 'raw': 'procedure: endoscopic surgery'}]",False,recurrent nasopharyngeal carcinoma,head/neck
452,Canada,Non Small Cell Lung Cancer|Complete Surgical Resection|Circulating Tumor DNA,DRUG: Nivolumab|DRUG: Pemetrexed|DRUG: Gemcitabine|DRUG: Cisplatin|DRUG: Carboplatin|PROCEDURE: ctDNA blood test,2,OTHER,"University Health Network, Toronto","['checkpoint inhibitor', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'chemotherapy', 'subtype': 'antifolate', 'raw': 'pemetrexed'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'gemcitabine'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}]",True,non small cell lung cancer complete surgical resection circulating tumor dna,lung/thoracic
453,Netherlands,Metastatic Breast Cancer,DRUG: Tiragolumab|DRUG: Atezolizumab|DRUG: Ipilimumab,2,OTHER,The Netherlands Cancer Institute,"['checkpoint inhibitor', 'antibody']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'tiragolumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'atezolizumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}]",True,metastatic breast cancer,breast
454,United States,Head and Neck Cancer|Lung Cancer,DRUG: Paclitaxel|DRUG: Pemetrexed|DRUG: 5Fluorouracil|DRUG: Carboplatin|DRUG: Pembrolizumab,2,OTHER,"Rutgers, The State University of New Jersey","['checkpoint inhibitor', 'other', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}, {'type': 'chemotherapy', 'subtype': 'antifolate', 'raw': 'pemetrexed'}, {'type': 'other', 'subtype': None, 'raw': '5fluorouracil'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",True,head and neck cancer lung cancer,lung/thoracic
455,"Argentina, Australia, Austria, Belgium, Brazil, France, Hong Kong, Hungary, Italy, Republic of, Romania, Spain, Taiwan, United Kingdom, United States",Non-small Cell Lung Cancer (NSCLC),DRUG: S095018|DRUG: S095024|DRUG: S095029|DRUG: S095018 Recommended Dose Expansion (RDE)|DRUG: S095024 RDE|DRUG: S095029 RDE|DRUG: Cemiplimab,12,INDUSTRY,Servier Bio-Innovation LLC,"['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 's095018'}, {'type': 'other', 'subtype': None, 'raw': 's095024'}, {'type': 'other', 'subtype': None, 'raw': 's095029'}, {'type': 'other', 'subtype': None, 'raw': 's095018 recommended dose expansion'}, {'type': 'other', 'subtype': None, 'raw': 's095024 rde'}, {'type': 'other', 'subtype': None, 'raw': 's095029 rde'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'cemiplimab'}]",True,non small cell lung cancer,lung/thoracic
456,"Argentina, Australia, Austria, Belgium, Brazil, Chile, France, Germany, Ireland, Italy, Mexico, Netherlands, Poland, Romania, Russian Federation, Spain, Switzerland, United Kingdom, United States",Non-small Cell Lung Cancer|Recurrent Non-small Cell Lung Cancer|Metastatic Non-small Cell Lung Cancer,BIOLOGICAL: Nivolumab|BIOLOGICAL: Relatlimab|DRUG: Carboplatin|DRUG: Cisplatin|DRUG: Paclitaxel|DRUG: Nab-Paclitaxel|DRUG: Pemetrexed,2,INDUSTRY,Bristol-Myers Squibb,"['checkpoint inhibitor', 'antibody', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'relatlimab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'nab-paclitaxel'}, {'type': 'chemotherapy', 'subtype': 'antifolate', 'raw': 'pemetrexed'}]",True,non small cell lung cancer recurrent non small cell lung cancer metastatic non small cell lung cancer,lung/thoracic
457,United States,Metastatic Hormone Refractory Prostate Cancer,DRUG: Cabozantinib|DRUG: Nivolumab|DRUG: Abiraterone acetate|DRUG: Prednisone|PROCEDURE: Peripheral blood collection,1,OTHER,Washington University School of Medicine,"['checkpoint inhibitor', 'targeted therapy', 'other', 'supportive care']","[{'type': 'targeted therapy', 'subtype': 'other', 'raw': 'cabozantinib'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'other', 'subtype': None, 'raw': 'abiraterone acetate'}, {'type': 'supportive care', 'subtype': 'steroid', 'raw': 'prednisone'}]",True,metastatic hormone refractory prostate cancer,genitourinary
458,United States,Advanced Lung Non-Small Cell Carcinoma|Stage IIIB Lung Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8|Stage IV Lung Cancer AJCC v8,DRUG: Carboplatin|PROCEDURE: Computed Tomography|PROCEDURE: Magnetic Resonance Imaging|DRUG: Nab-paclitaxel|DRUG: Paclitaxel|BIOLOGICAL: Pembrolizumab|DRUG: Pemetrexed|PROCEDURE: Positron Emission Tomography|OTHER: Questionnaire Administration,3,NIH,National Cancer Institute (NCI),"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'nab-paclitaxel'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'chemotherapy', 'subtype': 'antifolate', 'raw': 'pemetrexed'}]",True,advanced lung non small cell carcinoma stage iiib lung cancer ajcc v8 stage iiic lung cancer ajcc v8 stage iv lung cancer ajcc v8,lung/thoracic
459,China,Breast Cancer,"DRUG: Anlotinib ,|DRUG: Benmelstobart|DRUG: Capecitabine",2,OTHER,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,"['other', 'chemotherapy', 'kinase inhibitor']","[{'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'anlotinib'}, {'type': 'other', 'subtype': None, 'raw': 'benmelstobart'}, {'type': 'chemotherapy', 'subtype': 'fluoropyrimidine', 'raw': 'capecitabine'}]",True,breast cancer,breast
460,China,Metastatic Nasopharyngeal Cancer,RADIATION: Radiotherapy,2,OTHER,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",['other'],"[{'type': 'other', 'subtype': None, 'raw': 'radiation: radiotherapy'}]",False,metastatic nasopharyngeal cancer,head/neck
461,Canada,Pancreatic Cancer|Hepatocellular Cancer|Biliary Tract Cancer|Cholangiocarcinoma,BIOLOGICAL: Durvalumab|DRUG: Gemcitabine|DRUG: Nab paclitaxel|BIOLOGICAL: Tremelimumab|DRUG: Propranolol|DRUG: Cisplatin,2,OTHER,AHS Cancer Control Alberta,"['checkpoint inhibitor', 'other', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'gemcitabine'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'nab paclitaxel'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'tremelimumab'}, {'type': 'other', 'subtype': None, 'raw': 'propranolol'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}]",True,pancreatic cancer hepatocellular cancer biliary tract cancer cholangiocarcinoma,digestive
462,United States,Breast Cancer,BIOLOGICAL: PVX-410|BIOLOGICAL: Durvalumab|DRUG: Hiltonol,1,OTHER,Massachusetts General Hospital,"['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'pvx-410'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}, {'type': 'other', 'subtype': None, 'raw': 'hiltonol'}]",True,breast cancer,breast
463,United States,Gastric Cancer|GastroEsophageal Cancer|Adenocarcinoma,DRUG: Pembrolizumab Monotherapy|DRUG: Ramucirumab|DRUG: Paclitaxel,2,OTHER,Harry H Yoon,"['checkpoint inhibitor', 'antibody', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab monotherapy'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'ramucirumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}]",True,gastric cancer gastroesophageal cancer adenocarcinoma,digestive
464,United States,Minimal Residual Disease|KRAS G12D|KRAS G12R|NRAS G12D|NRAS G12R|Pancreatic Ductal Adenocarcinoma|Colorectal Cancer|Non-small Cell Lung Cancer|Ovarian Cancer|Cholangiocarcinoma|Bile Duct Cancer|Gallbladder Carcinoma,DRUG: ELI-002 2P,1,INDUSTRY,Elicio Therapeutics,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'eli-002 2p'}]",False,minimal residual disease kras g12d kras g12r nras g12d nras g12r pancreatic ductal adenocarcinoma colorectal cancer non small cell lung cancer ovarian cancer cholangiocarcinoma bile duct cancer gallbladder carcinoma,gynecologic
465,United States,Endometrial Cancer|Cancer of Endometrium|Carcinoma of Endometrium|Endometrial Carcinoma,BIOLOGICAL: AdHER2DC vaccine|BIOLOGICAL: Pembrolizumab|BIOLOGICAL: N-803|DRUG: Lenvatinib|DEVICE: PATHWAY HER2 (4B5) assay,12,NIH,National Cancer Institute (NCI),"['checkpoint inhibitor', 'vaccine', 'cytokine therapy', 'targeted therapy']","[{'type': 'vaccine', 'subtype': 'vaccine', 'raw': 'adher2dc vaccine'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'cytokine therapy', 'subtype': 'IL-15 superagonist', 'raw': 'n-803'}, {'type': 'targeted therapy', 'subtype': 'other', 'raw': 'lenvatinib'}]",True,endometrial cancer cancer of endometrium carcinoma of endometrium endometrial carcinoma,gynecologic
466,United States,Non-Small Cell Lung Cancer,DRUG: Nivolumab,2,FED,VA Office of Research and Development,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}]",False,non small cell lung cancer,lung/thoracic
467,China,Esophageal Cancer|Chemotherapy Effect|Chemoradiation|Surgery|Targeted Therapy|Immunotherapy|Esophagogastric Juction Cancer,DRUG: Platinum based chemotherapy|DRUG: Paclitaxel based chemotherapy|RADIATION: Radiotherpay|PROCEDURE: Surgery|DRUG: Immunotherapy|DRUG: 5-FU Analog based chemotherpay|DRUG: Nimotuzumab,3,OTHER,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","['other', 'antibody', 'chemotherapy', 'immunotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'platinum based chemotherapy'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel based chemotherapy'}, {'type': 'immunotherapy', 'subtype': 'unspecified', 'raw': 'immunotherapy'}, {'type': 'other', 'subtype': None, 'raw': '5-fu analog based chemotherpay'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'nimotuzumab'}]",True,esophageal cancer chemotherapy effect chemoradiation surgery targeted therapy immunotherapy esophagogastric juction cancer,digestive
468,China,HER2 Negative Breast Cancer,DRUG: Retinoic Acid|DRUG: anti-PD-1 antibody and chemotherapy,2,OTHER,Fudan University,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'retinoic acid'}, {'type': 'other', 'subtype': None, 'raw': 'anti-pd-1 antibody and chemotherapy'}]",False,her2 negative breast cancer,breast
469,Canada,B-Cell Leukemia|Non-Hodgkin's Lymphoma|B-cell Acute Lymphoblastic Leukemia|Diffuse Large B Cell Lymphoma|High-grade B-cell Lymphoma|Primary Mediastinal Large B-cell Lymphoma (PMBCL)|Mantle Cell Lymphoma|B-cell Lymphoma,BIOLOGICAL: CLIC-2201,1,OTHER,British Columbia Cancer Agency,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'clic-2201'}]",False,b cell leukemia non hodgkin s lymphoma b cell acute lymphoblastic leukemia diffuse large b cell lymphoma high grade b cell lymphoma primary mediastinal large b cell lymphoma mantle cell lymphoma b cell lymphoma,hematologic
470,China,Neoadjuvant Therapy|Esophageal Squamous Cell Carcinoma,DRUG: anlotinib|RADIATION: Thoracic radiotherapy,23,OTHER_GOV,Army Medical Center of PLA,['kinase inhibitor'],"[{'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'anlotinib'}]",False,neoadjuvant therapy esophageal squamous cell carcinoma,digestive
471,"United Kingdom, United States",Advanced Cancer|Angiosarcoma|Colorectal Cancer Without Liver Metastases|Endometrial Cancer|Fibrolamellar Carcinoma|Non-small-cell Lung Cancer|Ovarian Cancer|Prostate Cancer,DRUG: Botensilimab|DRUG: Balstilimab,1,INDUSTRY,Agenus Inc.,['antibody'],"[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'botensilimab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'balstilimab'}]",False,advanced cancer angiosarcoma colorectal cancer without liver metastases endometrial cancer fibrolamellar carcinoma non small cell lung cancer ovarian cancer prostate cancer,gynecologic
472,China,Ovarian Cancer,BIOLOGICAL: KM1|DRUG: Chemotherapy,1,OTHER,Tongji Hospital,"['other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'km1'}, {'type': 'chemotherapy', 'subtype': 'unspecified', 'raw': 'chemotherapy'}]",True,ovarian cancer,gynecologic
473,United States,Lung Non-Small Cell Carcinoma|Stage I Lung Cancer AJCC v8|Stage IA1 Lung Cancer AJCC v8|Stage IA2 Lung Cancer AJCC v8|Stage IA3 Lung Cancer AJCC v8|Stage IB Lung Cancer AJCC v8|Stage II Lung Cancer AJCC v8|Stage IIA Lung Cancer AJCC v8|Stage IIB Lung Cancer AJCC v8,BIOLOGICAL: Pembrolizumab|OTHER: Quality-of-Life Assessment|PROCEDURE: Computed Tomography|PROCEDURE: Biospecimen Collection,2,OTHER,M.D. Anderson Cancer Center,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",False,lung non small cell carcinoma stage i lung cancer ajcc v8 stage ia1 lung cancer ajcc v8 stage ia2 lung cancer ajcc v8 stage ia3 lung cancer ajcc v8 stage ib lung cancer ajcc v8 stage ii lung cancer ajcc v8 stage iia lung cancer ajcc v8 stage iib lung cancer ajcc v8,lung/thoracic
474,"Puerto Rico, United States",Endometrial Endometrioid Adenocarcinoma|Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8|Stage II Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8,PROCEDURE: Biospecimen Collection|RADIATION: Brachytherapy|PROCEDURE: Computed Tomography|RADIATION: External Beam Radiation Therapy|PROCEDURE: Magnetic Resonance Imaging|BIOLOGICAL: Pembrolizumab|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration|PROCEDURE: X-Ray Imaging,3,NIH,National Cancer Institute (NCI),['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",False,endometrial endometrioid adenocarcinoma stage i uterine corpus carcinoma or carcinosarcoma ajcc v8 stage ii uterine corpus carcinoma or carcinosarcoma ajcc v8,gynecologic
475,"Denmark, France",Metastatic Melanoma,BIOLOGICAL: TILT-123,1,INDUSTRY,TILT Biotherapeutics Ltd.,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'tilt-123'}]",False,metastatic melanoma,skin
476,"Australia, Belgium, Brazil, Canada, China, Denmark, Finland, Germany, Hungary, Italy, Japan, Netherlands, Norway, Poland, Republic of, Spain, Sweden, Switzerland, Taiwan, United Kingdom, United States",Endometrial Cancer,DRUG: Trastuzumab deruxtecan|DRUG: Rilvegostomig|DRUG: Pembrolizumab|DRUG: Carboplatin|DRUG: Paclitaxel|DRUG: Docetaxel,3,INDUSTRY,AstraZeneca,"['checkpoint inhibitor', 'other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'trastuzumab deruxtecan'}, {'type': 'checkpoint inhibitor', 'subtype': 'PD-1/CTLA-4 bispecific', 'raw': 'rilvegostomig'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'docetaxel'}]",True,endometrial cancer,gynecologic
477,China,"Carcinoma, Non-Small-Cell Lung",PROCEDURE: bronchial artery interventional therapy|DRUG: Chemotherapy drug|RADIATION: IMRT|DRUG: Immunotherapy,2,OTHER,Dong Wang,"['other', 'immunotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'chemotherapy drug'}, {'type': 'immunotherapy', 'subtype': 'unspecified', 'raw': 'immunotherapy'}]",True,carcinoma non small cell lung,lung/thoracic
478,United States,Lung Non-Small Cell Carcinoma|Stage IV Lung Cancer AJCC v8|Stage III Lung Cancer,PROCEDURE: Biospecimen Collection|DRUG: Carboplatin|PROCEDURE: Computed Tomography|OTHER: Fludeoxyglucose F-18|DRUG: Nab-paclitaxel|BIOLOGICAL: Pembrolizumab|DRUG: Pemetrexed|PROCEDURE: Positron Emission Tomography|RADIATION: Radiation Therapy|OTHER: [18-F] (fluoropropyl)-L-glutamate (FSPG) PET scan|BIOLOGICAL: Ipilimumab|BIOLOGICAL: Nivolumab|BIOLOGICAL: Cemiplimab|BIOLOGICAL: Atezolizumab,12,OTHER,Vanderbilt-Ingram Cancer Center,"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'nab-paclitaxel'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'chemotherapy', 'subtype': 'antifolate', 'raw': 'pemetrexed'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'cemiplimab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'atezolizumab'}]",True,lung non small cell carcinoma stage iv lung cancer ajcc v8 stage iii lung cancer,lung/thoracic
479,"Puerto Rico, United States",Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Early Stage Triple-Negative Breast Carcinoma,PROCEDURE: Biospecimen Collection|DRUG: Carboplatin|DRUG: Cyclophosphamide|DRUG: Docetaxel|DRUG: Doxorubicin|DRUG: Paclitaxel|BIOLOGICAL: Pembrolizumab|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration|PROCEDURE: Surgical Procedure,3,NETWORK,SWOG Cancer Research Network,"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'docetaxel'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'doxorubicin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",True,anatomic stage i breast cancer ajcc v8 anatomic stage ii breast cancer ajcc v8 anatomic stage iiia breast cancer ajcc v8 anatomic stage iiib breast cancer ajcc v8 early stage triple negative breast carcinoma,breast
480,"Australia, United States",Metastatic Head and Neck Squamous Cell Carcinoma|Recurrent Head and Neck Squamous Cell Carcinoma,DRUG: Ficerafusp alfa|DRUG: Pembrolizumab (KEYTRUDA®)|DRUG: Placebo,23,INDUSTRY,Bicara Therapeutics,"['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'ficerafusp alfa'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",True,metastatic head and neck squamous cell carcinoma recurrent head and neck squamous cell carcinoma,head/neck
481,China,Bile Duct Carcinoma|Gall Bladder Cancer|Biliary Tract Cancer|Cholangiocarcinoma,"DRUG: PD-1/CTLA-4 Dual Functional Antibody|DRUG: Gemcitabine, Cisplatin|DRUG: Anlotinib|DRUG: Oxaliplatin + 5-Fluorouracil/Leucovorin",2,OTHER,First Affiliated Hospital of Zhejiang University,"['other', 'chemotherapy', 'kinase inhibitor', 'checkpoint inhibitor', 'supportive care']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'pd-1'}, {'type': 'other', 'subtype': None, 'raw': 'ctla-4 dual functional antibody'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'gemcitabine'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'anlotinib'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'oxaliplatin'}, {'type': 'chemotherapy', 'subtype': 'antimetabolite', 'raw': '5-fluorouracil'}, {'type': 'supportive care', 'subtype': 'folinic acid', 'raw': 'leucovorin'}]",True,bile duct carcinoma gall bladder cancer biliary tract cancer cholangiocarcinoma,genitourinary
482,China,Esophageal Squamous Cell Carcinoma,DRUG: Tislelizumab,2,OTHER,Daping Hospital and the Research Institute of Surgery of the Third Military Medical University,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'tislelizumab'}]",False,esophageal squamous cell carcinoma,digestive
483,United States,Ependymoma,BIOLOGICAL: HLA-A2 restricted synthetic tumor antigen|DRUG: Imiquimod|OTHER: enzyme-linked immunosorbent assay|OTHER: flow cytometry|OTHER: immunohistochemistry staining method|OTHER: laboratory biomarker analysis,1,OTHER,James Felker,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'hla-a2 restricted synthetic tumor antigen'}, {'type': 'other', 'subtype': None, 'raw': 'imiquimod'}]",False,ependymoma,brain/CNS
484,United States,Gynecologic Cancer|Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cavity Cancer,DRUG: FT536|DRUG: Fludarabine|DRUG: CY,1,OTHER,"Masonic Cancer Center, University of Minnesota","['other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'ft536'}, {'type': 'chemotherapy', 'subtype': 'purine analog', 'raw': 'fludarabine'}, {'type': 'other', 'subtype': None, 'raw': 'cy'}]",True,gynecologic cancer ovarian cancer fallopian tube cancer primary peritoneal cavity cancer,gynecologic
485,China,Small Cell Lung Cancer Extensive Stage,RADIATION: thoracic radiotherapy,1,OTHER,Fudan University,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'radiation: thoracic radiotherapy'}]",False,small cell lung cancer extensive stage,lung/thoracic
486,United States,Triple Negative Breast Cancer,DRUG: Pembrolizumab|DRUG: Paclitaxel|DRUG: Capecitabine,12,OTHER,Providence Health & Services,"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}, {'type': 'chemotherapy', 'subtype': 'fluoropyrimidine', 'raw': 'capecitabine'}]",True,triple negative breast cancer,breast
487,China,Ovarian Cancer,DRUG: Fasudil Hydrochloride,2,OTHER,Zhejiang Provincial People's Hospital,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'fasudil hydrochloride'}]",False,ovarian cancer,gynecologic
488,United States,Stage IV Small Cell Lung Cancer,DRUG: Nivolumab|DRUG: Ipilimumab|RADIATION: Stereotactic body radiation therapy,1,OTHER,University of Chicago,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}]",False,stage iv small cell lung cancer,lung/thoracic
489,"Australia, New Zealand","Merkel Cell Carcinoma|Merkel Cell Carcinoma, Stage I|Merkel Cell Carcinoma, Stage II|Merkel Cell Carcinoma, Stage III|Neuroendocrine Tumors|Carcinoma Neuroendocrine Skin",DRUG: Avelumab|DRUG: Placebo,2,OTHER,Melanoma and Skin Cancer Trials Limited,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'avelumab'}]",False,merkel cell carcinoma merkel cell carcinoma stage i merkel cell carcinoma stage ii merkel cell carcinoma stage iii neuroendocrine tumors carcinoma neuroendocrine skin,skin
490,"Denmark, Lithuania, Netherlands, Norway, Sweden, Switzerland",Small-cell Lung Cancer,DRUG: Atezolizumab,2,OTHER,Norwegian University of Science and Technology,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'atezolizumab'}]",False,small cell lung cancer,lung/thoracic
491,Germany,Nasopharyngeal Carcinoma|Nasopharyngeal Cancer|Nasopharyngeal Neoplasms|Nasopharynx Cancer,DRUG: Nivolumab|DRUG: Cisplatin|DRUG: 5-Fluorouracil|DRUG: Gemcitabine|RADIATION: Radiotherapy|DRUG: Interferon beta-1a|PROCEDURE: MRI|PROCEDURE: PET|BEHAVIORAL: Patient-Reported Outcomes,2,OTHER,German Society for Pediatric Oncology and Hematology GPOH gGmbH,"['checkpoint inhibitor', 'other', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}, {'type': 'chemotherapy', 'subtype': 'antimetabolite', 'raw': '5-fluorouracil'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'gemcitabine'}, {'type': 'other', 'subtype': None, 'raw': 'interferon beta-1a'}]",True,nasopharyngeal carcinoma nasopharyngeal cancer nasopharyngeal neoplasms nasopharynx cancer,head/neck
492,Canada,Hepatocellular Carcinoma (HCC)|Macrovascular Invasion|Liver Transplant Surgery|Downstaging,BIOLOGICAL: Atezolizumab & Bevacizumab|DRUG: Yttrium-90 (Y-90)|RADIATION: Stereotactic body radiotherapy (SBRT),12,OTHER,"University Health Network, Toronto","['checkpoint inhibitor', 'other']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'atezolizumab & bevacizumab'}, {'type': 'other', 'subtype': None, 'raw': 'yttrium-90'}]",True,hepatocellular carcinoma macrovascular invasion liver transplant surgery downstaging,digestive
493,United Kingdom,Non Small Cell Lung Cancer,DRUG: Guadecitabine|DRUG: Pembrolizumab|DRUG: ASTX727,1,OTHER,Royal Marsden NHS Foundation Trust,"['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'guadecitabine'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'other', 'subtype': None, 'raw': 'astx727'}]",True,non small cell lung cancer,lung/thoracic
494,Netherlands,Stomach Cancer|Gastro Esophageal Junction Cancer,DRUG: Atezolizumab|DRUG: Capecitabine|DRUG: Oxaliplatin|DRUG: Docetaxel,2,OTHER,The Netherlands Cancer Institute,"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'atezolizumab'}, {'type': 'chemotherapy', 'subtype': 'fluoropyrimidine', 'raw': 'capecitabine'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'oxaliplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'docetaxel'}]",True,stomach cancer gastro esophageal junction cancer,digestive
495,Canada,Melanoma,DRUG: Fecal Microbial Transplantation,1,OTHER,London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'fecal microbial transplantation'}]",False,melanoma,skin
496,"Australia, Belgium, Canada, China, France, Germany, Italy, Japan, Poland, Republic of, Russian Federation, Spain, United Kingdom, United States",Non-muscle Invasive Bladder Cancer,DRUG: PF-06801591|DRUG: Bacillus Calmette-Guerin,3,INDUSTRY,Pfizer,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'pf-06801591'}, {'type': 'other', 'subtype': None, 'raw': 'bacillus calmette-guerin'}]",False,non muscle invasive bladder cancer,genitourinary
497,China,Esophageal Squamous Cell Carcinoma,RADIATION: Neoadjuvant Radiotherapy|DRUG: Neoadjuvant Chemotherapy|DRUG: Immunotherapy,2,OTHER,Zhejiang Cancer Hospital,"['chemotherapy', 'immunotherapy']","[{'type': 'chemotherapy', 'subtype': 'neoadjuvant', 'raw': 'neoadjuvant chemotherapy'}, {'type': 'immunotherapy', 'subtype': 'unspecified', 'raw': 'immunotherapy'}]",True,esophageal squamous cell carcinoma,digestive
498,Belgium,High Grade Glioma|Diffuse Intrinsic Pontine Glioma,BIOLOGICAL: Dendritic cell vaccination + temozolomide-based chemoradiation|BIOLOGICAL: Dendritic cell vaccination +- conventional next-line treatment,12,OTHER,"University Hospital, Antwerp","['other', 'chemotherapy', 'cell therapy']","[{'type': 'cell therapy', 'subtype': 'other', 'raw': 'dendritic cell vaccination'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'temozolomide-based chemoradiation'}, {'type': 'cell therapy', 'subtype': 'other', 'raw': 'dendritic cell vaccination'}, {'type': 'other', 'subtype': None, 'raw': '- conventional next-line treatment'}]",True,high grade glioma diffuse intrinsic pontine glioma,brain/CNS
499,China,Non-small Cell Lung Cancer|EGFR Activating Mutation,BIOLOGICAL: Sintilimab|DRUG: Carboplatin|DRUG: Nab paclitaxel,2,OTHER,Guangdong Provincial People's Hospital,"['antibody', 'chemotherapy']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'sintilimab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'nab paclitaxel'}]",True,non small cell lung cancer egfr activating mutation,lung/thoracic
500,China,Locally Recurrent Rectal Cancer,RADIATION: Conventional Radiotherapy|DRUG: Capecitabine|DRUG: 5-fluorouracil|DRUG: folinic acid|DRUG: Oxaliplatin|DRUG: Irinotecan|DRUG: Cetuximab|DRUG: Bevacizumab|RADIATION: Hypofractionated radiotherapy|DRUG: PD-1 antibody,2,OTHER,Fudan University,"['radiotherapy', 'antibody', 'supportive care', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'fluoropyrimidine', 'raw': 'capecitabine'}, {'type': 'chemotherapy', 'subtype': 'antimetabolite', 'raw': '5-fluorouracil'}, {'type': 'supportive care', 'subtype': 'rescue agent', 'raw': 'folinic acid'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'oxaliplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'irinotecan'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'cetuximab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'bevacizumab'}, {'type': 'radiotherapy', 'subtype': 'from title', 'raw': 'radiotherapy'}]",True,locally recurrent rectal cancer,digestive
501,United States,"Diffuse Intrinsic Pontine Glioma|Diffuse Midline Glioma|Recurrent CNS Tumor, Adult|Recurrent, CNS Tumor, Childhood|Refractory Primary Malignant Central Nervous System Neoplasm",BIOLOGICAL: SC-CAR4BRAIN,1,OTHER,Seattle Children's Hospital,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'sc-car4brain'}]",False,diffuse intrinsic pontine glioma diffuse midline glioma recurrent cns tumor adult recurrent cns tumor childhood refractory primary malignant central nervous system neoplasm,brain/CNS
502,"Australia, Brazil, Canada, China, Czechia, France, Germany, Greece, Hong Kong, Israel, Italy, Japan, Poland, Republic of, Singapore, Spain, Taiwan, United Kingdom, United States",Endometrial Cancer,DRUG: Sacituzumab govitecan-hziy|DRUG: Doxorubicin|DRUG: Paclitaxel,3,INDUSTRY,Gilead Sciences,"['other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'sacituzumab govitecan-hziy'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'doxorubicin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}]",True,endometrial cancer,gynecologic
503,China,Esophageal Cancer,DRUG: Arm A|DRUG: Arm A|RADIATION: Arm A|DRUG: Arm B|RADIATION: Arm B,2,OTHER,Tianjin Medical University Cancer Institute and Hospital,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'arm a'}, {'type': 'other', 'subtype': None, 'raw': 'arm a'}, {'type': 'other', 'subtype': None, 'raw': 'arm b'}]",False,esophageal cancer,digestive
504,China,Laryngeal Cancer|Hypopharyngeal Cancer,DRUG: Toripalimab,2,OTHER,Fudan University,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'toripalimab'}]",False,laryngeal cancer hypopharyngeal cancer,head/neck
505,United States,Non-Small Cell Lung Cancer|Small Cell Lung Cancer|Urothelial Carcinoma|Head and Neck Squamous Cell Carcinoma|Merkel Cell Carcinoma|Melanoma|Renal Cell Carcinoma|Gastric Cancer|Cervical Cancer|Hepatocellular Carcinoma|Microsatellite Instability|Mismatch Repair Deficiency|Colorectal Cancer,DRUG: N-803 + Pembrolizumab|DRUG: N-803 + Nivolumab|DRUG: N-803 + Atezolizumab|DRUG: N-803 + Avelumab|DRUG: N-803 + Durvalumab|DRUG: N-803 + Pembrolizumab + PD-L1 t-haNK|DRUG: N-803 + Nivolumab + PD-L1 t-haNK|DRUG: N-803 + Atezolizumab + PD-L1 t-haNK|DRUG: N-803 + Avelumab + PD-L1 t-haNK|DRUG: N-803 + Durvalumab + PD-L1 t-haNK|DRUG: N-803 + Docetaxel + Pembrolizumab|DRUG: N-803 + Docetaxel + Nivolumab,2,INDUSTRY,"ImmunityBio, Inc.","['checkpoint inhibitor', 'cytokine therapy', 'chemotherapy', 'cell therapy']","[{'type': 'cytokine therapy', 'subtype': 'IL-15 superagonist', 'raw': 'n-803'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'cytokine therapy', 'subtype': 'IL-15 superagonist', 'raw': 'n-803'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'cytokine therapy', 'subtype': 'IL-15 superagonist', 'raw': 'n-803'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'atezolizumab'}, {'type': 'cytokine therapy', 'subtype': 'IL-15 superagonist', 'raw': 'n-803'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'avelumab'}, {'type': 'cytokine therapy', 'subtype': 'IL-15 superagonist', 'raw': 'n-803'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}, {'type': 'cytokine therapy', 'subtype': 'IL-15 superagonist', 'raw': 'n-803'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'cell therapy', 'subtype': 'engineered T cell', 'raw': 'pd-l1 t-hank'}, {'type': 'cytokine therapy', 'subtype': 'IL-15 superagonist', 'raw': 'n-803'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'cell therapy', 'subtype': 'engineered T cell', 'raw': 'pd-l1 t-hank'}, {'type': 'cytokine therapy', 'subtype': 'IL-15 superagonist', 'raw': 'n-803'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'atezolizumab'}, {'type': 'cell therapy', 'subtype': 'engineered T cell', 'raw': 'pd-l1 t-hank'}, {'type': 'cytokine therapy', 'subtype': 'IL-15 superagonist', 'raw': 'n-803'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'avelumab'}, {'type': 'cell therapy', 'subtype': 'engineered T cell', 'raw': 'pd-l1 t-hank'}, {'type': 'cytokine therapy', 'subtype': 'IL-15 superagonist', 'raw': 'n-803'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}, {'type': 'cell therapy', 'subtype': 'engineered T cell', 'raw': 'pd-l1 t-hank'}, {'type': 'cytokine therapy', 'subtype': 'IL-15 superagonist', 'raw': 'n-803'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'docetaxel'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'cytokine therapy', 'subtype': 'IL-15 superagonist', 'raw': 'n-803'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'docetaxel'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}]",True,non small cell lung cancer small cell lung cancer urothelial carcinoma head and neck squamous cell carcinoma merkel cell carcinoma melanoma renal cell carcinoma gastric cancer cervical cancer hepatocellular carcinoma microsatellite instability mismatch repair deficiency colorectal cancer,gynecologic
506,China,Colorectal Liver Metastases,RADIATION: Radiation: High- and Low-dose radiotherapy|DRUG: PD-1 Inhibitors,1,OTHER,Jiangsu Cancer Institute & Hospital,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'pd-1 inhibitors'}]",False,colorectal liver metastases,digestive
507,China,Non-small Cell Lung Cancer,RADIATION: DCE-MRI based split-course hypo-RT|RADIATION: CT based split-course hypo-RT|DRUG: Concurrent chemotherapy|DRUG: Consolidative immunotherapy,3,OTHER,Sun Yat-sen University,"['other', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'concurrent', 'raw': 'concurrent chemotherapy'}, {'type': 'other', 'subtype': None, 'raw': 'consolidative immunotherapy'}]",True,non small cell lung cancer,lung/thoracic
508,Canada,Head and Neck Squamous Cell Carcinoma|Metastatic Squamous Cell Carcinoma,RADIATION: SBRT|DRUG: Durvalumab|DRUG: Tremelimumab,12,OTHER,Centre hospitalier de l'Université de Montréal (CHUM),['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'tremelimumab'}]",False,head and neck squamous cell carcinoma metastatic squamous cell carcinoma,head/neck
509,France,Non Small Cell Lung Cancer,DRUG: Paclitaxel|DRUG: Bevacizumab|DRUG: Atezolizumab,2,OTHER,Intergroupe Francophone de Cancerologie Thoracique,"['checkpoint inhibitor', 'antibody', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'bevacizumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'atezolizumab'}]",True,non small cell lung cancer,lung/thoracic
510,China,Cervical Cancer,DRUG: Cadonilimab,2,OTHER,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,['antibody'],"[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'cadonilimab'}]",False,cervical cancer,gynecologic
511,China,Head and Neck Neoplasms|Recurrent Disease|Metastatic Cancer,DRUG: Penpulimab combined with cetuximab,2,OTHER,Eye & ENT Hospital of Fudan University,['antibody'],"[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'penpulimab combined with cetuximab'}]",False,head and neck neoplasms recurrent disease metastatic cancer,head/neck
512,United States,HPV-Related Cervical Carcinoma|HPV Positive Oropharyngeal Squamous Cell Carcinoma,DRUG: Two IM injections Lenti-HPV-07|DRUG: One IM injection Lenti-HPV-07,12,INDUSTRY,Theravectys S.A.,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'two im injections lenti-hpv-07'}, {'type': 'other', 'subtype': None, 'raw': 'one im injection lenti-hpv-07'}]",False,hpv related cervical carcinoma hpv positive oropharyngeal squamous cell carcinoma,gynecologic
513,United States,Kidney Cancer,BIOLOGICAL: cell infusion,1,NIH,"National Heart, Lung, and Blood Institute (NHLBI)",['cell therapy'],"[{'type': 'cell therapy', 'subtype': 'other', 'raw': 'cell'}]",False,kidney cancer,genitourinary
514,United States,Triple Negative Breast Cancer|Metastatic Breast Cancer,DRUG: Pembrolizumab|BIOLOGICAL: PVX-410,1,OTHER,Massachusetts General Hospital,"['checkpoint inhibitor', 'other']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'other', 'subtype': None, 'raw': 'pvx-410'}]",True,triple negative breast cancer metastatic breast cancer,breast
515,United States,Anaplastic Thyroid Cancer|Thyroid Cancer|BRAF Mutation-Related Tumors,BIOLOGICAL: Cemiplimab|DRUG: XL092,1,OTHER,UNC Lineberger Comprehensive Cancer Center,"['checkpoint inhibitor', 'other']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'cemiplimab'}, {'type': 'other', 'subtype': None, 'raw': 'xl092'}]",True,anaplastic thyroid cancer thyroid cancer braf mutation related tumors,other
516,China,Recurrent Nasopharyngeal Carcinoma,"DRUG: Immunotherapy,Toripalimab Injection|DRUG: Chemotherapy,Gemcitabine based regimen",3,OTHER,Eye & ENT Hospital of Fudan University,"['checkpoint inhibitor', 'chemotherapy', 'immunotherapy']","[{'type': 'immunotherapy', 'subtype': 'unspecified', 'raw': 'immunotherapy'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'toripalimab injection'}, {'type': 'chemotherapy', 'subtype': 'unspecified', 'raw': 'chemotherapy'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'gemcitabine based regimen'}]",True,recurrent nasopharyngeal carcinoma,head/neck
517,China,Nasopharyngeal Carcinoma|Nasopharyngeal Cancer,DRUG: Cadonilimab|DRUG: Gemcitabine|DRUG: Cisplatin|RADIATION: Intensity-modulated radiotherapy,3,OTHER,Sun Yat-sen University,"['antibody', 'chemotherapy']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'cadonilimab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'gemcitabine'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}]",True,nasopharyngeal carcinoma nasopharyngeal cancer,head/neck
518,"Republic of, United States",Advanced Solid Tumor|Metastatic Solid Tumor|Soft Tissue Sarcoma (STS)|Platinum-resistant Ovarian Cancer (PROC)|Hepatocellular Carcinoma (HCC)|Colorectal Cancer (CRC)|HER2 Negative Breast Cancer|Cutaneous Melanoma|Renal Cell Carcinoma (RCC),DRUG: GI-102 subcutaneous (SC)|DRUG: GI-102|DRUG: doxorubicin|DRUG: paclitaxel|DRUG: bevacizumab|DRUG: eribulin|DRUG: trastuzumab deruxtecan (T-DXd)|DRUG: pembrolizumab|DRUG: GI-102,12,INDUSTRY,"GI Innovation, Inc.","['checkpoint inhibitor', 'other', 'antibody', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'gi-102'}, {'type': 'other', 'subtype': None, 'raw': 'gi-102'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'doxorubicin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'bevacizumab'}, {'type': 'other', 'subtype': None, 'raw': 'eribulin'}, {'type': 'other', 'subtype': None, 'raw': 'trastuzumab deruxtecan'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'other', 'subtype': None, 'raw': 'gi-102'}]",True,advanced solid tumor metastatic solid tumor soft tissue sarcoma platinum resistant ovarian cancer hepatocellular carcinoma colorectal cancer her2 negative breast cancer cutaneous melanoma renal cell carcinoma,gynecologic
519,"Australia, Belgium, Brazil, Canada, Chile, Czechia, France, Germany, Israel, Italy, Japan, Netherlands, Philippines, Poland, Republic of, Russian Federation, Spain, Taiwan, Turkey, United Kingdom, United States, Vietnam",Muscle Invasive Bladder Cancer,DRUG: Durvalumab|DRUG: Cisplatin|DRUG: Gemcitabine,3,INDUSTRY,AstraZeneca,"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'gemcitabine'}]",True,muscle invasive bladder cancer,genitourinary
520,France,Metastatic NSCLC,DRUG: Pembrolizumab before randomization|DRUG: Chemotherapy|DRUG: Pemetrexed|DRUG: Pembrolizumab after randomization,23,OTHER,Intergroupe Francophone de Cancerologie Thoracique,"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab before randomization'}, {'type': 'chemotherapy', 'subtype': 'unspecified', 'raw': 'chemotherapy'}, {'type': 'chemotherapy', 'subtype': 'antifolate', 'raw': 'pemetrexed'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab after randomization'}]",True,metastatic nsclc,lung/thoracic
521,United States,Non-Small Cell Lung Cancer Metastatic,DRUG: Durvalumab|DRUG: Pemetrexed|DRUG: Carboplatin,2,OTHER,University of Utah,"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}, {'type': 'chemotherapy', 'subtype': 'antifolate', 'raw': 'pemetrexed'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}]",True,non small cell lung cancer metastatic,lung/thoracic
522,China,Locally Advanced Rectal Cancer (LARC),DRUG: Sintilimab|RADIATION: Short-course radiotherapy|RADIATION: Long-course concurrent chemoradiotherapy|COMBINATION_PRODUCT: CAPOX,2,OTHER,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","['other', 'antibody']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'sintilimab'}, {'type': 'other', 'subtype': None, 'raw': 'capox'}]",True,locally advanced rectal cancer,digestive
523,"France, Spain, United Kingdom, United States",Squamous Cell Carcinoma of Head and Neck,DRUG: TG4050,12,INDUSTRY,Transgene,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'tg4050'}]",False,squamous cell carcinoma of head and neck,head/neck
524,United States,Castration-resistant Prostate Cancer|Metastatic Cancer|Prostate Cancer,BIOLOGICAL: pTVG-HP|BIOLOGICAL: pTVG-AR|DRUG: Pembrolizumab,2,OTHER,"University of Wisconsin, Madison","['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'ptvg-hp'}, {'type': 'other', 'subtype': None, 'raw': 'ptvg-ar'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",True,castration resistant prostate cancer metastatic cancer prostate cancer,genitourinary
525,China,Rectal Cancer,DRUG: AK112 with SCRT and CapeOX|DRUG: AK112 with SCRT,2,OTHER,fan li,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'ak112 with scrt and capeox'}, {'type': 'other', 'subtype': None, 'raw': 'ak112 with scrt'}]",False,rectal cancer,digestive
526,Norway,Glioblastoma,BIOLOGICAL: Dendritic cell immunization|DRUG: Adjuvant temozolomide,23,OTHER,Oslo University Hospital,"['chemotherapy', 'cell therapy']","[{'type': 'cell therapy', 'subtype': 'other', 'raw': 'dendritic cell immunization'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'adjuvant temozolomide'}]",True,glioblastoma,brain/CNS
527,United States,Recurrent Lung Non-Small Cell Carcinoma|Stage IV Lung Cancer AJCC v8,PROCEDURE: Biospecimen Collection|BIOLOGICAL: Cemiplimab|PROCEDURE: Computed Tomography|DRUG: Dexamethasone|DRUG: Docetaxel|PROCEDURE: Magnetic Resonance Imaging|BIOLOGICAL: Ramucirumab,23,NETWORK,SWOG Cancer Research Network,"['checkpoint inhibitor', 'antibody', 'supportive care', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'cemiplimab'}, {'type': 'supportive care', 'subtype': 'steroid', 'raw': 'dexamethasone'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'docetaxel'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'ramucirumab'}]",True,recurrent lung non small cell carcinoma stage iv lung cancer ajcc v8,lung/thoracic
528,United States,Epithelial Ovarian Cancer,DRUG: Pembrolizumab|DRUG: E7777,12,OTHER,"Alexander B Olawaiye, MD","['checkpoint inhibitor', 'other']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'other', 'subtype': None, 'raw': 'e7777'}]",True,epithelial ovarian cancer,gynecologic
529,China,Recurrent Rectal Cancer,DRUG: PD-1 antibody|DRUG: Capecitabine|DRUG: 5FU|DRUG: folinic acid|DRUG: Oxaliplatin|DRUG: Irinotecan|DRUG: Raltitrexed|DRUG: Cetuximab|DRUG: Bevacizumab|RADIATION: Radiation,2,OTHER,Fudan University,"['other', 'chemotherapy', 'antibody', 'radiotherapy', 'supportive care']","[{'type': 'radiotherapy', 'subtype': 'from title', 'raw': 'radiotherapy'}, {'type': 'chemotherapy', 'subtype': 'fluoropyrimidine', 'raw': 'capecitabine'}, {'type': 'other', 'subtype': None, 'raw': '5fu'}, {'type': 'supportive care', 'subtype': 'rescue agent', 'raw': 'folinic acid'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'oxaliplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'irinotecan'}, {'type': 'other', 'subtype': None, 'raw': 'raltitrexed'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'cetuximab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'bevacizumab'}]",True,recurrent rectal cancer,digestive
530,China,Esophageal Squamous Cell Carcinoma,RADIATION: Neoadjuvant chemoradiotherapy followed by immunotherapy|DRUG: Neoadjuvant chemoimmunotherapy,2,OTHER,Zhejiang Cancer Hospital,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'neoadjuvant chemoimmunotherapy'}]",False,esophageal squamous cell carcinoma,digestive
531,"Australia, Israel, Republic of, Spain, Taiwan, United Kingdom, United States",Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma,DRUG: 5-Fluorouracil (5-FU)|DRUG: Leucovorin|DRUG: Oxaliplatin|DRUG: Atezolizumab|DRUG: Cobimetinib|BIOLOGICAL: Ramucirumab|DRUG: Paclitaxel|BIOLOGICAL: PEGylated recombinant human hyaluronidase (PEGPH20)|DRUG: BL-8040|DRUG: Linagliptin|DRUG: Atezolizumab|DRUG: Cobimetinib|DRUG: Cisplatin|DRUG: Tiragolumab|DRUG: 5-Fluorouracil (5-FU),12,INDUSTRY,Hoffmann-La Roche,"['other', 'chemotherapy', 'kinase inhibitor', 'checkpoint inhibitor', 'antibody', 'supportive care']","[{'type': 'chemotherapy', 'subtype': 'antimetabolite', 'raw': '5-fluorouracil'}, {'type': 'supportive care', 'subtype': 'folinic acid', 'raw': 'leucovorin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'oxaliplatin'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'atezolizumab'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'cobimetinib'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'ramucirumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}, {'type': 'other', 'subtype': None, 'raw': 'pegylated recombinant human hyaluronidase'}, {'type': 'other', 'subtype': None, 'raw': 'bl-8040'}, {'type': 'other', 'subtype': None, 'raw': 'linagliptin'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'atezolizumab'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'cobimetinib'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'tiragolumab'}, {'type': 'chemotherapy', 'subtype': 'antimetabolite', 'raw': '5-fluorouracil'}]",True,gastric adenocarcinoma or gastroesophageal junction adenocarcinoma or esophageal carcinoma,digestive
532,"Australia, France, Israel, Republic of, Spain, Taiwan, United Kingdom, United States","Carcinoma, Non-Small-Cell Lung",DRUG: Atezolizumab|DRUG: Cobimetinib|DRUG: RO6958688|DRUG: Docetaxel|DRUG: CPI-444|DRUG: Pemetrexed|DRUG: Carboplatin|DRUG: Gemcitabine|DRUG: Linagliptin|DRUG: Tocilizumab|DRUG: Ipatasertib|DRUG: Bevacizumab|DRUG: Sacituzumab Govitecan|OTHER: Radiation|DRUG: Evolocumab|DRUG: Tiragolumab|DRUG: XL092|DRUG: Camonsertib,12,INDUSTRY,Hoffmann-La Roche,"['targeted therapy', 'other', 'chemotherapy', 'kinase inhibitor', 'checkpoint inhibitor', 'antibody', 'antibody-drug conjugate']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'atezolizumab'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'cobimetinib'}, {'type': 'other', 'subtype': None, 'raw': 'ro6958688'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'docetaxel'}, {'type': 'other', 'subtype': None, 'raw': 'cpi-444'}, {'type': 'chemotherapy', 'subtype': 'antifolate', 'raw': 'pemetrexed'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'gemcitabine'}, {'type': 'other', 'subtype': None, 'raw': 'linagliptin'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'tocilizumab'}, {'type': 'targeted therapy', 'subtype': 'AKT inhibitor', 'raw': 'ipatasertib'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'bevacizumab'}, {'type': 'antibody-drug conjugate', 'subtype': 'anti-Trop-2', 'raw': 'sacituzumab govitecan'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'evolocumab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'tiragolumab'}, {'type': 'other', 'subtype': None, 'raw': 'xl092'}, {'type': 'other', 'subtype': None, 'raw': 'camonsertib'}]",True,carcinoma non small cell lung,lung/thoracic
533,United States,Locally Advanced Rectal Adenocarcinoma,"DRUG: APX005M, mFOLFOX, and Radiation Therapy 5Gy x 5 days|DRUG: mFOLFOX and Radiation Therapy 5Gy x 5 days",2,OTHER,University of Texas Southwestern Medical Center,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'apx005m'}, {'type': 'other', 'subtype': None, 'raw': 'mfolfox'}, {'type': 'other', 'subtype': None, 'raw': 'and radiation therapy 5gy x 5 days'}, {'type': 'other', 'subtype': None, 'raw': 'mfolfox and radiation therapy 5gy x 5 days'}]",False,locally advanced rectal adenocarcinoma,digestive
534,United States,Pancreatic Cancer,DRUG: Tadalafil|DRUG: Pembrolizumab|DRUG: Ipilimumab|DRUG: CRS-207,2,OTHER,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,"['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'tadalafil'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}, {'type': 'other', 'subtype': None, 'raw': 'crs-207'}]",True,pancreatic cancer,digestive
535,France,Non Small Cell Lung Cancer Metastatic,DRUG: Carboplatin|DRUG: Paclitaxel|DRUG: Atezolizumab,3,OTHER,Intergroupe Francophone de Cancerologie Thoracique,"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'atezolizumab'}]",True,non small cell lung cancer metastatic,lung/thoracic
536,China,Endometrial Adenocarcinoma|Endometrial Cancer,DRUG: QL1706 combined with chemotherapy ± Bevacizumab,2,OTHER,Tianjin Medical University Cancer Institute and Hospital,['antibody'],"[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'ql1706 combined with chemotherapy ± bevacizumab'}]",False,endometrial adenocarcinoma endometrial cancer,gynecologic
537,United States,Non Small Cell Lung Cancer|Lung Cancer,DRUG: Pembrolizumab|DRUG: Difluoromethylornithine,12,OTHER,H. Lee Moffitt Cancer Center and Research Institute,"['checkpoint inhibitor', 'other']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'other', 'subtype': None, 'raw': 'difluoromethylornithine'}]",True,non small cell lung cancer lung cancer,lung/thoracic
538,United States,Breast Cancer,DRUG: SRG-514,1,INDUSTRY,SURGE Therapeutics,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'srg-514'}]",False,breast cancer,breast
539,United States,Breast Cancer,BIOLOGICAL: ESR1 peptide vaccine,1,OTHER,Herbert Lyerly,['vaccine'],"[{'type': 'vaccine', 'subtype': 'vaccine', 'raw': 'esr1 peptide vaccine'}]",False,breast cancer,breast
540,Italy,Small Cell Lung Cancer,RADIATION: Thoracic radiotherapy|DRUG: Atezolizumab 1200 mg e.v. q21,2,OTHER,Regina Elena Cancer Institute,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'atezolizumab 1200 e.v. q21'}]",False,small cell lung cancer,lung/thoracic
541,United States,Epithelial Ovarian Cancer|Non-small Cell Lung Cancer|Renal Cell Carcinoma,BIOLOGICAL: ITIL-306,1,INDUSTRY,Instil Bio,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'itil-306'}]",False,epithelial ovarian cancer non small cell lung cancer renal cell carcinoma,gynecologic
542,United States,"Solid Tumor, Adult|Cancer|Neoplasms|Sarcoma|Sarcoma,Soft Tissue|Chondrosarcoma","BIOLOGICAL: AdAPT-001|DRUG: Checkpoint Inhibitor, Immune",2,INDUSTRY,"EpicentRx, Inc.",['other'],"[{'type': 'other', 'subtype': None, 'raw': 'adapt-001'}, {'type': 'other', 'subtype': None, 'raw': 'checkpoint inhibitor'}, {'type': 'other', 'subtype': None, 'raw': 'immune'}]",False,solid tumor adult cancer neoplasms sarcoma sarcoma soft tissue chondrosarcoma,sarcoma
543,United States,Pancreatic Cancer,DRUG: AGEN2373|DRUG: Balstilimab|DRUG: Cyclophosphamide|DRUG: GVAX|DRUG: AGEN2373 (RP2D)|DRUG: Balstilimab|DRUG: mKRASvax,12,OTHER,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,"['other', 'antibody', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'agen2373'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'balstilimab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide'}, {'type': 'other', 'subtype': None, 'raw': 'gvax'}, {'type': 'other', 'subtype': None, 'raw': 'agen2373'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'balstilimab'}, {'type': 'other', 'subtype': None, 'raw': 'mkrasvax'}]",True,pancreatic cancer,digestive
544,Australia,Stage II Melanoma,DRUG: Relatlimab and nivolumab fixed dose combination (FDC),2,OTHER,Melanoma Institute Australia,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'relatlimab and nivolumab fixed dose combination'}]",False,stage ii melanoma,skin
545,"Belgium, France, Germany",Platinum-sensitive Ovarian Cancer|Relapsed Ovarian Cancer,DRUG: OSE2101|DRUG: Pembrolizumab 25 MG/ML [Keytruda],2,OTHER,ARCAGY/ GINECO GROUP,"['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'ose2101'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab 25'}, {'type': 'other', 'subtype': None, 'raw': '[keytruda]'}]",True,platinum sensitive ovarian cancer relapsed ovarian cancer,gynecologic
546,United States,Unresectable Melanoma,DRUG: Nivolumab|DRUG: Duvelisib,12,OTHER,John Kirkwood,"['checkpoint inhibitor', 'other']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'other', 'subtype': None, 'raw': 'duvelisib'}]",True,unresectable melanoma,skin
547,United States,Cervical Cancer|Advanced Cervical Carcinoma|Metastatic Cervical Cancer|Metastatic Cervical Carcinoma|Recurrent Cervical Carcinoma,DRUG: Dostarlimab|DRUG: Cobolimab,2,OTHER,Meghan Shea,['antibody'],"[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'dostarlimab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'cobolimab'}]",False,cervical cancer advanced cervical carcinoma metastatic cervical cancer metastatic cervical carcinoma recurrent cervical carcinoma,gynecologic
548,United States,Non-muscle-invasive Bladder Cancer,DRUG: STM-416,12,INDUSTRY,SURGE Therapeutics,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'stm-416'}]",False,non muscle invasive bladder cancer,genitourinary
549,France,Urothelial Carcinoma|Cancer,DRUG: Patients receiving neoadjuvant therapy before radical nephrectomy,2,OTHER,Centre Hospitalier Universitaire de Nīmes,['surgery'],"[{'type': 'surgery', 'subtype': 'procedure', 'raw': 'patients receiving neoadjuvant therapy before radical nephrectomy'}]",False,urothelial carcinoma cancer,genitourinary
550,China,Thyroid Cancer,DRUG: Tislelizumab|DRUG: Anlotinib|RADIATION: Radiotherapy,2,OTHER,West China Hospital,"['checkpoint inhibitor', 'kinase inhibitor']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'tislelizumab'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'anlotinib'}]",True,thyroid cancer,other
551,United States,Breast Cancer,DRUG: Pembrolizumab|DRUG: Olaparib,2,OTHER,Yuan Yuan,"['checkpoint inhibitor', 'targeted therapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'targeted therapy', 'subtype': 'PARP inhibitor', 'raw': 'olaparib'}]",True,breast cancer,breast
552,United States,"Chronic Lymphocytic Leukemia|B-Cell Chronic Lymphocytic Leukemia|Lymphoma, B-Cell",BIOLOGICAL: Anti-CD19 and anti-CD20 bicistronic CAR T- cells|DRUG: Cyclophosphamide|DRUG: Fludarabine,1,NIH,National Cancer Institute (NCI),"['chemotherapy', 'cell therapy']","[{'type': 'cell therapy', 'subtype': 'other', 'raw': 'anti-cd19 and anti-cd20 bicistronic car t- cells'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide'}, {'type': 'chemotherapy', 'subtype': 'purine analog', 'raw': 'fludarabine'}]",True,chronic lymphocytic leukemia b cell chronic lymphocytic leukemia lymphoma b cell,hematologic
553,France,Colorectal Cancer Metastatic|High Immune Infiltrate|Microsatellite Stable,DRUG: Capecitabine|DRUG: Oxaliplatin|DRUG: Bevacizumab|DRUG: Pembrolizumab,2,OTHER,Federation Francophone de Cancerologie Digestive,"['checkpoint inhibitor', 'antibody', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'fluoropyrimidine', 'raw': 'capecitabine'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'oxaliplatin'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'bevacizumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",True,colorectal cancer metastatic high immune infiltrate microsatellite stable,digestive
554,Australia,Cutaneous Squamous Cell Carcinoma|Cutaneous Squamous Cell Carcinoma of the Head and Neck|Neoplasms|Non-melanoma Skin Cancer,DRUG: Cemiplimab,2,OTHER,"Peter MacCallum Cancer Centre, Australia",['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'cemiplimab'}]",False,cutaneous squamous cell carcinoma cutaneous squamous cell carcinoma of the head and neck neoplasms non melanoma skin cancer,skin
555,United States,Relapsed Neuroblastoma|Refractory Neuroblastoma|Relapsed Osteosarcoma|Relapsed Ewing Sarcoma|Relapsed Rhabdomyosarcoma|Uveal Melanoma|Phyllodes Breast Tumor,GENETIC: C7R-GD2.CART cells,1,OTHER,Baylor College of Medicine,['cell therapy'],"[{'type': 'cell therapy', 'subtype': 'engineered cell', 'raw': 'genetic: c7r-gd2.cart cells'}]",False,relapsed neuroblastoma refractory neuroblastoma relapsed osteosarcoma relapsed ewing sarcoma relapsed rhabdomyosarcoma uveal melanoma phyllodes breast tumor,breast
556,"Germany, United States","Refractory Cancer|Recurrent Cancer|Solid Tumor, Adult|Cancer",BIOLOGICAL: IMA203 Product|BIOLOGICAL: IMA203 product- flat dose|BIOLOGICAL: IMA203CD8 Product|DRUG: nivolumab (Opdivo®)|DEVICE: IMADetect®,1,INDUSTRY,"Immatics US, Inc.","['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'ima203 product'}, {'type': 'other', 'subtype': None, 'raw': 'ima203 product- flat dose'}, {'type': 'other', 'subtype': None, 'raw': 'ima203cd8 product'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}]",True,refractory cancer recurrent cancer solid tumor adult cancer,multiple
557,"Canada, United States",Neuroblastoma,DRUG: Ceritinib|DRUG: dasatinib|DRUG: sorafenib|DRUG: vorinostat|DRUG: DFMO,2,OTHER,Giselle Sholler,"['targeted therapy', 'other', 'kinase inhibitor']","[{'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'ceritinib'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'dasatinib'}, {'type': 'targeted therapy', 'subtype': 'other', 'raw': 'sorafenib'}, {'type': 'other', 'subtype': None, 'raw': 'vorinostat'}, {'type': 'other', 'subtype': None, 'raw': 'dfmo'}]",True,neuroblastoma,other
558,China,Liver Transplantation|Hepatocellular Carcinoma,PROCEDURE: Downstaging procedures containing immunotherapy|PROCEDURE: Liver transplantation,2,OTHER,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,[],[],False,liver transplantation hepatocellular carcinoma,digestive
559,"Argentina, Belgium, Brazil, Finland, France, Germany, Greece, Hungary, Italy, Japan, Mexico, Netherlands, Poland, Portugal, Republic of, South Africa, Spain, Thailand, Turkey, United Arab Emirates, United Kingdom, United States","Lung Cancer, Non-Small Cell",DRUG: Pembrolizumab|DRUG: Dostarlimab|DRUG: Belrestotug|DRUG: Nelistotug,2,INDUSTRY,GlaxoSmithKline,"['checkpoint inhibitor', 'other', 'antibody']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'dostarlimab'}, {'type': 'other', 'subtype': None, 'raw': 'belrestotug'}, {'type': 'other', 'subtype': None, 'raw': 'nelistotug'}]",True,lung cancer non small cell,lung/thoracic
560,China,Non-small Cell Lung Cancer Stage II|Non-small Cell Lung Cancer Stage ⅢA|Non-small Cell Lung Cancer Stage IIIB,DRUG: nivolumab 4.5mg/kg+Paclitaxel (albumin-bound type) 260mg / m2+ Carboplatin AUC5,2,OTHER,Xiangya Hospital of Central South University,"['checkpoint inhibitor', 'other', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab 4.5mg'}, {'type': 'other', 'subtype': None, 'raw': 'kg'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel 260mg'}, {'type': 'other', 'subtype': None, 'raw': 'm2'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin auc5'}]",True,non small cell lung cancer stage ii non small cell lung cancer stage a non small cell lung cancer stage iiib,lung/thoracic
561,China,Pancreatic Cancer,DRUG: Camrelizumab+chemotherapy|RADIATION: hypofractionated radiotherapy,2,OTHER,Hebei Medical University Fourth Hospital,"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'camrelizumab'}, {'type': 'chemotherapy', 'subtype': 'unspecified', 'raw': 'chemotherapy'}]",True,pancreatic cancer,digestive
562,United States,"Carcinoma, Non-Small-Cell Lung",DRUG: MK-3475|DRUG: Gemcitabine,12,OTHER,Providence Health & Services,"['other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'mk-3475'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'gemcitabine'}]",True,carcinoma non small cell lung,lung/thoracic
563,China,Laryngeal Cancer|Hypopharynx Cancer,COMBINATION_PRODUCT: SBRT+Toripalimab Plus Docetaxel and Cisplatin,2,OTHER,Sun Yat-sen University,"['other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'sbrt'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'toripalimab plus docetaxel and cisplatin'}]",True,laryngeal cancer hypopharynx cancer,head/neck
564,United States,Metastatic Castration-Resistant Prostate Cancer (mCRPC),BIOLOGICAL: Sipuleucel-T,1,OTHER,University of Oklahoma,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'sipuleucel-t'}]",False,metastatic castration resistant prostate cancer,genitourinary
565,United States,Non Small Cell Lung Cancer|Non Small Cell Lung Cancer Metastatic|Non-small Cell Carcinoma|NSCLC|NSCLC Stage IV,RADIATION: L-SABR|BIOLOGICAL: Anti-PD-(L)1 based immunotherapy|DRUG: Platinum based chemotherapy,2,OTHER,Memorial Sloan Kettering Cancer Center,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'anti-pd-1 based immunotherapy'}, {'type': 'other', 'subtype': None, 'raw': 'platinum based chemotherapy'}]",False,non small cell lung cancer non small cell lung cancer metastatic non small cell carcinoma nsclc nsclc stage iv,lung/thoracic
566,"Argentina, Austria, Brazil, Canada, Chile, France, Germany, Greece, Hong Kong, Israel, Italy, Japan, Mexico, Netherlands, Poland, Portugal, Republic of, Serbia, Spain, Taiwan, Thailand, Turkey, United Kingdom, United States, Vietnam",Muscle Invasive Bladder Cancer,DRUG: Durvalumab|DRUG: Tremelimumab|DRUG: Enfortumab Vedotin|PROCEDURE: Radical Cystectomy,3,INDUSTRY,AstraZeneca,"['checkpoint inhibitor', 'antibody-drug conjugate']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'tremelimumab'}, {'type': 'antibody-drug conjugate', 'subtype': 'anti-Nectin-4', 'raw': 'enfortumab vedotin'}]",True,muscle invasive bladder cancer,genitourinary
567,"France, Germany, Italy, Poland, Spain, United States",Breast Cancer,BIOLOGICAL: Placebo|BIOLOGICAL: GLSI-100,3,INDUSTRY,"Greenwich LifeSciences, Inc.",['other'],"[{'type': 'other', 'subtype': None, 'raw': 'glsi-100'}]",False,breast cancer,breast
568,France,"Solid Tumor, Adult|Pancreatic Cancer|Virus-associated Tumors|Non Small Cell Lung Cancer|Melanoma|Bladder Cancer|Triple Negative Breast Cancer",DRUG: Association atezolizumab + BDB001 + RT|DRUG: Association atezolizumab + BDB001+ RT|DRUG: Association atezolizumab + BDB001+ RT|DRUG: Association atezolizumab + BDB001 + RT|DRUG: Association atezolizumab + BDB001 + RT|DRUG: Association atezolizumab + BDB001 + RT,2,OTHER,Institut Bergonié,"['checkpoint inhibitor', 'radiotherapy', 'immunotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'association atezolizumab'}, {'type': 'immunotherapy', 'subtype': 'STING agonist', 'raw': 'bdb001'}, {'type': 'radiotherapy', 'subtype': 'unspecified', 'raw': 'rt'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'association atezolizumab'}, {'type': 'immunotherapy', 'subtype': 'STING agonist', 'raw': 'bdb001'}, {'type': 'radiotherapy', 'subtype': 'unspecified', 'raw': 'rt'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'association atezolizumab'}, {'type': 'immunotherapy', 'subtype': 'STING agonist', 'raw': 'bdb001'}, {'type': 'radiotherapy', 'subtype': 'unspecified', 'raw': 'rt'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'association atezolizumab'}, {'type': 'immunotherapy', 'subtype': 'STING agonist', 'raw': 'bdb001'}, {'type': 'radiotherapy', 'subtype': 'unspecified', 'raw': 'rt'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'association atezolizumab'}, {'type': 'immunotherapy', 'subtype': 'STING agonist', 'raw': 'bdb001'}, {'type': 'radiotherapy', 'subtype': 'unspecified', 'raw': 'rt'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'association atezolizumab'}, {'type': 'immunotherapy', 'subtype': 'STING agonist', 'raw': 'bdb001'}, {'type': 'radiotherapy', 'subtype': 'unspecified', 'raw': 'rt'}]",True,solid tumor adult pancreatic cancer virus associated tumors non small cell lung cancer melanoma bladder cancer triple negative breast cancer,genitourinary
569,United States,Glioblastoma,COMBINATION_PRODUCT: IGV-001 Cell Immunotherapy|COMBINATION_PRODUCT: Placebo|PROCEDURE: Standard of Care (SOC): Radiation Therapy|DRUG: SOC: Temozolomide,2,INDUSTRY,Imvax,"['chemotherapy', 'cell therapy']","[{'type': 'cell therapy', 'subtype': 'other', 'raw': 'igv-001 cell immunotherapy'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'soc: temozolomide'}]",True,glioblastoma,brain/CNS
570,"Republic of, United States",Advanced Solid Tumor|Metastatic Solid Tumor|Non-small Cell Lung Cancer|Head and Neck Squamous Cell Carcinoma|Renal Cell Carcinoma|Urinary Bladder Cancer|Melanoma|Sarcoma|Microsatellite Stable Colorectal Carcinoma|Merkel Cell Carcinoma|Esophageal Squamous Cell Carcinoma|Cervical Cancer|Vaginal Cancer|Vulvar Cancer,DRUG: GI-101|DRUG: Pembrolizumab (KEYTRUDA®)|DRUG: Lenvatinib|RADIATION: Local Radiotherapy|DRUG: GI-101A,12,INDUSTRY,"GI Innovation, Inc.","['checkpoint inhibitor', 'targeted therapy', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'gi-101'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'targeted therapy', 'subtype': 'other', 'raw': 'lenvatinib'}, {'type': 'other', 'subtype': None, 'raw': 'gi-101a'}]",True,advanced solid tumor metastatic solid tumor non small cell lung cancer head and neck squamous cell carcinoma renal cell carcinoma urinary bladder cancer melanoma sarcoma microsatellite stable colorectal carcinoma merkel cell carcinoma esophageal squamous cell carcinoma cervical cancer vaginal cancer vulvar cancer,gynecologic
571,China,Colorectal Cancer Stage IV|Mismatch Repair-deficient (dMMR)|Microsatellite Instability-high (MSI-H),DRUG: Cadonilimab,12,OTHER,Sun Yat-sen University,['antibody'],"[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'cadonilimab'}]",False,colorectal cancer stage iv mismatch repair deficient microsatellite instability high,digestive
572,United States,Melanoma,DRUG: Pembrolizumab|DRUG: Ipilimumab,2,OTHER,University of Chicago,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}]",False,melanoma,skin
573,United States,Head and Neck Cancer|Head Cancer|Head Cancer Neck|Neck Cancer|Head and Neck Squamous Cell Carcinoma|HNSCC,DRUG: Cisplatin|DRUG: Carboplatin|DRUG: Docetaxel|DRUG: Cetuximab|DRUG: Cemiplimab|PROCEDURE: Surgical Resection of Primary +/- Neck Dissection|RADIATION: Post-operative radiation therapy|DRUG: Paclitaxel,1,OTHER,Memorial Sloan Kettering Cancer Center,"['checkpoint inhibitor', 'antibody', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'docetaxel'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'cetuximab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'cemiplimab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}]",True,head and neck cancer head cancer head cancer neck neck cancer head and neck squamous cell carcinoma hnscc,head/neck
574,United States,Advanced Melanoma,DRUG: Propranolol|DRUG: Naltrexone,1,OTHER,Ryan Stephenson,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'propranolol'}, {'type': 'other', 'subtype': None, 'raw': 'naltrexone'}]",False,advanced melanoma,skin
575,United States,Pancreatic Cancer,DRUG: Cyclophosphamide|DRUG: Cyclophosphamide Pill|BIOLOGICAL: GVAX Pancreas Vaccine,2,OTHER,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,"['vaccine', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide pill'}, {'type': 'vaccine', 'subtype': 'vaccine', 'raw': 'gvax pancreas vaccine'}]",True,pancreatic cancer,digestive
576,United States,Clinical Stage III Cutaneous Melanoma AJCC v8|Clinical Stage IV Cutaneous Melanoma AJCC v8|Metastatic Melanoma|Recurrent Melanoma|Unresectable Melanoma,PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|DRUG: Dabrafenib Mesylate|PROCEDURE: Echocardiography Test|BIOLOGICAL: Ipilimumab|PROCEDURE: Multigated Acquisition Scan|BIOLOGICAL: Nivolumab|OTHER: Quality-of-Life Assessment|DRUG: Trametinib Dimethyl Sulfoxide,3,NIH,National Cancer Institute (NCI),"['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'dabrafenib mesylate'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'other', 'subtype': None, 'raw': 'trametinib dimethyl sulfoxide'}]",True,clinical stage iii cutaneous melanoma ajcc v8 clinical stage iv cutaneous melanoma ajcc v8 metastatic melanoma recurrent melanoma unresectable melanoma,skin
577,United States,Gastric Cancer|Breast Cancer|Cervical Cancer|Lung Cancer,BIOLOGICAL: KK-LC-1 TCR-T cells|DRUG: Aldesleukin,1,OTHER,Christian Hinrichs,"['cytokine therapy', 'cell therapy']","[{'type': 'cell therapy', 'subtype': 'engineered cell', 'raw': 'kk-lc-1 tcr-t cells'}, {'type': 'cytokine therapy', 'subtype': 'IL-2', 'raw': 'aldesleukin'}]",True,gastric cancer breast cancer cervical cancer lung cancer,gynecologic
578,United States,Pancreatic Cancer,DRUG: Cyclophosphamide|BIOLOGICAL: GVAX pancreatic cancer|DRUG: Nivolumab|DRUG: Urelumab|DRUG: BMS-986253,2,OTHER,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,"['checkpoint inhibitor', 'other', 'antibody', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide'}, {'type': 'other', 'subtype': None, 'raw': 'gvax pancreatic cancer'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'urelumab'}, {'type': 'other', 'subtype': None, 'raw': 'bms-986253'}]",True,pancreatic cancer,digestive
579,United States,Glioblastoma,BIOLOGICAL: INO-5401|BIOLOGICAL: INO-9012|BIOLOGICAL: Cemiplimab|RADIATION: Radiation Therapy|DRUG: Temozolomide,12,INDUSTRY,Inovio Pharmaceuticals,"['checkpoint inhibitor', 'other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'ino-5401'}, {'type': 'other', 'subtype': None, 'raw': 'ino-9012'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'cemiplimab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'temozolomide'}]",True,glioblastoma,brain/CNS
580,United States,Bladder Cancer,DRUG: Nivolumab|DRUG: Ipilimumab|PROCEDURE: Radical cystectomy,2,OTHER,Memorial Sloan Kettering Cancer Center,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}]",False,bladder cancer,genitourinary
581,United States,Advanced Extrapulmonary Neuroendocrine Carcinoma|Metastatic Extrapulmonary Neuroendocrine Carcinoma|Recurrent Extrapulmonary Neuroendocrine Carcinoma|Unresectable Extrapulmonary Neuroendocrine Carcinoma,BIOLOGICAL: Atezolizumab|PROCEDURE: Biospecimen Collection|DRUG: Carboplatin|DRUG: Cisplatin|PROCEDURE: Computed Tomography|DRUG: Etoposide|PROCEDURE: Magnetic Resonance Imaging|OTHER: Patient Observation,23,NIH,National Cancer Institute (NCI),"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'atezolizumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'etoposide'}]",True,advanced extrapulmonary neuroendocrine carcinoma metastatic extrapulmonary neuroendocrine carcinoma recurrent extrapulmonary neuroendocrine carcinoma unresectable extrapulmonary neuroendocrine carcinoma,lung/thoracic
582,China,Breast Cancer,DRUG: Cadonilimab (AK104),2,OTHER,Hubei Cancer Hospital,['antibody'],"[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'cadonilimab'}]",False,breast cancer,breast
583,France,Immunotherapy,"DRUG: olaparib, durvalumab, tremelimumab",2,OTHER,Centre Georges Francois Leclerc,"['checkpoint inhibitor', 'targeted therapy']","[{'type': 'targeted therapy', 'subtype': 'PARP inhibitor', 'raw': 'olaparib'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'tremelimumab'}]",True,immunotherapy,hematologic
584,United States,Advanced Solid Tumor|Head and Neck Squamous Cell Carcinoma,DRUG: CHS-114|DRUG: toripalimab,1,INDUSTRY,"Coherus Biosciences, Inc.","['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'chs-114'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'toripalimab'}]",True,advanced solid tumor head and neck squamous cell carcinoma,head/neck
585,China,Rectal Cancer,RADIATION: node-sparing modified short-course radiotherapy|DRUG: PD-1 antibody|DRUG: Capecitabine|DRUG: Oxaliplatin|RADIATION: standard short-course radiotherapy,3,OTHER,Sir Run Run Shaw Hospital,"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1 (title)', 'raw': 'tislelizumab'}, {'type': 'chemotherapy', 'subtype': 'fluoropyrimidine', 'raw': 'capecitabine'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'oxaliplatin'}]",True,rectal cancer,digestive
586,United States,Pancreatic Cancer,DRUG: IRE + intratumoral mitazalimab (CD40 antibody) injection|DEVICE: NanoKnife,1,OTHER,"University of California, San Diego",['other'],"[{'type': 'other', 'subtype': None, 'raw': 'ire'}, {'type': 'other', 'subtype': None, 'raw': 'mitazalimab injection'}]",False,pancreatic cancer,digestive
587,China,Nasopharyngeal Cancinoma (NPC),OTHER: Low-dose radiotherapy combine with chemoimmunotherapy,2,OTHER,Hunan Cancer Hospital,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'other: low-dose radiotherapy combine with chemoimmunotherapy'}]",False,nasopharyngeal cancinoma,head/neck
588,China,Early Low Rectal Cancer,DRUG: PD-1 antibody|DRUG: Capecitabine|DRUG: Oxaliplatin|RADIATION: Short-course radiotherapy,2,OTHER,Fudan University,"['radiotherapy', 'chemotherapy']","[{'type': 'radiotherapy', 'subtype': 'from title', 'raw': 'radiotherapy'}, {'type': 'chemotherapy', 'subtype': 'fluoropyrimidine', 'raw': 'capecitabine'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'oxaliplatin'}]",True,early low rectal cancer,digestive
589,United States,Endometrial Cancer,DRUG: Paclitaxel|DRUG: Carboplatin|DRUG: Dostarlimab|DRUG: Cisplatin,1,OTHER,M.D. Anderson Cancer Center,"['antibody', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'dostarlimab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}]",True,endometrial cancer,gynecologic
590,Netherlands,Melanoma,DRUG: Ipilimumab|DRUG: Nivolumab|DRUG: Nivolumab,12,OTHER,The Netherlands Cancer Institute,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}]",False,melanoma,skin
591,"Australia, United States",Non Small Cell Lung Cancer|Non Small Cell Lung Cancer Stage IIIB|Non-small Cell Lung Cancer Stage IV|Squamous Non-small-cell Lung Cancer|Large Cell Carcinoma Lung|Adenocarcinoma Lung,BIOLOGICAL: IMU-201 (administered as PD1-Vaxx) - Regimen 1|BIOLOGICAL: IMU-201 (administered as PD1-Vaxx) - Regimen 2|BIOLOGICAL: IMU-201 (administered as PD1-Vaxx) - Regimen 3|DRUG: Atezolizumab|DRUG: Standard of care chemotherapy,1,INDUSTRY,Imugene Limited,"['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'imu-201 - regimen 1'}, {'type': 'other', 'subtype': None, 'raw': 'imu-201 - regimen 2'}, {'type': 'other', 'subtype': None, 'raw': 'imu-201 - regimen 3'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'atezolizumab'}, {'type': 'other', 'subtype': None, 'raw': 'standard of care chemotherapy'}]",True,non small cell lung cancer non small cell lung cancer stage iiib non small cell lung cancer stage iv squamous non small cell lung cancer large cell carcinoma lung adenocarcinoma lung,lung/thoracic
592,United States,Gastric Neoplasms|Esophageal Cancer|Liver Cancer|Liver Metastasis|MSS-CRC|MSS|Gastric Adenocarcinoma|Peritoneal Cancer|Peritoneal Carcinoma|Peritoneal Metastases|MSI-H|Gastric Cancer,BIOLOGICAL: vvDD-hIL-2-RG-1,1,OTHER,Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute),['other'],"[{'type': 'other', 'subtype': None, 'raw': 'vvdd-hil-2-rg-1'}]",False,gastric neoplasms esophageal cancer liver cancer liver metastasis mss crc mss gastric adenocarcinoma peritoneal cancer peritoneal carcinoma peritoneal metastases msi h gastric cancer,digestive
593,"Belgium, France","Carcinoma, Renal Cell|Carcinoma, Non-Small-Cell Lung",OTHER: Live Bacterial Product - Akkermansia muciniphila,2,INDUSTRY,EverImmune,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'other: live bacterial product - akkermansia muciniphila'}]",False,carcinoma renal cell carcinoma non small cell lung,genitourinary
594,China,Metastatic or Recurrent Gastric Adenocarcinoma,DRUG: Envafolimab|DRUG: Oxaliplatin|DRUG: S1,2,OTHER,Liangjun Zhu M.M.,"['other', 'antibody', 'chemotherapy']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'envafolimab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'oxaliplatin'}, {'type': 'other', 'subtype': None, 'raw': 's1'}]",True,metastatic or recurrent gastric adenocarcinoma,digestive
595,United States,"Head and Neck Cancer|Head and Neck Squamous Cell Carcinoma|Head and Neck Carcinoma|Head and Neck Cancer Stage III|Head and Neck Cancer Stage IV|Head and Neck Cancer Metastatic|Cancer|Cancer of Esophagus|Cancer, Metastatic|Cancer of Head and Neck|Cancer of Mouth|Cancer of Neck",DRUG: Pembrolizumab|DRUG: Tadalafil,2,OTHER,"University of California, San Diego","['checkpoint inhibitor', 'other']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'other', 'subtype': None, 'raw': 'tadalafil'}]",True,head and neck cancer head and neck squamous cell carcinoma head and neck carcinoma head and neck cancer stage iii head and neck cancer stage iv head and neck cancer metastatic cancer cancer of esophagus cancer metastatic cancer of head and neck cancer of mouth cancer of neck,head/neck
596,China,Colorectal Cancer|Liver Metastases,RADIATION: Stereotactic body radiation therapy|DRUG: PD-1 Monoclonal Antibody|DRUG: Chemotherapy,3,OTHER,Jun Huang,"['other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'pd-1 monoclonal antibody'}, {'type': 'chemotherapy', 'subtype': 'unspecified', 'raw': 'chemotherapy'}]",True,colorectal cancer liver metastases,digestive
597,"Australia, United States",Advanced Solid Tumor|Metastatic Cancer|Cutaneous Melanoma|Non-Small Cell Lung Cancer,DRUG: AU-007|DRUG: Aldesleukin|DRUG: Avelumab|DRUG: Nivolumab,12,INDUSTRY,"Aulos Bioscience, Inc.","['checkpoint inhibitor', 'other', 'cytokine therapy']","[{'type': 'other', 'subtype': None, 'raw': 'au-007'}, {'type': 'cytokine therapy', 'subtype': 'IL-2', 'raw': 'aldesleukin'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'avelumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}]",True,advanced solid tumor metastatic cancer cutaneous melanoma non small cell lung cancer,lung/thoracic
598,"Canada, United States",Basaloid Squamous Cell Carcinoma|Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8|Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8|Oropharyngeal Squamous Cell Carcinoma|Papillary Squamous Cell Carcinoma|Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8|Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8|Squamous Cell Carcinoma,PROCEDURE: Biopsy Procedure|PROCEDURE: Biospecimen Collection|DRUG: Cisplatin|PROCEDURE: Computed Tomography|OTHER: Fludeoxyglucose F-18|RADIATION: Image Guided Radiation Therapy|RADIATION: Intensity-Modulated Radiation Therapy|PROCEDURE: Magnetic Resonance Imaging|BIOLOGICAL: Nivolumab|PROCEDURE: Positron Emission Tomography|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration,23,NIH,National Cancer Institute (NCI),"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}]",True,basaloid squamous cell carcinoma clinical stage i hpv mediated oropharyngeal carcinoma ajcc v8 clinical stage ii hpv mediated oropharyngeal carcinoma ajcc v8 oropharyngeal squamous cell carcinoma papillary squamous cell carcinoma pathologic stage i hpv mediated oropharyngeal carcinoma ajcc v8 pathologic stage ii hpv mediated oropharyngeal carcinoma ajcc v8 squamous cell carcinoma,head/neck
599,China,Hepatocellular Carcinoma (HCC),"DRUG: Adebrelimab, Oxaliplatin, Fluorouracil,Leucovorin",12,OTHER,Zhejiang Cancer Hospital,"['antibody', 'supportive care', 'chemotherapy']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'adebrelimab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'oxaliplatin'}, {'type': 'chemotherapy', 'subtype': 'antimetabolite', 'raw': 'fluorouracil'}, {'type': 'supportive care', 'subtype': 'folinic acid', 'raw': 'leucovorin'}]",True,hepatocellular carcinoma,digestive
600,United States,Locally Advanced Pancreatic Adenocarcinoma|Metastatic Pancreatic Adenocarcinoma,DRUG: EGFR BATs after standard of care chemo,12,OTHER,University of Virginia,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'egfr bats after standard of care chemo'}]",False,locally advanced pancreatic adenocarcinoma metastatic pancreatic adenocarcinoma,digestive
601,"Australia, Brazil, Canada, France, Italy, Netherlands, Spain",Urinary Bladder Neoplasms|Immune Checkpoint Inhibitors|Methotrexate|Vinblastine|Doxorubicin|Cisplatin|Gemcitabine,DRUG: Durvalumab|DRUG: Methotrexate|DRUG: Vinblastine|DRUG: Doxorubicin|DRUG: Cisplatin|DRUG: Durvalumab|DRUG: Gemcitabine|DRUG: Cisplatin,3,INDUSTRY,AstraZeneca,"['checkpoint inhibitor', 'other', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}, {'type': 'chemotherapy', 'subtype': 'antifolate', 'raw': 'methotrexate'}, {'type': 'other', 'subtype': None, 'raw': 'vinblastine'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'doxorubicin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'gemcitabine'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}]",True,urinary bladder neoplasms immune checkpoint inhibitors methotrexate vinblastine doxorubicin cisplatin gemcitabine,genitourinary
602,China,Gastric Cancer|Diffuse Type Carcinoma,DRUG: Albumin paclitaxel+SOX+BEV+ PD-1 monoclonal antibody therapy,2,OTHER,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","['other', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'albumin paclitaxel'}, {'type': 'other', 'subtype': None, 'raw': 'sox'}, {'type': 'other', 'subtype': None, 'raw': 'bev'}, {'type': 'other', 'subtype': None, 'raw': 'pd-1 monoclonal antibody therapy'}]",True,gastric cancer diffuse type carcinoma,digestive
603,Switzerland,Rectum Cancer|Rectal Cancer,DRUG: Pembrolizumab,2,OTHER,"University Hospital, Geneva",['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",False,rectum cancer rectal cancer,digestive
604,China,IIIA Stage Non-small Cell Lung Cancer,DRUG: Sintilimab Injection,2,OTHER,The First Hospital of Jilin University,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'sintilimab injection'}]",False,iiia stage non small cell lung cancer,lung/thoracic
605,China,Breast Cancer|Triple Negative Breast Cancer (TNBC)|Early Stage Breast Cancer|Immunotherapy|Probiotic,OTHER: Biolosion (oral probiotic compound preparation),2,OTHER,Sun Yat-sen University,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'other: biolosion'}]",False,breast cancer triple negative breast cancer early stage breast cancer immunotherapy probiotic,breast
606,United States,Carcinomas|Renal Medullary Carcinoma,DRUG: Nivolumab|DRUG: Relatlimab,2,OTHER,M.D. Anderson Cancer Center,"['checkpoint inhibitor', 'antibody']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'relatlimab'}]",True,carcinomas renal medullary carcinoma,genitourinary
607,Japan,Bladder Cancer,DRUG: MK-3475|DRUG: ASG-22CE|PROCEDURE: maximal TURBT|RADIATION: Radiation therapy,2,OTHER,Kyoto University Hospital,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'mk-3475'}, {'type': 'other', 'subtype': None, 'raw': 'asg-22ce'}]",False,bladder cancer,genitourinary
608,United States,Melanoma,DRUG: Tavo|DRUG: Nivolumab|DEVICE: OncoSec Medical Electroporation Therapy System,2,OTHER,H. Lee Moffitt Cancer Center and Research Institute,"['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'tavo'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}]",True,melanoma,skin
609,Australia,"Lung Cancer, Nonsmall Cell|Renal Cell Carcinoma|Melanoma|Gastric Cancer|Hepatocellular Carcinoma|Endometrial Cancer|Mesothelioma",DIAGNOSTIC_TEST: Blood screening|DIAGNOSTIC_TEST: Tissue screening,12,OTHER,Western Sydney Local Health District,[],[],False,lung cancer nonsmall cell renal cell carcinoma melanoma gastric cancer hepatocellular carcinoma endometrial cancer mesothelioma,gynecologic
610,Spain,"Non Small Cell Lung Cancer|Brain Metastases, Adult|Lung Cancer",DRUG: Ipilimumab|DRUG: Nivolumab|DRUG: Carboplatin|DRUG: Cisplatin|DRUG: Paclitaxel|DRUG: Pemetrexed,2,OTHER,Fundación GECP,"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}, {'type': 'chemotherapy', 'subtype': 'antifolate', 'raw': 'pemetrexed'}]",True,non small cell lung cancer brain metastases adult lung cancer,lung/thoracic
611,China,Nasopharyngeal Carcinoma|De-escaltion Therapy,PROCEDURE: Reduced-target resection|PROCEDURE: Full-target resection|DRUG: Adjuvant immunotherapy,3,OTHER,Sun Yat-sen University,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'adjuvant immunotherapy'}]",False,nasopharyngeal carcinoma de escaltion therapy,head/neck
612,United States,High Risk Cancer|Pancreatic Cancer,DRUG: Cohort A: Patients at high risk of developing pancreatic cancer.|DRUG: Cohort B: Patients must have evidence of a pancreatic cystic neoplasm,1,OTHER,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'cohort a: patients at high risk of developing pancreatic cancer.'}, {'type': 'other', 'subtype': None, 'raw': 'cohort b: patients must have evidence of a pancreatic cystic neoplasm'}]",False,high risk cancer pancreatic cancer,digestive
613,United States,"HER2-positive|Adenocarcinoma|Bile Duct Cancer|Biliary Tract Cancer|Bladder Cancer|Breast Cancer|Breast Neoplasm|Carcinoma, Ductal|Carcinoma, Hepatocellular|Cancer|Lung Cancer, Non-Small-Cell|Carcinoma, Ovarian Epithelial|Carcinoma, Small Cell|Carcinoma, Squamous|Carcinoma, Transitional Cell|Colorectal Cancer|Esophagogastric Junction Neoplasms|Inflammatory Breast Cancer|Stomach Neoplasms|Malignant Neoplasms|Ovarian Neoplasms|Pancreatic Cancer|HER2-positive Solid Tumors|HER2-positive Breast Cancer|HER2-positive Gastric Cancer|HER-2 Protein Overexpression|HER-2 Gene Amplification|Prostate Cancer|Head and Neck Cancer|Endometrial Cancer|Lung Cancer, Small Cell",BIOLOGICAL: CT-0508|BIOLOGICAL: Pembrolizumab,1,INDUSTRY,Carisma Therapeutics Inc,"['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'ct-0508'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",True,her2 positive adenocarcinoma bile duct cancer biliary tract cancer bladder cancer breast cancer breast neoplasm carcinoma ductal carcinoma hepatocellular cancer lung cancer non small cell carcinoma ovarian epithelial carcinoma small cell carcinoma squamous carcinoma transitional cell colorectal cancer esophagogastric junction neoplasms inflammatory breast cancer stomach neoplasms malignant neoplasms ovarian neoplasms pancreatic cancer her2 positive solid tumors her2 positive breast cancer her2 positive gastric cancer her 2 protein overexpression her 2 gene amplification prostate cancer head and neck cancer endometrial cancer lung cancer small cell,gynecologic
614,United States,Stage I Colon Cancer|Stage II Colon Cancer|Stage III Colon Cancer,DRUG: Tecentriq 1200 MG in 20 ML Injection + Capecitabine 1000 mg/m2 + Oxaliplatin 130 mg/m2|DRUG: Oxaliplatin injection 85mg/m2 + Leucovorin 400mg/m2 + 5-Fluorouracil 2400mg/m2|DRUG: Oxaliplatin 130mg/m2 + Capecitabine 1000mg/m2,2,OTHER,Baylor College of Medicine,"['other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'tecentriq 1200 in 20 injection'}, {'type': 'other', 'subtype': None, 'raw': 'capecitabine 1000'}, {'type': 'other', 'subtype': None, 'raw': 'm2'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'oxaliplatin 130'}, {'type': 'other', 'subtype': None, 'raw': 'm2'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'oxaliplatin injection 85mg'}, {'type': 'other', 'subtype': None, 'raw': 'm2'}, {'type': 'other', 'subtype': None, 'raw': 'leucovorin 400mg'}, {'type': 'other', 'subtype': None, 'raw': 'm2'}, {'type': 'other', 'subtype': None, 'raw': '5-fluorouracil 2400mg'}, {'type': 'other', 'subtype': None, 'raw': 'm2'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'oxaliplatin 130mg'}, {'type': 'other', 'subtype': None, 'raw': 'm2'}, {'type': 'other', 'subtype': None, 'raw': 'capecitabine 1000mg'}, {'type': 'other', 'subtype': None, 'raw': 'm2'}]",True,stage i colon cancer stage ii colon cancer stage iii colon cancer,digestive
615,United States,"Brain Metastasis|Radiation Therapy|Immunotherapy, Active",RADIATION: F-Fluciclovine radiotracer,3,OTHER,"University of Wisconsin, Madison",['other'],"[{'type': 'other', 'subtype': None, 'raw': 'radiation: f-fluciclovine radiotracer'}]",False,brain metastasis radiation therapy immunotherapy active,hematologic
616,China,Esophageal Carcinoma,DRUG: Immune Checkpoint Inhibitors,12,OTHER_GOV,Anhui Provincial Hospital,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'immune checkpoint inhibitors'}]",False,esophageal carcinoma,digestive
617,United States,Genitourinary Cancer|Adrenocortical Carcinoma|Non-urothelial Bladder|Non-urothelial Upper Tract|Penile Cancer|Non-adenocarcinoma Prostate Cancer|Refractory Germ-cell|High Grade Neuroendocrine Carcinoma/Small Cell Carcinoma,DRUG: Ipilimumab|DRUG: Nivolumab,2,OTHER,Dana-Farber Cancer Institute,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}]",False,genitourinary cancer adrenocortical carcinoma non urothelial bladder non urothelial upper tract penile cancer non adenocarcinoma prostate cancer refractory germ cell high grade neuroendocrine carcinoma small cell carcinoma,genitourinary
618,United States,Prostate Cancer|Metastatic Castration-resistant Prostate Cancer,DRUG: Abemaciclib|DRUG: Atezolizumab,2,OTHER,Dana-Farber Cancer Institute,"['checkpoint inhibitor', 'targeted therapy']","[{'type': 'targeted therapy', 'subtype': 'CDK4/6 inhibitor', 'raw': 'abemaciclib'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'atezolizumab'}]",True,prostate cancer metastatic castration resistant prostate cancer,genitourinary
619,China,Radiotherapy|Immunotherapy|Liver Metastases|Colorectal Cancer,RADIATION: SBRT|DRUG: Chemotherapy|DRUG: PD-1 antibody,2,OTHER,Fudan University,"['radiotherapy', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'unspecified', 'raw': 'chemotherapy'}, {'type': 'radiotherapy', 'subtype': 'from title', 'raw': 'radiotherapy'}]",True,radiotherapy immunotherapy liver metastases colorectal cancer,digestive
620,United States,Common Warts (Verruca Vulgaris),"DRUG: Candin, Intradermal Solution|DRUG: Placebo",3,INDUSTRY,"Nielsen BioSciences, Inc.",['other'],"[{'type': 'other', 'subtype': None, 'raw': 'candin'}, {'type': 'other', 'subtype': None, 'raw': 'intradermal solution'}]",False,common warts,hematologic
621,United States,Metastatic Melanoma|Stage III Cutaneous Melanoma AJCC v7|Stage IIIA Cutaneous Melanoma AJCC v7|Stage IIIB Cutaneous Melanoma AJCC v7|Stage IIIC Cutaneous Melanoma AJCC v7|Stage IV Cutaneous Melanoma AJCC v6 and v7,BIOLOGICAL: Aldesleukin|DRUG: Cyclophosphamide|DRUG: Fludarabine Phosphate|OTHER: Laboratory Biomarker Analysis|BIOLOGICAL: NGFR-transduced Autologous T Lymphocytes|BIOLOGICAL: TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes,1,OTHER,M.D. Anderson Cancer Center,"['other', 'cytokine therapy', 'chemotherapy']","[{'type': 'cytokine therapy', 'subtype': 'IL-2', 'raw': 'aldesleukin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide'}, {'type': 'chemotherapy', 'subtype': 'purine analog', 'raw': 'fludarabine phosphate'}, {'type': 'other', 'subtype': None, 'raw': 'ngfr-transduced autologous t lymphocytes'}, {'type': 'other', 'subtype': None, 'raw': 'tgfbdnrii-transduced autologous tumor infiltrating lymphocytes'}]",True,metastatic melanoma stage iii cutaneous melanoma ajcc v7 stage iiia cutaneous melanoma ajcc v7 stage iiib cutaneous melanoma ajcc v7 stage iiic cutaneous melanoma ajcc v7 stage iv cutaneous melanoma ajcc v6 and v7,skin
622,United States,Lung Non-Small Cell Carcinoma|Stage IV Lung Cancer AJCC v8,PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|OTHER: Immunotherapy|RADIATION: Palliative Radiation Therapy|RADIATION: Spatially-fractionated Radiation Therapy,2,OTHER,Mayo Clinic,[],[],False,lung non small cell carcinoma stage iv lung cancer ajcc v8,lung/thoracic
623,"Canada, United States",Ovarian Cancer|Hepatocellular Carcinoma|Non-small Cell Lung Cancer|Bladder Cancer|Microsatellite Instability-High,OTHER: DPX-Survivac|DRUG: Cyclophosphamide|DRUG: Pembrolizumab,2,INDUSTRY,"ImmunoVaccine Technologies, Inc. (IMV Inc.)","['checkpoint inhibitor', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",True,ovarian cancer hepatocellular carcinoma non small cell lung cancer bladder cancer microsatellite instability high,gynecologic
624,China,PD-1|Neoadjuvant Chemoradiotherapy|Gastroesophageal Junction Cancer,DRUG: PD-1inhibitor,2,OTHER,"Wuhan Union Hospital, China",['other'],"[{'type': 'other', 'subtype': None, 'raw': 'pd-1inhibitor'}]",False,pd 1 neoadjuvant chemoradiotherapy gastroesophageal junction cancer,digestive
625,China,Locally Advanced Rectal Cancer,RADIATION: radiation|DRUG: PD-1 Monoclonal Antibody|PROCEDURE: TME surgery,2,OTHER,Peking University People's Hospital,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'pd-1 monoclonal antibody'}]",False,locally advanced rectal cancer,digestive
626,United States,Metastatic Pancreatic Adenocarcinoma,DRUG: Avelumab and Pepinemab,12,INDUSTRY,Vaccinex Inc.,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'avelumab and pepinemab'}]",False,metastatic pancreatic adenocarcinoma,digestive
627,"Finland, United States",Melanoma|Head and Neck Squamous Cell Carcinoma,BIOLOGICAL: TILT-123|DRUG: Avelumab,1,INDUSTRY,TILT Biotherapeutics Ltd.,"['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'tilt-123'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'avelumab'}]",True,melanoma head and neck squamous cell carcinoma,skin
628,United States,Microsatellite Stable Colorectal Cancer|Pancreatic Cancer|MSI High Colorectal Cancer,DRUG: Nivolumab|DRUG: Ipilimumab|RADIATION: Radiation Therapy,2,OTHER,Massachusetts General Hospital,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}]",False,microsatellite stable colorectal cancer pancreatic cancer msi high colorectal cancer,digestive
629,United States,Advanced Lung Cancer,BIOLOGICAL: BNT324|BIOLOGICAL: BNT327,12,INDUSTRY,BioNTech SE,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'bnt324'}, {'type': 'other', 'subtype': None, 'raw': 'bnt327'}]",False,advanced lung cancer,lung/thoracic
630,"Australia, Austria, Belgium, Brazil, Canada, France, Germany, Greece, Israel, Italy, Japan, Mexico, Netherlands, Poland, Portugal, Puerto Rico, Spain, Turkey, United Kingdom, United States",Non-Small Cell Lung Cancer,BIOLOGICAL: Sacituzumab Govitecan-hziy (SG)|DRUG: Docetaxel,3,INDUSTRY,Gilead Sciences,"['other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'sacituzumab govitecan-hziy'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'docetaxel'}]",True,non small cell lung cancer,lung/thoracic
631,China,Biliary Tract Cancer,DRUG: Durvalumab combined with S-1,2,OTHER,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab combined with s-1'}]",False,biliary tract cancer,digestive
632,United States,Sinonasal Melanoma|Anorectal Melanoma,PROCEDURE: Surgical resection,2,OTHER,M.D. Anderson Cancer Center,['surgery'],"[{'type': 'surgery', 'subtype': 'procedure', 'raw': 'procedure: surgical resection'}]",False,sinonasal melanoma anorectal melanoma,digestive
633,China,Limited Stage Small Cell Lung Cancer,DRUG: Sugemalimab|DRUG: Placebo,23,OTHER,Sun Yat-sen University,['antibody'],"[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'sugemalimab'}]",False,limited stage small cell lung cancer,lung/thoracic
634,Belgium,Muscle-Invasive Bladder Carcinoma,RADIATION: Metastasis directed therapy (MDT)|DRUG: Immunotherapy|PROCEDURE: Standard of care,2,OTHER,"University Hospital, Ghent",['immunotherapy'],"[{'type': 'immunotherapy', 'subtype': 'unspecified', 'raw': 'immunotherapy'}]",False,muscle invasive bladder carcinoma,genitourinary
635,United States,Renal Cell Carcinoma,"DRUG: Neoadjuvant Lenvatinib|DRUG: Neoadjuvant Pembrolizumab|PROCEDURE: Radical nephrectomy, IVC thrombectomy, retroperitoneal lymph node dissection|DRUG: Adjuvant Pembrolizumab",2,OTHER,University of Texas Southwestern Medical Center,"['checkpoint inhibitor', 'targeted therapy']","[{'type': 'targeted therapy', 'subtype': 'other', 'raw': 'neoadjuvant lenvatinib'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'neoadjuvant pembrolizumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'adjuvant pembrolizumab'}]",True,renal cell carcinoma,genitourinary
636,United States,Endometrial Cancer,BIOLOGICAL: Lifileucel,2,INDUSTRY,"Iovance Biotherapeutics, Inc.",['other'],"[{'type': 'other', 'subtype': None, 'raw': 'lifileucel'}]",False,endometrial cancer,gynecologic
637,Spain,"Lung Diseases|Carcinoma, Non-Small-Cell Lung|Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Respiratory Tract Neoplasms|Carcinoma Bronchiogenic Stage III|Thoracic Neoplasms",DRUG: Carboplatin|DRUG: Placlitaxel|DRUG: Atezolizumab,2,OTHER,Fundación GECP,"['checkpoint inhibitor', 'other', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'other', 'subtype': None, 'raw': 'placlitaxel'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'atezolizumab'}]",True,lung diseases carcinoma non small cell lung stage iiia non small cell lung cancer stage iiib non small cell lung cancer respiratory tract neoplasms carcinoma bronchiogenic stage iii thoracic neoplasms,lung/thoracic
638,Brazil,"Lung Cancer, Nonsmall Cell|Non-Small Cell Lung Cancer NSCLC",DRUG: Low-dose nivolumab combined with platinum-based doublet chemotherapy,2,OTHER,"Aline Fusco Fares, MD",['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'low-dose nivolumab combined with platinum-based doublet chemotherapy'}]",False,lung cancer nonsmall cell non small cell lung cancer nsclc,lung/thoracic
639,Italy,Melanoma,DRUG: Ipilimumab,2,OTHER,European Institute of Oncology,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}]",False,melanoma,skin
640,United States,Cholangiocarcinoma|Gallbladder Cancer|Gallbladder Carcinoma|Intrahepatic Cholangiocarcinoma|Extrahepatic Cholangiocarcinoma|Bile Duct Cancer|Gall Bladder Cancer|Gall Bladder Carcinoma,DRUG: certepetide|DRUG: Durvalumab|DRUG: Cisplatin|DRUG: Gemcitabine|DRUG: FOLFOX regimen|DRUG: Placebo,2,INDUSTRY,"Lisata Therapeutics, Inc.","['checkpoint inhibitor', 'other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'certepetide'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'gemcitabine'}, {'type': 'other', 'subtype': None, 'raw': 'folfox regimen'}]",True,cholangiocarcinoma gallbladder cancer gallbladder carcinoma intrahepatic cholangiocarcinoma extrahepatic cholangiocarcinoma bile duct cancer gall bladder cancer gall bladder carcinoma,genitourinary
641,,Refractory Metastatic Colorectal Cancer|pMMR|MSS,BIOLOGICAL: RP2|BIOLOGICAL: RP3|BIOLOGICAL: atezolizumab|BIOLOGICAL: bevacizumab,2,INDUSTRY,Replimune Inc.,"['checkpoint inhibitor', 'other', 'antibody']","[{'type': 'other', 'subtype': None, 'raw': 'rp2'}, {'type': 'other', 'subtype': None, 'raw': 'rp3'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'atezolizumab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'bevacizumab'}]",True,refractory metastatic colorectal cancer pmmr mss,digestive
642,United States,Squamous Cell Carcinoma of the Head and Neck,DRUG: Nivolumab+Relatlimab|DRUG: Nivolumab+Ipilimumab,2,OTHER,Dan Zandberg,"['checkpoint inhibitor', 'antibody']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'relatlimab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}]",True,squamous cell carcinoma of the head and neck,head/neck
643,United States,Metastatic Melanoma,DRUG: ipilimumab|DRUG: nivolumab,2,OTHER,Memorial Sloan Kettering Cancer Center,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}]",False,metastatic melanoma,skin
644,China,Non Small Cell Lung Cancer|EGFR Gene Mutation,DRUG: almonertinib|DRUG: Carboplatin|DRUG: Nab paclitaxel,2,OTHER,Guangdong Provincial People's Hospital,"['chemotherapy', 'kinase inhibitor']","[{'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'almonertinib'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'nab paclitaxel'}]",True,non small cell lung cancer egfr gene mutation,lung/thoracic
645,China,Hepatocellular Carcinoma|Chemotherapy Effect|Chemotherapeutic Toxicity,"DRUG: Oxaliplatin,calcium folinic acid, levofolinic acid, 5-FU|DRUG: Concurrent Lenvatinib|DRUG: Concurrent PD-1 antibody|DRUG: Sequential Lenvatinib|DRUG: Sequential PD-1 antibody",3,OTHER,Sun Yat-sen University,"['targeted therapy', 'other', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'oxaliplatin'}, {'type': 'other', 'subtype': None, 'raw': 'calcium folinic acid'}, {'type': 'other', 'subtype': None, 'raw': 'levofolinic acid'}, {'type': 'chemotherapy', 'subtype': 'antimetabolite', 'raw': '5-fu'}, {'type': 'targeted therapy', 'subtype': 'other', 'raw': 'concurrent lenvatinib'}, {'type': 'other', 'subtype': None, 'raw': 'concurrent pd-1 antibody'}, {'type': 'targeted therapy', 'subtype': 'other', 'raw': 'sequential lenvatinib'}, {'type': 'other', 'subtype': None, 'raw': 'sequential pd-1 antibody'}]",True,hepatocellular carcinoma chemotherapy effect chemotherapeutic toxicity,digestive
646,United States,Neuroblastoma,BIOLOGICAL: Hu3F8|DRUG: GM-CSF|DRUG: Isotretinoin,2,OTHER,Memorial Sloan Kettering Cancer Center,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'hu3f8'}, {'type': 'other', 'subtype': None, 'raw': 'gm-csf'}, {'type': 'other', 'subtype': None, 'raw': 'isotretinoin'}]",False,neuroblastoma,other
647,"Australia, France, Georgia, Italy, Poland, Republic of, Spain, Taiwan, United Kingdom, United States",Advanced Non-Small Cell Lung Cancer,DRUG: Domvanalimab|DRUG: Quemliclustat|DRUG: Zimberelimab|DRUG: Docetaxel|DRUG: Platinum-Based Doublet,2,INDUSTRY,Gilead Sciences,"['other', 'antibody', 'chemotherapy']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'domvanalimab'}, {'type': 'other', 'subtype': None, 'raw': 'quemliclustat'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'zimberelimab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'docetaxel'}, {'type': 'other', 'subtype': None, 'raw': 'platinum-based doublet'}]",True,advanced non small cell lung cancer,lung/thoracic
648,"Australia, France, Italy, Republic of, Spain, Taiwan, United States",Pancreatic Cancer,"COMBINATION_PRODUCT: TTX-030, nab-paclitaxel and gemcitabine|COMBINATION_PRODUCT: TTX-030, budigalimab, nab-paclitaxel and gemcitabine|COMBINATION_PRODUCT: Nab-Paclitaxel and gemcitabine",2,INDUSTRY,"Trishula Therapeutics, Inc.","['other', 'antibody', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'ttx-030'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'nab-paclitaxel and gemcitabine'}, {'type': 'other', 'subtype': None, 'raw': 'ttx-030'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'budigalimab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'nab-paclitaxel and gemcitabine'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'nab-paclitaxel and gemcitabine'}]",True,pancreatic cancer,digestive
649,"Austria, France, Germany, New Zealand, Republic of, Spain, Taiwan, United Kingdom, United States","Carcinoma, Hepatocellular",DRUG: Atezolizumab|DRUG: Bevacizumab|DRUG: Tiragolumab|DRUG: Tobemstomig,12,INDUSTRY,Hoffmann-La Roche,"['checkpoint inhibitor', 'other', 'antibody']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'atezolizumab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'bevacizumab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'tiragolumab'}, {'type': 'other', 'subtype': None, 'raw': 'tobemstomig'}]",True,carcinoma hepatocellular,digestive
650,France,Node; Prostate|Bone Metastases|Prostate Cancer Patients,COMBINATION_PRODUCT: SBRT + Durvalumab|RADIATION: SBRT,2,OTHER,Institut Cancerologie de l'Ouest,"['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'sbrt'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}]",True,node prostate bone metastases prostate cancer patients,genitourinary
651,United States,Pancreatic Cancer,DRUG: FOLFIRINOX|DRUG: Losartan|DRUG: Nivolumab|RADIATION: SBRT|PROCEDURE: Surgery,2,OTHER,Massachusetts General Hospital,"['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'folfirinox'}, {'type': 'other', 'subtype': None, 'raw': 'losartan'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}]",True,pancreatic cancer,digestive
652,Switzerland,Leptomeningeal Metastasis|Non-small Cell Lung Cancer Stage IV|Melanoma Stage IV,DRUG: intrathecal nivolumab and intrathecal ipilimumab,1,OTHER,University of Zurich,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'intrathecal nivolumab and intrathecal ipilimumab'}]",False,leptomeningeal metastasis non small cell lung cancer stage iv melanoma stage iv,lung/thoracic
653,China,Rectal Cancer,BIOLOGICAL: Envafolimab,3,OTHER,Sir Run Run Shaw Hospital,['antibody'],"[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'envafolimab'}]",False,rectal cancer,digestive
654,China,Gastric Cancer,DRUG: Short range radiotherapy with sequential Disitamab Vedotin combined with S-1 and xindilizumab,2,OTHER,"Wuhan Union Hospital, China",['antibody'],"[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'short range radiotherapy with sequential disitamab vedotin combined with s-1 and xindilizumab'}]",False,gastric cancer,digestive
655,United States,Clinical Stage 0 Gastric Cancer AJCC v8|Clinical Stage 0 Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage I Gastric Cancer AJCC v8|Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IIB Gastric Cancer AJCC v8|Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IVA Gastric Cancer AJCC v8|Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Gastric Adenocarcinoma|Localized Gastric Carcinoma|Localized Gastroesophageal Junction Adenocarcinoma|Pathologic Stage 0 Gastric Cancer AJCC v8|Pathologic Stage 0 Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage I Gastric Cancer AJCC v8|Pathologic Stage IA Gastric Cancer AJCC v8|Pathologic Stage IA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IB Gastric Cancer AJCC v8|Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIA Gastric Cancer AJCC v8|Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIB Gastric Cancer AJCC v8|Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIIA Gastric Cancer AJCC v8|Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8,DRUG: Fluorouracil|RADIATION: Intensity-Modulated Radiation Therapy|BIOLOGICAL: Ipilimumab|BIOLOGICAL: Nivolumab|DRUG: Oxaliplatin|PROCEDURE: Therapeutic Conventional Surgery,2,OTHER,M.D. Anderson Cancer Center,"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'antimetabolite', 'raw': 'fluorouracil'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'oxaliplatin'}]",True,clinical stage 0 gastric cancer ajcc v8 clinical stage 0 gastroesophageal junction adenocarcinoma ajcc v8 clinical stage i gastric cancer ajcc v8 clinical stage i gastroesophageal junction adenocarcinoma ajcc v8 clinical stage iib gastric cancer ajcc v8 clinical stage iib gastroesophageal junction adenocarcinoma ajcc v8 clinical stage iii gastroesophageal junction adenocarcinoma ajcc v8 clinical stage iva gastric cancer ajcc v8 clinical stage iva gastroesophageal junction adenocarcinoma ajcc v8 gastric adenocarcinoma localized gastric carcinoma localized gastroesophageal junction adenocarcinoma pathologic stage 0 gastric cancer ajcc v8 pathologic stage 0 gastroesophageal junction adenocarcinoma ajcc v8 pathologic stage i gastric cancer ajcc v8 pathologic stage ia gastric cancer ajcc v8 pathologic stage ia gastroesophageal junction adenocarcinoma ajcc v8 pathologic stage ib gastric cancer ajcc v8 pathologic stage ib gastroesophageal junction adenocarcinoma ajcc v8 pathologic stage ic gastroesophageal junction adenocarcinoma ajcc v8 pathologic stage ii gastroesophageal junction adenocarcinoma ajcc v8 pathologic stage iia gastric cancer ajcc v8 pathologic stage iia gastroesophageal junction adenocarcinoma ajcc v8 pathologic stage iib gastric cancer ajcc v8 pathologic stage iib gastroesophageal junction adenocarcinoma ajcc v8 pathologic stage iiia gastric cancer ajcc v8 pathologic stage iiib gastroesophageal junction adenocarcinoma ajcc v8 pathologic stage iva gastroesophageal junction adenocarcinoma ajcc v8,digestive
656,United States,Non-small Cell Lung Cancer|Squamous Cell Carcinoma of the Head and Neck,DRUG: Immune checkpoint inhibitor|RADIATION: Radiation Therapy,2,OTHER,"John L. Villano, MD, PhD",['other'],"[{'type': 'other', 'subtype': None, 'raw': 'immune checkpoint inhibitor'}]",False,non small cell lung cancer squamous cell carcinoma of the head and neck,lung/thoracic
657,"Germany, United States",Prostate Cancer,DRUG: Xaluritamig,1,INDUSTRY,Amgen,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'xaluritamig'}]",False,prostate cancer,genitourinary
658,France,Metastatic Breast Cancer,DRUG: AZD2014|DRUG: AZD4547|DRUG: AZD5363|DRUG: AZD8931|DRUG: Selumetinib|DRUG: Vandetanib|DRUG: Bicalutamide|DRUG: Olaparib|DRUG: Anthracyclines|DRUG: Taxanes|DRUG: cyclophosphamide|DRUG: DNA intercalators|DRUG: Methotrexate|DRUG: vinca alkaloids|DRUG: Platinum based chemotherapies|DRUG: Bevacizumab|DRUG: Mitomycin C|DRUG: Eribulin|DRUG: MEDI4736,2,OTHER,UNICANCER,"['targeted therapy', 'other', 'chemotherapy', 'kinase inhibitor', 'antibody']","[{'type': 'other', 'subtype': None, 'raw': 'azd2014'}, {'type': 'other', 'subtype': None, 'raw': 'azd4547'}, {'type': 'other', 'subtype': None, 'raw': 'azd5363'}, {'type': 'other', 'subtype': None, 'raw': 'azd8931'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'selumetinib'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'vandetanib'}, {'type': 'other', 'subtype': None, 'raw': 'bicalutamide'}, {'type': 'targeted therapy', 'subtype': 'PARP inhibitor', 'raw': 'olaparib'}, {'type': 'other', 'subtype': None, 'raw': 'anthracyclines'}, {'type': 'other', 'subtype': None, 'raw': 'taxanes'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide'}, {'type': 'other', 'subtype': None, 'raw': 'dna intercalators'}, {'type': 'chemotherapy', 'subtype': 'antifolate', 'raw': 'methotrexate'}, {'type': 'other', 'subtype': None, 'raw': 'vinca alkaloids'}, {'type': 'other', 'subtype': None, 'raw': 'platinum based chemotherapies'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'bevacizumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'mitomycin c'}, {'type': 'other', 'subtype': None, 'raw': 'eribulin'}, {'type': 'other', 'subtype': None, 'raw': 'medi4736'}]",True,metastatic breast cancer,breast
659,Norway,Melanoma Stage IV|Head and Neck Squamous Cell Carcinoma|Cutaneous Squamous Cell Carcinoma|MSI-High|Clear Cell Renal Cell Carcinoma|Non-small Cell Lung Cancer,BIOLOGICAL: Fecal Microbiota Transplant (FMT),2,OTHER,Oslo University Hospital,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'fecal microbiota transplant'}]",False,melanoma stage iv head and neck squamous cell carcinoma cutaneous squamous cell carcinoma msi high clear cell renal cell carcinoma non small cell lung cancer,genitourinary
660,United States,Glioblastoma|Medulloblastoma|Ependymoma|Diffuse Intrinsic Pontine Glioma,DRUG: Indoximod|RADIATION: Partial Radiation|RADIATION: Full-dose Radiation|DRUG: Temozolomide|DRUG: Cyclophosphamide|DRUG: Etoposide|DRUG: Lomustine,2,OTHER,Theodore S. Johnson,"['other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'indoximod'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'temozolomide'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'etoposide'}, {'type': 'other', 'subtype': None, 'raw': 'lomustine'}]",True,glioblastoma medulloblastoma ependymoma diffuse intrinsic pontine glioma,brain/CNS
661,Canada,Prostate Cancer,DRUG: Adavosertib|DRUG: Savolitinib|DRUG: Darolutamide|DRUG: CFI-400945|DRUG: Ipatasertib|DRUG: Durvalumab and Tremelimumab|DRUG: Carboplatin,2,NETWORK,Canadian Cancer Trials Group,"['targeted therapy', 'other', 'chemotherapy', 'kinase inhibitor', 'checkpoint inhibitor']","[{'type': 'other', 'subtype': None, 'raw': 'adavosertib'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'savolitinib'}, {'type': 'other', 'subtype': None, 'raw': 'darolutamide'}, {'type': 'other', 'subtype': None, 'raw': 'cfi-400945'}, {'type': 'targeted therapy', 'subtype': 'AKT inhibitor', 'raw': 'ipatasertib'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab and tremelimumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}]",True,prostate cancer,genitourinary
662,China,Cervical Cancer,DRUG: Cadonilimab|DRUG: Anlotinib|DRUG: Granulocyte-Macrophage Colony-Stimulating Factor,2,OTHER,Zhongnan Hospital,"['other', 'antibody', 'kinase inhibitor']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'cadonilimab'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'anlotinib'}, {'type': 'other', 'subtype': None, 'raw': 'granulocyte-macrophage colony-stimulating factor'}]",True,cervical cancer,gynecologic
663,United States,Triple Negative Breast Cancer|Breast Cancer,DRUG: Carboplatin|DRUG: Docetaxel|DRUG: Doxorubicin|DRUG: Cyclophosphamide|DRUG: Pembrolizumab,2,OTHER,University of Kansas Medical Center,"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'docetaxel'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'doxorubicin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",True,triple negative breast cancer breast cancer,breast
664,"Australia, Austria, Belgium, Canada, Czechia, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Romania, Spain, Sweden, Switzerland, United Kingdom, United States",Melanoma,BIOLOGICAL: Nivolumab|OTHER: Placebo,3,INDUSTRY,Bristol-Myers Squibb,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}]",False,melanoma,skin
665,Kazakhstan,"Monitoring, Immunologic",DIETARY_SUPPLEMENT: Adenorine|BIOLOGICAL: Placebo|DRUG: FOLFOX regimen,12,OTHER,MIPO Clinic,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'folfox regimen'}]",False,monitoring immunologic,hematologic
666,United States,Epstein-Barr Virus Infections|Cytomegalovirus Infections|Adenovirus|BK Virus Infection,DRUG: Rapidly generated virus specific T (R-MVST) cells,1,OTHER,Columbia University,['cell therapy'],"[{'type': 'cell therapy', 'subtype': 'other', 'raw': 'rapidly generated virus specific t cells'}]",False,epstein barr virus infections cytomegalovirus infections adenovirus bk virus infection,other
667,United States,Triple Negative Breast Cancer,DRUG: Paclitaxel|DRUG: Carboplatin|DRUG: Pembrolizumab|DRUG: Doxorubicin|DRUG: Cyclophosphamide|DRUG: Olaparib|DRUG: Capecitabine,2,OTHER,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,"['checkpoint inhibitor', 'targeted therapy', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'doxorubicin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide'}, {'type': 'targeted therapy', 'subtype': 'PARP inhibitor', 'raw': 'olaparib'}, {'type': 'chemotherapy', 'subtype': 'fluoropyrimidine', 'raw': 'capecitabine'}]",True,triple negative breast cancer,breast
668,United States,Cancer|Carcinoma|Squamous Cell Carcinoma|Head and Neck Cancer,BIOLOGICAL: Atezolizumab|BIOLOGICAL: Tocilizumab|BIOLOGICAL: Tiragolumab,2,OTHER,Alain Algazi,"['checkpoint inhibitor', 'antibody']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'atezolizumab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'tocilizumab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'tiragolumab'}]",True,cancer carcinoma squamous cell carcinoma head and neck cancer,head/neck
669,Italy,Follicular Lymphoma,DRUG: Immunochemotherapy regimen: Rituximab-bendamustine (Arm A)|DRUG: Immunochemotherapy regimen: Rituximab-bendamustine (Arm B)|DRUG: Immunochemotherapy regimen: R-CHOP (Arm A)|DRUG: Immunochemotherapy regimen: R-CHOP (Arm B)|DRUG: Immunochemotherapy regimen: G-bendamustine (Arm A)|DRUG: Immunochemotherapy regimen: G-bendamustine (Arm B)|DRUG: Immunochemotherapy regimen: G-CHOP (Arm A)|DRUG: Immunochemotherapy regimen: G-CHOP (Arm B)|DRUG: Immunochemotherapy regimen: G-CVP (Arm A)|DRUG: Immunochemotherapy regimen: G-CVP (Arm B),3,OTHER,Fondazione Italiana Linfomi - ETS,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'immunochemotherapy regimen: rituximab-bendamustine'}, {'type': 'other', 'subtype': None, 'raw': 'immunochemotherapy regimen: rituximab-bendamustine'}, {'type': 'other', 'subtype': None, 'raw': 'immunochemotherapy regimen: r-chop'}, {'type': 'other', 'subtype': None, 'raw': 'immunochemotherapy regimen: r-chop'}, {'type': 'other', 'subtype': None, 'raw': 'immunochemotherapy regimen: -bendamustine'}, {'type': 'other', 'subtype': None, 'raw': 'immunochemotherapy regimen: -bendamustine'}, {'type': 'other', 'subtype': None, 'raw': 'immunochemotherapy regimen: -chop'}, {'type': 'other', 'subtype': None, 'raw': 'immunochemotherapy regimen: -chop'}, {'type': 'other', 'subtype': None, 'raw': 'immunochemotherapy regimen: -cvp'}, {'type': 'other', 'subtype': None, 'raw': 'immunochemotherapy regimen: -cvp'}]",False,follicular lymphoma,hematologic
670,China,HNSCC|Lysogenic HSV Virus|Neoadjuvant Therapy|Immunotherapy|Targeted Therapy,BIOLOGICAL: Lysogenic HSV virus.|DRUG: Tislelizumab|DRUG: Afatinib,1,OTHER,West China Hospital,"['checkpoint inhibitor', 'other', 'kinase inhibitor']","[{'type': 'other', 'subtype': None, 'raw': 'lysogenic hsv virus.'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'tislelizumab'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'afatinib'}]",True,hnscc lysogenic hsv virus neoadjuvant therapy immunotherapy targeted therapy,hematologic
671,United States,Castration-resistant Prostate Cancer|Metastatic Cancer,DRUG: Cabozantinib|DRUG: Nivolumab,2,OTHER,"Rana McKay, MD","['checkpoint inhibitor', 'targeted therapy']","[{'type': 'targeted therapy', 'subtype': 'other', 'raw': 'cabozantinib'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}]",True,castration resistant prostate cancer metastatic cancer,genitourinary
672,China,Head and Neck Squamous Cell Carcinoma|Low-dose Radiotherapy|Immunotherapy|Targeted Therapy,DRUG: Tislelizumab|DRUG: Afatinib|RADIATION: Low dose radiotherapy,2,OTHER,West China Hospital,"['checkpoint inhibitor', 'kinase inhibitor']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'tislelizumab'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'afatinib'}]",True,head and neck squamous cell carcinoma low dose radiotherapy immunotherapy targeted therapy,hematologic
673,Egypt,Eye Infections,"BIOLOGICAL: Intralesional injection of Candida albicans 1:20 w/v 10 ml vial (Allergy Laboratories, INC. Oklahoma City, USA.)",2,OTHER_GOV,Zagazig University,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'intralesional injection of candida albicans 1:20 w'}, {'type': 'other', 'subtype': None, 'raw': 'v 10 vial'}]",False,eye infections,other
674,United States,Prostate Cancer,BIOLOGICAL: Pembrolizumab|DRUG: Olaparib|DRUG: Androgen Deprivation Therapy|RADIATION: Radiation Therapy,2,OTHER,Zin W Myint,"['checkpoint inhibitor', 'targeted therapy', 'hormonal therapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'targeted therapy', 'subtype': 'PARP inhibitor', 'raw': 'olaparib'}, {'type': 'hormonal therapy', 'subtype': 'ADT', 'raw': 'androgen deprivation therapy'}]",True,prostate cancer,genitourinary
675,United States,Melanoma,DRUG: Nivolumab|DRUG: Hydroxychloroquine|DRUG: Ipilimumab,12,OTHER,"Ravi Amaravadi, MD","['checkpoint inhibitor', 'other']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'other', 'subtype': None, 'raw': 'hydroxychloroquine'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}]",True,melanoma,skin
676,United States,Kidney Cancer|Renal Cell Carcinoma,DRUG: Cabozantinib|DRUG: Nivolumab|PROCEDURE: Cytoreductive nephrectomy,2,OTHER,Mark Stein,"['checkpoint inhibitor', 'targeted therapy']","[{'type': 'targeted therapy', 'subtype': 'other', 'raw': 'cabozantinib'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}]",True,kidney cancer renal cell carcinoma,genitourinary
677,China,Esophageal Squamous Cell Carcinoma,RADIATION: Split-course hypo-CCRT|DRUG: Induction chemo-immunotherapy|DRUG: Concurrent chemotherapy,1,OTHER,Sun Yat-sen University,"['other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'induction chemo-immunotherapy'}, {'type': 'chemotherapy', 'subtype': 'concurrent', 'raw': 'concurrent chemotherapy'}]",True,esophageal squamous cell carcinoma,digestive
678,China,Non-small Cell Lung Cancer|PDL1 Gene Mutation,DRUG: Serplulimab,2,OTHER,Zhejiang Cancer Hospital,['antibody'],"[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'serplulimab'}]",False,non small cell lung cancer pdl1 gene mutation,lung/thoracic
679,"Denmark, Finland, France, Germany, Italy, Netherlands, Poland, Spain, United Kingdom",Unresectable Stage III Melanoma|Stage IV Melanoma,DRUG: Nivolumab + Ipilimumab|DRUG: Encorafenib + Binimetinib,2,NETWORK,European Organisation for Research and Treatment of Cancer - EORTC,"['checkpoint inhibitor', 'kinase inhibitor']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'encorafenib'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'binimetinib'}]",True,unresectable stage iii melanoma stage iv melanoma,skin
680,"Japan, United States",Limited Stage Lung Small Cell Carcinoma|Stage I Lung Cancer AJCC v8|Stage II Lung Cancer AJCC v8|Stage III Lung Cancer AJCC v8,RADIATION: 3-Dimensional Conformal Radiation Therapy|DRUG: Atezolizumab|PROCEDURE: Biospecimen Collection|DRUG: Carboplatin|DRUG: Cisplatin|DRUG: Etoposide|RADIATION: Intensity-Modulated Radiation Therapy|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration,3,NIH,National Cancer Institute (NCI),"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'atezolizumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'etoposide'}]",True,limited stage lung small cell carcinoma stage i lung cancer ajcc v8 stage ii lung cancer ajcc v8 stage iii lung cancer ajcc v8,lung/thoracic
681,United States,Clinical Stage III Cutaneous Melanoma AJCC v8|Clinical Stage IV Cutaneous Melanoma AJCC v8|Metastatic Melanoma|Pathologic Stage III Cutaneous Melanoma AJCC v8|Pathologic Stage IV Cutaneous Melanoma AJCC v8|Unresectable Melanoma,OTHER: Dietary Intervention|OTHER: Dietary Intervention|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration,2,OTHER,M.D. Anderson Cancer Center,[],[],False,clinical stage iii cutaneous melanoma ajcc v8 clinical stage iv cutaneous melanoma ajcc v8 metastatic melanoma pathologic stage iii cutaneous melanoma ajcc v8 pathologic stage iv cutaneous melanoma ajcc v8 unresectable melanoma,skin
682,China,Colorectal Cancer,DRUG: Camrelizumab,2,OTHER,yue junhan,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'camrelizumab'}]",False,colorectal cancer,digestive
683,Israel,Follicular Lymphoma,DRUG: Bendamustin|DRUG: Obinutuzumab,2,OTHER,Meir Medical Center,"['other', 'antibody']","[{'type': 'other', 'subtype': None, 'raw': 'bendamustin'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'obinutuzumab'}]",True,follicular lymphoma,hematologic
684,"Canada, Spain, United States",HER2+/HR+ Breast Cancer,DRUG: ZW25 (Zanidatamab)|DRUG: Palbociclib|DRUG: Fulvestrant,2,INDUSTRY,Jazz Pharmaceuticals,"['targeted therapy', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'zw25'}, {'type': 'targeted therapy', 'subtype': 'CDK4/6 inhibitor', 'raw': 'palbociclib'}, {'type': 'other', 'subtype': None, 'raw': 'fulvestrant'}]",True,her2 hr breast cancer,breast
685,"Canada, United States",Locally Advanced Lung Non-Small Cell Carcinoma|Stage IIB Lung Cancer AJCC v8|Stage III Lung Cancer AJCC v8,DRUG: Carboplatin|DRUG: Cisplatin|PROCEDURE: Computed Tomography|BIOLOGICAL: Durvalumab|DRUG: Etoposide|RADIATION: Image Guided Radiation Therapy|DRUG: Nab-paclitaxel|DRUG: Paclitaxel|DRUG: Pemetrexed|PROCEDURE: Positron Emission Tomography|OTHER: Questionnaire Administration|RADIATION: Stereotactic Body Radiation Therapy,3,OTHER,NRG Oncology,"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'etoposide'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'nab-paclitaxel'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}, {'type': 'chemotherapy', 'subtype': 'antifolate', 'raw': 'pemetrexed'}]",True,locally advanced lung non small cell carcinoma stage iib lung cancer ajcc v8 stage iii lung cancer ajcc v8,lung/thoracic
686,"Australia, Republic of, Turkey, United Kingdom, United States",Non-small Cell Lung Cancer,DRUG: BNT327|DRUG: Pembrolizumab|DRUG: Carboplatin|DRUG: Pemetrexed|DRUG: Paclitaxel,23,INDUSTRY,BioNTech SE,"['checkpoint inhibitor', 'other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'bnt327'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'chemotherapy', 'subtype': 'antifolate', 'raw': 'pemetrexed'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}]",True,non small cell lung cancer,lung/thoracic
687,"Canada, United States",Advanced Bladder Urothelial Carcinoma|Advanced Renal Pelvis Urothelial Carcinoma|Advanced Ureter Urothelial Carcinoma|Advanced Urethral Urothelial Carcinoma|Metastatic Bladder Urothelial Carcinoma|Metastatic Renal Pelvis Urothelial Carcinoma|Metastatic Ureter Urothelial Carcinoma|Metastatic Urethral Urothelial Carcinoma|Stage III Bladder Cancer AJCC v8|Stage III Renal Pelvis and Ureter Cancer AJCC v8|Stage III Renal Pelvis Cancer AJCC v8|Stage III Ureter Cancer AJCC v8|Stage III Urethral Cancer AJCC v8|Stage IV Bladder Cancer AJCC v8|Stage IV Renal Pelvis and Ureter Cancer AJCC v8|Stage IV Renal Pelvis Cancer AJCC v8|Stage IV Ureter Cancer AJCC v8|Stage IV Urethral Cancer AJCC v8,DRUG: Avelumab|PROCEDURE: Biospecimen Collection|PROCEDURE: Bone Scan|DRUG: Cabozantinib S-malate|PROCEDURE: Computed Tomography|PROCEDURE: Magnetic Resonance Imaging|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration,3,NIH,National Cancer Institute (NCI),"['checkpoint inhibitor', 'targeted therapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'avelumab'}, {'type': 'targeted therapy', 'subtype': 'other', 'raw': 'cabozantinib s-malate'}]",True,advanced bladder urothelial carcinoma advanced renal pelvis urothelial carcinoma advanced ureter urothelial carcinoma advanced urethral urothelial carcinoma metastatic bladder urothelial carcinoma metastatic renal pelvis urothelial carcinoma metastatic ureter urothelial carcinoma metastatic urethral urothelial carcinoma stage iii bladder cancer ajcc v8 stage iii renal pelvis and ureter cancer ajcc v8 stage iii renal pelvis cancer ajcc v8 stage iii ureter cancer ajcc v8 stage iii urethral cancer ajcc v8 stage iv bladder cancer ajcc v8 stage iv renal pelvis and ureter cancer ajcc v8 stage iv renal pelvis cancer ajcc v8 stage iv ureter cancer ajcc v8 stage iv urethral cancer ajcc v8,genitourinary
688,France,Non-Small Cell Lung Cancer Metastatic,DRUG: Ipilimumab|DRUG: Nivolumab,3,OTHER,Intergroupe Francophone de Cancerologie Thoracique,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}]",False,non small cell lung cancer metastatic,lung/thoracic
689,"Czechia, France, Germany, Israel, Italy, Norway, Poland, Spain, United Kingdom",Gastric and Esophagogastric Junction Adenocarcinoma,DRUG: Nivolumab and Ipilimumab|OTHER: chemotherapy,2,NETWORK,European Organisation for Research and Treatment of Cancer - EORTC,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab and ipilimumab'}]",False,gastric and esophagogastric junction adenocarcinoma,digestive
690,China,"Gastric Cancer|Peritoneal Metastases|Ascites, Malignant","DRUG: Sintilimab in Combination With S-1/oxaliplatin With nab-paclitaxel intraperitoneal infusion|OTHER: Blood samples, tumor biopsy specimens, ascites, and feces samples will be collected",2,OTHER,Zhejiang Cancer Hospital,"['other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'sintilimab in combination with s-1'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'oxaliplatin with nab-paclitaxel intraperitoneal'}]",True,gastric cancer peritoneal metastases ascites malignant,digestive
691,"France, Germany, Spain, United States",Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer|Esophageal Adenocarcinoma|Esophageal Squamous Cell Cancer|Siewert Type 1 GEJ Cancer|Pancreatic Cancer,DRUG: Futibatinib|DRUG: Pembrolizumab|DRUG: Cisplatin|DRUG: 5-FU|DRUG: Oxaliplatin|DRUG: Leucovorin|DRUG: Levoleucovorin|DRUG: Irinotecan,2,INDUSTRY,"Taiho Oncology, Inc.","['other', 'chemotherapy', 'kinase inhibitor', 'checkpoint inhibitor', 'supportive care']","[{'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'futibatinib'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}, {'type': 'chemotherapy', 'subtype': 'antimetabolite', 'raw': '5-fu'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'oxaliplatin'}, {'type': 'supportive care', 'subtype': 'folinic acid', 'raw': 'leucovorin'}, {'type': 'other', 'subtype': None, 'raw': 'levoleucovorin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'irinotecan'}]",True,locally advanced unresectable or metastatic solid tumors including esophageal cancer esophageal adenocarcinoma esophageal squamous cell cancer siewert type 1 gej cancer pancreatic cancer,digestive
692,"Canada, Guam, United States",Lung Non-Squamous Non-Small Cell Carcinoma|Stage IIIB Lung Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8|Stage IV Lung Cancer AJCC v8,PROCEDURE: Biospecimen Collection|DRUG: Carboplatin|PROCEDURE: Computed Tomography|PROCEDURE: Magnetic Resonance Imaging|BIOLOGICAL: Pembrolizumab|DRUG: Pemetrexed|PROCEDURE: Positron Emission Tomography,3,NIH,National Cancer Institute (NCI),"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'chemotherapy', 'subtype': 'antifolate', 'raw': 'pemetrexed'}]",True,lung non squamous non small cell carcinoma stage iiib lung cancer ajcc v8 stage iiic lung cancer ajcc v8 stage iv lung cancer ajcc v8,lung/thoracic
693,United States,Extensive Stage Lung Small Cell Carcinoma,DRUG: Atezolizumab|PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|PROCEDURE: Magnetic Resonance Imaging|PROCEDURE: Positron Emission Tomography|RADIATION: Radiation Therapy,23,NIH,National Cancer Institute (NCI),['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'atezolizumab'}]",False,extensive stage lung small cell carcinoma,lung/thoracic
694,United States,Pancreatic Ductal Adenocarcinoma,DRUG: Neoadjuvant Chemotherapy (NAC)|DRUG: Immunotherapy (pembrolizumab)|DEVICE: Endoscopic ultrasound (EUS)-guided radiofrequency ablation (RFA),2,OTHER,"The University of Texas Health Science Center, Houston","['chemotherapy', 'immunotherapy']","[{'type': 'chemotherapy', 'subtype': 'neoadjuvant', 'raw': 'neoadjuvant chemotherapy'}, {'type': 'immunotherapy', 'subtype': 'unspecified', 'raw': 'immunotherapy'}]",True,pancreatic ductal adenocarcinoma,digestive
695,China,Locally Advanced Rectal Carcinoma,DRUG: Tislelizumab,23,OTHER,Beijing Friendship Hospital,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'tislelizumab'}]",False,locally advanced rectal carcinoma,digestive
696,United Kingdom,Locally Advanced Gastric Adenocarcinoma|MSI-H/dMMR Gastric Cancer|MSI-H/dMMR Gastroesophageal-junction Cancer,DRUG: Single agent zimberelimab|DRUG: Combination zimberelimab + domvanalimab,2,OTHER,Royal Marsden NHS Foundation Trust,['antibody'],"[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'single agent zimberelimab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'combination zimberelimab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'domvanalimab'}]",False,locally advanced gastric adenocarcinoma msi h dmmr gastric cancer msi h dmmr gastroesophageal junction cancer,digestive
697,United States,Non Small Cell Lung Cancer,DIAGNOSTIC_TEST: Circulating Tumor Deoxyribonucleic acid (ctDNA) Assay|DRUG: Pembrolizumab|DRUG: Platinum Doublet Chemotherapy,2,OTHER,University of Miami,"['checkpoint inhibitor', 'other']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'other', 'subtype': None, 'raw': 'platinum doublet chemotherapy'}]",True,non small cell lung cancer,lung/thoracic
698,China,Lung Cancer,DRUG: Tafolecimab|DRUG: Sintilimab|DRUG: Nab paclitaxel|DRUG: Docetaxel|DRUG: Gemcitabine,2,OTHER,Jinghui Wang,"['antibody', 'chemotherapy']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'tafolecimab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'sintilimab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'nab paclitaxel'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'docetaxel'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'gemcitabine'}]",True,lung cancer,lung/thoracic
699,China,HR+/HER2- Breast Cancer,DRUG: Neoadjuvant Chemotherapy in Combination with Toripalimab|DRUG: Neoadjuvant Chemotherapy,3,OTHER,First Affiliated Hospital of Zhejiang University,"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'neoadjuvant chemotherapy in combination with toripalimab'}, {'type': 'chemotherapy', 'subtype': 'neoadjuvant', 'raw': 'neoadjuvant chemotherapy'}]",True,hr her2 breast cancer,breast
700,Hong Kong,HCC,DRUG: Zabadinostat (CXD101) and Geptanolimab|DRUG: Lenvatinib and Sorafenib,2,OTHER,Stephen Chan Lam,"['targeted therapy', 'antibody']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'zabadinostat and geptanolimab'}, {'type': 'targeted therapy', 'subtype': 'other', 'raw': 'lenvatinib and sorafenib'}]",True,hcc,other
701,Denmark,"Bladder Cancer|Bladder Cancer, Metastatic",DRUG: Atezolizumab,2,OTHER,Jørgen Bjerggaard Jensen,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'atezolizumab'}]",False,bladder cancer bladder cancer metastatic,genitourinary
702,"Belgium, United States",Unresectable Metastatic Colorectal Cancer,DRUG: CYAD-101|DRUG: FOLFOX|DRUG: FOLFIRI,1,INDUSTRY,Celyad Oncology SA,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'cyad-101'}, {'type': 'other', 'subtype': None, 'raw': 'folfox'}, {'type': 'other', 'subtype': None, 'raw': 'folfiri'}]",False,unresectable metastatic colorectal cancer,digestive
703,Republic of,Bile Duct Cancer|Chemotherapy Effect,DRUG: AZD6738|DRUG: Durvalumab,2,OTHER,Seoul National University Hospital,"['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'azd6738'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}]",True,bile duct cancer chemotherapy effect,other
704,"Australia, Canada, New Zealand, Puerto Rico, United States",Localized Resectable Neuroblastoma|Localized Unresectable Neuroblastoma|Recurrent Neuroblastoma|Regional Neuroblastoma|Stage 4 Neuroblastoma|Stage 4S Neuroblastoma,BIOLOGICAL: Aldesleukin|BIOLOGICAL: Dinutuximab|DRUG: Isotretinoin|OTHER: Laboratory Biomarker Analysis|OTHER: Pharmacological Study|OTHER: Quality-of-Life Assessment|BIOLOGICAL: Sargramostim,3,NIH,National Cancer Institute (NCI),"['other', 'antibody', 'cytokine therapy']","[{'type': 'cytokine therapy', 'subtype': 'IL-2', 'raw': 'aldesleukin'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'dinutuximab'}, {'type': 'other', 'subtype': None, 'raw': 'isotretinoin'}, {'type': 'other', 'subtype': None, 'raw': 'sargramostim'}]",True,localized resectable neuroblastoma localized unresectable neuroblastoma recurrent neuroblastoma regional neuroblastoma stage 4 neuroblastoma stage 4s neuroblastoma,other
705,"Belgium, France, Germany, Italy, Japan, Singapore, Spain, Taiwan, United States","Carcinoma, Non-Small-Cell Lung|Carcinoma, Renal Cell|Esophageal Squamous Cell Carcinoma|Squamous Cell Carcinoma of Head and Neck",BIOLOGICAL: QEQ278,1,INDUSTRY,Novartis Pharmaceuticals,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'qeq278'}]",False,carcinoma non small cell lung carcinoma renal cell esophageal squamous cell carcinoma squamous cell carcinoma of head and neck,genitourinary
706,China,Breast Cancer,DRUG: Lvonescimab (AK112),2,OTHER,Hubei Cancer Hospital,['antibody'],"[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'lvonescimab'}]",False,breast cancer,breast
707,United Kingdom,"Lung Cancer, Nonsmall Cell",DRUG: Pembrolizumab 25 MG/ML [Keytruda],3,OTHER,Imperial College London,"['checkpoint inhibitor', 'other']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab 25'}, {'type': 'other', 'subtype': None, 'raw': '[keytruda]'}]",True,lung cancer nonsmall cell,lung/thoracic
708,Chile,Melanoma Stage IIIc|Melanoma Stage IV,BIOLOGICAL: TRIMELVAX,1,OTHER,University of Chile,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'trimelvax'}]",False,melanoma stage iiic melanoma stage iv,skin
709,United States,Cervical Carcinoma|Vaginal Carcinoma|Vulvar Carcinoma|HPV (Human Papillomavirus)-Associated Carcinoma,"DRUG: HPV vaccine, Imiquimod, and metformin combination therapy",2,OTHER,Baylor College of Medicine,"['vaccine', 'other']","[{'type': 'vaccine', 'subtype': 'vaccine', 'raw': 'hpv vaccine'}, {'type': 'other', 'subtype': None, 'raw': 'imiquimod'}, {'type': 'other', 'subtype': None, 'raw': 'and metformin combination therapy'}]",True,cervical carcinoma vaginal carcinoma vulvar carcinoma hpv associated carcinoma,gynecologic
710,"Netherlands, United Kingdom",Renal Cell Carcinoma,DRUG: Neoadjuvant nivolumab|DRUG: Neoadjuvant ipilimumab|DRUG: Neoadjuvant relatlimab,2,OTHER,The Netherlands Cancer Institute,"['checkpoint inhibitor', 'antibody']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'neoadjuvant nivolumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'neoadjuvant ipilimumab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'neoadjuvant relatlimab'}]",True,renal cell carcinoma,genitourinary
711,"Belgium, Brazil, France, Georgia, Italy, Russian Federation, Spain, United States",Metastatic Colorectal Cancer,DRUG: Botensilimab|DRUG: Balstilimab|DRUG: Standard of Care,2,INDUSTRY,Agenus Inc.,"['antibody', 'non-therapeutic']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'botensilimab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'balstilimab'}, {'type': 'non-therapeutic', 'subtype': 'supportive', 'raw': 'standard of care'}]",True,metastatic colorectal cancer,digestive
712,United States,Cutaneous Melanoma,DRUG: Pembrolizumab|DRUG: Talimogene Laherparepvec,2,OTHER,University of Louisville,"['checkpoint inhibitor', 'other']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'other', 'subtype': None, 'raw': 'talimogene laherparepvec'}]",True,cutaneous melanoma,skin
713,United States,Malignant Melanoma,DRUG: Peginterferon alfa-2b|DRUG: Temozolomide|DRUG: Recombinant interferon alfa-2b,2,OTHER,St. Jude Children's Research Hospital,"['other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'peginterferon alfa-2b'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'temozolomide'}, {'type': 'other', 'subtype': None, 'raw': 'recombinant interferon alfa-2b'}]",True,malignant melanoma,skin
714,United States,Colorectal Cancer,DRUG: Cemiplimab|DRUG: Fianlimab,2,OTHER,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,"['checkpoint inhibitor', 'antibody']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'cemiplimab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'fianlimab'}]",True,colorectal cancer,digestive
715,United States,Muscle-Invasive Bladder Carcinoma,BIOLOGICAL: Synthetic long peptide personalized cancer vaccine|DRUG: Poly ICLC|DEVICE: Signatera assay,1,OTHER,Washington University School of Medicine,"['vaccine', 'other']","[{'type': 'vaccine', 'subtype': 'vaccine', 'raw': 'synthetic long peptide personalized cancer vaccine'}, {'type': 'other', 'subtype': None, 'raw': 'poly iclc'}]",True,muscle invasive bladder carcinoma,genitourinary
716,United States,Muscle-invasive Urothelial Cancer of the Bladder,BIOLOGICAL: Pembrolizumab|PROCEDURE: Transurethral Resection of Bladder Tumor|DRUG: Gemcitabine|RADIATION: External Beam Radiation Therapy,2,OTHER,NYU Langone Health,"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'gemcitabine'}]",True,muscle invasive urothelial cancer of the bladder,genitourinary
717,China,Triple-Negative Breast Cancer (TNBC),"RADIATION: radiotherapy 5 Gy × 5 fractions, once a day|RADIATION: radiotherapy 8 Gy × 5 fractions, once a day|RADIATION: radiotherapy 8 Gy × 3 fractions, once every other day|RADIATION: radiotherapy 10 Gy× 3 fractions, once every other day|RADIATION: radiotehrapy 0.5Gy twice-a-day × 2 days, repeat for 4 cycles (total 8Gy)|DRUG: Toripalimab|DRUG: chemotherapy regimen selected by the investigator",2,OTHER,Sun Yat-sen University,"['checkpoint inhibitor', 'other']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'toripalimab'}, {'type': 'other', 'subtype': None, 'raw': 'chemotherapy regimen selected by the investigator'}]",True,triple negative breast cancer,breast
718,United States,Advanced Merkel Cell Carcinoma|Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8|Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8|Metastatic Merkel Cell Carcinoma|Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8|Pathologic Stage IIIA Cutaneous Merkel Cell Carcinoma AJCC v8|Pathologic Stage IIIB Cutaneous Merkel Cell Carcinoma AJCC v8|Pathologic Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8,BIOLOGICAL: Pembrolizumab|RADIATION: Stereotactic Body Radiation Therapy,2,NIH,National Cancer Institute (NCI),['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",False,advanced merkel cell carcinoma clinical stage iii cutaneous merkel cell carcinoma ajcc v8 clinical stage iv cutaneous merkel cell carcinoma ajcc v8 metastatic merkel cell carcinoma pathologic stage iii cutaneous merkel cell carcinoma ajcc v8 pathologic stage iiia cutaneous merkel cell carcinoma ajcc v8 pathologic stage iiib cutaneous merkel cell carcinoma ajcc v8 pathologic stage iv cutaneous merkel cell carcinoma ajcc v8,skin
719,United States,Pancreatic Adenocarcinoma|Pancreatic Cancer|Pancreatic Adenosquamous Carcinoma,BIOLOGICAL: Autologous DC Therapy,1,INDUSTRY,Diakonos Oncology Corporation,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'autologous dc therapy'}]",False,pancreatic adenocarcinoma pancreatic cancer pancreatic adenosquamous carcinoma,digestive
720,Taiwan,Locally Advanced Esophageal Squamous Cell Carcinoma,DRUG: Tiragolumab,12,OTHER,National Taiwan University Hospital,['antibody'],"[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'tiragolumab'}]",False,locally advanced esophageal squamous cell carcinoma,digestive
721,"Canada, United States",Muscle Invasive Bladder Urothelial Carcinoma|Muscle Invasive Renal Pelvis Urothelial Carcinoma|Muscle Invasive Ureter Urothelial Carcinoma|Muscle Invasive Urethral Urothelial Carcinoma|Stage II Bladder Urothelial Carcinoma AJCC v6 and v7|Stage III Bladder Urothelial Carcinoma AJCC v6 and v7|Stage IV Bladder Urothelial Carcinoma AJCC v7,PROCEDURE: Biospecimen Collection|OTHER: cfDNA or ctDNA Measurement|PROCEDURE: Computed Tomography|PROCEDURE: Cystoscopy|PROCEDURE: Magnetic Resonance Imaging|BIOLOGICAL: Nivolumab|OTHER: Questionnaire Administration|BIOLOGICAL: Relatlimab,23,NIH,National Cancer Institute (NCI),"['checkpoint inhibitor', 'antibody']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'relatlimab'}]",True,muscle invasive bladder urothelial carcinoma muscle invasive renal pelvis urothelial carcinoma muscle invasive ureter urothelial carcinoma muscle invasive urethral urothelial carcinoma stage ii bladder urothelial carcinoma ajcc v6 and v7 stage iii bladder urothelial carcinoma ajcc v6 and v7 stage iv bladder urothelial carcinoma ajcc v7,genitourinary
722,Denmark,Pancreatic Cancer,DRUG: Nivolumab|DRUG: Ipilimumab|RADIATION: SBRT|BIOLOGICAL: TGFβ-B-15 peptide,1,OTHER,"Inna Chen, MD","['checkpoint inhibitor', 'other']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}, {'type': 'other', 'subtype': None, 'raw': 'tgfβ-b-15 peptide'}]",True,pancreatic cancer,digestive
723,United States,Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Non-Hodgkin Lymphoma,PROCEDURE: Autologous Hematopoietic Stem Cell Transplantation|BIOLOGICAL: Filgrastim|BIOLOGICAL: Genetically Engineered Lymphocyte Therapy|OTHER: Laboratory Biomarker Analysis|PROCEDURE: Peripheral Blood Stem Cell Transplantation|DRUG: Plerixafor|BIOLOGICAL: Rituximab,12,OTHER,City of Hope Medical Center,"['other', 'antibody', 'supportive care']","[{'type': 'supportive care', 'subtype': 'G-CSF', 'raw': 'filgrastim'}, {'type': 'other', 'subtype': None, 'raw': 'genetically engineered lymphocyte therapy'}, {'type': 'other', 'subtype': None, 'raw': 'plerixafor'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'rituximab'}]",True,recurrent grade 1 follicular lymphoma recurrent grade 2 follicular lymphoma recurrent grade 3 follicular lymphoma recurrent mantle cell lymphoma recurrent non hodgkin lymphoma,hematologic
724,China,Esophageal Squamous Cell Carcinoma Stage II|Esophageal Squamous Cell Carcinoma Stage III,PROCEDURE: Neoadjuvant Chemoradiotherapy|DRUG: Tislelizumab|PROCEDURE: Ivor-Lewis or Mckeown Esophagectomy(Mckeown Esophagectomy recommended),23,OTHER,Shanghai Zhongshan Hospital,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'tislelizumab'}]",False,esophageal squamous cell carcinoma stage ii esophageal squamous cell carcinoma stage iii,digestive
725,United States,Glioblastoma Multiforme,DRUG: MBG453,1,OTHER,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'mbg453'}]",False,glioblastoma multiforme,brain/CNS
726,United States,Advanced Lung Non-Small Cell Carcinoma|Metastatic Lung Non-Small Cell Carcinoma|Stage III Lung Cancer AJCC v8|Stage IV Lung Cancer AJCC v8,BIOLOGICAL: Atezolizumab|PROCEDURE: Biospecimen Collection|BIOLOGICAL: Cemiplimab|PROCEDURE: Computed Tomography|DRUG: Diclofenac Potassium|OTHER: Electronic Health Record Review|PROCEDURE: Magnetic Resonance Imaging|BIOLOGICAL: Nivolumab|BIOLOGICAL: Pembrolizumab|PROCEDURE: Positron Emission Tomography,2,OTHER,Emory University,"['checkpoint inhibitor', 'other']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'atezolizumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'cemiplimab'}, {'type': 'other', 'subtype': None, 'raw': 'diclofenac potassium'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",True,advanced lung non small cell carcinoma metastatic lung non small cell carcinoma stage iii lung cancer ajcc v8 stage iv lung cancer ajcc v8,lung/thoracic
727,China,Metastatic Non-Small Cell Lung Cancer|NSCLC Stage IV|OligoProgressive Metastatic Disease,RADIATION: Stereotactic Body Radiotherapy|DRUG: second-line systemic therapy,3,OTHER,"Second Affiliated Hospital, School of Medicine, Zhejiang University",['other'],"[{'type': 'other', 'subtype': None, 'raw': 'second-line systemic therapy'}]",False,metastatic non small cell lung cancer nsclc stage iv oligoprogressive metastatic disease,lung/thoracic
728,China,Locally Advanced Esophageal Squamous Cell Carcinoma|Sintilimab|Radiotherapy|Concurrent Chemoradiotherapy|Immunonutrition,RADIATION: Radiotherapy|DRUG: Programmed Cell Death Protein 1 Inhibitor|DIETARY_SUPPLEMENT: Immunonutrition support,2,OTHER,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",['cell therapy'],"[{'type': 'cell therapy', 'subtype': 'other', 'raw': 'programmed cell death protein 1 inhibitor'}]",False,locally advanced esophageal squamous cell carcinoma sintilimab radiotherapy concurrent chemoradiotherapy immunonutrition,digestive
729,United States,Metastatic Breast Cancer,BIOLOGICAL: huMNC2-CAR44 CAR T cells or huMNC2-CAR22 CAR T cells|BIOLOGICAL: huMNC2-CAR44 CAR T cells or huMNC2-CAR22 CAR T cells @ RP2D,1,INDUSTRY,Minerva Biotechnologies Corporation,['cell therapy'],"[{'type': 'cell therapy', 'subtype': 'other', 'raw': 'humnc2-car44 car t cells or humnc2-car22 car t cells'}, {'type': 'cell therapy', 'subtype': 'other', 'raw': 'humnc2-car44 car t cells or humnc2-car22 car t cells @ rp2d'}]",False,metastatic breast cancer,breast
730,United States,"B-NHL|B-Non Hodgkin Lymphoma|Acute Lymphocytic Leukemia|Acute Lymphoblastic Leukemia|B-precursor ALL|B-All|Lymphoma, Non-Hodgkin|Leukemia, Lymphocytic, B Cell|B-Cell Lymphoma|B-Cell Leukemia|Acute Lymphoid Leukemia",BIOLOGICAL: CD19/CD22-CAR-transduced T cells|DRUG: cyclophosphamide|DRUG: fludarabine,12,NIH,National Cancer Institute (NCI),"['other', 'chemotherapy', 'cell therapy']","[{'type': 'other', 'subtype': None, 'raw': 'cd19'}, {'type': 'cell therapy', 'subtype': 'engineered cell', 'raw': 'cd22-car-transduced t cells'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide'}, {'type': 'chemotherapy', 'subtype': 'purine analog', 'raw': 'fludarabine'}]",True,b nhl b non hodgkin lymphoma acute lymphocytic leukemia acute lymphoblastic leukemia b precursor all b all lymphoma non hodgkin leukemia lymphocytic b cell b cell lymphoma b cell leukemia acute lymphoid leukemia,hematologic
731,Russian Federation,Anaplastic Thyroid Cancer,DRUG: Pembrolizumab + Lenvatinib,2,OTHER,"Saint Petersburg State University, Russia","['checkpoint inhibitor', 'targeted therapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'targeted therapy', 'subtype': 'other', 'raw': 'lenvatinib'}]",True,anaplastic thyroid cancer,other
732,United States,"Diffuse Astrocytoma, IDH-Mutant|Glioblastoma, IDH-wildtype|Brain Metastases, Adult|Cervical Cancer|Colorectal Cancer|Esophageal Cancer|Esophageal Squamous Cell Carcinoma|Gastric Cancer|Gastroesophageal Junction Adenocarcinoma|Head and Neck Squamous Cell Carcinoma|Melanoma|Merkel Cell Carcinoma|Microsatellite Instability-High Solid Malignant Tumor|Mismatch Repair Deficient Solid Malignant Tumor|Microsatellite Instability-High Colorectal Cancer|Mismatch Repair Deficient Colorectal Cancer|Non-small Cell Lung Cancer|Renal Cell Carcinoma|Small Cell Lung Cancer|Squamous Cell Carcinoma|Urothelial Carcinoma",DRUG: NEO212 Oral Capsule|DRUG: Ipilimumab|DRUG: Pembrolizumab|DRUG: Nivolumab|DRUG: Regorafenib|DRUG: Carboplatin|DRUG: Paclitaxel|DRUG: FOLFIRI Protocol|DRUG: Bevacizumab,12,INDUSTRY,"Neonc Technologies, Inc.","['other', 'chemotherapy', 'kinase inhibitor', 'checkpoint inhibitor', 'antibody']","[{'type': 'other', 'subtype': None, 'raw': 'neo212 capsule'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'regorafenib'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}, {'type': 'other', 'subtype': None, 'raw': 'folfiri protocol'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'bevacizumab'}]",True,diffuse astrocytoma idh mutant glioblastoma idh wildtype brain metastases adult cervical cancer colorectal cancer esophageal cancer esophageal squamous cell carcinoma gastric cancer gastroesophageal junction adenocarcinoma head and neck squamous cell carcinoma melanoma merkel cell carcinoma microsatellite instability high solid malignant tumor mismatch repair deficient solid malignant tumor microsatellite instability high colorectal cancer mismatch repair deficient colorectal cancer non small cell lung cancer renal cell carcinoma small cell lung cancer squamous cell carcinoma urothelial carcinoma,gynecologic
733,Armenia,Non-small Cell Lung Cancer,DRUG: Botensilimab + Balstilimab,2,OTHER,Immune Oncology Research Institute,['antibody'],"[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'botensilimab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'balstilimab'}]",False,non small cell lung cancer,lung/thoracic
734,China,T-Cell Acute Lymphoblastic Leukemia,BIOLOGICAL: Antigen-specific T cells CAR-T/CTL and DCvac,1,OTHER,Shenzhen Geno-Immune Medical Institute,"['other', 'cell therapy']","[{'type': 'cell therapy', 'subtype': 'engineered cell', 'raw': 'antigen-specific t cells car-t'}, {'type': 'other', 'subtype': None, 'raw': 'ctl and dcvac'}]",True,t cell acute lymphoblastic leukemia,hematologic
735,United States,"Diffuse Midline Glioma, H3 K27M-Mutant|Recurrent High Grade Glioma",DRUG: Treatment with CD200AR-L,1,INDUSTRY,OX2 Therapeutics,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'treatment with cd200ar-l'}]",False,diffuse midline glioma h3 k27m mutant recurrent high grade glioma,brain/CNS
736,China,B-Cell Acute Lymphoblastic Leukemia,BIOLOGICAL: Antigen-specific T cells CART/CTL and DCvac,1,OTHER,Shenzhen Geno-Immune Medical Institute,"['other', 'cell therapy']","[{'type': 'cell therapy', 'subtype': 'engineered cell', 'raw': 'antigen-specific t cells cart'}, {'type': 'other', 'subtype': None, 'raw': 'ctl and dcvac'}]",True,b cell acute lymphoblastic leukemia,hematologic
737,United States,Non-muscle Invasive Bladder Cancer,BIOLOGICAL: BCG+N-803( 50mg BCG/ Instillation+ N-803( 400 μg/instillation). )|BIOLOGICAL: BCG( 50mg/Instillation),12,INDUSTRY,"ImmunityBio, Inc.",['other'],"[{'type': 'other', 'subtype': None, 'raw': 'bcg'}, {'type': 'other', 'subtype': None, 'raw': 'n-803. )'}, {'type': 'other', 'subtype': None, 'raw': 'bcg'}]",False,non muscle invasive bladder cancer,genitourinary
738,United States,Breast Cancer|Metastatic HER2-negative Breast,DRUG: Cyclophosphamide|BIOLOGICAL: Mesothelin-targeted T cells|DRUG: AP1903,1,OTHER,Memorial Sloan Kettering Cancer Center,"['other', 'chemotherapy', 'cell therapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide'}, {'type': 'cell therapy', 'subtype': 'other', 'raw': 'mesothelin-targeted t cells'}, {'type': 'other', 'subtype': None, 'raw': 'ap1903'}]",True,breast cancer metastatic her2 negative breast,breast
739,United States,Clinical Stage IV Cutaneous Melanoma AJCC v8|Melanoma of Unknown Primary|Metastatic Malignant Neoplasm in the Brain|Metastatic Melanoma|Metastatic Mucosal Melanoma|Metastatic Ocular Melanoma|Pathologic Stage IV Cutaneous Melanoma AJCC v8,BIOLOGICAL: Ipilimumab|BIOLOGICAL: Nivolumab|BIOLOGICAL: Pembrolizumab|RADIATION: Stereotactic Radiosurgery|PROCEDURE: Tumor Treating Fields Therapy,1,OTHER,Emory University,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",False,clinical stage iv cutaneous melanoma ajcc v8 melanoma of unknown primary metastatic malignant neoplasm in the brain metastatic melanoma metastatic mucosal melanoma metastatic ocular melanoma pathologic stage iv cutaneous melanoma ajcc v8,skin
740,China,Nasopharyngeal Cancinoma (NPC)|Nasopharyngeal Cancer,DRUG: QL1706|DRUG: Gemcitabine|DRUG: Cisplatin|RADIATION: Intensity-modulated radiotherapy,3,OTHER,Sun Yat-sen University,"['other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'ql1706'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'gemcitabine'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}]",True,nasopharyngeal cancinoma nasopharyngeal cancer,head/neck
741,United States,Clinical Stage III Cutaneous Melanoma AJCC v8|Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8|Clinical Stage IV Cutaneous Melanoma AJCC v8|Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8|Locally Recurrent Head and Neck Squamous Cell Carcinoma|Locally Recurrent Hypopharyngeal Squamous Cell Carcinoma|Locally Recurrent Laryngeal Squamous Cell Carcinoma|Locally Recurrent Oral Cavity Squamous Cell Carcinoma|Locally Recurrent Oropharyngeal Squamous Cell Carcinoma|Metastatic Head and Neck Squamous Cell Carcinoma|Metastatic Hypopharyngeal Squamous Cell Carcinoma|Metastatic Laryngeal Squamous Cell Carcinoma|Metastatic Melanoma|Metastatic Oral Cavity Squamous Cell Carcinoma|Metastatic Oropharyngeal Squamous Cell Carcinoma|Recurrent Melanoma|Stage III Hypopharyngeal Carcinoma AJCC v8|Stage III Laryngeal Cancer AJCC v8|Stage III Lip and Oral Cavity Cancer AJCC v8|Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8|Stage IV Hypopharyngeal Carcinoma AJCC v8|Stage IV Laryngeal Cancer AJCC v8|Stage IV Lip and Oral Cavity Cancer AJCC v8|Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8|Unresectable Melanoma,PROCEDURE: Biopsy Procedure|PROCEDURE: Biospecimen Collection|DRUG: Cabozantinib S-malate|PROCEDURE: Computed Tomography|PROCEDURE: Magnetic Resonance Imaging|BIOLOGICAL: Nivolumab,2,NIH,National Cancer Institute (NCI),"['checkpoint inhibitor', 'targeted therapy']","[{'type': 'targeted therapy', 'subtype': 'other', 'raw': 'cabozantinib s-malate'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}]",True,clinical stage iii cutaneous melanoma ajcc v8 clinical stage iii hpv mediated oropharyngeal carcinoma ajcc v8 clinical stage iv cutaneous melanoma ajcc v8 clinical stage iv hpv mediated oropharyngeal carcinoma ajcc v8 locally recurrent head and neck squamous cell carcinoma locally recurrent hypopharyngeal squamous cell carcinoma locally recurrent laryngeal squamous cell carcinoma locally recurrent oral cavity squamous cell carcinoma locally recurrent oropharyngeal squamous cell carcinoma metastatic head and neck squamous cell carcinoma metastatic hypopharyngeal squamous cell carcinoma metastatic laryngeal squamous cell carcinoma metastatic melanoma metastatic oral cavity squamous cell carcinoma metastatic oropharyngeal squamous cell carcinoma recurrent melanoma stage iii hypopharyngeal carcinoma ajcc v8 stage iii laryngeal cancer ajcc v8 stage iii lip and oral cavity cancer ajcc v8 stage iii oropharyngeal carcinoma ajcc v8 stage iv hypopharyngeal carcinoma ajcc v8 stage iv laryngeal cancer ajcc v8 stage iv lip and oral cavity cancer ajcc v8 stage iv oropharyngeal carcinoma ajcc v8 unresectable melanoma,skin
742,United States,Lung Non-Small Cell Carcinoma|Stage II Lung Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIB Lung Cancer AJCC v8,PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|BIOLOGICAL: Durvalumab|OTHER: Patient Observation|OTHER: Questionnaire Administration,3,NIH,National Cancer Institute (NCI),['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}]",False,lung non small cell carcinoma stage ii lung cancer ajcc v8 stage iiia lung cancer ajcc v8 stage iiib lung cancer ajcc v8,lung/thoracic
743,China,Lung Cancer|Inoperable Disease,"DRUG: ipilimumab+pembrolizumab or ipilimumab+durvalumab, idarubicin, bevacizumab",2,OTHER,Second Affiliated Hospital of Guangzhou Medical University,"['checkpoint inhibitor', 'antibody', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab or ipilimumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}, {'type': 'chemotherapy', 'subtype': 'anthracycline', 'raw': 'idarubicin'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'bevacizumab'}]",True,lung cancer inoperable disease,lung/thoracic
744,China,Extensive Small Cell Lung Cancer,DRUG: Adebelizumab+Carboplatin+Etoposide+Concurrent Radiotherapy,2,OTHER,Qianfoshan Hospital,"['other', 'antibody', 'chemotherapy']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'adebelizumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'etoposide'}, {'type': 'other', 'subtype': None, 'raw': 'concurrent radiotherapy'}]",True,extensive small cell lung cancer,lung/thoracic
745,United States,Epithelial Ovarian Cancer|Primary Peritoneal Carcinoma|Fallopian Tube Cancer,OTHER: 27T51|DRUG: Cemiplimab|DRUG: Bevacizumab,1,INDUSTRY,Regeneron Pharmaceuticals,"['checkpoint inhibitor', 'antibody']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'cemiplimab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'bevacizumab'}]",True,epithelial ovarian cancer primary peritoneal carcinoma fallopian tube cancer,gynecologic
746,United States,Neuroblastoma,DRUG: Universal Donor (UD) TGFβi NK Cells|DRUG: Temozolomide|DRUG: Irinotecan|DRUG: Dinutuximab|DRUG: GM-CSF,2,OTHER,New Approaches to Neuroblastoma Therapy Consortium,"['other', 'antibody', 'chemotherapy', 'cell therapy']","[{'type': 'cell therapy', 'subtype': 'other', 'raw': 'universal donor tgfβi nk cells'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'temozolomide'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'irinotecan'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'dinutuximab'}, {'type': 'other', 'subtype': None, 'raw': 'gm-csf'}]",True,neuroblastoma,other
747,Japan,Metastatic Breast Cancer,DRUG: Induction therapy,2,OTHER,Japan Breast Cancer Research Group,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'induction therapy'}]",False,metastatic breast cancer,breast
748,Japan,Pancreatic Cancer Stage III|Pancreatic Cancer Stage IV,BIOLOGICAL: TBI-1401(HF10)|DRUG: Gemcitabine|DRUG: Nab-paclitaxel|DRUG: TS-1,1,INDUSTRY,Takara Bio Inc.,"['other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'tbi-1401'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'gemcitabine'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'nab-paclitaxel'}, {'type': 'other', 'subtype': None, 'raw': 'ts-1'}]",True,pancreatic cancer stage iii pancreatic cancer stage iv,digestive
749,United States,Breast Cancer,DRUG: Pembrolizumab|DRUG: Nab-Paclitaxel,2,OTHER,NYU Langone Health,"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'nab-paclitaxel'}]",True,breast cancer,breast
750,United States,Chronic Lymphocytic Leukemia,DRUG: IPI-145|DRUG: Fludarabine|DRUG: Cyclophosphamide|DRUG: Rituximab,12,OTHER,Dana-Farber Cancer Institute,"['other', 'antibody', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'ipi-145'}, {'type': 'chemotherapy', 'subtype': 'purine analog', 'raw': 'fludarabine'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'rituximab'}]",True,chronic lymphocytic leukemia,hematologic
751,China,Rectal Cancer Patients,COMBINATION_PRODUCT: lparomlimab and Tuvonralimab Injection and regorafenib and CPAOX and short-course radiotherapy|COMBINATION_PRODUCT: lparomlimab and Tuvonralimab Injection and regorafenib and CPAOX and short-course radiotherapy,2,OTHER,Sun Yat-sen University,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'lparomlimab and tuvonralimab injection and regorafenib and cpaox and short-course radiotherapy'}, {'type': 'other', 'subtype': None, 'raw': 'lparomlimab and tuvonralimab injection and regorafenib and cpaox and short-course radiotherapy'}]",False,rectal cancer patients,digestive
752,Japan,Recurrent Triple-Negative Breast Cancer,DRUG: Pembrolizumab|DRUG: Paclitaxel|DRUG: Bevacizumab,2,OTHER,Yukinori Ozaki,"['checkpoint inhibitor', 'antibody', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'bevacizumab'}]",True,recurrent triple negative breast cancer,breast
753,Canada,Renal Cell Carcinoma,DRUG: Fecal Microbiota Transplantation,1,OTHER,London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'fecal microbiota transplantation'}]",False,renal cell carcinoma,genitourinary
754,Australia,"Glioblastoma Multiforme|Astrocytoma, Grade IV",BIOLOGICAL: Allogeneic cytomegalovirus-specific T cells|DRUG: Pembrolizumab,12,OTHER,Queensland Institute of Medical Research,"['checkpoint inhibitor', 'cell therapy']","[{'type': 'cell therapy', 'subtype': 'other', 'raw': 'allogeneic cytomegalovirus-specific t cells'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",True,glioblastoma multiforme astrocytoma grade iv,brain/CNS
755,"France, Spain",Triple-negative Breast Cancer,DRUG: Pembrolizumab 25 mg/ml|DRUG: Paclitaxel injection,2,OTHER,UNICANCER,"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab 25'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel injection'}]",True,triple negative breast cancer,breast
756,China,Esophageal Cancer,DRUG: PD-1 monoclonal antibody consolidation therapy,2,OTHER,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",['other'],"[{'type': 'other', 'subtype': None, 'raw': 'pd-1 monoclonal antibody consolidation therapy'}]",False,esophageal cancer,digestive
757,United States,Cancer Of Prostate,DRUG: M9241|RADIATION: Stereotactic Body Radiation Therapy (SBRT),2,NIH,National Cancer Institute (NCI),['other'],"[{'type': 'other', 'subtype': None, 'raw': 'm9241'}]",False,cancer of prostate,genitourinary
758,United States,Triple Negative Breast Cancer|TNBC - Triple-Negative Breast Cancer|Breast Cancer|Metastatic Breast Cancer,DRUG: Pembrolizumab|DRUG: Olaparib|RADIATION: Radiation,2,OTHER,Memorial Sloan Kettering Cancer Center,"['checkpoint inhibitor', 'targeted therapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'targeted therapy', 'subtype': 'PARP inhibitor', 'raw': 'olaparib'}]",True,triple negative breast cancer tnbc triple negative breast cancer breast cancer metastatic breast cancer,breast
759,"Jordan, Lebanon",Locally Advanced Rectal Cancer,DRUG: COMPOUND 2055269|RADIATION: Radiation Therapy|DRUG: mFOLFOX|PROCEDURE: Total Mesorectal Excision,2,OTHER,Ali Shamseddine,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'compound 2055269'}, {'type': 'other', 'subtype': None, 'raw': 'mfolfox'}]",False,locally advanced rectal cancer,digestive
760,Israel,Metastatic Lung Cancer,DRUG: Antibiotics|OTHER: FMT (Fecal Microbiota Transplantation),2,OTHER,Soroka University Medical Center,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'antibiotics'}]",False,metastatic lung cancer,lung/thoracic
761,United States,Advanced Renal Cell Carcinoma,DRUG: Botensilimab|DRUG: Balstilimab|DRUG: Ipilimumab|DRUG: Nivolumab,2,OTHER,"Michael B. Atkins, MD","['checkpoint inhibitor', 'antibody']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'botensilimab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'balstilimab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}]",True,advanced renal cell carcinoma,genitourinary
762,United States,Colorectal Cancer|Pancreatic Cancer,DRUG: KRAS Vaccine with Poly-ICLC adjuvant|DRUG: Balstilimab|DRUG: Botensilimab,1,OTHER,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,"['vaccine', 'antibody']","[{'type': 'vaccine', 'subtype': 'vaccine', 'raw': 'kras vaccine with poly-iclc adjuvant'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'balstilimab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'botensilimab'}]",True,colorectal cancer pancreatic cancer,digestive
763,Italy,Triple Negative Breast Cancer Metastatic,DRUG: Ceralasertib|DRUG: Durvalumab|DRUG: Nab-paclitaxel,2,OTHER,IFOM ETS - The AIRC Institute of Molecular Oncology,"['checkpoint inhibitor', 'targeted therapy', 'chemotherapy']","[{'type': 'targeted therapy', 'subtype': 'ATR inhibitor', 'raw': 'ceralasertib'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'nab-paclitaxel'}]",True,triple negative breast cancer metastatic,breast
764,Australia,Extensive-Stage Small-Cell Lung Cancer,RADIATION: Thoracic Radiotherapy|DRUG: Etoposide with Carboplatin or Cisplatin|DRUG: Durvalumab,2,OTHER,Trans Tasman Radiation Oncology Group,"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'etoposide with carboplatin or cisplatin'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}]",True,extensive stage small cell lung cancer,lung/thoracic
765,United States,Small Cell Carcinoma of the Bladder|High Grade Neuroendocrine Tumors of the Urinary Tract,DRUG: Lurbinectedin|DRUG: Avelumab,2,NIH,National Cancer Institute (NCI),"['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'lurbinectedin'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'avelumab'}]",True,small cell carcinoma of the bladder high grade neuroendocrine tumors of the urinary tract,genitourinary
766,United States,Colorectal Cancer|Pancreatic Cancer,DRUG: KRAS peptide vaccine|DRUG: Nivolumab|DRUG: Ipilimumab,1,OTHER,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,"['checkpoint inhibitor', 'vaccine']","[{'type': 'vaccine', 'subtype': 'vaccine', 'raw': 'kras peptide vaccine'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}]",True,colorectal cancer pancreatic cancer,digestive
767,France,Lung Cancer Metastatic|Renal Cell Carcinoma|Head and Neck Cancer|Triple Negative Breast Cancer|Merkel Cell Carcinoma|Hepatocellular Carcinoma|Melanoma|Urothelial Carcinoma|Colorectal Carcinoma With Microsatellite Instability|Esophageal Squamous Cell Carcinoma|Endometrial Carcinoma|Cervical Cancer|Gastric/Gastro-esophageal Junction/Esophageal Adenocarcinoma|Basal Cell Carcinoma|Squamous Skin Carcinoma,DRUG: Reduced dose intensity of IO,3,OTHER,UNICANCER,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'reduced dose intensity of io'}]",False,lung cancer metastatic renal cell carcinoma head and neck cancer triple negative breast cancer merkel cell carcinoma hepatocellular carcinoma melanoma urothelial carcinoma colorectal carcinoma with microsatellite instability esophageal squamous cell carcinoma endometrial carcinoma cervical cancer gastric gastro esophageal junction esophageal adenocarcinoma basal cell carcinoma squamous skin carcinoma,gynecologic
768,"Canada, Japan, Puerto Rico, Republic of, United States",Endometrial Clear Cell Adenocarcinoma|Endometrial Dedifferentiated Carcinoma|Endometrial Endometrioid Adenocarcinoma|Endometrial Mixed Cell Adenocarcinoma|Endometrial Serous Adenocarcinoma|Endometrial Undifferentiated Carcinoma|Recurrent Endometrial Adenocarcinoma|Recurrent Endometrial Carcinoma|Recurrent Endometrial Clear Cell Adenocarcinoma|Recurrent Endometrial Dedifferentiated Carcinoma|Recurrent Endometrial Endometrioid Adenocarcinoma|Recurrent Endometrial Mixed Cell Adenocarcinoma|Recurrent Endometrial Serous Adenocarcinoma|Recurrent Endometrial Undifferentiated Carcinoma|Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8|Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8,DRUG: Carboplatin|PROCEDURE: Computed Tomography|DRUG: Paclitaxel|BIOLOGICAL: Pembrolizumab|OTHER: Placebo Administration|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration,3,NIH,National Cancer Institute (NCI),"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",True,endometrial clear cell adenocarcinoma endometrial dedifferentiated carcinoma endometrial endometrioid adenocarcinoma endometrial mixed cell adenocarcinoma endometrial serous adenocarcinoma endometrial undifferentiated carcinoma recurrent endometrial adenocarcinoma recurrent endometrial carcinoma recurrent endometrial clear cell adenocarcinoma recurrent endometrial dedifferentiated carcinoma recurrent endometrial endometrioid adenocarcinoma recurrent endometrial mixed cell adenocarcinoma recurrent endometrial serous adenocarcinoma recurrent endometrial undifferentiated carcinoma stage iii uterine corpus carcinoma or carcinosarcoma ajcc v8 stage iv uterine corpus carcinoma or carcinosarcoma ajcc v8,gynecologic
769,China,Small Cell Lung Cancer,DRUG: Serplulimab,2,OTHER,Peking Union Medical College Hospital,['antibody'],"[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'serplulimab'}]",False,small cell lung cancer,lung/thoracic
770,China,Nasopharyngeal Carcinoma|Nasopharyngeal Cancer,DRUG: Adebrelimab,2,OTHER,Sun Yat-sen University,['antibody'],"[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'adebrelimab'}]",False,nasopharyngeal carcinoma nasopharyngeal cancer,head/neck
771,"Republic of, Taiwan, United States","Carcinoma, Non-Small-Cell Lung",BIOLOGICAL: Oleclumab|DRUG: Osimertinib|DRUG: AZD4635,12,INDUSTRY,MedImmune LLC,"['other', 'antibody', 'kinase inhibitor']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'oleclumab'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'osimertinib'}, {'type': 'other', 'subtype': None, 'raw': 'azd4635'}]",True,carcinoma non small cell lung,lung/thoracic
772,"Taiwan, United States","Hepatocellular Carcinoma|Liver Cancer, Adult|Liver Neoplasm|Metastatic Liver Cancer","BIOLOGICAL: ECT204 T cells|DRUG: Regorafenib (STIVARGA®, BAY73-4506)",2,INDUSTRY,Eureka Therapeutics Inc.,"['kinase inhibitor', 'cell therapy']","[{'type': 'cell therapy', 'subtype': 'other', 'raw': 'ect204 t cells'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'regorafenib'}]",True,hepatocellular carcinoma liver cancer adult liver neoplasm metastatic liver cancer,digestive
773,United States,"Renal Cell Carcinoma (RCC)|Clear Cell Renal Cell Carcinoma (ccRCC)|Kidney Cancer|Renal Cancer|Renal Cell Carcinoma|Renal Cell Cancer Metastatic|Renal Cell Carcinoma Recurrent|Renal Cell Cancer, Recurrent|Kidney",DRUG: Belzutifan|DRUG: Cabozantinib,2,INDUSTRY,"Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","['targeted therapy', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'belzutifan'}, {'type': 'targeted therapy', 'subtype': 'other', 'raw': 'cabozantinib'}]",True,renal cell carcinoma clear cell renal cell carcinoma kidney cancer renal cancer renal cell carcinoma renal cell cancer metastatic renal cell carcinoma recurrent renal cell cancer recurrent kidney,genitourinary
774,United States,Non Small Cell Lung Cancer,BIOLOGICAL: Aglatimagene besadenovec,2,INDUSTRY,"Candel Therapeutics, Inc.",['gene therapy'],"[{'type': 'gene therapy', 'subtype': 'adenoviral vector', 'raw': 'aglatimagene besadenovec'}]",False,non small cell lung cancer,lung/thoracic
775,"Australia, Austria, Belgium, Canada, France, Italy, Spain, United Kingdom, United States",Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)|Solid Organ Transplant Complications|Lymphoproliferative Disorders|Allogeneic Hematopoietic Cell Transplant|Stem Cell Transplant Complications,BIOLOGICAL: tabelecleucel,3,INDUSTRY,Pierre Fabre Medicament,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'tabelecleucel'}]",False,epstein barr virus associated post transplant lymphoproliferative disease solid organ transplant complications lymphoproliferative disorders allogeneic hematopoietic cell transplant stem cell transplant complications,other
776,France,Pancreatic Adenocarcinoma|Ampulla of Vater Carcinoma|Adrenocortical Carcinoma|Neuroendocrine Carcinoma|Soft Tissue Sarcoma|Small Bowel Adenocarcinoma|Duodenum Adenocarcinoma|Gastric Adenocarcinoma,DRUG: Dostarlimab|DRUG: Chemotherapy,2,OTHER,UNICANCER,"['antibody', 'chemotherapy']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'dostarlimab'}, {'type': 'chemotherapy', 'subtype': 'unspecified', 'raw': 'chemotherapy'}]",True,pancreatic adenocarcinoma ampulla of vater carcinoma adrenocortical carcinoma neuroendocrine carcinoma soft tissue sarcoma small bowel adenocarcinoma duodenum adenocarcinoma gastric adenocarcinoma,digestive
777,United States,Lung Non-Small Cell Carcinoma|Stage II Lung Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIB Lung Cancer AJCC v8,PROCEDURE: Biospecimen Collection|DRUG: Ceralasertib|PROCEDURE: Computed Tomography|BIOLOGICAL: Durvalumab|PROCEDURE: Echocardiography Test,3,NIH,National Cancer Institute (NCI),"['checkpoint inhibitor', 'targeted therapy']","[{'type': 'targeted therapy', 'subtype': 'ATR inhibitor', 'raw': 'ceralasertib'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}]",True,lung non small cell carcinoma stage ii lung cancer ajcc v8 stage iiia lung cancer ajcc v8 stage iiib lung cancer ajcc v8,lung/thoracic
778,Hong Kong,HCC,PROCEDURE: TACE|RADIATION: SBRT|DRUG: Durvalumab|DRUG: Tremelimumab,2,OTHER,The University of Hong Kong,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'tremelimumab'}]",False,hcc,other
779,United States,"Non Small Cell Lung Cancer|NSCLC, Stage III|Nsclc",DRUG: Durvalumab|DRUG: Carboplatin|DRUG: Pemetrexed|DRUG: Paclitaxel|DRUG: Cisplatin|DEVICE: AVENIO ctDNA Surveillance Kit|DRUG: Tremelimumab,3,OTHER,Maximilian Diehn,"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'chemotherapy', 'subtype': 'antifolate', 'raw': 'pemetrexed'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'tremelimumab'}]",True,non small cell lung cancer nsclc stage iii nsclc,lung/thoracic
780,United States,Pancreatic Cancer|Adenocarcinoma of the Pancreas|Adenocarcinoma,DRUG: Motixafortide|DRUG: Cemiplimab|DRUG: Gemcitabine|DRUG: Nab paclitaxel,2,OTHER,Gulam Manji,"['checkpoint inhibitor', 'other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'motixafortide'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'cemiplimab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'gemcitabine'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'nab paclitaxel'}]",True,pancreatic cancer adenocarcinoma of the pancreas adenocarcinoma,digestive
781,China,Non-small Cell Lung Cancer Stage III,DRUG: Sintilimab|DRUG: Chemotherapy,2,OTHER,"Shanghai Pulmonary Hospital, Shanghai, China","['antibody', 'chemotherapy']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'sintilimab'}, {'type': 'chemotherapy', 'subtype': 'unspecified', 'raw': 'chemotherapy'}]",True,non small cell lung cancer stage iii,lung/thoracic
782,United States,"Relapsed/Refractory AML|AML, Adult|MDS|Refractory Myelodysplastic Syndromes",BIOLOGICAL: NKX101 - CAR NK cell therapy,1,INDUSTRY,"Nkarta, Inc.",['cell therapy'],"[{'type': 'cell therapy', 'subtype': 'other', 'raw': 'nkx101 - car nk cell therapy'}]",False,relapsed refractory aml aml adult mds refractory myelodysplastic syndromes,hematologic
783,United States,Melanoma,BIOLOGICAL: Escalating Doses,1,OTHER,Loyola University,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'escalating doses'}]",False,melanoma,skin
784,"Australia, Republic of, United States",Renal Cell Carcinoma,BIOLOGICAL: Pexastimogene Devacirepvec (Pexa-Vec)|BIOLOGICAL: Cemiplimab,12,INDUSTRY,"SillaJen, Inc.","['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'pexastimogene devacirepvec'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'cemiplimab'}]",True,renal cell carcinoma,genitourinary
785,United States,"Anemia, Iron Deficiency|Melanoma",DRUG: Iron dextran 1000 mg IV,2,OTHER,Indiana University,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'iron dextran 1000'}]",False,anemia iron deficiency melanoma,skin
786,China,Rectal Cancer|Advanced Stage Colorectal Cancer|Radiotherapy,DRUG: Adebrelimab Injection combined with radiotherapy and chemotherapy,2,OTHER_GOV,Feng Tian,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'adebrelimab injection combined with radiotherapy and chemotherapy'}]",False,rectal cancer advanced stage colorectal cancer radiotherapy,digestive
787,Netherlands,Urothelial Carcinoma,DRUG: Avelumab,2,OTHER,Erasmus Medical Center,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'avelumab'}]",False,urothelial carcinoma,genitourinary
788,China,Hepatic Carcinoma,DRUG: Sintilimab|PROCEDURE: Microwave Ablation|PROCEDURE: TACE,1,OTHER,Shanghai Zhongshan Hospital,['antibody'],"[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'sintilimab'}]",False,hepatic carcinoma,other
789,United States,Spine Metastases,RADIATION: Prophylactic Radiotherapy|DRUG: Standard of care systemic therapy,12,OTHER,Baptist Health South Florida,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'standard of care systemic therapy'}]",False,spine metastases,other
790,United States,Melanoma|Melanoma Stage III,DIAGNOSTIC_TEST: PET Scan|DRUG: Nivolumab|DRUG: Ipilimumab|PROCEDURE: Surgical Resection of Melanoma,2,OTHER,Memorial Sloan Kettering Cancer Center,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}]",False,melanoma melanoma stage iii,skin
791,United States,Breast Carcinoma|Colorectal Carcinoma,PROCEDURE: Biopsy|PROCEDURE: Biospecimen Collection|PROCEDURE: Bone Scan|PROCEDURE: Computed Tomography|DRUG: Immunotherapy|PROCEDURE: Magnetic Resonance Imaging|PROCEDURE: Positron Emission Tomography|RADIATION: Stereotactic Body Radiation Therapy,1,OTHER,City of Hope Medical Center,['immunotherapy'],"[{'type': 'immunotherapy', 'subtype': 'unspecified', 'raw': 'immunotherapy'}]",False,breast carcinoma colorectal carcinoma,digestive
792,China,Locally Advanced Head and Neck Squamous Cell Carcinoma,DRUG: immunotherapy：pembrolizumab；chemo：albumin-bound paclitaxel and cisplatin,12,OTHER,Ruijin Hospital,['chemotherapy'],"[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'immunotherapy：pembrolizumab；chemo：albumin-bound paclitaxel and cisplatin'}]",False,locally advanced head and neck squamous cell carcinoma,head/neck
793,Germany,Non-small Cell Lung Cancer,DRUG: Atezolizumab|DRUG: Tiragolumab,2,OTHER,Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest,"['checkpoint inhibitor', 'antibody']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'atezolizumab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'tiragolumab'}]",True,non small cell lung cancer,lung/thoracic
794,France,Metastatic Non Small Cell Lung Cancer|Metastatic Bladder Cancer|Metastatic Renal Cell Carcinoma|Metastatic Head and Neck Cancer,DRUG: Atezolizumab 60 MG/1 ML Intravenous Solution [TECENTRIQ]|DRUG: Tiragolumab|RADIATION: Stereotactic body radiation therapy (SBRT),1,OTHER,Centre Georges Francois Leclerc,"['checkpoint inhibitor', 'other', 'antibody']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'atezolizumab 60'}, {'type': 'other', 'subtype': None, 'raw': '1 intravenous solution [tecentriq]'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'tiragolumab'}]",True,metastatic non small cell lung cancer metastatic bladder cancer metastatic renal cell carcinoma metastatic head and neck cancer,genitourinary
795,China,Non-small Cell Lung Cancer Metastatic|First-line Treatment,BIOLOGICAL: CIK cells injection|DRUG: Sintilimab Injection|DRUG: Pemetrexed|DRUG: Albumin paclitaxel|DRUG: Carboplatin,2,OTHER,Tianjin Medical University Cancer Institute and Hospital,"['other', 'chemotherapy', 'cell therapy']","[{'type': 'cell therapy', 'subtype': 'other', 'raw': 'cik cells injection'}, {'type': 'other', 'subtype': None, 'raw': 'sintilimab injection'}, {'type': 'chemotherapy', 'subtype': 'antifolate', 'raw': 'pemetrexed'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'albumin paclitaxel'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}]",True,non small cell lung cancer metastatic first line treatment,lung/thoracic
796,China,Adenocarcinoma|Stomach Neoplasm|Gastroesophageal-junction Cancer|Oligometastatic Disease|Metastatic Cancer|Metastatic Gastric Cancer|Adenocarcinoma of the Stomach|Gastroesophageal Junction Adenocarcinoma|Metastatic Adenocarcinoma,RADIATION: Radiotherapy targeted to the primary lesion|RADIATION: Radiotherapy targeted to the metastatic lesions|BIOLOGICAL: Anti-PD-1 monoclonal antibody|BIOLOGICAL: Trastuzumab|DRUG: Chemotherapy|PROCEDURE: R0 total/subtotal gastrectomy with D2 lymphadenectomy|PROCEDURE: Metastasectomy|PROCEDURE: Local ablative therapies,2,OTHER,Fudan University,"['checkpoint inhibitor', 'antibody', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'anti-pd-1 monoclonal antibody'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'trastuzumab'}, {'type': 'chemotherapy', 'subtype': 'unspecified', 'raw': 'chemotherapy'}]",True,adenocarcinoma stomach neoplasm gastroesophageal junction cancer oligometastatic disease metastatic cancer metastatic gastric cancer adenocarcinoma of the stomach gastroesophageal junction adenocarcinoma metastatic adenocarcinoma,digestive
797,United States,Advanced Non-Small Cell Lung Cancer|Squamous Cell Carcinoma|Advanced NSCLC|Adenosquamous Carcinoma|Adenocarcinoma,DRUG: Aldesleukin|DRUG: Fludarabine|DRUG: Cyclophosphamide|BIOLOGICAL: Young TIL,2,NIH,National Cancer Institute (NCI),"['other', 'cytokine therapy', 'chemotherapy']","[{'type': 'cytokine therapy', 'subtype': 'IL-2', 'raw': 'aldesleukin'}, {'type': 'chemotherapy', 'subtype': 'purine analog', 'raw': 'fludarabine'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide'}, {'type': 'other', 'subtype': None, 'raw': 'young til'}]",True,advanced non small cell lung cancer squamous cell carcinoma advanced nsclc adenosquamous carcinoma adenocarcinoma,lung/thoracic
798,United States,Non Small Cell Lung Cancer,DRUG: N-803 + Pembrolizumab|DRUG: N-803 + Carboplatin + Nab-paclitaxel + Pembrolizumab|DRUG: N-803 + Cisplatin or Carboplatin + Pembrolizumab + Pemetrexed|DRUG: Pembrolizumab|DRUG: Carboplatin + Nab-paclitaxel or Paclitaxel + Pembrolizumab|DRUG: Cisplatin or Carboplatin + Pembrolizumab + Pemetrexed|DRUG: N-803 + Carboplatin + Nab-paclitaxel + Ipilimumab + Nivolumab,3,INDUSTRY,"ImmunityBio, Inc.","['checkpoint inhibitor', 'cytokine therapy', 'chemotherapy']","[{'type': 'cytokine therapy', 'subtype': 'IL-15 superagonist', 'raw': 'n-803'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'cytokine therapy', 'subtype': 'IL-15 superagonist', 'raw': 'n-803'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'nab-paclitaxel'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'cytokine therapy', 'subtype': 'IL-15 superagonist', 'raw': 'n-803'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin or carboplatin'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'chemotherapy', 'subtype': 'antifolate', 'raw': 'pemetrexed'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'nab-paclitaxel or paclitaxel'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin or carboplatin'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'chemotherapy', 'subtype': 'antifolate', 'raw': 'pemetrexed'}, {'type': 'cytokine therapy', 'subtype': 'IL-15 superagonist', 'raw': 'n-803'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'nab-paclitaxel'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}]",True,non small cell lung cancer,lung/thoracic
799,United States,Advanced Soft Tissue Sarcoma|Metastatic Soft Tissue Sarcoma,DRUG: Trabectedin|DRUG: Ipilimumab|DRUG: Nivolumab,12,OTHER,"Sarcoma Oncology Research Center, LLC","['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'trabectedin'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}]",True,advanced soft tissue sarcoma metastatic soft tissue sarcoma,sarcoma
800,United States,Metastatic Breast Cancer|Metastatic Gastrointestinal Carcinoma|HER2-positive Breast Cancer|HER2-positive Gastric Cancer|EGFR Overexpression,BIOLOGICAL: Combination of MVF-HER-2 (597-626) and MVF-HER-2 (266-296) emulsified with ISA 720,1,OTHER,Pravin T.P Kaumaya,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'combination of mvf-her-2 and mvf-her-2 emulsified with isa 720'}]",False,metastatic breast cancer metastatic gastrointestinal carcinoma her2 positive breast cancer her2 positive gastric cancer egfr overexpression,digestive
801,China,Nasopharyngeal Cancer,DRUG: Toripalimab|OTHER: Induction chemotherapy and concurrent chemoradiation,2,OTHER,Fudan University,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'toripalimab'}]",False,nasopharyngeal cancer,head/neck
802,United States,Breast Cancer,DRUG: Pembrolizumab|PROCEDURE: Core Biopsy/Cryoablation|PROCEDURE: Breast Surgery|DRUG: Ipilimumab|DRUG: Nivolumab,2,OTHER,University of Texas Southwestern Medical Center,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}]",False,breast cancer,breast
803,United States,Stage III Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer|Invasive Breast Carcinoma|Recurrent Breast Carcinoma|Triple-Negative Breast Carcinoma|Unresectable Breast Carcinoma,BIOLOGICAL: Anti-OX40 Antibody PF-04518600|DRUG: Avelumab|DRUG: Binimetinib|BIOLOGICAL: Utomilumab|DRUG: Liposomal Doxorubicin|DRUG: Sacituzumab Govitecan,2,OTHER,"Laura Huppert, MD, BA","['other', 'chemotherapy', 'kinase inhibitor', 'checkpoint inhibitor', 'antibody', 'antibody-drug conjugate']","[{'type': 'other', 'subtype': None, 'raw': 'anti-ox40 antibody pf-04518600'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'avelumab'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'binimetinib'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'utomilumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'liposomal doxorubicin'}, {'type': 'antibody-drug conjugate', 'subtype': 'anti-Trop-2', 'raw': 'sacituzumab govitecan'}]",True,stage iii breast cancer stage iiia breast cancer stage iiib breast cancer stage iiic breast cancer stage iv breast cancer invasive breast carcinoma recurrent breast carcinoma triple negative breast carcinoma unresectable breast carcinoma,breast
804,China,Triple Negative Breast Cancer,DRUG: Sintilimab|DRUG: Anlotinib|DRUG: Nab paclitaxel|DRUG: Carboplatin|DRUG: Epirubicin|DRUG: Cyclophosphamide,2,OTHER,Guangdong Provincial People's Hospital,"['antibody', 'chemotherapy', 'kinase inhibitor']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'sintilimab'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'anlotinib'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'nab paclitaxel'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'chemotherapy', 'subtype': 'anthracycline', 'raw': 'epirubicin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide'}]",True,triple negative breast cancer,breast
805,United States,Squamous Cell Carcinoma of the Head and Neck,DRUG: Intratumoral Ipilimumab,1,OTHER,Providence Health & Services,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}]",False,squamous cell carcinoma of the head and neck,head/neck
806,Italy,Breast Cancer|Triple Negative Breast Cancer|Dietary Exposure|Fasting,"DIETARY_SUPPLEMENT: Control diet (ARM A) or Fasting-Like Approach (FLA, ARM B)",2,OTHER,"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano",['other'],"[{'type': 'other', 'subtype': None, 'raw': 'dietary_supplement: control diet or fasting-like approach'}]",False,breast cancer triple negative breast cancer dietary exposure fasting,breast
807,United States,Recurrent Lung Non-Small Cell Carcinoma|Stage IV Lung Cancer AJCC v8,DRUG: Chemotherapy|BIOLOGICAL: Pembrolizumab|BIOLOGICAL: Ramucirumab,3,NETWORK,SWOG Cancer Research Network,"['checkpoint inhibitor', 'antibody', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'unspecified', 'raw': 'chemotherapy'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'ramucirumab'}]",True,recurrent lung non small cell carcinoma stage iv lung cancer ajcc v8,lung/thoracic
808,Italy,Glioblastoma Multiforme,DRUG: Temferon,12,INDUSTRY,Genenta Science,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'temferon'}]",False,glioblastoma multiforme,brain/CNS
809,"France, Spain",Melanoma,DRUG: BO-112 plus pembrolizumab|PROCEDURE: Tissue Biopsies,2,INDUSTRY,Highlight Therapeutics,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'bo-112 plus pembrolizumab'}]",False,melanoma,skin
810,United States,Cancer of the Head and Neck,DRUG: INCAGN01876|DRUG: INCMGA00012|BIOLOGICAL: DPV-001,1,OTHER,Providence Health & Services,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'incagn01876'}, {'type': 'other', 'subtype': None, 'raw': 'incmga00012'}, {'type': 'other', 'subtype': None, 'raw': 'dpv-001'}]",False,cancer of the head and neck,head/neck
811,United States,Microsatellite Stable (MSS) Colorectal Cancer (CRC)|Metastatic Colorectal Cancer (CRC)|Colorectal Cancer Stage IV,PROCEDURE: Pre-Treatment Biopsy|PROCEDURE: On-Treatment Biopsy|DRUG: Tiragolumab|DRUG: Atezolizumab|DRUG: Bevacizumab,2,OTHER,"University of Colorado, Denver","['checkpoint inhibitor', 'antibody']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'tiragolumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'atezolizumab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'bevacizumab'}]",True,microsatellite stable colorectal cancer metastatic colorectal cancer colorectal cancer stage iv,digestive
812,United States,Glioblastoma (GBM),BIOLOGICAL: DOC1021|PROCEDURE: Tumor resection|DRUG: Temodar (Temozolomide)|RADIATION: SOC cranial radiation,2,INDUSTRY,Diakonos Oncology Corporation,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'doc1021'}, {'type': 'other', 'subtype': None, 'raw': 'temodar'}]",False,glioblastoma,brain/CNS
813,"Australia, Austria, Belgium, Brazil, Canada, China, Czechia, France, Germany, Hong Kong, India, Italy, Japan, Malaysia, Netherlands, Philippines, Poland, Republic of, Saudi Arabia, Slovakia, Spain, Taiwan, Thailand, Turkey, United Kingdom, United States, Vietnam",Biliary Tract Cancer,DRUG: Gemcitabine|DRUG: Cisplatin|DRUG: Durvalumab|DRUG: Trastuzumab deruxtecan|DRUG: Rilvegostomig|DIAGNOSTIC_TEST: Agilent HercepTest™ mAb pharmDx|DIAGNOSTIC_TEST: Ventana PD-L1 SP263 assay,3,INDUSTRY,AstraZeneca,"['checkpoint inhibitor', 'other', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'gemcitabine'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}, {'type': 'other', 'subtype': None, 'raw': 'trastuzumab deruxtecan'}, {'type': 'checkpoint inhibitor', 'subtype': 'PD-1/CTLA-4 bispecific', 'raw': 'rilvegostomig'}]",True,biliary tract cancer,digestive
814,,Melanoma,BIOLOGICAL: pembrolizumab|DRUG: placebo,3,INDUSTRY,Merck Sharp & Dohme LLC,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",False,melanoma,skin
815,"Australia, United States","Lymphoma, Non-Hodgkin|B-cell Acute Lymphoblastic Leukemia|Large B-cell Lymphoma|Mantle Cell Lymphoma|Indolent Lymphoma|Waldenstrom Macroglobulinemia|Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma|Aggressive Lymphoma|Large-cell Lymphoma",BIOLOGICAL: NKX019,1,INDUSTRY,"Nkarta, Inc.",['other'],"[{'type': 'other', 'subtype': None, 'raw': 'nkx019'}]",False,lymphoma non hodgkin b cell acute lymphoblastic leukemia large b cell lymphoma mantle cell lymphoma indolent lymphoma waldenstrom macroglobulinemia chronic lymphocytic leukemia small lymphocytic lymphoma aggressive lymphoma large cell lymphoma,hematologic
816,China,Metastatic Triple-negative Breast Cancer,DRUG: trop2-ADC|DRUG: ADC +anti-angiogenic drug|DRUG: ADC + PD1 monoclonal antibody +anti-angiogenic drug,2,OTHER,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'trop2-adc'}, {'type': 'other', 'subtype': None, 'raw': 'adc'}, {'type': 'other', 'subtype': None, 'raw': 'anti-angiogenic drug'}, {'type': 'other', 'subtype': None, 'raw': 'adc'}, {'type': 'other', 'subtype': None, 'raw': 'pd1 monoclonal antibody'}, {'type': 'other', 'subtype': None, 'raw': 'anti-angiogenic drug'}]",False,metastatic triple negative breast cancer,breast
817,United States,Metastatic Melanoma,DRUG: High Dose Interleukin-2 (IL-2)|PROCEDURE: ACT with TIL Infusion|DRUG: Vemurafenib|DRUG: Lymphodepletion,2,OTHER,H. Lee Moffitt Cancer Center and Research Institute,"['other', 'kinase inhibitor']","[{'type': 'other', 'subtype': None, 'raw': 'high dose interleukin-2'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'vemurafenib'}, {'type': 'other', 'subtype': None, 'raw': 'lymphodepletion'}]",True,metastatic melanoma,skin
818,"Guam, United States",Lung Non-Small Cell Carcinoma|Lung Non-Small Cell Squamous Carcinoma|Lung Non-Squamous Non-Small Cell Carcinoma|Stage II Lung Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIB Lung Cancer AJCC v8,PROCEDURE: Biospecimen Collection|DRUG: Carboplatin|DRUG: Cisplatin|PROCEDURE: Computed Tomography|PROCEDURE: Echocardiography Test|DRUG: Gemcitabine Hydrochloride|PROCEDURE: Magnetic Resonance Imaging|OTHER: Observation Activity|DRUG: Paclitaxel|BIOLOGICAL: Pembrolizumab|DRUG: Pemetrexed Disodium|OTHER: Questionnaire Administration,3,NIH,National Cancer Institute (NCI),"['checkpoint inhibitor', 'other', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'gemcitabine hydrochloride'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'other', 'subtype': None, 'raw': 'pemetrexed disodium'}]",True,lung non small cell carcinoma lung non small cell squamous carcinoma lung non squamous non small cell carcinoma stage ii lung cancer ajcc v8 stage iiia lung cancer ajcc v8 stage iiib lung cancer ajcc v8,lung/thoracic
819,"Ireland, Puerto Rico, United Kingdom, United States","Metastatic Head and Neck Cancer|Recurrent Head and Neck Cancer|HPV Positive Oropharyngeal Squamous Cell Carcinoma|Neoplasms, Head and Neck",COMBINATION_PRODUCT: Pembrolizumab (KEYTRUDA®) and PDS0101,2,INDUSTRY,PDS Biotechnology Corp.,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab and pds0101'}]",False,metastatic head and neck cancer recurrent head and neck cancer hpv positive oropharyngeal squamous cell carcinoma neoplasms head and neck,head/neck
820,United States,Glioblastoma Multiforme of Brain,BIOLOGICAL: TVI-Brain-1|PROCEDURE: Standard of Care|RADIATION: Radiotherapy|DRUG: Temozolomide,23,INDUSTRY,TVAX Biomedical,"['other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'tvi-brain-1'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'temozolomide'}]",True,glioblastoma multiforme of brain,brain/CNS
821,China,Thymic Carcinoma,OTHER: Envolizumab combined with radiotherapy,2,OTHER,"Shanghai Pulmonary Hospital, Shanghai, China",['other'],"[{'type': 'other', 'subtype': None, 'raw': 'other: envolizumab combined with radiotherapy'}]",False,thymic carcinoma,other
822,United States,Breast Cancer,DRUG: HCQ|DRUG: Avelumab|DRUG: Palbociclib,2,OTHER,Abramson Cancer Center at Penn Medicine,"['checkpoint inhibitor', 'targeted therapy', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'hcq'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'avelumab'}, {'type': 'targeted therapy', 'subtype': 'CDK4/6 inhibitor', 'raw': 'palbociclib'}]",True,breast cancer,breast
823,China,Non Small Cell Lung Cancer|Perioperative Complication,DRUG: Modified Si Jun Zi Tang,2,OTHER,First Affiliated Hospital of Zhejiang University,['traditional medicine'],"[{'type': 'traditional medicine', 'subtype': None, 'raw': 'modified si jun zi tang'}]",False,non small cell lung cancer perioperative complication,lung/thoracic
824,United States,Newly Diagnosed MGMT Unmethylated Glioblastoma,DRUG: D2C7-IT|DRUG: 2141-V11,12,OTHER,Darell Bigner,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'd2c7-it'}, {'type': 'other', 'subtype': None, 'raw': '2141-v11'}]",False,newly diagnosed mgmt unmethylated glioblastoma,brain/CNS
825,United States,CD19+ Acute Leukemia,BIOLOGICAL: Patient Derived CD19 specific CAR T cells also expressing an EGFRt,12,OTHER,Seattle Children's Hospital,['cell therapy'],"[{'type': 'cell therapy', 'subtype': 'other', 'raw': 'patient derived cd19 specific car t cells also expressing an egfrt'}]",False,cd19 acute leukemia,hematologic
826,China,Breast Cancer Metastatic,DRUG: standard of care|RADIATION: radiotherapy + standard of care,3,OTHER,Chinese Academy of Medical Sciences,['non-therapeutic'],"[{'type': 'non-therapeutic', 'subtype': 'supportive', 'raw': 'standard of care'}]",False,breast cancer metastatic,breast
827,China,Toripalimab|Surufatinib|Chemoradiotherapy|Limited-stage Small Cell Lung Cancer (LS-SCLC),DRUG: Chemotherapy|DRUG: Immunotherapy|DRUG: Angio-immuno kinase inhibitor|RADIATION: radiotherapy|RADIATION: Prophylactic Cranial Irradiation|DRUG: Consolidation Therapy with Toripalimab and Surufatinib,2,OTHER,Sun Yat-sen University,"['checkpoint inhibitor', 'other', 'chemotherapy', 'immunotherapy']","[{'type': 'chemotherapy', 'subtype': 'unspecified', 'raw': 'chemotherapy'}, {'type': 'immunotherapy', 'subtype': 'unspecified', 'raw': 'immunotherapy'}, {'type': 'other', 'subtype': None, 'raw': 'angio-immuno kinase inhibitor'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'consolidation therapy with toripalimab and surufatinib'}]",True,toripalimab surufatinib chemoradiotherapy limited stage small cell lung cancer,lung/thoracic
828,China,High-Risk Localized Soft Tissue Sarcoma,DRUG: Pegylated Liposomal Doxorubicin|DRUG: Doxorubicin|DRUG: Anti-PD-1 monoclonal antibody|RADIATION: Radiotherapy,12,OTHER,Fudan University,"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'pegylated liposomal doxorubicin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'doxorubicin'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'anti-pd-1 monoclonal antibody'}]",True,high risk localized soft tissue sarcoma,sarcoma
829,Italy,Merkel Cell Carcinoma,DRUG: Retifanlimab|DRUG: Cisplatin|DRUG: Etoposide,2,OTHER,Gruppo Oncologico del Nord-Ovest,"['antibody', 'chemotherapy']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'retifanlimab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'etoposide'}]",True,merkel cell carcinoma,skin
830,"Puerto Rico, United States",Head and Neck Carcinoma|Adenoid Cystic Carcinoma|Lung Cancer|Non-Small Cell Lung Cancer|Breast Cancer|Pancreatic Cancer|Mesothelioma|Thymic Carcinoma|Cervical Cancer|Ovarian Cancer|Bladder Cancer|Esophageal Cancer|Uterine Cancer|Sarcoma|Any Solid Tumors Progressed After a Prior Immunotherapy|Thymoma|Appendiceal Cancer|Olfactory Neuroblastoma,DRUG: VMD-928 300 mg Tablet (ongoing); 100 mg Capsule (complete),1,INDUSTRY,"VM Oncology, LLC",['other'],"[{'type': 'other', 'subtype': None, 'raw': 'vmd-928 300 tablet ; 100 capsule'}]",False,head and neck carcinoma adenoid cystic carcinoma lung cancer non small cell lung cancer breast cancer pancreatic cancer mesothelioma thymic carcinoma cervical cancer ovarian cancer bladder cancer esophageal cancer uterine cancer sarcoma any solid tumors progressed after a prior immunotherapy thymoma appendiceal cancer olfactory neuroblastoma,gynecologic
831,"Australia, Belgium, Czechia, Denmark, France, Germany, Hungary, Israel, Italy, Netherlands, Poland, South Africa, Spain, Turkey, United Kingdom, United States",Metastatic Melanoma|Unresectable Melanoma,DRUG: IO102-IO103|DRUG: Pembrolizumab,3,INDUSTRY,IO Biotech,"['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'io102-io103'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",True,metastatic melanoma unresectable melanoma,skin
832,United States,Ovarian Cancer,DRUG: Pembrolizumab|DRUG: ALX148|DRUG: Doxorubicin,2,OTHER,"Alexander B Olawaiye, MD","['checkpoint inhibitor', 'other', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'other', 'subtype': None, 'raw': 'alx148'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'doxorubicin'}]",True,ovarian cancer,gynecologic
833,"Australia, China, Germany, Japan, Portugal, Republic of, Spain, Switzerland, Taiwan, United States",Prostate Cancer,DRUG: AMG 509|DRUG: Abiraterone|DRUG: Enzalutamide,1,INDUSTRY,Amgen,"['targeted therapy', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'amg 509'}, {'type': 'other', 'subtype': None, 'raw': 'abiraterone'}, {'type': 'targeted therapy', 'subtype': 'other', 'raw': 'enzalutamide'}]",True,prostate cancer,genitourinary
834,United States,Multiple Myeloma,DRUG: Elrantamab|DEVICE: clonoSEQ,2,OTHER,Washington University School of Medicine,['antibody'],"[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'elrantamab'}]",False,multiple myeloma,hematologic
835,"Australia, United States",Prostate Cancer,DRUG: STM-416p,1,INDUSTRY,SURGE Therapeutics,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'stm-416p'}]",False,prostate cancer,genitourinary
836,United States,Renal Cancer|Kidney Cancer|Renal Cell Carcinoma|Inferior Vena Cava Thrombosis,DRUG: Axitinib|DRUG: Pembrolizumab,2,OTHER,"University of Colorado, Denver","['checkpoint inhibitor', 'kinase inhibitor']","[{'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'axitinib'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",True,renal cancer kidney cancer renal cell carcinoma inferior vena cava thrombosis,genitourinary
837,Canada,Melanoma (Skin),DIETARY_SUPPLEMENT: C-PAN|BIOLOGICAL: Nivolumab|BIOLOGICAL: Ipilimumab,1,OTHER,"University Health Network, Toronto",['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}]",False,melanoma,skin
838,"France, Italy, Netherlands, Poland, Spain, Switzerland, United Kingdom, United States",Chronic Lymphocytic Leukemia (CLL)|Small Lymphocytic Lymphoma (SLL)|Diffuse Large B Cell Lymphoma (DLBCL)|Follicular Lymphoma (FL)|Mantle Cell Lymphoma (MCL)|Marginal Zone Lymphoma (MZL)|Waldenstrom Macroglobulinemia (WM)|Primary Central Nervous System Lymphoma (PCNSL)|Secondary Central Nervous System Lymphoma (SCNSL),DRUG: NX-5948,1,INDUSTRY,"Nurix Therapeutics, Inc.",['other'],"[{'type': 'other', 'subtype': None, 'raw': 'nx-5948'}]",False,chronic lymphocytic leukemia small lymphocytic lymphoma diffuse large b cell lymphoma follicular lymphoma mantle cell lymphoma marginal zone lymphoma waldenstrom macroglobulinemia primary central nervous system lymphoma secondary central nervous system lymphoma,hematologic
839,"Australia, Canada, China, France, Germany, Italy, Netherlands, Republic of, Spain, Taiwan, United Kingdom, United States",Metastatic Colorectal Cancer,"DRUG: Volrustomig|DRUG: FOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan)|DRUG: Bevacizumab",2,INDUSTRY,AstraZeneca,"['other', 'antibody', 'supportive care', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'volrustomig'}, {'type': 'other', 'subtype': None, 'raw': 'folfiri'}, {'type': 'supportive care', 'subtype': 'folinic acid', 'raw': 'leucovorin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'irinotecan)'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'bevacizumab'}]",True,metastatic colorectal cancer,digestive
840,France,Mesotheliomas Pleural|Malignant Pleural Mesothelioma,DEVICE: intrapleural photodynamic therapy with videothoracoscopy|DRUG: Nivolumab Injection,2,OTHER,"University Hospital, Lille",['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab injection'}]",False,mesotheliomas pleural malignant pleural mesothelioma,lung/thoracic
841,Poland,Small Cell Lung Carcinoma,RADIATION: Palliative Radiotherapy|RADIATION: Radical/Ablative Radiotherapy,2,OTHER,Copernicus Memorial Hospital,[],[],False,small cell lung carcinoma,lung/thoracic
842,United States,Metastatic Melanoma|Skin Cancer,DRUG: Ipilimumab|DRUG: Nivolumab|PROCEDURE: Cryoablation,2,OTHER,Massachusetts General Hospital,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}]",False,metastatic melanoma skin cancer,skin
843,"Italy, Netherlands, Spain, Switzerland, United Kingdom",Non-Small Cell Lung Cancer|Melanoma,RADIATION: Stereotactic radiosurgery|DRUG: Immune checkpoint inhibitor,3,NETWORK,ETOP IBCSG Partners Foundation,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'immune checkpoint inhibitor'}]",False,non small cell lung cancer melanoma,lung/thoracic
844,United States,Vulvar Cancer|Vulvar Squamous Cell Carcinoma,DRUG: Cisplatin|DRUG: Pembrolizumab|RADIATION: Radiation Therapy,2,OTHER,Massachusetts General Hospital,"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",True,vulvar cancer vulvar squamous cell carcinoma,gynecologic
845,United States,Head and Neck Cancer|Head and Neck Squamous Cell Carcinoma,DRUG: Pembrolizumab|RADIATION: Stereotactic Body Radiation Therapy (5 days)|PROCEDURE: Surgical Resection,2,OTHER,Providence Health & Services,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",False,head and neck cancer head and neck squamous cell carcinoma,head/neck
846,United States,Pancreatic Cancer|Adenocarcinoma of the Pancreas|Squamous Cell Carcinoma of Pancreas|Adenosquamous Carcinoma of the Pancreas,DRUG: ZIMBERELIMAB|DRUG: DOMVANALIMAB|DRUG: APX005M|DRUG: FOLFIRI,12,OTHER,"James Cleary, MD, PhD","['other', 'antibody']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'zimberelimab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'domvanalimab'}, {'type': 'other', 'subtype': None, 'raw': 'apx005m'}, {'type': 'other', 'subtype': None, 'raw': 'folfiri'}]",True,pancreatic cancer adenocarcinoma of the pancreas squamous cell carcinoma of pancreas adenosquamous carcinoma of the pancreas,digestive
847,China,Non-Small Cell Lung Cancer,DRUG: SHR-1701 Combined With Fluazopalil,2,OTHER,Hunan Province Tumor Hospital,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'shr-1701 combined with fluazopalil'}]",False,non small cell lung cancer,lung/thoracic
848,United States,NMIBC|High Risk NMIBC|Non Muscle Invasive Bladder Cancer,DRUG: ZH9,1,INDUSTRY,Prokarium Ltd,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'zh9'}]",False,nmibc high risk nmibc non muscle invasive bladder cancer,genitourinary
849,United States,"Head and Neck Cancer|Head and Neck Squamous Cell Carcinoma|Melanoma|Cell Cancer, Squamous|Carcinoma, Squamous Cell",DRUG: MEDI0562,1,OTHER,Providence Health & Services,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'medi0562'}]",False,head and neck cancer head and neck squamous cell carcinoma melanoma cell cancer squamous carcinoma squamous cell,skin
850,United States,Squamous Cell Carcinoma of the Head and Neck,DRUG: Nivolumab|DRUG: Lirilumab,2,OTHER,Dana-Farber Cancer Institute,"['checkpoint inhibitor', 'antibody']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'lirilumab'}]",True,squamous cell carcinoma of the head and neck,head/neck
851,United States,"Cancer of Head and Neck|Head and Neck Cancer|Neoplasms, Head and Neck|Carcinoma, Squamous Cell of Head and Neck|Squamous Cell Carcinoma of the Head and Neck|Squamous Cell Carcinoma, Head and Neck",BIOLOGICAL: MK-3475 (neoadjuvant)|PROCEDURE: Surgery|RADIATION: Intensity modulated radiation therapy|RADIATION: Image-guided radiation therapy|DRUG: Cisplatin|BIOLOGICAL: MK-3475 (adjuvant)|PROCEDURE: Peripheral blood,2,OTHER,Washington University School of Medicine,"['other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'mk-3475'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}, {'type': 'other', 'subtype': None, 'raw': 'mk-3475'}]",True,cancer of head and neck head and neck cancer neoplasms head and neck carcinoma squamous cell of head and neck squamous cell carcinoma of the head and neck squamous cell carcinoma head and neck,head/neck
852,"Belgium, Italy, Spain",Non-Squamous Non-Small Cell Lung Cancer (NSCLC)|Advanced Non Squamous NSCLC,DRUG: roginolisib|DRUG: Dostarlimab|DRUG: Docetaxel,12,INDUSTRY,iOnctura,"['other', 'antibody', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'roginolisib'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'dostarlimab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'docetaxel'}]",True,non squamous non small cell lung cancer advanced non squamous nsclc,lung/thoracic
853,Lebanon,Cancer|Solid Tumor|Thromboembolism|Cardiovascular Diseases|Immune System Diseases|Inflammatory Diseases|Colon Cancer|Breast Cancer|Prostate Cancer|Hepatocellular Carcinoma|Lung Cancer|Chemotherapy|Immunotherapy,DRUG: Palbociclib|DRUG: Rivaroxaban|GENETIC: SNP,1,OTHER,Lebanese University,"['targeted therapy', 'other']","[{'type': 'targeted therapy', 'subtype': 'CDK4/6 inhibitor', 'raw': 'palbociclib'}, {'type': 'other', 'subtype': None, 'raw': 'rivaroxaban'}]",True,cancer solid tumor thromboembolism cardiovascular diseases immune system diseases inflammatory diseases colon cancer breast cancer prostate cancer hepatocellular carcinoma lung cancer chemotherapy immunotherapy,genitourinary
854,United States,Small-cell Lung Cancer|Extensive-stage Small-cell Lung Cancer|Lung Cancer,RADIATION: Ablative Radiation|DRUG: Durvalumab|DRUG: Etoposide|DRUG: Carboplatin,2,OTHER,University of Chicago,"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'etoposide'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}]",True,small cell lung cancer extensive stage small cell lung cancer lung cancer,lung/thoracic
855,United States,Lung Cancer|Small-cell Lung Cancer|Non Small Cell Lung Cancer,DRUG: Carboplatin|DRUG: Pemetrexed|DRUG: Paclitaxel|DRUG: Nab paclitaxel|DRUG: Docetaxel|DRUG: Gemcitabine|DRUG: Etoposide|DRUG: Irinotecan|DRUG: Topotecan|DRUG: Lurbinectedin,2,OTHER,Fox Chase Cancer Center,"['other', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'chemotherapy', 'subtype': 'antifolate', 'raw': 'pemetrexed'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'nab paclitaxel'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'docetaxel'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'gemcitabine'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'etoposide'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'irinotecan'}, {'type': 'other', 'subtype': None, 'raw': 'topotecan'}, {'type': 'other', 'subtype': None, 'raw': 'lurbinectedin'}]",True,lung cancer small cell lung cancer non small cell lung cancer,lung/thoracic
856,United States,Pancreatic Cancer,DRUG: Tislelizumab|DRUG: SX-682,2,OTHER,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,"['checkpoint inhibitor', 'targeted therapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'tislelizumab'}, {'type': 'targeted therapy', 'subtype': 'CXCR1/2 inhibitor', 'raw': 'sx-682'}]",True,pancreatic cancer,digestive
857,Italy,"NSCLC, Stage III",DRUG: Durvalumab,2,OTHER,Fondazione IRCCS Policlinico San Matteo di Pavia,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}]",False,nsclc stage iii,lung/thoracic
858,"Australia, Austria, Belgium, Czechia, Denmark, France, Greece, Hungary, Ireland, Israel, Italy, Norway, Poland, Portugal, Slovakia, Slovenia, Spain, Sweden, Switzerland, United Kingdom",Neuroblastoma,DRUG: Vincristine|DRUG: Aldesleukin|DRUG: ch14.18/CHO|DRUG: Carboplatin|DRUG: Etoposide|DRUG: Cisplatin|DRUG: Cyclophosphamide|DRUG: Doxorubicin|DRUG: G-CSF|DRUG: Busulfan|DRUG: Melphalan,3,OTHER,St. Anna Kinderkrebsforschung,"['other', 'cytokine therapy', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'vincristine'}, {'type': 'cytokine therapy', 'subtype': 'IL-2', 'raw': 'aldesleukin'}, {'type': 'other', 'subtype': None, 'raw': 'ch14.18'}, {'type': 'other', 'subtype': None, 'raw': 'cho'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'etoposide'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'doxorubicin'}, {'type': 'other', 'subtype': None, 'raw': '-csf'}, {'type': 'other', 'subtype': None, 'raw': 'busulfan'}, {'type': 'other', 'subtype': None, 'raw': 'melphalan'}]",True,neuroblastoma,other
859,Italy,Colorectal Cancer Metastatic|Microsatellite Stable Colorectal Carcinoma|Refractory Mismatch-repair-proficient (pMMR) Metastatic Colorectal Cancer,BIOLOGICAL: Autologous Dendritic Cell (DC) Vaccine,2,OTHER,Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS,['vaccine'],"[{'type': 'vaccine', 'subtype': 'vaccine', 'raw': 'autologous dendritic cell vaccine'}]",False,colorectal cancer metastatic microsatellite stable colorectal carcinoma refractory mismatch repair proficient metastatic colorectal cancer,digestive
860,United States,Stage IIB Non-Small Cell Lung Cancer|Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IIIC Non-Small Cell Lung Cancer,DEVICE: ViewRay MR-Linear Accelerator|RADIATION: Radiation therapy|DRUG: Paclitaxel|DRUG: Carboplatin AUC|BIOLOGICAL: Durvalumab,2,OTHER,Washington University School of Medicine,"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin auc'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}]",True,stage iib non small cell lung cancer stage iiia non small cell lung cancer stage iiib non small cell lung cancer stage iiic non small cell lung cancer,lung/thoracic
861,Australia,Melanoma|Brain Metastases,DRUG: Nivolumab|DRUG: Ipilimumab,2,OTHER,Melanoma Institute Australia,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}]",False,melanoma brain metastases,skin
862,United States,Metastatic Lung Non-Small Cell Squamous Carcinoma|Metastatic Lung Non-Squamous Non-Small Cell Carcinoma|Stage IIIB Lung Cancer AJCC v8|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8|Unresectable Lung Non-Small Cell Carcinoma|Unresectable Lung Non-Squamous Non-Small Cell Carcinoma,DRUG: Carboplatin|DRUG: Paclitaxel|DRUG: Pevonedistat,2,NIH,National Cancer Institute (NCI),"['other', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}, {'type': 'other', 'subtype': None, 'raw': 'pevonedistat'}]",True,metastatic lung non small cell squamous carcinoma metastatic lung non squamous non small cell carcinoma stage iiib lung cancer ajcc v8 stage iv lung cancer ajcc v8 stage iva lung cancer ajcc v8 stage ivb lung cancer ajcc v8 unresectable lung non small cell carcinoma unresectable lung non squamous non small cell carcinoma,lung/thoracic
863,China,Non-small Cell Lung Cancer,"DRUG: TQB2450 injection, docetaxel injection matching placebo, AL2846 capsules|DRUG: TQB2450 placebo, docetaxel injection, AL2846 matching placebo",3,INDUSTRY,"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","['other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'tqb2450 injection'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'docetaxel injection matching'}, {'type': 'other', 'subtype': None, 'raw': 'al2846 capsules'}, {'type': 'other', 'subtype': None, 'raw': 'tqb2450'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'docetaxel injection'}, {'type': 'other', 'subtype': None, 'raw': 'al2846 matching'}]",True,non small cell lung cancer,lung/thoracic
864,China,Hepatocellular Carcinoma|Immunotherapy|CAR|GPC3 Gene Inactivation|T Cell|Squamous Cell Lung Cancer,BIOLOGICAL: GPC3 and/or TGFβ targeting CAR-T cells,1,OTHER,Second Affiliated Hospital of Guangzhou Medical University,"['other', 'cell therapy']","[{'type': 'other', 'subtype': None, 'raw': 'gpc3 and'}, {'type': 'cell therapy', 'subtype': 'engineered cell', 'raw': 'or tgfβ targeting car-t cells'}]",True,hepatocellular carcinoma immunotherapy car gpc3 gene inactivation t cell squamous cell lung cancer,digestive
865,Austria,Oropharyngeal Squamous Cell Carcinoma (SCC),BIOLOGICAL: FluBHPVE6E7,1,INDUSTRY,BlueSky Immunotherapies GmbH,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'flubhpve6e7'}]",False,oropharyngeal squamous cell carcinoma,head/neck
866,China,Non-Small Cell Lung Cancer,DRUG: Benmelstobart,2,OTHER,"Shanghai Pulmonary Hospital, Shanghai, China",['other'],"[{'type': 'other', 'subtype': None, 'raw': 'benmelstobart'}]",False,non small cell lung cancer,lung/thoracic
867,China,Non Small Cell Lung Cancer Metastatic,DRUG: Pembrolizumab in Combination with Plinabulin and Docetaxel,2,OTHER,Peking Union Medical College Hospital,['chemotherapy'],"[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'pembrolizumab in combination with plinabulin and docetaxel'}]",False,non small cell lung cancer metastatic,lung/thoracic
868,China,Stage III Hepatocellular Cancer (CNLC Staging),DRUG: mFOLFOX7+Camrelizumab+Apatinib,2,OTHER,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,"['checkpoint inhibitor', 'other', 'kinase inhibitor']","[{'type': 'other', 'subtype': None, 'raw': 'mfolfox7'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'camrelizumab'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'apatinib'}]",True,stage iii hepatocellular cancer,digestive
869,United States,Clinical Stage I Gastric Cancer AJCC v8|Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage II Gastric Cancer AJCC v8|Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage III Gastric Cancer AJCC v8|Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IVA Gastric Cancer AJCC v8|Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Gastric Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma,BIOLOGICAL: Atezolizumab|PROCEDURE: Biospecimen Collection|DRUG: Capecitabine|PROCEDURE: Computed Tomography|DRUG: Docetaxel|PROCEDURE: Echocardiography Test|DRUG: Fluorouracil|DRUG: Leucovorin Calcium|PROCEDURE: Lymphadenectomy|PROCEDURE: Magnetic Resonance Imaging|DRUG: Oxaliplatin|PROCEDURE: Positron Emission Tomography|PROCEDURE: Surgical Procedure,2,NIH,National Cancer Institute (NCI),"['checkpoint inhibitor', 'other', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'atezolizumab'}, {'type': 'chemotherapy', 'subtype': 'fluoropyrimidine', 'raw': 'capecitabine'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'docetaxel'}, {'type': 'chemotherapy', 'subtype': 'antimetabolite', 'raw': 'fluorouracil'}, {'type': 'other', 'subtype': None, 'raw': 'leucovorin calcium'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'oxaliplatin'}]",True,clinical stage i gastric cancer ajcc v8 clinical stage i gastroesophageal junction adenocarcinoma ajcc v8 clinical stage ii gastric cancer ajcc v8 clinical stage ii gastroesophageal junction adenocarcinoma ajcc v8 clinical stage iii gastric cancer ajcc v8 clinical stage iii gastroesophageal junction adenocarcinoma ajcc v8 clinical stage iva gastric cancer ajcc v8 clinical stage iva gastroesophageal junction adenocarcinoma ajcc v8 gastric adenocarcinoma gastroesophageal junction adenocarcinoma,digestive
870,Israel,Non-small Cell Lung Cancer|Melanoma|Renal Cell Carcinoma,DRUG: BMC128|DRUG: Nivolumab,1,INDUSTRY,Biomica Ltd.,"['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'bmc128'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}]",True,non small cell lung cancer melanoma renal cell carcinoma,genitourinary
871,Denmark,Metastatic Melanoma,BIOLOGICAL: TILT-123|BIOLOGICAL: TIL|DRUG: Cyclophosphamide|DRUG: Fludarabine,1,INDUSTRY,TILT Biotherapeutics Ltd.,"['other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'tilt-123'}, {'type': 'other', 'subtype': None, 'raw': 'til'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide'}, {'type': 'chemotherapy', 'subtype': 'purine analog', 'raw': 'fludarabine'}]",True,metastatic melanoma,skin
872,Poland,High-Risk Neuroblastoma,COMBINATION_PRODUCT: Chemoimmunotherapy (Dinutuximab beta in combination with chemotherapy),1,OTHER,Jagiellonian University,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'chemoimmunotherapy'}]",False,high risk neuroblastoma,other
873,Australia,Metastatic Merkel Cell Carcinoma,DRUG: Avelumab|RADIATION: External Beam Radiation Therapy (EBRT)|RADIATION: Lutetium-177 (177Lu)-DOTATATE,12,OTHER,Melanoma and Skin Cancer Trials Limited,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'avelumab'}]",False,metastatic merkel cell carcinoma,skin
874,"Australia, Belgium, Brazil, Canada, China, Denmark, France, Germany, Hong Kong, India, Italy, Japan, Norway, Poland, Republic of, Spain, Taiwan, Thailand, Turkey, United Kingdom, United States",Biliary Tract Cancer,DRUG: Rilvegostomig|DRUG: Placebo|DRUG: Capecitabine|DRUG: Gemcitabine/Cisplatin|DRUG: S-1 [Tegafur/Oteracil/gimeracil],3,INDUSTRY,AstraZeneca,"['checkpoint inhibitor', 'other', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'PD-1/CTLA-4 bispecific', 'raw': 'rilvegostomig'}, {'type': 'chemotherapy', 'subtype': 'fluoropyrimidine', 'raw': 'capecitabine'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'gemcitabine'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}, {'type': 'other', 'subtype': None, 'raw': 's-1 [tegafur'}, {'type': 'other', 'subtype': None, 'raw': 'oteracil'}, {'type': 'other', 'subtype': None, 'raw': 'gimeracil]'}]",True,biliary tract cancer,digestive
875,China,Hypopharyngeal Carcinoma|Immunotherapy|Chemotherapy,DRUG: Docetaxel|DRUG: Cisplatin|DRUG: Capecitabine|DRUG: Camrelizumab,2,OTHER,Eye & ENT Hospital of Fudan University,"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'docetaxel'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}, {'type': 'chemotherapy', 'subtype': 'fluoropyrimidine', 'raw': 'capecitabine'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'camrelizumab'}]",True,hypopharyngeal carcinoma immunotherapy chemotherapy,hematologic
876,United States,Neuroblastoma,GENETIC: iC9-GD2 T Cells - frozen|GENETIC: iC9-GD2 T Cells - fresh|DRUG: Cytoxan|DRUG: Fludara|DRUG: Keytruda|GENETIC: iC9-GD2 T cells,1,OTHER,Baylor College of Medicine,"['other', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'alkylating agent', 'raw': 'cytoxan'}, {'type': 'other', 'subtype': None, 'raw': 'fludara'}, {'type': 'other', 'subtype': None, 'raw': 'keytruda'}]",True,neuroblastoma,other
877,United States,"B-Cell Chronic Lymphocytic Leukemia|Leukemia, Lymphocytic, Chronic, B-Cell|B-Lymphocytic Leukemia, Chronic",BIOLOGICAL: Autologous HuCD19 ( Anti-CD19)CAR T cells|DRUG: Cyclophosphamide|DRUG: Fludarabine|DRUG: Rituximab,12,NIH,National Cancer Institute (NCI),"['antibody', 'chemotherapy', 'cell therapy']","[{'type': 'cell therapy', 'subtype': 'other', 'raw': 'autologous hucd19 car t cells'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide'}, {'type': 'chemotherapy', 'subtype': 'purine analog', 'raw': 'fludarabine'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'rituximab'}]",True,b cell chronic lymphocytic leukemia leukemia lymphocytic chronic b cell b lymphocytic leukemia chronic,hematologic
878,China,Osteosarcoma,COMBINATION_PRODUCT: metastasectomy and pre-operative immunotherapy (gemcitabine and penpulimab ) and stereotactic body radiotherapy,2,OTHER,Ruijin Hospital,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'metastasectomy and pre-operative immunotherapy and stereotactic body radiotherapy'}]",False,osteosarcoma,sarcoma
879,United States,Solid Tumor|Non-Small Cell Lung Cancer|Head and Neck Cancer|Melanoma|Gastric Cancer|Renal Cell Carcinoma|Urothelial Carcinoma,DRUG: INBRX-106 - Hexavalent OX40 agonist antibody|DRUG: pembrolizumab 200 mg|DRUG: pembrolizumab 400 mg|DRUG: Carboplatin AUC-5|DRUG: Carboplatin AUC-6|DRUG: Pemetrexed 500 mg/m2|DRUG: Cisplatin 75mg/m2|DRUG: Paclitaxel 200mg/m2|DRUG: Nab paclitaxel 100mg/m2,12,INDUSTRY,"Inhibrx Biosciences, Inc","['checkpoint inhibitor', 'other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'inbrx-106 - hexavalent ox40 agonist antibody'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab 200'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab 400'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin auc-5'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin auc-6'}, {'type': 'other', 'subtype': None, 'raw': 'pemetrexed 500'}, {'type': 'other', 'subtype': None, 'raw': 'm2'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin 75mg'}, {'type': 'other', 'subtype': None, 'raw': 'm2'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel 200mg'}, {'type': 'other', 'subtype': None, 'raw': 'm2'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'nab paclitaxel 100mg'}, {'type': 'other', 'subtype': None, 'raw': 'm2'}]",True,solid tumor non small cell lung cancer head and neck cancer melanoma gastric cancer renal cell carcinoma urothelial carcinoma,genitourinary
880,United States,Lung Atypical Carcinoid Tumor|Lung Neuroendocrine Neoplasm|Lung Non-Small Cell Squamous Carcinoma|Minimally Invasive Lung Adenocarcinoma|Neuroendocrine Carcinoma|Recurrent Lung Adenocarcinoma|Recurrent Lung Large Cell Carcinoma|Recurrent Lung Non-Small Cell Carcinoma|Stage I Lung Cancer AJCC v8|Stage IA1 Lung Cancer AJCC v8|Stage IA2 Lung Cancer AJCC v8|Stage IA3 Lung Cancer AJCC v8|Stage IB Lung Cancer AJCC v8|Stage IIA Lung Cancer AJCC v8,BIOLOGICAL: Nivolumab|RADIATION: Stereotactic Body Radiation Therapy,2,OTHER,M.D. Anderson Cancer Center,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}]",False,lung atypical carcinoid tumor lung neuroendocrine neoplasm lung non small cell squamous carcinoma minimally invasive lung adenocarcinoma neuroendocrine carcinoma recurrent lung adenocarcinoma recurrent lung large cell carcinoma recurrent lung non small cell carcinoma stage i lung cancer ajcc v8 stage ia1 lung cancer ajcc v8 stage ia2 lung cancer ajcc v8 stage ia3 lung cancer ajcc v8 stage ib lung cancer ajcc v8 stage iia lung cancer ajcc v8,lung/thoracic
881,United States,Extensive Stage Small Cell Lung Cancer,DRUG: Cisplatin|DRUG: Carboplatin|DRUG: Etoposide|DRUG: Durvalumab|DRUG: Ceralasertib,2,OTHER,Muhammad Furqan,"['checkpoint inhibitor', 'targeted therapy', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'etoposide'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}, {'type': 'targeted therapy', 'subtype': 'ATR inhibitor', 'raw': 'ceralasertib'}]",True,extensive stage small cell lung cancer,lung/thoracic
882,China,Unresectable Non-small Cell Lung Cancer,DRUG: neoadjuvant therapy:Tislelizumab With Recombinant human endostatin combined with Chemotherapy|PROCEDURE: surgery|DRUG: Adjuvant therapy:Tislelizumab and Recombinant Human Endostatin Injection (Endostar)|OTHER: Standard Treatment,2,OTHER_GOV,Hua Zhang,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'neoadjuvant therapy:tislelizumab with recombinant human endostatin combined with chemotherapy'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'adjuvant therapy:tislelizumab and recombinant human endostatin injection'}]",False,unresectable non small cell lung cancer,lung/thoracic
883,United States,Melanoma,BIOLOGICAL: young TIL|DRUG: Pembrolizumab|DRUG: Aldesleukin|DRUG: Fludarabine|DRUG: Cyclophosphamide,2,NIH,National Cancer Institute (NCI),"['checkpoint inhibitor', 'other', 'cytokine therapy', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'young til'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'cytokine therapy', 'subtype': 'IL-2', 'raw': 'aldesleukin'}, {'type': 'chemotherapy', 'subtype': 'purine analog', 'raw': 'fludarabine'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide'}]",True,melanoma,skin
884,Denmark,Malignant Melanoma,DRUG: Pembrolizumab Injection [Keytruda]|DRUG: Ipilimumab Injection [Yervoy]|DRUG: Nivolumab Injection [Opdivo]|DRUG: Encorafenib|DRUG: Binimetinib|DRUG: Dabrafenib|DRUG: Trametinib,2,OTHER,Inge Marie Svane,"['checkpoint inhibitor', 'kinase inhibitor']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab injection [keytruda]'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab injection [yervoy]'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab injection [opdivo]'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'encorafenib'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'binimetinib'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'dabrafenib'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'trametinib'}]",True,malignant melanoma,skin
885,China,Renal Cell Carcinoma (Kidney Cancer)|Kidney Cancer Metastatic|Renal Cell Carcinoma Metastatic,"RADIATION: Stereotactic body radiotherapy (SBRT)|DRUG: axitinib ± immune checkpoint inhibitors (ICIs), lenvatinib ± ICIs, cabozantinib ± ICIs, sunitinib and pazopanib",3,OTHER,Sun Yat-sen University,"['targeted therapy', 'other', 'kinase inhibitor']","[{'type': 'other', 'subtype': None, 'raw': 'axitinib ± immune checkpoint inhibitors'}, {'type': 'targeted therapy', 'subtype': 'other', 'raw': 'lenvatinib ± icis'}, {'type': 'targeted therapy', 'subtype': 'other', 'raw': 'cabozantinib ± icis'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'sunitinib and pazopanib'}]",True,renal cell carcinoma kidney cancer metastatic renal cell carcinoma metastatic,genitourinary
886,China,"HR-positive,HER2-negative Breast Cancer",DRUG: TORIPALIMAB INJECTION(JS001 )|RADIATION: Stereotactic Body Radiation Therapy (SBRT),2,OTHER,First Affiliated Hospital of Zhejiang University,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'toripalimab injection'}]",False,hr positive her2 negative breast cancer,breast
887,United States,Cutaneous Squamous Cell Carcinoma|Skin Cancer|Squamous Cell Carcinoma|Locally Advanced Squamous Cell Carcinoma|Locally Advanced Squamous Cell Carcinoma of the Skin|Locally Advanced Cutaneous Squamous Cell Carcinoma|Locally Advanced Skin Squamous Cell Carcinoma,DRUG: Cemiplimab|RADIATION: Radiotherapy,2,OTHER,Memorial Sloan Kettering Cancer Center,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'cemiplimab'}]",False,cutaneous squamous cell carcinoma skin cancer squamous cell carcinoma locally advanced squamous cell carcinoma locally advanced squamous cell carcinoma of the skin locally advanced cutaneous squamous cell carcinoma locally advanced skin squamous cell carcinoma,skin
888,"Belarus, India, Russian Federation",Melanoma|Melanoma (Skin)|Melanoma Stage III|Melanoma Stage IV|Melanoma Unresectable|Melanoma Metastatic|Melanoma Advanced,BIOLOGICAL: BCD-217|BIOLOGICAL: BCD-100|BIOLOGICAL: Placebo,3,INDUSTRY,Biocad,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'bcd-217'}, {'type': 'other', 'subtype': None, 'raw': 'bcd-100'}]",False,melanoma melanoma melanoma stage iii melanoma stage iv melanoma unresectable melanoma metastatic melanoma advanced,skin
889,"Australia, United States",Prostate Cancer|High-risk Biochemical Recurrence|High Risk Biochemical Recurrence of Non-metastatic Castration-sensitive Prostate Cancer|Non-metastatic Castration-sensitive Prostate Cancer,DRUG: Xaluritamig,1,INDUSTRY,Amgen,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'xaluritamig'}]",False,prostate cancer high risk biochemical recurrence high risk biochemical recurrence of non metastatic castration sensitive prostate cancer non metastatic castration sensitive prostate cancer,genitourinary
890,Israel,Stage IV Pancreatic Cancer,DRUG: Nivolumab|DRUG: ipilimumab|RADIATION: Stereotactic body radiation therapy|RADIATION: Low dose irradiation,1,OTHER_GOV,Sheba Medical Center,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}]",False,stage iv pancreatic cancer,digestive
891,China,Locally Advanced Gastric Carcinoma,"DRUG: Oxaliplatin by arterial infusion plus S-1|DRUG: SOX neoadjuvant|DRUG: Sintilimab neoadjuvant|PROCEDURE: gastrectomy plus D2 lymph node dissection|DRUG: SOX adjuvant, Sequential S-1|DRUG: Sintilimab adjuvant",3,OTHER,Zhejiang University,"['other', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'oxaliplatin by arterial plus s-1'}, {'type': 'other', 'subtype': None, 'raw': 'sox neoadjuvant'}, {'type': 'other', 'subtype': None, 'raw': 'sintilimab neoadjuvant'}, {'type': 'other', 'subtype': None, 'raw': 'sox adjuvant'}, {'type': 'other', 'subtype': None, 'raw': 'sequential s-1'}, {'type': 'other', 'subtype': None, 'raw': 'sintilimab adjuvant'}]",True,locally advanced gastric carcinoma,digestive
892,China,Melanoma,"DRUG: tunlametinib|DRUG: paclitaxel +carboplatin, or temozolomide +cisplatin, or dacarbazine +cisplatin",3,INDUSTRY,"Shanghai Kechow Pharma, Inc.","['other', 'chemotherapy', 'kinase inhibitor']","[{'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'tunlametinib'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'or temozolomide'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}, {'type': 'other', 'subtype': None, 'raw': 'or dacarbazine'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}]",True,melanoma,skin
893,"Canada, Ireland, United States",Metastatic Renal Cell Carcinoma|Stage III Renal Cell Cancer AJCC v8|Stage IV Renal Cell Cancer AJCC v8|Unresectable Renal Cell Carcinoma,BIOLOGICAL: Avelumab|DRUG: Axitinib|PROCEDURE: Biospecimen Collection|PROCEDURE: Bone Scan|DRUG: Cabozantinib|PROCEDURE: Computed Tomography|BIOLOGICAL: Ipilimumab|DRUG: Lenvatinib|PROCEDURE: Magnetic Resonance Imaging|BIOLOGICAL: Nivolumab|BIOLOGICAL: Pembrolizumab|RADIATION: Stereotactic Ablative Radiotherapy,2,OTHER,NRG Oncology,"['checkpoint inhibitor', 'targeted therapy', 'kinase inhibitor']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'avelumab'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'axitinib'}, {'type': 'targeted therapy', 'subtype': 'other', 'raw': 'cabozantinib'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}, {'type': 'targeted therapy', 'subtype': 'other', 'raw': 'lenvatinib'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",True,metastatic renal cell carcinoma stage iii renal cell cancer ajcc v8 stage iv renal cell cancer ajcc v8 unresectable renal cell carcinoma,genitourinary
894,Singapore,Hepatocellular Carcinoma|Hepatocellular Cancer|Colorectal Cancer|Colorectal Carcinoma|Liver Metastases,BIOLOGICAL: Neoantigen Dendritic Cell Vaccine|DRUG: Nivolumab,2,OTHER,"National Cancer Centre, Singapore","['checkpoint inhibitor', 'vaccine']","[{'type': 'vaccine', 'subtype': 'vaccine', 'raw': 'neoantigen dendritic cell vaccine'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}]",True,hepatocellular carcinoma hepatocellular cancer colorectal cancer colorectal carcinoma liver metastases,digestive
895,United States,Nonsmall Cell Lung Cancer|Performance Status,"DRUG: Pembrolizumab|DRUG: Carboplatin|DRUG: Paclitaxel|DRUG: Nab paclitaxel|OTHER: Quality of Life Questionnaire, lung cancer-specific (QLQ-LC13)|OTHER: QLQ-C30 Global Health/Quality of Life Questionnaire|OTHER: COPD Assessment Test and modified Medical Research Council Dyspnea Patient Reported Outcomes|DRUG: Pemetrexed",2,OTHER,Wake Forest University Health Sciences,"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'nab paclitaxel'}, {'type': 'chemotherapy', 'subtype': 'antifolate', 'raw': 'pemetrexed'}]",True,nonsmall cell lung cancer performance status,lung/thoracic
896,United States,Urinary Bladder Cancer,DRUG: gemcitabine + docetaxel,2,OTHER,University of Arizona,['chemotherapy'],"[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'gemcitabine'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'docetaxel'}]",False,urinary bladder cancer,genitourinary
897,China,Locally Advanced Rectal Cancer,RADIATION: node-sparing short-course radiotherapy|DRUG: Sintilimab|DRUG: Capecitabine|DRUG: Oxaliplatin|PROCEDURE: TME surgery|PROCEDURE: watch and wait,2,OTHER,Jinhua Central Hospital,"['antibody', 'chemotherapy']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'sintilimab'}, {'type': 'chemotherapy', 'subtype': 'fluoropyrimidine', 'raw': 'capecitabine'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'oxaliplatin'}]",True,locally advanced rectal cancer,digestive
898,China,TNBC - Triple-Negative Breast Cancer,DRUG: LM-108|DRUG: Toripalimab|DRUG: Eribulin|DRUG: Nab paclitaxel,2,OTHER,Fudan University,"['checkpoint inhibitor', 'other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'lm-108'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'toripalimab'}, {'type': 'other', 'subtype': None, 'raw': 'eribulin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'nab paclitaxel'}]",True,tnbc triple negative breast cancer,breast
899,"Germany, Switzerland",Non-small Cell Lung Cancer|NSCLC,DRUG: Durvalumab|RADIATION: Radiotherapy,2,OTHER,Swiss Group for Clinical Cancer Research,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}]",False,non small cell lung cancer nsclc,lung/thoracic
900,China,Esophageal Squamous Cell Carcinoma|Oligometastatic Disease|Radiotherapy,COMBINATION_PRODUCT: PD-1 inhibitor+/- chemotherapy combined with local therapy|DRUG: systemic therapy alone,3,OTHER,Fudan University,"['checkpoint inhibitor', 'other']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'pd-1 inhibitor'}, {'type': 'other', 'subtype': None, 'raw': '- chemotherapy combined with local therapy'}, {'type': 'other', 'subtype': None, 'raw': 'systemic therapy alone'}]",True,esophageal squamous cell carcinoma oligometastatic disease radiotherapy,digestive
901,China,MCRC,"DRUG: Thymalfasin (Thymosin alpha 1, Ta1)|DRUG: Regorafenib (BAY 73-4506)|DRUG: Tislelizumab (BGB-A317)",2,OTHER,Beijing Friendship Hospital,"['checkpoint inhibitor', 'other', 'kinase inhibitor']","[{'type': 'other', 'subtype': None, 'raw': 'thymalfasin'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'regorafenib'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'tislelizumab'}]",True,mcrc,other
902,China,Rectal Adenocarcinoma|High-Risk Cancer|MSS,RADIATION: Short-Course Radiotherapy|DRUG: PD-1 monoclonal antibody|DRUG: mFOLFOX6 regimen|DRUG: Cetuximab|DRUG: Bevacizumab|PROCEDURE: Surgical resection,2,OTHER,"Sixth Affiliated Hospital, Sun Yat-sen University","['other', 'antibody']","[{'type': 'other', 'subtype': None, 'raw': 'pd-1 monoclonal antibody'}, {'type': 'other', 'subtype': None, 'raw': 'mfolfox6 regimen'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'cetuximab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'bevacizumab'}]",True,rectal adenocarcinoma high risk cancer mss,digestive
903,United States,"Kita-kyushu Lung Cancer Antigen 1, Human",DRUG: IL-2 (Aldesleukin)|DRUG: Cyclophosphamide|BIOLOGICAL: KK-LC-1 TCR|DRUG: Fludarabine,1,NIH,National Cancer Institute (NCI),"['cytokine therapy', 'chemotherapy', 'cell therapy']","[{'type': 'cytokine therapy', 'subtype': 'IL-2', 'raw': 'il-2'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide'}, {'type': 'cell therapy', 'subtype': 'engineered cell', 'raw': 'kk-lc-1 tcr'}, {'type': 'chemotherapy', 'subtype': 'purine analog', 'raw': 'fludarabine'}]",True,kita kyushu lung cancer antigen 1 human,lung/thoracic
904,United States,Diffuse Large B Cell Lymphoma (DLBCL),BIOLOGICAL: bbT369,12,INDUSTRY,Regeneron Pharmaceuticals,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'bbt369'}]",False,diffuse large b cell lymphoma,hematologic
905,"Australia, Brazil, Canada, France, Germany, Italy, Netherlands, Republic of, Spain, United States",Merkel Cell Carcinoma,DRUG: KRT-232|DRUG: Avelumab,12,INDUSTRY,"Kartos Therapeutics, Inc.","['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'krt-232'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'avelumab'}]",True,merkel cell carcinoma,skin
906,Netherlands,"Carcinoma, Non-Small-Cell Lung",DRUG: Durvalumab|RADIATION: low-dose PCI,3,OTHER,Association NVALT Studies,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}]",False,carcinoma non small cell lung,lung/thoracic
907,China,Head and Neck Cancer,DRUG: Toripalimab|RADIATION: Radiation Therapy|DRUG: Cisplatin,2,OTHER,Tianjin Medical University Cancer Institute and Hospital,"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'toripalimab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}]",True,head and neck cancer,head/neck
908,United States,Non-small Cell Lung Cancer Stage III,DRUG: Cemiplimab-Rwlc,2,OTHER,Georgetown University,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'cemiplimab-rwlc'}]",False,non small cell lung cancer stage iii,lung/thoracic
909,China,"Carcinoma, Non-Small-Cell Lung",RADIATION: SBRT|DRUG: Tislelizumab,2,OTHER,Sun Yat-sen University,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'tislelizumab'}]",False,carcinoma non small cell lung,lung/thoracic
910,United States,Non Small Cell Lung Cancer,RADIATION: Stereotactic radiation therapy|DRUG: Durvalumab,2,OTHER,University of Texas Southwestern Medical Center,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}]",False,non small cell lung cancer,lung/thoracic
911,"France, Italy, Japan, Republic of, Taiwan, United States",Pharmacokinetics of Zolbetuximab|Gastric Cancer|Gastro-esophageal Junction (GEJ) Cancer|Pharmacokinetics of Oxaliplatin|Pharmacokinetics of Fluorouracil Bolus (5-FU),DRUG: zolbetuximab|DRUG: oxaliplatin|DRUG: leucovorin|DRUG: fluorouracil|DRUG: Pembrolizumab|DRUG: folinic acid|DRUG: nivolumab|DRUG: Docetaxel,2,INDUSTRY,"Astellas Pharma Global Development, Inc.","['checkpoint inhibitor', 'antibody', 'supportive care', 'chemotherapy']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'zolbetuximab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'oxaliplatin'}, {'type': 'supportive care', 'subtype': 'folinic acid', 'raw': 'leucovorin'}, {'type': 'chemotherapy', 'subtype': 'antimetabolite', 'raw': 'fluorouracil'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'supportive care', 'subtype': 'rescue agent', 'raw': 'folinic acid'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'docetaxel'}]",True,pharmacokinetics of zolbetuximab gastric cancer gastro esophageal junction cancer pharmacokinetics of oxaliplatin pharmacokinetics of fluorouracil bolus,digestive
912,China,Advanced NSCLC,RADIATION: Radiotherapy|DRUG: PD-1 inhibitor|DRUG: Neoantigen-loaded DC vaccine,2,OTHER,The First Affiliated Hospital of Nanchang University,"['checkpoint inhibitor', 'vaccine']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'pd-1 inhibitor'}, {'type': 'vaccine', 'subtype': 'vaccine', 'raw': 'neoantigen-loaded dc vaccine'}]",True,advanced nsclc,lung/thoracic
913,United States,Glioblastoma,DRUG: INCMGA00012|DRUG: INCAGN01876|DRUG: SRS|PROCEDURE: Brain surgery,2,OTHER,University of Pennsylvania,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'incmga00012'}, {'type': 'other', 'subtype': None, 'raw': 'incagn01876'}, {'type': 'other', 'subtype': None, 'raw': 'srs'}]",False,glioblastoma,brain/CNS
914,United States,Metastatic Pancreatic Ductal Adenocarcinoma,DRUG: Botensilimab|DRUG: Gemcitabine|DRUG: Nab-paclitaxel,2,INDUSTRY,Agenus Inc.,"['antibody', 'chemotherapy']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'botensilimab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'gemcitabine'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'nab-paclitaxel'}]",True,metastatic pancreatic ductal adenocarcinoma,digestive
915,United States,Malignant Glioma of Brain|Astrocytoma|Malignant Astrocytoma|Oligodendroglioma|Anaplastic Oligodendroglioma of Brain (Diagnosis)|Mixed Oligo-Astrocytoma|Ependymoma|Ganglioglioma|Pylocytic/Pylomyxoid Astrocytoma|Brain Tumor|Glioma|Brain Cancer|Glioblastoma|Glioblastoma Multiforme,DRUG: rQNestin|DRUG: Cyclophosphamide|PROCEDURE: Stereotactic biopsy,1,OTHER,Dana-Farber Cancer Institute,"['other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'rqnestin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide'}]",True,malignant glioma of brain astrocytoma malignant astrocytoma oligodendroglioma anaplastic oligodendroglioma of brain mixed oligo astrocytoma ependymoma ganglioglioma pylocytic pylomyxoid astrocytoma brain tumor glioma brain cancer glioblastoma glioblastoma multiforme,brain/CNS
916,China,Multiple Myeloma,BIOLOGICAL: KQ-2003 CAR-T cells,12,OTHER,Shanxi Province Cancer Hospital,['cell therapy'],"[{'type': 'cell therapy', 'subtype': 'engineered cell', 'raw': 'kq-2003 car-t cells'}]",False,multiple myeloma,hematologic
917,United States,Lung Non-Small Cell Carcinoma|Pleural Disorder,DRUG: Porfimer Sodium|PROCEDURE: Video-Assisted Thoracic Surgery|DRUG: Photodynamic Therapy|DEVICE: Intraoperative PDT,1,OTHER,Roswell Park Cancer Institute,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'porfimer sodium'}, {'type': 'other', 'subtype': None, 'raw': 'photodynamic therapy'}]",False,lung non small cell carcinoma pleural disorder,lung/thoracic
918,Spain,Urothelial Bladder Carcinoma,DRUG: Sacituzumab govitecan|DRUG: Zimberelimab|DRUG: Domvanalimab,2,OTHER,Fundación para el Progreso de la Oncología en Cantabria,"['antibody-drug conjugate', 'antibody']","[{'type': 'antibody-drug conjugate', 'subtype': 'anti-Trop-2', 'raw': 'sacituzumab govitecan'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'zimberelimab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'domvanalimab'}]",True,urothelial bladder carcinoma,genitourinary
919,China,Head and Neck Cancer,BIOLOGICAL: Tislelizumab|DRUG: Afatinib,2,OTHER,West China Hospital,"['checkpoint inhibitor', 'kinase inhibitor']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'tislelizumab'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'afatinib'}]",True,head and neck cancer,head/neck
920,United States,Small Cell Lung Cancer|SCLC|Extensive Stage Small Cell Lung Cancer,DRUG: Durvalumab|DRUG: Monalizumab|DRUG: Carboplatin or Cisplatin|DRUG: Etoposide,2,OTHER,Hirva Mamdani,"['checkpoint inhibitor', 'antibody', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'monalizumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin or cisplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'etoposide'}]",True,small cell lung cancer sclc extensive stage small cell lung cancer,lung/thoracic
921,United States,Glioblastoma Multiforme,BIOLOGICAL: VBI-1901|DRUG: Carmustine|DRUG: Lomustine,12,INDUSTRY,VBI Vaccines Inc.,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'vbi-1901'}, {'type': 'other', 'subtype': None, 'raw': 'carmustine'}, {'type': 'other', 'subtype': None, 'raw': 'lomustine'}]",False,glioblastoma multiforme,brain/CNS
922,China,Locally Advanced Rectal Cancer (LARC)|Immunotherapy|Radiotherapy|Total Neoadjuvant Therapy|Anal Function Preservation,DRUG: Anti-PD-1 antibody drug named Serplulimab|RADIATION: Radiotherapy|DRUG: Chemotherapy,3,OTHER,West China Hospital,"['antibody', 'chemotherapy']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'anti-pd-1 antibody drug named serplulimab'}, {'type': 'chemotherapy', 'subtype': 'unspecified', 'raw': 'chemotherapy'}]",True,locally advanced rectal cancer immunotherapy radiotherapy total neoadjuvant therapy anal function preservation,digestive
923,United States,Metastatic Pancreatic Ductal Adenocarcinoma|Metastatic Pancreatic Cancer,RADIATION: Stereotactic Body Radiation Therapy|DRUG: Botensilimab|DRUG: Balstilimab,2,OTHER,Benjamin Spieler,['antibody'],"[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'botensilimab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'balstilimab'}]",False,metastatic pancreatic ductal adenocarcinoma metastatic pancreatic cancer,digestive
924,United States,Recurrent Glioblastoma IDH Wildtype,DRUG: D2C7-IT|DRUG: 2141 V11,1,OTHER,Darell Bigner,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'd2c7-it'}, {'type': 'other', 'subtype': None, 'raw': '2141 v11'}]",False,recurrent glioblastoma idh wildtype,brain/CNS
925,China,Non-small Cell Lung Cancer|Cardiovascular Complication,"DRUG: Multiple cardiovascular drugs related to ""Golden Triangle""",3,OTHER,Sun Yat-sen University,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'multiple cardiovascular drugs related to ""golden triangle""'}]",False,non small cell lung cancer cardiovascular complication,lung/thoracic
926,Russian Federation,Bone Sarcoma|Embryonal Rhabdomyosarcoma|Alveolar Rhabdomyosarcoma,DRUG: dinutuximab beta,3,OTHER,N.N. Petrov National Medical Research Center of Oncology,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'dinutuximab beta'}]",False,bone sarcoma embryonal rhabdomyosarcoma alveolar rhabdomyosarcoma,sarcoma
927,China,Advanced NSCLC,RADIATION: Radiotherapy|DRUG: PD-1 inhibitor|DRUG: Neoantigen-based peptide vaccine,2,OTHER,The First Affiliated Hospital of Nanchang University,"['checkpoint inhibitor', 'vaccine']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'pd-1 inhibitor'}, {'type': 'vaccine', 'subtype': 'vaccine', 'raw': 'neoantigen-based peptide vaccine'}]",True,advanced nsclc,lung/thoracic
928,United States,"Human Papilloma Virus|Warts|Warts, Genital|Condyloma|Condylomata Acuminata",BIOLOGICAL: nonavalent human papillomavirus vaccine,12,OTHER,"University of California, San Francisco",['vaccine'],"[{'type': 'vaccine', 'subtype': 'vaccine', 'raw': 'nonavalent human papillomavirus vaccine'}]",False,human papilloma virus warts warts genital condyloma condylomata acuminata,other
929,France,Advanced Biliary Tract Carcinoma,DRUG: Durvalumab|DRUG: Tremelimumab,2,OTHER,GERCOR - Multidisciplinary Oncology Cooperative Group,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'tremelimumab'}]",False,advanced biliary tract carcinoma,digestive
930,United States,Clear Cell Renal Cell Carcinoma|Renal Cell Carcinoma (RCC)|Stage II Renal Pelvis Cancer AJCC v8|Stage III Renal Pelvis Cancer AJCC v8,BIOLOGICAL: Pembrolizumab|DRUG: Tivozanib|PROCEDURE: Biospecimen Collection|PROCEDURE: MRI|PROCEDURE: Computed Tomography|PROCEDURE: Biopsy|OTHER: Questionnaire Administration,3,OTHER,Alliance for Clinical Trials in Oncology,"['checkpoint inhibitor', 'kinase inhibitor']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'tivozanib'}]",True,clear cell renal cell carcinoma renal cell carcinoma stage ii renal pelvis cancer ajcc v8 stage iii renal pelvis cancer ajcc v8,genitourinary
931,"Canada, Hong Kong, United States",Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma|Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7|Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7|Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7|Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7|Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7|Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7|Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7|Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7,DRUG: Atezolizumab|PROCEDURE: Biopsy Procedure|PROCEDURE: Biospecimen Collection|BIOLOGICAL: Cetuximab|DRUG: Cisplatin|PROCEDURE: Computed Tomography|DRUG: Docetaxel|RADIATION: Intensity-Modulated Radiation Therapy|PROCEDURE: Magnetic Resonance Imaging|OTHER: Survey Administration,23,NIH,National Cancer Institute (NCI),"['checkpoint inhibitor', 'antibody', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'atezolizumab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'cetuximab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'docetaxel'}]",True,oropharyngeal p16ink4a negative squamous cell carcinoma stage iii hypopharyngeal squamous cell carcinoma ajcc v7 stage iii laryngeal squamous cell carcinoma ajcc v6 and v7 stage iii oral cavity squamous cell carcinoma ajcc v6 and v7 stage iii oropharyngeal squamous cell carcinoma ajcc v7 stage iv hypopharyngeal squamous cell carcinoma ajcc v7 stage iv laryngeal squamous cell carcinoma ajcc v7 stage iv oral cavity squamous cell carcinoma ajcc v6 and v7 stage iv oropharyngeal squamous cell carcinoma ajcc v7,head/neck
932,Israel,Metastatic or Locally Advanced NSCLC,DRUG: Durvalumab|DRUG: Tremelimumab|RADIATION: Low dose irradiation,2,OTHER_GOV,Sheba Medical Center,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'tremelimumab'}]",False,metastatic or locally advanced nsclc,lung/thoracic
933,China,Non-small Cell Lung Cancer,DRUG: Cadonilimab (AK104),2,OTHER,Xin-Hua Xu,['antibody'],"[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'cadonilimab'}]",False,non small cell lung cancer,lung/thoracic
934,"Australia, Netherlands, United States",Malignant Melanoma Stage III,DRUG: Neoadjuvant ipilimumab + nivolumab|DRUG: Adjuvant nivolumab,3,OTHER,The Netherlands Cancer Institute,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'neoadjuvant ipilimumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'adjuvant nivolumab'}]",False,malignant melanoma stage iii,skin
935,Russian Federation,Advanced or Metastatic NSCLC,DRUG: Ceralasertib|DRUG: Durvalumab,2,INDUSTRY,AstraZeneca,"['checkpoint inhibitor', 'targeted therapy']","[{'type': 'targeted therapy', 'subtype': 'ATR inhibitor', 'raw': 'ceralasertib'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}]",True,advanced or metastatic nsclc,lung/thoracic
936,United States,Bladder Urothelial Carcinoma|Stage III Bladder Cancer AJCC v8,PROCEDURE: Biopsy of Bladder|PROCEDURE: Biospecimen Collection|DRUG: Cisplatin|PROCEDURE: Computed Tomography|PROCEDURE: Cystoscopy|BIOLOGICAL: Durvalumab|DRUG: Fluorouracil|DRUG: Gemcitabine Hydrochloride|PROCEDURE: Magnetic Resonance Imaging|DRUG: Mitomycin|OTHER: Patient Observation|RADIATION: Radiation Therapy,2,NIH,National Cancer Institute (NCI),"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}, {'type': 'chemotherapy', 'subtype': 'antimetabolite', 'raw': 'fluorouracil'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'gemcitabine hydrochloride'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'mitomycin'}]",True,bladder urothelial carcinoma stage iii bladder cancer ajcc v8,genitourinary
937,"France, Germany, Spain",Multiple Myeloma,DRUG: SLAMF7 CAR-T,12,OTHER,Wuerzburg University Hospital,['cell therapy'],"[{'type': 'cell therapy', 'subtype': 'engineered cell', 'raw': 'slamf7 car-t'}]",False,multiple myeloma,hematologic
938,United States,B Acute Lymphoblastic Leukemia|Recurrent Acute Lymphoblastic Leukemia|Refractory Acute Lymphoblastic Leukemia,BIOLOGICAL: CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes|BIOLOGICAL: CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes|OTHER: Laboratory Biomarker Analysis,1,OTHER,City of Hope Medical Center,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'cd19car-cd28-cd3zeta-egfrt-expressing tcm-enriched t-lymphocytes'}, {'type': 'other', 'subtype': None, 'raw': 'cd19car-cd28-cd3zeta-egfrt-expressing tn'}, {'type': 'other', 'subtype': None, 'raw': 'mem-enriched t-lymphocytes'}]",False,b acute lymphoblastic leukemia recurrent acute lymphoblastic leukemia refractory acute lymphoblastic leukemia,hematologic
939,Canada,"Lung Cancer, Nonsmall Cell",DRUG: Pembrolizumab|DRUG: Carboplatin|DRUG: Paclitaxel|DRUG: Pemetrexed,2,OTHER,McGill University Health Centre/Research Institute of the McGill University Health Centre,"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}, {'type': 'chemotherapy', 'subtype': 'antifolate', 'raw': 'pemetrexed'}]",True,lung cancer nonsmall cell,lung/thoracic
940,Japan,"Lymphoblastic Leukemia, Acute Adult",BIOLOGICAL: TBI-1501,12,INDUSTRY,Takara Bio Inc.,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'tbi-1501'}]",False,lymphoblastic leukemia acute adult,hematologic
941,United States,Recurrent Oligodendroglioma|Progressive Oligodendroglioma,BIOLOGICAL: TTRNA-DC vaccines with GM-CSF|BIOLOGICAL: Autologous Hematopoietic Stem cells (HSCs)|BIOLOGICAL: TTRNA-xALT|DRUG: Td vaccine,1,OTHER,University of Florida,"['vaccine', 'other', 'cell therapy']","[{'type': 'vaccine', 'subtype': 'vaccine', 'raw': 'ttrna-dc vaccines with gm-csf'}, {'type': 'cell therapy', 'subtype': 'other', 'raw': 'autologous hematopoietic stem cells'}, {'type': 'other', 'subtype': None, 'raw': 'ttrna-xalt'}, {'type': 'vaccine', 'subtype': 'vaccine', 'raw': 'td vaccine'}]",True,recurrent oligodendroglioma progressive oligodendroglioma,brain/CNS
942,Italy,Clear Cell RCC,GENETIC: Temferon|BIOLOGICAL: Pembrolizumab|DRUG: Cabozantinib,12,INDUSTRY,Genenta Science,"['checkpoint inhibitor', 'targeted therapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'targeted therapy', 'subtype': 'other', 'raw': 'cabozantinib'}]",True,clear cell rcc,other
943,United States,Glioblastoma,DRUG: ITI-1001,1,INDUSTRY,"Immunomic Therapeutics, Inc.",['other'],"[{'type': 'other', 'subtype': None, 'raw': 'iti-1001'}]",False,glioblastoma,brain/CNS
944,United States,Osteogenic Sarcoma Recurrent,DRUG: Iscador*P,2,OTHER,Hackensack Meridian Health,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'iscador*p'}]",False,osteogenic sarcoma recurrent,sarcoma
945,China,AML (Acute Myelogenous Leukemia)|NK Cell|CD123+ Acute Myeloid Leukemia,DRUG: Donor-derived CD123-CD16 bispecific antibody-modified NK cells,1,OTHER,Chunji Gao,['cell therapy'],"[{'type': 'cell therapy', 'subtype': 'other', 'raw': 'donor-derived cd123-cd16 bispecific antibody-modified nk cells'}]",False,aml nk cell cd123 acute myeloid leukemia,hematologic
946,United States,Glioblastoma Multiforme of Brain|Anaplastic Astrocytoma of Brain|Gliosarcoma of Brain,BIOLOGICAL: C134,1,OTHER,University of Alabama at Birmingham,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'c134'}]",False,glioblastoma multiforme of brain anaplastic astrocytoma of brain gliosarcoma of brain,brain/CNS
947,China,Recurrent Glioblastoma,"GENETIC: Inverse correlated dual-target, truncated IL7Ra modified CAR -expressing autologous T-lymphocytes.",1,OTHER,Beijing Tiantan Hospital,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'genetic: inverse correlated dual-target'}, {'type': 'other', 'subtype': None, 'raw': 'truncated il7ra modified car -expressing autologous t-lymphocytes.'}]",False,recurrent glioblastoma,brain/CNS
948,United States,Platinum-resistant Ovarian Cancer|Platinum-refractory Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer|High-grade Serous Ovarian Cancer|Endometrioid Ovarian Cancer|Ovarian Clear Cell Carcinoma,"BIOLOGICAL: olvimulogene nanivacirepvec|DRUG: Platinum chemotherapy: carboplatin (preferred) or cisplatin|DRUG: Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin|DRUG: Bevacizumab (or biosimilar)",3,INDUSTRY,Genelux Corporation,"['other', 'antibody', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'olvimulogene nanivacirepvec'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'platinum chemotherapy: carboplatin or cisplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': ""non-platinum chemotherapy: physician's choice of gemcitabine""}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'taxane or pegylated liposomal doxorubicin'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'bevacizumab'}]",True,platinum resistant ovarian cancer platinum refractory ovarian cancer fallopian tube cancer primary peritoneal cancer high grade serous ovarian cancer endometrioid ovarian cancer ovarian clear cell carcinoma,gynecologic
949,United States,Fallopian Tube Endometrioid Tumor|Fallopian Tube High Grade Serous Adenocarcinoma|Malignant Ovarian Endometrioid Tumor|Ovarian High Grade Serous Adenocarcinoma|Platinum-Sensitive Fallopian Tube Carcinoma|Platinum-Sensitive Ovarian Carcinoma|Platinum-Sensitive Primary Peritoneal Carcinoma|Primary Peritoneal High Grade Serous Adenocarcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Fallopian Tube Endometrioid Adenocarcinoma|Recurrent Ovarian Endometrioid Adenocarcinoma|Recurrent Ovarian Serous Adenocarcinoma|Recurrent Primary Peritoneal Carcinoma|Recurrent Primary Peritoneal Endometrioid Adenocarcinoma,PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|PROCEDURE: Magnetic Resonance Imaging|DRUG: Olaparib|BIOLOGICAL: Tremelimumab,2,NIH,National Cancer Institute (NCI),"['checkpoint inhibitor', 'targeted therapy']","[{'type': 'targeted therapy', 'subtype': 'PARP inhibitor', 'raw': 'olaparib'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'tremelimumab'}]",True,fallopian tube endometrioid tumor fallopian tube high grade serous adenocarcinoma malignant ovarian endometrioid tumor ovarian high grade serous adenocarcinoma platinum sensitive fallopian tube carcinoma platinum sensitive ovarian carcinoma platinum sensitive primary peritoneal carcinoma primary peritoneal high grade serous adenocarcinoma recurrent fallopian tube carcinoma recurrent fallopian tube endometrioid adenocarcinoma recurrent ovarian endometrioid adenocarcinoma recurrent ovarian serous adenocarcinoma recurrent primary peritoneal carcinoma recurrent primary peritoneal endometrioid adenocarcinoma,gynecologic
950,United States,Recurrent B-Cell Non-Hodgkin Lymphoma|Recurrent Chronic Lymphocytic Leukemia|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Follicular Lymphoma|Recurrent Lymphoplasmacytic Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Follicular Lymphoma|Refractory Lymphoplasmacytic Lymphoma|Refractory Mantle Cell Lymphoma|Refractory Transformed Non-Hodgkin Lymphoma|Recurrent Transformed B-Cell Non-Hodgkin Lymphoma|Recurrent Transformed Chronic Lymphocytic Leukemia|Refractory Marginal Zone Lymphoma|Refractory Transformed B-Cell Non-Hodgkin Lymphoma|Refractory Transformed Chronic Lymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Small Lymphocytic Lymphoma|Recurrent Central Nervous System Lymphoma|Refractory Central Nervous System Lymphoma,BIOLOGICAL: Chimeric Antigen Receptor T-Cell Therapy|DRUG: Cyclophosphamide|OTHER: Laboratory Biomarker Analysis|PROCEDURE: Leukapheresis|DRUG: Fludarabine Phosphate,12,OTHER,Fred Hutchinson Cancer Center,"['chemotherapy', 'cell therapy']","[{'type': 'cell therapy', 'subtype': 'other', 'raw': 'chimeric antigen receptor t-cell therapy'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide'}, {'type': 'chemotherapy', 'subtype': 'purine analog', 'raw': 'fludarabine phosphate'}]",True,recurrent b cell non hodgkin lymphoma recurrent chronic lymphocytic leukemia recurrent diffuse large b cell lymphoma recurrent follicular lymphoma recurrent lymphoplasmacytic lymphoma recurrent mantle cell lymphoma recurrent marginal zone lymphoma refractory b cell non hodgkin lymphoma refractory diffuse large b cell lymphoma refractory follicular lymphoma refractory lymphoplasmacytic lymphoma refractory mantle cell lymphoma refractory transformed non hodgkin lymphoma recurrent transformed b cell non hodgkin lymphoma recurrent transformed chronic lymphocytic leukemia refractory marginal zone lymphoma refractory transformed b cell non hodgkin lymphoma refractory transformed chronic lymphocytic leukemia recurrent small lymphocytic lymphoma refractory chronic lymphocytic leukemia refractory small lymphocytic lymphoma recurrent central nervous system lymphoma refractory central nervous system lymphoma,hematologic
951,United States,Advanced Pancreatic Ductal Adenocarcinoma|Pancreatic Ductal Adenocarcinoma|Pancreatic Cancer,DRUG: AGEN1423|DRUG: Botensilimab|DRUG: Gemcitabine|DRUG: Nab-paclitaxel,2,OTHER,Bruno Bockorny,"['other', 'antibody', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'agen1423'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'botensilimab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'gemcitabine'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'nab-paclitaxel'}]",True,advanced pancreatic ductal adenocarcinoma pancreatic ductal adenocarcinoma pancreatic cancer,digestive
952,China,De-escalated Radiotherapy; Head and Neck Cancer,"RADIATION: Continuous, hyperfractionated, accelerated radiotherapy(CHART)",2,OTHER,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'radiation: continuous'}, {'type': 'other', 'subtype': None, 'raw': 'hyperfractionated'}, {'type': 'other', 'subtype': None, 'raw': 'accelerated radiotherapy'}]",False,de escalated radiotherapy head and neck cancer,head/neck
953,United States,CD 19+ Acute Leukemia,BIOLOGICAL: T-cell Antigen Presenting Cells expressing truncated CD19 (T-APC),1,OTHER,Seattle Children's Hospital,['cell therapy'],"[{'type': 'cell therapy', 'subtype': 'other', 'raw': 't-cell antigen presenting cells expressing truncated cd19'}]",False,cd 19 acute leukemia,hematologic
954,United States,Hepatocellular Carcinoma|Cirrhosis|Portal Hypertension,DRUG: Durvalumab|DRUG: Tremelimumab|PROCEDURE: Liver Transplant,2,OTHER,Davendra Sohal,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'tremelimumab'}]",False,hepatocellular carcinoma cirrhosis portal hypertension,digestive
955,China,Extensive-stage Small-cell Lung Cancer,RADIATION: Thoracic Radiotherapy,2,OTHER_GOV,Henan Cancer Hospital,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'radiation: thoracic radiotherapy'}]",False,extensive stage small cell lung cancer,lung/thoracic
956,China,Gastric or Gastroesophageal Junction Adenocarcinoma,COMBINATION_PRODUCT: neoadjuvant chemo-hypofractionated radiotherapy plus PD-1 antibody (Tislelizumab),2,OTHER,Jiangsu Cancer Institute & Hospital,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'neoadjuvant chemo-hypofractionated radiotherapy plus pd-1 antibody'}]",False,gastric or gastroesophageal junction adenocarcinoma,digestive
957,United States,B-Cell Lymphoblastic Leukemia|Acute Lymphoblastic Leukemia,DRUG: Tecartus,2,OTHER,H. Lee Moffitt Cancer Center and Research Institute,['cell therapy'],"[{'type': 'cell therapy', 'subtype': 'engineered cell', 'raw': 'tecartus'}]",False,b cell lymphoblastic leukemia acute lymphoblastic leukemia,hematologic
958,Germany,Glioblastoma,"BIOLOGICAL: Autologous, tumor lysate-loaded, mature dendritic cells (DC)|DRUG: standard therapy",2,OTHER,"Heinrich-Heine University, Duesseldorf","['other', 'cell therapy']","[{'type': 'other', 'subtype': None, 'raw': 'autologous'}, {'type': 'other', 'subtype': None, 'raw': 'tumor lysate-loaded'}, {'type': 'cell therapy', 'subtype': 'other', 'raw': 'mature dendritic cells'}, {'type': 'other', 'subtype': None, 'raw': 'standard therapy'}]",True,glioblastoma,brain/CNS
959,United States,Non-muscle Invasive Bladder Cancer With Carcinoma in Situ,DRUG: Nadofaragene Firadenovec|DRUG: Gemcitabine|DRUG: Docetaxel|DRUG: Pembrolizumab,3,INDUSTRY,Ferring Pharmaceuticals,"['checkpoint inhibitor', 'other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'nadofaragene firadenovec'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'gemcitabine'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'docetaxel'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",True,non muscle invasive bladder cancer with carcinoma in situ,genitourinary
960,United States,Follicular Lymphoma,DRUG: Rituximab|BIOLOGICAL: Neo Vax|DRUG: Pembrolizumab,1,OTHER,Dana-Farber Cancer Institute,"['checkpoint inhibitor', 'other', 'antibody']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'rituximab'}, {'type': 'other', 'subtype': None, 'raw': 'neo vax'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",True,follicular lymphoma,hematologic
961,United States,Non Small Cell Lung Cancer Stage,RADIATION: Hypo-Fractionation|RADIATION: Standard-Fractionation,2,OTHER,University of Kansas Medical Center,[],[],False,non small cell lung cancer stage,lung/thoracic
962,"Australia, United Kingdom, United States",Extensive-stage Small-cell Lung Cancer,DRUG: BNT327|DRUG: Atezolizumab|DRUG: Etoposide|DRUG: Carboplatin,3,INDUSTRY,BioNTech SE,"['checkpoint inhibitor', 'other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'bnt327'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'atezolizumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'etoposide'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}]",True,extensive stage small cell lung cancer,lung/thoracic
963,United States,Endometrial Cancer|ARID1A Gene Mutation|Recurrent Endometrial Carcinoma,DRUG: Avelumab|DRUG: M1774,2,OTHER,"Panagiotis Konstantinopoulos, MD, PhD","['checkpoint inhibitor', 'other']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'avelumab'}, {'type': 'other', 'subtype': None, 'raw': 'm1774'}]",True,endometrial cancer arid1a gene mutation recurrent endometrial carcinoma,gynecologic
964,"Belgium, Brazil, France, Germany, Italy, Russian Federation, Spain, Switzerland, United Kingdom, United States",Advanced Melanoma,DRUG: Botensilimab|DRUG: Balstilimab,2,INDUSTRY,Agenus Inc.,['antibody'],"[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'botensilimab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'balstilimab'}]",False,advanced melanoma,skin
965,China,"Lymphoma, B-Cell",BIOLOGICAL: CD19-CD22 CAR-T cells,12,OTHER,Shanxi Province Cancer Hospital,['cell therapy'],"[{'type': 'cell therapy', 'subtype': 'engineered cell', 'raw': 'cd19-cd22 car-t cells'}]",False,lymphoma b cell,hematologic
966,Republic of,Advanced Hepatocellular Carcinoma (HCC),RADIATION: Particle beam radiation therapy,2,OTHER_GOV,"National Cancer Center, Korea",['other'],"[{'type': 'other', 'subtype': None, 'raw': 'radiation: particle beam radiation therapy'}]",False,advanced hepatocellular carcinoma,digestive
967,China,Esophageal Squamous Cell Carcinoma,DRUG: Tirelizumab|DRUG: Nab paclitaxel|DRUG: Carboplatin|RADIATION: Radiotherapy,2,OTHER,Ruijin Hospital,"['antibody', 'chemotherapy']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'tirelizumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'nab paclitaxel'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}]",True,esophageal squamous cell carcinoma,digestive
968,United States,Esophageal Adenocarcinoma|Gastric Adenocarcinoma,DRUG: Nal-IRI|DRUG: Oxaliplatin|DRUG: 5-FU|DRUG: Trastuzumab|DRUG: Pembrolizumab|DRUG: Nivolumab,2,OTHER,"University of Wisconsin, Madison","['checkpoint inhibitor', 'other', 'antibody', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'nal-iri'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'oxaliplatin'}, {'type': 'chemotherapy', 'subtype': 'antimetabolite', 'raw': '5-fu'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'trastuzumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}]",True,esophageal adenocarcinoma gastric adenocarcinoma,digestive
969,United States,Merkel Cell Carcinoma,DRUG: Pembrolizumab|DRUG: Lutetium Lu 177 dotatate,2,OTHER,Weill Medical College of Cornell University,"['checkpoint inhibitor', 'other']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'other', 'subtype': None, 'raw': 'lutetium lu 177 dotatate'}]",True,merkel cell carcinoma,skin
970,United States,Leukemia,BIOLOGICAL: Patient-derived CD22-specific CAR T-cells also expressing an EGFRt,1,OTHER,Seattle Children's Hospital,['cell therapy'],"[{'type': 'cell therapy', 'subtype': 'other', 'raw': 'patient-derived cd22-specific car t-cells also expressing an egfrt'}]",False,leukemia,hematologic
971,United States,T-Cell Lymphoma|Peripheral T-Cell Lymphoma Refractory|Cutaneous T-Cell Lymphoma Refractory|Cutaneous T-Cell Lymphoma Recurrent|Peripheral T-Cell Lymphoma Recurrent,BIOLOGICAL: LB1901,1,INDUSTRY,Legend Biotech USA Inc,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'lb1901'}]",False,t cell lymphoma peripheral t cell lymphoma refractory cutaneous t cell lymphoma refractory cutaneous t cell lymphoma recurrent peripheral t cell lymphoma recurrent,hematologic
972,China,Advanced Hepatocellular Carcinoma,PROCEDURE: Palliative Hepatectomy|DRUG: Durvalumab|DRUG: Lenvatinib,1,OTHER,Zhiyong Huang,"['checkpoint inhibitor', 'targeted therapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}, {'type': 'targeted therapy', 'subtype': 'other', 'raw': 'lenvatinib'}]",True,advanced hepatocellular carcinoma,digestive
973,China,Non-Small Cell Lung Cancer|RET Driver Mutation|BRAF V600 Mutation|Erb-B2 Receptor Tyrosine Kinase Exon 20 Mutation|MET Amplification|MET Exon 14 Skipping Mutation,BIOLOGICAL: Toripalimab|DRUG: Nab paclitaxel|DRUG: Pemetrexed|DRUG: Carboplatin,2,OTHER,Guangdong Provincial People's Hospital,"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'toripalimab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'nab paclitaxel'}, {'type': 'chemotherapy', 'subtype': 'antifolate', 'raw': 'pemetrexed'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}]",True,non small cell lung cancer ret driver mutation braf v600 mutation erb b2 receptor tyrosine kinase exon 20 mutation met amplification met exon 14 skipping mutation,lung/thoracic
974,"Puerto Rico, United States",Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|HER2-Negative Breast Carcinoma|Hormone Receptor-Positive Breast Carcinoma,PROCEDURE: Biospecimen Collection|DRUG: Cyclophosphamide|DRUG: Doxorubicin|BIOLOGICAL: Durvalumab|OTHER: Genetic Testing|PROCEDURE: Mammography|DRUG: Paclitaxel|OTHER: Quality-of-Life Assessment,3,NIH,National Cancer Institute (NCI),"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'doxorubicin'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}]",True,anatomic stage ii breast cancer ajcc v8 anatomic stage iii breast cancer ajcc v8 her2 negative breast carcinoma hormone receptor positive breast carcinoma,breast
975,"Republic of, Singapore, United States",Advanced Solid Tumor|Clear Cell Renal Cell Carcinoma|Hepatocellular Carcinoma|Non-small Cell Lung Cancer,DRUG: CHS-388|DRUG: Pembrolizumab|DRUG: Toripalimab,1,INDUSTRY,"Coherus Biosciences, Inc.","['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'chs-388'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'toripalimab'}]",True,advanced solid tumor clear cell renal cell carcinoma hepatocellular carcinoma non small cell lung cancer,genitourinary
976,United States,Locally Advanced Pancreatic Adenocarcinoma|Pancreatic Acinar Cell Carcinoma|Pancreatic Ductal Adenocarcinoma|Stage III Pancreatic Cancer AJCC v6 and v7|Stage IV Pancreatic Cancer AJCC v6 and v7,BIOLOGICAL: Falimarev|BIOLOGICAL: Inalimarev|OTHER: Laboratory Biomarker Analysis|BIOLOGICAL: Sargramostim,1,NIH,National Cancer Institute (NCI),['other'],"[{'type': 'other', 'subtype': None, 'raw': 'falimarev'}, {'type': 'other', 'subtype': None, 'raw': 'inalimarev'}, {'type': 'other', 'subtype': None, 'raw': 'sargramostim'}]",False,locally advanced pancreatic adenocarcinoma pancreatic acinar cell carcinoma pancreatic ductal adenocarcinoma stage iii pancreatic cancer ajcc v6 and v7 stage iv pancreatic cancer ajcc v6 and v7,digestive
977,Sweden,Uveal Melanoma|Liver Metastases,DEVICE: PHP|DRUG: IPI1/NIVO3|DRUG: IPI3/NIVO1,3,OTHER_GOV,Vastra Gotaland Region,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'ipi1'}, {'type': 'other', 'subtype': None, 'raw': 'nivo3'}, {'type': 'other', 'subtype': None, 'raw': 'ipi3'}, {'type': 'other', 'subtype': None, 'raw': 'nivo1'}]",False,uveal melanoma liver metastases,digestive
978,"Israel, Poland, Republic of, Spain, Taiwan, United States",Diffuse Large B-cell Lymphoma,DRUG: Mosunetuzumab Intravenous (IV)|DRUG: Mosunetuzumab Subcutaneous (SC)|DRUG: Polatuzumab Vedotin|DRUG: Tocilizumab,12,INDUSTRY,Hoffmann-La Roche,"['other', 'antibody']","[{'type': 'other', 'subtype': None, 'raw': 'mosunetuzumab intravenous'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'mosunetuzumab'}, {'type': 'other', 'subtype': None, 'raw': 'polatuzumab vedotin'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'tocilizumab'}]",True,diffuse large b cell lymphoma,hematologic
979,United States,Advanced Hepatocellular Carcinoma|Stage III Hepatocellular Carcinoma AJCC V8|Stage IV Hepatocellular Carcinoma AJCC V8|Unresectable Hepatocellular Carcinoma,PROCEDURE: Computed Tomography|DRUG: Gallium Ga 68 Gozetotide|PROCEDURE: Positron Emission Tomography,2,OTHER,Mayo Clinic,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'gallium ga 68 gozetotide'}]",False,advanced hepatocellular carcinoma stage iii hepatocellular carcinoma ajcc v8 stage iv hepatocellular carcinoma ajcc v8 unresectable hepatocellular carcinoma,digestive
980,United States,Head and Neck Squamous Cell Carcinoma|Metastatic Head and Neck Squamous Cell Carcinoma|Metastatic Hypopharyngeal Squamous Cell Carcinoma|Metastatic Laryngeal Squamous Cell Carcinoma|Metastatic Oral Cavity Squamous Cell Carcinoma|Metastatic Oropharyngeal Squamous Cell Carcinoma|Recurrent Head and Neck Squamous Cell Carcinoma|Recurrent Hypopharyngeal Squamous Cell Carcinoma|Recurrent Laryngeal Squamous Cell Carcinoma|Recurrent Oral Cavity Squamous Cell Carcinoma|Recurrent Oropharyngeal Squamous Cell Carcinoma|Stage IV Hypopharyngeal Carcinoma AJCC v8|Stage IV Laryngeal Cancer AJCC v8|Stage IV Lip and Oral Cavity Cancer AJCC v8|Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8,PROCEDURE: Biopsy Procedure|PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|DRUG: Ipatasertib|BIOLOGICAL: Pembrolizumab,2,NIH,National Cancer Institute (NCI),"['checkpoint inhibitor', 'targeted therapy']","[{'type': 'targeted therapy', 'subtype': 'AKT inhibitor', 'raw': 'ipatasertib'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",True,head and neck squamous cell carcinoma metastatic head and neck squamous cell carcinoma metastatic hypopharyngeal squamous cell carcinoma metastatic laryngeal squamous cell carcinoma metastatic oral cavity squamous cell carcinoma metastatic oropharyngeal squamous cell carcinoma recurrent head and neck squamous cell carcinoma recurrent hypopharyngeal squamous cell carcinoma recurrent laryngeal squamous cell carcinoma recurrent oral cavity squamous cell carcinoma recurrent oropharyngeal squamous cell carcinoma stage iv hypopharyngeal carcinoma ajcc v8 stage iv laryngeal cancer ajcc v8 stage iv lip and oral cavity cancer ajcc v8 stage iv oropharyngeal carcinoma ajcc v8,head/neck
981,United States,Pleural Biphasic Mesothelioma|Pleural Sarcomatoid Mesothelioma,BIOLOGICAL: Nivolumab|BIOLOGICAL: Ipilimumab|PROCEDURE: Surgical Procedure|PROCEDURE: Computed Tomography|PROCEDURE: Magnetic Resonance Imaging|PROCEDURE: Positron Emission Tomography,2,OTHER,Alliance for Clinical Trials in Oncology,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}]",False,pleural biphasic mesothelioma pleural sarcomatoid mesothelioma,lung/thoracic
982,China,Efficacy and Safety of Neoadjuvant Immunotherapy for Small Cell Lung Cancer,DRUG: adebrelimab and chemotherapy,2,OTHER,Zhejiang Cancer Hospital,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'adebrelimab and chemotherapy'}]",False,efficacy and safety of neoadjuvant immunotherapy for small cell lung cancer,lung/thoracic
983,"Denmark, Finland, Norway, Republic of, Sweden",MCL|Mantle Cell Lymphoma,DRUG: Acalabrutinib-rituximab in patients with untreated mantle cell lymphoma,2,NETWORK,Nordic Lymphoma Group,['cell therapy'],"[{'type': 'cell therapy', 'subtype': 'other', 'raw': 'acalabrutinib-rituximab in patients with untreated mantle cell lymphoma'}]",False,mcl mantle cell lymphoma,hematologic
984,Australia,Metastatic Triple Negative Breast Cancer,DRUG: Atezolizumab|DRUG: Bevacizumab|DRUG: Gemcitabine|DRUG: Carboplatin,2,OTHER,"Peter MacCallum Cancer Centre, Australia","['checkpoint inhibitor', 'antibody', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'atezolizumab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'bevacizumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'gemcitabine'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}]",True,metastatic triple negative breast cancer,breast
985,"Belgium, Canada, Czechia, France, Germany, Italy, Poland, Spain, Switzerland, United Kingdom, United States",Metastatic NSCLC - Non-Small Cell Lung Cancer|Locally Advanced NSCLC - Non-Small Cell Lung Cancer,DRUG: inupadenant|DRUG: Placebo|DRUG: Carboplatin|DRUG: Pemetrexed,2,INDUSTRY,iTeos Therapeutics,"['other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'inupadenant'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'chemotherapy', 'subtype': 'antifolate', 'raw': 'pemetrexed'}]",True,metastatic nsclc non small cell lung cancer locally advanced nsclc non small cell lung cancer,lung/thoracic
986,"France, Italy, Spain",Metastatic Non Small Cell Lung Cancer,DRUG: Tedopi|DRUG: Nivolumab|DRUG: Docetaxel,2,OTHER,Fondazione Ricerca Traslazionale,"['checkpoint inhibitor', 'other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'tedopi'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'docetaxel'}]",True,metastatic non small cell lung cancer,lung/thoracic
987,United States,Hepatocellular Cancer|Hepatocellular Carcinoma|Metastatic Hepatocellular Carcinoma,DRUG: durvalumab|DRUG: Doxorubicin-Eluting Beads|PROCEDURE: TACE|DRUG: bevacizumab|DRUG: Tremelimumab,2,NIH,National Cancer Institute (NCI),"['checkpoint inhibitor', 'antibody', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'doxorubicin-eluting beads'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'bevacizumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'tremelimumab'}]",True,hepatocellular cancer hepatocellular carcinoma metastatic hepatocellular carcinoma,digestive
988,United States,Metastatic Pancreatic Cancer,DRUG: Nab-paclitaxel|DRUG: Gemcitabine|DRUG: Cisplatin|DRUG: Irinotecan|DRUG: Capecitabine|DRUG: Pembrolizumab|DRUG: Olaparib,2,OTHER,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,"['checkpoint inhibitor', 'targeted therapy', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'nab-paclitaxel'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'gemcitabine'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'irinotecan'}, {'type': 'chemotherapy', 'subtype': 'fluoropyrimidine', 'raw': 'capecitabine'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'targeted therapy', 'subtype': 'PARP inhibitor', 'raw': 'olaparib'}]",True,metastatic pancreatic cancer,digestive
989,United States,Advanced Melanoma|Unresectable Melanoma,DRUG: Nivolumab|DRUG: Axitinib,2,OTHER,Yana Najjar,"['checkpoint inhibitor', 'kinase inhibitor']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'axitinib'}]",True,advanced melanoma unresectable melanoma,skin
990,China,Esophagogastric Junction Adenocarcinoma,DRUG: Sintilimab,2,OTHER,Sun Yat-sen University,['antibody'],"[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'sintilimab'}]",False,esophagogastric junction adenocarcinoma,digestive
991,Belgium,Recurrent Glioblastoma,DRUG: Neo-adjuvant nivolumab and ipililumab IV + adjuvant nivolumab and ipililumab IV|PROCEDURE: Neurosurgery and intracavitary injection nivolumab and ipililumab|DRUG: Adjuvant nivolumab IV + nivolumab and ipililumab intracavitary,1,OTHER,Universitair Ziekenhuis Brussel,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'neo-adjuvant nivolumab and ipililumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'adjuvant nivolumab and ipililumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'adjuvant nivolumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab and ipililumab intracavitary'}]",False,recurrent glioblastoma,brain/CNS
992,United States,Squamous Cell Carcinoma|the Nasal Cavity|Paranasal Sinuses,DRUG: Pembrolizumab|DRUG: Docetaxel|DRUG: Cisplatin|DRUG: Carboplatin,2,OTHER,M.D. Anderson Cancer Center,"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'docetaxel'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}]",True,squamous cell carcinoma the nasal cavity paranasal sinuses,other
993,United States,Recurrent Glioblastoma Multiforme|Progressive Glioblastoma Multiforme|Anaplastic Astrocytoma or Gliosarcoma,BIOLOGICAL: M032 (NSC 733972),1,OTHER,University of Alabama at Birmingham,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'm032'}]",False,recurrent glioblastoma multiforme progressive glioblastoma multiforme anaplastic astrocytoma or gliosarcoma,brain/CNS
994,United Kingdom,Primary CNS Lymphoma,BIOLOGICAL: CD19CAR T-cells,1,OTHER,"University College, London",['cell therapy'],"[{'type': 'cell therapy', 'subtype': 'other', 'raw': 'cd19car t-cells'}]",False,primary cns lymphoma,hematologic
995,France,Head and Neck Mucosal Melanomas,DRUG: Pembrolizumab|PROCEDURE: Surgery|RADIATION: IMRT|DRUG: Lenvatinib,2,OTHER,"Gustave Roussy, Cancer Campus, Grand Paris","['checkpoint inhibitor', 'targeted therapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'targeted therapy', 'subtype': 'other', 'raw': 'lenvatinib'}]",True,head and neck mucosal melanomas,skin
996,United States,Breast Neoplasms|Breast Cancer|Breast Tumors|Angiosarcoma|TNBC - Triple-Negative Breast Cancer|HER2-positive Breast Cancer|HER2-negative Breast Cancer|Hormone Receptor Positive Tumor|Hormone Receptor Negative Tumor|Early-stage Breast Cancer|Locally Advanced Breast Cancer,DRUG: Standard Therapy|DRUG: AMG 386 with or without Trastuzumab|DRUG: AMG 479 (Ganitumab) plus Metformin|DRUG: MK-2206 with or without Trastuzumab|DRUG: AMG 386 and Trastuzumab|DRUG: T-DM1 and Pertuzumab|DRUG: Pertuzumab and Trastuzumab|DRUG: Ganetespib|DRUG: ABT-888|DRUG: Neratinib|DRUG: PLX3397|DRUG: Pembrolizumab - 4 cycle|DRUG: Talazoparib plus Irinotecan|DRUG: Patritumab and Trastuzumab|DRUG: Pembrolizumab - 8 cycle|DRUG: SGN-LIV1A|DRUG: Durvalumab plus Olaparib|DRUG: SD-101 + Pembrolizumab|DRUG: Tucatinib plus trastuzumab and pertuzumab|DRUG: Cemiplimab|DRUG: Cemiplimab plus REGN3767|DRUG: Trilaciclib with or without trastuzumab + pertuzumab|DRUG: SYD985 ([vic-]trastuzumab duocarmazine)|DRUG: Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab|DRUG: Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab|DRUG: Amcenestrant|DRUG: Amcenestrant + Abemaciclib|DRUG: Amcenestrant + Letrozole|DRUG: ARX788|DRUG: ARX788 + Cemiplimab|DRUG: VV1 + Cemiplimab|DRUG: Datopotamab deruxtecan|DRUG: Datopotamab deruxtecan + Durvalumab|DRUG: Zanidatamab|DRUG: Lasofoxifene|DRUG: Z-endoxifen|DRUG: ARV-471|DRUG: ARV-471 + Letrozole|DRUG: ARV-471 + Abemaciclib|DRUG: Endoxifen + Abemaciclib|DRUG: Rilvegostomig + TDXd|DRUG: Dan222 + Niraparib|DRUG: Sarilumab + Cemiplimab + Paclitaxel,2,OTHER,QuantumLeap Healthcare Collaborative,"['targeted therapy', 'other', 'chemotherapy', 'kinase inhibitor', 'checkpoint inhibitor', 'antibody']","[{'type': 'other', 'subtype': None, 'raw': 'standard therapy'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'amg 386 with or without trastuzumab'}, {'type': 'other', 'subtype': None, 'raw': 'amg 479 plus metformin'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'mk-2206 with or without trastuzumab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'amg 386 and trastuzumab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 't-dm1 and pertuzumab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'pertuzumab and trastuzumab'}, {'type': 'other', 'subtype': None, 'raw': 'ganetespib'}, {'type': 'other', 'subtype': None, 'raw': 'abt-888'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'neratinib'}, {'type': 'other', 'subtype': None, 'raw': 'plx3397'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab - 4 cycle'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'talazoparib plus irinotecan'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'patritumab and trastuzumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab - 8 cycle'}, {'type': 'other', 'subtype': None, 'raw': 'sgn-liv1a'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab plus olaparib'}, {'type': 'other', 'subtype': None, 'raw': 'sd-101'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'tucatinib plus trastuzumab and pertuzumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'cemiplimab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'cemiplimab plus regn3767'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'trilaciclib with or without trastuzumab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'pertuzumab'}, {'type': 'other', 'subtype': None, 'raw': 'syd985'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}, {'type': 'other', 'subtype': None, 'raw': 'encequidar'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'dostarlimab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin with or without trastuzumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}, {'type': 'other', 'subtype': None, 'raw': 'encequidar'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'dostarlimab with or without trastuzumab'}, {'type': 'other', 'subtype': None, 'raw': 'amcenestrant'}, {'type': 'other', 'subtype': None, 'raw': 'amcenestrant'}, {'type': 'targeted therapy', 'subtype': 'CDK4/6 inhibitor', 'raw': 'abemaciclib'}, {'type': 'other', 'subtype': None, 'raw': 'amcenestrant'}, {'type': 'other', 'subtype': None, 'raw': 'letrozole'}, {'type': 'other', 'subtype': None, 'raw': 'arx788'}, {'type': 'other', 'subtype': None, 'raw': 'arx788'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'cemiplimab'}, {'type': 'other', 'subtype': None, 'raw': 'vv1'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'cemiplimab'}, {'type': 'other', 'subtype': None, 'raw': 'datopotamab deruxtecan'}, {'type': 'other', 'subtype': None, 'raw': 'datopotamab deruxtecan'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'zanidatamab'}, {'type': 'other', 'subtype': None, 'raw': 'lasofoxifene'}, {'type': 'other', 'subtype': None, 'raw': 'z-endoxifen'}, {'type': 'other', 'subtype': None, 'raw': 'arv-471'}, {'type': 'other', 'subtype': None, 'raw': 'arv-471'}, {'type': 'other', 'subtype': None, 'raw': 'letrozole'}, {'type': 'other', 'subtype': None, 'raw': 'arv-471'}, {'type': 'targeted therapy', 'subtype': 'CDK4/6 inhibitor', 'raw': 'abemaciclib'}, {'type': 'other', 'subtype': None, 'raw': 'endoxifen'}, {'type': 'targeted therapy', 'subtype': 'CDK4/6 inhibitor', 'raw': 'abemaciclib'}, {'type': 'checkpoint inhibitor', 'subtype': 'PD-1/CTLA-4 bispecific', 'raw': 'rilvegostomig'}, {'type': 'other', 'subtype': None, 'raw': 'tdxd'}, {'type': 'other', 'subtype': None, 'raw': 'dan222'}, {'type': 'targeted therapy', 'subtype': 'PARP inhibitor', 'raw': 'niraparib'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'sarilumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'cemiplimab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}]",True,breast neoplasms breast cancer breast tumors angiosarcoma tnbc triple negative breast cancer her2 positive breast cancer her2 negative breast cancer hormone receptor positive tumor hormone receptor negative tumor early stage breast cancer locally advanced breast cancer,breast
997,China,HCC|Precision Therapy,DRUG: HAIC + Tislelizumab +lenvatinib,1,OTHER,Chen Xiaoping,"['checkpoint inhibitor', 'targeted therapy', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'haic'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'tislelizumab'}, {'type': 'targeted therapy', 'subtype': 'other', 'raw': 'lenvatinib'}]",True,hcc precision therapy,other
998,"Australia, Canada, Puerto Rico, United States",Primary Mediastinal Large B-Cell Lymphoma,PROCEDURE: Biospecimen Collection|PROCEDURE: Bone Marrow Aspiration|PROCEDURE: Bone Marrow Biopsy|PROCEDURE: Computed Tomography|DRUG: Cyclophosphamide|DRUG: Doxorubicin Hydrochloride|PROCEDURE: Echocardiography Test|DRUG: Etoposide Phosphate|BIOLOGICAL: Filgrastim|PROCEDURE: Lumbar Puncture|BIOLOGICAL: Nivolumab|BIOLOGICAL: Pegfilgrastim|PROCEDURE: Positron Emission Tomography|DRUG: Prednisolone|DRUG: Prednisone|RADIATION: Radiation Therapy|BIOLOGICAL: Rituximab|BIOLOGICAL: Rituximab and Hyaluronidase Human|DRUG: Vincristine Sulfate,3,NIH,National Cancer Institute (NCI),"['other', 'chemotherapy', 'checkpoint inhibitor', 'antibody', 'supportive care']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'doxorubicin hydrochloride'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'etoposide phosphate'}, {'type': 'supportive care', 'subtype': 'G-CSF', 'raw': 'filgrastim'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'other', 'subtype': None, 'raw': 'pegfilgrastim'}, {'type': 'supportive care', 'subtype': 'steroid', 'raw': 'prednisolone'}, {'type': 'supportive care', 'subtype': 'steroid', 'raw': 'prednisone'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'rituximab'}, {'type': 'other', 'subtype': None, 'raw': 'rituximab and hyaluronidase human'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'vincristine sulfate'}]",True,primary mediastinal large b cell lymphoma,hematologic
999,"Italy, Spain",Colon Cancer Stage II|Colon Cancer Stage III,DRUG: Oxaliplatin|DRUG: Capecitabine|DRUG: Folinic acid|DRUG: Fluorouracil|DRUG: Temozolomide|DRUG: Irinotecan|DRUG: Nivolumab|DRUG: Ipilimumab|DRUG: Trastuzumab|DRUG: Pertuzumab|DRUG: Panitumumab,3,OTHER,IFOM ETS - The AIRC Institute of Molecular Oncology,"['checkpoint inhibitor', 'antibody', 'supportive care', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'oxaliplatin'}, {'type': 'chemotherapy', 'subtype': 'fluoropyrimidine', 'raw': 'capecitabine'}, {'type': 'supportive care', 'subtype': 'rescue agent', 'raw': 'folinic acid'}, {'type': 'chemotherapy', 'subtype': 'antimetabolite', 'raw': 'fluorouracil'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'temozolomide'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'irinotecan'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'trastuzumab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'pertuzumab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'panitumumab'}]",True,colon cancer stage ii colon cancer stage iii,digestive
1000,United States,Metastatic Melanoma,OTHER: Radiation therapy and high-dose IL-2|DRUG: High-dose IL-2,2,OTHER,Providence Health & Services,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'high-dose il-2'}]",False,metastatic melanoma,skin
1001,United Kingdom,Advanced Cancer|Non Small Cell Lung Cancer,DRUG: Tepotinib|DRUG: Pembrolizumab,1,OTHER,"Institute of Cancer Research, United Kingdom","['checkpoint inhibitor', 'kinase inhibitor']","[{'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'tepotinib'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",True,advanced cancer non small cell lung cancer,lung/thoracic
1002,Germany,Polycythemia Vera (PV)|Essential Thrombocythemia (ET),DRUG: Ruxolitinib|DRUG: BAT,2,OTHER,RWTH Aachen University,"['other', 'kinase inhibitor']","[{'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'ruxolitinib'}, {'type': 'other', 'subtype': None, 'raw': 'bat'}]",True,polycythemia vera essential thrombocythemia,other
1003,United States,Metastatic Pancreatic Adenocarcinoma,"DRUG: Nivolumab (Cohort A)|DRUG: Ipilimumab (Cohort A, B and C)|DRUG: Hydroxychloroquine (HCQ) (Cohort B)|DRUG: Nab-paclitaxel (nP) (Cohort A, B and C)|DRUG: Gemcitabine (gem) (Cohort A, B and C)|DRUG: NG350A (Cohort C)",1,INDUSTRY,"Cancer Insight, LLC","['checkpoint inhibitor', 'other', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}, {'type': 'other', 'subtype': None, 'raw': 'hydroxychloroquine'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'nab-paclitaxel'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'gemcitabine'}, {'type': 'other', 'subtype': None, 'raw': 'ng350a'}]",True,metastatic pancreatic adenocarcinoma,digestive
1004,China,Glioma,BIOLOGICAL: IL13Rα2 CAR-T,1,OTHER,Yang Zhang,['cell therapy'],"[{'type': 'cell therapy', 'subtype': 'engineered cell', 'raw': 'il13rα2 car-t'}]",False,glioma,brain/CNS
1005,"Italy, Netherlands, Republic of, Spain, United States",Non-small Cell Lung Cancer,DRUG: encorafenib|DRUG: binimetinib,2,INDUSTRY,Pfizer,['kinase inhibitor'],"[{'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'encorafenib'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'binimetinib'}]",False,non small cell lung cancer,lung/thoracic
1006,United States,Low Grade Glioma|High Grade Glioma,"DRUG: Trametinib and Nivolumab|DRUG: Dabrafenib, trametinib, nivolumab",12,OTHER,Ann & Robert H Lurie Children's Hospital of Chicago,"['checkpoint inhibitor', 'kinase inhibitor']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'trametinib and nivolumab'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'dabrafenib'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'trametinib'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}]",True,low grade glioma high grade glioma,brain/CNS
1007,United States,Glioblastoma|Malignant Glioma|Recurrent Glioma|Refractory Glioma|WHO Grade III Glioma,BIOLOGICAL: HER2(EQ)BBζ/CD19t+ T cells|OTHER: Laboratory Biomarker Analysis|PROCEDURE: Leukapheresis,1,OTHER,City of Hope Medical Center,"['other', 'cell therapy']","[{'type': 'other', 'subtype': None, 'raw': 'her2bbζ'}, {'type': 'other', 'subtype': None, 'raw': 'cd19t'}, {'type': 'cell therapy', 'subtype': 'other', 'raw': 't cells'}]",True,glioblastoma malignant glioma recurrent glioma refractory glioma who grade iii glioma,brain/CNS
1008,United States,Advanced Melanoma|Clinical Stage III Cutaneous Melanoma AJCC v8|Clinical Stage IV Cutaneous Melanoma AJCC v8|Melanoma of Unknown Primary|Pathologic Stage IIIB Cutaneous Melanoma AJCC v8|Pathologic Stage IIIC Cutaneous Melanoma AJCC v8|Pathologic Stage IIID Cutaneous Melanoma AJCC v8|Pathologic Stage IV Cutaneous Melanoma AJCC v8|Unresectable Acral Lentiginous Melanoma|Unresectable Melanoma|Unresectable Mucosal Melanoma,BIOLOGICAL: Ipilimumab|BIOLOGICAL: Nivolumab|OTHER: Patient Observation|BIOLOGICAL: Pembrolizumab,2,NETWORK,ECOG-ACRIN Cancer Research Group,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",False,advanced melanoma clinical stage iii cutaneous melanoma ajcc v8 clinical stage iv cutaneous melanoma ajcc v8 melanoma of unknown primary pathologic stage iiib cutaneous melanoma ajcc v8 pathologic stage iiic cutaneous melanoma ajcc v8 pathologic stage iiid cutaneous melanoma ajcc v8 pathologic stage iv cutaneous melanoma ajcc v8 unresectable acral lentiginous melanoma unresectable melanoma unresectable mucosal melanoma,skin
1009,United States,Non Small Cell Lung Cancer,DRUG: Nivolumab|DRUG: Ramucirumab,2,OTHER,Fox Chase Cancer Center,"['checkpoint inhibitor', 'antibody']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'ramucirumab'}]",True,non small cell lung cancer,lung/thoracic
1010,Belgium,Malignant Pleural Mesothelioma,BIOLOGICAL: Dendritic cell vaccination|DRUG: Atezolizumab|DRUG: Platinum/pemetrexed based chemotherapy,12,OTHER,"University Hospital, Antwerp","['checkpoint inhibitor', 'other', 'cell therapy']","[{'type': 'cell therapy', 'subtype': 'other', 'raw': 'dendritic cell vaccination'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'atezolizumab'}, {'type': 'other', 'subtype': None, 'raw': 'platinum'}, {'type': 'other', 'subtype': None, 'raw': 'pemetrexed based chemotherapy'}]",True,malignant pleural mesothelioma,lung/thoracic
1011,"Austria, Belgium, France, Italy, Spain, United Kingdom, United States",Epstein-Barr Virus (EBV)-Associated Diseases|EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD)|EBV+ Lymphoproliferative Disease With Acquired (Non-congenital) Immunodeficiency (EBV+ AID LPD)|EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (EBV+ CNS PTLD)|EBV+ Post-transplant Lymphoproliferative Disease (EBV+ PTLD)|Solid Organ Transplant Complications|Lymphoproliferative Disorders|Allogeneic Hematopoietic Cell Transplant|Stem Cell Transplant Complications|EBV+ Sarcomas|Leiomyosarcoma,BIOLOGICAL: Tabelecleucel,2,INDUSTRY,Atara Biotherapeutics,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'tabelecleucel'}]",False,epstein barr virus associated diseases ebv lymphoproliferative disease with primary immunodeficiency ebv lymphoproliferative disease with acquired immunodeficiency ebv posttransplant lymphoproliferative disease in central nervous system ebv post transplant lymphoproliferative disease solid organ transplant complications lymphoproliferative disorders allogeneic hematopoietic cell transplant stem cell transplant complications ebv sarcomas leiomyosarcoma,hematologic
1012,United States,Advanced Clear Cell Renal Cell Carcinoma|Metastatic Clear Cell Renal Cell Carcinoma|Stage IV Renal Cell Cancer AJCC v8,BIOLOGICAL: Nivolumab|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration|DRUG: Sitravatinib,2,OTHER,M.D. Anderson Cancer Center,"['checkpoint inhibitor', 'kinase inhibitor']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'sitravatinib'}]",True,advanced clear cell renal cell carcinoma metastatic clear cell renal cell carcinoma stage iv renal cell cancer ajcc v8,genitourinary
1013,China,Non-small Cell Lung Cancer|Older People|Carbon Ion Radiotherapy|Radiotherapy Side Effect,RADIATION: carbon ion radiotherapy|OTHER: targeted therapy|OTHER: single regimen chemotherapy in sequence with radiotherapy,2,OTHER,Jian Chen,[],[],False,non small cell lung cancer older people carbon ion radiotherapy radiotherapy side effect,lung/thoracic
1014,"Belgium, France, Italy, Netherlands, Spain",NSCLC Stage IV,DRUG: Cemiplimab|DRUG: Placebo,2,NETWORK,European Organisation for Research and Treatment of Cancer - EORTC,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'cemiplimab'}]",False,nsclc stage iv,lung/thoracic
1015,United States,"Pediatric Sarcoma, Refractory|Pediatric Sarcoma, Relapsed",BIOLOGICAL: GEM/DOX + TGFBi expanded NK cells,12,OTHER,Nationwide Children's Hospital,"['other', 'cell therapy']","[{'type': 'other', 'subtype': None, 'raw': 'gem'}, {'type': 'other', 'subtype': None, 'raw': 'dox'}, {'type': 'cell therapy', 'subtype': 'other', 'raw': 'tgfbi expanded nk cells'}]",True,pediatric sarcoma refractory pediatric sarcoma relapsed,sarcoma
1016,Germany,Intrahepatic Cholangiocarcinoma,DRUG: Durvalumab|DRUG: Tremelimumab,2,OTHER,Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'tremelimumab'}]",False,intrahepatic cholangiocarcinoma,other
1017,"France, Italy, Spain, United Kingdom",Melanoma,BIOLOGICAL: MB097|BIOLOGICAL: Pembrolizumab|DRUG: Vancomycin,1,INDUSTRY,Microbiotica Ltd,"['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'mb097'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'other', 'subtype': None, 'raw': 'vancomycin'}]",True,melanoma,skin
1018,United States,Locally Advanced Alveolar Soft Part Sarcoma|Metastatic Alveolar Soft Part Sarcoma|Locally Advanced Non Small Cell Lung Cancer|Metastatic Non Small Cell Lung Cancer|Locally Advanced Small Cell Lung Cancer|Metastatic Small Cell Lung Cancer|Locally Advanced Hepatocellular Carcinoma|Metastatic Hepatocellular Carcinoma|Locally Advanced Melanoma|Metastatic Melanoma,DRUG: Atezolizumab,1,NIH,National Cancer Institute (NCI),['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'atezolizumab'}]",False,locally advanced alveolar soft part sarcoma metastatic alveolar soft part sarcoma locally advanced non small cell lung cancer metastatic non small cell lung cancer locally advanced small cell lung cancer metastatic small cell lung cancer locally advanced hepatocellular carcinoma metastatic hepatocellular carcinoma locally advanced melanoma metastatic melanoma,digestive
1019,China,Vinorelbine,DRUG: vinorelbine,2,OTHER,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",['other'],"[{'type': 'other', 'subtype': None, 'raw': 'vinorelbine'}]",False,vinorelbine,other
1020,United States,Head Neck Cancer|Metastatic Squamous Cell Carcinoma|Oral Cavity Squamous Cell Carcinoma|Oropharynx Squamous Cell Carcinoma|Hypopharynx Squamous Cell Carcinoma|Larynx Squamous Cell Carcinoma,DRUG: Pembrolizumab|DRUG: Carboplatin|DRUG: Paclitaxel,2,OTHER,Wake Forest University Health Sciences,"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}]",True,head neck cancer metastatic squamous cell carcinoma oral cavity squamous cell carcinoma oropharynx squamous cell carcinoma hypopharynx squamous cell carcinoma larynx squamous cell carcinoma,head/neck
1021,United States,Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Transformed Non-Hodgkin Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Transformed Non-Hodgkin Lymphoma|Richter Syndrome|Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma,DRUG: Atezolizumab|PROCEDURE: Biopsy Procedure|PROCEDURE: Biospecimen Collection|PROCEDURE: Bone Marrow Biopsy|PROCEDURE: Computed Tomography|DRUG: Gemcitabine|PROCEDURE: Magnetic Resonance Imaging|DRUG: Oxaliplatin|PROCEDURE: Positron Emission Tomography|BIOLOGICAL: Rituximab,1,NIH,National Cancer Institute (NCI),"['checkpoint inhibitor', 'antibody', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'atezolizumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'gemcitabine'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'oxaliplatin'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'rituximab'}]",True,recurrent diffuse large b cell lymphoma recurrent transformed non hodgkin lymphoma refractory diffuse large b cell lymphoma refractory transformed non hodgkin lymphoma richter syndrome transformed follicular lymphoma to diffuse large b cell lymphoma,hematologic
1022,France,Hepatocellular Carcinoma by BCLC Stage,DRUG: Tislelizumab,2,OTHER,UNICANCER,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'tislelizumab'}]",False,hepatocellular carcinoma by bclc stage,digestive
1023,China,Oral Squamous Cell Carcinoma,DRUG: Camrelizumab plus TP|DRUG: TP,3,OTHER,"Hospital of Stomatology, Wuhan University","['checkpoint inhibitor', 'other']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'camrelizumab plus tp'}, {'type': 'other', 'subtype': None, 'raw': 'tp'}]",True,oral squamous cell carcinoma,head/neck
1024,United States,Peritoneal Malignant Mesothelioma,BIOLOGICAL: Atezolizumab|BIOLOGICAL: Bevacizumab|PROCEDURE: Biospecimen Collection|DRUG: Carboplatin|PROCEDURE: Computed Tomography|PROCEDURE: Cytoreductive Surgery|DRUG: Hyperthermic Intraperitoneal Chemotherapy|DRUG: Pemetrexed|PROCEDURE: Positron Emission Tomography,2,NIH,National Cancer Institute (NCI),"['checkpoint inhibitor', 'other', 'antibody', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'atezolizumab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'bevacizumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'other', 'subtype': None, 'raw': 'hyperthermic intraperitoneal chemotherapy'}, {'type': 'chemotherapy', 'subtype': 'antifolate', 'raw': 'pemetrexed'}]",True,peritoneal malignant mesothelioma,lung/thoracic
1025,"Australia, United States",Melanoma,DRUG: mRNA-4157|BIOLOGICAL: Pembrolizumab,2,INDUSTRY,"ModernaTX, Inc.","['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'mrna-4157'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",True,melanoma,skin
1026,United States,Recurrent Glioblastoma,"BIOLOGICAL: pp65 RNA loaded lipid particles, pp65 RNA-LPs (Drug Product 1 or DP1)|BIOLOGICAL: RNA loaded lipid particles, RNA-LPs (Drug Product 2 or DP2)",1,OTHER,University of Florida,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'pp65 rna loaded lipid particles'}, {'type': 'other', 'subtype': None, 'raw': 'pp65 rna-lps'}, {'type': 'other', 'subtype': None, 'raw': 'rna loaded lipid particles'}, {'type': 'other', 'subtype': None, 'raw': 'rna-lps'}]",False,recurrent glioblastoma,brain/CNS
1027,United States,Head and Neck Squamous Cell Carcinoma|Recurrent Head and Neck Squamous Cell Carcinoma|Metastatic Head-and-neck Squamous-cell Carcinoma,DRUG: Cetuximab|OTHER: Questionnaire administration|OTHER: Quality of life assessment,2,OTHER,Wake Forest University Health Sciences,['antibody'],"[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'cetuximab'}]",False,head and neck squamous cell carcinoma recurrent head and neck squamous cell carcinoma metastatic head and neck squamous cell carcinoma,head/neck
1028,Hong Kong,Hepatocellular Carcinoma,DRUG: Durvalumab|DRUG: Tremelimumab|RADIATION: Yttrium-90 radioembolisation,2,OTHER,The University of Hong Kong,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'tremelimumab'}]",False,hepatocellular carcinoma,digestive
1029,China,Renal Cell Carcinoma|Radiotherapy|Immune Checkpoint Inhibitor,RADIATION: High-dose Radiotherapy (HDRT)|RADIATION: Low-dose Radiotherapy (LDRT)|DRUG: Anti-PD-1 monoclonal antibody,2,OTHER,"Jinling Hospital, China",['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'anti-pd-1 monoclonal antibody'}]",False,renal cell carcinoma radiotherapy immune checkpoint inhibitor,genitourinary
1030,United States,Metastatic Urothelial Carcinoma|Unresectable Urothelial Carcinoma,PROCEDURE: Biopsy Procedure|PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|BIOLOGICAL: Emavusertib|PROCEDURE: Magnetic Resonance Imaging|BIOLOGICAL: Pembrolizumab|PROCEDURE: Positron Emission Tomography,1,NIH,National Cancer Institute (NCI),"['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'emavusertib'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",True,metastatic urothelial carcinoma unresectable urothelial carcinoma,genitourinary
1031,United Kingdom,Non-small Cell Lung Cancer,DRUG: MPDL3280A|DRUG: Vemurafenib|DRUG: Alectinib|DRUG: Trastuzumab emtansine,2,OTHER,"University College, London","['other', 'kinase inhibitor']","[{'type': 'other', 'subtype': None, 'raw': 'mpdl3280a'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'vemurafenib'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'alectinib'}, {'type': 'other', 'subtype': None, 'raw': 'trastuzumab emtansine'}]",True,non small cell lung cancer,lung/thoracic
1032,China,Advanced Triple-negative Breast Cancer,DRUG: Adebry single antibody + VEX metronomic chemotherapy + radiotherapy|DRUG: debry single antibody + VEX metronomic chemotherapy,2,OTHER,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",['other'],"[{'type': 'other', 'subtype': None, 'raw': 'adebry single antibody'}, {'type': 'other', 'subtype': None, 'raw': 'vex metronomic chemotherapy'}, {'type': 'other', 'subtype': None, 'raw': 'radiotherapy'}, {'type': 'other', 'subtype': None, 'raw': 'debry single antibody'}, {'type': 'other', 'subtype': None, 'raw': 'vex metronomic chemotherapy'}]",False,advanced triple negative breast cancer,breast
1033,China,Esophageal Squamous Cell Carcinoma|Efficacy|Toxicity,DRUG: Induction Immunotherapy-Toripalimab|DRUG: Induction Chemotherapy-Albumin-paclitaxel combined with cisplatin|RADIATION: Radiotherapy|DRUG: Apatinib|DRUG: Capecitabine,2,OTHER,Sun Yat-sen University,"['checkpoint inhibitor', 'chemotherapy', 'kinase inhibitor']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'induction immunotherapy-toripalimab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'induction chemotherapy-albumin-paclitaxel combined with cisplatin'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'apatinib'}, {'type': 'chemotherapy', 'subtype': 'fluoropyrimidine', 'raw': 'capecitabine'}]",True,esophageal squamous cell carcinoma efficacy toxicity,digestive
1034,United Kingdom,Gastric Adenocarcinoma|Oesophageal Adenocarcinoma,DRUG: FLOT-A,2,OTHER,Royal Marsden NHS Foundation Trust,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'flot-a'}]",False,gastric adenocarcinoma oesophageal adenocarcinoma,digestive
1035,"Australia, Belgium, Canada, France, Israel, Italy, Malaysia, Netherlands, Philippines, Poland, Republic of, Singapore, Spain, Taiwan, Thailand, Turkey, United States",Locally Advanced or Metastatic Non-Small Cell Lung Cancer,DRUG: T-DXd|BIOLOGICAL: Durvalumab|DRUG: Cisplatin|DRUG: Carboplatin|DRUG: Pemetrexed|DRUG: Volrustomig|DRUG: Rilvegostomig,1,INDUSTRY,AstraZeneca,"['checkpoint inhibitor', 'other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 't-dxd'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'chemotherapy', 'subtype': 'antifolate', 'raw': 'pemetrexed'}, {'type': 'other', 'subtype': None, 'raw': 'volrustomig'}, {'type': 'checkpoint inhibitor', 'subtype': 'PD-1/CTLA-4 bispecific', 'raw': 'rilvegostomig'}]",True,locally advanced or metastatic non small cell lung cancer,lung/thoracic
1036,Germany,"ALL, Recurrent, Adult",DRUG: Blinatumomab|DRUG: Venetoclax,12,OTHER,Goethe University,"['targeted therapy', 'antibody']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'blinatumomab'}, {'type': 'targeted therapy', 'subtype': 'BCL-2 inhibitor', 'raw': 'venetoclax'}]",True,all recurrent adult,other
1037,United States,EGFR Gene Mutation|Glioblastoma|MGMT-Unmethylated Glioblastoma|Recurrent Glioblastoma,BIOLOGICAL: E-SYNC T Cells|DRUG: Cyclophosphamide (non-investigational)|DRUG: Fludarabine (non-investigational)|PROCEDURE: Leukapheresis|PROCEDURE: Surgical resection,1,OTHER,"Hideho Okada, MD, PhD","['chemotherapy', 'cell therapy']","[{'type': 'cell therapy', 'subtype': 'other', 'raw': 'e-sync t cells'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide'}, {'type': 'chemotherapy', 'subtype': 'purine analog', 'raw': 'fludarabine'}]",True,egfr gene mutation glioblastoma mgmt unmethylated glioblastoma recurrent glioblastoma,brain/CNS
1038,France,Squamous Cell Carcinoma of the Anus Stage III,BIOLOGICAL: Blood sample collection|PROCEDURE: Biopsy,2,OTHER,Centre Hospitalier Universitaire de Besancon,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'blood sample collection'}]",False,squamous cell carcinoma of the anus stage iii,other
1039,China,MSI-H,DRUG: Sintilimab|DRUG: IBI310&Sintilimab|PROCEDURE: Radical surgery,3,INDUSTRY,Innovent Biologics (Suzhou) Co. Ltd.,['antibody'],"[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'sintilimab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'ibi310&sintilimab'}]",False,msi h,other
1040,United States,Rectal Adenocarcinoma,DRUG: LY2157299|DRUG: Capecitabine|DRUG: Fluorouracil|PROCEDURE: Tumor specific mesorectal excision,2,OTHER,Providence Health & Services,"['other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'ly2157299'}, {'type': 'chemotherapy', 'subtype': 'fluoropyrimidine', 'raw': 'capecitabine'}, {'type': 'chemotherapy', 'subtype': 'antimetabolite', 'raw': 'fluorouracil'}]",True,rectal adenocarcinoma,digestive
1041,"Canada, United States",Locally Advanced Bladder Urothelial Carcinoma|Locally Advanced Renal Pelvis Urothelial Carcinoma|Locally Advanced Ureter Urothelial Carcinoma|Locally Advanced Urethral Urothelial Carcinoma|Locally Advanced Urothelial Carcinoma|Metastatic Bladder Urothelial Carcinoma|Metastatic Renal Pelvis Urothelial Carcinoma|Metastatic Ureter Urothelial Carcinoma|Metastatic Urethral Urothelial Carcinoma|Metastatic Urothelial Carcinoma|Recurrent Bladder Urothelial Carcinoma|Recurrent Renal Pelvis Urothelial Carcinoma|Recurrent Ureter Urothelial Carcinoma|Recurrent Urethral Urothelial Carcinoma|Recurrent Urothelial Carcinoma|Stage IIIB Bladder Cancer AJCC v8|Stage IV Bladder Cancer AJCC v8|Stage IV Renal Pelvis Cancer AJCC v8|Stage IV Ureter Cancer AJCC v8|Stage IV Urethral Cancer AJCC v8,PROCEDURE: Biospecimen Collection|PROCEDURE: Bone Scan|PROCEDURE: Computed Tomography|PROCEDURE: Echocardiography Test|DRUG: Enfortumab Vedotin|DRUG: Erdafitinib|PROCEDURE: Multigated Acquisition Scan,1,NIH,National Cancer Institute (NCI),"['antibody-drug conjugate', 'kinase inhibitor']","[{'type': 'antibody-drug conjugate', 'subtype': 'anti-Nectin-4', 'raw': 'enfortumab vedotin'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'erdafitinib'}]",True,locally advanced bladder urothelial carcinoma locally advanced renal pelvis urothelial carcinoma locally advanced ureter urothelial carcinoma locally advanced urethral urothelial carcinoma locally advanced urothelial carcinoma metastatic bladder urothelial carcinoma metastatic renal pelvis urothelial carcinoma metastatic ureter urothelial carcinoma metastatic urethral urothelial carcinoma metastatic urothelial carcinoma recurrent bladder urothelial carcinoma recurrent renal pelvis urothelial carcinoma recurrent ureter urothelial carcinoma recurrent urethral urothelial carcinoma recurrent urothelial carcinoma stage iiib bladder cancer ajcc v8 stage iv bladder cancer ajcc v8 stage iv renal pelvis cancer ajcc v8 stage iv ureter cancer ajcc v8 stage iv urethral cancer ajcc v8,genitourinary
1042,Republic of,Non-small Cell Lung Cancer,DRUG: Bojungikki-tang(BJIKT)|DRUG: Pembrolizumab,2,OTHER_GOV,Korea Institute of Oriental Medicine,"['checkpoint inhibitor', 'traditional medicine']","[{'type': 'traditional medicine', 'subtype': None, 'raw': 'bojungikki-tang'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",True,non small cell lung cancer,lung/thoracic
1043,United States,"Leukemia, Myeloid, Acute",BIOLOGICAL: VCAR33,12,INDUSTRY,Vor Biopharma,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'vcar33'}]",False,leukemia myeloid acute,hematologic
1044,China,Adjuvant Radiotherapy,RADIATION: Adjuvant radiotherapy|OTHER: Observation,2,OTHER,Zhejiang Cancer Hospital,[],[],False,adjuvant radiotherapy,other
1045,Poland,"Neoadjuvant|Immunotherapy|Sarcoma,Soft Tissue|Radiation Therapy","DRUG: Pembrolizumab, Eftilagimod alpha",2,OTHER,Maria Sklodowska-Curie National Research Institute of Oncology,"['checkpoint inhibitor', 'other']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'other', 'subtype': None, 'raw': 'eftilagimod alpha'}]",True,neoadjuvant immunotherapy sarcoma soft tissue radiation therapy,hematologic
1046,France,Soft Tissue Sarcoma Adult|Advanced Cancer,DRUG: Association of Nivolumab + Relatlimab|DRUG: Nivolumab,2,OTHER,Institut Bergonié,"['checkpoint inhibitor', 'antibody']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'association of nivolumab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'relatlimab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}]",True,soft tissue sarcoma adult advanced cancer,sarcoma
1047,China,Envafolimab Combined With Chemoradiotherapy in the Treatment of Locally Advanced pMMR/MSS Rectal Cancer,DRUG: Envafolimab combined with chemoradiotherapy in the whole course of neoadjuvant therapy,2,OTHER,Yunnan Cancer Hospital,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'envafolimab combined with chemoradiotherapy in the whole course of neoadjuvant therapy'}]",False,envafolimab combined with chemoradiotherapy in the treatment of locally advanced pmmr mss rectal cancer,digestive
1048,Netherlands,"Acute Myeloid Leukemia Refractory|Acute Myeloid Leukemia, Relapsed, Adult",BIOLOGICAL: UCB-NK cells|DRUG: IL-2,12,OTHER,Radboud University Medical Center,"['cytokine therapy', 'cell therapy']","[{'type': 'cell therapy', 'subtype': 'other', 'raw': 'ucb-nk cells'}, {'type': 'cytokine therapy', 'subtype': 'IL-2', 'raw': 'il-2'}]",True,acute myeloid leukemia refractory acute myeloid leukemia relapsed adult,hematologic
1049,United States,Lung Adenocarcinoma|Lung Non-Small Cell Carcinoma|Stage IV Lung Cancer AJCC v8,BIOLOGICAL: Ipilimumab|PROCEDURE: Local Consolidation Therapy|BIOLOGICAL: Nivolumab|OTHER: Quality-of-Life Assessment|RADIATION: Radiation Therapy|PROCEDURE: Therapeutic Conventional Surgery,3,OTHER,M.D. Anderson Cancer Center,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}]",False,lung adenocarcinoma lung non small cell carcinoma stage iv lung cancer ajcc v8,lung/thoracic
1050,China,Hepatocellular Carcinoma,RADIATION: Stereotactic body radiotherapy|DRUG: Sintilimab,2,OTHER,Sun Yat-sen University,['antibody'],"[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'sintilimab'}]",False,hepatocellular carcinoma,digestive
1051,"Canada, United States",Leukemia|Lymphoma,BIOLOGICAL: Patient-derived CD19- and CD22 specific CAR,1,OTHER,Seattle Children's Hospital,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'patient-derived cd19- and cd22 specific car'}]",False,leukemia lymphoma,hematologic
1052,United States,Melanoma Stage III|Melanoma Stage IV,DRUG: SX-682|BIOLOGICAL: Pembrolizumab,1,INDUSTRY,"Syntrix Biosystems, Inc.","['checkpoint inhibitor', 'targeted therapy']","[{'type': 'targeted therapy', 'subtype': 'CXCR1/2 inhibitor', 'raw': 'sx-682'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",True,melanoma stage iii melanoma stage iv,skin
1053,France,HNSCC,DRUG: Cetuximab|DRUG: avelumab|DRUG: Cisplatin|RADIATION: IMRT,3,OTHER,Groupe Oncologie Radiotherapie Tete et Cou,"['checkpoint inhibitor', 'antibody', 'chemotherapy']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'cetuximab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'avelumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}]",True,hnscc,other
1054,"France, Italy, Spain",Non-small Cell Lung Cancer Stage III,COMBINATION_PRODUCT: durvalumab plus platinum-based chemotherapy (cisplatin or carboplatin plus vinorelbine or pemetrexed)|COMBINATION_PRODUCT: Durvalumab plus radiotherapy|BIOLOGICAL: durvalumab,2,OTHER,Mario Negri Institute for Pharmacological Research,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab plus platinum-based chemotherapy'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab plus radiotherapy'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}]",False,non small cell lung cancer stage iii,lung/thoracic
1055,United States,Bile Duct Cancer|Cholangiocarcinoma|Cholangiocarcinoma Non-resectable|Cholangiocarcinoma Metastatic|Metastatic Intrahepatic Cholangiocarcinoma,DRUG: Gemcitabine|DRUG: Cisplatin|DRUG: Durvalumab|RADIATION: Yttrium-90,2,OTHER,Beth Israel Deaconess Medical Center,"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'gemcitabine'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}]",True,bile duct cancer cholangiocarcinoma cholangiocarcinoma non resectable cholangiocarcinoma metastatic metastatic intrahepatic cholangiocarcinoma,multiple
1056,United States,Head and Neck Cancer|Cervical Cancer|Non-small Cell Carcinoma|Melanoma|Ovarian Cancer|Anogenital Cancers|HPV - Anogenital Human Papilloma Virus Infection|HPV-Related Cervical Carcinoma|HPV-Related Carcinoma|HPV-Related Squamous Cell Carcinoma|HPV-Related Malignancy|HPV-Related Adenocarcinoma|HPV Positive Oropharyngeal Squamous Cell Carcinoma|HPV-Related Adenosquamous Carcinoma|HPV-Associated Vaginal Adenocarcinoma|HPV-Related Endocervical Adenocarcinoma|HPV-Related Anal Squamous Cell Carcinoma|HPV-Related Verrucous Carcinoma|HPV-Related Penile Squamous Cell Carcinoma|HPV-Related Vulvar Squamous Cell Carcinoma|HPV Positive Rectal Squamous Cell Carcinoma,BIOLOGICAL: TSC-204-A0201|BIOLOGICAL: TSC-204-C0702|BIOLOGICAL: TSC-200-A0201|BIOLOGICAL: TSC-204-A0201 + TSC-204-C0702|BIOLOGICAL: TSC-204-A0201 + TSC-200-A0201|BIOLOGICAL: TSC-204-C0702 + TSC-200-A0201|BIOLOGICAL: TSC-204-A0201 + TSC-203-A0201|BIOLOGICAL: TSC-204-C0702 + TSC-203-A0201|BIOLOGICAL: TSC-200-A0201 + TSC-203-A0201|BIOLOGICAL: TSC-203-A0201|BIOLOGICAL: TSC-204-A0101|BIOLOGICAL: TSC-201-B0702|BIOLOGICAL: TSC-204-A0201 + TSC-204-A0101|BIOLOGICAL: TSC-204-A0201 + TSC-201-B0702|BIOLOGICAL: TSC-204-C0702 + TSC-204-A0101|BIOLOGICAL: TSC-204-C0702 + TSC-201-B0702|BIOLOGICAL: TSC-200-A0201 + TSC-204-A0101|BIOLOGICAL: TSC-200-A0201 + TSC-201-B0702|BIOLOGICAL: TSC-203-A0201 + TSC-204-A0101|BIOLOGICAL: TSC-203-A0201 + TSC-201-B0702|BIOLOGICAL: TSC-202-A0201|BIOLOGICAL: TSC-204-A0201 + TSC-202-A0201|BIOLOGICAL: TSC-204-C0702 + TSC-202-A0201|BIOLOGICAL: TSC-200-A0201 + TSC-202-A0201|BIOLOGICAL: TSC-203-A0201 + TSC-202-A0201|BIOLOGICAL: TSC-204-A0101 + TSC-202-A0201|BIOLOGICAL: TSC-201-B0702 + TSC-202-A0201,1,INDUSTRY,"TScan Therapeutics, Inc.",['other'],"[{'type': 'other', 'subtype': None, 'raw': 'tsc-204-a0201'}, {'type': 'other', 'subtype': None, 'raw': 'tsc-204-c0702'}, {'type': 'other', 'subtype': None, 'raw': 'tsc-200-a0201'}, {'type': 'other', 'subtype': None, 'raw': 'tsc-204-a0201'}, {'type': 'other', 'subtype': None, 'raw': 'tsc-204-c0702'}, {'type': 'other', 'subtype': None, 'raw': 'tsc-204-a0201'}, {'type': 'other', 'subtype': None, 'raw': 'tsc-200-a0201'}, {'type': 'other', 'subtype': None, 'raw': 'tsc-204-c0702'}, {'type': 'other', 'subtype': None, 'raw': 'tsc-200-a0201'}, {'type': 'other', 'subtype': None, 'raw': 'tsc-204-a0201'}, {'type': 'other', 'subtype': None, 'raw': 'tsc-203-a0201'}, {'type': 'other', 'subtype': None, 'raw': 'tsc-204-c0702'}, {'type': 'other', 'subtype': None, 'raw': 'tsc-203-a0201'}, {'type': 'other', 'subtype': None, 'raw': 'tsc-200-a0201'}, {'type': 'other', 'subtype': None, 'raw': 'tsc-203-a0201'}, {'type': 'other', 'subtype': None, 'raw': 'tsc-203-a0201'}, {'type': 'other', 'subtype': None, 'raw': 'tsc-204-a0101'}, {'type': 'other', 'subtype': None, 'raw': 'tsc-201-b0702'}, {'type': 'other', 'subtype': None, 'raw': 'tsc-204-a0201'}, {'type': 'other', 'subtype': None, 'raw': 'tsc-204-a0101'}, {'type': 'other', 'subtype': None, 'raw': 'tsc-204-a0201'}, {'type': 'other', 'subtype': None, 'raw': 'tsc-201-b0702'}, {'type': 'other', 'subtype': None, 'raw': 'tsc-204-c0702'}, {'type': 'other', 'subtype': None, 'raw': 'tsc-204-a0101'}, {'type': 'other', 'subtype': None, 'raw': 'tsc-204-c0702'}, {'type': 'other', 'subtype': None, 'raw': 'tsc-201-b0702'}, {'type': 'other', 'subtype': None, 'raw': 'tsc-200-a0201'}, {'type': 'other', 'subtype': None, 'raw': 'tsc-204-a0101'}, {'type': 'other', 'subtype': None, 'raw': 'tsc-200-a0201'}, {'type': 'other', 'subtype': None, 'raw': 'tsc-201-b0702'}, {'type': 'other', 'subtype': None, 'raw': 'tsc-203-a0201'}, {'type': 'other', 'subtype': None, 'raw': 'tsc-204-a0101'}, {'type': 'other', 'subtype': None, 'raw': 'tsc-203-a0201'}, {'type': 'other', 'subtype': None, 'raw': 'tsc-201-b0702'}, {'type': 'other', 'subtype': None, 'raw': 'tsc-202-a0201'}, {'type': 'other', 'subtype': None, 'raw': 'tsc-204-a0201'}, {'type': 'other', 'subtype': None, 'raw': 'tsc-202-a0201'}, {'type': 'other', 'subtype': None, 'raw': 'tsc-204-c0702'}, {'type': 'other', 'subtype': None, 'raw': 'tsc-202-a0201'}, {'type': 'other', 'subtype': None, 'raw': 'tsc-200-a0201'}, {'type': 'other', 'subtype': None, 'raw': 'tsc-202-a0201'}, {'type': 'other', 'subtype': None, 'raw': 'tsc-203-a0201'}, {'type': 'other', 'subtype': None, 'raw': 'tsc-202-a0201'}, {'type': 'other', 'subtype': None, 'raw': 'tsc-204-a0101'}, {'type': 'other', 'subtype': None, 'raw': 'tsc-202-a0201'}, {'type': 'other', 'subtype': None, 'raw': 'tsc-201-b0702'}, {'type': 'other', 'subtype': None, 'raw': 'tsc-202-a0201'}]",False,head and neck cancer cervical cancer non small cell carcinoma melanoma ovarian cancer anogenital cancers hpv anogenital human papilloma virus infection hpv related cervical carcinoma hpv related carcinoma hpv related squamous cell carcinoma hpv related malignancy hpv related adenocarcinoma hpv positive oropharyngeal squamous cell carcinoma hpv related adenosquamous carcinoma hpv associated vaginal adenocarcinoma hpv related endocervical adenocarcinoma hpv related anal squamous cell carcinoma hpv related verrucous carcinoma hpv related penile squamous cell carcinoma hpv related vulvar squamous cell carcinoma hpv positive rectal squamous cell carcinoma,gynecologic
1057,United States,Metastatic Clear Cell Renal Cell Carcinoma|Metastatic Renal Cell Carcinoma|Stage IV Renal Cell Cancer AJCC v8,PROCEDURE: Cytoreductive Nephrectomy|DRUG: Active Comparator,3,NETWORK,SWOG Cancer Research Network,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'active comparator'}]",False,metastatic clear cell renal cell carcinoma metastatic renal cell carcinoma stage iv renal cell cancer ajcc v8,genitourinary
1058,United States,Mesothelioma,DRUG: Durvalumab / tremelimumab|DRUG: Platinum cisplatin or carboplatin and pemetrexed chemotherapy plus durvalumab/tremelimumab,12,OTHER,Baylor College of Medicine,"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'tremelimumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'platinum cisplatin or carboplatin and pemetrexed chemotherapy plus durvalumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'tremelimumab'}]",True,mesothelioma,lung/thoracic
1059,United States,Metastatic Renal Cell Carcinoma,DRUG: Evolocumab|DRUG: Nivolumab,2,OTHER,M.D. Anderson Cancer Center,"['checkpoint inhibitor', 'antibody']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'evolocumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}]",True,metastatic renal cell carcinoma,genitourinary
1060,United States,Clear Cell Renal Cell Carcinoma|Clear Cell Renal Cell Carcinoma Metastatic,DRUG: Selenomethionine (SLM)|DRUG: Axitinib|DRUG: Pembrolizumab,12,OTHER,Mohammed Milhem,"['checkpoint inhibitor', 'other', 'kinase inhibitor']","[{'type': 'other', 'subtype': None, 'raw': 'selenomethionine'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'axitinib'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",True,clear cell renal cell carcinoma clear cell renal cell carcinoma metastatic,genitourinary
1061,Australia,NSCLC,RADIATION: Radiotherapy|DRUG: SoC systemic therapy,1,OTHER,"Peter MacCallum Cancer Centre, Australia",['other'],"[{'type': 'other', 'subtype': None, 'raw': 'soc systemic therapy'}]",False,nsclc,lung/thoracic
1062,China,Gastroesophageal Junction Adenocarcinoma,RADIATION: Sintilimab combined with chemotherapy and local treatment|COMBINATION_PRODUCT: Sintilimab combined with chemotherapy only,2,OTHER,Jiangsu Cancer Institute & Hospital,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'sintilimab combined with chemotherapy only'}]",False,gastroesophageal junction adenocarcinoma,digestive
1063,"Finland, Germany, Netherlands, Norway, Sweden",Acute Myeloid Leukemia in Remission,BIOLOGICAL: DCP-001,2,INDUSTRY,Mendus,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'dcp-001'}]",False,acute myeloid leukemia in remission,hematologic
1064,China,"TNBC, Triple Negative Breast Cancer",DRUG: Neoadjuvant chemotherapy combined with Toripalimab,2,OTHER,First Affiliated Hospital of Zhejiang University,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'neoadjuvant chemotherapy combined with toripalimab'}]",False,tnbc triple negative breast cancer,breast
1065,United States,Small Cell Carcinoma of the Bladder|Small Cell Carcinoma of the Urinary Tract|Squamous Cell Carcinoma of the Bladder|Squamous Cell Carcinoma of the Urinary Tract|Primary Adenocarcinoma of the Bladder|Primary Adenocarcinoma of the Urinary Tract|Renal Medullary Carcinoma|Squamous Cell Carcinoma of the Penis,DRUG: Sacituzumab govitecan|DRUG: Atezolizumab,2,NIH,National Cancer Institute (NCI),"['checkpoint inhibitor', 'antibody-drug conjugate']","[{'type': 'antibody-drug conjugate', 'subtype': 'anti-Trop-2', 'raw': 'sacituzumab govitecan'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'atezolizumab'}]",True,small cell carcinoma of the bladder small cell carcinoma of the urinary tract squamous cell carcinoma of the bladder squamous cell carcinoma of the urinary tract primary adenocarcinoma of the bladder primary adenocarcinoma of the urinary tract renal medullary carcinoma squamous cell carcinoma of the penis,genitourinary
1066,United States,Non-hodgkin Lymphoma|Hodgkin Lymphoma,"DRUG: DOC Group B|DRUG: Pv-COMRAD 1 and 2 Group B|DRUG: Pv-R-CYM 1 and 2 Group B|DRUG: DOC Group C|DRUG: MAD CPR 1 and 2|DRUG: Pv-R CYVE 1 and 2|DRUG: Pv-R CYVE-MTX 1 and 2|DRUG: MAD CP|DRUG: Pv-Cytarabine/etoposide|DRUG: AD CP|DRUG: Bv-AVD-R 1 and 2: COHORT IIa|DRUG: Bv-NVD-R, Cycle 1-2|DRUG: Bv-NVD-R, Cycle 1-4 SER|DRUG: Bv-AVD-R|DRUG: Bv-NVD-R, Cycle 1-4 RER|DRUG: Bv-NAVD-R, Cycle 1-2|RADIATION: Involved Site Radiation Therapy",2,OTHER,New York Medical College,"['other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'doc group b'}, {'type': 'other', 'subtype': None, 'raw': 'pv-comrad 1 and 2 group b'}, {'type': 'other', 'subtype': None, 'raw': 'pv-r-cym 1 and 2 group b'}, {'type': 'other', 'subtype': None, 'raw': 'doc group c'}, {'type': 'other', 'subtype': None, 'raw': 'mad cpr 1 and 2'}, {'type': 'other', 'subtype': None, 'raw': 'pv-r cyve 1 and 2'}, {'type': 'other', 'subtype': None, 'raw': 'pv-r cyve-mtx 1 and 2'}, {'type': 'other', 'subtype': None, 'raw': 'mad cp'}, {'type': 'other', 'subtype': None, 'raw': 'pv-cytarabine'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'etoposide'}, {'type': 'other', 'subtype': None, 'raw': 'ad cp'}, {'type': 'other', 'subtype': None, 'raw': 'bv-avd-r 1 and 2: cohort iia'}, {'type': 'other', 'subtype': None, 'raw': 'bv-nvd-r'}, {'type': 'other', 'subtype': None, 'raw': 'cycle 1-2'}, {'type': 'other', 'subtype': None, 'raw': 'bv-nvd-r'}, {'type': 'other', 'subtype': None, 'raw': 'cycle 1-4 ser'}, {'type': 'other', 'subtype': None, 'raw': 'bv-avd-r'}, {'type': 'other', 'subtype': None, 'raw': 'bv-nvd-r'}, {'type': 'other', 'subtype': None, 'raw': 'cycle 1-4 rer'}, {'type': 'other', 'subtype': None, 'raw': 'bv-navd-r'}, {'type': 'other', 'subtype': None, 'raw': 'cycle 1-2'}]",True,non hodgkin lymphoma hodgkin lymphoma,hematologic
1067,China,Advanced Gastric or Gastroesophageal Junction Adenocarcinoma,DRUG: Serplulimab|DRUG: Lenvatinib|DRUG: Paclitaxel/Paclitaxel-albumin/Paclitaxel liposome,2,OTHER,Qilu Hospital of Shandong University,"['targeted therapy', 'antibody', 'chemotherapy']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'serplulimab'}, {'type': 'targeted therapy', 'subtype': 'other', 'raw': 'lenvatinib'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel-albumin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel liposome'}]",True,advanced gastric or gastroesophageal junction adenocarcinoma,digestive
1068,China,NSCLC Stage IV,RADIATION: SBRT or LDRT|DRUG: PD-1/PD-L1 inhibitor combined with platinum-based chemotherapy,2,OTHER,Fudan University,"['checkpoint inhibitor', 'other']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'pd-1'}, {'type': 'other', 'subtype': None, 'raw': 'pd-l1 inhibitor combined with platinum-based chemotherapy'}]",True,nsclc stage iv,lung/thoracic
1069,United States,"Colorectal Cancer|Hematologic Malignancy|Rectum Cancer|Acute Myeloid Leukemia|Myelodysplastic Syndromes|Acute Lymphoblastic Leukemia|Chronic Myeloid Leukemia|Chronic Lymphocytic Leukemia|Hodgkin Lymphoma|Non Hodgkin Lymphoma|Myeloproliferative Syndrome|Plasma Cell Myeloma|Gastric Cancer|Esophageal Cancer|Esophagus Cancer|Gastric Cancer, Metastatic|Unresectable Esophageal Cancer|Metastatic Esophageal Cancer",DRUG: Vactosertib|DRUG: Fludarabine Phosphate|DRUG: Cyclophosphamide|DRUG: IL-2|DRUG: Natural Killer Cells,1,OTHER,David Wald,"['other', 'cytokine therapy', 'chemotherapy', 'cell therapy']","[{'type': 'other', 'subtype': None, 'raw': 'vactosertib'}, {'type': 'chemotherapy', 'subtype': 'purine analog', 'raw': 'fludarabine phosphate'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide'}, {'type': 'cytokine therapy', 'subtype': 'IL-2', 'raw': 'il-2'}, {'type': 'cell therapy', 'subtype': 'other', 'raw': 'natural killer cells'}]",True,colorectal cancer hematologic malignancy rectum cancer acute myeloid leukemia myelodysplastic syndromes acute lymphoblastic leukemia chronic myeloid leukemia chronic lymphocytic leukemia hodgkin lymphoma non hodgkin lymphoma myeloproliferative syndrome plasma cell myeloma gastric cancer esophageal cancer esophagus cancer gastric cancer metastatic unresectable esophageal cancer metastatic esophageal cancer,digestive
1070,China,Hepatocellular Carcinoma,PROCEDURE: FOLFOX-HAIC|DRUG: Camrelizumab|DRUG: Apatinib,3,OTHER,Sun Yat-sen University,"['checkpoint inhibitor', 'kinase inhibitor']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'camrelizumab'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'apatinib'}]",True,hepatocellular carcinoma,digestive
1071,United States,Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8|Metastatic Head and Neck Squamous Cell Carcinoma|Metastatic Hypopharyngeal Squamous Cell Carcinoma|Metastatic Laryngeal Squamous Cell Carcinoma|Metastatic Oral Cavity Squamous Cell Carcinoma|Metastatic Oropharyngeal Squamous Cell Carcinoma|Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8|Stage IV Hypopharyngeal Carcinoma AJCC v8|Stage IV Laryngeal Cancer AJCC v8|Stage IV Lip and Oral Cavity Cancer AJCC v8|Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8,DRUG: Carboplatin|DRUG: Cisplatin|PROCEDURE: Computed Tomography|DRUG: Fluorouracil|PROCEDURE: Magnetic Resonance Imaging|DRUG: Paclitaxel|BIOLOGICAL: Pembrolizumab|PROCEDURE: Positron Emission Tomography|OTHER: Quality-of-Life Assessment|RADIATION: Radiation Therapy,3,NETWORK,ECOG-ACRIN Cancer Research Group,"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}, {'type': 'chemotherapy', 'subtype': 'antimetabolite', 'raw': 'fluorouracil'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",True,clinical stage iv hpv mediated oropharyngeal carcinoma ajcc v8 metastatic head and neck squamous cell carcinoma metastatic hypopharyngeal squamous cell carcinoma metastatic laryngeal squamous cell carcinoma metastatic oral cavity squamous cell carcinoma metastatic oropharyngeal squamous cell carcinoma stage iv cutaneous squamous cell carcinoma of the head and neck ajcc v8 stage iv hypopharyngeal carcinoma ajcc v8 stage iv laryngeal cancer ajcc v8 stage iv lip and oral cavity cancer ajcc v8 stage iv oropharyngeal carcinoma ajcc v8,skin
1072,United States,Metastatic Pancreatic Adenocarcinoma|Stage IV Pancreatic Cancer AJCC v8,PROCEDURE: Biopsy Procedure|PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|PROCEDURE: Magnetic Resonance Imaging|DRUG: Olaparib|BIOLOGICAL: Pembrolizumab,2,NIH,National Cancer Institute (NCI),"['checkpoint inhibitor', 'targeted therapy']","[{'type': 'targeted therapy', 'subtype': 'PARP inhibitor', 'raw': 'olaparib'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",True,metastatic pancreatic adenocarcinoma stage iv pancreatic cancer ajcc v8,digestive
1073,"Canada, Puerto Rico, United States",Ann Arbor Stage III Hodgkin Lymphoma|Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma|Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma|Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma|Ann Arbor Stage IV Hodgkin Lymphoma|Ann Arbor Stage IV Lymphocyte-Depleted Classic Hodgkin Lymphoma|Ann Arbor Stage IV Mixed Cellularity Classic Hodgkin Lymphoma|Ann Arbor Stage IV Nodular Sclerosis Classic Hodgkin Lymphoma|Classic Hodgkin Lymphoma|Lymphocyte-Rich Classic Hodgkin Lymphoma,PROCEDURE: Biospecimen Collection|DRUG: Brentuximab Vedotin|PROCEDURE: Computed Tomography|DRUG: Dacarbazine|DRUG: Doxorubicin Hydrochloride|BIOLOGICAL: Filgrastim|PROCEDURE: Magnetic Resonance Imaging|BIOLOGICAL: Nivolumab|BIOLOGICAL: Pegfilgrastim|PROCEDURE: Positron Emission Tomography|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration|RADIATION: Radiation Therapy|DRUG: Vinblastine Sulfate,3,NIH,National Cancer Institute (NCI),"['checkpoint inhibitor', 'other', 'supportive care', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'brentuximab vedotin'}, {'type': 'chemotherapy', 'subtype': 'alkylating agent', 'raw': 'dacarbazine'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'doxorubicin hydrochloride'}, {'type': 'supportive care', 'subtype': 'G-CSF', 'raw': 'filgrastim'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'other', 'subtype': None, 'raw': 'pegfilgrastim'}, {'type': 'other', 'subtype': None, 'raw': 'vinblastine sulfate'}]",True,ann arbor stage iii hodgkin lymphoma ann arbor stage iii lymphocyte depleted classic hodgkin lymphoma ann arbor stage iii mixed cellularity classic hodgkin lymphoma ann arbor stage iii nodular sclerosis classic hodgkin lymphoma ann arbor stage iv hodgkin lymphoma ann arbor stage iv lymphocyte depleted classic hodgkin lymphoma ann arbor stage iv mixed cellularity classic hodgkin lymphoma ann arbor stage iv nodular sclerosis classic hodgkin lymphoma classic hodgkin lymphoma lymphocyte rich classic hodgkin lymphoma,hematologic
1074,China,"Leukemia, B-cell",BIOLOGICAL: CART-19/22,12,INDUSTRY,"Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd","['other', 'cell therapy']","[{'type': 'cell therapy', 'subtype': 'engineered cell', 'raw': 'cart-19'}, {'type': 'other', 'subtype': None, 'raw': '22'}]",True,leukemia b cell,hematologic
1075,Canada,"Mesothelioma, Malignant",DRUG: Cyclophosphamide|DRUG: Tremelimumab|DRUG: Durvalumab,2,OTHER,"University Health Network, Toronto","['checkpoint inhibitor', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'tremelimumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}]",True,mesothelioma malignant,lung/thoracic
1076,China,"SCLC, Limited Stage",DRUG: Durvalumab|DRUG: Chemotherapy drug of EP regimen|RADIATION: radiotherapy,2,OTHER,Hebei Medical University Fourth Hospital,"['checkpoint inhibitor', 'other']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}, {'type': 'other', 'subtype': None, 'raw': 'chemotherapy drug of ep regimen'}]",True,sclc limited stage,other
1077,China,Esophageal Squamous Cell Carcinoma,DRUG: Tislelizumab,1,OTHER,Affiliated Cancer Hospital of Shantou University Medical College,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'tislelizumab'}]",False,esophageal squamous cell carcinoma,digestive
1078,United States,High-risk Smoldering Multiple Myeloma|Smoldering Multiple Myeloma|Multiple Myeloma,DRUG: Teclistamab|DRUG: Lenalidomide|DRUG: Dexamethasone,2,OTHER,"Irene Ghobrial, MD","['other', 'antibody', 'supportive care']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'teclistamab'}, {'type': 'other', 'subtype': None, 'raw': 'lenalidomide'}, {'type': 'supportive care', 'subtype': 'steroid', 'raw': 'dexamethasone'}]",True,high risk smoldering multiple myeloma smoldering multiple myeloma multiple myeloma,hematologic
1079,China,Esophageal Squamous Cell Carcinoma|Oligometastatic Disease,DRUG: PD-1 combined with SBRT,2,OTHER,Sun Yat-sen University,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'pd-1 combined with sbrt'}]",False,esophageal squamous cell carcinoma oligometastatic disease,digestive
1080,United States,Head and Neck Cancer|Head and Neck Squamous Cell Carcinoma|Metastatic Head and Neck Cancer|Recurrent Head and Neck Cancer|Metastatic Head-and-neck Squamous-cell Carcinoma|Recurrent Head and Neck Squamous Cell Carcinoma,BIOLOGICAL: PD-L1 t-haNK|DRUG: Cetuximab|BIOLOGICAL: N-803,2,OTHER,Glenn J. Hanna,"['antibody', 'cytokine therapy', 'cell therapy']","[{'type': 'cell therapy', 'subtype': 'engineered T cell', 'raw': 'pd-l1 t-hank'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'cetuximab'}, {'type': 'cytokine therapy', 'subtype': 'IL-15 superagonist', 'raw': 'n-803'}]",True,head and neck cancer head and neck squamous cell carcinoma metastatic head and neck cancer recurrent head and neck cancer metastatic head and neck squamous cell carcinoma recurrent head and neck squamous cell carcinoma,head/neck
1081,China,Locally Advanced Esophageal Squamous Cell Carcinoma,DRUG: S-1|DRUG: Toripalimab|RADIATION: Intensity-modulated radiotherapy,2,OTHER,Sun Yat-sen University,"['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 's-1'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'toripalimab'}]",True,locally advanced esophageal squamous cell carcinoma,digestive
1082,China,NSCLC,RADIATION: SBRT+LDRT|DRUG: Toripalimab|DRUG: Chemotherapy drug|DRUG: Toripalimab,2,OTHER,Shanghai Chest Hospital,"['checkpoint inhibitor', 'other']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'toripalimab'}, {'type': 'other', 'subtype': None, 'raw': 'chemotherapy drug'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'toripalimab'}]",True,nsclc,lung/thoracic
1083,United States,Recurrent Head and Neck Cutaneous Squamous Cell Carcinoma|Recurrent Skin Squamous Cell Carcinoma|Resectable Head and Neck Cutaneous Squamous Cell Carcinoma|Resectable Skin Squamous Cell Carcinoma|Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8|Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8,PROCEDURE: Biospecimen Collection|BIOLOGICAL: Cemiplimab|PROCEDURE: Computed Tomography|RADIATION: Image Guided Radiation Therapy|RADIATION: Intensity-Modulated Radiation Therapy|PROCEDURE: Magnetic Resonance Imaging|PROCEDURE: Positron Emission Tomography|OTHER: Questionnaire Administration|PROCEDURE: Surgical Procedure|PROCEDURE: Surgical Procedure,3,NIH,National Cancer Institute (NCI),['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'cemiplimab'}]",False,recurrent head and neck cutaneous squamous cell carcinoma recurrent skin squamous cell carcinoma resectable head and neck cutaneous squamous cell carcinoma resectable skin squamous cell carcinoma stage iii head and neck cutaneous squamous cell carcinoma ajcc v8 stage iv head and neck cutaneous squamous cell carcinoma ajcc v8,skin
1084,China,Head and Neck Squamous Cell Carcinoma,DRUG: Anti-PD-1 monoclonal antibody|OTHER: Postoperative CCRT,2,OTHER,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'anti-pd-1 monoclonal antibody'}]",False,head and neck squamous cell carcinoma,head/neck
1085,France,Small Cell Lung Carcinoma,DRUG: Durvalumab,2,OTHER,UNICANCER,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}]",False,small cell lung carcinoma,lung/thoracic
1086,Switzerland,NSCLC Stage IV,DRUG: Atezolizumab,2,OTHER,Oncology Institute of Southern Switzerland,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'atezolizumab'}]",False,nsclc stage iv,lung/thoracic
1087,United States,Prostate Cancer Patients on Active Surveillance,"DRUG: Poly-ICLC intramuscular (IM) injection|DRUG: Poly-ICLC, Intertumoral (IT) injection",2,OTHER,Ashutosh Kumar Tewari,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'poly-iclc intramuscular injection'}, {'type': 'other', 'subtype': None, 'raw': 'poly-iclc'}, {'type': 'other', 'subtype': None, 'raw': 'intertumoral injection'}]",False,prostate cancer patients on active surveillance,genitourinary
1088,United States,Hepatocellular Carcinoma Non-resectable,COMBINATION_PRODUCT: Fluorine-18 fluorocholine,2,OTHER,Queen's Medical Center,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'fluorine-18 fluorocholine'}]",False,hepatocellular carcinoma non resectable,digestive
1089,United States,High-grade Glioma,BIOLOGICAL: Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cells,1,OTHER,University of Florida,['cell therapy'],"[{'type': 'cell therapy', 'subtype': 'other', 'raw': 'ex-vivo expanded autologous il-8 receptor modified cd70 car t cells'}]",False,high grade glioma,brain/CNS
1090,"Belgium, France, Italy, Spain, United Kingdom","Carcinoma, Squamous Cell of Head and Neck",DRUG: Afatinib|DRUG: Palbociclib|DRUG: standard of care|DRUG: IPH2201|DRUG: Durvalumab|DRUG: Niraparib|DRUG: INCAGN01876,2,NETWORK,European Organisation for Research and Treatment of Cancer - EORTC,"['targeted therapy', 'other', 'non-therapeutic', 'kinase inhibitor', 'checkpoint inhibitor']","[{'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'afatinib'}, {'type': 'targeted therapy', 'subtype': 'CDK4/6 inhibitor', 'raw': 'palbociclib'}, {'type': 'non-therapeutic', 'subtype': 'supportive', 'raw': 'standard of care'}, {'type': 'other', 'subtype': None, 'raw': 'iph2201'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}, {'type': 'targeted therapy', 'subtype': 'PARP inhibitor', 'raw': 'niraparib'}, {'type': 'other', 'subtype': None, 'raw': 'incagn01876'}]",True,carcinoma squamous cell of head and neck,head/neck
1091,United States,Lung Non-Small Cell Carcinoma|Stage III Lung Cancer AJCC V8,BIOLOGICAL: Durvalumab|RADIATION: Radiation Therapy|PROCEDURE: Biospecimen Collection,2,OTHER,Mayo Clinic,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}]",False,lung non small cell carcinoma stage iii lung cancer ajcc v8,lung/thoracic
1092,United States,Metastatic Melanoma|Advanced Locoregional Melanoma|Metastatic Renal Cell Carcinoma|Clear Cell Histology,DRUG: Pembrolizumab|DRUG: Aldesleukin,2,NIH,National Cancer Institute (NCI),"['checkpoint inhibitor', 'cytokine therapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'cytokine therapy', 'subtype': 'IL-2', 'raw': 'aldesleukin'}]",True,metastatic melanoma advanced locoregional melanoma metastatic renal cell carcinoma clear cell histology,genitourinary
1093,United States,Melanoma Stage III|Melanoma Stage IV|Inoperable Disease,DRUG: Interleukin-2|DRUG: Ipilimumab|DRUG: Nivolumab,2,OTHER,H. Lee Moffitt Cancer Center and Research Institute,"['checkpoint inhibitor', 'cytokine therapy']","[{'type': 'cytokine therapy', 'subtype': 'IL-2', 'raw': 'interleukin-2'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}]",True,melanoma stage iii melanoma stage iv inoperable disease,skin
1094,China,Head and Neck Squamous Cell Carcinoma,DRUG: Tislelizumab-jsgr|DRUG: Cisplatin|DRUG: Albumin-Bound Paclitaxel|RADIATION: Radiotherapy,2,OTHER,Beijing Tongren Hospital,"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'tislelizumab-jsgr'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'albumin-bound paclitaxel'}]",True,head and neck squamous cell carcinoma,head/neck
1095,United States,Lymphoplasmacytic Lymphoma,BIOLOGICAL: Autologous Lymphoma Immunoglobulin-derived scFv-chemokine DNA Vaccine|OTHER: Laboratory Biomarker Analysis,1,OTHER,M.D. Anderson Cancer Center,['vaccine'],"[{'type': 'vaccine', 'subtype': 'vaccine', 'raw': 'autologous lymphoma immunoglobulin-derived scfv-chemokine dna vaccine'}]",False,lymphoplasmacytic lymphoma,hematologic
1096,"Australia, United States",Acute Lymphoblastic Leukemia|Acute Lymphoblastic Lymphoma,DRUG: Prednisone|DRUG: Vincristine|DRUG: Daunorubicin|DRUG: Pegaspargase|DRUG: Erwinase®|DRUG: Cyclophosphamide|DRUG: Cytarabine|DRUG: Mercaptopurine|DRUG: Dasatinib|DRUG: Methotrexate|DRUG: Blinatumomab|DRUG: Ruxolitinib|DRUG: Bortezomib|DRUG: Dexamethasone|DRUG: Doxorubicin|DRUG: Etoposide|DRUG: Clofarabine|DRUG: Vorinostat|DRUG: Idarubicin|DRUG: Nelarabine|DRUG: Thioguanine|DRUG: Asparaginase Erwinia chrysanthemi (recombinant)-rywn|DRUG: Calaspargase Pegol,23,OTHER,St. Jude Children's Research Hospital,"['other', 'chemotherapy', 'kinase inhibitor', 'antibody', 'supportive care']","[{'type': 'supportive care', 'subtype': 'steroid', 'raw': 'prednisone'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'vincristine'}, {'type': 'other', 'subtype': None, 'raw': 'daunorubicin'}, {'type': 'other', 'subtype': None, 'raw': 'pegaspargase'}, {'type': 'other', 'subtype': None, 'raw': 'erwinase®'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide'}, {'type': 'chemotherapy', 'subtype': 'antimetabolite', 'raw': 'cytarabine'}, {'type': 'chemotherapy', 'subtype': 'purine analog', 'raw': 'mercaptopurine'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'dasatinib'}, {'type': 'chemotherapy', 'subtype': 'antifolate', 'raw': 'methotrexate'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'blinatumomab'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'ruxolitinib'}, {'type': 'other', 'subtype': None, 'raw': 'bortezomib'}, {'type': 'supportive care', 'subtype': 'steroid', 'raw': 'dexamethasone'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'doxorubicin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'etoposide'}, {'type': 'other', 'subtype': None, 'raw': 'clofarabine'}, {'type': 'other', 'subtype': None, 'raw': 'vorinostat'}, {'type': 'chemotherapy', 'subtype': 'anthracycline', 'raw': 'idarubicin'}, {'type': 'other', 'subtype': None, 'raw': 'nelarabine'}, {'type': 'other', 'subtype': None, 'raw': 'thioguanine'}, {'type': 'other', 'subtype': None, 'raw': 'asparaginase erwinia chrysanthemi -rywn'}, {'type': 'other', 'subtype': None, 'raw': 'calaspargase pegol'}]",True,acute lymphoblastic leukemia acute lymphoblastic lymphoma,hematologic
1097,"Australia, United States","Triple Negative Breast Cancer|Diffuse Large B Cell Lymphoma|Follicular Lymphoma|Lymphoma, Non-Hodgkin|Mantle Cell Lymphoma|Bladder Cancer|Uveal Melanoma, Recurrent|Cervix Cancer|Carcinoma in Situ|Head and Neck Squamous Cell Carcinoma|Skin Cancer|Metastatic Cancer|Tumor, Solid|Tumor Recurrence",DRUG: ONM-501|DRUG: Cemiplimab,1,INDUSTRY,"OncoNano Medicine, Inc.","['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'onm-501'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'cemiplimab'}]",True,triple negative breast cancer diffuse large b cell lymphoma follicular lymphoma lymphoma non hodgkin mantle cell lymphoma bladder cancer uveal melanoma recurrent cervix cancer carcinoma in situ head and neck squamous cell carcinoma skin cancer metastatic cancer tumor solid tumor recurrence,genitourinary
1098,"Australia, Belgium, Italy, Malaysia, Poland, Republic of, Romania, Spain, Taiwan, United Kingdom, United States",Head and Neck Squamous Cell Carcinoma (HNSCC),DRUG: INBRX-106|DRUG: Pembrolizumab,23,INDUSTRY,"Inhibrx Biosciences, Inc","['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'inbrx-106'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",True,head and neck squamous cell carcinoma,head/neck
1099,"Australia, United States",Glioblastoma|Malignant Glioma|Recurrent Glioblastoma|Recurrent Malignant Glioma|Recurrent Grade III Glioma|Grade III Glioma,BIOLOGICAL: Nivolumab|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration,1,OTHER,"Sabine Mueller, MD, PhD",['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}]",False,glioblastoma malignant glioma recurrent glioblastoma recurrent malignant glioma recurrent grade iii glioma grade iii glioma,brain/CNS
1100,China,Hepatocellular Carcinoma,DRUG: Sintilimab,2,OTHER,Xin-Hua Xu,['antibody'],"[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'sintilimab'}]",False,hepatocellular carcinoma,digestive
1101,United States,Pancreatic Adenocarcinoma,DRUG: Nivolumab|PROCEDURE: Irreversible Electroporation,2,OTHER,University of Louisville,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}]",False,pancreatic adenocarcinoma,digestive
1102,Italy,Pleural Mesothelioma,DRUG: Carboplatin/Cisplatin - Pemetrexed - Pembrolizumab,2,OTHER,Istituto Oncologico Veneto IRCCS,['chemotherapy'],"[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin - pemetrexed - pembrolizumab'}]",False,pleural mesothelioma,lung/thoracic
1103,United States,Sarcoma,DRUG: Palbociclib|DRUG: Pembrolizumab,1,OTHER,John Rieth,"['checkpoint inhibitor', 'targeted therapy']","[{'type': 'targeted therapy', 'subtype': 'CDK4/6 inhibitor', 'raw': 'palbociclib'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",True,sarcoma,sarcoma
1104,China,Non Small Cell Lung Cancer|Brain Metastases|Stereotactic Radiation|Immunotherapy,DRUG: Cadonilimab combined with SRS,2,OTHER,Rongrong Zhou,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'cadonilimab combined with srs'}]",False,non small cell lung cancer brain metastases stereotactic radiation immunotherapy,lung/thoracic
1105,United States,Diarrhea|Enterocolitis,BIOLOGICAL: SER-155,1,OTHER,Memorial Sloan Kettering Cancer Center,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'ser-155'}]",False,diarrhea enterocolitis,other
1106,United States,"Grade I Meningioma, Adult|Grade II Meningioma, Adult|Grade III Meningioma, Adult|Recurrent Meningioma",DRUG: Pembrolizumab|PROCEDURE: Stereotactic Radiosurgery,2,OTHER,"Nancy Ann Oberheim Bush, MD",['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",False,grade i meningioma adult grade ii meningioma adult grade iii meningioma adult recurrent meningioma,other
1107,"United Kingdom, United States",Non-small Cell Lung Cancer,DRUG: BNT327|DRUG: Docetaxel,2,INDUSTRY,BioNTech SE,"['other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'bnt327'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'docetaxel'}]",True,non small cell lung cancer,lung/thoracic
1108,Belarus,B-cell Acute Lymphoblastic Leukemia|Lymphoblastic B-Cell Lymphoma,BIOLOGICAL: CD19 CAR-T-cells|DRUG: Tocilizumab,1,OTHER,"Belarusian Research Center for Pediatric Oncology, Hematology and Immunology","['antibody', 'cell therapy']","[{'type': 'cell therapy', 'subtype': 'engineered cell', 'raw': 'cd19 car-t-cells'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'tocilizumab'}]",True,b cell acute lymphoblastic leukemia lymphoblastic b cell lymphoma,hematologic
1109,China,Head and Neck Squamous Cell Carcinoma,DRUG: Ivonescimab combined with TP|DRUG: Cadonilimab combined with TP|DRUG: Penpulimab combined with TP,2,OTHER,Lei Liu,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'ivonescimab combined with tp'}, {'type': 'other', 'subtype': None, 'raw': 'cadonilimab combined with tp'}, {'type': 'other', 'subtype': None, 'raw': 'penpulimab combined with tp'}]",False,head and neck squamous cell carcinoma,head/neck
1110,"Georgia, Germany, Republic of, Spain, Taiwan, Turkey, United States",Advanced Non-Small Cell Lung Cancer,DRUG: BNT116|DRUG: Cemiplimab,2,INDUSTRY,Regeneron Pharmaceuticals,"['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'bnt116'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'cemiplimab'}]",True,advanced non small cell lung cancer,lung/thoracic
1111,United States,Fibrolamellar Hepatocellular Carcinoma,DRUG: Durvalumab|DRUG: DRP-104,12,OTHER,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,"['checkpoint inhibitor', 'other']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}, {'type': 'other', 'subtype': None, 'raw': 'drp-104'}]",True,fibrolamellar hepatocellular carcinoma,digestive
1112,"Belarus, Russian Federation",Melanoma Stage III|Melanoma (Skin),BIOLOGICAL: BCD-217|BIOLOGICAL: anti-PD1|PROCEDURE: Excision of the primary lesion|PROCEDURE: Regional lymphadenectomy,3,INDUSTRY,Biocad,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'bcd-217'}, {'type': 'other', 'subtype': None, 'raw': 'anti-pd1'}]",False,melanoma stage iii melanoma,skin
1113,China,T-lymphoblastic Lymphoma|T-ALL,BIOLOGICAL: CAR-T,1,INDUSTRY,"Hebei Senlang Biotechnology Inc., Ltd.",['cell therapy'],"[{'type': 'cell therapy', 'subtype': 'engineered cell', 'raw': 'car-t'}]",False,t lymphoblastic lymphoma t all,hematologic
1114,United States,Metastatic Castration-resistant Prostate Cancer,DRUG: Testosterone Cypionate|DRUG: Sipuleucel-T,2,OTHER,Yale University,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'testosterone cypionate'}, {'type': 'other', 'subtype': None, 'raw': 'sipuleucel-t'}]",False,metastatic castration resistant prostate cancer,genitourinary
1115,United States,Microsatellite Stable Rectal Carcinoma|Locally Advanced Rectal Adenocarcinoma,DRUG: Balstilimab|DRUG: Botensilimab,2,OTHER,Memorial Sloan Kettering Cancer Center,['antibody'],"[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'balstilimab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'botensilimab'}]",False,microsatellite stable rectal carcinoma locally advanced rectal adenocarcinoma,digestive
1116,Italy,Mesotheliomas Pleural,DRUG: Atezolizumab 1200 mg in 20 ML Injection|DRUG: Placebo,3,OTHER,Gruppo Oncologico Italiano di Ricerca Clinica,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'atezolizumab 1200 in 20 injection'}]",False,mesotheliomas pleural,lung/thoracic
1117,"Canada, United States",Metastatic Undifferentiated Pleomorphic Sarcoma|Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8|Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8|Unresectable Undifferentiated Pleomorphic Sarcoma,PROCEDURE: Biospecimen Collection|PROCEDURE: Diagnostic Imaging Testing|DRUG: Doxorubicin|PROCEDURE: Echocardiography Test|PROCEDURE: Multigated Acquisition Scan|BIOLOGICAL: Pembrolizumab,3,NIH,National Cancer Institute (NCI),"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'doxorubicin'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",True,metastatic undifferentiated pleomorphic sarcoma stage iii soft tissue sarcoma of the trunk and extremities ajcc v8 stage iv soft tissue sarcoma of the trunk and extremities ajcc v8 unresectable undifferentiated pleomorphic sarcoma,sarcoma
1118,United States,Renal Cell Carcinoma|Clear Cell Renal Cell Carcinoma,DRUG: Pembrolizumab|DRUG: Axitinib,2,OTHER,H. Lee Moffitt Cancer Center and Research Institute,"['checkpoint inhibitor', 'kinase inhibitor']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'axitinib'}]",True,renal cell carcinoma clear cell renal cell carcinoma,genitourinary
1119,China,Cervical Cancer|Neoadjuvant Chemoimmunotherapy|Radical Hysterectomy|Extrafascial Hysterectomy,DRUG: Cadonilimab|DRUG: Paclitaxel-albumin|DRUG: Cisplatin|PROCEDURE: Extrafascial hysterectomy|PROCEDURE: Radical hysterectomy|PROCEDURE: Cone biopsy,2,OTHER,Tongji Hospital,"['antibody', 'chemotherapy']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'cadonilimab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel-albumin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}]",True,cervical cancer neoadjuvant chemoimmunotherapy radical hysterectomy extrafascial hysterectomy,gynecologic
1120,United States,Esophageal Adenocarcinoma|Gastric Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma,DRUG: OBP-301|DRUG: Pembrolizumab,2,OTHER,Weill Medical College of Cornell University,"['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'obp-301'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",True,esophageal adenocarcinoma gastric adenocarcinoma gastroesophageal junction adenocarcinoma,digestive
1121,France,Lung Adenocarcinoma|Cryotherapy Effect,DEVICE: Cryoablation|DRUG: Pembrolizumab|DRUG: Pemetrexed|DRUG: Carboplatin,3,OTHER,Institut Bergonié,"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'chemotherapy', 'subtype': 'antifolate', 'raw': 'pemetrexed'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}]",True,lung adenocarcinoma cryotherapy effect,lung/thoracic
1122,"France, Israel, United Kingdom, United States",Glioblastoma,DEVICE: Optune® device|DRUG: Temozolomide|DRUG: Pembrolizumab|DRUG: Placebo,3,INDUSTRY,NovoCure GmbH,"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'temozolomide'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",True,glioblastoma,brain/CNS
1123,"Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, France, Germany, Greece, Hong Kong, Hungary, India, Ireland, Israel, Italy, Japan, Mexico, Netherlands, Poland, Portugal, Republic of, Romania, Saudi Arabia, Spain, Switzerland, Taiwan, Thailand, Turkey, United Kingdom, United States","Carcinoma, Non-Small-Cell Lung",DRUG: Adagrasib|DRUG: Pembrolizumab|DRUG: Carboplatin|DRUG: Pemetrexed|DRUG: Placebo|DRUG: Cisplatin,3,INDUSTRY,Mirati Therapeutics Inc.,"['checkpoint inhibitor', 'other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'adagrasib'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'chemotherapy', 'subtype': 'antifolate', 'raw': 'pemetrexed'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}]",True,carcinoma non small cell lung,lung/thoracic
1124,"Canada, United States",Head and Neck Squamous Cell Carcinoma (HNSCC),DRUG: Pembrolizumab|RADIATION: Stereotactic Body Radiation Therapy (SBRT),2,OTHER,"RTOG Foundation, Inc.",['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",False,head and neck squamous cell carcinoma,head/neck
1125,United States,NSCLC,DRUG: Atezolizumab|DRUG: Tiragolumab,2,OTHER,"Alliance Foundation Trials, LLC.","['checkpoint inhibitor', 'antibody']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'atezolizumab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'tiragolumab'}]",True,nsclc,lung/thoracic
1126,China,Renal Cell Carcinoma Stage I,DRUG: Volonib combined with Everolimus Formation,2,OTHER,Sun Yat-sen University,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'volonib combined with everolimus formation'}]",False,renal cell carcinoma stage i,genitourinary
1127,China,Nasopharyngeal Carcinoma,DRUG: GP combine with Tislelizumab neoadjuvant therapy+CCRT,2,OTHER,Sun Yat-sen University,"['checkpoint inhibitor', 'other']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'gp combine with tislelizumab neoadjuvant therapy'}, {'type': 'other', 'subtype': None, 'raw': 'ccrt'}]",True,nasopharyngeal carcinoma,head/neck
1128,Italy,Head and Neck Squamous Cell Carcinoma (HNSCC)|Recurrent Head and Neck Cancer|Metastatic Head and Neck Cancer,DRUG: Cetuximab/avelumab,2,OTHER,Gruppo Oncologico del Nord-Ovest,"['checkpoint inhibitor', 'antibody']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'cetuximab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'avelumab'}]",True,head and neck squamous cell carcinoma recurrent head and neck cancer metastatic head and neck cancer,head/neck
1129,Italy,Head and Neck Squamous Cell Carcinoma,DRUG: Niraparib,2,OTHER,Gruppo Oncologico del Nord-Ovest,['targeted therapy'],"[{'type': 'targeted therapy', 'subtype': 'PARP inhibitor', 'raw': 'niraparib'}]",False,head and neck squamous cell carcinoma,head/neck
1130,France,Head and Neck Squamous Cell Carcinoma,DRUG: Nivolumab|DRUG: Ipilimumab,2,OTHER,"Gustave Roussy, Cancer Campus, Grand Paris",['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}]",False,head and neck squamous cell carcinoma,head/neck
1131,"Australia, Austria, Belgium, Czechia, Denmark, Finland, France, Germany, Greece, Israel, Italy, Lithuania, Netherlands, Norway, Slovakia, Slovenia, Spain, Sweden, Switzerland, United Kingdom",High-Risk Neuroblastoma|Patient With Insufficient Response Chemoimmunotherapy,DRUG: Vincristine|DRUG: Carboplatin|DRUG: Etoposide|DRUG: Vindesine|DRUG: Dacarbazine|DRUG: Ifosfamide|DRUG: Doxorubicin|DRUG: Busulfan|DRUG: Melphalan|DRUG: Thiotepa|RADIATION: Radiotherapy|DRUG: Dinutuximab Beta|DRUG: Cisplatin|DRUG: Temozolomide 100 MG|DRUG: Irinotecan|DRUG: Cyclophosphamid,3,OTHER,"Gustave Roussy, Cancer Campus, Grand Paris","['other', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'vincristine'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'etoposide'}, {'type': 'other', 'subtype': None, 'raw': 'vindesine'}, {'type': 'chemotherapy', 'subtype': 'alkylating agent', 'raw': 'dacarbazine'}, {'type': 'chemotherapy', 'subtype': 'alkylating agent', 'raw': 'ifosfamide'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'doxorubicin'}, {'type': 'other', 'subtype': None, 'raw': 'busulfan'}, {'type': 'other', 'subtype': None, 'raw': 'melphalan'}, {'type': 'other', 'subtype': None, 'raw': 'thiotepa'}, {'type': 'other', 'subtype': None, 'raw': 'dinutuximab beta'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'temozolomide 100'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'irinotecan'}, {'type': 'other', 'subtype': None, 'raw': 'cyclophosphamid'}]",True,high risk neuroblastoma patient with insufficient response chemoimmunotherapy,hematologic
1132,United States,Neuroblastoma|Diffuse Intrinsic Pontine Glioma,BIOLOGICAL: Tumor-specific ex vivo expanded autologous lymphocyte transfer (TTRNA-xALT),1,OTHER,University of Florida,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'tumor-specific ex vivo expanded autologous lymphocyte transfer'}]",False,neuroblastoma diffuse intrinsic pontine glioma,brain/CNS
1133,China,"Sarcoma|Sarcoma,Soft Tissue|Sarcoma of Bone",COMBINATION_PRODUCT: Camrelizumab and fluzoparib with concurrent stereotactic body radiotherapy (SBRT),2,OTHER,Ruijin Hospital,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'camrelizumab and fluzoparib with concurrent stereotactic body radiotherapy'}]",False,sarcoma sarcoma soft tissue sarcoma of bone,sarcoma
1134,United States,Platinum-Resistant Lung Small Cell Carcinoma|Platinum-Sensitive Lung Small Cell Carcinoma|Recurrent Extensive Stage Lung Small Cell Carcinoma|Refractory Extensive Stage Lung Small Cell Carcinoma,BIOLOGICAL: Durvalumab|DRUG: Lurbinectedin,2,OTHER,Mayo Clinic,"['checkpoint inhibitor', 'other']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}, {'type': 'other', 'subtype': None, 'raw': 'lurbinectedin'}]",True,platinum resistant lung small cell carcinoma platinum sensitive lung small cell carcinoma recurrent extensive stage lung small cell carcinoma refractory extensive stage lung small cell carcinoma,lung/thoracic
1135,China,Locally Advanced Esophageal Squamous Cell Carcinoma,"DRUG: Toripalimab (240mg day1, Q3W*3cycle)",2,OTHER,"Nanfang Hospital, Southern Medical University",['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'toripalimab'}]",False,locally advanced esophageal squamous cell carcinoma,digestive
1136,China,Esophageal Squamous Cell Carcinoma (ESCC),DRUG: Induction chemoimmunotherapy|RADIATION: Hypofractionated Radiation Therapy|RADIATION: Conventional Fractionated Radiation Therapy|DRUG: Concurrent Chemotherapy,2,OTHER,Sun Yat-sen University,"['other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'induction chemoimmunotherapy'}, {'type': 'chemotherapy', 'subtype': 'concurrent', 'raw': 'concurrent chemotherapy'}]",True,esophageal squamous cell carcinoma,digestive
1137,United States,Squamous Cell Carcinoma of the Head and Neck|Oropharynx|Human Papillomavirus Viruses|Drug Therapy|Cancer Vaccine,DRUG: Docetaxel|DRUG: Cisplatin|DRUG: PRGN-2009,2,NIH,National Cancer Institute (NCI),"['other', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'docetaxel'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}, {'type': 'other', 'subtype': None, 'raw': 'prgn-2009'}]",True,squamous cell carcinoma of the head and neck oropharynx human papillomavirus viruses drug therapy cancer vaccine,head/neck
1138,United States,Multiple Myeloma,DRUG: Carfilzomib|DRUG: Lenalidomide|DRUG: Dexamethasone|DRUG: Daratumumab|PROCEDURE: autologous hematopoietic cell transplantation,2,OTHER,Memorial Sloan Kettering Cancer Center,"['other', 'antibody', 'supportive care']","[{'type': 'other', 'subtype': None, 'raw': 'carfilzomib'}, {'type': 'other', 'subtype': None, 'raw': 'lenalidomide'}, {'type': 'supportive care', 'subtype': 'steroid', 'raw': 'dexamethasone'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'daratumumab'}]",True,multiple myeloma,hematologic
1139,Malaysia,NSCLC (Non-small Cell Lung Carcinoma)|First Line Therapy|Locally Advanced/Metastatic NSCLC,"DRUG: Nivolumab 40mg|DRUG: Cisplatin, Carboplatin, Pemetrexed, Gemcitabine, Paclitaxel, Docetaxel",3,OTHER_GOV,Dr Arvindran A/L Alaga,"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab 40mg'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'chemotherapy', 'subtype': 'antifolate', 'raw': 'pemetrexed'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'gemcitabine'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'docetaxel'}]",True,nsclc first line therapy locally advanced metastatic nsclc,lung/thoracic
1140,China,Esophageal Squamous Cell Carcinoma|Neoadjuvant Therapies,DRUG: Cardenilimab Combined With Chemotherapy,2,OTHER,Li Zhang,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'cardenilimab combined with chemotherapy'}]",False,esophageal squamous cell carcinoma neoadjuvant therapies,digestive
1141,United States,Glioblastoma Multiforme|Glioblastoma,BIOLOGICAL: Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cells,1,OTHER,University of Florida,['cell therapy'],"[{'type': 'cell therapy', 'subtype': 'other', 'raw': 'ex-vivo expanded autologous il-8 receptor modified cd70 car t cells'}]",False,glioblastoma multiforme glioblastoma,brain/CNS
1142,United States,Diffuse Large-Cell Lymphoma|Primary Mediastinal Large B-Cell Lymphoma (PMBCL)|Transformed Follicular Lymphoma (TFL)|High-grade B-cell Lymphoma (HGBCL)|Follicular Lymphoma,BIOLOGICAL: Pneumococcal conjugate vaccine (PCV13)|BIOLOGICAL: CD19 targeted CAR T Cell Therapy,2,OTHER,H. Lee Moffitt Cancer Center and Research Institute,"['vaccine', 'cell therapy']","[{'type': 'vaccine', 'subtype': 'vaccine', 'raw': 'pneumococcal conjugate vaccine'}, {'type': 'cell therapy', 'subtype': 'other', 'raw': 'cd19 targeted car t cell therapy'}]",True,diffuse large cell lymphoma primary mediastinal large b cell lymphoma transformed follicular lymphoma high grade b cell lymphoma follicular lymphoma,hematologic
1143,United States,NSCLC Stage IV|NSCLC Stage IIIB,DRUG: Ipatasertib,2,OTHER,"Jun Zhang, MD, PhD",['targeted therapy'],"[{'type': 'targeted therapy', 'subtype': 'AKT inhibitor', 'raw': 'ipatasertib'}]",False,nsclc stage iv nsclc stage iiib,lung/thoracic
1144,China,Intrahepatic Cholangiocarcinoma|Transarterial Chemoembolization|Apatinib|PD-1 Antibody,COMBINATION_PRODUCT: DEB-TACE combined with apatinib and PD-1 antibody,2,OTHER,Sichuan Cancer Hospital and Research Institute,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'deb-tace combined with apatinib and pd-1 antibody'}]",False,intrahepatic cholangiocarcinoma transarterial chemoembolization apatinib pd 1 antibody,other
1145,United States,Adult Glioblastoma|High Grade Glioma|WHO Grade III or IV Malignant Glioma,"BIOLOGICAL: Autologous total tumor mRNA and pp65 full length (fl) lysosomal associated membrane protein (LAMP) mRNA loaded DOTAP liposome vaccine administered intravenously (RNA loaded lipid particles, RNA-LPs)",1,OTHER,University of Florida,['vaccine'],"[{'type': 'vaccine', 'subtype': 'mRNA', 'raw': 'autologous total tumor mrna and pp65 full length lysosomal associated membrane protein mrna loaded dotap liposome vaccine administered intravenously'}]",False,adult glioblastoma high grade glioma who grade iii or iv malignant glioma,brain/CNS
1146,"Australia, Belgium, Canada, France, Germany, Italy, Netherlands, Poland, Russian Federation, Spain, Switzerland, Ukraine, United Kingdom, United States",Uveal Melanoma,BIOLOGICAL: IMCgp100|DRUG: Dacarbazine|BIOLOGICAL: Ipilimumab|BIOLOGICAL: Pembrolizumab,2,INDUSTRY,Immunocore Ltd,"['checkpoint inhibitor', 'other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'imcgp100'}, {'type': 'chemotherapy', 'subtype': 'alkylating agent', 'raw': 'dacarbazine'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",True,uveal melanoma,skin
1147,Germany,Classical Hodgkin Lymphoma,DRUG: Tislelizumab,2,OTHER,University of Cologne,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'tislelizumab'}]",False,classical hodgkin lymphoma,hematologic
1148,United States,Adult Grade III Lymphomatoid Granulomatosis|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Post-transplant Lymphoproliferative Disorder|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Hairy Cell Leukemia|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Testicular Lymphoma|Waldenström Macroglobulinemia,BIOLOGICAL: autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells|PROCEDURE: autologous hematopoietic stem cell transplantation|OTHER: laboratory biomarker analysis,1,OTHER,City of Hope Medical Center,['cell therapy'],"[{'type': 'cell therapy', 'subtype': 'other', 'raw': 'autologous cd19car-cd28-cd3zeta-egfrt-expressing tcm-enriched t cells'}]",False,adult grade iii lymphomatoid granulomatosis cutaneous b cell non hodgkin lymphoma extranodal marginal zone b cell lymphoma of mucosa associated lymphoid tissue intraocular lymphoma nodal marginal zone b cell lymphoma post transplant lymphoproliferative disorder recurrent adult burkitt lymphoma recurrent adult diffuse large cell lymphoma recurrent adult diffuse mixed cell lymphoma recurrent adult diffuse small cleaved cell lymphoma recurrent adult grade iii lymphomatoid granulomatosis recurrent adult immunoblastic large cell lymphoma recurrent adult lymphoblastic lymphoma recurrent grade 1 follicular lymphoma recurrent grade 2 follicular lymphoma recurrent grade 3 follicular lymphoma recurrent mantle cell lymphoma recurrent marginal zone lymphoma recurrent small lymphocytic lymphoma refractory hairy cell leukemia small intestine lymphoma splenic marginal zone lymphoma testicular lymphoma waldenstr m macroglobulinemia,genitourinary
1149,"Germany, Hungary, Poland, Spain, Turkey, United Kingdom, United States",Non-Small Cell Lung Cancer,BIOLOGICAL: BNT116|BIOLOGICAL: Cemiplimab|DRUG: Docetaxel|DRUG: Carboplatin|DRUG: Paclitaxel|BIOLOGICAL: BNT316|BIOLOGICAL: anti-B7-H3 antibody conjugated to topoisomerase I inhibitor|BIOLOGICAL: anti-HER3 antibody conjugated to topoisomerase I inhibitor,1,INDUSTRY,BioNTech SE,"['checkpoint inhibitor', 'other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'bnt116'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'cemiplimab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'docetaxel'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}, {'type': 'other', 'subtype': None, 'raw': 'bnt316'}, {'type': 'other', 'subtype': None, 'raw': 'anti-b7-h3 antibody conjugated to topoisomerase i inhibitor'}, {'type': 'other', 'subtype': None, 'raw': 'anti-her3 antibody conjugated to topoisomerase i inhibitor'}]",True,non small cell lung cancer,lung/thoracic
1150,"Turkey, United States","Carcinoma, Non-Small-Cell Lung",DRUG: JNJ-90301900|BIOLOGICAL: Durvalumab|RADIATION: Concurrent Chemo/Radiation Therapy (cCRT)|DRUG: Concurrent Chemo/Radiation Therapy (cCRT): Carboplatin|DRUG: Concurrent Chemo/Radiation Therapy (cCRT): Paclitaxel,2,INDUSTRY,Johnson & Johnson Enterprise Innovation Inc.,"['checkpoint inhibitor', 'other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'jnj-90301900'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}, {'type': 'other', 'subtype': None, 'raw': 'concurrent chemo'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'radiation therapy : carboplatin'}, {'type': 'other', 'subtype': None, 'raw': 'concurrent chemo'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'radiation therapy : paclitaxel'}]",True,carcinoma non small cell lung,lung/thoracic
1151,United States,Actinic Keratosis,PROCEDURE: Biopsy|DRUG: Calcipotriene|DRUG: Fluorouracil,2,OTHER,University of Arizona,"['other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'calcipotriene'}, {'type': 'chemotherapy', 'subtype': 'antimetabolite', 'raw': 'fluorouracil'}]",True,actinic keratosis,other
1152,United States,Clinical Stage II Esophageal Adenocarcinoma AJCC v8|Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8|Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8|Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage III Esophageal Adenocarcinoma AJCC v8|Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IB Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IC Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage II Esophageal Adenocarcinoma AJCC v8|Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage III Esophageal Adenocarcinoma AJCC v8|Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8,DRUG: Atezolizumab|PROCEDURE: Conventional Surgery|DRUG: Fluorouracil|DRUG: Oxaliplatin|DRUG: Tiragolumab,2,OTHER,M.D. Anderson Cancer Center,"['checkpoint inhibitor', 'antibody', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'atezolizumab'}, {'type': 'chemotherapy', 'subtype': 'antimetabolite', 'raw': 'fluorouracil'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'oxaliplatin'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'tiragolumab'}]",True,clinical stage ii esophageal adenocarcinoma ajcc v8 clinical stage ii gastroesophageal junction adenocarcinoma ajcc v8 clinical stage iia esophageal adenocarcinoma ajcc v8 clinical stage iia gastroesophageal junction adenocarcinoma ajcc v8 clinical stage iib esophageal adenocarcinoma ajcc v8 clinical stage iib gastroesophageal junction adenocarcinoma ajcc v8 clinical stage iii esophageal adenocarcinoma ajcc v8 clinical stage iii gastroesophageal junction adenocarcinoma ajcc v8 pathologic stage ib esophageal adenocarcinoma ajcc v8 pathologic stage ib gastroesophageal junction adenocarcinoma ajcc v8 pathologic stage ic esophageal adenocarcinoma ajcc v8 pathologic stage ic gastroesophageal junction adenocarcinoma ajcc v8 pathologic stage ii esophageal adenocarcinoma ajcc v8 pathologic stage ii gastroesophageal junction adenocarcinoma ajcc v8 pathologic stage iia esophageal adenocarcinoma ajcc v8 pathologic stage iia gastroesophageal junction adenocarcinoma ajcc v8 pathologic stage iib esophageal adenocarcinoma ajcc v8 pathologic stage iib gastroesophageal junction adenocarcinoma ajcc v8 pathologic stage iii esophageal adenocarcinoma ajcc v8 pathologic stage iii gastroesophageal junction adenocarcinoma ajcc v8 pathologic stage iiia esophageal adenocarcinoma ajcc v8 pathologic stage iiia gastroesophageal junction adenocarcinoma ajcc v8 pathologic stage iiib esophageal adenocarcinoma ajcc v8 pathologic stage iiib gastroesophageal junction adenocarcinoma ajcc v8,digestive
1153,United States,Metastatic Nasopharyngeal Carcinoma|Recurrent Nasopharyngeal Carcinoma|Stage IV Nasopharyngeal Carcinoma AJCC v8,PROCEDURE: Biospecimen Collection|DRUG: Cabozantinib S-malate|PROCEDURE: Computed Tomography|BIOLOGICAL: Ipilimumab|PROCEDURE: Magnetic Resonance Imaging|BIOLOGICAL: Nivolumab,2,NIH,National Cancer Institute (NCI),"['checkpoint inhibitor', 'targeted therapy']","[{'type': 'targeted therapy', 'subtype': 'other', 'raw': 'cabozantinib s-malate'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}]",True,metastatic nasopharyngeal carcinoma recurrent nasopharyngeal carcinoma stage iv nasopharyngeal carcinoma ajcc v8,head/neck
1154,Italy,Cholangiocarcinoma,DRUG: Durvalumab 1120 mg|DRUG: Durvalumab 1500 mg|DRUG: Tremelimumab i.v. at 300 mg|COMBINATION_PRODUCT: Cisplatin (CDDP) 25 mg/mq i.v|COMBINATION_PRODUCT: Gemcitabine (GEM) 1000 mg/mq i.v.,2,OTHER,"National Cancer Institute, Naples","['checkpoint inhibitor', 'other', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab 1120'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab 1500'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'tremelimumab i.v. at 300'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin 25'}, {'type': 'other', 'subtype': None, 'raw': 'mq i.v'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'gemcitabine 1000'}, {'type': 'other', 'subtype': None, 'raw': 'mq i.v.'}]",True,cholangiocarcinoma,other
1155,Germany,Newly Diagnosed H3-mutated Glioma,DRUG: Tecentriq 1200 MG in 20 ML Injection|BIOLOGICAL: H3K27M peptide vaccine|OTHER: Imiquimod (5%),1,OTHER,German Cancer Research Center,"['vaccine', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'tecentriq 1200 in 20 injection'}, {'type': 'vaccine', 'subtype': 'vaccine', 'raw': 'h3k27m peptide vaccine'}]",True,newly diagnosed h3 mutated glioma,brain/CNS
1156,"Australia, Canada",Metastatic Renal Cell Carcinoma,DRUG: Ipilimumab/ Nivolumab|RADIATION: SBRT + Ipilimumab/Nivolumab,2,OTHER,Ontario Clinical Oncology Group (OCOG),['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}]",False,metastatic renal cell carcinoma,genitourinary
1157,China,Nasopharyngeal Carcinoma|De-escalation Therapy,DRUG: Full course of PD-1/PD-L1 blockades|DRUG: Cisplatin-based induction chemotherapy|RADIATION: Standard-dose IMRT|RADIATION: Gradient Fractionated IMRT|DRUG: Concurrent Chemotherapy,3,OTHER,Sun Yat-sen University,"['other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'full course of pd-1'}, {'type': 'other', 'subtype': None, 'raw': 'pd-l1 blockades'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin-based induction chemotherapy'}, {'type': 'chemotherapy', 'subtype': 'concurrent', 'raw': 'concurrent chemotherapy'}]",True,nasopharyngeal carcinoma de escalation therapy,head/neck
1158,China,Pancreatic Adenocarcinoma Metastatic,DRUG: Penpulimab|DRUG: Anlotinib|DRUG: Nab paclitaxel|DRUG: Gemcitabine,2,OTHER,The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School,"['antibody', 'chemotherapy', 'kinase inhibitor']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'penpulimab'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'anlotinib'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'nab paclitaxel'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'gemcitabine'}]",True,pancreatic adenocarcinoma metastatic,digestive
1159,United States,"Juvenile Myelomonocytic Leukemia|Recurrent Acute Biphenotypic Leukemia|Recurrent Acute Undifferentiated Leukemia|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Refractory Acute Lymphoblastic Leukemia|Refractory Adult Acute Lymphoblastic Leukemia|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm|Recurrent Myelodysplastic Syndrome|Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm|Refractory Myelodysplastic Syndrome|Acute Undifferentiated Leukemia|Mixed Phenotype Acute Leukemia|Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Recurrent Acute Lymphoblastic Leukemia|Recurrent Acute Myeloid Leukemia|Myelodysplastic Syndrome|Acute Myeloid Leukemia|Acute Lymphoblastic Leukemia|Acute Biphenotypic Leukemia|Chronic Myeloid Leukemia|Chronic Myelomonocytic Leukemia|Minimal Residual Disease|Recurrent Chronic Myelomonocytic Leukemia|Recurrent Mixed Phenotype Acute Leukemia|Leukemia",BIOLOGICAL: CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR|OTHER: Laboratory Biomarker Analysis,1,OTHER,Fred Hutchinson Cancer Center,"['other', 'cell therapy']","[{'type': 'other', 'subtype': None, 'raw': 'cd8'}, {'type': 'other', 'subtype': None, 'raw': 'and cd4'}, {'type': 'cell therapy', 'subtype': 'engineered cell', 'raw': 'donor memory t-cells-expressing ha1-specific tcr'}]",True,juvenile myelomonocytic leukemia recurrent acute biphenotypic leukemia recurrent acute undifferentiated leukemia recurrent childhood acute lymphoblastic leukemia recurrent childhood acute myeloid leukemia refractory acute lymphoblastic leukemia refractory adult acute lymphoblastic leukemia blast phase chronic myelogenous leukemia bcr abl1 positive recurrent blastic plasmacytoid dendritic cell neoplasm recurrent myelodysplastic syndrome refractory blastic plasmacytoid dendritic cell neoplasm refractory myelodysplastic syndrome acute undifferentiated leukemia mixed phenotype acute leukemia recurrent chronic myelogenous leukemia bcr abl1 positive refractory chronic myelogenous leukemia bcr abl1 positive recurrent acute lymphoblastic leukemia recurrent acute myeloid leukemia myelodysplastic syndrome acute myeloid leukemia acute lymphoblastic leukemia acute biphenotypic leukemia chronic myeloid leukemia chronic myelomonocytic leukemia minimal residual disease recurrent chronic myelomonocytic leukemia recurrent mixed phenotype acute leukemia leukemia,hematologic
1160,"China, Hong Kong, Italy, Japan, Republic of, Singapore, Spain, Taiwan, United States",Hepatocellular Carcinoma,BIOLOGICAL: Tremelimumab|BIOLOGICAL: Durvalumab|BIOLOGICAL: Bevacizumab,2,INDUSTRY,MedImmune LLC,"['checkpoint inhibitor', 'antibody']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'tremelimumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'bevacizumab'}]",True,hepatocellular carcinoma,digestive
1161,"Finland, Norway, Sweden","NSCLC, Stage I",DRUG: Durvalumab,2,OTHER_GOV,Vastra Gotaland Region,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}]",False,nsclc stage i,lung/thoracic
1162,China,Head and Neck Squamous Carcinoma,RADIATION: SBRT+immunochemotherpy|DRUG: Immunochemotherapy|DRUG: cetuximab+immunochemotharpy,2,OTHER,Jiang Feng,"['other', 'antibody']","[{'type': 'other', 'subtype': None, 'raw': 'immunochemotherapy'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'cetuximab'}, {'type': 'other', 'subtype': None, 'raw': 'immunochemotharpy'}]",True,head and neck squamous carcinoma,head/neck
1163,China,Esophageal Squamous Cell Carcinoma,DRUG: Tislelizumab|RADIATION: Low-dose radiotherapy|DRUG: Nab-paclitaxel|DRUG: Cisplatin,2,OTHER,Sichuan University,"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'tislelizumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'nab-paclitaxel'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}]",True,esophageal squamous cell carcinoma,digestive
1164,United States,Triple Negative Breast Cancer|Non Small Cell Lung Cancer|Metastatic Breast Cancer|Metastatic Non-Small Cell Lung Carcinoma,RADIATION: Stereotactic Body Radiotherapy/SBRT|DRUG: Systemic Therapy/Standard of Care,2,OTHER,Memorial Sloan Kettering Cancer Center,"['other', 'non-therapeutic']","[{'type': 'other', 'subtype': None, 'raw': 'systemic therapy'}, {'type': 'non-therapeutic', 'subtype': 'supportive', 'raw': 'standard of care'}]",True,triple negative breast cancer non small cell lung cancer metastatic breast cancer metastatic non small cell lung carcinoma,lung/thoracic
1165,"Australia, Norway, Sweden",Melanoma Stage Iv,DRUG: Ipilimumab|DRUG: Nivolumab|RADIATION: Stereotactic Radiotherapy|OTHER: Salvage therapy,2,OTHER,Melanoma Institute Australia,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}]",False,melanoma stage iv,skin
1166,"Belgium, France, Italy, Japan, Poland, Republic of, Spain, Taiwan, Turkey, United States",Advanced or Metastatic NSCLC,DRUG: Datopotamab deruxtecan|DRUG: Durvalumab|DRUG: Carboplatin|DRUG: AZD2936|DRUG: MEDI5752|DRUG: AZD7789,1,INDUSTRY,AstraZeneca,"['checkpoint inhibitor', 'other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'datopotamab deruxtecan'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'other', 'subtype': None, 'raw': 'azd2936'}, {'type': 'other', 'subtype': None, 'raw': 'medi5752'}, {'type': 'other', 'subtype': None, 'raw': 'azd7789'}]",True,advanced or metastatic nsclc,lung/thoracic
1167,United States,Lung Cancer Metastatic|EGFR Gene Mutation,DRUG: Osimertinib|DRUG: Alisertib,1,OTHER,Collin Blakely,"['other', 'kinase inhibitor']","[{'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'osimertinib'}, {'type': 'other', 'subtype': None, 'raw': 'alisertib'}]",True,lung cancer metastatic egfr gene mutation,lung/thoracic
1168,"Australia, Republic of, Taiwan, United States",Hepatocellular Carcinoma,DRUG: SRF388|DRUG: Atezolizumab|DRUG: Bevacizumab|DRUG: Placebo,2,INDUSTRY,"Coherus Biosciences, Inc.","['checkpoint inhibitor', 'other', 'antibody']","[{'type': 'other', 'subtype': None, 'raw': 'srf388'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'atezolizumab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'bevacizumab'}]",True,hepatocellular carcinoma,digestive
1169,China,Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma,DRUG: Adebrelimab|DRUG: Apatinib|DRUG: Tegafur,2,OTHER,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,"['other', 'antibody', 'kinase inhibitor']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'adebrelimab'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'apatinib'}, {'type': 'other', 'subtype': None, 'raw': 'tegafur'}]",True,locally advanced or metastatic esophageal squamous cell carcinoma,digestive
1170,Netherlands,Colon Carcinoma,DRUG: Nivolumab|DRUG: Ipilimumab|DRUG: Celecoxib 200mg|DRUG: BMS-986253|DRUG: BMS-986016,2,OTHER,The Netherlands Cancer Institute,"['checkpoint inhibitor', 'other']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}, {'type': 'other', 'subtype': None, 'raw': 'celecoxib 200mg'}, {'type': 'other', 'subtype': None, 'raw': 'bms-986253'}, {'type': 'other', 'subtype': None, 'raw': 'bms-986016'}]",True,colon carcinoma,digestive
1171,China,Nasopharyngeal Cancinoma (NPC)|SBRT|Immunotherapy,DRUG: SBRT combined with Nimotuzumab followed by Tislelizumab,2,OTHER,The First Affiliated Hospital of Xiamen University,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'sbrt combined with nimotuzumab followed by tislelizumab'}]",False,nasopharyngeal cancinoma sbrt immunotherapy,hematologic
1172,"Canada, Hong Kong, Singapore, United States",Metastatic Nasopharyngeal Carcinoma|Recurrent Nasopharyngeal Carcinoma|Stage IV Nasopharyngeal Carcinoma AJCC v8,PROCEDURE: Biospecimen Collection|PROCEDURE: Bone Scan|DRUG: Carboplatin|DRUG: Cisplatin|PROCEDURE: Computed Tomography|DRUG: Gemcitabine|PROCEDURE: Magnetic Resonance Imaging|BIOLOGICAL: Nivolumab|PROCEDURE: Positron Emission Tomography|BIOLOGICAL: Relatlimab,2,NIH,National Cancer Institute (NCI),"['checkpoint inhibitor', 'antibody', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'gemcitabine'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'relatlimab'}]",True,metastatic nasopharyngeal carcinoma recurrent nasopharyngeal carcinoma stage iv nasopharyngeal carcinoma ajcc v8,head/neck
1173,United States,Advanced Gastric Adenocarcinoma,DRUG: Paclitaxel|DRUG: Olaparib|DRUG: Pembrolizumab,2,OTHER,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,"['checkpoint inhibitor', 'targeted therapy', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}, {'type': 'targeted therapy', 'subtype': 'PARP inhibitor', 'raw': 'olaparib'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",True,advanced gastric adenocarcinoma,digestive
1174,Italy,Cutaneous Squamous Cell Carcinoma,DRUG: Cemiplimab,2,OTHER,Fondazione Melanoma Onlus,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'cemiplimab'}]",False,cutaneous squamous cell carcinoma,skin
1175,United States,Hairy Cell Leukemia|Hairy Cell Leukemia Variant,BIOLOGICAL: CD22CART cell infusion,1,NIH,National Cancer Institute (NCI),['cell therapy'],"[{'type': 'cell therapy', 'subtype': 'engineered cell', 'raw': 'cd22cart cell'}]",False,hairy cell leukemia hairy cell leukemia variant,hematologic
1176,United States,Neoplasms|High Grade Glioma|Glioblastoma Multiforme|Malignant Glioma of Brain|Anaplastic Astrocytoma of Brain|High-grade Glioma|Anaplastic Glioma|Giant Cell Glioblastoma,BIOLOGICAL: Biological G207,2,NETWORK,Pediatric Brain Tumor Consortium,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'biological g207'}]",False,neoplasms high grade glioma glioblastoma multiforme malignant glioma of brain anaplastic astrocytoma of brain high grade glioma anaplastic glioma giant cell glioblastoma,brain/CNS
1177,United States,Non-Muscle Invasive Bladder Urothelial Carcinoma|Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma|Stage I Bladder Cancer AJCC v8,PROCEDURE: Biospecimen Collection|DRUG: Cisplatin|PROCEDURE: Computed Tomography|DRUG: Fluorouracil|DRUG: Gemcitabine|PROCEDURE: Magnetic Resonance Imaging|DRUG: Mitomycin|BIOLOGICAL: Pembrolizumab|OTHER: Questionnaire Administration|RADIATION: Radiation Therapy,2,NIH,National Cancer Institute (NCI),"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}, {'type': 'chemotherapy', 'subtype': 'antimetabolite', 'raw': 'fluorouracil'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'gemcitabine'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'mitomycin'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",True,non muscle invasive bladder urothelial carcinoma recurrent non muscle invasive bladder urothelial carcinoma stage i bladder cancer ajcc v8,genitourinary
1178,China,Esophagogastric Junction Adenocarcinoma,DRUG: Adebrelimab (anti-PD-L1) + XELOX,2,OTHER,Ruijin Hospital,"['other', 'antibody']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'adebrelimab'}, {'type': 'other', 'subtype': None, 'raw': 'xelox'}]",True,esophagogastric junction adenocarcinoma,digestive
1179,China,Hepatocellular Carcinoma,DRUG: HAIC+STRIDE+Len,2,OTHER,Sulai Liu,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'haic'}, {'type': 'other', 'subtype': None, 'raw': 'stride'}, {'type': 'other', 'subtype': None, 'raw': 'len'}]",False,hepatocellular carcinoma,digestive
1180,"Australia, Austria, Belgium, Brazil, Chile, China, Czechia, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Netherlands, Norway, Poland, Portugal, Republic of, Romania, Slovakia, Spain, Sweden, Switzerland, Taiwan, Turkey, United Kingdom, United States","Carcinoma, Non-Small-Cell Lung",DRUG: Olomorasib|DRUG: Pembrolizumab|DRUG: Durvalumab|DRUG: Placebo,3,INDUSTRY,Eli Lilly and Company,"['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'olomorasib'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}]",True,carcinoma non small cell lung,lung/thoracic
1181,France,Localized Oesogastric Adenocarcimona|MSI and or dMMR,DRUG: Nivolumab 10 MG/ML|DRUG: Ipilimumab 200 MG in 40 ML Injection,2,OTHER,GERCOR - Multidisciplinary Oncology Cooperative Group,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab 10'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab 200 in 40 injection'}]",False,localized oesogastric adenocarcimona msi and or dmmr,digestive
1182,Russian Federation,Primary Mediastinal Lymphoma,DRUG: Cyclophosphamide|DRUG: Doxorubicin Hydrochloride|DRUG: Etoposide Phosphate|DRUG: Prednisolone|DRUG: Rituximab|DRUG: Vincristine Sulfate|DRUG: Filgrastim|DRUG: Pegfilgrastim|DRUG: Nivolumab 40 mg in 4 ml Injection,3,NETWORK,"National Research Center for Hematology, Russia","['other', 'chemotherapy', 'checkpoint inhibitor', 'antibody', 'supportive care']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'doxorubicin hydrochloride'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'etoposide phosphate'}, {'type': 'supportive care', 'subtype': 'steroid', 'raw': 'prednisolone'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'rituximab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'vincristine sulfate'}, {'type': 'supportive care', 'subtype': 'G-CSF', 'raw': 'filgrastim'}, {'type': 'other', 'subtype': None, 'raw': 'pegfilgrastim'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab 40 in 4 injection'}]",True,primary mediastinal lymphoma,hematologic
1183,China,Cholangiocarcinoma,COMBINATION_PRODUCT: Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil,2,OTHER,West China Hospital,['chemotherapy'],"[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cadonilimab combined with liposomal irinotecan plus leucovorin and fluorouracil'}]",False,cholangiocarcinoma,other
1184,"Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, China, Denmark, France, Germany, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, Malaysia, New Zealand, Norway, Poland, Republic of, Russian Federation, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, United States",Hepatocellular Carcinoma,BIOLOGICAL: Pembrolizumab|DRUG: Placebo,3,INDUSTRY,Merck Sharp & Dohme LLC,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",False,hepatocellular carcinoma,digestive
1185,"Mexico, United States",Borderline Resectable Pancreatic Adenocarcinoma,BIOLOGICAL: Aglatimagene besadenovec|RADIATION: Chemoradiation|RADIATION: Stereotactic body radiation therapy|PROCEDURE: Surgery,2,INDUSTRY,"Candel Therapeutics, Inc.",['gene therapy'],"[{'type': 'gene therapy', 'subtype': 'adenoviral vector', 'raw': 'aglatimagene besadenovec'}]",False,borderline resectable pancreatic adenocarcinoma,digestive
1186,United States,B-cell Acute Lymphoblastic Leukemia,BIOLOGICAL: Tisagenlecleucel,2,OTHER,Memorial Sloan Kettering Cancer Center,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'tisagenlecleucel'}]",False,b cell acute lymphoblastic leukemia,hematologic
1187,United States,Glioblastoma|Malignant Glioma|Recurrent Glioblastoma|Recurrent Glioma,DRUG: CARv3-TEAM-E T cells,1,OTHER,"Marcela V. Maus, M.D.,Ph.D.",['cell therapy'],"[{'type': 'cell therapy', 'subtype': 'other', 'raw': 'carv3-team-e t cells'}]",False,glioblastoma malignant glioma recurrent glioblastoma recurrent glioma,brain/CNS
1188,China,Esophageal Squamous Cell Carcinoma,DRUG: Serplulimab|DRUG: Paclitaxel+Cisplatin (Neoadjuvant Chemotherapy)|DRUG: Paclitaxel+Cisplatin(Concurrent Chemoradiotherapy)|RADIATION: Radiotherapy,2,OTHER,Fujian Medical University Union Hospital,"['antibody', 'chemotherapy']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'serplulimab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}]",True,esophageal squamous cell carcinoma,digestive
1189,China,Liver Carcinoma|Hepatic Cell Carcinoma,BIOLOGICAL: CAR-GPC3 T cells,1,INDUSTRY,"Shanghai Ming Ju Biotechnology Co., Ltd.",['cell therapy'],"[{'type': 'cell therapy', 'subtype': 'other', 'raw': 'car-gpc3 t cells'}]",False,liver carcinoma hepatic cell carcinoma,digestive
1190,China,Nasopharyngeal Carcinoma,"DRUG: Apatinib, Camrelizumab, Chemotherapy (gemcitabine/ capecitabine/ docetaxel)|DRUG: Apatinib, Camrelizumab|DRUG: Camrelizumab, Chemotherapy (gemcitabine/ capecitabine/ docetaxel)|DRUG: Chemotherapy (gemcitabine/ capecitabine/ docetaxel)",2,OTHER,Sun Yat-sen University,"['checkpoint inhibitor', 'chemotherapy', 'kinase inhibitor']","[{'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'apatinib'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'camrelizumab'}, {'type': 'chemotherapy', 'subtype': 'unspecified', 'raw': 'chemotherapy'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'apatinib'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'camrelizumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'camrelizumab'}, {'type': 'chemotherapy', 'subtype': 'unspecified', 'raw': 'chemotherapy'}, {'type': 'chemotherapy', 'subtype': 'unspecified', 'raw': 'chemotherapy'}]",True,nasopharyngeal carcinoma,head/neck
1191,Australia,Endometrial Cancer Stage I|Mmr Deficiency|Endometrioid Endometrial Adenocarcinoma|Immune-related Adverse Event,DRUG: Dostarlimab-Gxly 50 MG/1 ML Intravenous Solution [JEMPERLI],2,OTHER_GOV,Queensland Centre for Gynaecological Cancer,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'dostarlimab-gxly 50'}, {'type': 'other', 'subtype': None, 'raw': '1 intravenous solution [jemperli]'}]",False,endometrial cancer stage i mmr deficiency endometrioid endometrial adenocarcinoma immune related adverse event,gynecologic
1192,United States,Acute Lymphocytic Leukemia|Acute Myeloid Leukemia|Ambiguous Lineage Leukemia or Lymphoma|Myeloma,DRUG: FLT,1,OTHER,University of Oklahoma,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'flt'}]",False,acute lymphocytic leukemia acute myeloid leukemia ambiguous lineage leukemia or lymphoma myeloma,hematologic
1193,United States,"Myeloma-Multiple|Myeloma, Plasma-Cell",DRUG: Cyclophosphamide|DRUG: Fludarabine|BIOLOGICAL: Anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptors (CARs) T cells,1,NIH,National Cancer Institute (NCI),"['chemotherapy', 'cell therapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide'}, {'type': 'chemotherapy', 'subtype': 'purine analog', 'raw': 'fludarabine'}, {'type': 'cell therapy', 'subtype': 'other', 'raw': 'anti-b cell maturation antigen chimeric antigen receptors t cells'}]",True,myeloma multiple myeloma plasma cell,hematologic
1194,United States,Head and Neck Squamous Cell Carcinoma|Head and Neck Cancer|Head and Neck Carcinoma|Head and Neck Cancer Stage IV|Head and Neck Cancer Stage III|HPV-Related Carcinoma|HPV-Related Malignancy|HPV-Related Squamous Cell Carcinoma,DRUG: IPI-549,2,OTHER,Ezra Cohen,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'ipi-549'}]",False,head and neck squamous cell carcinoma head and neck cancer head and neck carcinoma head and neck cancer stage iv head and neck cancer stage iii hpv related carcinoma hpv related malignancy hpv related squamous cell carcinoma,head/neck
1195,United States,T-cell Acute Lymphoblastic Leukemia|T-Cell Acute Lymphoblastic Lymphoma,DRUG: Daratumumab,1,OTHER,New York Medical College,['antibody'],"[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'daratumumab'}]",False,t cell acute lymphoblastic leukemia t cell acute lymphoblastic lymphoma,hematologic
1196,Netherlands,Gastric Adenocarcinoma|Esophageal Adenocarcinoma,DRUG: Capecitabine|DRUG: Oxaliplatin|DRUG: Retifanlimab,2,OTHER,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA),"['antibody', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'fluoropyrimidine', 'raw': 'capecitabine'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'oxaliplatin'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'retifanlimab'}]",True,gastric adenocarcinoma esophageal adenocarcinoma,digestive
1197,China,Esophageal Squamous Cell Carcinoma,BIOLOGICAL: Pembrolizumab|DRUG: Paclitaxel|DRUG: Cisplatin|RADIATION: neoadjuvant chemoradiotherapy,3,OTHER,Tianjin Medical University Cancer Institute and Hospital,"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}]",True,esophageal squamous cell carcinoma,digestive
1198,China,Nasopharyngeal Carcinoma,DRUG: camrelizumab|RADIATION: stereotactic body radiotherapy,3,OTHER,Sun Yat-sen University,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'camrelizumab'}]",False,nasopharyngeal carcinoma,head/neck
1199,France,Adenocarcinoma - GEJ|Gastric Adenocarcinoma,DRUG: Dostarlimab,2,OTHER,GERCOR - Multidisciplinary Oncology Cooperative Group,['antibody'],"[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'dostarlimab'}]",False,adenocarcinoma gej gastric adenocarcinoma,digestive
1200,Australia,Cutaneous Squamous Cell Carcinoma,DRUG: Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination,2,OTHER,Melanoma Institute Australia,"['checkpoint inhibitor', 'other']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab 240'}, {'type': 'other', 'subtype': None, 'raw': 'relatlimab 80 in a fixed dose combination'}]",True,cutaneous squamous cell carcinoma,skin
1201,France,Squamous Cell Anal Carcinoma|Metastatic Squamous Cell Carcinoma,BIOLOGICAL: Sample collection,2,OTHER,Centre Hospitalier Universitaire de Besancon,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'sample collection'}]",False,squamous cell anal carcinoma metastatic squamous cell carcinoma,digestive
1202,"Argentina, Australia, Brazil, Chile, China, Costa Rica, Czechia, Dominican Republic, Germany, Greece, Guatemala, Israel, Italy, Japan, Malaysia, Mexico, Philippines, Portugal, Republic of, Romania, South Africa, Spain, Turkey, Ukraine, United States","Carcinoma, Non-Small-Cell Lung",BIOLOGICAL: pembrolizumab/vibostolimab|BIOLOGICAL: durvalumab|DRUG: cisplatin|DRUG: pemetrexed|DRUG: etoposide|DRUG: carboplatin|DRUG: paclitaxel|RADIATION: thoracic radiotherapy,3,INDUSTRY,Merck Sharp & Dohme LLC,"['checkpoint inhibitor', 'antibody', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'vibostolimab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}, {'type': 'chemotherapy', 'subtype': 'antifolate', 'raw': 'pemetrexed'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'etoposide'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}]",True,carcinoma non small cell lung,lung/thoracic
1203,United States,Melanoma Stage III|Melanoma Stage IV|Skin Cancer Stage III|Skin Cancer Stage IV|Drug-Induced Colitis|Drug Toxicity|Immune-related Adverse Event,DRUG: Infliximab|DRUG: Methylprednisolone|DRUG: Prednisone,2,OTHER,Massachusetts General Hospital,"['other', 'antibody', 'supportive care']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'infliximab'}, {'type': 'other', 'subtype': None, 'raw': 'methylprednisolone'}, {'type': 'supportive care', 'subtype': 'steroid', 'raw': 'prednisone'}]",True,melanoma stage iii melanoma stage iv skin cancer stage iii skin cancer stage iv drug induced colitis drug toxicity immune related adverse event,hematologic
1204,United Kingdom,Acute Lymphoblastic Leukemia,PROCEDURE: Leukapheresis|RADIATION: Total Body Irradiation (TBI)|DRUG: Lymphodepletion with Fludarabine|DRUG: Lymphodepletion with Cyclophosphamide|BIOLOGICAL: CD19+CD22 CAR T-cells,1,OTHER,"University College, London","['other', 'chemotherapy', 'cell therapy']","[{'type': 'other', 'subtype': None, 'raw': 'lymphodepletion with fludarabine'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'lymphodepletion with cyclophosphamide'}, {'type': 'other', 'subtype': None, 'raw': 'cd19'}, {'type': 'cell therapy', 'subtype': 'other', 'raw': 'cd22 car t-cells'}]",True,acute lymphoblastic leukemia,hematologic
1205,China,SBRT,COMBINATION_PRODUCT: SBRT+chemoimmunotherapy,2,OTHER,Sun Yat-sen University,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'sbrt'}, {'type': 'other', 'subtype': None, 'raw': 'chemoimmunotherapy'}]",False,sbrt,other
1206,United States,Advanced Renal Cell Carcinoma|Metastatic Renal Cell Carcinoma|Clear Cell Renal Cell Carcinoma,DRUG: XL092|DRUG: Nivolumab,2,OTHER,Karie Runcie,"['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'xl092'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}]",True,advanced renal cell carcinoma metastatic renal cell carcinoma clear cell renal cell carcinoma,genitourinary
1207,"Australia, Brazil, Canada, Colombia, Denmark, France, Israel, Norway, Portugal, Republic of, Romania, Spain, Taiwan, United Kingdom, United States",Squamous Cell Carcinoma of Head and Neck,DRUG: Lenvatinib|BIOLOGICAL: Pembrolizumab|DRUG: Docetaxel|DRUG: Capecitabine|DRUG: Paclitaxel|DRUG: Cetuximab|DRUG: Lenvatinib,2,INDUSTRY,Merck Sharp & Dohme LLC,"['checkpoint inhibitor', 'targeted therapy', 'antibody', 'chemotherapy']","[{'type': 'targeted therapy', 'subtype': 'other', 'raw': 'lenvatinib'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'docetaxel'}, {'type': 'chemotherapy', 'subtype': 'fluoropyrimidine', 'raw': 'capecitabine'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'cetuximab'}, {'type': 'targeted therapy', 'subtype': 'other', 'raw': 'lenvatinib'}]",True,squamous cell carcinoma of head and neck,head/neck
1208,United States,High Grade Glioma|Diffuse Intrinsic Pontine Glioma|Recurrent Medulloblastoma,BIOLOGICAL: PEP-CMV|DRUG: Temozolomide|BIOLOGICAL: Tetanus Diphtheria Vaccine,2,OTHER,Nationwide Children's Hospital,"['vaccine', 'other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'pep-cmv'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'temozolomide'}, {'type': 'vaccine', 'subtype': 'vaccine', 'raw': 'tetanus diphtheria vaccine'}]",True,high grade glioma diffuse intrinsic pontine glioma recurrent medulloblastoma,brain/CNS
1209,China,Adrenocortical Carcinoma,DRUG: Triprolizumab|DEVICE: rodiotherapy,2,OTHER,Sun Yat-sen University,['antibody'],"[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'triprolizumab'}]",False,adrenocortical carcinoma,other
1210,Indonesia,Hepatocellular Carcinoma,DRUG: Autologous Natural Killer Cell Therapy|DEVICE: Clinimacs Plus,1,OTHER,Dr Cipto Mangunkusumo General Hospital,['cell therapy'],"[{'type': 'cell therapy', 'subtype': 'other', 'raw': 'autologous natural killer cell therapy'}]",False,hepatocellular carcinoma,digestive
1211,China,Lung Squamous Cell Carcinoma,RADIATION: low-dose radiation therapy and stereotactic body radiation therapy|DRUG: chemotherapy|DRUG: Sintilimab,2,OTHER,Sichuan University,"['antibody', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'unspecified', 'raw': 'chemotherapy'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'sintilimab'}]",True,lung squamous cell carcinoma,lung/thoracic
1212,China,Untreated Mantle Cell Lymphoma,DRUG: zanubrutinib and rituximab|DRUG: zanubrutinib and rituximab|DRUG: BEAM pretreatment|DRUG: zanubrutinib maintenance,2,OTHER,The First Affiliated Hospital of Soochow University,"['other', 'antibody']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'zanubrutinib and rituximab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'zanubrutinib and rituximab'}, {'type': 'other', 'subtype': None, 'raw': 'beam pretreatment'}, {'type': 'other', 'subtype': None, 'raw': 'zanubrutinib maintenance'}]",True,untreated mantle cell lymphoma,hematologic
1213,China,Collecting Duct Carcinoma,DRUG: PD-(L)1 inhibitor|DRUG: Axitinib,2,OTHER,Peking University Cancer Hospital & Institute,"['checkpoint inhibitor', 'kinase inhibitor']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'pd-1 inhibitor'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'axitinib'}]",True,collecting duct carcinoma,other
1214,"Australia, Austria, Belgium, France, Germany, Italy, Poland, Spain, Switzerland, United Kingdom, United States",Advanced Melanoma,DRUG: Tebentafusp|DRUG: Tebentafusp with Pembrolizumab|DRUG: Investigators Choice,3,INDUSTRY,Immunocore Ltd,"['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'tebentafusp'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'tebentafusp with pembrolizumab'}, {'type': 'other', 'subtype': None, 'raw': 'investigators choice'}]",True,advanced melanoma,skin
1215,China,Hepatocellular Carcinoma,DRUG: Donafenib + Envafolimab,2,OTHER_GOV,Anhui Provincial Hospital,"['antibody', 'kinase inhibitor']","[{'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'donafenib'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'envafolimab'}]",True,hepatocellular carcinoma,digestive
1216,China,Rectal Adenocarcinoma,DRUG: Adebrelimab|DRUG: Oxaliplatin|DRUG: Capecitabine|RADIATION: Short-course Radiation|PROCEDURE: Biopsy,2,OTHER,Sir Run Run Shaw Hospital,"['antibody', 'chemotherapy']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'adebrelimab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'oxaliplatin'}, {'type': 'chemotherapy', 'subtype': 'fluoropyrimidine', 'raw': 'capecitabine'}]",True,rectal adenocarcinoma,digestive
1217,China,Melanoma of Skin|Acral Melanoma|Stage II Melanoma,DRUG: Toripalimab combined with Endostar,2,OTHER,Fudan University,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'toripalimab combined with endostar'}]",False,melanoma of skin acral melanoma stage ii melanoma,skin
1218,United States,Small Cell Neuroendocrine Carcinoma of Bladder|Bladder Cancer|Urothelial Carcinoma Bladder,DRUG: Atezolizumab|DRUG: Carboplatin|DRUG: Cisplatin|DRUG: Etoposide|PROCEDURE: Cystectomy,2,OTHER,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'atezolizumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'etoposide'}]",True,small cell neuroendocrine carcinoma of bladder bladder cancer urothelial carcinoma bladder,genitourinary
1219,Germany,Hepatocellular Carcinoma Non-resectable|HCC,DRUG: Tremelimumab|DRUG: Durvalumab|PROCEDURE: Y-90 SIRT|PROCEDURE: DEB-TACE,2,OTHER,Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'tremelimumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}]",False,hepatocellular carcinoma non resectable hcc,digestive
1220,China,Nasopharyngeal Carcinoma|De-escalation Therapy,DRUG: Cisplatin-based induction chemotherapy|DRUG: Full course of PD-1/PD-L1 blockades|RADIATION: Reduced-dose IMRT|RADIATION: Standard-dose IMRT|DRUG: Concurrent Chemotherapy,3,OTHER,Sun Yat-sen University,"['other', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin-based induction chemotherapy'}, {'type': 'other', 'subtype': None, 'raw': 'full course of pd-1'}, {'type': 'other', 'subtype': None, 'raw': 'pd-l1 blockades'}, {'type': 'chemotherapy', 'subtype': 'concurrent', 'raw': 'concurrent chemotherapy'}]",True,nasopharyngeal carcinoma de escalation therapy,head/neck
1221,China,Clear Cell Renal Cell Carcinoma、Resistance to Immunotherapy,"DRUG: AK104（anti-PD-1/CTLA-4 bi-specific antibody ，intravenously）,lenvatinib（ targeted VEGFR 1-3、FGFR、PDGFRα， small molecule TKI，orally",2,OTHER,RenJi Hospital,"['targeted therapy', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'ak104（anti-pd-1'}, {'type': 'other', 'subtype': None, 'raw': 'ctla-4 bi-specific antibody ，intravenously）'}, {'type': 'targeted therapy', 'subtype': 'other', 'raw': 'lenvatinib（ targeted vegfr 1-3、fgfr、pdgfrα， small molecule tki，orally'}]",True,clear cell renal cell carcinoma resistance to immunotherapy,genitourinary
1222,Australia,Cutaneous Squamous Cell Carcinoma of the Head and Neck|Head and Neck Cancer,DRUG: Pembrolizumab,2,OTHER_GOV,Queensland Health,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",False,cutaneous squamous cell carcinoma of the head and neck head and neck cancer,skin
1223,United States,"Lymphoma|Lymphoma, Large B-Cell, Diffuse",DRUG: Glofitamab|DRUG: Polatuzumab|DRUG: Rituximab|DRUG: Doxorubicin Hydrochloride|DRUG: Cyclophosphamide|DRUG: Prednisone,2,OTHER,"Jennifer Crombie, MD","['antibody', 'supportive care', 'chemotherapy']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'glofitamab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'polatuzumab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'rituximab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'doxorubicin hydrochloride'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide'}, {'type': 'supportive care', 'subtype': 'steroid', 'raw': 'prednisone'}]",True,lymphoma lymphoma large b cell diffuse,hematologic
1224,United States,Acute Leukemia of Ambiguous Lineage|B Acute Lymphoblastic Leukemia,DRUG: Asparaginase Erwinia chrysanthemi|PROCEDURE: Biospecimen Collection|BIOLOGICAL: Blinatumomab|PROCEDURE: Bone Marrow Aspiration|DRUG: Calaspargase Pegol|PROCEDURE: Computed Tomography|DRUG: Cyclophosphamide|DRUG: Cytarabine|DRUG: Daunorubicin|DRUG: Dexamethasone|DRUG: Doxorubicin|PROCEDURE: Echocardiography Test|PROCEDURE: FDG-Positron Emission Tomography|DRUG: Leucovorin|DRUG: Levoleucovorin|PROCEDURE: Lumbar Puncture|PROCEDURE: Magnetic Resonance Imaging|DRUG: Mercaptopurine|DRUG: Methotrexate|DRUG: Methylprednisolone|PROCEDURE: Multigated Acquisition Scan|DRUG: Prednisolone|DRUG: Prednisone|DRUG: Therapeutic Hydrocortisone|DRUG: Thioguanine|DRUG: Venetoclax|DRUG: Vincristine,2,NIH,National Cancer Institute (NCI),"['targeted therapy', 'other', 'chemotherapy', 'antibody', 'supportive care']","[{'type': 'other', 'subtype': None, 'raw': 'asparaginase erwinia chrysanthemi'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'blinatumomab'}, {'type': 'other', 'subtype': None, 'raw': 'calaspargase pegol'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide'}, {'type': 'chemotherapy', 'subtype': 'antimetabolite', 'raw': 'cytarabine'}, {'type': 'other', 'subtype': None, 'raw': 'daunorubicin'}, {'type': 'supportive care', 'subtype': 'steroid', 'raw': 'dexamethasone'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'doxorubicin'}, {'type': 'supportive care', 'subtype': 'folinic acid', 'raw': 'leucovorin'}, {'type': 'other', 'subtype': None, 'raw': 'levoleucovorin'}, {'type': 'chemotherapy', 'subtype': 'purine analog', 'raw': 'mercaptopurine'}, {'type': 'chemotherapy', 'subtype': 'antifolate', 'raw': 'methotrexate'}, {'type': 'other', 'subtype': None, 'raw': 'methylprednisolone'}, {'type': 'supportive care', 'subtype': 'steroid', 'raw': 'prednisolone'}, {'type': 'supportive care', 'subtype': 'steroid', 'raw': 'prednisone'}, {'type': 'other', 'subtype': None, 'raw': 'therapeutic hydrocortisone'}, {'type': 'other', 'subtype': None, 'raw': 'thioguanine'}, {'type': 'targeted therapy', 'subtype': 'BCL-2 inhibitor', 'raw': 'venetoclax'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'vincristine'}]",True,acute leukemia of ambiguous lineage b acute lymphoblastic leukemia,hematologic
1225,United States,B Cell Leukemia,BIOLOGICAL: Autologous CD19 CAR+ EGFTt + T cells,1,OTHER,Seattle Children's Hospital,"['other', 'cell therapy']","[{'type': 'other', 'subtype': None, 'raw': 'autologous cd19 car'}, {'type': 'other', 'subtype': None, 'raw': 'egftt'}, {'type': 'cell therapy', 'subtype': 'other', 'raw': 't cells'}]",True,b cell leukemia,hematologic
1226,Italy,Colorectal Cancer|Resectable Colorectal Carcinoma,DRUG: Trastuzumab deruxtecan|DRUG: Durvalumab|DRUG: Panitumumab|DRUG: Botensilimab|DRUG: Balstilimab|DRUG: Sotorasib|DRUG: Vorbipiprant|DRUG: Nivolumab,2,OTHER,Gruppo Oncologico del Nord-Ovest,"['checkpoint inhibitor', 'other', 'antibody']","[{'type': 'other', 'subtype': None, 'raw': 'trastuzumab deruxtecan'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'panitumumab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'botensilimab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'balstilimab'}, {'type': 'other', 'subtype': None, 'raw': 'sotorasib'}, {'type': 'other', 'subtype': None, 'raw': 'vorbipiprant'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}]",True,colorectal cancer resectable colorectal carcinoma,digestive
1227,"Denmark, France, United Kingdom",Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma,DRUG: Nivolumab cohort 1|DRUG: Nivolumab cohort 2,2,OTHER,"Gustave Roussy, Cancer Campus, Grand Paris",['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab cohort 1'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab cohort 2'}]",False,relapsing refractory alk anaplastic large cell lymphoma,hematologic
1228,China,Hepatocellular Carcinoma,DRUG: Tislelizumab + Sitravatinib,2,OTHER_GOV,Anhui Provincial Hospital,"['checkpoint inhibitor', 'kinase inhibitor']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'tislelizumab'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'sitravatinib'}]",True,hepatocellular carcinoma,digestive
1229,China,Gastric/Gastroesophageal Junction Adenocarcinoma,DRUG: Paclitaxel for injection (albumin-bound)|DRUG: Adebrelimab|DRUG: Apatinib mesylate,2,OTHER,The First Affiliated Hospital of Xiamen University,"['other', 'antibody', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel for injection'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'adebrelimab'}, {'type': 'other', 'subtype': None, 'raw': 'apatinib mesylate'}]",True,gastric gastroesophageal junction adenocarcinoma,digestive
1230,"Guam, United States",Skin Angiosarcoma|Skin Radiation-Related Angiosarcoma|Visceral Angiosarcoma,PROCEDURE: Biospecimen Collection|DRUG: Cabozantinib S-malate|PROCEDURE: Computed Tomography|PROCEDURE: FDG-Positron Emission Tomography|PROCEDURE: Magnetic Resonance Imaging|BIOLOGICAL: Nivolumab|DRUG: Paclitaxel|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration,2,NIH,National Cancer Institute (NCI),"['checkpoint inhibitor', 'targeted therapy', 'chemotherapy']","[{'type': 'targeted therapy', 'subtype': 'other', 'raw': 'cabozantinib s-malate'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}]",True,skin angiosarcoma skin radiation related angiosarcoma visceral angiosarcoma,skin
1231,China,Esophageal Squamous Cell Carcinoma (ESCC)|Neoantigen-loaded Dendritic Cell Vaccine|Immune Checkpoint Inhibitors (ICIs),BIOLOGICAL: neoantigen-loaded dendritic cell vaccine (NeoDC-Vac),2,OTHER,Sichuan University,['vaccine'],"[{'type': 'vaccine', 'subtype': 'vaccine', 'raw': 'neoantigen-loaded dendritic cell vaccine'}]",False,esophageal squamous cell carcinoma neoantigen loaded dendritic cell vaccine immune checkpoint inhibitors,digestive
1232,United States,"B Cell Lymphoma|Lymphoma|Lymphoma, B-Cell|Diffuse Large B Cell Lymphoma|High-grade B-cell Lymphoma",DRUG: Pembrolizumab|DRUG: R-CHOP Protocol,2,OTHER,University of Chicago,"['checkpoint inhibitor', 'other']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'other', 'subtype': None, 'raw': 'r-chop protocol'}]",True,b cell lymphoma lymphoma lymphoma b cell diffuse large b cell lymphoma high grade b cell lymphoma,hematologic
1233,"Australia, Belgium, Brazil, Canada, Czechia, Denmark, France, Hong Kong, Hungary, Italy, Japan, Norway, Poland, Republic of, Russian Federation, South Africa, Spain, Taiwan, Turkey, United Kingdom, United States",Hodgkin Lymphoma,DRUG: brentuximab vedotin|DRUG: doxorubicin|DRUG: bleomycin|DRUG: vinblastine|DRUG: dacarbazine,3,INDUSTRY,Takeda,"['other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'brentuximab vedotin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'doxorubicin'}, {'type': 'other', 'subtype': None, 'raw': 'bleomycin'}, {'type': 'other', 'subtype': None, 'raw': 'vinblastine'}, {'type': 'chemotherapy', 'subtype': 'alkylating agent', 'raw': 'dacarbazine'}]",True,hodgkin lymphoma,hematologic
1234,China,"Carcinoma, Non-Small-Cell Lung",DRUG: Sugemalimab and Chemotherapy,2,OTHER,Hunan Cancer Hospital,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'sugemalimab and chemotherapy'}]",False,carcinoma non small cell lung,lung/thoracic
1235,United States,"Newly Diagnosed Glioblastoma|Glioblastoma, Isocitric Dehydrogenase (IDH)-Wildtype|Gliosarcoma|Glioblastoma Multiforme",DRUG: Balstilimab|DRUG: Botensilimab|DRUG: Liposomal Doxorubicin|DEVICE: Sonocloud-9 (SC-9),2,OTHER,Northwestern University,"['antibody', 'chemotherapy']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'balstilimab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'botensilimab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'liposomal doxorubicin'}]",True,newly diagnosed glioblastoma glioblastoma isocitric dehydrogenase wildtype gliosarcoma glioblastoma multiforme,brain/CNS
1236,Germany,Esophagus Adenocarcinoma,DRUG: Durvalumab|DRUG: FLOT|DRUG: mFOLFOX-6|RADIATION: Radiotherapy,2,OTHER,Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest,"['checkpoint inhibitor', 'other']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}, {'type': 'other', 'subtype': None, 'raw': 'flot'}, {'type': 'other', 'subtype': None, 'raw': 'mfolfox-6'}]",True,esophagus adenocarcinoma,other
1237,United States,Acute Myeloid Leukemia|Recurrent Adult Acute Myeloid Leukemia|Refractory Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia,BIOLOGICAL: Anti-CD33 CAR T-cells|PROCEDURE: Lymphodepletion Therapy,1,OTHER,City of Hope Medical Center,['cell therapy'],"[{'type': 'cell therapy', 'subtype': 'other', 'raw': 'anti-cd33 car t-cells'}]",False,acute myeloid leukemia recurrent adult acute myeloid leukemia refractory acute myeloid leukemia secondary acute myeloid leukemia,hematologic
1238,China,Nasopharyngeal Carcinoma,"DRUG: Camrelizumab, gemcitabin, cisplatin|RADIATION: Stereotactic Body Radiotherapy, Intensity modulated-radiotherapy",2,OTHER,Sun Yat-sen University,"['checkpoint inhibitor', 'other', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'camrelizumab'}, {'type': 'other', 'subtype': None, 'raw': 'gemcitabin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}]",True,nasopharyngeal carcinoma,head/neck
1239,China,NSCLC|Neoadjuvant Immunotherapy|Low Dose Radiotherapy|Sintilimab,RADIATION: Experimental|DRUG: Active comparator,2,OTHER,Anhui Provincial Cancer Hospital,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'active comparator'}]",False,nsclc neoadjuvant immunotherapy low dose radiotherapy sintilimab,lung/thoracic
1240,United States,Glioblastoma,DRUG: Bevacizumab|DRUG: PD-L1 t-haNK|DRUG: N-803,2,INDUSTRY,"ImmunityBio, Inc.","['antibody', 'cytokine therapy', 'cell therapy']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'bevacizumab'}, {'type': 'cell therapy', 'subtype': 'engineered T cell', 'raw': 'pd-l1 t-hank'}, {'type': 'cytokine therapy', 'subtype': 'IL-15 superagonist', 'raw': 'n-803'}]",True,glioblastoma,brain/CNS
1241,China,Esophageal Squamous Cell Carcinoma (ESCC)|Immunotherapy,RADIATION: low-dose involved-field radiotherapy combined with immunochemotherapy,2,OTHER,Sichuan University,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'radiation: low-dose involved-field radiotherapy combined with immunochemotherapy'}]",False,esophageal squamous cell carcinoma immunotherapy,digestive
1242,Russian Federation,"Acute Lymphoblastic Leukemia, Pediatric|ALL, Infants",COMBINATION_PRODUCT: the risk-adapted choice of therapy and the use of a combination of chemotherapy with immunotherapy and hematopoietic stem cell transplantation for patients with risk factors.,3,OTHER,"Federal Research Institute of Pediatric Hematology, Oncology and Immunology",['cell therapy'],"[{'type': 'cell therapy', 'subtype': 'other', 'raw': 'the risk-adapted choice of therapy and the use of a combination of chemotherapy with immunotherapy and hematopoietic stem cell transplantation for patients with risk factors.'}]",False,acute lymphoblastic leukemia pediatric all infants,hematologic
1243,United States,"B-Cell Chronic Lymphocytic Leukemia|B-Lymphocytic Leukemia, Chronic|Chronic Lymphocytic Leukemia|Leukemia, Chronic Lymphatic|Leukemia, Chronic Lymphocytic, B-Cell|Leukemia, Lymphocytic, Chronic|Leukemia, Lymphocytic, Chronic, B-Cell|Lymphocytic Leukemia, Chronic, B Cell|Lymphocytic Leukemia, Chronic, B-Cell",DRUG: Ibrutinib|DRUG: Fludarabine|DRUG: Pembrolizumab,2,NIH,"National Heart, Lung, and Blood Institute (NHLBI)","['checkpoint inhibitor', 'chemotherapy', 'kinase inhibitor']","[{'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'ibrutinib'}, {'type': 'chemotherapy', 'subtype': 'purine analog', 'raw': 'fludarabine'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",True,b cell chronic lymphocytic leukemia b lymphocytic leukemia chronic chronic lymphocytic leukemia leukemia chronic lymphatic leukemia chronic lymphocytic b cell leukemia lymphocytic chronic leukemia lymphocytic chronic b cell lymphocytic leukemia chronic b cell lymphocytic leukemia chronic b cell,hematologic
1244,United Kingdom,Renal Cell Carcinoma,DRUG: Durvalumab|DRUG: Tremelimumab,3,OTHER,"University College, London",['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'tremelimumab'}]",False,renal cell carcinoma,genitourinary
1245,"Denmark, Norway, Sweden",Soft Tissue Sarcoma Adult|Angiosarcoma|Undifferentiated Pleomorphic Sarcoma,DRUG: Propranolol|DRUG: Pembrolizumab,2,OTHER,Niels Junker,"['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'propranolol'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",True,soft tissue sarcoma adult angiosarcoma undifferentiated pleomorphic sarcoma,sarcoma
1246,China,Nasopharyngeal Carcinoma,DRUG: Anrotinib plus Tirelizumab,2,OTHER,"Zhongshan People's Hospital, Guangdong, China",['antibody'],"[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'anrotinib plus tirelizumab'}]",False,nasopharyngeal carcinoma,head/neck
1247,United States,T Cell Non-Hodgkin Lymphoma,DRUG: Senza5 CART5,1,INDUSTRY,Vittoria Biotherapeutics,['cell therapy'],"[{'type': 'cell therapy', 'subtype': 'engineered cell', 'raw': 'senza5 cart5'}]",False,t cell non hodgkin lymphoma,hematologic
1248,China,Epithelial Ovarian Carcinoma|Fallopian Tube Carcinoma|Primary Peritoneal Carcinoma,COMBINATION_PRODUCT: DCVAC/OvCa|COMBINATION_PRODUCT: Placebo,2,OTHER,Peking University Third Hospital,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'dcvac'}, {'type': 'other', 'subtype': None, 'raw': 'ovca'}]",False,epithelial ovarian carcinoma fallopian tube carcinoma primary peritoneal carcinoma,gynecologic
1249,United States,Resectable Pancreatic Ductal Adenocarcinoma (PDAC)|Pancreatic Ductal Adenocarcinoma,DRUG: Pembrolizumab|DRUG: Defactinib,2,OTHER,The University of Texas Health Science Center at San Antonio,"['checkpoint inhibitor', 'kinase inhibitor']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'defactinib'}]",True,resectable pancreatic ductal adenocarcinoma pancreatic ductal adenocarcinoma,digestive
1250,China,Hepatocellular Carcinoma,RADIATION: Stereotactic body radiotherapy|DRUG: Adebrelimab|DRUG: Lenvatinib,2,OTHER,Mian XI,"['targeted therapy', 'antibody']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'adebrelimab'}, {'type': 'targeted therapy', 'subtype': 'other', 'raw': 'lenvatinib'}]",True,hepatocellular carcinoma,digestive
1251,China,Advanced Urothelial Carcinoma|Probiotics|Immunotherapy,DRUG: Probiotics Compound (Biolosion)|DRUG: Nab-paclitaxel|DRUG: Cisplatin|DRUG: Gemcitabine|DRUG: Disitamab vedotin|DRUG: Enfortumab Vedotin|DRUG: Pembrolizumab|DRUG: Toripalimab,2,OTHER,Sun Yat-sen University,"['checkpoint inhibitor', 'antibody-drug conjugate', 'other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'probiotics compound'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'nab-paclitaxel'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'gemcitabine'}, {'type': 'other', 'subtype': None, 'raw': 'disitamab vedotin'}, {'type': 'antibody-drug conjugate', 'subtype': 'anti-Nectin-4', 'raw': 'enfortumab vedotin'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'toripalimab'}]",True,advanced urothelial carcinoma probiotics immunotherapy,genitourinary
1252,China,Esophageal Squamous Cell Carcinoma,RADIATION: Intensity-modulated radiotherapy (IMRT)|DRUG: Tislelizumab|DRUG: Cisplatin|DRUG: Nab paclitaxel,3,OTHER,Renmin Hospital of Wuhan University,"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'tislelizumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'nab paclitaxel'}]",True,esophageal squamous cell carcinoma,digestive
1253,China,Head and Neck Squamous Cell Carcinoma,DRUG: Pembrolizumab combined with Chemotherapy,2,OTHER,Yuankai Shi,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab combined with chemotherapy'}]",False,head and neck squamous cell carcinoma,head/neck
1254,France,HCC - Hepatocellular Carcinoma,DRUG: Durvalumab/Tremelimumab in neoadjuvant and Durvalumab in adjuvant setting,2,OTHER,Assistance Publique - Hôpitaux de Paris,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'tremelimumab in neoadjuvant and durvalumab in adjuvant setting'}]",False,hcc hepatocellular carcinoma,digestive
1255,United States,Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Mantle Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Mantle Cell Lymphoma|Transformed Recurrent Non-Hodgkin Lymphoma,BIOLOGICAL: Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells|BIOLOGICAL: Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes|OTHER: Laboratory Biomarker Analysis,1,OTHER,City of Hope Medical Center,"['other', 'cell therapy']","[{'type': 'cell therapy', 'subtype': 'other', 'raw': 'autologous cd19car-cd28-cd3zeta-egfrt-expressing tcm-enriched t cells'}, {'type': 'other', 'subtype': None, 'raw': 'autologous cd19car-cd28-cd3zeta-egfrt-expressing tn'}, {'type': 'other', 'subtype': None, 'raw': 'mem-enriched t-lymphocytes'}]",True,recurrent diffuse large b cell lymphoma recurrent mantle cell lymphoma refractory diffuse large b cell lymphoma refractory mantle cell lymphoma transformed recurrent non hodgkin lymphoma,hematologic
1256,China,Recurrent Nasopharyngeal Carcinoma,DRUG: Toripalimab,3,OTHER,Cancer Hospital of Guangxi Medical University,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'toripalimab'}]",False,recurrent nasopharyngeal carcinoma,head/neck
1257,China,Esophageal Squamous Cell Carcinoma,DRUG: Adebrelimab|DRUG: Dalpiciclib 100mg|DRUG: Dalpiciclib 150mg,1,OTHER,West China Hospital,"['other', 'antibody']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'adebrelimab'}, {'type': 'other', 'subtype': None, 'raw': 'dalpiciclib 100mg'}, {'type': 'other', 'subtype': None, 'raw': 'dalpiciclib 150mg'}]",True,esophageal squamous cell carcinoma,digestive
1258,Spain,"Lung Diseases|Carcinoma, Non-Small-Cell Lung|Resectable Lung Non-Small Cell Carcinoma",DRUG: Zimberelimab|DRUG: Sacituzumab govitecan|DRUG: Cisplatin|DRUG: Carboplatin,3,OTHER,Fundación GECP,"['antibody-drug conjugate', 'antibody', 'chemotherapy']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'zimberelimab'}, {'type': 'antibody-drug conjugate', 'subtype': 'anti-Trop-2', 'raw': 'sacituzumab govitecan'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}]",True,lung diseases carcinoma non small cell lung resectable lung non small cell carcinoma,lung/thoracic
1259,United States,Hepatocellular Carcinoma,BIOLOGICAL: RP2|BIOLOGICAL: Bevacizumab|BIOLOGICAL: Atezolizumab,2,INDUSTRY,Replimune Inc.,"['checkpoint inhibitor', 'other', 'antibody']","[{'type': 'other', 'subtype': None, 'raw': 'rp2'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'bevacizumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'atezolizumab'}]",True,hepatocellular carcinoma,digestive
1260,China,Advanced Hepatocellular Carcinoma,DRUG: Rituximab+PD-1 or PD-L1 inhibitors+targeted therapy,2,OTHER,Tianjin Medical University Cancer Institute and Hospital,"['other', 'antibody']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'rituximab'}, {'type': 'other', 'subtype': None, 'raw': 'pd-1 or pd-l1 inhibitors'}, {'type': 'other', 'subtype': None, 'raw': 'targeted therapy'}]",True,advanced hepatocellular carcinoma,digestive
1261,Australia,Melanoma,DRUG: Standard therapy or clinical trial|DRUG: Matched targeted therapy|DRUG: Trametinib and / or supportive care|DRUG: CDK4/6 and MEK inhibitor|DRUG: Compassionate Access Targeted Therapy,2,OTHER,Melanoma Institute Australia,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'standard therapy or clinical trial'}, {'type': 'other', 'subtype': None, 'raw': 'matched targeted therapy'}, {'type': 'other', 'subtype': None, 'raw': 'trametinib and'}, {'type': 'other', 'subtype': None, 'raw': 'or supportive care'}, {'type': 'other', 'subtype': None, 'raw': 'cdk4'}, {'type': 'other', 'subtype': None, 'raw': '6 and mek inhibitor'}, {'type': 'other', 'subtype': None, 'raw': 'compassionate access targeted therapy'}]",False,melanoma,skin
1262,China,Radiotherapy|PD-1 Inhibitor|Capecitabine|Nasopharyngeal Carcinoma,RADIATION: SBRT radiotherapy + Conventionally fractionated radiotherapy|DRUG: PD-1 inhibitor|DRUG: Capecitabine,2,OTHER,"Fifth Affiliated Hospital, Sun Yat-Sen University","['checkpoint inhibitor', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'pd-1 inhibitor'}, {'type': 'chemotherapy', 'subtype': 'fluoropyrimidine', 'raw': 'capecitabine'}]",True,radiotherapy pd 1 inhibitor capecitabine nasopharyngeal carcinoma,head/neck
1263,China,Esophageal Squamous Cell Carcinoma,DRUG: QL1706,2,OTHER,Tianjin Medical University Cancer Institute and Hospital,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'ql1706'}]",False,esophageal squamous cell carcinoma,digestive
1264,China,Precursor B-Cell Acute Lymphoblastic Leukemia,DRUG: Blinatumomab plus Reduced-dose Chemotherapy,2,OTHER,First Affiliated Hospital of Zhejiang University,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'blinatumomab plus reduced-dose chemotherapy'}]",False,precursor b cell acute lymphoblastic leukemia,hematologic
1265,"Canada, United States",Nodular Lymphocyte Predominant B-Cell Lymphoma|Recurrent Nodular Lymphocyte Predominant B-Cell Lymphoma|Refractory Nodular Lymphocyte Predominant B-Cell Lymphoma,PROCEDURE: Biopsy Procedure|PROCEDURE: Biospecimen Collection|PROCEDURE: Bone Marrow Biopsy|PROCEDURE: Computed Tomography|OTHER: Fludeoxyglucose F-18|BIOLOGICAL: Mosunetuzumab|PROCEDURE: Positron Emission Tomography|BIOLOGICAL: Rituximab|BIOLOGICAL: Rituximab and Hyaluronidase Human,2,NIH,National Cancer Institute (NCI),"['other', 'antibody']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'mosunetuzumab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'rituximab'}, {'type': 'other', 'subtype': None, 'raw': 'rituximab and hyaluronidase human'}]",True,nodular lymphocyte predominant b cell lymphoma recurrent nodular lymphocyte predominant b cell lymphoma refractory nodular lymphocyte predominant b cell lymphoma,hematologic
1266,United States,Relapsed B-Cell Acute Lymphoblastic Leukemia,PROCEDURE: leukapheresis or collection of PBMCs|DRUG: cyclophosphamide based chemotherapy regimens|BIOLOGICAL: modified T cells,1,OTHER,Memorial Sloan Kettering Cancer Center,"['chemotherapy', 'cell therapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide based chemotherapy regimens'}, {'type': 'cell therapy', 'subtype': 'other', 'raw': 'modified t cells'}]",True,relapsed b cell acute lymphoblastic leukemia,hematologic
1267,China,Rectal Squamous Cell Carcinoma,COMBINATION_PRODUCT: PD-1 and CRT,2,OTHER,"Sixth Affiliated Hospital, Sun Yat-sen University",['other'],"[{'type': 'other', 'subtype': None, 'raw': 'pd-1 and crt'}]",False,rectal squamous cell carcinoma,digestive
1268,China,Esophageal Squamous Cell Carcinoma,"DRUG: Adebrelimab: 20mg/kg day1, Q3W, 3 times",2,OTHER,"Nanfang Hospital, Southern Medical University",['other'],"[{'type': 'other', 'subtype': None, 'raw': 'adebrelimab: 20mg'}, {'type': 'other', 'subtype': None, 'raw': 'kg day1'}, {'type': 'other', 'subtype': None, 'raw': 'q3w'}, {'type': 'other', 'subtype': None, 'raw': '3 times'}]",False,esophageal squamous cell carcinoma,digestive
1269,United States,Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC),DRUG: Pembrolizumab|DRUG: Carboplatin|DRUG: Paclitaxel,2,OTHER,Dan Zandberg,"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}]",True,recurrent metastatic head and neck squamous cell carcinoma,head/neck
1270,China,Nasopharyngeal Carcinoma,DRUG: PD-1 blocking antibody|DRUG: Gemcitabine|DRUG: Cisplatin (80 mg/m2)|RADIATION: Reduced-dose Intensity-modulated radiotherapy|RADIATION: Conventional-dose Intensity-modulated radiotherapy|DRUG: Cisplatin (100 mg/m2)|DRUG: Capecitabine,3,OTHER,Sun Yat-sen University,"['other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'pd-1 blocking antibody'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'gemcitabine'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}, {'type': 'chemotherapy', 'subtype': 'fluoropyrimidine', 'raw': 'capecitabine'}]",True,nasopharyngeal carcinoma,head/neck
1271,United States,Advanced Non-squamous Non-small-cell Lung Cancer|Advanced Squamous Non-Small Cell Lung Carcinoma|Metastatic Non-squamous Non Small Cell Lung Cancer|Metastatic Squamous Non-Small Cell Lung Carcinoma|Non-small Cell Lung Cancer|Non-small Cell Lung Cancer Stage III|Non-small Cell Lung Cancer Stage IV|Non-small Cell Lung Cancer Recurrent,"BIOLOGICAL: Olvimulogene nanivacirepvec|DRUG: Platinum chemotherapy: carboplatin or cisplatin|DRUG: Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLC|DRUG: Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab, nivolumab, cemiplimab, atezolizumab, durvalumab|DRUG: Docetaxel",2,INDUSTRY,Genelux Corporation,"['checkpoint inhibitor', 'other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'olvimulogene nanivacirepvec'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'platinum chemotherapy: carboplatin or cisplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell nsclc or pemetrexed for nonsquamous cell nsclc'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': ""physician's choice of immune checkpoint inhibitor: pembrolizumab""}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'cemiplimab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'atezolizumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'docetaxel'}]",True,advanced non squamous non small cell lung cancer advanced squamous non small cell lung carcinoma metastatic non squamous non small cell lung cancer metastatic squamous non small cell lung carcinoma non small cell lung cancer non small cell lung cancer stage iii non small cell lung cancer stage iv non small cell lung cancer recurrent,lung/thoracic
1272,"Australia, Austria, Belgium, Brazil, China, France, Germany, Hong Kong, Italy, Japan, Netherlands, Norway, Singapore, Spain, Switzerland, Taiwan, United Kingdom, United States",Non-Hodgkin Lymphoma,DRUG: Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy|DRUG: Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT),3,INDUSTRY,Novartis Pharmaceuticals,"['other', 'cell therapy']","[{'type': 'other', 'subtype': None, 'raw': 'tisagenlecleucel after optional bridging and lymphodepleting chemotherapy'}, {'type': 'cell therapy', 'subtype': 'other', 'raw': 'platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant'}]",True,non hodgkin lymphoma,hematologic
1273,China,Head and Neck Squamous Cell Carcinoma,DRUG: Camrelizumab|DRUG: Dalpiciclib 100mg|DRUG: Dalpiciclib 150mg,1,OTHER,West China Hospital,"['checkpoint inhibitor', 'other']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'camrelizumab'}, {'type': 'other', 'subtype': None, 'raw': 'dalpiciclib 100mg'}, {'type': 'other', 'subtype': None, 'raw': 'dalpiciclib 150mg'}]",True,head and neck squamous cell carcinoma,head/neck
1274,United States,"Recurrent Head and Neck Cancer|Metastatic Head and Neck Cancer|HPV Positive Oropharyngeal Squamous Cell Carcinoma|Neoplasms, Head and Neck|Unresectable Head and Neck Squamous Cell Carcinoma",COMBINATION_PRODUCT: Combination Treatment of PDS0101 and Pembrolizumab|DRUG: Pembrolizumab Monotherapy,3,INDUSTRY,PDS Biotechnology Corp.,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'combination treatment of pds0101 and pembrolizumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab monotherapy'}]",False,recurrent head and neck cancer metastatic head and neck cancer hpv positive oropharyngeal squamous cell carcinoma neoplasms head and neck unresectable head and neck squamous cell carcinoma,head/neck
1275,Israel,Esophageal Squamous Cell Carcinoma,DRUG: Cisplatin|DRUG: 5-FU|RADIATION: Radiation therapy|DRUG: Cetuximab|DRUG: Nivolumab,2,OTHER,Baruch Brenner,"['checkpoint inhibitor', 'antibody', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}, {'type': 'chemotherapy', 'subtype': 'antimetabolite', 'raw': '5-fu'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'cetuximab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}]",True,esophageal squamous cell carcinoma,digestive
1276,Italy,"Myasthenia Gravis, Generalized",DRUG: Rituximab|OTHER: Placebo,3,OTHER,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,['antibody'],"[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'rituximab'}]",False,myasthenia gravis generalized,other
1277,"Israel, Puerto Rico, United States",B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1,PROCEDURE: Biospecimen Collection|BIOLOGICAL: Blinatumomab|PROCEDURE: Bone Marrow Aspiration and Biopsy|DRUG: Cyclophosphamide|DRUG: Cytarabine|DRUG: Dasatinib|DRUG: Dexamethasone|DRUG: Doxorubicin Hydrochloride|PROCEDURE: Echocardiography Test|PROCEDURE: Electrocardiography|PROCEDURE: Lumbar Puncture|DRUG: Mesna|DRUG: Methotrexate|PROCEDURE: Multigated Acquisition Scan|DRUG: Ponatinib Hydrochloride|DRUG: Prednisone|DRUG: Vincristine Sulfate,3,NIH,National Cancer Institute (NCI),"['other', 'chemotherapy', 'kinase inhibitor', 'antibody', 'supportive care']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'blinatumomab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide'}, {'type': 'chemotherapy', 'subtype': 'antimetabolite', 'raw': 'cytarabine'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'dasatinib'}, {'type': 'supportive care', 'subtype': 'steroid', 'raw': 'dexamethasone'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'doxorubicin hydrochloride'}, {'type': 'other', 'subtype': None, 'raw': 'mesna'}, {'type': 'chemotherapy', 'subtype': 'antifolate', 'raw': 'methotrexate'}, {'type': 'other', 'subtype': None, 'raw': 'ponatinib hydrochloride'}, {'type': 'supportive care', 'subtype': 'steroid', 'raw': 'prednisone'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'vincristine sulfate'}]",True,b acute lymphoblastic leukemia with t bcr abl1,hematologic
1278,Australia,Extramedullary Myeloma,BIOLOGICAL: Combination Product: JNJ-68284528 (Cilta-cel) & 64Cu SPION dual PET-MR imaging agent,1,OTHER,"Peter MacCallum Cancer Centre, Australia",['other'],"[{'type': 'other', 'subtype': None, 'raw': 'combination product: jnj-68284528 & 64cu spion dual pet-mr imaging agent'}]",False,extramedullary myeloma,hematologic
1279,China,Renal Cell Carcinoma (RCC),DRUG: Toripalimab|DRUG: Lenvatinib,2,OTHER,"Jinling Hospital, China","['checkpoint inhibitor', 'targeted therapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'toripalimab'}, {'type': 'targeted therapy', 'subtype': 'other', 'raw': 'lenvatinib'}]",True,renal cell carcinoma,genitourinary
1280,China,Gastric or Gastroesophageal Junction Adenocarcinoma,DRUG: LM-302+Candonilimab+Capecitabine,2,OTHER,Shanghai Zhongshan Hospital,"['other', 'antibody', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'lm-302'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'candonilimab'}, {'type': 'chemotherapy', 'subtype': 'fluoropyrimidine', 'raw': 'capecitabine'}]",True,gastric or gastroesophageal junction adenocarcinoma,digestive
1281,Canada,Non-small Cell Carcinoma,DRUG: Binimetinib|DRUG: Pembrolizumab,1,OTHER,"University Health Network, Toronto","['checkpoint inhibitor', 'kinase inhibitor']","[{'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'binimetinib'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",True,non small cell carcinoma,lung/thoracic
1282,United States,Hepatocellular Carcinoma|Intrahepatic Cholangiocarcinoma,DRUG: VG161|DRUG: Nivolumab Injection [Opdivo],2,INDUSTRY,Virogin Biotech Canada Ltd,"['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'vg161'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab injection [opdivo]'}]",True,hepatocellular carcinoma intrahepatic cholangiocarcinoma,digestive
1283,China,Esophageal Squamous Cell Carcinoma|Neoadjuvant Therapy,"COMBINATION_PRODUCT: Serplulimab, Albumin paclitaxel, carboplatin AUC=5, neoadjuvant therapy|PROCEDURE: Esophagectomy|OTHER: sample",2,OTHER,"Second Affiliated Hospital, School of Medicine, Zhejiang University","['other', 'antibody', 'chemotherapy']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'serplulimab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'albumin paclitaxel'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin auc=5'}, {'type': 'other', 'subtype': None, 'raw': 'neoadjuvant therapy'}]",True,esophageal squamous cell carcinoma neoadjuvant therapy,digestive
1284,United States,Multiple Myeloma|Smoldering Multiple Myeloma,DRUG: Ciltacabtagene Autoleucel|DRUG: Cyclophosphamide|DRUG: Fludarabine Phosphate,2,OTHER,Dana-Farber Cancer Institute,"['other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'ciltacabtagene autoleucel'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide'}, {'type': 'chemotherapy', 'subtype': 'purine analog', 'raw': 'fludarabine phosphate'}]",True,multiple myeloma smoldering multiple myeloma,hematologic
1285,China,Clinical IVb Stage Oral Squamous Cell Carcinomas Patients,DRUG: Adebrelimab,2,OTHER,"Hospital of Stomatology, Wuhan University",['antibody'],"[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'adebrelimab'}]",False,clinical ivb stage oral squamous cell carcinomas patients,head/neck
1286,China,Esophageal Squamous Cell Carcinoma|Neoadjuvant Chemoimmunotherapy|Adjuvant Therapy,DRUG: Tislelizumab,2,OTHER,Guo Xufeng,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'tislelizumab'}]",False,esophageal squamous cell carcinoma neoadjuvant chemoimmunotherapy adjuvant therapy,digestive
1287,United States,Hodgkin's Lymphoma|Non-Hodgkin Lymphoma,GENETIC: CAR T Cells,1,OTHER,Baylor College of Medicine,['cell therapy'],"[{'type': 'cell therapy', 'subtype': 'other', 'raw': 'genetic: car t cells'}]",False,hodgkin s lymphoma non hodgkin lymphoma,hematologic
1288,United States,Multiple Myeloma,DRUG: Cyclophosphamide|DRUG: Ciltacabtagene Autoleucel|RADIATION: Total body irradiation,1,OTHER,Washington University School of Medicine,"['other', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide'}, {'type': 'other', 'subtype': None, 'raw': 'ciltacabtagene autoleucel'}]",True,multiple myeloma,hematologic
1289,France,Advanced Soft-tissue Sarcoma|Metastatic Soft-tissue Sarcoma,DRUG: Bintrafusp alfa|DRUG: Doxorubicin,2,OTHER,Institut Bergonié,"['other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'bintrafusp alfa'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'doxorubicin'}]",True,advanced soft tissue sarcoma metastatic soft tissue sarcoma,sarcoma
1290,China,Myelodysplastic Syndromes|Dendritic Cell|Hypomethylating Agents|Immunotherapy,BIOLOGICAL: DC vaccine,1,OTHER,Affiliated Hospital to Academy of Military Medical Sciences,['vaccine'],"[{'type': 'vaccine', 'subtype': 'vaccine', 'raw': 'dc vaccine'}]",False,myelodysplastic syndromes dendritic cell hypomethylating agents immunotherapy,hematologic
1291,Israel,Advanced Glioblastoma|Metastatic Melanoma in the Central Nervous System|MGMT-Unmethylated Glioblastoma,DRUG: Crizanlizumab-Tmca 10 MG/1 ML Intravenous Solution [ADAKVEO]|DRUG: Nivolumab 10 MG/1 ML Intravenous Solution [OPDIVO],2,OTHER_GOV,Sheba Medical Center,"['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'crizanlizumab-tmca 10'}, {'type': 'other', 'subtype': None, 'raw': '1 intravenous solution [adakveo]'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab 10'}, {'type': 'other', 'subtype': None, 'raw': '1 intravenous solution [opdivo]'}]",True,advanced glioblastoma metastatic melanoma in the central nervous system mgmt unmethylated glioblastoma,skin
1292,China,Neoadjuvant Immunotherapy,DRUG: tislelizumab+disitamab-vedotin,2,OTHER,Tianjin Medical University Second Hospital,"['checkpoint inhibitor', 'other']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'tislelizumab'}, {'type': 'other', 'subtype': None, 'raw': 'disitamab-vedotin'}]",True,neoadjuvant immunotherapy,hematologic
1293,United Kingdom,"Leukemia, Lymphoblastic, Acute, Lymphoma",BIOLOGICAL: CD19CAT-41BBZ CAR T-cells,1,OTHER,"University College, London",['cell therapy'],"[{'type': 'cell therapy', 'subtype': 'other', 'raw': 'cd19cat-41bbz car t-cells'}]",False,leukemia lymphoblastic acute lymphoma,hematologic
1294,China,Diffuse Large B Cell Lymphoma,DRUG: autologous hematopoietic stem cell,2,OTHER,Ruijin Hospital,['cell therapy'],"[{'type': 'cell therapy', 'subtype': 'other', 'raw': 'autologous hematopoietic stem cell'}]",False,diffuse large b cell lymphoma,hematologic
1295,Italy,Follicular Lymphoma,RADIATION: Radiotherapy|OTHER: Radiotherapy plus Obinutuzumab,3,OTHER,Fondazione Italiana Linfomi - ETS,[],[],False,follicular lymphoma,hematologic
1296,United States,Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma,PROCEDURE: CS1-CAR T Therapy|DRUG: Cyclophosphamide|DRUG: Fludarabine|PROCEDURE: Leukapheresis,1,OTHER,City of Hope Medical Center,['chemotherapy'],"[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide'}, {'type': 'chemotherapy', 'subtype': 'purine analog', 'raw': 'fludarabine'}]",False,recurrent plasma cell myeloma refractory plasma cell myeloma,hematologic
1297,Italy,Sinonasal Undifferentiated Carcinoma,DRUG: Pembrolizumab|DRUG: Cisplatin|DRUG: Docetaxel|DRUG: Carboplatin,2,OTHER,Istituti Clinici Scientifici Maugeri SpA,"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'docetaxel'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}]",True,sinonasal undifferentiated carcinoma,other
1298,China,Relapsed/Refractory Multiple Myeloma|Plasma Cell Leukemia,DRUG: CAR-GPRC5D,1,INDUSTRY,"Nanjing IASO Biotechnology Co., Ltd.",['other'],"[{'type': 'other', 'subtype': None, 'raw': 'car-gprc5d'}]",False,relapsed refractory multiple myeloma plasma cell leukemia,hematologic
1299,United States,Hepatocellular Carcinoma,DRUG: Nivolumab|DRUG: Relatlimab,1,OTHER,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,"['checkpoint inhibitor', 'antibody']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'relatlimab'}]",True,hepatocellular carcinoma,digestive
1300,United States,"Follicular Lymphoma|Low Grade Non-Hodgkin's Lymphoma, Adult",DRUG: Epcoritamab|DRUG: Rituximab,2,OTHER,"Reid Merryman, MD",['antibody'],"[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'epcoritamab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'rituximab'}]",False,follicular lymphoma low grade non hodgkin s lymphoma adult,hematologic
1301,China,Relapsed/Refractory Multiple Myeloma|Plasma Cell Leukemia,DRUG: CAR-T (CAR-GPRC5D),1,OTHER,Chunrui Li,['cell therapy'],"[{'type': 'cell therapy', 'subtype': 'engineered cell', 'raw': 'car-t'}]",False,relapsed refractory multiple myeloma plasma cell leukemia,hematologic
1302,United Kingdom,Relapsed Follicular Lymphoma|Refractory Follicular Lymphoma,DRUG: Epcoritamab|DRUG: Lenalidomide|DRUG: Rituximab|DRUG: Obinutuzumab|DRUG: Bendamustine|DRUG: Vincristine|DRUG: Doxorubicin|DRUG: Cyclophosphamide|DRUG: Prednisone|DRUG: Investigation agent 2|DRUG: Investigation agent 3,2,OTHER,University of Birmingham,"['other', 'antibody', 'supportive care', 'chemotherapy']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'epcoritamab'}, {'type': 'other', 'subtype': None, 'raw': 'lenalidomide'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'rituximab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'obinutuzumab'}, {'type': 'chemotherapy', 'subtype': 'alkylating agent', 'raw': 'bendamustine'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'vincristine'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'doxorubicin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide'}, {'type': 'supportive care', 'subtype': 'steroid', 'raw': 'prednisone'}, {'type': 'other', 'subtype': None, 'raw': 'investigation agent 2'}, {'type': 'other', 'subtype': None, 'raw': 'investigation agent 3'}]",True,relapsed follicular lymphoma refractory follicular lymphoma,hematologic
1303,China,Cadonilimab|Clear Cell Renal Cell Carcinoma|Neoadjuvant Therapy,DRUG: Cadonilimab Combined With Lenvatinib,2,OTHER,Sun Yat-sen University,['targeted therapy'],"[{'type': 'targeted therapy', 'subtype': 'other', 'raw': 'cadonilimab combined with lenvatinib'}]",False,cadonilimab clear cell renal cell carcinoma neoadjuvant therapy,genitourinary
1304,United States,Recurrent Head and Neck Squamous Cell Carcinoma|Recurrent Hypopharyngeal Squamous Cell Carcinoma|Recurrent Laryngeal Squamous Cell Carcinoma|Recurrent Oral Cavity Squamous Cell Carcinoma|Recurrent Oropharyngeal Squamous Cell Carcinoma,DRUG: Carboplatin|DRUG: Cisplatin|PROCEDURE: Computed Tomography|RADIATION: Intensity-Modulated Radiation Therapy|PROCEDURE: Magnetic Resonance Imaging|BIOLOGICAL: Pembrolizumab|RADIATION: Proton Beam Radiation Therapy,2,NIH,National Cancer Institute (NCI),"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",True,recurrent head and neck squamous cell carcinoma recurrent hypopharyngeal squamous cell carcinoma recurrent laryngeal squamous cell carcinoma recurrent oral cavity squamous cell carcinoma recurrent oropharyngeal squamous cell carcinoma,head/neck
1305,United States,Myelodysplastic Syndromes,DRUG: SX-682|DRUG: Decitabine,1,INDUSTRY,"Syntrix Biosystems, Inc.","['targeted therapy', 'other']","[{'type': 'targeted therapy', 'subtype': 'CXCR1/2 inhibitor', 'raw': 'sx-682'}, {'type': 'other', 'subtype': None, 'raw': 'decitabine'}]",True,myelodysplastic syndromes,hematologic
1306,"Canada, Denmark, France, Italy, Spain, United Kingdom, United States",Relapsed or Refractory Classical Hodgkin Lymphoma,DRUG: Sabestomig (AZD7789),1,INDUSTRY,AstraZeneca,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'sabestomig'}]",False,relapsed or refractory classical hodgkin lymphoma,hematologic
1307,China,Clear Cell Renal Cell Carcinoma,DRUG: 68Ga-NY104 PET/CT|DRUG: 18F-FDG PET/CT|RADIATION: Radiation Therapy|DRUG: Systemic therapy,2,OTHER,Peking Union Medical College Hospital,['other'],"[{'type': 'other', 'subtype': None, 'raw': '68ga-ny104 pet'}, {'type': 'other', 'subtype': None, 'raw': 'ct'}, {'type': 'other', 'subtype': None, 'raw': '18f-fdg pet'}, {'type': 'other', 'subtype': None, 'raw': 'ct'}, {'type': 'other', 'subtype': None, 'raw': 'systemic therapy'}]",False,clear cell renal cell carcinoma,genitourinary
1308,United States,Urothelial Carcinoma Bladder,DRUG: Sasanlimab|RADIATION: Stereotactic Body Radiation Therapy|PROCEDURE: Radical Cystectomy + pelvic lymph node dissection + urinary diversion,2,OTHER,The Methodist Hospital Research Institute,['antibody'],"[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'sasanlimab'}]",False,urothelial carcinoma bladder,genitourinary
1309,Italy,Intrahepatic Cholangiocarcinoma,RADIATION: radioembolization with Y-90|DRUG: Durvalumab|DRUG: Cisplatin|DRUG: Gemcitabine,2,OTHER,Francesco De Cobelli,"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'gemcitabine'}]",True,intrahepatic cholangiocarcinoma,other
1310,United States,"Diffuse Intrinsic Pontine Glioma|Diffuse Midline Glioma, H3 K27M-Mutant",BIOLOGICAL: rHSC-DIPGVax|DRUG: Balstilimab|DRUG: Zalifrelimab,1,OTHER,Ann & Robert H Lurie Children's Hospital of Chicago,"['other', 'antibody']","[{'type': 'other', 'subtype': None, 'raw': 'rhsc-dipgvax'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'balstilimab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'zalifrelimab'}]",True,diffuse intrinsic pontine glioma diffuse midline glioma h3 k27m mutant,brain/CNS
1311,"Australia, Austria, Czechia, Germany, Israel, Italy, Slovakia, Switzerland","Acute Lymphoblastic Leukemia, Pediatric",DRUG: Blinatumomab|DRUG: Bortezomib|DRUG: Cyclophosphamide|DRUG: Cytarabine|DRUG: Daunorubicin|DRUG: Myocet|DRUG: Dexamethasone|DRUG: Doxorubicin|DRUG: Etoposide|DRUG: Fludarabine Phosphate|DRUG: Ifosfamide|DRUG: 6-Mercaptopurine|DRUG: Methotrexate|DRUG: Pegaspargase|DRUG: Prednisolone|DRUG: Tioguanin|DRUG: Vincristine|DRUG: Vindesine|DRUG: Erwinase,3,OTHER,Martin Schrappe,"['other', 'antibody', 'supportive care', 'chemotherapy']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'blinatumomab'}, {'type': 'other', 'subtype': None, 'raw': 'bortezomib'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide'}, {'type': 'chemotherapy', 'subtype': 'antimetabolite', 'raw': 'cytarabine'}, {'type': 'other', 'subtype': None, 'raw': 'daunorubicin'}, {'type': 'other', 'subtype': None, 'raw': 'myocet'}, {'type': 'supportive care', 'subtype': 'steroid', 'raw': 'dexamethasone'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'doxorubicin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'etoposide'}, {'type': 'chemotherapy', 'subtype': 'purine analog', 'raw': 'fludarabine phosphate'}, {'type': 'chemotherapy', 'subtype': 'alkylating agent', 'raw': 'ifosfamide'}, {'type': 'other', 'subtype': None, 'raw': '6-mercaptopurine'}, {'type': 'chemotherapy', 'subtype': 'antifolate', 'raw': 'methotrexate'}, {'type': 'other', 'subtype': None, 'raw': 'pegaspargase'}, {'type': 'supportive care', 'subtype': 'steroid', 'raw': 'prednisolone'}, {'type': 'other', 'subtype': None, 'raw': 'tioguanin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'vincristine'}, {'type': 'other', 'subtype': None, 'raw': 'vindesine'}, {'type': 'other', 'subtype': None, 'raw': 'erwinase'}]",True,acute lymphoblastic leukemia pediatric,hematologic
1312,"Canada, Italy, Spain",Hepatocellular Carcinoma,DRUG: Tremelimumab,2,OTHER,"University Health Network, Toronto",['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'tremelimumab'}]",False,hepatocellular carcinoma,digestive
1313,Canada,Relapsed or Refractory CD19+ B-cell Lymphoma|Relapsed or Refractory Chronic Lymphocytic Leukemia|Relapsed or Refractory Small Lymphocytic Lymphoma,BIOLOGICAL: TBI-2001|DRUG: Cyclophosphamide|DRUG: Fludarabine,1,OTHER,"University Health Network, Toronto","['other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'tbi-2001'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide'}, {'type': 'chemotherapy', 'subtype': 'purine analog', 'raw': 'fludarabine'}]",True,relapsed or refractory cd19 b cell lymphoma relapsed or refractory chronic lymphocytic leukemia relapsed or refractory small lymphocytic lymphoma,hematologic
1314,China,B Cell Leukemia|B Cell Lymphoma,BIOLOGICAL: ICAR19 CAR-T cells,1,INDUSTRY,"Immune Cell, Inc.",['cell therapy'],"[{'type': 'cell therapy', 'subtype': 'engineered cell', 'raw': 'icar19 car-t cells'}]",False,b cell leukemia b cell lymphoma,hematologic
1315,United States,Follicular Lymphoma|Marginal Zone Lymphoma|Indolent Non-hodgkin Lymphoma,DRUG: Obinutuzumab|DRUG: Glofitamab,2,OTHER,"Reid Merryman, MD",['antibody'],"[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'obinutuzumab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'glofitamab'}]",False,follicular lymphoma marginal zone lymphoma indolent non hodgkin lymphoma,hematologic
1316,United States,"Soft Tissue Sarcoma|Sarcoma,Soft Tissue",DRUG: Talimogene Laherparepvec|RADIATION: Neoadjuvant Radiation|PROCEDURE: Surgery,2,OTHER,John Rieth,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'talimogene laherparepvec'}]",False,soft tissue sarcoma sarcoma soft tissue,sarcoma
1317,"Spain, United States",Monoclonal Gammopathy of Undetermined Significance (MGUS)|Smoldering Multiple Myeloma (SMM),DRUG: Linvoseltamab,2,INDUSTRY,Regeneron Pharmaceuticals,['antibody'],"[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'linvoseltamab'}]",False,monoclonal gammopathy of undetermined significance smoldering multiple myeloma,hematologic
1318,"Malaysia, Singapore",B Lymphoblastic Leukemia,DRUG: Prednisolone|DRUG: Dexamethasone|DRUG: Vincristine|DRUG: Methotrexate|DRUG: L-Asparaginase|DRUG: Pegylated asparaginase|DRUG: Erwinase|DRUG: Dasatinib|DRUG: Imatinib|DRUG: Cyclophosphamide|DRUG: Cytarabine|DRUG: Mercaptopurine|DRUG: Thioguanine|DRUG: Rituximab|DRUG: Doxorubicin|DRUG: Fludarabine,2,OTHER,"National University Hospital, Singapore","['other', 'chemotherapy', 'kinase inhibitor', 'antibody', 'supportive care']","[{'type': 'supportive care', 'subtype': 'steroid', 'raw': 'prednisolone'}, {'type': 'supportive care', 'subtype': 'steroid', 'raw': 'dexamethasone'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'vincristine'}, {'type': 'chemotherapy', 'subtype': 'antifolate', 'raw': 'methotrexate'}, {'type': 'other', 'subtype': None, 'raw': 'l-asparaginase'}, {'type': 'other', 'subtype': None, 'raw': 'pegylated asparaginase'}, {'type': 'other', 'subtype': None, 'raw': 'erwinase'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'dasatinib'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'imatinib'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide'}, {'type': 'chemotherapy', 'subtype': 'antimetabolite', 'raw': 'cytarabine'}, {'type': 'chemotherapy', 'subtype': 'purine analog', 'raw': 'mercaptopurine'}, {'type': 'other', 'subtype': None, 'raw': 'thioguanine'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'rituximab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'doxorubicin'}, {'type': 'chemotherapy', 'subtype': 'purine analog', 'raw': 'fludarabine'}]",True,b lymphoblastic leukemia,hematologic
1319,China,C-staged Hepatocellular Carcinoma in BCLC Classification,COMBINATION_PRODUCT: Hepatic Arterial Infusion combined with Apatinib and Camrelizumab,2,OTHER,Sun Yat-sen University,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'hepatic arterial combined with apatinib and camrelizumab'}]",False,c staged hepatocellular carcinoma in bclc classification,digestive
1320,Russian Federation,Hodgkin Lymphoma,DRUG: Prolgolimab|DRUG: Combination with prolgolimab and bendamustine,2,OTHER,St. Petersburg State Pavlov Medical University,"['other', 'antibody']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'prolgolimab'}, {'type': 'other', 'subtype': None, 'raw': 'combination with prolgolimab and bendamustine'}]",True,hodgkin lymphoma,hematologic
1321,United States,Fibrolamellar Hepatocellular Carcinoma (FLC),DRUG: DNAJB1-PRKACA peptide vaccine|DRUG: Nivolumab|DRUG: Ipilimumab,1,OTHER,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,"['checkpoint inhibitor', 'vaccine']","[{'type': 'vaccine', 'subtype': 'vaccine', 'raw': 'dnajb1-prkaca peptide vaccine'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}]",True,fibrolamellar hepatocellular carcinoma,digestive
1322,"Australia, Canada, France, Hungary, New Zealand, Poland, Romania, Serbia, Spain, United States",Relapsed Diffuse Large B-cell Lymphoma|Refractory Diffuse Large B-cell Lymphoma,DRUG: DPX-Survivac|DRUG: Pembrolizumab|DRUG: CPA,2,INDUSTRY,"ImmunoVaccine Technologies, Inc. (IMV Inc.)","['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'dpx-survivac'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'other', 'subtype': None, 'raw': 'cpa'}]",True,relapsed diffuse large b cell lymphoma refractory diffuse large b cell lymphoma,hematologic
1323,United States,"Leukemia, B-Cell",GENETIC: Autologous TRICAR-ALL T-cells and lymphodepletion chemotherapy,1,OTHER,Baylor College of Medicine,['cell therapy'],"[{'type': 'cell therapy', 'subtype': 'other', 'raw': 'genetic: autologous tricar-all t-cells and lymphodepletion chemotherapy'}]",False,leukemia b cell,hematologic
1324,United States,Squamous Cell Carcinoma of Head and Neck,DRUG: Combination 5-azacytidine and nivolumab|DRUG: 5-azacytidine|DRUG: Nivolumab,2,OTHER,Barbara Burtness,"['checkpoint inhibitor', 'other']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'combination 5-azacytidine and nivolumab'}, {'type': 'other', 'subtype': None, 'raw': '5-azacytidine'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}]",True,squamous cell carcinoma of head and neck,head/neck
1325,Spain,Squamous Cell Carcinoma of the Anal Canal,DRUG: Atezolizumab plus Tiraglolumab,2,OTHER,Grupo Espanol Multidisciplinario del Cancer Digestivo,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'atezolizumab plus tiraglolumab'}]",False,squamous cell carcinoma of the anal canal,digestive
1326,United States,T-Cell Lymphoma,DRUG: Brentuximab vedotin|DRUG: Pembrolizumab,2,OTHER,Yale University,"['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'brentuximab vedotin'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",True,t cell lymphoma,hematologic
1327,"Japan, Taiwan, United States",Recurrent Head and Neck Squamous Cell Carcinoma,COMBINATION_PRODUCT: ASP-1929 Photoimmunotherapy|BIOLOGICAL: Pembrolizumab|DRUG: Carboplatin|DRUG: Cisplatin|DRUG: 5-fluorouracil|DRUG: Paclitaxel|DRUG: Docetaxel,3,INDUSTRY,"Rakuten Medical, Inc.","['checkpoint inhibitor', 'other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'asp-1929 photoimmunotherapy'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}, {'type': 'chemotherapy', 'subtype': 'antimetabolite', 'raw': '5-fluorouracil'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'docetaxel'}]",True,recurrent head and neck squamous cell carcinoma,head/neck
1328,United Kingdom,Diffuse Large B Cell Lymphoma,DRUG: Pembrolizumab|DRUG: Rituximab|DRUG: Ifosfamide|DRUG: Carboplatin|DRUG: Etoposide,2,OTHER,University of Southampton,"['checkpoint inhibitor', 'antibody', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'rituximab'}, {'type': 'chemotherapy', 'subtype': 'alkylating agent', 'raw': 'ifosfamide'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'etoposide'}]",True,diffuse large b cell lymphoma,hematologic
1329,Denmark,"Hepatitis, Drug-Induced",DRUG: Mycophenolate Mofetil|DRUG: Solu-Medrol|DRUG: Ursodeoxycholic acid|DRUG: Prednisone tablet,2,OTHER,Inge Marie Svane,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'mycophenolate mofetil'}, {'type': 'other', 'subtype': None, 'raw': 'solu-medrol'}, {'type': 'other', 'subtype': None, 'raw': 'ursodeoxycholic acid'}, {'type': 'other', 'subtype': None, 'raw': 'prednisone tablet'}]",False,hepatitis drug induced,other
1330,China,Primary Mediastinal Diffuse Large B-cell Lymphoma,"DRUG: Sintlimab+Rituximab follwed by R-CHOP(Cyclophosphamide, doxorubicin, vincristine, prednisone)",2,OTHER,Sun Yat-sen University,"['other', 'antibody']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'sintlimab'}, {'type': 'other', 'subtype': None, 'raw': 'rituximab follwed by r-chop'}]",True,primary mediastinal diffuse large b cell lymphoma,hematologic
1331,China,Esophageal Squamous Cell Carcinoma|Neoadjuvant Treatment,"DRUG: Adbelimumab, Albumin paclitaxel, Carboplatin, Apatinib|PROCEDURE: Esophagectomy|OTHER: Collecting samples from participant",2,OTHER,"Second Affiliated Hospital, School of Medicine, Zhejiang University","['antibody', 'chemotherapy', 'kinase inhibitor']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'adbelimumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'albumin paclitaxel'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'apatinib'}]",True,esophageal squamous cell carcinoma neoadjuvant treatment,digestive
1332,United States,Metastatic Soft Tissue Sarcoma|Advanced Soft Tissue Sarcoma,DRUG: Balstilimab|DRUG: Zalifrelimab|DRUG: Doxorubicin|DRUG: Botensilimab,2,OTHER,"University of Colorado, Denver","['antibody', 'chemotherapy']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'balstilimab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'zalifrelimab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'doxorubicin'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'botensilimab'}]",True,metastatic soft tissue sarcoma advanced soft tissue sarcoma,sarcoma
1333,"Puerto Rico, United States",Hepatocellular Carcinoma,DRUG: Atezolizumab|DRUG: Bevacizumab,2,INDUSTRY,"Genentech, Inc.","['checkpoint inhibitor', 'antibody']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'atezolizumab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'bevacizumab'}]",True,hepatocellular carcinoma,digestive
1334,New Zealand,"Large B-cell Lymphoma|Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|Primary Mediastinal Large B-cell Lymphoma (PMBCL)|Transformed Non-Hodgkin Lymphoma",DRUG: Fludarabine|DRUG: Cyclophosphamide|BIOLOGICAL: WZTL-002 CAR T-cells,2,OTHER,Malaghan Institute of Medical Research,"['chemotherapy', 'cell therapy']","[{'type': 'chemotherapy', 'subtype': 'purine analog', 'raw': 'fludarabine'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide'}, {'type': 'cell therapy', 'subtype': 'other', 'raw': 'wztl-002 car t-cells'}]",True,large b cell lymphoma diffuse large b cell lymphoma not otherwise specified primary mediastinal large b cell lymphoma transformed non hodgkin lymphoma,hematologic
1335,United States,MuSK Myasthenia Gravis,BIOLOGICAL: MuSK-CAART,1,INDUSTRY,Cabaletta Bio,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'musk-caart'}]",False,musk myasthenia gravis,other
1336,Australia,"HIV|Organ Transplantation|Lymphoma, Non-Hodgkin|Chronic Lymphocytic Leukemia|Multiple Myeloma|COVID-19 Vaccines",BIOLOGICAL: Pfizer Bivalent COVID-19 Vaccine|BIOLOGICAL: Moderna Bivalent mRNA vaccine,3,OTHER_GOV,Bayside Health,['vaccine'],"[{'type': 'vaccine', 'subtype': 'vaccine', 'raw': 'pfizer bivalent covid-19 vaccine'}, {'type': 'vaccine', 'subtype': 'mRNA', 'raw': 'moderna bivalent mrna vaccine'}]",False,hiv organ transplantation lymphoma non hodgkin chronic lymphocytic leukemia multiple myeloma covid 19 vaccines,hematologic
1337,"Canada, United States",Refractory Diffuse Large B Cell Lymphoma (DLBCL)|Relapsed Diffuse Large B Cell Lymphoma|High Grade B-cell Lymphoma (HGBCL)|Primary Mediastinal B-cell Lymphoma (PMBCL)|Transformed Lymphoma|Central Nervous System Lymphoma|Mantle Cell Lymphoma (MCL)|Richter Transformation,BIOLOGICAL: zamtocabtagene autoleucel (MB-CART2019.1)|DRUG: Cyclophosphamide|DRUG: Fludarabine|DRUG: Bendamustine,2,INDUSTRY,Miltenyi Biomedicine GmbH,"['other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'zamtocabtagene autoleucel'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide'}, {'type': 'chemotherapy', 'subtype': 'purine analog', 'raw': 'fludarabine'}, {'type': 'chemotherapy', 'subtype': 'alkylating agent', 'raw': 'bendamustine'}]",True,refractory diffuse large b cell lymphoma relapsed diffuse large b cell lymphoma high grade b cell lymphoma primary mediastinal b cell lymphoma transformed lymphoma central nervous system lymphoma mantle cell lymphoma richter transformation,hematologic
1338,Norway,Glioblastoma,Autologous cancer stem cell mRNA transfected dendritic cells,12,Hospital/Clinic/Other health care facility,Oslo University Hospital HF,['cell therapy'],"[{'type': 'cell therapy', 'subtype': 'other', 'raw': 'autologous cancer stem cell mrna transfected dendritic cells'}]",False,glioblastoma,brain/CNS
1339,Netherlands,BRAF V600 mutation–positive unresectable or metastatic melanoma,"OPDIVO 10 mg/mL concentrate for solution for infusion., YERVOY 5 mg/ml concentrate for solution for infusion, Braftovi 75 mg hard capsules, YERVOY 5 mg/ml concentrate for solution for infusion, Mektovi 15 mg film-coated tablets",12,Patient organisation/association,European Organisation For Research And Treatment Of Cancer,"['checkpoint inhibitor', 'other']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'opdivo 10'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1 (title)', 'raw': 'nivolumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'yervoy 5'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1 (title)', 'raw': 'nivolumab'}, {'type': 'other', 'subtype': None, 'raw': 'braftovi 75 hard capsules'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'yervoy 5'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1 (title)', 'raw': 'nivolumab'}, {'type': 'other', 'subtype': None, 'raw': 'mektovi 15 film-coated tablets'}]",True,braf v600 mutation positive unresectable or metastatic melanoma,skin
1340,France,pleural mesothelioma,ivonescimab,12,Patient organisation/association,Intergroupe Francophone De Cancerologie Thoracique,['antibody'],"[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'ivonescimab'}]",False,pleural mesothelioma,lung/thoracic
1341,Spain,Non-small cell lung cancer,"Placebo, CEMIPLIMAB",12,Patient organisation/association,European Organisation For Research And Treatment Of Cancer,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'cemiplimab'}]",False,non small cell lung cancer,lung/thoracic
1342,Spain,MSS and MSI colorectal and endometrial tumors,"DURVALUMAB, TREMELIMUMAB",12,Laboratory/Research/Testing facility,Vall D Hebron Institute Of Oncology,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'tremelimumab'}]",False,mss and msi colorectal and endometrial tumors,gynecologic
1343,Italy,"Cancer in the stomach or in the junction between the stomach and the oesophagus, without metastases in other organs and surgically resectable, with microsatellite instability and no EBV infection.","DURVALUMAB, TREMELIMUMAB",12,Patient organisation/association,Gruppo Oncologico Del Nord Ovest,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'tremelimumab'}]",False,cancer in the stomach or in the junction between the stomach and the oesophagus without metastases in other organs and surgically resectable with microsatellite instability and no ebv infection,digestive
1344,Spain,Sarcomas,"Allogeneic peripheral blood-derived CD56+ natural killer cells, co-cultured with K562-mb15-41BBI cell line",12,"Hospital/Clinic/Other health care facility, Hospital/Clinic/Other health care facility","Hospital Universitario La Paz, Hospital Universitario La Paz","['other', 'cell therapy']","[{'type': 'other', 'subtype': None, 'raw': 'allogeneic peripheral blood-derived cd56'}, {'type': 'cell therapy', 'subtype': 'other', 'raw': 'natural killer cells'}, {'type': 'cell therapy', 'subtype': 'other', 'raw': 'co-cultured with k562-mb15-41bbi cell line'}]",True,sarcomas,sarcoma
1345,Hungary,"Neoplasms, Head and Neck",JEMPERLI 500 mg concentrate for solution for infusion,12,Pharmaceutical company,Glaxosmithkline Research & Development Limited,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'jemperli 500 concentrate for solution for'}]",False,neoplasms head and neck,head/neck
1346,France,Renal Cell Carcinoma,"IMJUDO 20 mg/ml concentrate for solution for infusion., IMFINZI 50 mg/mL concentrate for solution for infusion.",12,Educational Institution,University College London,"['checkpoint inhibitor', 'other']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'imjudo 20'}, {'type': 'other', 'subtype': None, 'raw': 'concentrate for solution for .'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-L1', 'raw': 'imfinzi 50'}, {'type': 'other', 'subtype': None, 'raw': 'concentrate for solution for .'}]",True,renal cell carcinoma,genitourinary
1347,Netherlands,"non-small cell lung cancer (NSCLC) of clinical stages IB, II and selected stage III A","Relatlimab intravenous, OPDIVO 10 mg/mL concentrate for solution for infusion.",12,"Hospital/Clinic/Other health care facility, Hospital/Clinic/Other health care facility","Universitaetsklinikum Essen AöR, Universitaetsklinikum Essen AöR","['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'relatlimab intravenous'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'opdivo 10'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1 (title)', 'raw': 'nivolumab'}]",True,non small cell lung cancer of clinical stages ib ii and selected stage iii a,lung/thoracic
1348,Netherlands,"Pancreatic cancer, Borderline resectable pancreatic cancer (BRPC)","Oxaliplatine Fresenius Kabi 5 mg/ml concentraat voor oplossing voor infusie, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Folikabi 10 mg/ml oplossing voor injectie/infusie, Fluorouracil Accord 50 mg/ml, oplossing voor injectie of infusie, Irinotecan HCl-trihydraat Fresenius Kabi 20 mg/ml, concentraat voor oplossing voor infusie",12,Hospital/Clinic/Other health care facility,Amsterdam UMC,"['checkpoint inhibitor', 'other', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'oxaliplatine fresenius kabi 5'}, {'type': 'other', 'subtype': None, 'raw': 'concentraat voor oplossing voor infusie'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'keytruda 25'}, {'type': 'other', 'subtype': None, 'raw': 'concentrate for solution for'}, {'type': 'other', 'subtype': None, 'raw': 'folikabi 10'}, {'type': 'other', 'subtype': None, 'raw': 'oplossing voor injectie'}, {'type': 'other', 'subtype': None, 'raw': 'infusie'}, {'type': 'other', 'subtype': None, 'raw': 'fluorouracil accord 50'}, {'type': 'other', 'subtype': None, 'raw': 'oplossing voor injectie of infusie'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'irinotecan hcl-trihydraat fresenius kabi 20'}, {'type': 'other', 'subtype': None, 'raw': 'concentraat voor oplossing voor infusie'}]",True,pancreatic cancer borderline resectable pancreatic cancer,digestive
1349,France,Unresectable stage III Non-Small Cell Lung Cancer,"LIBTAYO 350 mg concentrate for solution for infusion., CARBOPLATIN, PACLITAXEL",12,Patient organisation/association,Intergroupe Francophone De Cancerologie Thoracique,"['other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'libtayo 350 concentrate for solution for .'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}]",True,unresectable stage iii non small cell lung cancer,lung/thoracic
1350,France,Advanced Non-Small Cell Lung Cancer,"Carboplatine Hikma 450 mg/45 ml oplossing voor infusie, Paclitaxel Ribosepharm 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed STADA 25 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Docetaxel Hikma 160 mg/8 ml Konzentrat zur Herstellung einer Infusionslösung, Docetaxel AqVida 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Quemliclustat, CARBO-cell® 10 mg/ml Infusionslösung, Konzentrat zur Herstellung einer Infusionslösung, Cisplatine Teva 1 mg/ml solution à diluer pour perfusion., Pemetrexed Ribosepharm 25 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Cisplatine Teva 1 mg/ml concentraat voor oplossing voor infusie, Pemetrexed NeoCorp 25 mg/ml Konzentrat zur Herstellung einer Infusionslösung, DOMVANALIMAB, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Abraxane 5 mg/ml powder for dispersion for infusion., Carboplatine Hikma 450 mg/45 ml Infusionslösung, Paclitaxel AqVida 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed Fresenius Kabi 25 mg/ml concentrate for solution for infusion, Cisplatine 1 mg/ml PCH, concentraat voor oplossing voor infusie, Pemetrexed Hexal 25 mg/ml infuusiokonsentraatti, liuosta varten, Cisplatin NeoCorp 1 mg/ml - Konzentrat zur Herstellung einer Infusionslösung, Carboplatine Hikma 450 mg/45 ml solution pour perfusion, Zimberelimab, CISPLATINE TEVA 1 mg/ml KONZENTRAT ZUR HERSTELLUNG EINER INFUSIONSLÖSUNG",12,Pharmaceutical company,Gilead Sciences Inc.,"['other', 'antibody', 'chemotherapy', 'cell therapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatine hikma 450'}, {'type': 'other', 'subtype': None, 'raw': '45 oplossing voor infusie'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel ribosepharm 6'}, {'type': 'other', 'subtype': None, 'raw': 'konzentrat zur herstellung einer infusionslösung'}, {'type': 'other', 'subtype': None, 'raw': 'pemetrexed stada 25'}, {'type': 'other', 'subtype': None, 'raw': 'konzentrat zur herstellung einer infusionslösung'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'docetaxel hikma 160'}, {'type': 'other', 'subtype': None, 'raw': '8 konzentrat zur herstellung einer infusionslösung'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'docetaxel aqvida 20'}, {'type': 'other', 'subtype': None, 'raw': 'konzentrat zur herstellung einer infusionslösung'}, {'type': 'other', 'subtype': None, 'raw': 'quemliclustat'}, {'type': 'cell therapy', 'subtype': 'other', 'raw': 'carbo-cell® 10'}, {'type': 'other', 'subtype': None, 'raw': 'infusionslösung'}, {'type': 'other', 'subtype': None, 'raw': 'konzentrat zur herstellung einer infusionslösung'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatine teva 1'}, {'type': 'other', 'subtype': None, 'raw': 'solution à diluer pour perfusion.'}, {'type': 'other', 'subtype': None, 'raw': 'pemetrexed ribosepharm 25'}, {'type': 'other', 'subtype': None, 'raw': 'konzentrat zur herstellung einer infusionslösung'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatine teva 1'}, {'type': 'other', 'subtype': None, 'raw': 'concentraat voor oplossing voor infusie'}, {'type': 'other', 'subtype': None, 'raw': 'pemetrexed neocorp 25'}, {'type': 'other', 'subtype': None, 'raw': 'konzentrat zur herstellung einer infusionslösung'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'domvanalimab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin hikma 10'}, {'type': 'other', 'subtype': None, 'raw': 'konzentrat zur herstellung einer infusionslösung'}, {'type': 'other', 'subtype': None, 'raw': 'abraxane 5'}, {'type': 'other', 'subtype': None, 'raw': 'powder for dispersion for .'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatine hikma 450'}, {'type': 'other', 'subtype': None, 'raw': '45 infusionslösung'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel aqvida 6'}, {'type': 'other', 'subtype': None, 'raw': 'konzentrat zur herstellung einer infusionslösung'}, {'type': 'other', 'subtype': None, 'raw': 'pemetrexed fresenius kabi 25'}, {'type': 'other', 'subtype': None, 'raw': 'concentrate for solution for'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatine 1'}, {'type': 'other', 'subtype': None, 'raw': 'pch'}, {'type': 'other', 'subtype': None, 'raw': 'concentraat voor oplossing voor infusie'}, {'type': 'other', 'subtype': None, 'raw': 'pemetrexed hexal 25'}, {'type': 'other', 'subtype': None, 'raw': 'infuusiokonsentraatti'}, {'type': 'other', 'subtype': None, 'raw': 'liuosta varten'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin neocorp 1'}, {'type': 'other', 'subtype': None, 'raw': '- konzentrat zur herstellung einer infusionslösung'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatine hikma 450'}, {'type': 'other', 'subtype': None, 'raw': '45 solution pour perfusion'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'zimberelimab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatine teva 1'}, {'type': 'other', 'subtype': None, 'raw': 'konzentrat zur herstellung einer infusionslösung'}]",True,advanced non small cell lung cancer,lung/thoracic
1351,Netherlands,"dMMR tumors consisting of but not limited to; Colorectal cancer, oesophageal cancer, GEJ-cancer, Gastric cancer, Duodenal and small bowel cancer, endometrial cancer, breastcancer, prostate cancer and sarcoma. 
pMMR tumors: To be defined","BOTENSILIMAB, BALSTILIMAB",12,Laboratory/Research/Testing facility,Netherlands Cancer Institute,['antibody'],"[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'botensilimab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'balstilimab'}]",False,dmmr tumors consisting of but not limited to colorectal cancer oesophageal cancer gej cancer gastric cancer duodenal and small bowel cancer endometrial cancer breastcancer prostate cancer and sarcoma pmmr tumors to be defined,gynecologic
1352,Belgium,"Advanced-stage, relapsed/refractory cancer",KEYTRUDA 25 mg/mL concentrate for solution for infusion,12,Pharmaceutical company,Imcheck Therapeutics,"['checkpoint inhibitor', 'other']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'keytruda 25'}, {'type': 'other', 'subtype': None, 'raw': 'concentrate for solution for'}]",True,advanced stage relapsed refractory cancer,multiple
1353,Poland,HER2 negative breast cancer,"Paclitaxelum Accord, 6 mg/ml, koncentrat do sporządzania roztworu do infuzji, Carbomedac, 10 mg/ml, koncentrat do sporządzania roztworu do infuzji, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Natrium Chloratum 0,9% Baxter, roztwór do infuzji",12,Hospital/Clinic/Other health care facility,Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie-Panstwowy Instytut Badawczy,"['checkpoint inhibitor', 'other', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxelum accord'}, {'type': 'other', 'subtype': None, 'raw': '6'}, {'type': 'other', 'subtype': None, 'raw': 'koncentrat do sporządzania roztworu do infuzji'}, {'type': 'other', 'subtype': None, 'raw': 'carbomedac'}, {'type': 'other', 'subtype': None, 'raw': '10'}, {'type': 'other', 'subtype': None, 'raw': 'koncentrat do sporządzania roztworu do infuzji'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'keytruda 25'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1 (title)', 'raw': 'pembrolizumab'}, {'type': 'other', 'subtype': None, 'raw': 'natrium chloratum 0'}, {'type': 'other', 'subtype': None, 'raw': '9% baxter'}, {'type': 'other', 'subtype': None, 'raw': 'roztwór do infuzji'}]",True,her2 negative breast cancer,breast
1355,Austria,Non-Small-Cell Lung Cancer,"KEYTRUDA 25 mg/mL concentrate for solution for infusion, Lenvatinib, Lenvatinib",12,Educational Institution,Medizinische Universitaet Innsbruck,"['checkpoint inhibitor', 'targeted therapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'keytruda 25'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1 (title)', 'raw': 'pembrolizumab'}, {'type': 'targeted therapy', 'subtype': 'other', 'raw': 'lenvatinib'}, {'type': 'targeted therapy', 'subtype': 'other', 'raw': 'lenvatinib'}]",True,non small cell lung cancer,lung/thoracic
1356,France,Metastatic non-small cell lung cancer (NSCLC),"Avastin 25 mg/ml concentrate for solution for infusion., Tecentriq, Trajenta 5 mg film-coated tablets, Docetaxel Accord 80 mg/4 ml concentrate for solution for infusion, Camonsertib",12,"Pharmaceutical company, Pharmaceutical company","F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AG","['other', 'antibody', 'chemotherapy']","[{'type': 'antibody', 'subtype': 'anti-VEGF', 'raw': 'avastin 25'}, {'type': 'other', 'subtype': None, 'raw': 'concentrate for solution for .'}, {'type': 'other', 'subtype': None, 'raw': 'tecentriq'}, {'type': 'other', 'subtype': None, 'raw': 'trajenta 5 film-coated tablets'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'docetaxel accord 80'}, {'type': 'other', 'subtype': None, 'raw': '4 concentrate for solution for'}, {'type': 'other', 'subtype': None, 'raw': 'camonsertib'}]",True,metastatic non small cell lung cancer,lung/thoracic
1359,Italy,Merkel cell carcinoma without metastases in other organs and surgically resectable,"ZYNYZ 500 mg concentrate for solution for infusion, CARBOPLATIN, ETOPOSIDE, CISPLATIN",12,Patient organisation/association,Gruppo Oncologico Del Nord Ovest,"['other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'zynyz 500 concentrate for solution for'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'etoposide'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}]",True,merkel cell carcinoma without metastases in other organs and surgically resectable,skin
1360,Portugal,"Lung Cancer, Non-Small Cell","KEYTRUDA 25 mg/mL concentrate for solution for infusion, JEMPERLI 500 mg concentrate for solution for infusion",12,"Pharmaceutical company, Pharmaceutical company","Glaxosmithkline Research & Development Limited, Glaxosmithkline Research & Development Limited","['checkpoint inhibitor', 'other']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'keytruda 25'}, {'type': 'other', 'subtype': None, 'raw': 'concentrate for solution for'}, {'type': 'other', 'subtype': None, 'raw': 'jemperli 500 concentrate for solution for'}]",True,lung cancer non small cell,lung/thoracic
1361,France,Triple Negative Breast Cancer with residual disease after neoadjuvant chemo-immunotherapy.,"CAPECITABINE, CAPECITABINE, PEMBROLIZUMAB",12,Hospital/Clinic/Other health care facility,Unicancer,"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'fluoropyrimidine', 'raw': 'capecitabine'}, {'type': 'chemotherapy', 'subtype': 'fluoropyrimidine', 'raw': 'capecitabine'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",True,triple negative breast cancer with residual disease after neoadjuvant chemo immunotherapy,breast
1362,France,malignant pleural mesothelioma,"Gliolan 30 mg/ml powder for oral solution., OPDIVO 10 mg/mL concentrate for solution for infusion.",12,Hospital/Clinic/Other health care facility,Centre Hospitalier Universitaire De Lille,"['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'gliolan 30'}, {'type': 'other', 'subtype': None, 'raw': 'powder for solution.'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'opdivo 10'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1 (title)', 'raw': 'nivolumab'}]",True,malignant pleural mesothelioma,lung/thoracic
1363,Denmark,cancer,"OPDIVO 10 mg/mL concentrate for solution for infusion., YERVOY 5 mg/ml concentrate for solution for infusion",12,Hospital/Clinic/Other health care facility,Odense University Hospital,"['checkpoint inhibitor', 'other']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'opdivo 10'}, {'type': 'other', 'subtype': None, 'raw': 'concentrate for solution for .'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'yervoy 5'}, {'type': 'other', 'subtype': None, 'raw': 'concentrate for solution for'}]",True,cancer,other
1365,France,Advanced MET exon 14 Mutated Non-Small Cell Lung Cancer,"NIVOLUMAB, GEMCITABINE, TEPMETKO 225 mg film-coated tablets, PACLITAXEL, DOCETAXEL, ATEZOLIZUMAB, BEVACIZUMAB, PEMBROLIZUMAB, VINORELBINE, PEMETREXED",12,Patient organisation/association,Intergroupe Francophone De Cancerologie Thoracique,"['checkpoint inhibitor', 'other', 'antibody', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'gemcitabine'}, {'type': 'other', 'subtype': None, 'raw': 'tepmetko 225 film-coated tablets'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'docetaxel'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'atezolizumab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'bevacizumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'other', 'subtype': None, 'raw': 'vinorelbine'}, {'type': 'chemotherapy', 'subtype': 'antifolate', 'raw': 'pemetrexed'}]",True,advanced met exon 14 mutated non small cell lung cancer,lung/thoracic
1366,France,Synchronous oligometastatic non-small cell lung cancer (NSCLC),"CARBOPLATINE KABI 10 mg/ml, solution à diluer pour perfusion, YERVOY 5 mg/ml concentrate for solution for infusion, PACLITAXEL SANDOZ 6 mg/ml, solution à diluer pour perfusion, LIBTAYO 350 mg concentrate for solution for infusion., Tecentriq 840 mg concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Pemetrexed Accord 25 mg/ml concentrate for solution for infusion, Cisplatine Accord 1 mg/ml concentraat voor oplossing voor infusie, OPDIVO 10 mg/mL concentrate for solution for infusion.",12,Hospital/Clinic/Other health care facility,Institut Gustave Roussy,"['checkpoint inhibitor', 'other', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatine kabi 10'}, {'type': 'other', 'subtype': None, 'raw': 'solution à diluer pour perfusion'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'yervoy 5'}, {'type': 'other', 'subtype': None, 'raw': 'concentrate for solution for'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel sandoz 6'}, {'type': 'other', 'subtype': None, 'raw': 'solution à diluer pour perfusion'}, {'type': 'other', 'subtype': None, 'raw': 'libtayo 350 concentrate for solution for .'}, {'type': 'other', 'subtype': None, 'raw': 'tecentriq 840 concentrate for solution for'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'keytruda 25'}, {'type': 'other', 'subtype': None, 'raw': 'concentrate for solution for'}, {'type': 'other', 'subtype': None, 'raw': 'pemetrexed accord 25'}, {'type': 'other', 'subtype': None, 'raw': 'concentrate for solution for'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatine accord 1'}, {'type': 'other', 'subtype': None, 'raw': 'concentraat voor oplossing voor infusie'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'opdivo 10'}, {'type': 'other', 'subtype': None, 'raw': 'concentrate for solution for .'}]",True,synchronous oligometastatic non small cell lung cancer,lung/thoracic
1367,France,"Localised unresectable adenocarcinoma or squamous cell carcinoma of the oesophagus without any prior chemotherapy, surgery, or radiotherapy","IMFINZI 50 mg/mL concentrate for solution for infusion., FLUOROURACIL, FOLINIC ACID, OXALIPLATIN",12,Hospital/Clinic/Other health care facility,Unicancer,"['checkpoint inhibitor', 'other', 'supportive care', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-L1', 'raw': 'imfinzi 50'}, {'type': 'other', 'subtype': None, 'raw': 'concentrate for solution for .'}, {'type': 'chemotherapy', 'subtype': 'antimetabolite', 'raw': 'fluorouracil'}, {'type': 'supportive care', 'subtype': 'rescue agent', 'raw': 'folinic acid'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'oxaliplatin'}]",True,localised unresectable adenocarcinoma or squamous cell carcinoma of the oesophagus without any prior chemotherapy surgery or radiotherapy,other
1368,France,MSI/dMMR tumors or EBV+ gastric cancer,KEYTRUDA 25 mg/mL concentrate for solution for infusion,12,Hospital/Clinic/Other health care facility,Centre Leon Berard,"['checkpoint inhibitor', 'other']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'keytruda 25'}, {'type': 'other', 'subtype': None, 'raw': 'concentrate for solution for'}]",True,msi dmmr tumors or ebv gastric cancer,digestive
1369,Spain,Resectable Non-small cell lung cancer,OPDIVO 10 mg/mL concentrate for solution for infusion.,12,Patient organisation/association,Fundacion GECP,"['checkpoint inhibitor', 'other']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'opdivo 10'}, {'type': 'other', 'subtype': None, 'raw': 'concentrate for solution for .'}]",True,resectable non small cell lung cancer,lung/thoracic
1370,Austria,Hepatocellular Carcinoma (Morpheus-Neo HCC),"Avastin 25 mg/ml concentrate for solution for infusion., Tiragolumab, Tecentriq 1,200 mg concentrate for solution for infusion, RO7247669",12,Pharmaceutical company,F. Hoffmann-La Roche AG,"['other', 'antibody']","[{'type': 'antibody', 'subtype': 'anti-VEGF', 'raw': 'avastin 25'}, {'type': 'other', 'subtype': None, 'raw': 'concentrate for solution for .'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'tiragolumab'}, {'type': 'other', 'subtype': None, 'raw': 'tecentriq 1'}, {'type': 'other', 'subtype': None, 'raw': '200 concentrate for solution for'}, {'type': 'other', 'subtype': None, 'raw': 'ro7247669'}]",True,hepatocellular carcinoma,digestive
1371,Germany,"Resectable, locally advanced non-small cell lung cancer (NSCLC, N2)","Pemetrexed medac 100 mg Pulver für ein Konzentrat zur Herstellung einer Infusionslösung, Carboplat onkovis 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed medac 500 mg Pulver für ein Konzentrat zur Herstellung einer Infusionslösung, Paclitaxel onkovis, 6 mg/ml, Konzentrat zur Herstellung einer Infusionslösung, IMFINZI 50 mg/mL concentrate for solution for infusion., Doce onkovis 20 mg/ ml Konzentrat zur Herstellung einer Infusionslösung, Vinorelbin onkovis 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Cisplatin Teva® 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung",12,Pharmaceutical company,Swiss Group for Clinical Cancer Research,"['checkpoint inhibitor', 'radiotherapy', 'other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'pemetrexed medac 100 pulver für ein konzentrat zur herstellung einer infusionslösung'}, {'type': 'other', 'subtype': None, 'raw': 'carboplat onkovis 10'}, {'type': 'other', 'subtype': None, 'raw': 'konzentrat zur herstellung einer infusionslösung'}, {'type': 'other', 'subtype': None, 'raw': 'pemetrexed medac 500 pulver für ein konzentrat zur herstellung einer infusionslösung'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel onkovis'}, {'type': 'other', 'subtype': None, 'raw': '6'}, {'type': 'other', 'subtype': None, 'raw': 'konzentrat zur herstellung einer infusionslösung'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-L1', 'raw': 'imfinzi 50'}, {'type': 'radiotherapy', 'subtype': 'from title', 'raw': 'radiotherapy'}, {'type': 'other', 'subtype': None, 'raw': 'doce onkovis 20'}, {'type': 'other', 'subtype': None, 'raw': 'konzentrat zur herstellung einer infusionslösung'}, {'type': 'other', 'subtype': None, 'raw': 'vinorelbin onkovis 10'}, {'type': 'other', 'subtype': None, 'raw': 'konzentrat zur herstellung einer infusionslösung'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin teva® 1'}, {'type': 'other', 'subtype': None, 'raw': 'konzentrat zur herstellung einer infusionslösung'}]",True,resectable locally advanced non small cell lung cancer,lung/thoracic
1372,Belgium,"Non-Small Cell Lung Cancer (NSCLC), Renal Cell Carcinoma (RCC)","Tecentriq 1 200 mg concentrate for solution for infusion, YERVOY 5 mg/ml concentrate for solution for infusion, OPDIVO 10 mg/mL concentrate for solution for infusion., Oncobax®-AK, KEYTRUDA 25 mg/mL concentrate for solution for infusion, LIBTAYO 350 mg concentrate for solution for infusion.",12,Pharmaceutical company,Everimmune,"['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'tecentriq 1 200 concentrate for solution for'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'yervoy 5'}, {'type': 'other', 'subtype': None, 'raw': 'concentrate for solution for'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'opdivo 10'}, {'type': 'other', 'subtype': None, 'raw': 'concentrate for solution for .'}, {'type': 'other', 'subtype': None, 'raw': 'oncobax®-ak'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'keytruda 25'}, {'type': 'other', 'subtype': None, 'raw': 'concentrate for solution for'}, {'type': 'other', 'subtype': None, 'raw': 'libtayo 350 concentrate for solution for .'}]",True,non small cell lung cancer renal cell carcinoma,genitourinary
1373,Italy,Adrenocortical carcinoma,"Lysodren 500 mg tablets, LIBTAYO 350 mg concentrate for solution for infusion.",12,Hospital/Clinic/Other health care facility,Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'lysodren 500 tablets'}, {'type': 'other', 'subtype': None, 'raw': 'libtayo 350 concentrate for solution for .'}]",False,adrenocortical carcinoma,other
1374,France,"MICROSATELLITE STABLE (MSS) METASTATIC COLORECTAL CANCER AND
A HIGH IMMUNE INFILTRATE","KEYTRUDA 25 mg/mL concentrate for solution for infusion, Avastin 25 mg/ml concentrate for solution for infusion., OXALIPLATINE HOSPIRA 5 mg/ml, solution à diluer pour perfusion, CAPECITABINE BIOGARAN 500 mg, comprimé pelliculé, Avastin 25 mg/ml concentrate for solution for infusion.",12,Hospital/Clinic/Other health care facility,Fondation Franc.Cancerologie Digestive,"['checkpoint inhibitor', 'other', 'antibody', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'keytruda 25'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1 (title)', 'raw': 'pembrolizumab'}, {'type': 'antibody', 'subtype': 'anti-VEGF', 'raw': 'avastin 25'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1 (title)', 'raw': 'pembrolizumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'oxaliplatine hospira 5'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1 (title)', 'raw': 'pembrolizumab'}, {'type': 'other', 'subtype': None, 'raw': 'capecitabine biogaran 500'}, {'type': 'other', 'subtype': None, 'raw': 'comprimé pelliculé'}, {'type': 'antibody', 'subtype': 'anti-VEGF', 'raw': 'avastin 25'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1 (title)', 'raw': 'pembrolizumab'}]",True,microsatellite stable metastatic colorectal cancer and a high immune infiltrate,digestive
1375,Netherlands,Cutaneous squamous cell carcinoma,"YERVOY 5 mg/ml concentrate for solution for infusion, OPDIVO 10 mg/mL concentrate for solution for infusion.",12,Hospital/Clinic/Other health care facility,Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting,"['checkpoint inhibitor', 'radiotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'yervoy 5'}, {'type': 'radiotherapy', 'subtype': 'from title', 'raw': 'radiotherapy'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'opdivo 10'}, {'type': 'radiotherapy', 'subtype': 'from title', 'raw': 'radiotherapy'}]",True,cutaneous squamous cell carcinoma,skin
1376,France,Cancer,"NIVOLUMAB, PEMBROLIZUMAB",1,Hospital/Clinic/Other health care facility,Centre Hospitalier Regional De Marseille,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",False,cancer,other
1377,Spain,Triple negative breast cancer,"KEYTRUDA 25 mg/mL concentrate for solution for infusion, PACLITAXEL",12,"Hospital/Clinic/Other health care facility, Hospital/Clinic/Other health care facility","Unicancer, Institut Gustave Roussy","['checkpoint inhibitor', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'keytruda 25'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1 (title)', 'raw': 'pembrolizumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}]",True,triple negative breast cancer,breast
1378,Italy,thyroid cancers,KEYTRUDA 25 mg/mL concentrate for solution for infusion,12,Hospital/Clinic/Other health care facility,Istituti Clinici Scientifici Maugeri In Forma Abbreviata Istituti Clinici Scientifici Maugeri O Anche Ics Maugeri O Maugeri S.p.A. Sb,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'keytruda 25'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1 (title)', 'raw': 'pembrolizumab'}]",False,thyroid cancers,other
1379,France,Patients with dMMR/MSI (non-colorectal/non-endometrial) locally advanced or metastatic cancer,"OXALIPLATIN, ETOPOSIDE, CISPLATIN, CALCIUM FOLINATE, CAPECITABINE, IRINOTECAN, PACLITAXEL, FLUOROURACIL, TRABECTEDIN, DOCETAXEL, IFOSFAMIDE, PACLITAXEL ALBUMIN-BOUND, DOXORUBICIN, MITOTANE, CARBOPLATIN, GEMCITABINE",12,Hospital/Clinic/Other health care facility,Unicancer,"['other', 'supportive care', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'oxaliplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'etoposide'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}, {'type': 'supportive care', 'subtype': 'rescue agent', 'raw': 'calcium folinate'}, {'type': 'chemotherapy', 'subtype': 'fluoropyrimidine', 'raw': 'capecitabine'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'irinotecan'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}, {'type': 'chemotherapy', 'subtype': 'antimetabolite', 'raw': 'fluorouracil'}, {'type': 'other', 'subtype': None, 'raw': 'trabectedin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'docetaxel'}, {'type': 'chemotherapy', 'subtype': 'alkylating agent', 'raw': 'ifosfamide'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel albumin-bound'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'doxorubicin'}, {'type': 'other', 'subtype': None, 'raw': 'mitotane'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'gemcitabine'}]",True,patients with dmmr msi locally advanced or metastatic cancer,gynecologic
1380,Denmark,Colorectal Cancer,"Influvactetra, injektionsvæske, suspension i fyldt injektionssprøjte, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Influvac Tetra Saison 2024/2025 Injektionssuspension in einer Fertigspritze Influenza-Impfstoff aus Oberflächenantigen (inaktiviert)",12,Hospital/Clinic/Other health care facility,Zealand University Hospital,"['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'influvactetra'}, {'type': 'other', 'subtype': None, 'raw': 'injektionsvæske'}, {'type': 'other', 'subtype': None, 'raw': 'suspension i fyldt injektionssprøjte'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'keytruda 25'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1 (title)', 'raw': 'pembrolizumab'}, {'type': 'other', 'subtype': None, 'raw': 'influvac tetra saison 2024'}, {'type': 'other', 'subtype': None, 'raw': '2025 injektionssuspension in einer fertigspritze influenza-impfstoff aus oberflächenantigen'}]",True,colorectal cancer,digestive
1381,Hungary,"Advanced epithelial ovarian, fallopian tube or peritoneal carcinoma","Powder for solution for infusion, Oregovomab",12,Pharmaceutical company,Canariabio Inc.,"['other', 'antibody']","[{'type': 'other', 'subtype': None, 'raw': 'powder for solution for'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'oregovomab'}]",True,advanced epithelial ovarian fallopian tube or peritoneal carcinoma,gynecologic
1382,Spain,peritoneal metastases of colorectal cancer,Mitomicina Accord 40 mg polvo para solución inyectable y para perfusión EFG,1,Hospital/Clinic/Other health care facility,Hospital Universitario De Fuenlabrada,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'mitomicina accord 40 polvo para solución inyectable y para perfusión efg'}]",False,peritoneal metastases of colorectal cancer,digestive
1383,France,"Histologically confirmed frail Limited Disease Small Cell Lung Cancer (ECOG PS 2, ECOG PS 0-1 and older than 70 or did not receive a concomitant thoracic CRT because of comorbidities) previously untreated",IMFINZI 50 mg/mL concentrate for solution for infusion.,12,Hospital/Clinic/Other health care facility,Unicancer,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-L1', 'raw': 'imfinzi 50'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1 (title)', 'raw': 'durvalumab'}]",False,histologically confirmed frail limited disease small cell lung cancer previously untreated,lung/thoracic
1384,Italy,patients affected by small cell lung cancer (SCLC),Tecentriq 1 200 mg concentrate for solution for infusion,12,Patient organisation/association,G.O.I.R.C. Gruppo Oncologico Italiano Di Ricerca Clinica,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'tecentriq 1 200 concentrate for solution for'}]",False,patients affected by small cell lung cancer,lung/thoracic
1385,Italy,"Unresectable or metastatic melanoma, Locally advanced or metastatic urothelial carcinoma, Locally advanced or metastatic non-small cell lung cancer (NSCLC), Untreated recurrent/metastatic head & neck sqamous cell carcinoma (HNSCC)","PEMBROLIZUMAB, ATEZOLIZUMAB, NIVOLUMAB, CEMIPLIMAB",12,Patient organisation/association,Fondazione Centro Nazionale Di Adroterapia Oncologica,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'atezolizumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'cemiplimab'}]",False,unresectable or metastatic melanoma locally advanced or metastatic urothelial carcinoma locally advanced or metastatic non small cell lung cancer untreated recurrent metastatic head neck sqamous cell carcinoma,genitourinary
1386,France,Early and metastatic triple negative breast cancer,"CARBOPLATINE HOSPIRA 10 mg/ml, solution injectable pour perfusion, Tecentriq 1,200 mg concentrate for solution for infusion, Cyclophosphamide 500 mg Powder for Solution for Injection or Infusion, 68Ga-FAPI-46, Doxorubicin Accord Healthcare 2 mg/ml solution à diluer pour perfusion, Tiragolumab, Abraxane 5 mg/ml powder for dispersion for infusion.",12,"Laboratory/Research/Testing facility, Hospital/Clinic/Other health care facility","Institut Curie, Institut Curie","['checkpoint inhibitor', 'other', 'antibody', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatine hospira 10'}, {'type': 'other', 'subtype': None, 'raw': 'solution injectable pour perfusion'}, {'type': 'other', 'subtype': None, 'raw': 'tecentriq 1'}, {'type': 'other', 'subtype': None, 'raw': '200 concentrate for solution for'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide 500 powder for solution for injection or'}, {'type': 'other', 'subtype': None, 'raw': '68ga-fapi-46'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'doxorubicin accord healthcare 2'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1 (title)', 'raw': 'atezolizumab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'tiragolumab'}, {'type': 'other', 'subtype': None, 'raw': 'abraxane 5'}, {'type': 'other', 'subtype': None, 'raw': 'powder for dispersion for .'}]",True,early and metastatic triple negative breast cancer,breast
1387,Belgium,type B3 thymoma and thymic carcinoma,"IPILIMUMAB, NIVOLUMAB",12,Patient organisation/association,European Organisation For Research And Treatment Of Cancer,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}]",False,type b3 thymoma and thymic carcinoma,other
1388,Germany,Male and female adult patients with locally advanced or metastatic large-cell neuroendocrine carcinoma of the lung not eligible for curative treatment,"CISPLATIN, CARBOPLATIN, ETOPOSIDE, Tecentriq 1 200 mg concentrate for solution for infusion",12,Educational Institution,Technische Universitaet Dresden,"['other', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'etoposide'}, {'type': 'other', 'subtype': None, 'raw': 'tecentriq 1 200 concentrate for solution for'}]",True,male and female adult patients with locally advanced or metastatic large cell neuroendocrine carcinoma of the lung not eligible for curative treatment,lung/thoracic
1389,Bulgaria,"Completely resected primary stage IB (≥ 4cm), II and IIIA non-small cell lung cancer patients","MEDI4736 Placebo, DURVALUMAB",12,"Patient organisation/association, Patient organisation/association, Patient organisation/association, Educational Institution, Pharmaceutical company","NVALT-studies Stichting, Intergroupe Francophone De Cancerologie Thoracique, Fundacion GECP, Queen's University, Clinipace Global Limited","['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'medi4736'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}]",True,completely resected primary stage ib ii and iiia non small cell lung cancer patients,lung/thoracic
1390,France,"Upper Gastrointestinal Tract Cancer, Advanced Upper Gastrointestinal Tract Malignancies, Gastrointestinal Tract Malignancies","Zimberelimab, CALCIUM FOLINATE, FLUOROURACIL, OXALIPLATIN, DOMVANALIMAB, Quemliclustat",12,Pharmaceutical company,Arcus Biosciences Inc.,"['other', 'antibody', 'supportive care', 'chemotherapy']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'zimberelimab'}, {'type': 'supportive care', 'subtype': 'rescue agent', 'raw': 'calcium folinate'}, {'type': 'chemotherapy', 'subtype': 'antimetabolite', 'raw': 'fluorouracil'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'oxaliplatin'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'domvanalimab'}, {'type': 'other', 'subtype': None, 'raw': 'quemliclustat'}]",True,upper gastrointestinal tract cancer advanced upper gastrointestinal tract malignancies gastrointestinal tract malignancies,digestive
1391,Czechia,Endometrial cancer,"-, PACLITAXEL, DOXORUBICIN, PARACETAMOL, COMBINATIONS EXCL. PSYCHOLEPTICS, MK-2870, -, -",12,Pharmaceutical company,Merck Sharp & Dohme LLC,"['other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': '-'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'doxorubicin'}, {'type': 'other', 'subtype': None, 'raw': 'paracetamol'}, {'type': 'other', 'subtype': None, 'raw': 'combinations excl. psycholeptics'}, {'type': 'other', 'subtype': None, 'raw': 'mk-2870'}, {'type': 'other', 'subtype': None, 'raw': '-'}, {'type': 'other', 'subtype': None, 'raw': '-'}]",True,endometrial cancer,gynecologic
1392,France,Adjuvant therapy after salvage surgery of high risk recurrent head and neck squamous cell carcinoma (HNSCC),"Ipilimumab, OPDIVO 10 mg/mL concentrate for solution for infusion., Ipilimumab",12,Hospital/Clinic/Other health care facility,Institut Gustave Roussy,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'opdivo 10'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1 (title)', 'raw': 'nivolumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}]",False,adjuvant therapy after salvage surgery of high risk recurrent head and neck squamous cell carcinoma,head/neck
1393,Italy,"Adult patients affected by recurrent/metastatic, platinum resistant nasopharyngeal cancer","KEYTRUDA 25 mg/mL concentrate for solution for infusion, Olaparib, Olaparib",12,Patient organisation/association,Gruppo Oncologico Del Nord Ovest,"['checkpoint inhibitor', 'targeted therapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'keytruda 25'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1 (title)', 'raw': 'pembrolizumab'}, {'type': 'targeted therapy', 'subtype': 'PARP inhibitor', 'raw': 'olaparib'}, {'type': 'targeted therapy', 'subtype': 'PARP inhibitor', 'raw': 'olaparib'}]",True,adult patients affected by recurrent metastatic platinum resistant nasopharyngeal cancer,head/neck
1394,Norway,KRAS G12C-mutated non-small cell lung cancer,SOTORASIB,12,Hospital/Clinic/Other health care facility,Vestre Viken HF,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'sotorasib'}]",False,kras g12c mutated non small cell lung cancer,lung/thoracic
1395,France,Metastatic or unresectable advanced rare sarcomas,"IPILIMUMAB, NIVOLUMAB, PAZOPANIB",12,Hospital/Clinic/Other health care facility,Centre Leon Berard,"['checkpoint inhibitor', 'kinase inhibitor']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'pazopanib'}]",True,metastatic or unresectable advanced rare sarcomas,sarcoma
1396,Netherlands,Cervical Cancer,,1,Hospital/Clinic/Other health care facility,Amsterdam UMC,[],[],False,cervical cancer,gynecologic
1398,Italy,Stage IIB-IIIB (N2) resectable non small cell lung cancer,"IMFINZI 50 mg/mL concentrate for solution for infusion., GEMCITABINE, CARBOPLATIN, CISPLATIN, PACLITAXEL, PEMETREXED",12,Laboratory/Research/Testing facility,ETOP IBCSG Partners Foundation,"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-L1', 'raw': 'imfinzi 50'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1 (title)', 'raw': 'durvalumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'gemcitabine'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}, {'type': 'chemotherapy', 'subtype': 'antifolate', 'raw': 'pemetrexed'}]",True,stage iib iiib resectable non small cell lung cancer,lung/thoracic
1399,Norway,Non-small cell lung cancer (Stage IV),"Tecentriq 1 200 mg concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, OPDIVO 10 mg/mL concentrate for solution for infusion., LIBTAYO 350 mg concentrate for solution for infusion.",12,Hospital/Clinic/Other health care facility,Oslo University Hospital HF,"['checkpoint inhibitor', 'radiotherapy', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'tecentriq 1 200 concentrate for solution for'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'keytruda 25'}, {'type': 'radiotherapy', 'subtype': 'from title', 'raw': 'radiotherapy'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'opdivo 10'}, {'type': 'radiotherapy', 'subtype': 'from title', 'raw': 'radiotherapy'}, {'type': 'other', 'subtype': None, 'raw': 'libtayo 350 concentrate for solution for .'}]",True,non small cell lung cancer,lung/thoracic
1400,Italy,Non Small Cell Lung Cancer,DURVALUMAB,12,Hospital/Clinic/Other health care facility,Fondazione IRCCS Policlinico San Matteo,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}]",False,non small cell lung cancer,lung/thoracic
1401,France,Soft Tissue Sarcoma,Tecentriq 1 200 mg concentrate for solution for infusion,12,Hospital/Clinic/Other health care facility,Centre Antoine Lacassagne,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'tecentriq 1 200 concentrate for solution for'}]",False,soft tissue sarcoma,sarcoma
1402,France,"Poor general status, Non small cell lung cancer",IMFINZI 50 mg/mL concentrate for solution for infusion.,12,Patient organisation/association,Intergroupe Francophone De Cancerologie Thoracique,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-L1', 'raw': 'imfinzi 50'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1 (title)', 'raw': 'durvalumab'}]",False,poor general status non small cell lung cancer,lung/thoracic
1403,Portugal,"Stage III melanoma (AJCC R0) with histologically confirmed cutaneous melanoma metastatic to lymph node, classified as (AJCC, 2010): Stage IIIA with metastasis > 1 mm; any Stage IIIB or IIIC (no in-transit metastases)","KEYTRUDA 25 mg/mL concentrate for solution for infusion, Saline Solution",12,Pharmaceutical company,Merck Sharp & Dohme LLC,"['checkpoint inhibitor', 'other']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'keytruda 25'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1 (title)', 'raw': 'pembrolizumab'}, {'type': 'other', 'subtype': None, 'raw': 'saline solution'}]",True,stage iii melanoma with histologically confirmed cutaneous melanoma metastatic to lymph node classified as stage iiia with metastasis 1 mm any stage iiib or iiic,hematologic
1404,Italy,Locoregional Hepatocellular Carcinoma (HCC),"INFLIXIMAB, IMFINZI 50 mg/mL concentrate for solution for infusion., BEVACIZUMAB, BEVACIZUMAB, MYCOPHENOLATE MOFETIL, Placebo",12,Pharmaceutical company,AstraZeneca AB,"['checkpoint inhibitor', 'other', 'antibody']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'infliximab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-L1', 'raw': 'imfinzi 50'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1 (title)', 'raw': 'durvalumab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'bevacizumab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'bevacizumab'}, {'type': 'other', 'subtype': None, 'raw': 'mycophenolate mofetil'}]",True,locoregional hepatocellular carcinoma,digestive
1405,Netherlands,"Resectable intermediate to high-risk clear cell RCC (according to RECIST 1.1) that can be biopsied, no history of distant metastases, naïve for CTLA-4/PD-1/PD-L1/LAG-3 directed immunotherapy, and more than 18 years old","RELATLIMAB, YERVOY 5 mg/ml concentrate for solution for infusion, OPDIVO 10 mg/mL concentrate for solution for infusion.",12,Hospital/Clinic/Other health care facility,Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting,"['checkpoint inhibitor', 'other', 'antibody']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'relatlimab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'yervoy 5'}, {'type': 'other', 'subtype': None, 'raw': 'concentrate for solution for'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'opdivo 10'}, {'type': 'other', 'subtype': None, 'raw': 'concentrate for solution for .'}]",True,resectable intermediate to high risk clear cell rcc that can be biopsied no history of distant metastases na ve for ctla 4 pd 1 pd l1 lag 3 directed immunotherapy and more than 18 years old,hematologic
1408,France,"Non-small cell lung cancer (NSCLC):
- Locally advanced NSCLC where participants are not candidates for surgical resection and/or definitive chemoradiation, or
- Metastatic NSCLC","S095024/Sym024, S095018/Sym023, S095029/Sym025, LIBTAYO 350 mg concentrate for solution for infusion.",12,Pharmaceutical company,Institut De Recherches Internationales Servier IRIS,['other'],"[{'type': 'other', 'subtype': None, 'raw': 's095024'}, {'type': 'other', 'subtype': None, 'raw': 'sym024'}, {'type': 'other', 'subtype': None, 'raw': 's095018'}, {'type': 'other', 'subtype': None, 'raw': 'sym023'}, {'type': 'other', 'subtype': None, 'raw': 's095029'}, {'type': 'other', 'subtype': None, 'raw': 'sym025'}, {'type': 'other', 'subtype': None, 'raw': 'libtayo 350 concentrate for solution for .'}]",False,non small cell lung cancer locally advanced nsclc where participants are not candidates for surgical resection and or definitive chemoradiation or metastatic nsclc,lung/thoracic
1409,Italy,Endometrial cancer,"IMFINZI 50 mg/mL concentrate for solution for infusion., Ogivri 150 mg powder for concentrate for solution for infusion, IMFINZI 50 mg/mL concentrate for solution for infusion., Akynzeo 300 mg/0.5 mg hard capsules, Ogivri 420 mg powder for concentrate for solution for infusion, CARBOPLATINO Pfizer 10 mg/ml soluzione per infusione, Paclitaxel Kabi 6 mg/ml concentrato per soluzione per infusione, Akynzeo 300 mg/0.5 mg hard capsules, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Tecentriq 1 200 mg concentrate for solution for infusion, Akynzeo 300 mg/0.5 mg hard capsules, JEMPERLI 500 mg concentrate for solution for infusion, Decadron “4 mg/1 ml Soluzione iniettabile”, Akynzeo 300 mg/0.5 mg hard capsules",1,Hospital/Clinic/Other health care facility,Fondazione IRCCS Istituto Nazionale Dei Tumori,"['checkpoint inhibitor', 'other', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-L1', 'raw': 'imfinzi 50'}, {'type': 'other', 'subtype': None, 'raw': 'concentrate for solution for .'}, {'type': 'other', 'subtype': None, 'raw': 'ogivri 150 powder for concentrate for solution for'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-L1', 'raw': 'imfinzi 50'}, {'type': 'other', 'subtype': None, 'raw': 'concentrate for solution for .'}, {'type': 'other', 'subtype': None, 'raw': 'akynzeo 300'}, {'type': 'other', 'subtype': None, 'raw': '0.5 hard capsules'}, {'type': 'other', 'subtype': None, 'raw': 'ogivri 420 powder for concentrate for solution for'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatino pfizer 10'}, {'type': 'other', 'subtype': None, 'raw': 'soluzione per infusione'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel kabi 6'}, {'type': 'other', 'subtype': None, 'raw': 'concentrato per soluzione per infusione'}, {'type': 'other', 'subtype': None, 'raw': 'akynzeo 300'}, {'type': 'other', 'subtype': None, 'raw': '0.5 hard capsules'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'keytruda 25'}, {'type': 'other', 'subtype': None, 'raw': 'concentrate for solution for'}, {'type': 'other', 'subtype': None, 'raw': 'tecentriq 1 200 concentrate for solution for'}, {'type': 'other', 'subtype': None, 'raw': 'akynzeo 300'}, {'type': 'other', 'subtype': None, 'raw': '0.5 hard capsules'}, {'type': 'other', 'subtype': None, 'raw': 'jemperli 500 concentrate for solution for'}, {'type': 'other', 'subtype': None, 'raw': 'decadron “4'}, {'type': 'other', 'subtype': None, 'raw': '1 soluzione iniettabile”'}, {'type': 'other', 'subtype': None, 'raw': 'akynzeo 300'}, {'type': 'other', 'subtype': None, 'raw': '0.5 hard capsules'}]",True,endometrial cancer,gynecologic
1410,France,Patients with locally advanced or metastasic Non-Small Cell Lung Carcinoma.,"CISPLATINE VIATRIS 25 mg/25 ml, solution à diluer pour perfusion, Tecentriq 1 200 mg concentrate for solution for infusion, CARBOPLATINE ACCORD 10 mg/ml, solution pour perfusion, Paclitaxel Accord Healthcare 6 mg/ml solution à diluer pour perfusion, OPDIVO 10 mg/mL concentrate for solution for infusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion, ALIMTA 500 mg powder for concentrate for solution for infusion",12,Hospital/Clinic/Other health care facility,Institut Bergonie,"['checkpoint inhibitor', 'other', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatine viatris 25'}, {'type': 'other', 'subtype': None, 'raw': '25'}, {'type': 'other', 'subtype': None, 'raw': 'solution à diluer pour perfusion'}, {'type': 'other', 'subtype': None, 'raw': 'tecentriq 1 200 concentrate for solution for'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatine accord 10'}, {'type': 'other', 'subtype': None, 'raw': 'solution pour perfusion'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel accord healthcare 6'}, {'type': 'other', 'subtype': None, 'raw': 'solution à diluer pour perfusion'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'opdivo 10'}, {'type': 'other', 'subtype': None, 'raw': 'concentrate for solution for .'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'keytruda 25'}, {'type': 'other', 'subtype': None, 'raw': 'concentrate for solution for'}, {'type': 'other', 'subtype': None, 'raw': 'alimta 500 powder for concentrate for solution for'}]",True,patients with locally advanced or metastasic non small cell lung carcinoma,lung/thoracic
1411,Spain,Extensive-disease small cell lung cancer and high SLFN11-expression,"IMFINZI 50 mg/mL concentrate for solution for infusion., Tecentriq 1 200 mg concentrate for solution for infusion, Tecentriq 840 mg concentrate for solution for infusion, IMFINZI 50 mg/mL concentrate for solution for infusion.",12,"Laboratory/Research/Testing facility, Laboratory/Research/Testing facility","ETOP IBCSG Partners Foundation, ETOP IBCSG Partners Foundation","['checkpoint inhibitor', 'other']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-L1', 'raw': 'imfinzi 50'}, {'type': 'other', 'subtype': None, 'raw': 'concentrate for solution for .'}, {'type': 'other', 'subtype': None, 'raw': 'tecentriq 1 200 concentrate for solution for'}, {'type': 'other', 'subtype': None, 'raw': 'tecentriq 840 concentrate for solution for'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-L1', 'raw': 'imfinzi 50'}, {'type': 'other', 'subtype': None, 'raw': 'concentrate for solution for .'}]",True,extensive disease small cell lung cancer and high slfn11 expression,lung/thoracic
1412,Netherlands,locally advanced urothelial cancer.,Bavencio 20 mg/mL concentrate for solution for infusion,12,Hospital/Clinic/Other health care facility,Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC),['other'],"[{'type': 'other', 'subtype': None, 'raw': 'bavencio 20'}, {'type': 'other', 'subtype': None, 'raw': 'concentrate for solution for'}]",False,locally advanced urothelial cancer,genitourinary
1413,Germany,"non-small cell lung cancer stages IIIA (N2) and selected resectable
stages IIIB",IMFINZI 50 mg/mL concentrate for solution for infusion.,12,Hospital/Clinic/Other health care facility,Universitaetsklinikum Essen AöR,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-L1', 'raw': 'imfinzi 50'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1 (title)', 'raw': 'durvalumab'}]",False,non small cell lung cancer stages iiia and selected resectable stages iiib,lung/thoracic
1414,France,KRAS G12D/G12V Mutated Pancreatic Ductal Adenocarcinoma,,1,Pharmaceutical company,Amal Therapeutics S.A.,[],[],False,kras g12d g12v mutated pancreatic ductal adenocarcinoma,digestive
1415,France,Non small cell lung cancer,"OPDIVO 10 mg/mL concentrate for solution for infusion., YERVOY 5 mg/ml concentrate for solution for infusion",12,Patient organisation/association,Intergroupe Francophone De Cancerologie Thoracique,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'opdivo 10'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1 (title)', 'raw': 'nivolumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'yervoy 5'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1 (title)', 'raw': 'nivolumab'}]",False,non small cell lung cancer,lung/thoracic
1416,Austria,Advanced non small lung cancer,Allegra 120 mg Filmtabletten,12,Educational Institution,Medical University Of Vienna,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'allegra 120 filmtabletten'}]",False,advanced non small lung cancer,lung/thoracic
1417,France,"Only patients with oncologic locally advanced or metastatic tumour (lung cancer, renal cell cancer
(except IMDC favorable-risk treated Tyrosine Kinase Inhibitor [TKI] / immunotherapy [IO]
combination), head and neck cancer, urothelial carcinoma, triple negative breast cancer, Merkel
cancer, melanoma, hepatocellular carcinoma, colorectal carcinoma with microsatellite instability
[MSI], esophageal squamous cell carcinoma, endometrial carcinoma, or cervical cancer,
gastric/gastro-esophageal junction/esophageal adenocarcinoma, basal cell carcinoma or
squamous skin carcinoma) in partial or complete response (except for melanoma, only patients in
partial response) after 6 months of standard IO treatment (monotherapy or previously in
combination with other immunotherapy (ipilimumab) or chemotherapy or continuous combination
with pemetrexed or bevacizumab or TKI).","AVELUMAB, DURVALUMAB, NIVOLUMAB, NIVOLUMAB, ATEZOLIZUMAB, DOSTARLIMAB, ATEZOLIZUMAB, AVELUMAB, DOSTARLIMAB, PEMBROLIZUMAB, CEMIPLIMAB, CEMIPLIMAB, PEMBROLIZUMAB, DURVALUMAB",12,Hospital/Clinic/Other health care facility,Unicancer,"['checkpoint inhibitor', 'antibody']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'avelumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'atezolizumab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'dostarlimab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'atezolizumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'avelumab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'dostarlimab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'cemiplimab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'cemiplimab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}]",True,only patients with oncologic locally advanced or metastatic tumour head and neck cancer urothelial carcinoma triple negative breast cancer merkel cancer melanoma hepatocellular carcinoma colorectal carcinoma with microsatellite instability msi esophageal squamous cell carcinoma endometrial carcinoma or cervical cancer gastric gastro esophageal junction esophageal adenocarcinoma basal cell carcinoma or squamous skin carcinoma in partial or complete response after 6 months of standard io treatment or chemotherapy or continuous combination with pemetrexed or bevacizumab or tki,gynecologic
1418,Norway,Non-small cell lung cancer (NSCLC),IMFINZI 50 mg/mL concentrate for solution for infusion.,12,Hospital/Clinic/Other health care facility,Vaestra Goetalandsregionen,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-L1', 'raw': 'imfinzi 50'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1 (title)', 'raw': 'durvalumab'}]",False,non small cell lung cancer,lung/thoracic
1419,Belgium,Resectable peritoneal metastases of a colorectal origin,"Avastin 25 mg/ml concentrate for solution for infusion., Leucovorin-Teva 10 mg/ml Concentrate for Solution for Infusion, Oxaliplatin Eugia 5 mg/ml concentraat voor oplossing voor infusie, Xeloda 150 mg film-coated tablets, 5-Fluorouracil Sandoz 50 mg/ml koncentrátum oldatos infúzióhoz, IRINOTECAN MYLAN GENERICS 20 mg/ml concentrato per soluzione per infusione",12,Hospital/Clinic/Other health care facility,Catharina Ziekenhuis Stichting,"['other', 'antibody', 'chemotherapy']","[{'type': 'antibody', 'subtype': 'anti-VEGF', 'raw': 'avastin 25'}, {'type': 'other', 'subtype': None, 'raw': 'concentrate for solution for .'}, {'type': 'other', 'subtype': None, 'raw': 'leucovorin-teva 10'}, {'type': 'other', 'subtype': None, 'raw': 'concentrate for solution for'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'oxaliplatin eugia 5'}, {'type': 'other', 'subtype': None, 'raw': 'concentraat voor oplossing voor infusie'}, {'type': 'other', 'subtype': None, 'raw': 'xeloda 150 film-coated tablets'}, {'type': 'other', 'subtype': None, 'raw': '5-fluorouracil sandoz 50'}, {'type': 'other', 'subtype': None, 'raw': 'koncentrátum oldatos infúzióhoz'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'irinotecan mylan generics 20'}, {'type': 'other', 'subtype': None, 'raw': 'concentrato per soluzione per infusione'}]",True,resectable peritoneal metastases of a colorectal origin,digestive
1420,France,advanced non-squamous non-small cell lung cancer,"BEVACIZUMAB, PACLITAXEL, Tecentriq 1,200 mg concentrate for solution for infusion",12,Pharmaceutical company,Intergroupe Francophone de Cancerologie Thoracique,"['other', 'antibody', 'chemotherapy']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'bevacizumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}, {'type': 'other', 'subtype': None, 'raw': 'tecentriq 1'}, {'type': 'other', 'subtype': None, 'raw': '200 concentrate for solution for'}]",True,advanced non squamous non small cell lung cancer,lung/thoracic
1421,Denmark,Esophageal Cancer,"Trazimera 150 mg powder for concentrate for solution for infusion, FLUOROURACIL, CAPECITABINE, PEMBROLIZUMAB, CAPECITABINE, OXALIPLATIN",12,"Hospital/Clinic/Other health care facility, Hospital/Clinic/Other health care facility","Rigshospitalet, Frederiksberg Hospital","['checkpoint inhibitor', 'other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'trazimera 150 powder for concentrate for solution for'}, {'type': 'chemotherapy', 'subtype': 'antimetabolite', 'raw': 'fluorouracil'}, {'type': 'chemotherapy', 'subtype': 'fluoropyrimidine', 'raw': 'capecitabine'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'chemotherapy', 'subtype': 'fluoropyrimidine', 'raw': 'capecitabine'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'oxaliplatin'}]",True,esophageal cancer,digestive
1423,Italy,Squamous cell carcinoma of head and neck,PEMBROLIZUMAB,12,Patient organisation/association,European Organisation For Research And Treatment Of Cancer,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}]",False,squamous cell carcinoma of head and neck,head/neck
1424,Netherlands,"HNSCC, metastatic deficient mismatch repair (dMMR)/MSI-high (MSI-H) tumors, irresectable or metastatic melanoma, locally advanced or metastatic solid tumor","Tiragolumab, Tecentriq 1 200 mg concentrate for solution for infusion",12,Hospital/Clinic/Other health care facility,Universitair Medisch Centrum Groningen,"['other', 'antibody']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'tiragolumab'}, {'type': 'other', 'subtype': None, 'raw': 'tecentriq 1 200 concentrate for solution for'}]",True,hnscc metastatic deficient mismatch repair msi high tumors irresectable or metastatic melanoma locally advanced or metastatic solid tumor,hematologic
1425,Italy,stage III PD-L1 positive Non-Small Cell Lung Cancer (NSCLC),"Pemetrexed Ever Pharma 25 mg/ml concentrato per soluzione per infusione, Cisplatino Hikma 1mg/ml concentrato per soluzione per infusione, Carboplatino Hikma 10 mg/ml soluzione per infusione, Paclitaxel Accord Healthcare Italia 6 mg/ml, concentrato per soluzione per infusione, Tevimbra 100 mg concentrate for solution for infusion",12,Laboratory/Research/Testing facility,Fondazione Ricerca Traslazionale,"['other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'pemetrexed ever pharma 25'}, {'type': 'other', 'subtype': None, 'raw': 'concentrato per soluzione per infusione'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatino hikma 1mg'}, {'type': 'other', 'subtype': None, 'raw': 'concentrato per soluzione per infusione'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatino hikma 10'}, {'type': 'other', 'subtype': None, 'raw': 'soluzione per infusione'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel accord healthcare italia 6'}, {'type': 'other', 'subtype': None, 'raw': 'concentrato per soluzione per infusione'}, {'type': 'other', 'subtype': None, 'raw': 'tevimbra 100 concentrate for solution for'}]",True,stage iii pd l1 positive non small cell lung cancer,lung/thoracic
1426,Germany,Intermediate stage hepatocellular carcinoma (HCC),"TREMELIMUMAB, IMFINZI 50 mg/mL concentrate for solution for infusion.",12,Pharmaceutical company,Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'tremelimumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-L1', 'raw': 'imfinzi 50'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1 (title)', 'raw': 'durvalumab'}]",False,intermediate stage hepatocellular carcinoma,digestive
1427,Germany,Colorectal liver metastases (CRLM),"Tecentriq 840 mg concentrate for solution for infusion, Tecentriq 840 mg concentrate for solution for infusion, Tecentriq 840 mg concentrate for solution for infusion, Tiragolumab, Tecentriq 840 mg concentrate for solution for infusion",12,Hospital/Clinic/Other health care facility,Universitaetsklinikum Essen AöR,"['other', 'antibody']","[{'type': 'other', 'subtype': None, 'raw': 'tecentriq 840 concentrate for solution for'}, {'type': 'other', 'subtype': None, 'raw': 'tecentriq 840 concentrate for solution for'}, {'type': 'other', 'subtype': None, 'raw': 'tecentriq 840 concentrate for solution for'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'tiragolumab'}, {'type': 'other', 'subtype': None, 'raw': 'tecentriq 840 concentrate for solution for'}]",True,colorectal liver metastases,digestive
1429,Belgium,Glioblastoma grade IV,WT1 LAMP mRNA DC,12,Hospital/Clinic/Other health care facility,Antwerp University Hospital,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'wt1 lamp mrna dc'}]",False,glioblastoma grade iv,brain/CNS
1430,France,The patient has a histologically-confirmed (ureteroscopic biopsy) or cytologically(urine cytology)-confirmed diagnosis of high-grade urothelial carcinoma of the renal pelvis or ureter.,"IMFINZI 50 mg/mL concentrate for solution for infusion., CARBOPLATINE MEDAC 10 mg/mL, solution à diluer pour perfusion, CISPLATINE VIATRIS 1 mg/1 ml, solution à diluer pour perfusion, Gemcitabine Accord 100 mg/ml koncentrátum oldatos infúzióhoz",12,Hospital/Clinic/Other health care facility,Centre Hospitalier Universitaire De Nimes,"['checkpoint inhibitor', 'other', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-L1', 'raw': 'imfinzi 50'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1 (title)', 'raw': 'durvalumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatine medac 10'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1 (title)', 'raw': 'durvalumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatine viatris 1'}, {'type': 'other', 'subtype': None, 'raw': '1'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1 (title)', 'raw': 'durvalumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'gemcitabine accord 100'}, {'type': 'other', 'subtype': None, 'raw': 'koncentrátum oldatos infúzióhoz'}]",True,the patient has a histologically confirmed or cytologically confirmed diagnosis of high grade urothelial carcinoma of the renal pelvis or ureter,genitourinary
1431,Finland,cutaneous malignant melanoma,"KEYTRUDA 25 mg/mL concentrate for solution for infusion, OPDIVO 10 mg/mL concentrate for solution for infusion.",12,Hospital/Clinic/Other health care facility,Uppsala University Hospital,"['checkpoint inhibitor', 'other']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'keytruda 25'}, {'type': 'other', 'subtype': None, 'raw': 'concentrate for solution for'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'opdivo 10'}, {'type': 'other', 'subtype': None, 'raw': 'concentrate for solution for .'}]",True,cutaneous malignant melanoma,skin
1432,Italy,Extensive-Stage Small-Cell Lung Cancer (ES SCLC),"Cisplatino Sandoz 1 mg/ml – Concentrato per soluzione per infusione, KEYTRUDA 25 mg/mL concentrate for solution for infusion, ETOPOSIDE TEVA 20 mg/ml, concentrato per soluzione per infusione, Olaparib, CARBOPLATINO TEVA 10 mg/ml, Olaparib",12,Hospital/Clinic/Other health care facility,Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.,"['checkpoint inhibitor', 'targeted therapy', 'other', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatino sandoz 1'}, {'type': 'other', 'subtype': None, 'raw': '– concentrato per soluzione per infusione'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'keytruda 25'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1 (title)', 'raw': 'pembrolizumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'etoposide teva 20'}, {'type': 'other', 'subtype': None, 'raw': 'concentrato per soluzione per infusione'}, {'type': 'targeted therapy', 'subtype': 'PARP inhibitor', 'raw': 'olaparib'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatino teva 10'}, {'type': 'targeted therapy', 'subtype': 'PARP inhibitor', 'raw': 'olaparib'}]",True,extensive stage small cell lung cancer,lung/thoracic
1433,Italy,locally advanced cholangiocarcinoma,"DURVALUMAB, CISPLATINO Pfizer 50 mg/50 ml soluzione per infusione, Gemcitabina Accord 100 mg/ml concentrato per soluzione per infusione., TREMELIMUMAB",12,Hospital/Clinic/Other health care facility,IRCCS Istituto Nazionale Tumori Fondazione Pascale,"['checkpoint inhibitor', 'other', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatino pfizer 50'}, {'type': 'other', 'subtype': None, 'raw': '50 soluzione per infusione'}, {'type': 'other', 'subtype': None, 'raw': 'gemcitabina accord 100'}, {'type': 'other', 'subtype': None, 'raw': 'concentrato per soluzione per infusione.'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'tremelimumab'}]",True,locally advanced cholangiocarcinoma,multiple
1434,Germany,"T1-T2N0 esophageal adenocarcinoma including gastroesophageal
junction (GEJ) with indication for radical surgery","5-FU medac 50 mg/ml, Injektionslösung, Leucovorin 10 mg/ml Lösung zur Injektion/ Infusion, TAXOTERE 20 mg/1 ml concentrate for solution for infusion, medoxa 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, IMFINZI 50 mg/mL concentrate for solution for infusion.",12,Pharmaceutical company,Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH,"['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': '5-fu medac 50'}, {'type': 'other', 'subtype': None, 'raw': 'injektionslösung'}, {'type': 'other', 'subtype': None, 'raw': 'leucovorin 10'}, {'type': 'other', 'subtype': None, 'raw': 'lösung zur injektion'}, {'type': 'other', 'subtype': None, 'raw': 'taxotere 20'}, {'type': 'other', 'subtype': None, 'raw': '1 concentrate for solution for'}, {'type': 'other', 'subtype': None, 'raw': 'medoxa 5'}, {'type': 'other', 'subtype': None, 'raw': 'konzentrat zur herstellung einer infusionslösung'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-L1', 'raw': 'imfinzi 50'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1 (title)', 'raw': 'durvalumab'}]",True,t1 t2n0 esophageal adenocarcinoma including gastroesophageal junction with indication for radical surgery,digestive
1435,Belgium,Non-small cell lung cancer,"Docetaxel Accord 20 mg/1 ml concentrate for solution for infusion, Trodelvy 200 mg powder for concentrate for solution for infusion",12,Pharmaceutical company,Gilead Sciences Inc.,"['other', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'docetaxel accord 20'}, {'type': 'other', 'subtype': None, 'raw': '1 concentrate for solution for'}, {'type': 'other', 'subtype': None, 'raw': 'trodelvy 200 powder for concentrate for solution for'}]",True,non small cell lung cancer,lung/thoracic
1436,France,Resectable mucosal melanomas,"LENVIMA 10 mg hard capsules, KEYTRUDA 25 mg/mL concentrate for solution for infusion",12,Hospital/Clinic/Other health care facility,Institut Gustave Roussy,"['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'lenvima 10 hard capsules'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'keytruda 25'}, {'type': 'other', 'subtype': None, 'raw': 'concentrate for solution for'}]",True,resectable mucosal melanomas,skin
1437,Norway,Colorectal cancer,"Adrenalin Aguettant 1 mg/ml injeksjonsvæske, oppløsning i ferdigfylt sprøyte, Kalsiumfolinat Pfizer 10 mg/ml injeksjonsvæske, oppløsning, OPDIVO 10 mg/mL concentrate for solution for infusion., Dexamethasone Krka 4 mg tabletter, Solu-Cortef 250 mg pulver og væske til injeksjonsvæske, oppløsning i tokammerhetteglass, Fluorouracil Accord 50 mg/ml injeksjons-/infusjonsvæske, oppløsning, Ondansetron Bluefish 8 mg tabletter, filmdrasjerte, Paracet 1 g tabletter, Metoclopramide Accord 10 mg tabletter, Oxaliplatin Fresenius Kabi 5 mg/ml konsentrat til infusjonsvæske, oppløsning",12,Hospital/Clinic/Other health care facility,Akershus University Hospital,"['checkpoint inhibitor', 'other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'adrenalin aguettant 1'}, {'type': 'other', 'subtype': None, 'raw': 'injeksjonsvæske'}, {'type': 'other', 'subtype': None, 'raw': 'oppløsning i ferdigfylt sprøyte'}, {'type': 'other', 'subtype': None, 'raw': 'kalsiumfolinat pfizer 10'}, {'type': 'other', 'subtype': None, 'raw': 'injeksjonsvæske'}, {'type': 'other', 'subtype': None, 'raw': 'oppløsning'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'opdivo 10'}, {'type': 'other', 'subtype': None, 'raw': 'concentrate for solution for .'}, {'type': 'other', 'subtype': None, 'raw': 'dexamethasone krka 4 tabletter'}, {'type': 'other', 'subtype': None, 'raw': 'solu-cortef 250 pulver og væske til injeksjonsvæske'}, {'type': 'other', 'subtype': None, 'raw': 'oppløsning i tokammerhetteglass'}, {'type': 'other', 'subtype': None, 'raw': 'fluorouracil accord 50'}, {'type': 'other', 'subtype': None, 'raw': 'injeksjons-'}, {'type': 'other', 'subtype': None, 'raw': 'infusjonsvæske'}, {'type': 'other', 'subtype': None, 'raw': 'oppløsning'}, {'type': 'other', 'subtype': None, 'raw': 'ondansetron bluefish 8 tabletter'}, {'type': 'other', 'subtype': None, 'raw': 'filmdrasjerte'}, {'type': 'other', 'subtype': None, 'raw': 'paracet 1 tabletter'}, {'type': 'other', 'subtype': None, 'raw': 'metoclopramide accord 10 tabletter'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'oxaliplatin fresenius kabi 5'}, {'type': 'other', 'subtype': None, 'raw': 'konsentrat til infusjonsvæske'}, {'type': 'other', 'subtype': None, 'raw': 'oppløsning'}]",True,colorectal cancer,digestive
1438,Belgium,Oropharyngeal Squamous Cell Carcinoma,"IMFINZI 50 mg/mL concentrate for solution for infusion., CISPLATIN",12,Patient organisation/association,European Organisation For Research And Treatment Of Cancer,"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-L1', 'raw': 'imfinzi 50'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1 (title)', 'raw': 'durvalumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}]",True,oropharyngeal squamous cell carcinoma,head/neck
1439,Spain,Non-small cell lung cancer (NSCLC),OPDIVO 10 mg/mL concentrate for solution for infusion.,12,Patient organisation/association,Fundacion GECP,"['checkpoint inhibitor', 'other']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'opdivo 10'}, {'type': 'other', 'subtype': None, 'raw': 'concentrate for solution for .'}]",True,non small cell lung cancer,lung/thoracic
1440,Spain,"Nonsquamous non-small cell lung cancer, Nonsquamous non-small cell lung cancer","Inupadenant HCl, Placebo to Inupadenant, Inupadenant HCl",12,Pharmaceutical company,iTeos Belgium,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'inupadenant hcl'}, {'type': 'other', 'subtype': None, 'raw': 'to inupadenant'}, {'type': 'other', 'subtype': None, 'raw': 'inupadenant hcl'}]",False,nonsquamous non small cell lung cancer nonsquamous non small cell lung cancer,lung/thoracic
1441,Sweden,Oral squamous cell carcinoma (OSCC),OPDIVO 10 mg/mL concentrate for solution for infusion.,12,Hospital/Clinic/Other health care facility,Karolinska University Hospital,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'opdivo 10'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1 (title)', 'raw': 'nivolumab'}]",False,oral squamous cell carcinoma,head/neck
1442,Italy,HPV-negative Head and Neck Squamous Cell Carcinoma (HNSCC),"Zejula 100 mg film-coated tablets, JEMPERLI 500 mg concentrate for solution for infusion, Zejula 100 mg film-coated tablets",12,Patient organisation/association,Gruppo Oncologico Del Nord Ovest,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'zejula 100 film-coated tablets'}, {'type': 'other', 'subtype': None, 'raw': 'jemperli 500 concentrate for solution for'}, {'type': 'other', 'subtype': None, 'raw': 'zejula 100 film-coated tablets'}]",False,hpv negative head and neck squamous cell carcinoma,head/neck
1443,Italy,"Muscle invasive bladder cancer set to undergo radical cystectomy who cannot receive or
refuse to receive cisplatin-based chemotherapy","OPDIVO 10 mg/mL concentrate for solution for infusion., OPDIVO 10 mg/mL concentrate for solution for infusion., SODIO CLORURO BAXTER S.P.A. 0,9% Soluzione per infusione, Visugromab (CTL-002), OPDIVO 10 mg/mL concentrate for solution for infusion., OPDIVO 10 mg/mL concentrate for solution for infusion.",12,Pharmaceutical company,CatalYm GmbH,"['checkpoint inhibitor', 'other', 'antibody']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'opdivo 10'}, {'type': 'other', 'subtype': None, 'raw': 'concentrate for solution for .'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'opdivo 10'}, {'type': 'other', 'subtype': None, 'raw': 'concentrate for solution for .'}, {'type': 'other', 'subtype': None, 'raw': 'sodio cloruro baxter s.p.a. 0'}, {'type': 'other', 'subtype': None, 'raw': '9% soluzione per infusione'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'visugromab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'opdivo 10'}, {'type': 'other', 'subtype': None, 'raw': 'concentrate for solution for .'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'opdivo 10'}, {'type': 'other', 'subtype': None, 'raw': 'concentrate for solution for .'}]",True,muscle invasive bladder cancer set to undergo radical cystectomy who cannot receive or refuse to receive cisplatin based chemotherapy,genitourinary
1444,Germany,"Patients (18-75 years) with metastatic and/or refractory soft-tissue
sarcoma after failure of anthracycline-containing 1st line therapy or with
contraindications to anthracyclines (CD13 positivity: grade >/= 1+)","tTF-NGR, TRABECTEDIN",12,"Educational Institution, Educational Institution","Universitaet Muenster, Universitaet Muenster",['other'],"[{'type': 'other', 'subtype': None, 'raw': 'ttf-ngr'}, {'type': 'other', 'subtype': None, 'raw': 'trabectedin'}]",False,patients with metastatic and or refractory soft tissue sarcoma after failure of anthracycline containing 1st line therapy or with contraindications to anthracyclines,sarcoma
1445,Italy,Advanced cancer of the stomach or the gastroesophageal junction,"OPDIVO 10 mg/mL concentrate for solution for infusion., Fluorouracil 50mg/ml Injection., OPDIVO 10 mg/mL concentrate for solution for infusion., Calcium Folinate 10 mg/ml Injection, Oxaliplatin Hospira 5 mg/ml concentrate for solution for infusion, OPDIVO 10 mg/mL concentrate for solution for infusion., ASP8951",12,Pharmaceutical company,Astellas Pharma Global Development Inc.,"['checkpoint inhibitor', 'other', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'opdivo 10'}, {'type': 'other', 'subtype': None, 'raw': 'concentrate for solution for .'}, {'type': 'other', 'subtype': None, 'raw': 'fluorouracil 50mg'}, {'type': 'other', 'subtype': None, 'raw': 'injection.'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'opdivo 10'}, {'type': 'other', 'subtype': None, 'raw': 'concentrate for solution for .'}, {'type': 'other', 'subtype': None, 'raw': 'calcium folinate 10'}, {'type': 'other', 'subtype': None, 'raw': 'injection'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'oxaliplatin hospira 5'}, {'type': 'other', 'subtype': None, 'raw': 'concentrate for solution for'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'opdivo 10'}, {'type': 'other', 'subtype': None, 'raw': 'concentrate for solution for .'}, {'type': 'other', 'subtype': None, 'raw': 'asp8951'}]",True,advanced cancer of the stomach or the gastroesophageal junction,digestive
1446,Germany,hepatocellular carcinoma,"DURVALUMAB, TREMELIMUMAB",12,Hospital/Clinic/Other health care facility,Klinikum der Universitaet Muenchen AöR,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'tremelimumab'}]",False,hepatocellular carcinoma,digestive
1447,Belgium,Completely resected Stage IIb/c melanoma,"5% Dextrose for Injection; Solution for injection, 0.9% sodium chloride injection. Solution for injection., OPDIVO 10 mg/mL concentrate for solution for infusion., OPDIVO 10 mg/mL concentrate for solution for infusion.",12,Pharmaceutical company,Bristol Myers Squibb International Corporation,"['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': '5% dextrose for injection; solution for injection'}, {'type': 'other', 'subtype': None, 'raw': '0.9% sodium chloride injection. solution for injection.'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'opdivo 10'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1 (title)', 'raw': 'nivolumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'opdivo 10'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1 (title)', 'raw': 'nivolumab'}]",True,completely resected stage iib c melanoma,skin
1448,Sweden,colorectal cancer,,1,Pharmaceutical company,NEOGAP Therapeutics AB,[],[],False,colorectal cancer,digestive
1449,France,Kidney cancer,"NIVOLUMAB, IPILIMUMAB",12,Patient organisation/association,ARTIC,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}]",False,kidney cancer,genitourinary
1450,Germany,Advanced stage intrahepatic biliary tract cancer (BTC),"IMFINZI 50 mg/mL concentrate for solution for infusion., IMJUDO 20 mg/ml concentrate for solution for infusion.",12,Pharmaceutical company,Institut fuer Klinische Krebsforschung IKF GmbH,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-L1', 'raw': 'imfinzi 50'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1 (title)', 'raw': 'durvalumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'imjudo 20'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1 (title)', 'raw': 'durvalumab'}]",False,advanced stage intrahepatic biliary tract cancer,digestive
1451,Netherlands,castration-resistant prostate cancer,"YERVOY 5 mg/ml concentrate for solution for infusion, OPDIVO 10 mg/mL concentrate for solution for infusion.",12,Hospital/Clinic/Other health care facility,Stichting Radboud universitair medisch centrum,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'yervoy 5'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1 (title)', 'raw': 'nivolumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'opdivo 10'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1 (title)', 'raw': 'nivolumab'}]",False,castration resistant prostate cancer,genitourinary
1452,Belgium,metastatic clear cell Renal Carcinoma Cell,GOZETOTIDE,12,Hospital/Clinic/Other health care facility,Cliniques Universitaires Saint-Luc,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'gozetotide'}]",False,metastatic clear cell renal carcinoma cell,genitourinary
1453,France,Breast cancer,"Cyclophosphamid beta 500 mg/ml Konzentrat zur Herstellung einer Injektions-/Infusionslösung, Paclitaxel Kabi 6 mg/ml koncentrátum oldatos infúzióhoz, DOXORUBICINE ARROW 2 mg/ml, solution pour perfusion, Epirubicin Eugia 2 mg/ml oplossing voor injectie, KEYTRUDA 25 mg/mL concentrate for solution for infusion, CARBOPLATINE MEDAC 10 mg/mL, solution à diluer pour perfusion, 68Ga-FAPI-46",12,Hospital/Clinic/Other health care facility,Institut Curie,"['checkpoint inhibitor', 'other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'cyclophosphamid beta 500'}, {'type': 'other', 'subtype': None, 'raw': 'konzentrat zur herstellung einer injektions-'}, {'type': 'other', 'subtype': None, 'raw': 'infusionslösung'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel kabi 6'}, {'type': 'other', 'subtype': None, 'raw': 'koncentrátum oldatos infúzióhoz'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'doxorubicine arrow 2'}, {'type': 'other', 'subtype': None, 'raw': 'solution pour perfusion'}, {'type': 'other', 'subtype': None, 'raw': 'epirubicin eugia 2'}, {'type': 'other', 'subtype': None, 'raw': 'oplossing voor injectie'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'keytruda 25'}, {'type': 'other', 'subtype': None, 'raw': 'concentrate for solution for'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatine medac 10'}, {'type': 'other', 'subtype': None, 'raw': 'solution à diluer pour perfusion'}, {'type': 'other', 'subtype': None, 'raw': '68ga-fapi-46'}]",True,breast cancer,breast
1454,Portugal,Non-Small Cell Lung Cancer (NSCLC),IMFINZI 50 mg/mL concentrate for solution for infusion.,12,Hospital/Clinic/Other health care facility,Instituto Portugues De Oncologia Do Porto Francisco Gentil E.P.E.,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-L1', 'raw': 'imfinzi 50'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1 (title)', 'raw': 'durvalumab'}]",False,non small cell lung cancer,lung/thoracic
1456,France,Unresectable locally advanced or metastatic colorectal cancer,"OXALIPLATIN, Leukine, CALCIUM FOLINATE, FLUOROURACIL, ENDOXAN 50 mg, comprimé enrobé, STC-1010",12,Pharmaceutical company,Brenus Pharma,"['other', 'supportive care', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'oxaliplatin'}, {'type': 'other', 'subtype': None, 'raw': 'leukine'}, {'type': 'supportive care', 'subtype': 'rescue agent', 'raw': 'calcium folinate'}, {'type': 'chemotherapy', 'subtype': 'antimetabolite', 'raw': 'fluorouracil'}, {'type': 'other', 'subtype': None, 'raw': 'endoxan 50'}, {'type': 'other', 'subtype': None, 'raw': 'comprimé enrobé'}, {'type': 'other', 'subtype': None, 'raw': 'stc-1010'}]",True,unresectable locally advanced or metastatic colorectal cancer,digestive
1457,France,Advanced liver cancers,"RO7247669, RO7791094, RoActemra 20 mg/mL concentrate for solution for infusion, ADG126, RO7790118, Tecentriq 1 200 mg concentrate for solution for infusion, RO7790118, TPST-1120, Avastin 25 mg/ml concentrate for solution for infusion., Tiragolumab, RO7790118",12,Pharmaceutical company,F. Hoffmann-La Roche AG,"['other', 'antibody']","[{'type': 'other', 'subtype': None, 'raw': 'ro7247669'}, {'type': 'other', 'subtype': None, 'raw': 'ro7791094'}, {'type': 'other', 'subtype': None, 'raw': 'roactemra 20'}, {'type': 'other', 'subtype': None, 'raw': 'concentrate for solution for'}, {'type': 'other', 'subtype': None, 'raw': 'adg126'}, {'type': 'other', 'subtype': None, 'raw': 'ro7790118'}, {'type': 'other', 'subtype': None, 'raw': 'tecentriq 1 200 concentrate for solution for'}, {'type': 'other', 'subtype': None, 'raw': 'ro7790118'}, {'type': 'other', 'subtype': None, 'raw': 'tpst-1120'}, {'type': 'antibody', 'subtype': 'anti-VEGF', 'raw': 'avastin 25'}, {'type': 'other', 'subtype': None, 'raw': 'concentrate for solution for .'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'tiragolumab'}, {'type': 'other', 'subtype': None, 'raw': 'ro7790118'}]",True,advanced liver cancers,digestive
1458,Italy,Hepatocellular carcinoma,"CABOMETYX 60 mg film-coated tablets, CABOMETYX 20 mg film-coated tablets, CABOMETYX 40 mg film-coated tablets",12,Hospital/Clinic/Other health care facility,Humanitas Mirasole S.p.A.,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'cabometyx 60 film-coated tablets'}, {'type': 'other', 'subtype': None, 'raw': 'cabometyx 20 film-coated tablets'}, {'type': 'other', 'subtype': None, 'raw': 'cabometyx 40 film-coated tablets'}]",False,hepatocellular carcinoma,digestive
1459,Italy,ADVANCED TRIPLE NEGATIVE BREAST CANCER,"DURVALUMAB, Ceralasertib, PACLITAXEL ALBUMIN-BOUND",12,Laboratory/Research/Testing facility,IFOM Istituto Fondazione Di Oncologia Molecolare Ets In Breve Ifom Ets,"['checkpoint inhibitor', 'targeted therapy', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}, {'type': 'targeted therapy', 'subtype': 'ATR inhibitor', 'raw': 'ceralasertib'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel albumin-bound'}]",True,advanced triple negative breast cancer,breast
1460,France,Non small cell lung cancer,"PACLITAXEL, CISPLATIN, CARBOPLATIN, CISPLATIN, CARBOPLATIN, PACLITAXEL, PEMBROLIZUMAB, PEMETREXED, KEYTRUDA 25 mg/mL concentrate for solution for infusion, PEMETREXED",12,Patient organisation/association,Intergroupe Francophone De Cancerologie Thoracique,"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'chemotherapy', 'subtype': 'antifolate', 'raw': 'pemetrexed'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'keytruda 25'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1 (title)', 'raw': 'pembrolizumab'}, {'type': 'chemotherapy', 'subtype': 'antifolate', 'raw': 'pemetrexed'}]",True,non small cell lung cancer,lung/thoracic
1461,France,Patients with a confirmed diagnosis of ovarian small cell carcinoma.,"ADRIBLASTINE 10 mg, poudre pour solution injectable en flacon, Etoposide 20 mg/ml  Concentrate for solution for infusion  , Cyclophosphamide Sandoz, 100 mg/mL, koncentrat do sporządzania roztworu do wstrzykiwań / do infuzji, Cisplatine Teva 1 mg/ml solution à diluer pour perfusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion",12,Laboratory/Research/Testing facility,Asso De Recherche Cancers Gynecologiques,"['checkpoint inhibitor', 'other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'adriblastine 10'}, {'type': 'other', 'subtype': None, 'raw': 'poudre pour solution injectable en flacon'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'etoposide 20'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1 (title)', 'raw': 'pembrolizumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide sandoz'}, {'type': 'other', 'subtype': None, 'raw': '100'}, {'type': 'other', 'subtype': None, 'raw': 'koncentrat do sporządzania roztworu do wstrzykiwań'}, {'type': 'other', 'subtype': None, 'raw': 'do infuzji'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatine teva 1'}, {'type': 'other', 'subtype': None, 'raw': 'solution à diluer pour perfusion.'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'keytruda 25'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1 (title)', 'raw': 'pembrolizumab'}]",True,patients with a confirmed diagnosis of ovarian small cell carcinoma,gynecologic
1462,Netherlands,Stage III melanoma,"OPDIVO 10 mg/mL concentrate for solution for infusion., YERVOY 5 mg/ml concentrate for solution for infusion",12,Hospital/Clinic/Other health care facility,Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'opdivo 10'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1 (title)', 'raw': 'nivolumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'yervoy 5'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1 (title)', 'raw': 'nivolumab'}]",False,stage iii melanoma,skin
1463,Portugal,High risk (TILs-positive) HR-/HER2- (triple negative) breast cancer,"CARBOPLATIN, EPIRUBICIN, KEYTRUDA 25 mg/mL concentrate for solution for infusion, PEGFILGRASTIM, PACLITAXEL, DOXORUBICIN, CYCLOPHOSPHAMIDE, FILGRASTIM",12,Hospital/Clinic/Other health care facility,Champalimaud Clinical Centre,"['checkpoint inhibitor', 'other', 'supportive care', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'chemotherapy', 'subtype': 'anthracycline', 'raw': 'epirubicin'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'keytruda 25'}, {'type': 'other', 'subtype': None, 'raw': 'concentrate for solution for'}, {'type': 'other', 'subtype': None, 'raw': 'pegfilgrastim'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'doxorubicin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide'}, {'type': 'supportive care', 'subtype': 'G-CSF', 'raw': 'filgrastim'}]",True,high risk hr her2 breast cancer,breast
1464,Denmark,"Borderline resectable, locally advanced or metastatic pancreatic cancer (BRPC, LAPC or mPC)","OPDIVO 10 mg/mL concentrate for solution for infusion., Abraxane 5 mg/ml powder for dispersion for infusion., Abraxane 5 mg/ml powder for dispersion for infusion., YERVOY 5 mg/ml concentrate for solution for infusion, GEMCITABINE HYDROCHLORIDE",12,Hospital/Clinic/Other health care facility,Region Hovedstaden,"['checkpoint inhibitor', 'radiotherapy', 'other', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'opdivo 10'}, {'type': 'radiotherapy', 'subtype': 'from title', 'raw': 'radiotherapy'}, {'type': 'other', 'subtype': None, 'raw': 'abraxane 5'}, {'type': 'other', 'subtype': None, 'raw': 'powder for dispersion for .'}, {'type': 'other', 'subtype': None, 'raw': 'abraxane 5'}, {'type': 'other', 'subtype': None, 'raw': 'powder for dispersion for .'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'yervoy 5'}, {'type': 'radiotherapy', 'subtype': 'from title', 'raw': 'radiotherapy'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'gemcitabine hydrochloride'}]",True,borderline resectable locally advanced or metastatic pancreatic cancer,digestive
1465,Poland,Resectable soft tissue sarcomas,"IMP321, KEYTRUDA 25 mg/mL concentrate for solution for infusion",12,Hospital/Clinic/Other health care facility,Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy,"['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'imp321'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'keytruda 25'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1 (title)', 'raw': 'pembrolizumab'}]",True,resectable soft tissue sarcomas,sarcoma
1466,Italy,recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC),"AVELUMAB, Erbitux 5 mg/mL solution for infusion",12,Patient organisation/association,Gruppo Oncologico Del Nord Ovest,"['checkpoint inhibitor', 'other']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'avelumab'}, {'type': 'other', 'subtype': None, 'raw': 'erbitux 5'}, {'type': 'other', 'subtype': None, 'raw': 'solution for'}]",True,recurrent metastatic head and neck squamous cell carcinoma,head/neck
1467,Germany,Limited Disease Small Cell Lung Cancer,"IMFINZI 50 mg/mL concentrate for solution for infusion., ETOPOSIDE, CARBOPLATIN, CISPLATIN",12,Hospital/Clinic/Other health care facility,Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR,"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-L1', 'raw': 'imfinzi 50'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1 (title)', 'raw': 'durvalumab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'etoposide'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}]",True,limited disease small cell lung cancer,lung/thoracic
1468,Italy,"Cutaneaous Squamous Cell Carcinoma, surgically resectable, high risk stage III/IV (M0) Cutaneaous Squamous Cell Carcinoma",CEMIPLIMAB,12,"Laboratory/Research/Testing facility, Laboratory/Research/Testing facility","Fondazione Melanoma Onlus, Fondazione Melanoma Onlus",['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'cemiplimab'}]",False,cutaneaous squamous cell carcinoma surgically resectable high risk stage iii iv cutaneaous squamous cell carcinoma,other
1469,Netherlands,"Small-cell lung cancer, extensive stage",IMFINZI 50 mg/mL concentrate for solution for infusion.,12,Educational Institution,Norwegian University Of Science And Technolology,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-L1', 'raw': 'imfinzi 50'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1 (title)', 'raw': 'durvalumab'}]",False,small cell lung cancer extensive stage,lung/thoracic
1470,France,Patients with HLA-A2 positive phenotype and metastatic Non-Small Cell Lung Cancer.,"TEDOPI, DOCETAXEL",12,Pharmaceutical company,OSE Immunotherapeutics,"['other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'tedopi'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'docetaxel'}]",True,patients with hla a2 positive phenotype and metastatic non small cell lung cancer,lung/thoracic
1472,Czechia,Previously untreated Chronic Lymphocytic Leukemia Without del(17p) or TP53 Mutation,"BENDAMUSTINE, VENETOCLAX, OBINUTUZUMAB, VENETOCLAX, CYCLOPHOSPHAMIDE, FLUDARABINE, VENETOCLAX, RITUXIMAB, ACALABRUTINIB",12,Pharmaceutical company,Acerta Pharma B.V.,"['targeted therapy', 'antibody', 'chemotherapy', 'kinase inhibitor']","[{'type': 'chemotherapy', 'subtype': 'alkylating agent', 'raw': 'bendamustine'}, {'type': 'targeted therapy', 'subtype': 'BCL-2 inhibitor', 'raw': 'venetoclax'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'obinutuzumab'}, {'type': 'targeted therapy', 'subtype': 'BCL-2 inhibitor', 'raw': 'venetoclax'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide'}, {'type': 'chemotherapy', 'subtype': 'purine analog', 'raw': 'fludarabine'}, {'type': 'targeted therapy', 'subtype': 'BCL-2 inhibitor', 'raw': 'venetoclax'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'rituximab'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'acalabrutinib'}]",True,previously untreated chronic lymphocytic leukemia without del or tp53 mutation,hematologic
1473,Netherlands,"NSCLC, synchronous oligo-metastatic","IMJUDO 20 mg/ml concentrate for solution for infusion., IMFINZI 50 mg/mL concentrate for solution for infusion.",12,Laboratory/Research/Testing facility,ETOP IBCSG Partners Foundation,"['checkpoint inhibitor', 'radiotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'imjudo 20'}, {'type': 'radiotherapy', 'subtype': 'from title', 'raw': 'radiotherapy'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-L1', 'raw': 'imfinzi 50'}, {'type': 'radiotherapy', 'subtype': 'from title', 'raw': 'radiotherapy'}]",True,nsclc synchronous oligo metastatic,lung/thoracic
1474,Italy,melanoma brain metastases,"YERVOY 5 mg/ml concentrate for solution for infusion, OPDIVO 10 mg/mL concentrate for solution for infusion.",12,Hospital/Clinic/Other health care facility,Melanoma Institute Australia,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'yervoy 5'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1 (title)', 'raw': 'nivolumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'opdivo 10'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1 (title)', 'raw': 'nivolumab'}]",False,melanoma brain metastases,skin
1475,Germany,"Sarcoma, Melanoma, Non-small cell lung cancer, Colorectal cancer, Triple negative breast cancer",,1,Pharmaceutical company,Valo Therapeutics Oy,[],[],False,sarcoma melanoma non small cell lung cancer colorectal cancer triple negative breast cancer,digestive
1476,Germany,"Immune related adverse events induced by treatment with
immunotherapy",UVADEX 20 Mikrogramm/ml Lösung zur Modifikation einer Blutfraktion,12,Hospital/Clinic/Other health care facility,Medical Center - University Of Freiburg,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'uvadex 20 mikrogramm'}, {'type': 'other', 'subtype': None, 'raw': 'lösung zur modifikation einer blutfraktion'}]",False,immune related adverse events induced by treatment with immunotherapy,hematologic
1477,Poland,Advanced or metastatic non-squamous non-small lung cancer (mNSCLC) with human epidermal growth factor receptor 2 (HER2) overexpression (OE),,1,Pharmaceutical company,AstraZeneca AB,[],[],False,advanced or metastatic non squamous non small lung cancer with human epidermal growth factor receptor 2 overexpression,lung/thoracic
1478,Germany,Melanoma,"PEMBROLIZUMAB, NIVOLUMAB, IPILIMUMAB, DACARBAZINE",12,"Hospital/Clinic/Other health care facility, Hospital/Clinic/Other health care facility","Universitaetsklinikum Erlangen AöR, Universitaetsklinikum Erlangen AöR","['checkpoint inhibitor', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'pembrolizumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}, {'type': 'chemotherapy', 'subtype': 'alkylating agent', 'raw': 'dacarbazine'}]",True,melanoma,skin
1479,Italy,Head and neck cancer,"CETUXIMAB, TEPOTINIB",12,"Hospital/Clinic/Other health care facility, Hospital/Clinic/Other health care facility","Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia, Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia","['antibody', 'kinase inhibitor']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'cetuximab'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'tepotinib'}]",True,head and neck cancer,head/neck
1480,Belgium,"Patients with lateralised oropharyngeal, laryngeal and hypopharyngeal squamous cell carcinoma","CETUXIMAB, CISPLATIN, TRETINOIN",12,Hospital/Clinic/Other health care facility,Centre Leon Berard,"['other', 'antibody', 'chemotherapy']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'cetuximab'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}, {'type': 'other', 'subtype': None, 'raw': 'tretinoin'}]",True,patients with lateralised oropharyngeal laryngeal and hypopharyngeal squamous cell carcinoma,head/neck
1482,Italy,advanced or metastatic gastrooesophageal carcinoma HER2 negative and ARID1A mutated,"OPDIVO 10 mg/mL concentrate for solution for infusion., FLUOROURACIL, Oxaliplatino Sandoz, LEDERFOLIN 175 mg polvere per soluzione per infusione, FLUOROURACIL, SIMVASTATIN, CAPECITABINE",12,Hospital/Clinic/Other health care facility,IRCCS Istituto Nazionale Tumori Fondazione Pascale,"['checkpoint inhibitor', 'other', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'opdivo 10'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1 (title)', 'raw': 'nivolumab'}, {'type': 'chemotherapy', 'subtype': 'antimetabolite', 'raw': 'fluorouracil'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'oxaliplatino sandoz'}, {'type': 'other', 'subtype': None, 'raw': 'lederfolin 175 polvere per soluzione per infusione'}, {'type': 'chemotherapy', 'subtype': 'antimetabolite', 'raw': 'fluorouracil'}, {'type': 'other', 'subtype': None, 'raw': 'simvastatin'}, {'type': 'chemotherapy', 'subtype': 'fluoropyrimidine', 'raw': 'capecitabine'}]",True,advanced or metastatic gastrooesophageal carcinoma her2 negative and arid1a mutated,digestive
1483,France,cell penile carcinoma,AVELUMAB,12,Hospital/Clinic/Other health care facility,Centre Hospitalier Regional Universitaire,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'avelumab'}]",False,cell penile carcinoma,genitourinary
1484,Spain,Resectable Non-small cell lung cancer Pancoast tumor,OPDIVO 10 mg/mL concentrate for solution for infusion.,12,Patient organisation/association,Fundacion GECP,"['checkpoint inhibitor', 'other']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'opdivo 10'}, {'type': 'other', 'subtype': None, 'raw': 'concentrate for solution for .'}]",True,resectable non small cell lung cancer pancoast tumor,lung/thoracic
1486,France,metastatic clear cell renal cancer with progressive disease after 2 lines of therapy in the advanced/metastatic setting including at least 1 line of anti-VEGFR and 1 line of immunotherapy.,,12,"Hospital/Clinic/Other health care facility, Hospital/Clinic/Other health care facility, Hospital/Clinic/Other health care facility","Centre Leon Berard, Centre Leon Berard, Centre Leon Berard",[],[],False,metastatic clear cell renal cancer with progressive disease after 2 lines of therapy in the advanced metastatic setting including at least 1 line of anti vegfr and 1 line of immunotherapy,genitourinary
1487,Belgium,inoperable pleural mesothelioma,"YERVOY 5 mg/ml concentrate for solution for infusion, Armisarte 25 mg/ml concentrate for solution for infusion, Cisplatin Accord Healthcare 1 mg/ml concentraat voor oplossing voor infusie, OPDIVO 10 mg/mL concentrate for solution for infusion., Carboplatine Fresenius Kabi 10 mg/ml concentraat voor oplossing voor infusie",12,Hospital/Clinic/Other health care facility,Antwerp University Hospital,"['checkpoint inhibitor', 'other', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'yervoy 5'}, {'type': 'other', 'subtype': None, 'raw': 'concentrate for solution for'}, {'type': 'other', 'subtype': None, 'raw': 'armisarte 25'}, {'type': 'other', 'subtype': None, 'raw': 'concentrate for solution for'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin accord healthcare 1'}, {'type': 'other', 'subtype': None, 'raw': 'concentraat voor oplossing voor infusie'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'opdivo 10'}, {'type': 'other', 'subtype': None, 'raw': 'concentrate for solution for .'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatine fresenius kabi 10'}, {'type': 'other', 'subtype': None, 'raw': 'concentraat voor oplossing voor infusie'}]",True,inoperable pleural mesothelioma,lung/thoracic
1488,Spain,Bladder Cancer,"Domvanalimab, Zimberelimab, Trodelvy 200 mg powder for concentrate for solution for infusion",12,Hospital/Clinic/Other health care facility,Fundacion Para El Progreso De La Oncologia En Cantabria,"['other', 'antibody']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'domvanalimab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'zimberelimab'}, {'type': 'other', 'subtype': None, 'raw': 'trodelvy 200 powder for concentrate for solution for'}]",True,bladder cancer,genitourinary
1489,Romania,Recurrent or advanced/metastatic solid tumors who are immunotherapy naive and may or may not have been treated with prior therapy for their disease.,INCB099280,12,Pharmaceutical company,Incyte Corp.,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'incb099280'}]",False,recurrent or advanced metastatic solid tumors who are immunotherapy naive and may or may not have been treated with prior therapy for their disease,hematologic
1490,Spain,Non-muscle invasive bladder cancer,MITOMYCIN,1,Pharmaceutical company,Presurgy S.L.,['chemotherapy'],"[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'mitomycin'}]",False,non muscle invasive bladder cancer,genitourinary
1491,France,metastatic gastric cancer,JEMPERLI 500 mg concentrate for solution for infusion,12,Pharmaceutical company,Gercor,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'jemperli 500 concentrate for solution for'}]",False,metastatic gastric cancer,digestive
1492,Denmark,Advanced melanoma,"DABRAFENIB, ENCORAFENIB, BINIMETINIB, TRAMETINIB, KEYTRUDA 25 mg/mL concentrate for solution for infusion, YERVOY 5 mg/ml concentrate for solution for infusion, OPDIVO 10 mg/mL concentrate for solution for infusion.",12,Hospital/Clinic/Other health care facility,Region Hovedstaden,"['checkpoint inhibitor', 'other', 'kinase inhibitor']","[{'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'dabrafenib'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'encorafenib'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'binimetinib'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'trametinib'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'keytruda 25'}, {'type': 'other', 'subtype': None, 'raw': 'concentrate for solution for'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'yervoy 5'}, {'type': 'other', 'subtype': None, 'raw': 'concentrate for solution for'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'opdivo 10'}, {'type': 'other', 'subtype': None, 'raw': 'concentrate for solution for .'}]",True,advanced melanoma,skin
1493,France,microsatellite stable (MSS) colorectal cancer with liver-dominant metastasis,"Tecentriq 1 200 mg concentrate for solution for infusion, OXALIPLATINE HOSPIRA 5 mg/ml, solution à diluer pour perfusion, Avastin 25 mg/ml concentrate for solution for infusion., CAPECITABINE VIATRIS 500 mg, comprimé pelliculé",12,Hospital/Clinic/Other health care facility,Fondation Franc.Cancerologie Digestive,"['checkpoint inhibitor', 'other', 'antibody', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'tecentriq 1 200 concentrate for solution for'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'oxaliplatine hospira 5'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1 (title)', 'raw': 'atezolizumab'}, {'type': 'antibody', 'subtype': 'anti-VEGF', 'raw': 'avastin 25'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1 (title)', 'raw': 'atezolizumab'}, {'type': 'other', 'subtype': None, 'raw': 'capecitabine viatris 500'}, {'type': 'other', 'subtype': None, 'raw': 'comprimé pelliculé'}]",True,microsatellite stable colorectal cancer with liver dominant metastasis,digestive
1495,Italy,Relapsed/refractory malignant central nervous system tumors,"CYCLOPHOSPHAMIDE, FLUDARABINE",1,Hospital/Clinic/Other health care facility,Ospedale Pediatrico Bambino Gesu,['chemotherapy'],"[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide'}, {'type': 'chemotherapy', 'subtype': 'purine analog', 'raw': 'fludarabine'}]",False,relapsed refractory malignant central nervous system tumors,multiple
1496,Netherlands,Urothelial carcinoma of the bladder and bladder cancer,"NIVOLUMAB, IPILIMUMAB",12,Hospital/Clinic/Other health care facility,Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'ipilimumab'}]",False,urothelial carcinoma of the bladder and bladder cancer,genitourinary
1497,Austria,Locally Advanced/Metastatic Squamous Cell Carcinoma of the Skin,"OPDIVO 10 mg/mL concentrate for solution for infusion., Nivolumab/Relatlimab",12,Hospital/Clinic/Other health care facility,Gemeinnutzige Salzburger Landes kliniken Betriebsgesellschaft mbH,"['checkpoint inhibitor', 'antibody']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'opdivo 10'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1 (title)', 'raw': 'nivolumab'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'nivolumab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'relatlimab'}]",True,locally advanced metastatic squamous cell carcinoma of the skin,skin
1498,Spain,Hepatocellular Carcinoma,"CellCept 500 mg powder for concentrate for solution for infusion, IMJUDO 20 mg/ml concentrate for solution for infusion., Remicade 100 mg powder for concentrate for solution for infusion., IMFINZI 50 mg/mL concentrate for solution for infusion.",12,"Pharmaceutical company, Pharmaceutical company","Biocompatibles UK Limited, Biocompatibles UK Limited","['checkpoint inhibitor', 'other', 'cell therapy']","[{'type': 'cell therapy', 'subtype': 'other', 'raw': 'cellcept 500 powder for concentrate for solution for'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'imjudo 20'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1 (title)', 'raw': 'durvalumab'}, {'type': 'other', 'subtype': None, 'raw': 'remicade 100 powder for concentrate for solution for .'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-L1', 'raw': 'imfinzi 50'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1 (title)', 'raw': 'durvalumab'}]",True,hepatocellular carcinoma,digestive
1499,France,"The patients enrolled in IMMUNORARE will be adult patients with  5 rare cancers: 
-Cohort 1: Peritoneal mesotheliomas (PM)
-Cohort 2: Gestational trophoblastic tumors (GTT)
-Cohort 3: B3 thymomas and thymic carcinomas (TET)
-Cohort 4: Anaplastic thyroid carcinomas (ATC)
-Cohort 5: GEP-NET & carcinoid tumors (GEP-NET/TCT/UP-NET)

Patients will have advanced/metastatic cancers found to be progressive/resistant after at least one previous line of standard systemic treatment.","OXALIPLATINE KABI 5 mg/ml, solution à diluer pour perfusion., FOLINATE DE CALCIUM KALCEKS 10 mg/mL, solution injectable/pour perfusion, DOMVANALIMAB, Zimberelimab, FLUOROURACILE PFIZER 50 mg/mL, solution à diluer pour perfusion",12,Hospital/Clinic/Other health care facility,Hospices Civils De Lyon,"['other', 'antibody', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'oxaliplatine kabi 5'}, {'type': 'other', 'subtype': None, 'raw': 'solution à diluer pour perfusion.'}, {'type': 'other', 'subtype': None, 'raw': 'folinate de calcium kalceks 10'}, {'type': 'other', 'subtype': None, 'raw': 'solution injectable'}, {'type': 'other', 'subtype': None, 'raw': 'pour perfusion'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'domvanalimab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'zimberelimab'}, {'type': 'other', 'subtype': None, 'raw': 'fluorouracile pfizer 50'}, {'type': 'other', 'subtype': None, 'raw': 'solution à diluer pour perfusion'}]",True,the patients enrolled in immunorare will be adult patients with 5 rare cancers cohort 1 peritoneal mesotheliomas cohort 2 gestational trophoblastic tumors cohort 3 b3 thymomas and thymic carcinomas cohort 4 anaplastic thyroid carcinomas cohort 5 gep net carcinoid tumors patients will have advanced metastatic cancers found to be progressive resistant after at least one previous line of standard systemic treatment,lung/thoracic
1500,France,"Patients with locally advanced, metastatic or unresectable hepatocellular carcinoma","Tecentriq 1,200 mg concentrate for solution for infusion, MVASI 25 mg/mL concentrate for solution for infusion, UCPVax 1mg/2ml",12,"Hospital/Clinic/Other health care facility, Hospital/Clinic/Other health care facility","CHUR Of Besançon, Centre Hospitalier Regional Universitaire","['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'tecentriq 1'}, {'type': 'other', 'subtype': None, 'raw': '200 concentrate for solution for'}, {'type': 'other', 'subtype': None, 'raw': 'mvasi 25'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1 (title)', 'raw': 'atezolizumab'}, {'type': 'other', 'subtype': None, 'raw': 'ucpvax 1mg'}, {'type': 'other', 'subtype': None, 'raw': '2ml'}]",True,patients with locally advanced metastatic or unresectable hepatocellular carcinoma,digestive
1501,Germany,resectable and borderline resectable stage IIIA/B NSCLC,"Paclitaxel onkovis, 6 mg/ml, Konzentrat zur Herstellung einer Infusionslösung, Cisplatin Teva® 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Paclitaxel onkovis, 6 mg/ml, Konzentrat zur Herstellung einer Infusionslösung, DURVALUMAB, Vinorelbin NC 10 mg/ml - Konzentrat zur Herstellung einer Infusionslösung, Cisplatin Teva® 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Carboplat onkovis 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Paclitaxel onkovis, 6 mg/ml, Konzentrat zur Herstellung einer Infusionslösung, DURVALUMAB",12,Educational Institution,Rheinische Friedrich-Wilhelms-Universitaet Bonn,"['checkpoint inhibitor', 'other', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel onkovis'}, {'type': 'other', 'subtype': None, 'raw': '6'}, {'type': 'other', 'subtype': None, 'raw': 'konzentrat zur herstellung einer infusionslösung'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin teva® 1'}, {'type': 'other', 'subtype': None, 'raw': 'konzentrat zur herstellung einer infusionslösung'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel onkovis'}, {'type': 'other', 'subtype': None, 'raw': '6'}, {'type': 'other', 'subtype': None, 'raw': 'konzentrat zur herstellung einer infusionslösung'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}, {'type': 'other', 'subtype': None, 'raw': 'vinorelbin nc 10'}, {'type': 'other', 'subtype': None, 'raw': '- konzentrat zur herstellung einer infusionslösung'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin teva® 1'}, {'type': 'other', 'subtype': None, 'raw': 'konzentrat zur herstellung einer infusionslösung'}, {'type': 'other', 'subtype': None, 'raw': 'carboplat onkovis 10'}, {'type': 'other', 'subtype': None, 'raw': 'konzentrat zur herstellung einer infusionslösung'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel onkovis'}, {'type': 'other', 'subtype': None, 'raw': '6'}, {'type': 'other', 'subtype': None, 'raw': 'konzentrat zur herstellung einer infusionslösung'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'durvalumab'}]",True,resectable and borderline resectable stage iiia b nsclc,lung/thoracic
1502,Germany,"Relapsed or refractory CD19 positive B cell malignancies (pediatric acute lymphatic leukemia [ALL], aggressive NHL), Relapsed or refractory CD19 positive B cell malignancies (adult ALL, adult NHL/chronic lymphatic leukemia [CLL]), Refractory/relapsed B-NHL",MB-CART19.1,12,Pharmaceutical company,Miltenyi Biomedicine GmbH,['cell therapy'],"[{'type': 'cell therapy', 'subtype': 'engineered cell', 'raw': 'mb-cart19.1'}]",False,relapsed or refractory cd19 positive b cell malignancies relapsed or refractory cd19 positive b cell malignancies refractory relapsed b nhl,hematologic
1503,Belgium,advanced non-squamous non-small cell lung cancer (NSCLC),"JEMPERLI 500 mg concentrate for solution for infusion, Docetaxel 20 mg/ml concentrate for solution for infusion, IOA-244",12,Pharmaceutical company,iOnctura SA,"['other', 'chemotherapy']","[{'type': 'other', 'subtype': None, 'raw': 'jemperli 500 concentrate for solution for'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'docetaxel 20'}, {'type': 'other', 'subtype': None, 'raw': 'concentrate for solution for'}, {'type': 'other', 'subtype': None, 'raw': 'ioa-244'}]",True,advanced non squamous non small cell lung cancer,lung/thoracic
1504,France,"For patients with advanced/metastatic gastric adenocarcinomas in
progression",,12,Hospital/Clinic/Other health care facility,Hospices Civils De Lyon,[],[],False,for patients with advanced metastatic gastric adenocarcinomas in progression,digestive
1506,Italy,Malignant Pleural Mesothelioma,"KEYTRUDA 25 mg/mL concentrate for solution for infusion, PEMETREXED, CISPLATIN, CARBOPLATIN",12,Hospital/Clinic/Other health care facility,Istituto Oncologico Veneto,"['checkpoint inhibitor', 'chemotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'keytruda 25'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1 (title)', 'raw': 'pembrolizumab'}, {'type': 'chemotherapy', 'subtype': 'antifolate', 'raw': 'pemetrexed'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cisplatin'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'carboplatin'}]",True,malignant pleural mesothelioma,lung/thoracic
1507,France,Relapsing/Refractory ALK+ Anaplastic Large cell Lymphoma,OPDIVO 10 mg/mL concentrate for solution for infusion.,12,Hospital/Clinic/Other health care facility,Institut Gustave Roussy,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'opdivo 10'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1 (title)', 'raw': 'nivolumab'}]",False,relapsing refractory alk anaplastic large cell lymphoma,hematologic
1508,France,Localised and operable soft tissue sarcomas,Tecentriq 1 200 mg concentrate for solution for infusion,12,Hospital/Clinic/Other health care facility,Centre Leon Berard,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'tecentriq 1 200 concentrate for solution for'}]",False,localised and operable soft tissue sarcomas,sarcoma
1509,Netherlands,early stage NSCLC,IMFINZI 50 mg/mL concentrate for solution for infusion.,12,Hospital/Clinic/Other health care facility,Stichting Amsterdam UMC,"['checkpoint inhibitor', 'radiotherapy']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-L1', 'raw': 'imfinzi 50'}, {'type': 'radiotherapy', 'subtype': 'from title', 'raw': 'radiotherapy'}]",True,early stage nsclc,lung/thoracic
1510,Belgium,"High-grade glioma (HGG), Diffuse intrinsic pontine glioma (DIPG)",WT1 LAMP mRNA DC,12,Hospital/Clinic/Other health care facility,Antwerp University Hospital,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'wt1 lamp mrna dc'}]",False,high grade glioma diffuse intrinsic pontine glioma,brain/CNS
1511,Netherlands,"Locally advanced, irresectable dMMR colorectal cancers",KEYTRUDA 25 mg/mL concentrate for solution for infusion,12,Hospital/Clinic/Other health care facility,Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting,['checkpoint inhibitor'],"[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'keytruda 25'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1 (title)', 'raw': 'pembrolizumab'}]",False,locally advanced irresectable dmmr colorectal cancers,digestive
1512,Spain,Treatment of immunotherapy-naive patients with previously untreated or recurrent locally advanced or metastatic cSCC not amenable to curative surgery and/or radiotherapy,INCB099280,12,"Pharmaceutical company, Pharmaceutical company","Incyte Corp., Incyte Corp.",['other'],"[{'type': 'other', 'subtype': None, 'raw': 'incb099280'}]",False,treatment of immunotherapy naive patients with previously untreated or recurrent locally advanced or metastatic cscc not amenable to curative surgery and or radiotherapy,hematologic
1513,Spain,Advanced Solid Tumors,"KEYTRUDA 25 mg/mL concentrate for solution for infusion, ASP1570, ASP1570",12,Pharmaceutical company,Astellas Pharma Global Development Inc.,"['checkpoint inhibitor', 'other']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'keytruda 25'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1 (title)', 'raw': 'pembrolizumab'}, {'type': 'other', 'subtype': None, 'raw': 'asp1570'}, {'type': 'other', 'subtype': None, 'raw': 'asp1570'}]",True,advanced solid tumors,multiple
1514,France,Advanced / Metastatic cancers,"Lynparza 150 mg film-coated tablets, IMFINZI 50 mg/mL concentrate for solution for infusion., Lynparza 100 mg film-coated tablets, IMJUDO 20 mg/ml concentrate for solution for infusion., Tasigna 200 mg hard capsules",12,Hospital/Clinic/Other health care facility,Centre Leon Berard,"['checkpoint inhibitor', 'other']","[{'type': 'other', 'subtype': None, 'raw': 'lynparza 150 film-coated tablets'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-L1', 'raw': 'imfinzi 50'}, {'type': 'other', 'subtype': None, 'raw': 'concentrate for solution for .'}, {'type': 'other', 'subtype': None, 'raw': 'lynparza 100 film-coated tablets'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-CTLA-4', 'raw': 'imjudo 20'}, {'type': 'other', 'subtype': None, 'raw': 'concentrate for solution for .'}, {'type': 'other', 'subtype': None, 'raw': 'tasigna 200 hard capsules'}]",True,advanced metastatic cancers,multiple
1515,Netherlands,Metastatic Melanoma,"Zirconium Zr 89 crefmirlimab berdoxam, TIL cells, PEGINTERFERON ALFA-2A",12,Hospital/Clinic/Other health care facility,Leids Universitair Medisch Centrum (LUMC),"['other', 'cell therapy']","[{'type': 'other', 'subtype': None, 'raw': 'zirconium zr 89 crefmirlimab berdoxam'}, {'type': 'cell therapy', 'subtype': 'other', 'raw': 'til cells'}, {'type': 'other', 'subtype': None, 'raw': 'peginterferon alfa-2a'}]",True,metastatic melanoma,skin
1516,Sweden,Patients with histologically (or via cytology) confirmed cancer that develop arthritis secondary to treatment with immune checkpoint inhibitors.,"Prednisolon Pfizer 5 mg tabletter, RoActemra 162 mg solution for injection in pre-filled pen., Prednisolon Pfizer 2,5 mg tabletter",12,Hospital/Clinic/Other health care facility,Karolinska University Hospital,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'prednisolon pfizer 5 tabletter'}, {'type': 'other', 'subtype': None, 'raw': 'roactemra 162 solution for injection in pre-filled pen.'}, {'type': 'other', 'subtype': None, 'raw': 'prednisolon pfizer 2'}, {'type': 'other', 'subtype': None, 'raw': '5 tabletter'}]",False,patients with histologically confirmed cancer that develop arthritis secondary to treatment with immune checkpoint inhibitors,hematologic
1517,Netherlands,"MDS with excess blasts, MDS/AML or AML patients",Proleukin 18 x 106 IE Poeder voor oplossing voor injectie of infusie,12,Hospital/Clinic/Other health care facility,Stichting Radboud universitair medisch centrum,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'proleukin 18 x 106 ie poeder voor oplossing voor injectie of infusie'}]",False,mds with excess blasts mds aml or aml patients,hematologic
1518,Norway,Acute Lymphoblastic Leukaemia,"MERCAPTOPURINE, IMATINIB, BLINCYTO 38.5 micrograms powder for concentrate and solution for solution for infusion, BESPONSA 1 mg powder for concentrate for solution for infusion, MERCAPTOPURINE, METHOTREXATE, PREDNISOLONE SODIUM SUCCINATE, HYDROCORTISONE SODIUM SUCCINATE, MERCAPTOPURINE, METHOTREXATE, METHYLPREDNISOLONE SODIUM SUCCINATE, MERCAPTOPURINE, VINCRISTINE SULFATE, TIOGUANINE, CYTARABINE, METHOTREXATE, VINCRISTINE SULFATE, DEXAMETHASONE, DEXAMETHASONE, DOXORUBICIN, HYDROCORTISONE SODIUM PHOSPHATE",12,Hospital/Clinic/Other health care facility,Karolinska University Hospital,"['other', 'supportive care', 'chemotherapy', 'kinase inhibitor']","[{'type': 'chemotherapy', 'subtype': 'purine analog', 'raw': 'mercaptopurine'}, {'type': 'kinase inhibitor', 'subtype': 'TKI', 'raw': 'imatinib'}, {'type': 'other', 'subtype': None, 'raw': 'blincyto 38.5 micrograms powder for concentrate and solution for solution for'}, {'type': 'other', 'subtype': None, 'raw': 'besponsa 1 powder for concentrate for solution for'}, {'type': 'chemotherapy', 'subtype': 'purine analog', 'raw': 'mercaptopurine'}, {'type': 'chemotherapy', 'subtype': 'antifolate', 'raw': 'methotrexate'}, {'type': 'supportive care', 'subtype': 'steroid', 'raw': 'prednisolone sodium succinate'}, {'type': 'other', 'subtype': None, 'raw': 'hydrocortisone sodium succinate'}, {'type': 'chemotherapy', 'subtype': 'purine analog', 'raw': 'mercaptopurine'}, {'type': 'chemotherapy', 'subtype': 'antifolate', 'raw': 'methotrexate'}, {'type': 'other', 'subtype': None, 'raw': 'methylprednisolone sodium succinate'}, {'type': 'chemotherapy', 'subtype': 'purine analog', 'raw': 'mercaptopurine'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'vincristine sulfate'}, {'type': 'other', 'subtype': None, 'raw': 'tioguanine'}, {'type': 'chemotherapy', 'subtype': 'antimetabolite', 'raw': 'cytarabine'}, {'type': 'chemotherapy', 'subtype': 'antifolate', 'raw': 'methotrexate'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'vincristine sulfate'}, {'type': 'supportive care', 'subtype': 'steroid', 'raw': 'dexamethasone'}, {'type': 'supportive care', 'subtype': 'steroid', 'raw': 'dexamethasone'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'doxorubicin'}, {'type': 'other', 'subtype': None, 'raw': 'hydrocortisone sodium phosphate'}]",True,acute lymphoblastic leukaemia,other
1519,France,liver transplanted patients with advanced hepatocellular carcinoma,"ATEZOLIZUMAB, BEVACIZUMAB",12,Hospital/Clinic/Other health care facility,Assistance Publique Hopitaux De Paris,"['checkpoint inhibitor', 'antibody']","[{'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1', 'raw': 'atezolizumab'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'bevacizumab'}]",True,liver transplanted patients with advanced hepatocellular carcinoma,digestive
1520,Finland,"Melanoma, SCCHN",,1,Pharmaceutical company,TILT Biotherapeutics Oy,[],[],False,melanoma scchn,skin
1521,Poland,Acute lymphoblastic leukemia,"BLINATUMOMAB, BORTEZOMIB, PREDNISONE, IFOSFAMIDE, CRISANTASPASE, ETOPOSIDE, PREDNISOLONE, DEXAMETHASONE, CYCLOPHOSPHAMIDE, PREDNISOLONE SODIUM SUCCINATE, IFOSFAMIDE, PREDNISOLONE SODIUM SUCCINATE, METHOTREXATE, VINCRISTINE SULFATE, PREDNISONE, PREDNISONE, METHOTREXATE, ETOPOSIDE, DOXORUBICIN HYDROCHLORIDE, METHOTREXATE DISODIUM, DEXAMETHASONE, DEXAMETHASONE PHOSPHATE, METHOTREXATE, ETOPOSIDE, DOXORUBICIN HYDROCHLORIDE, CYTARABINE, PEGASPARGASE, CYTARABINE, PREDNISONE, VINDESINE SULFATE, MERCAPTOPURINE, CYTARABINE, METHOTREXATE, DAUNORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE, TIOGUANINE, PREDNISOLONE SODIUM SUCCINATE, ETOPOSIDE, CYTARABINE, PREDNISOLONE SODIUM SUCCINATE, DOXORUBICIN HYDROCHLORIDE, FLUDARABINE PHOSPHATE",12,Educational Institution,Medical University Of Silesia Katowice Poland,"['other', 'antibody', 'supportive care', 'chemotherapy']","[{'type': 'antibody', 'subtype': 'mAb', 'raw': 'blinatumomab'}, {'type': 'other', 'subtype': None, 'raw': 'bortezomib'}, {'type': 'supportive care', 'subtype': 'steroid', 'raw': 'prednisone'}, {'type': 'chemotherapy', 'subtype': 'alkylating agent', 'raw': 'ifosfamide'}, {'type': 'other', 'subtype': None, 'raw': 'crisantaspase'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'etoposide'}, {'type': 'supportive care', 'subtype': 'steroid', 'raw': 'prednisolone'}, {'type': 'supportive care', 'subtype': 'steroid', 'raw': 'dexamethasone'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'cyclophosphamide'}, {'type': 'supportive care', 'subtype': 'steroid', 'raw': 'prednisolone sodium succinate'}, {'type': 'chemotherapy', 'subtype': 'alkylating agent', 'raw': 'ifosfamide'}, {'type': 'supportive care', 'subtype': 'steroid', 'raw': 'prednisolone sodium succinate'}, {'type': 'chemotherapy', 'subtype': 'antifolate', 'raw': 'methotrexate'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'vincristine sulfate'}, {'type': 'supportive care', 'subtype': 'steroid', 'raw': 'prednisone'}, {'type': 'supportive care', 'subtype': 'steroid', 'raw': 'prednisone'}, {'type': 'chemotherapy', 'subtype': 'antifolate', 'raw': 'methotrexate'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'etoposide'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'doxorubicin hydrochloride'}, {'type': 'other', 'subtype': None, 'raw': 'methotrexate disodium'}, {'type': 'supportive care', 'subtype': 'steroid', 'raw': 'dexamethasone'}, {'type': 'other', 'subtype': None, 'raw': 'dexamethasone phosphate'}, {'type': 'chemotherapy', 'subtype': 'antifolate', 'raw': 'methotrexate'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'etoposide'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'doxorubicin hydrochloride'}, {'type': 'chemotherapy', 'subtype': 'antimetabolite', 'raw': 'cytarabine'}, {'type': 'other', 'subtype': None, 'raw': 'pegaspargase'}, {'type': 'chemotherapy', 'subtype': 'antimetabolite', 'raw': 'cytarabine'}, {'type': 'supportive care', 'subtype': 'steroid', 'raw': 'prednisone'}, {'type': 'other', 'subtype': None, 'raw': 'vindesine sulfate'}, {'type': 'chemotherapy', 'subtype': 'purine analog', 'raw': 'mercaptopurine'}, {'type': 'chemotherapy', 'subtype': 'antimetabolite', 'raw': 'cytarabine'}, {'type': 'chemotherapy', 'subtype': 'antifolate', 'raw': 'methotrexate'}, {'type': 'other', 'subtype': None, 'raw': 'daunorubicin hydrochloride'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'doxorubicin hydrochloride'}, {'type': 'other', 'subtype': None, 'raw': 'tioguanine'}, {'type': 'supportive care', 'subtype': 'steroid', 'raw': 'prednisolone sodium succinate'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'etoposide'}, {'type': 'chemotherapy', 'subtype': 'antimetabolite', 'raw': 'cytarabine'}, {'type': 'supportive care', 'subtype': 'steroid', 'raw': 'prednisolone sodium succinate'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'doxorubicin hydrochloride'}, {'type': 'chemotherapy', 'subtype': 'purine analog', 'raw': 'fludarabine phosphate'}]",True,acute lymphoblastic leukemia,hematologic
1522,Norway,Recurrent or metastatic squamous cell carcinoma of the head and neck,"PACLITAXEL, DOCETAXEL, Lenvatinib, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Lenvatinib, CETUXIMAB, CAPECITABINE",12,Pharmaceutical company,Merck Sharp & Dohme LLC,"['checkpoint inhibitor', 'targeted therapy', 'antibody', 'chemotherapy']","[{'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'paclitaxel'}, {'type': 'chemotherapy', 'subtype': 'cytotoxic agent', 'raw': 'docetaxel'}, {'type': 'targeted therapy', 'subtype': 'other', 'raw': 'lenvatinib'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1', 'raw': 'keytruda 25'}, {'type': 'checkpoint inhibitor', 'subtype': 'anti-PD-1/PD-L1 (title)', 'raw': 'pembrolizumab'}, {'type': 'targeted therapy', 'subtype': 'other', 'raw': 'lenvatinib'}, {'type': 'antibody', 'subtype': 'mAb', 'raw': 'cetuximab'}, {'type': 'chemotherapy', 'subtype': 'fluoropyrimidine', 'raw': 'capecitabine'}]",True,recurrent or metastatic squamous cell carcinoma of the head and neck,head/neck
1523,Spain,Advanced Melanoma,,1,Pharmaceutical company,Microbiotica Limited,[],[],False,advanced melanoma,skin
1524,Poland,"Light chain amyloidosis (AL amyloidosis) is an incurable plasma cell neoplasm and the most common among a heterogeneous group of over 30 rare and ultra-rare diseases known as amyloidoses. In AL amyloidosis the deposition of amyloid fibrils resulting from misfolded immunoglobulin light chains leads to end-stage failure of the affected organs, most often of the heart or kidneys. Current therapy of AL amyloidosis is based on the destruction of clonal plasma cells with chemotherapy or immunotherapy, which leads to the inhibition of the production of immunoglobulin light chains, which are the precursors of amyloid. Effective inhibition of amyloid production enables slow resorption of already formed deposits, which results in organ responses in some patients. In vitro and in vivo studies showed amyloid deposits removal via phagocytosis by macrophages and neutrophils.So far, no therapies have been approved that would directly affect the amyloid deposits, however, clinical trials with opsonizing antibodies are ongoing,he mechanism of which is binding and neutralization of amyloid deposits in the process of phagocytosis. 
In 2021, based on the results of the ANDROMEDA phase III clinical trial, the most effective therapy for AL amyloidosis was registered so far: the D-VCD regimen combining anti-CD38 monoclonal antibody, daratumumab, with standard chemotherapy bortezomib, cyclophosphamide and dexamethasone. The recombinant granulocyte macrophage colony stimulating factor (GM-CSF) sargramostim will be used in this study with the D-VCD regimen. Currently, the indication for its use in the USA includes mobilization of progenitor cells and support for the reconstruction of white blood cells after autologous bone marrow transplantation, induction treatment of acute myeloid leukemia and myelosuppressive radiation.In patients with rheumatoid arthritis, a relationship between high levels of GM-CSF in the synovial fluid and a lower risk of developing Alzheimer's disease, which is associated with the accumulation of amyloid beta deposits in the brain, has been observed. In studies in a transgenic mouse model, it was shown that injections of GM-CSF led to a rapid reduction in the amount of beta amyloid in the brain and to neurological improvement. In a recent clinical trial in patients with Alzheimer's disease, a 3-week treatment with sargramostim resulted in improved cognitive function, decrease plasma markers of neurodegeneration and increase of amyloid beta (decreased in AD) compared to placebo. We assume that activation of tissue phagocytes thanks to the use of sargramostim will result in more effective phagocytosis of amyloid deposits, which, together with the active destruction of clonal plasma cells by D-VCd immunochemotherapy, may lead to an increase in the frequency of organ responses.","Dexamethasone Krka, 20 mg, tabletki, DARZALEX 1800 mg solution for injection, Endoxan® „Baxter“ 50 mg - Dragees, VELCADE 3.5 mg powder for solution for injection, VELCADE 1 mg powder for solution for injection, Endoxan 200 mg pulbere pentru solutie perfuzabila/injectabila, Dexamethasone Krka, 4 mg/ml, roztwór do wstrzykiwań/do infuzji",12,Educational Institution,Medical University Of Warsaw,['other'],"[{'type': 'other', 'subtype': None, 'raw': 'dexamethasone krka'}, {'type': 'other', 'subtype': None, 'raw': '20'}, {'type': 'other', 'subtype': None, 'raw': 'tabletki'}, {'type': 'other', 'subtype': None, 'raw': 'darzalex 1800 solution for injection'}, {'type': 'other', 'subtype': None, 'raw': 'endoxan® „baxter“ 50 - dragees'}, {'type': 'other', 'subtype': None, 'raw': 'velcade 3.5 powder for solution for injection'}, {'type': 'other', 'subtype': None, 'raw': 'velcade 1 powder for solution for injection'}, {'type': 'other', 'subtype': None, 'raw': 'endoxan 200 pulbere pentru solutie perfuzabila'}, {'type': 'other', 'subtype': None, 'raw': 'injectabila'}, {'type': 'other', 'subtype': None, 'raw': 'dexamethasone krka'}, {'type': 'other', 'subtype': None, 'raw': '4'}, {'type': 'other', 'subtype': None, 'raw': 'roztwór do wstrzykiwań'}, {'type': 'other', 'subtype': None, 'raw': 'do infuzji'}]",False,light chain amyloidosis is an incurable plasma cell neoplasm and the most common among a heterogeneous group of over 30 rare and ultra rare diseases known as amyloidoses in al amyloidosis the deposition of amyloid fibrils resulting from misfolded immunoglobulin light chains leads to end stage failure of the affected organs most often of the heart or kidneys current therapy of al amyloidosis is based on the destruction of clonal plasma cells with chemotherapy or immunotherapy which leads to the inhibition of the production of immunoglobulin light chains which are the precursors of amyloid effective inhibition of amyloid production enables slow resorption of already formed deposits which results in organ responses in some patients in vitro and in vivo studies showed amyloid deposits removal via phagocytosis by macrophages and neutrophils so far no therapies have been approved that would directly affect the amyloid deposits however clinical trials with opsonizing antibodies are ongoing he mechanism of which is binding and neutralization of amyloid deposits in the process of phagocytosis in 2021 based on the results of the andromeda phase iii clinical trial the most effective therapy for al amyloidosis was registered so far the d vcd regimen combining anti cd38 monoclonal antibody daratumumab with standard chemotherapy bortezomib cyclophosphamide and dexamethasone the recombinant granulocyte macrophage colony stimulating factor sargramostim will be used in this study with the d vcd regimen currently the indication for its use in the usa includes mobilization of progenitor cells and support for the reconstruction of white blood cells after autologous bone marrow transplantation induction treatment of acute myeloid leukemia and myelosuppressive radiation in patients with rheumatoid arthritis a relationship between high levels of gm csf in the synovial fluid and a lower risk of developing alzheimer s disease which is associated with the accumulation of amyloid beta deposits in the brain has been observed in studies in a transgenic mouse model it was shown that injections of gm csf led to a rapid reduction in the amount of beta amyloid in the brain and to neurological improvement in a recent clinical trial in patients with alzheimer s disease a 3 week treatment with sargramostim resulted in improved cognitive function decrease plasma markers of neurodegeneration and increase of amyloid beta compared to placebo we assume that activation of tissue phagocytes thanks to the use of sargramostim will result in more effective phagocytosis of amyloid deposits which together with the active destruction of clonal plasma cells by d vcd immunochemotherapy may lead to an increase in the frequency of organ responses,genitourinary
